0000764180-21-000127.txt : 20211028 0000764180-21-000127.hdr.sgml : 20211028 20211028101006 ACCESSION NUMBER: 0000764180-21-000127 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 105 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211028 DATE AS OF CHANGE: 20211028 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALTRIA GROUP, INC. CENTRAL INDEX KEY: 0000764180 STANDARD INDUSTRIAL CLASSIFICATION: CIGARETTES [2111] IRS NUMBER: 133260245 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-08940 FILM NUMBER: 211355713 BUSINESS ADDRESS: STREET 1: 6601 WEST BROAD STREET CITY: RICHMOND STATE: VA ZIP: 23230 BUSINESS PHONE: (804) 274-2200 MAIL ADDRESS: STREET 1: 6601 WEST BROAD STREET CITY: RICHMOND STATE: VA ZIP: 23230 FORMER COMPANY: FORMER CONFORMED NAME: ALTRIA GROUP INC DATE OF NAME CHANGE: 20030127 FORMER COMPANY: FORMER CONFORMED NAME: PHILIP MORRIS COMPANIES INC DATE OF NAME CHANGE: 19920703 10-Q 1 mo-20210930.htm 10-Q mo-20210930
false2021Q3000076418012/310.33330.3333P5YP3YP1Y2100007641802021-01-012021-09-300000764180mo:CommonStock0.3313ParValueMember2021-01-012021-09-300000764180mo:CommonStock1.000NotesDue2023Member2021-01-012021-09-300000764180mo:CommonStock1.700NotesDue2025Member2021-01-012021-09-300000764180mo:CommonStock2.200NotesDue2027Member2021-01-012021-09-300000764180mo:CommonStock3.125NotesDue2031Member2021-01-012021-09-30xbrli:shares00007641802021-10-21iso4217:USD00007641802021-09-3000007641802020-12-31iso4217:USDxbrli:shares00007641802020-01-012020-09-3000007641802021-07-012021-09-3000007641802020-07-012020-09-300000764180us-gaap:CommonStockMember2020-12-310000764180us-gaap:AdditionalPaidInCapitalMember2020-12-310000764180us-gaap:RetainedEarningsMember2020-12-310000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000764180us-gaap:TreasuryStockMember2020-12-310000764180us-gaap:NoncontrollingInterestMember2020-12-310000764180us-gaap:RetainedEarningsMember2021-01-012021-09-300000764180us-gaap:NoncontrollingInterestMember2021-01-012021-09-300000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000764180us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300000764180us-gaap:TreasuryStockMember2021-01-012021-09-300000764180us-gaap:CommonStockMember2021-09-300000764180us-gaap:AdditionalPaidInCapitalMember2021-09-300000764180us-gaap:RetainedEarningsMember2021-09-300000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300000764180us-gaap:TreasuryStockMember2021-09-300000764180us-gaap:NoncontrollingInterestMember2021-09-300000764180us-gaap:CommonStockMember2019-12-310000764180us-gaap:AdditionalPaidInCapitalMember2019-12-310000764180us-gaap:RetainedEarningsMember2019-12-310000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000764180us-gaap:TreasuryStockMember2019-12-310000764180us-gaap:NoncontrollingInterestMember2019-12-3100007641802019-12-310000764180us-gaap:RetainedEarningsMember2020-01-012020-09-300000764180us-gaap:NoncontrollingInterestMember2020-01-012020-09-300000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300000764180us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-300000764180us-gaap:TreasuryStockMember2020-01-012020-09-300000764180us-gaap:CommonStockMember2020-09-300000764180us-gaap:AdditionalPaidInCapitalMember2020-09-300000764180us-gaap:RetainedEarningsMember2020-09-300000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300000764180us-gaap:TreasuryStockMember2020-09-300000764180us-gaap:NoncontrollingInterestMember2020-09-3000007641802020-09-300000764180us-gaap:CommonStockMember2021-06-300000764180us-gaap:AdditionalPaidInCapitalMember2021-06-300000764180us-gaap:RetainedEarningsMember2021-06-300000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000764180us-gaap:TreasuryStockMember2021-06-300000764180us-gaap:NoncontrollingInterestMember2021-06-3000007641802021-06-300000764180us-gaap:RetainedEarningsMember2021-07-012021-09-300000764180us-gaap:NoncontrollingInterestMember2021-07-012021-09-300000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000764180us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300000764180us-gaap:TreasuryStockMember2021-07-012021-09-300000764180us-gaap:CommonStockMember2020-06-300000764180us-gaap:AdditionalPaidInCapitalMember2020-06-300000764180us-gaap:RetainedEarningsMember2020-06-300000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300000764180us-gaap:TreasuryStockMember2020-06-300000764180us-gaap:NoncontrollingInterestMember2020-06-3000007641802020-06-300000764180us-gaap:RetainedEarningsMember2020-07-012020-09-300000764180us-gaap:NoncontrollingInterestMember2020-07-012020-09-300000764180us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000764180us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300000764180us-gaap:TreasuryStockMember2020-07-012020-09-30xbrli:pure0000764180mo:HelixInnovationsLLCMember2020-12-012021-04-2900007641802020-12-012021-04-2900007641802021-08-012021-08-3100007641802021-04-012021-06-300000764180mo:July2019ShareRepurchaseProgramMember2019-07-310000764180mo:July2019ShareRepurchaseProgramMember2020-04-300000764180mo:July2019ShareRepurchaseProgramMember2020-01-012020-12-310000764180mo:January2021ShareRepurchaseProgramMember2021-01-310000764180mo:January2021ShareRepurchaseProgramMember2021-09-300000764180mo:January2021ShareRepurchaseProgramMemberus-gaap:SubsequentEventMember2021-10-280000764180mo:January2021ShareRepurchaseProgramMember2021-01-012021-09-300000764180mo:January2021ShareRepurchaseProgramMember2021-07-012021-09-300000764180us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2021-09-300000764180mo:SteMichelleTransactionMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberus-gaap:SubsequentEventMember2021-10-010000764180us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermo:SteMichelleTransactionMember2021-01-012021-09-300000764180us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermo:WineSegmentMembermo:SteMichelleTransactionMembermo:MarketingAdministrationAndResearchCostsMember2021-01-012021-09-300000764180us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermo:SteMichelleTransactionMemberus-gaap:SubsequentEventMember2021-10-012021-10-010000764180us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermo:SteMichelleTransactionsMember2021-09-300000764180us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermo:SteMichelleTransactionsMember2021-01-012021-09-300000764180mo:ABInBevMember2021-09-300000764180mo:ABInBevMember2020-12-310000764180mo:JUULMember2021-09-300000764180mo:JUULMember2020-12-310000764180mo:CronosGroupInc.Member2021-09-300000764180mo:CronosGroupInc.Member2020-12-310000764180us-gaap:CommonStockMembermo:CronosGroupInc.Member2021-09-300000764180mo:EquityContractWarrantMembermo:CronosGroupInc.Member2021-09-300000764180mo:CronosGroupInc.Membermo:EquityContractPreemptiveRIghtsMember2021-09-300000764180us-gaap:CommonStockMembermo:CronosGroupInc.Member2020-12-310000764180mo:EquityContractWarrantMembermo:CronosGroupInc.Member2020-12-310000764180mo:CronosGroupInc.Membermo:EquityContractPreemptiveRIghtsMember2020-12-310000764180mo:ABInBevMember2021-01-012021-09-300000764180mo:ABInBevMember2020-01-012020-09-300000764180mo:ABInBevMember2021-07-012021-09-300000764180mo:ABInBevMember2020-07-012020-09-300000764180mo:CronosGroupInc.Member2021-01-012021-09-300000764180mo:CronosGroupInc.Member2020-01-012020-09-300000764180mo:CronosGroupInc.Member2021-07-012021-09-300000764180mo:CronosGroupInc.Member2020-07-012020-09-300000764180mo:JUULMember2021-01-012021-09-300000764180mo:JUULMember2020-01-012020-09-300000764180mo:JUULMember2021-07-012021-09-300000764180mo:JUULMember2020-07-012020-09-300000764180us-gaap:FairValueInputsLevel1Membermo:ABInBevMember2020-12-310000764180mo:ABInBevMember2020-01-012020-12-310000764180mo:JUULMember2018-12-310000764180mo:EquityMethodInvestmentsFairValueOptionMembermo:JUULMember2020-12-310000764180mo:EquityMethodInvestmentsFairValueOptionMembermo:JUULMember2021-01-012021-09-300000764180mo:EquityMethodInvestmentsFairValueOptionMembermo:JUULMember2021-09-300000764180mo:JUULMember2020-10-3100007641802020-10-31iso4217:CADxbrli:sharesiso4217:CAD0000764180mo:EquityContractWarrantMembermo:CronosGroupInc.Member2021-01-012021-09-300000764180mo:CronosGroupInc.Membermo:EquityContractPreemptiveRIghtsMember2021-01-012021-09-300000764180mo:EquityContractWarrantMembermo:CronosGroupInc.Memberus-gaap:SubsequentEventMember2021-10-252021-10-250000764180mo:CronosGroupInc.Memberus-gaap:SubsequentEventMembermo:EquityContractPreemptiveRIghtsMember2021-10-252021-10-250000764180mo:EquityContractWarrantAndEquityContractPreemptiveRightsMembermo:CronosGroupInc.Member2021-01-012021-09-300000764180mo:CronosGroupInc.Member2020-01-012020-12-310000764180us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2021-09-300000764180us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2020-12-310000764180mo:ForeignCurrencyDenominatedDebtMember2021-09-300000764180mo:ForeignCurrencyDenominatedDebtMember2020-12-310000764180us-gaap:MeasurementInputSharePriceMembermo:EquityContractPreemptiveRIghtsMember2021-09-300000764180us-gaap:MeasurementInputSharePriceMembermo:EquityContractPreemptiveRIghtsMember2020-12-310000764180mo:EquityContractWarrantMemberus-gaap:MeasurementInputSharePriceMember2021-09-300000764180mo:EquityContractWarrantMemberus-gaap:MeasurementInputSharePriceMember2020-12-31mo:year0000764180us-gaap:MeasurementInputExpectedTermMembermo:EquityContractPreemptiveRIghtsMember2021-09-300000764180us-gaap:MeasurementInputExpectedTermMembermo:EquityContractPreemptiveRIghtsMember2020-12-310000764180mo:EquityContractWarrantMemberus-gaap:MeasurementInputExpectedTermMember2021-09-300000764180mo:EquityContractWarrantMemberus-gaap:MeasurementInputExpectedTermMember2020-12-310000764180us-gaap:MeasurementInputPriceVolatilityMembermo:EquityContractPreemptiveRIghtsMember2021-09-300000764180us-gaap:MeasurementInputPriceVolatilityMembermo:EquityContractPreemptiveRIghtsMember2020-12-310000764180mo:EquityContractWarrantMemberus-gaap:MeasurementInputPriceVolatilityMember2021-09-300000764180mo:EquityContractWarrantMemberus-gaap:MeasurementInputPriceVolatilityMember2020-12-310000764180us-gaap:MeasurementInputRiskFreeInterestRateMembermo:EquityContractPreemptiveRIghtsMember2021-09-300000764180us-gaap:MeasurementInputRiskFreeInterestRateMembermo:EquityContractPreemptiveRIghtsMember2020-12-310000764180mo:EquityContractWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-09-300000764180mo:EquityContractWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2020-12-310000764180us-gaap:MeasurementInputExpectedDividendRateMembermo:EquityContractPreemptiveRIghtsMember2021-09-300000764180us-gaap:MeasurementInputExpectedDividendRateMembermo:EquityContractPreemptiveRIghtsMember2020-12-310000764180mo:EquityContractWarrantMemberus-gaap:MeasurementInputExpectedDividendRateMember2021-09-300000764180mo:EquityContractWarrantMemberus-gaap:MeasurementInputExpectedDividendRateMember2020-12-310000764180mo:MeasurementInputWeightedAverageExpectedTermMembersrt:MinimumMembermo:EquityContractPreemptiveRIghtsMember2021-09-300000764180mo:MeasurementInputWeightedAverageExpectedTermMembersrt:MaximumMembermo:EquityContractPreemptiveRIghtsMember2021-09-300000764180mo:MeasurementInputWeightedAverageExpectedTermMembersrt:MinimumMembermo:EquityContractPreemptiveRIghtsMember2020-12-310000764180mo:MeasurementInputWeightedAverageExpectedTermMembersrt:MaximumMembermo:EquityContractPreemptiveRIghtsMember2020-12-310000764180us-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMembermo:EquityContractPreemptiveRIghtsMember2021-09-300000764180us-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMembermo:EquityContractPreemptiveRIghtsMember2021-09-300000764180us-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMembermo:EquityContractPreemptiveRIghtsMember2020-12-310000764180us-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMembermo:EquityContractPreemptiveRIghtsMember2020-12-310000764180us-gaap:EquityContractMemberus-gaap:FairValueInputsLevel3Member2019-12-310000764180us-gaap:EquityContractMemberus-gaap:FairValueInputsLevel3Member2020-01-012020-12-310000764180us-gaap:EquityContractMemberus-gaap:FairValueInputsLevel3Member2020-12-310000764180us-gaap:EquityContractMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-09-300000764180us-gaap:EquityContractMemberus-gaap:FairValueInputsLevel3Member2021-09-300000764180us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-09-300000764180us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000764180mo:OtherAccruedLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-09-300000764180mo:OtherAccruedLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000764180us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherAssetsMember2021-09-300000764180us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherAssetsMember2020-12-310000764180us-gaap:ForeignExchangeContractMemberus-gaap:OtherLiabilitiesMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-09-300000764180us-gaap:ForeignExchangeContractMemberus-gaap:OtherLiabilitiesMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000764180us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-09-300000764180us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000764180us-gaap:NondesignatedMembermo:InvestmentsInEquitySecuritiesMembermo:EquityContractWarrantMemberus-gaap:NetInvestmentHedgingMember2021-09-300000764180us-gaap:NondesignatedMembermo:InvestmentsInEquitySecuritiesMembermo:EquityContractWarrantMemberus-gaap:NetInvestmentHedgingMember2020-12-310000764180us-gaap:NondesignatedMembermo:InvestmentsInEquitySecuritiesMemberus-gaap:NetInvestmentHedgingMembermo:EquityContractPreemptiveRIghtsMember2021-09-300000764180us-gaap:NondesignatedMembermo:InvestmentsInEquitySecuritiesMemberus-gaap:NetInvestmentHedgingMembermo:EquityContractPreemptiveRIghtsMember2020-12-310000764180us-gaap:NondesignatedMemberus-gaap:NetInvestmentHedgingMemberus-gaap:EquityContractMember2021-09-300000764180us-gaap:NondesignatedMemberus-gaap:NetInvestmentHedgingMemberus-gaap:EquityContractMember2020-12-310000764180us-gaap:NetInvestmentHedgingMember2021-09-300000764180us-gaap:NetInvestmentHedgingMember2020-12-310000764180mo:EquityContractPreemptiveRIghtsMember2021-01-012021-09-300000764180mo:EquityContractPreemptiveRIghtsMember2020-01-012020-09-300000764180mo:EquityContractPreemptiveRIghtsMember2021-07-012021-09-300000764180mo:EquityContractPreemptiveRIghtsMember2020-07-012020-09-300000764180mo:EquityContractWarrantMember2021-01-012021-09-300000764180mo:EquityContractWarrantMember2020-01-012020-09-300000764180mo:EquityContractWarrantMember2021-07-012021-09-300000764180mo:EquityContractWarrantMember2020-07-012020-09-300000764180us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2021-01-012021-09-300000764180us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2020-01-012020-09-300000764180us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2021-07-012021-09-300000764180us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2020-07-012020-09-300000764180mo:ForeignCurrencyDenominatedDebtMemberus-gaap:NetInvestmentHedgingMember2021-01-012021-09-300000764180mo:ForeignCurrencyDenominatedDebtMemberus-gaap:NetInvestmentHedgingMember2020-01-012020-09-300000764180mo:ForeignCurrencyDenominatedDebtMemberus-gaap:NetInvestmentHedgingMember2021-07-012021-09-300000764180mo:ForeignCurrencyDenominatedDebtMemberus-gaap:NetInvestmentHedgingMember2020-07-012020-09-300000764180us-gaap:NetInvestmentHedgingMember2021-01-012021-09-300000764180us-gaap:NetInvestmentHedgingMember2020-01-012020-09-300000764180us-gaap:NetInvestmentHedgingMember2021-07-012021-09-300000764180us-gaap:NetInvestmentHedgingMember2020-07-012020-09-300000764180us-gaap:PensionPlansDefinedBenefitMember2021-01-012021-09-300000764180us-gaap:PensionPlansDefinedBenefitMember2020-01-012020-09-300000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-09-300000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-01-012020-09-300000764180us-gaap:PensionPlansDefinedBenefitMember2021-07-012021-09-300000764180us-gaap:PensionPlansDefinedBenefitMember2020-07-012020-09-300000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-07-012021-09-300000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-07-012020-09-300000764180us-gaap:PensionPlansDefinedBenefitMembersrt:MaximumMember2021-09-300000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembersrt:MaximumMember2021-09-300000764180us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-05-312021-05-310000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember2020-12-310000764180us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-09-300000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember2021-01-012021-09-300000764180us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-09-300000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-09-300000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember2021-09-300000764180us-gaap:AccumulatedTranslationAdjustmentMember2021-09-300000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-06-300000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember2021-06-300000764180us-gaap:AccumulatedTranslationAdjustmentMember2021-06-300000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-07-012021-09-300000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember2021-07-012021-09-300000764180us-gaap:AccumulatedTranslationAdjustmentMember2021-07-012021-09-300000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember2019-12-310000764180us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-09-300000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember2020-01-012020-09-300000764180us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-09-300000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-09-300000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember2020-09-300000764180us-gaap:AccumulatedTranslationAdjustmentMember2020-09-300000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-06-300000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember2020-06-300000764180us-gaap:AccumulatedTranslationAdjustmentMember2020-06-300000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-07-012020-09-300000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember2020-07-012020-09-300000764180us-gaap:AccumulatedTranslationAdjustmentMember2020-07-012020-09-300000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000764180us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-09-300000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-09-300000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-07-012021-09-300000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-07-012020-09-300000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000764180mo:AccumulatedEquityMethodInvestmentsAttributableToParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-09-300000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-09-300000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMember2021-07-012021-09-300000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMember2020-07-012020-09-300000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000764180us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000764180mo:SmokeableProductsSegmentMember2021-01-012021-09-300000764180mo:SmokeableProductsSegmentMember2020-01-012020-09-300000764180mo:SmokeableProductsSegmentMember2021-07-012021-09-300000764180mo:SmokeableProductsSegmentMember2020-07-012020-09-300000764180mo:OralTobaccoSegmentMember2021-01-012021-09-300000764180mo:OralTobaccoSegmentMember2020-01-012020-09-300000764180mo:OralTobaccoSegmentMember2021-07-012021-09-300000764180mo:OralTobaccoSegmentMember2020-07-012020-09-300000764180mo:WineSegmentMember2021-01-012021-09-300000764180mo:WineSegmentMember2020-01-012020-09-300000764180mo:WineSegmentMember2021-07-012021-09-300000764180mo:WineSegmentMember2020-07-012020-09-300000764180us-gaap:AllOtherSegmentsMember2021-01-012021-09-300000764180us-gaap:AllOtherSegmentsMember2020-01-012020-09-300000764180us-gaap:AllOtherSegmentsMember2021-07-012021-09-300000764180us-gaap:AllOtherSegmentsMember2020-07-012020-09-300000764180us-gaap:MaterialReconcilingItemsMember2021-01-012021-09-300000764180us-gaap:MaterialReconcilingItemsMember2020-01-012020-09-300000764180us-gaap:MaterialReconcilingItemsMember2021-07-012021-09-300000764180us-gaap:MaterialReconcilingItemsMember2020-07-012020-09-300000764180us-gaap:CorporateNonSegmentMember2021-01-012021-09-300000764180us-gaap:CorporateNonSegmentMember2020-01-012020-09-300000764180us-gaap:CorporateNonSegmentMember2021-07-012021-09-300000764180us-gaap:CorporateNonSegmentMember2020-07-012020-09-300000764180us-gaap:OperatingIncomeLossMembermo:NpmAdjustmentToCostOfSalesMembermo:PhilipMorrisUSAMemberus-gaap:OperatingSegmentsMembermo:NonParticipatingManufacturerArbitrationPanelDecisionMembermo:SmokeableProductsSegmentMember2021-01-012021-09-300000764180us-gaap:OperatingIncomeLossMembermo:NpmAdjustmentToCostOfSalesMembermo:PhilipMorrisUSAMemberus-gaap:OperatingSegmentsMembermo:NonParticipatingManufacturerArbitrationPanelDecisionMembermo:SmokeableProductsSegmentMember2021-07-012021-09-300000764180mo:InterestAndOtherDebtExpenseNetMembermo:NpmAdjustmentToCostOfSalesMembermo:NonParticipatingManufacturerArbitrationPanelDecisionMemberus-gaap:MaterialReconcilingItemsMember2021-01-012021-09-300000764180mo:InterestAndOtherDebtExpenseNetMembermo:NpmAdjustmentToCostOfSalesMembermo:NonParticipatingManufacturerArbitrationPanelDecisionMemberus-gaap:MaterialReconcilingItemsMember2021-07-012021-09-300000764180mo:NpmAdjustmentToCostOfSalesMembermo:NonParticipatingManufacturerArbitrationPanelDecisionMember2021-01-012021-09-300000764180mo:NpmAdjustmentToCostOfSalesMembermo:NonParticipatingManufacturerArbitrationPanelDecisionMember2021-07-012021-09-300000764180mo:TobaccoandHealthLitigationCasesMembermo:PhilipMorrisUSAMemberus-gaap:OperatingSegmentsMembermo:SmokeableProductsSegmentMember2021-01-012021-09-300000764180mo:TobaccoandHealthLitigationCasesMembermo:PhilipMorrisUSAMemberus-gaap:OperatingSegmentsMembermo:SmokeableProductsSegmentMember2020-01-012020-09-300000764180mo:TobaccoandHealthLitigationCasesMembermo:PhilipMorrisUSAMemberus-gaap:OperatingSegmentsMembermo:SmokeableProductsSegmentMember2021-07-012021-09-300000764180mo:TobaccoandHealthLitigationCasesMembermo:PhilipMorrisUSAMemberus-gaap:OperatingSegmentsMembermo:SmokeableProductsSegmentMember2020-07-012020-09-300000764180us-gaap:CorporateNonSegmentMembermo:TobaccoandHealthLitigationCasesMember2021-01-012021-09-300000764180us-gaap:CorporateNonSegmentMembermo:TobaccoandHealthLitigationCasesMember2020-01-012020-09-300000764180us-gaap:CorporateNonSegmentMembermo:TobaccoandHealthLitigationCasesMember2021-07-012021-09-300000764180us-gaap:CorporateNonSegmentMembermo:TobaccoandHealthLitigationCasesMember2020-07-012020-09-300000764180mo:TobaccoandHealthLitigationCasesMemberus-gaap:MaterialReconcilingItemsMember2021-01-012021-09-300000764180mo:TobaccoandHealthLitigationCasesMemberus-gaap:MaterialReconcilingItemsMember2020-01-012020-09-300000764180mo:TobaccoandHealthLitigationCasesMemberus-gaap:MaterialReconcilingItemsMember2021-07-012021-09-300000764180mo:TobaccoandHealthLitigationCasesMemberus-gaap:MaterialReconcilingItemsMember2020-07-012020-09-300000764180mo:TobaccoandHealthLitigationCasesMember2021-01-012021-09-300000764180mo:TobaccoandHealthLitigationCasesMember2020-01-012020-09-300000764180mo:TobaccoandHealthLitigationCasesMember2021-07-012021-09-300000764180mo:TobaccoandHealthLitigationCasesMember2020-07-012020-09-300000764180mo:COVID19Member2020-01-012020-09-300000764180mo:COVID19Member2020-07-012020-09-300000764180mo:COVID19Membermo:SmokeableProductsSegmentMember2020-01-012020-09-300000764180mo:COVID19Membermo:SmokeableProductsSegmentMember2020-07-012020-09-300000764180mo:COVID19Membermo:OralTobaccoSegmentMember2020-01-012020-09-300000764180mo:COVID19Membermo:OralTobaccoSegmentMember2020-07-012020-09-300000764180mo:InventoryDisposalCostsandOtherMembermo:WineBusinessStrategicResetMember2020-01-012020-09-300000764180mo:InventoryWriteOffMembermo:WineBusinessStrategicResetMember2020-01-012020-09-300000764180us-gaap:PurchaseCommitmentMembermo:WineBusinessStrategicResetMember2020-01-012020-09-300000764180us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembermo:RevolvingCreditFacilityDueAugust2024Member2021-09-300000764180us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembermo:RevolvingCreditFacilityDueAugust2024Member2021-01-012021-09-300000764180us-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembermo:RevolvingCreditFacilityDueAugust2024Member2021-01-012021-09-300000764180us-gaap:RevolvingCreditFacilityMember2021-01-012021-09-300000764180us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembermo:RevolvingCreditFacilityDueAugust2024Member2020-03-012020-03-310000764180mo:USDDenominatedNotesMemberus-gaap:SeniorNotesMember2021-05-012021-05-310000764180mo:USDDenominatedNotesMemberus-gaap:SeniorNotesMember2021-02-280000764180us-gaap:SeniorNotesMembermo:USDDenominatedNotesDue2032Member2021-02-280000764180us-gaap:SeniorNotesMembermo:USDDenominatedNotesDue2041Member2021-02-280000764180us-gaap:SeniorNotesMembermo:USDDenominatedNotesDue2051Member2021-02-280000764180us-gaap:SeniorNotesMembermo:USDDenominatedNotesDue2061Member2021-02-280000764180us-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2021-02-012021-02-280000764180us-gaap:SeniorNotesMember2021-09-300000764180us-gaap:SeniorNotesMembermo:USDDenominatedNotes2850PercentDue2022Member2021-09-300000764180us-gaap:SeniorNotesMembermo:USDDenominatedNotes2950PercentDue2023Member2021-09-300000764180us-gaap:SeniorNotesMembermo:USDDenominatedNotes4000PercentDue2024Member2021-09-300000764180us-gaap:SeniorNotesMembermo:USDDenominatedNotes3800PercentDue2024Member2021-09-300000764180us-gaap:SeniorNotesMembermo:USDDenominatedNotes4400PercentDue2026Member2021-09-300000764180mo:USDDenominatedNotes4800PercentDue2029Memberus-gaap:SeniorNotesMember2021-09-300000764180mo:USDDenominatedNotes9950PercentDue2038Memberus-gaap:SeniorNotesMember2021-09-300000764180us-gaap:SeniorNotesMembermo:USDDenominatedDebt10200PercentDue2039Member2021-09-300000764180us-gaap:SeniorNotesMembermo:USDDenominatedDebt6200PercentDue2059Member2021-09-300000764180us-gaap:SeniorNotesMembermo:USDDenominatedNotes3490PercentDue2022Member2021-03-310000764180us-gaap:SeniorNotesMembermo:USDDenominatedNotes3490PercentDue2022Member2021-01-012021-03-3100007641802021-01-012021-03-31mo:state0000764180mo:TobaccoandHealthJudgmentMember2004-10-012021-09-300000764180mo:EngleProgenyCasesMember2004-10-012021-09-300000764180mo:TobaccoandHealthJudgmentMembermo:LitigationCasesResultsMember2021-01-012021-09-300000764180mo:TobaccoandHealthJudgmentMembermo:LitigationCasesResultsMember2020-01-012020-09-300000764180mo:TobaccoandHealthJudgmentMembermo:LitigationCasesResultsMember2021-07-012021-09-300000764180mo:TobaccoandHealthJudgmentMembermo:LitigationCasesResultsMember2020-07-012020-09-300000764180mo:InterestExpenseRelatedToLitigationMember2021-01-012021-09-300000764180mo:InterestExpenseRelatedToLitigationMember2020-01-012020-09-300000764180mo:InterestExpenseRelatedToLitigationMember2021-07-012021-09-300000764180mo:InterestExpenseRelatedToLitigationMember2020-07-012020-09-300000764180us-gaap:PendingLitigationMemberus-gaap:AssetsMembermo:PhilipMorrisUSAMember2021-09-30mo:claim0000764180mo:IndividualSmokingAndHealthCasesMemberus-gaap:SubsequentEventMember2021-10-250000764180mo:IndividualSmokingAndHealthCasesMember2020-10-270000764180mo:IndividualSmokingAndHealthCasesMember2019-10-280000764180mo:HealthCareCostRecoveryActionsMemberus-gaap:SubsequentEventMember2021-10-250000764180mo:HealthCareCostRecoveryActionsMember2020-10-270000764180mo:HealthCareCostRecoveryActionsMember2019-10-280000764180mo:EvaporLitigationMemberus-gaap:SubsequentEventMember2021-10-250000764180mo:EvaporLitigationMember2020-10-270000764180mo:EvaporLitigationMember2019-10-280000764180mo:OtherTabaccoRelatedCasesMemberus-gaap:SubsequentEventMember2021-10-250000764180mo:OtherTabaccoRelatedCasesMember2020-10-270000764180mo:OtherTabaccoRelatedCasesMember2019-10-280000764180us-gaap:PendingLitigationMembermo:IndividualSmokingAndHealthCasesMemberstpr:ILus-gaap:SubsequentEventMember2021-10-250000764180us-gaap:PendingLitigationMembermo:IndividualSmokingAndHealthCasesMemberus-gaap:SubsequentEventMemberstpr:NM2021-10-250000764180us-gaap:PendingLitigationMemberstpr:MAmo:IndividualSmokingAndHealthCasesMemberus-gaap:SubsequentEventMember2021-10-250000764180us-gaap:PendingLitigationMemberstpr:FLmo:IndividualSmokingAndHealthCasesMemberus-gaap:SubsequentEventMember2021-10-25mo:case0000764180us-gaap:PendingLitigationMembermo:ETSSmokingandHealthCaseFlightAttendantsMemberus-gaap:SubsequentEventMember2021-10-252021-10-25mo:lawsuit0000764180mo:PendingIndividualLawsuitsMembermo:EvaporLitigationMemberus-gaap:SubsequentEventMember2021-10-250000764180mo:PendingLawsuitsFiledByStateOrLocalGovernmentsMembermo:EvaporLitigationMemberus-gaap:SubsequentEventMember2021-10-250000764180mo:ClassActionLawsuitMembermo:EvaporLitigationMemberus-gaap:SubsequentEventMember2021-10-250000764180country:CAmo:HealthCareCostRecoveryActionsMemberus-gaap:SubsequentEventMember2021-10-250000764180country:CAmo:HealthCareCostRecoveryActionsMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember2021-10-250000764180country:CAmo:HealthCareCostRecoveryActionsMembermo:PhilipMorrisUSAandAltriaGroupMemberus-gaap:SubsequentEventMember2021-10-250000764180country:CAmo:PhilipMorrisUSAandAltriaGroupMembermo:SmokingAndHealthClassActionsMemberus-gaap:SubsequentEventMember2021-10-250000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesMemberus-gaap:SubsequentEventMember2021-10-250000764180mo:NonEngleProgenyCasesMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember1999-01-012021-10-250000764180stpr:AKmo:NonEngleProgenyCasesMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember1999-01-012021-10-250000764180stpr:CAmo:NonEngleProgenyCasesMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember1999-01-012021-10-250000764180mo:NonEngleProgenyCasesMembermo:PhilipMorrisUSAMemberstpr:CTus-gaap:SubsequentEventMember1999-01-012021-10-250000764180stpr:FLmo:NonEngleProgenyCasesMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember1999-01-012021-10-250000764180stpr:LAmo:NonEngleProgenyCasesMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember1999-01-012021-10-250000764180stpr:MAmo:NonEngleProgenyCasesMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember1999-01-012021-10-250000764180mo:NonEngleProgenyCasesMemberstpr:MSmo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember1999-01-012021-10-250000764180stpr:MOmo:NonEngleProgenyCasesMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember1999-01-012021-10-250000764180mo:NonEngleProgenyCasesMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMemberstpr:NH1999-01-012021-10-250000764180mo:NonEngleProgenyCasesMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMemberstpr:NJ1999-01-012021-10-250000764180stpr:NYmo:NonEngleProgenyCasesMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember1999-01-012021-10-250000764180mo:NonEngleProgenyCasesMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMemberstpr:OH1999-01-012021-10-250000764180stpr:PAmo:NonEngleProgenyCasesMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember1999-01-012021-10-250000764180stpr:RImo:NonEngleProgenyCasesMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember1999-01-012021-10-250000764180mo:NonEngleProgenyCasesMemberstpr:TNmo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember1999-01-012021-10-250000764180stpr:WVmo:NonEngleProgenyCasesMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember1999-01-012021-10-250000764180mo:NonEngleProgenySmokingAndHealthCasePrincipeMember2020-02-290000764180mo:NonEngleProgenySmokingandHealthCaseGreeneMember2019-09-300000764180mo:NonEngleProgenySmokingandHealthCaseGreeneMember2020-05-310000764180mo:NonEngleProgenySmokingandHealthCaseGreeneMember2021-02-280000764180mo:NonEngleProgenySmokingandHealthCaseLaramieMember2019-08-310000764180mo:NonEngleProgenySmokingandHealthCaseLaramieMember2021-09-012021-09-300000764180mo:NonEngleProgenySmokingandHealthCaseGentileMember2017-10-310000764180mo:PhilipMorrisUSAMembermo:NonEngleProgenySmokingandHealthCaseGentileMember2017-10-310000764180mo:EngleProgenyCasesMember2000-07-310000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesMember2000-07-310000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesMember2006-07-012006-07-310000764180mo:EngleProgenyCasesMember2008-01-310000764180mo:EngleProgenyCasesStateMemberus-gaap:SubsequentEventMember2021-10-25mo:plantiff0000764180mo:EngleProgenyCasesStateMemberus-gaap:SubsequentEventMember2021-10-252021-10-250000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesFederalMemberus-gaap:SubsequentEventMember2021-10-250000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesMemberus-gaap:SubsequentEventMember2021-10-252021-10-250000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesStateMemberus-gaap:SubsequentEventMember2021-10-252021-10-250000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesPearsonDCohenCollarChaconMemberMemberus-gaap:SubsequentEventMember2021-10-252021-10-250000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesReiderandBanksMemberus-gaap:SubsequentEventMember2021-10-252021-10-250000764180mo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:EngleProgenyCasesWeingartandHancockMember2021-10-252021-10-250000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesPollariMemberus-gaap:SubsequentEventMember2021-10-252021-10-250000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesGlogerRintoulandDuignamMemberus-gaap:SubsequentEventMember2021-10-252021-10-250000764180mo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMembermo:EngleProgenyCasesFreemanMember2021-10-252021-10-250000764180mo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember2021-10-250000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesLippMember2021-09-300000764180us-gaap:PendingLitigationMembermo:PhilipMorrisUSAMembermo:EngleProgenyCasesLippMember2021-09-300000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesGarciaMember2021-05-310000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesDuignanMember2020-02-290000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesDuignanMembermo:PhilipMorrisUSAMember2020-02-290000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesCuddiheeMember2020-01-310000764180us-gaap:PendingLitigationMembermo:PhilipMorrisUSAMembermo:EngleProgenyCasesCuddiheeMember2020-01-310000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesRintoulMember2019-11-300000764180us-gaap:PendingLitigationMembermo:PhilipMorrisUSAMembermo:EngleProgenyCasesRintoulMember2019-11-300000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesGlogerMember2019-11-300000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesGlogerMembermo:PhilipMorrisUSAMember2019-11-300000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesMcCallMember2019-03-310000764180us-gaap:PendingLitigationMembermo:PhilipMorrisUSAMembermo:EngleProgenyCasesMcCallMember2019-03-310000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesNeffMember2019-03-310000764180us-gaap:PendingLitigationMembermo:PhilipMorrisUSAMembermo:EngleProgenyCasesNeffMember2019-03-310000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesMahfuzMember2019-02-280000764180us-gaap:PendingLitigationMembermo:PhilipMorrisUSAMembermo:EngleProgenyCasesMahfuzMember2019-02-280000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesHollimanMember2019-02-280000764180us-gaap:PendingLitigationMembermo:PhilipMorrisUSAMembermo:EngleProgenyCasesHollimanMember2019-02-280000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesChadwellMember2018-09-300000764180us-gaap:PendingLitigationMembermo:PhilipMorrisUSAMembermo:EngleProgenyCasesChadwellMember2018-09-300000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesKaplanMember2018-07-310000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesKaplanMembermo:PhilipMorrisUSAMember2018-07-310000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesR.DouglasMember2017-11-300000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesR.DouglasMembermo:PhilipMorrisUSAMember2017-11-300000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesSommersMember2017-04-300000764180us-gaap:PendingLitigationMembermo:PhilipMorrisUSAMembermo:EngleProgenyCasesSommersMember2017-04-300000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesSommersMember2021-01-012021-09-300000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesCooperMember2015-09-300000764180us-gaap:PendingLitigationMembermo:PhilipMorrisUSAMembermo:EngleProgenyCasesCooperMember2015-09-300000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesD.BrownMember2015-01-310000764180us-gaap:PendingLitigationMembermo:EngleProgenyCasesD.BrownMembermo:PhilipMorrisUSAMember2015-01-310000764180us-gaap:SettledLitigationMembermo:EngleProgenyCasesBergerMember2018-10-012018-12-310000764180us-gaap:SettledLitigationMembermo:EngleProgenyCasesBergerMember2021-01-012021-03-310000764180mo:EngleProgenyCasesSantoroMemberus-gaap:SettledLitigationMember2020-04-012020-06-300000764180mo:EngleProgenyCasesSantoroMemberus-gaap:SettledLitigationMember2021-01-012021-03-310000764180mo:EngleProgenyCasesNaugleGoreMBrownJordanTheisAndLandiMembermo:PhilipMorrisUSAMember2021-09-300000764180mo:EngleProgenyCasesNaugleMembermo:PhilipMorrisUSAMember2021-01-012021-09-300000764180mo:EngleProgenyCasesGoreMembermo:PhilipMorrisUSAMember2021-01-012021-09-300000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesM.BrownMember2021-01-012021-09-300000764180mo:EngleProgenyCasesJordanMembermo:PhilipMorrisUSAMember2021-01-012021-09-300000764180mo:EngleProgenyCasesTheisMembermo:PhilipMorrisUSAMember2021-01-012021-09-300000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesLandiMember2021-01-012021-09-300000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesM.BrownMember2021-04-012021-04-290000764180mo:EngleProgenyCasesTheisMembermo:PhilipMorrisUSAMember2021-05-012021-05-310000764180mo:PhilipMorrisUSAMembermo:EngleProgenyCasesLandiMember2021-07-012021-07-310000764180mo:EngleProgenyCasesRJReynoldsMembermo:PhilipMorrisUSAMember2021-07-012021-07-310000764180stpr:FLmo:EngleProgenyCasesStateMember2009-06-300000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMember1996-05-012021-09-300000764180stpr:ARmo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMember1996-05-012021-09-300000764180stpr:CAmo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMember1996-05-012021-09-300000764180stpr:DEmo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMember1996-05-012021-09-300000764180stpr:DCmo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMember1996-05-012021-09-300000764180stpr:FLmo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMember1996-05-012021-09-300000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMemberstpr:IL1996-05-012021-09-300000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMemberstpr:IA1996-05-012021-09-300000764180stpr:KSmo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMember1996-05-012021-09-300000764180stpr:LAmo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMember1996-05-012021-09-300000764180stpr:MDmo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMember1996-05-012021-09-300000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMemberstpr:MI1996-05-012021-09-300000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMemberstpr:MN1996-05-012021-09-300000764180stpr:NVmo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMember1996-05-012021-09-300000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMemberstpr:NJ1996-05-012021-09-300000764180stpr:NYmo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMember1996-05-012021-09-300000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMemberstpr:OH1996-05-012021-09-300000764180mo:PhilipMorrisUSAMemberstpr:OKmo:SmokingAndHealthClassActionsMember1996-05-012021-09-300000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMemberstpr:OR1996-05-012021-09-300000764180stpr:PAmo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMember1996-05-012021-09-300000764180country:PRmo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMember1996-05-012021-09-300000764180stpr:SCmo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMember1996-05-012021-09-300000764180mo:PhilipMorrisUSAMemberstpr:TXmo:SmokingAndHealthClassActionsMember1996-05-012021-09-300000764180mo:PhilipMorrisUSAMembermo:SmokingAndHealthClassActionsMemberstpr:WI1996-05-012021-09-300000764180mo:PhilipMorrisUSAandAltriaGroupMembermo:SmokingAndHealthClassActionsMembermo:BritishColumbiaSaskatchewanMemberus-gaap:SubsequentEventMember2021-10-25mo:manufacture0000764180country:CAmo:CanadianTobaccoManufacturersMembermo:SmokingAndHealthClassActionsMember2019-03-310000764180mo:AltriaGroupMembercountry:CAmo:SmokingAndHealthClassActionsMember2019-03-31mo:ruling0000764180country:CAmo:CanadianTobaccoManufacturersMembermo:SmokingAndHealthClassActionsMember2019-03-012019-03-310000764180us-gaap:ThreatenedLitigationMembercountry:CAmo:HealthCareCostRecoveryActionsMember2021-09-300000764180country:CAmo:CanadianTobaccoManufacturersMembermo:SmokingAndHealthClassActionsMember2021-09-300000764180mo:HealthCareCostRecoveryActionsMember1998-11-011998-11-300000764180mo:HealthCareCostRecoveryActionsMember1998-11-300000764180mo:HealthCareCostRecoveryActionsMember2021-07-012021-09-300000764180mo:HealthCareCostRecoveryActionsMember2020-07-012020-09-300000764180mo:HealthCareCostRecoveryActionsMember2021-01-012021-09-300000764180mo:HealthCareCostRecoveryActionsMember2020-01-012020-09-300000764180mo:HealthCareCostRecoveryActions2004NPMAdjustmentMembermo:PhilipMorrisUSAMember2021-01-012021-09-300000764180mo:HealthCareCostRecoveryActions2005NPMAdjustmentMembermo:PhilipMorrisUSAMember2021-01-012021-09-300000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2006NPMAdjustmentMember2021-01-012021-09-300000764180mo:HealthCareCostRecoveryActions2007NPMAdjustmentMembermo:PhilipMorrisUSAMember2021-01-012021-09-300000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2008NPMAdjustmentMember2021-01-012021-09-300000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2009NPMAdjustmentMember2021-01-012021-09-300000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2010NPMAdjustmentMember2021-01-012021-09-300000764180mo:HealthCareCostRecoveryActions2011NPMAdjustmentMembermo:PhilipMorrisUSAMember2021-01-012021-09-300000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2012NPMAdjustmentMember2021-01-012021-09-300000764180mo:HealthCareCostRecoveryActions2013NPMAdjustmentMembermo:PhilipMorrisUSAMember2021-01-012021-09-300000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2014NPMAdjustmentMember2021-01-012021-09-300000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2015NPMAdjustmentsMember2021-01-012021-09-300000764180mo:HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMembermo:PhilipMorrisUSAMember2021-01-012021-09-300000764180mo:HealthCareCostRecoveryActions2017NPMAdjustmentsMembermo:PhilipMorrisUSAMember2021-01-012021-09-300000764180mo:HealthCareCostRecoveryActions2018NPMAdjustmentsMembermo:PhilipMorrisUSAMember2021-01-012021-09-300000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2019NPMAdjustmentsMember2021-01-012021-09-300000764180mo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions2020NPMAdjustmentsMember2021-01-012021-09-300000764180mo:HealthCareCostRecoveryActionsMembermo:PhilipMorrisUSAMember2018-01-012018-12-310000764180mo:HealthCareCostRecoveryActionsMemberus-gaap:SettledLitigationMembermo:PhilipMorrisUSAMember2018-01-012018-12-310000764180us-gaap:PendingLitigationMembermo:HealthCareCostRecoveryActionsMembermo:PhilipMorrisUSAMember2018-01-012018-12-310000764180mo:HealthCareCostRecoveryActionsMembermo:PhilipMorrisUSAMember2021-01-012021-09-300000764180mo:HealthCareCostRecoveryActionsTransitionYears20042020Memberstpr:NYus-gaap:SettledLitigationMembermo:PhilipMorrisUSAMember2015-01-012015-12-310000764180us-gaap:SettledLitigationMembermo:PhilipMorrisUSAMemberstpr:MT2020-01-012020-12-310000764180us-gaap:PendingLitigationMembermo:HealthCareCostRecoveryActions2004NPMAdjustmentMembermo:PhilipMorrisUSAMember2021-01-012021-09-300000764180us-gaap:PendingLitigationMembermo:HealthCareCostRecoveryActions2004NPMAdjustmentMembermo:PhilipMorrisUSAMemberus-gaap:CostOfSalesMember2021-01-012021-09-300000764180us-gaap:PendingLitigationMembermo:HealthCareCostRecoveryActions2004NPMAdjustmentMembermo:PhilipMorrisUSAMember2021-07-012021-09-300000764180us-gaap:PendingLitigationMembermo:PhilipMorrisUSAMembermo:HealthCareCostRecoveryActions20052007NPMAdjustmentMember2021-01-012021-09-300000764180us-gaap:PendingLitigationMembermo:PhilipMorrisUSAMembermo:PeriodOneMembermo:HealthCareCostRecoveryActions20052007NPMAdjustmentMember2021-01-012021-09-300000764180us-gaap:PendingLitigationMembermo:PhilipMorrisUSAMembermo:PeriodTwoMembermo:HealthCareCostRecoveryActions20052007NPMAdjustmentMember2021-01-012021-09-300000764180mo:OtherDisputesUndertheStateSettlementAgreementsMembermo:PhilipMorrisUSAMember2021-01-012021-01-310000764180mo:FederalGovernmentsLawsuitMember2006-08-012006-08-310000764180mo:ImplementationofCorrectiveCommunicationsMembermo:FederalGovernmentsLawsuitMembermo:PhilipMorrisUSAMember2019-01-012019-12-310000764180mo:ImplementationofCorrectiveCommunicationsMembermo:FederalGovernmentsLawsuitMembermo:PhilipMorrisUSAMember2014-01-012014-12-310000764180mo:AltriaGroupMembermo:ImplementationofCorrectiveCommunicationsMembermo:FederalGovernmentsLawsuitMember2019-01-012019-12-310000764180mo:AltriaGroupMembermo:ImplementationofCorrectiveCommunicationsMembermo:FederalGovernmentsLawsuitMember2014-01-012014-12-310000764180mo:EvaporLitigationMemberus-gaap:SubsequentEventMembermo:PendingLawsuitFiledBySchoolDistrictMember2021-10-250000764180mo:EvaporLitigationMember2020-12-012020-12-310000764180mo:EvaporLitigationMember2021-09-300000764180us-gaap:SettledLitigationMembermo:EvaporLitigationMember2021-01-012021-09-300000764180mo:IQOSMember2020-04-012020-04-300000764180mo:JUULMember2020-04-300000764180us-gaap:SubsequentEventMember2021-10-25mo:complaint00007641802020-11-30mo:shareholder00007641802019-10-012019-12-3100007641802020-08-012020-08-3100007641802020-10-012021-03-3100007641802021-04-012021-04-3000007641802020-09-012021-08-310000764180mo:LightsMemberus-gaap:SubsequentEventMember2021-10-250000764180mo:SmokingAndHealthClassActionsMemberus-gaap:SubsequentEventMember2021-10-250000764180mo:PendingIndividualLawsuitsMembermo:USTLitigationMemberus-gaap:SubsequentEventMember2021-10-250000764180us-gaap:LetterOfCreditMember2021-09-300000764180us-gaap:RevolvingCreditFacilityMembermo:CreditAgreementMember2021-09-30mo:court0000764180mo:LightsMembermo:PhilipMorrisUSAMemberus-gaap:SubsequentEventMember2021-10-25

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2021
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                     to                    
Commission File Number 1-08940
Altria Group, Inc.
(Exact name of registrant as specified in its charter)
Virginia 13-3260245
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer
Identification No.)
6601 West Broad Street,Richmond,Virginia23230
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (804) 274-2200 
 Former name, former address and former fiscal year, if changed since last report
Securities registered pursuant to Section 12(b) of the Act:
               Title of each class               
Trading SymbolsName of each exchange on which registered
Common Stock, $0.33 1/3 par value
MONew York Stock Exchange
1.000% Notes due 2023
MO23ANew York Stock Exchange
1.700% Notes due 2025
MO25New York Stock Exchange
2.200% Notes due 2027
MO27New York Stock Exchange
3.125% Notes due 2031
MO31New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes   þ     No   ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes   þ    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer þAccelerated filer☐
Non-accelerated filer ☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes  ☐  No   þ
At October 21, 2021, there were 1,836,988,822 shares outstanding of the registrant’s common stock, par value $0.33 1/3 per share.



ALTRIA GROUP, INC.
TABLE OF CONTENTS
 
  Page No.
PART I -FINANCIAL INFORMATION
Item 1.Financial Statements (Unaudited)
Item 2.
Item 3.
Item 4.
PART II -OTHER INFORMATION
Item 1.
Item 1A.
Item 2.
Item 6.
Signature

2
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
Altria Group, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in millions of dollars)
(Unaudited)
______________________________
 
September 30, 2021December 31, 2020
Assets
Cash and cash equivalents$2,957 $4,945 
Receivables36 137 
Inventories:
Leaf tobacco644 844 
Other raw materials159 200 
Work in process30 502 
Finished product300 420 
1,133 1,966 
Assets held for sale1,490 — 
Other current assets404 69 
Total current assets6,020 7,117 
Property, plant and equipment, at cost4,418 5,150 
Less accumulated depreciation2,900 3,138 
1,518 2,012 
Goodwill5,177 5,177 
Other intangible assets, net12,326 12,615 
Investments in equity securities ($1,740 million and $1,868 million at September 30, 2021 and December 31, 2020, respectively, measured at fair value)
13,874 19,529 
Other assets649 964 
Total Assets$39,564 $47,414 
 
See notes to condensed consolidated financial statements.
3
Altria Group, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets (Continued)
(in millions of dollars, except share and per share data)
(Unaudited)
________________________________________________
 
September 30, 2021December 31, 2020
Liabilities
Current portion of long-term debt$1,105 $1,500 
Accounts payable266 380 
Accrued liabilities:
Marketing680 523 
Settlement charges2,996 3,564 
Other1,109 1,494 
Dividends payable1,661 1,602 
Liabilities held for sale295 — 
Total current liabilities8,112 9,063 
Long-term debt27,022 27,971 
Deferred income taxes3,557 4,532 
Accrued pension costs280 551 
Accrued postretirement health care costs1,512 1,951 
Other liabilities307 381 
Total liabilities40,790 44,449 
Contingencies (Note 12)
Redeemable noncontrolling interest39 40 
Stockholders’ (Deficit) Equity
Common stock, par value $0.33 1/3 per share
(2,805,961,317 shares issued)
935 935 
Additional paid-in capital5,846 5,910 
Earnings reinvested in the business30,685 34,679 
Accumulated other comprehensive losses(3,430)(4,341)
Cost of repurchased stock
(967,321,022 shares at September 30, 2021 and
947,542,152 shares at December 31, 2020)
(35,303)(34,344)
Total stockholders’ (deficit) equity attributable to Altria(1,267)2,839 
Noncontrolling interests2 86 
Total stockholders’ (deficit) equity(1,265)2,925 
Total Liabilities and Stockholders’ (Deficit) Equity$39,564 $47,414 
See notes to condensed consolidated financial statements.

4
Altria Group, Inc. and Subsidiaries
Condensed Consolidated Statements of Earnings (Losses)
(in millions of dollars, except per share data)
(Unaudited)
_____________________________________ 
For the Nine Months Ended September 30,For the Three Months Ended September 30,
2021202020212020
Net revenues$19,758 $19,849 $6,786 $7,123 
Cost of sales5,348 5,909 1,858 1,961 
Excise taxes on products3,733 4,063 1,255 1,445 
Gross profit10,677 9,877 3,673 3,717 
Marketing, administration and research costs1,850 1,585 722 557 
Operating income8,827 8,292 2,951 3,160 
Interest and other debt expense, net869 893 266 310 
Loss on early extinguishment of debt649 — — — 
Net periodic benefit income, excluding service cost(152)(58)(63)(3)
(Income) losses from equity investments5,789 306 5,915 472 
Impairment of JUUL equity securities— 2,600 — 2,600 
(Gain) loss on Cronos-related financial instruments128 202 135 105 
Earnings (losses) before income taxes1,544 4,349 (3,302)(324)
Provision (benefit) for income taxes693 1,817 (582)632 
Net earnings (losses)851 2,532 (2,720)(956)
Net (earnings) losses attributable to noncontrolling interests— 11 (2)4 
Net earnings (losses) attributable to Altria$851 $2,543 $(2,722)$(952)
Per share data:
Basic earnings (losses) per share attributable to Altria$0.46 $1.37 $(1.48)$(0.51)
Diluted earnings (losses) per share attributable to Altria$0.46 $1.36 $(1.48)$(0.51)
See notes to condensed consolidated financial statements.

5
Altria Group, Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Earnings (Losses)
(in millions of dollars)
(Unaudited)
_____________________
For the Nine Months Ended September 30,For the Three Months Ended September 30,
2021202020212020
Net earnings (losses)$851 $2,532 $(2,720)$(956)
Other comprehensive earnings (losses), net of deferred income taxes:
Benefit plans383 27 6 (15)
ABI495 (928)161 (15)
Currency translation adjustments and other33 (16)5 23 
Other comprehensive earnings (losses), net of deferred
income taxes
911 (917)172 (7)
Comprehensive earnings (losses)1,762 1,615 (2,548)(963)
Comprehensive (earnings) losses attributable to noncontrolling interests— 11 (2)4 
Comprehensive earnings (losses) attributable to Altria$1,762 $1,626 $(2,550)$(959)
See notes to condensed consolidated financial statements.
6
Altria Group, Inc. and Subsidiaries
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity
for the Nine Months Ended September 30, 2021 and 2020
(in millions of dollars, except per share data)
(Unaudited)
_______________________________________
 
 Attributable to Altria  
 Common
Stock		Additional
Paid-in
Capital		Earnings
Reinvested
in the
Business		Accumulated
Other
Comprehensive
Losses		Cost of
Repurchased
Stock		Non-
controlling
Interests		Total
Stockholders’
(Deficit) Equity
Balances, December 31, 2020$935 $5,910 $34,679 $(4,341)$(34,344)$86 $2,925 
Net earnings (losses) (1)
— — 851 — — (4)847 
Other comprehensive earnings (losses), net of deferred income taxes
— — — 911 — — 911 
Stock award activity— 13 — — 13 — 26 
Cash dividends declared ($2.62 per share)
— — (4,845)— — — (4,845)
Repurchases of common stock— — — — (972)— (972)
Other (2)
— (77)— — — (80)(157)
Balances, September 30, 2021$935 $5,846 $30,685 $(3,430)$(35,303)$2 $(1,265)


 Attributable to Altria  
 Common
Stock		Additional
Paid-in
Capital		Earnings
Reinvested
in the
Business		Accumulated
Other
Comprehensive
Losses		Cost of
Repurchased
Stock		Non-
controlling
Interests		Total
Stockholders’
(Deficit) Equity
Balances, December 31, 2019$935 $5,970 $36,539 $(2,864)$(34,358)$97 $6,319 
Net earnings (losses) (1)
— — 2,543 — — (13)2,530 
Other comprehensive earnings (losses), net of deferred income taxes
— — — (917)— — (917)
Stock award activity
— 3 — — 14 — 17 
Cash dividends declared ($2.54 per share)
— — (4,726)— — — (4,726)
Other— — — — — 9 9 
Balances, September 30, 2020$935 $5,973 $34,356 $(3,781)$(34,344)$93 $3,232 

(1)Amounts attributable to noncontrolling interests for the nine months ended September 30, 2021 and 2020 exclude net earnings of $4 million and $2 million, respectively, due to the redeemable noncontrolling interest related to Stag’s Leap Wine Cellars, which is reported in the mezzanine equity section on the condensed consolidated balance sheets.
(2) Represents the purchase of the remaining noncontrolling interests in Helix. For additional information, see Note 1. Background and Basis of Presentation.


See notes to condensed consolidated financial statements.


7
Altria Group, Inc. and Subsidiaries
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity
for the Three Months Ended September 30, 2021 and 2020
(in millions of dollars, except per share data)
(Unaudited)
_______________________________________ 

 Attributable to Altria  
 Common
Stock		Additional
Paid-in
Capital		Earnings
Reinvested
in the
Business		Accumulated
Other
Comprehensive
Losses		Cost of
Repurchased
Stock		Non-
controlling
Interests		Total
Stockholders’
(Deficit) Equity
Balances, June 30, 2021$935 $5,840 $35,065 $(3,602)$(34,981)$2 $3,259 
Net earnings (losses) (1)
— — (2,722)— — — (2,722)
Other comprehensive earnings (losses), net of deferred income taxes
— — — 172 — — 172 
Stock award activity
— 6 — — — — 6 
Cash dividends declared $0.90 per share)
— — (1,658)— — — (1,658)
Repurchases of common stock— — — — (322)— (322)
Balances, September 30, 2021
$935 $5,846 $30,685 $(3,430)$(35,303)$2 $(1,265)


 Attributable to Altria  
 Common
Stock		Additional
Paid-in
Capital		Earnings
Reinvested
in the
Business		Accumulated
Other
Comprehensive
Losses		Cost of
Repurchased
Stock		Non-
controlling
Interests		Total
Stockholders’
(Deficit) Equity
Balances, June 30, 2020$935 $5,964 $36,908 $(3,774)$(34,345)$98 $5,786 
Net earnings (losses) (1)
— — (952)— — (5)(957)
Other comprehensive earnings (losses), net of deferred income taxes
— — — (7)— — (7)
Stock award activity
— 9 — — 1 — 10 
Cash dividends declared ($0.86 per share)
— — (1,600)— — — (1,600)
Balances, September 30, 2020$935 $5,973 $34,356 $(3,781)$(34,344)$93 $3,232 

(1) Amounts attributable to noncontrolling interests for the three months ended September 30, 2021 and 2020 exclude net earnings of $2 million and $1 million, respectively, due to the redeemable noncontrolling interest related to Stag’s Leap Wine Cellars, which is reported in the mezzanine equity section on the condensed consolidated balance sheets.

See notes to condensed consolidated financial statements.


8
Altria Group, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(in millions of dollars)
(Unaudited)
_____________________
For the Nine Months Ended September 30,20212020
Cash Provided by (Used in) Operating Activities
Net earnings (losses)$851 $2,532 
Adjustments to reconcile net earnings (losses) to operating cash flows:
Depreciation and amortization190 192 
Deferred income tax provision (benefit)(1,180)(111)
(Income) losses from equity investments5,789 306 
Dividends from ABI119 108 
(Gain) loss on Cronos-related financial instruments128 202 
Impairment of JUUL equity securities— 2,600 
Loss on early extinguishment of debt649 — 
Cash effects of changes:
Receivables(7)1 
Inventories118 136 
Accounts payable3 24 
Income taxes(200)— 
Accrued liabilities and other current assets(104)(504)
Accrued settlement charges(568)(140)
Pension plan contributions(23)(16)
Pension provisions and postretirement, net(127)(35)
Other, net (1)
104 549 
Net cash provided by (used in) operating activities5,742 5,844 
Cash Provided by (Used in) Investing Activities
Capital expenditures(102)(162)
Other, net60 55 
Net cash provided by (used in) investing activities$(42)$(107)
(1) 2020 primarily reflects inventory-related amounts associated with the wine business strategic reset. For further discussion, see Note 9. Segment Reporting.

See notes to condensed consolidated financial statements.

9
Altria Group, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Continued)
(in millions of dollars)
(Unaudited)
_____________________
For the Nine Months Ended September 30,20212020
Cash Provided by (Used in) Financing Activities
Proceeds from short-term borrowings$— $3,000 
Repayment of short-term borrowings— (3,000)
Long-term debt issued5,472 1,993 
Long-term debt repaid(6,542)(1,000)
Repurchases of common stock(972)— 
Dividends paid on common stock(4,787)(4,690)
Premiums and fees related to early extinguishment of debt(623)— 
Other, net(216)(16)
Net cash provided by (used in) financing activities(7,668)(3,713)
Cash, cash equivalents and restricted cash:
Increase (decrease)(1,968)2,024 
Balance at beginning of period5,006 2,160 
Balance at end of period$3,038 $4,184 
The following table provides a reconciliation of cash, cash equivalents and restricted cash to the amounts reported on Altria’s condensed consolidated balance sheets:
At September 30, 2021At December 31, 2020
Cash and cash equivalents$2,957 $4,945 
Restricted cash included in other current assets (1)
— 1 
Restricted cash included in other assets (1)
45 60 
Cash included in assets held for sale (2)
36 — 
Cash, cash equivalents and restricted cash$3,038 $5,006 
(1)Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 12. Contingencies.
(2) Cash included in assets held for sale at September 30, 2021 is related to the Ste. Michelle Transaction. For further discussion, see Note 3. Assets Held for Sale.

See notes to condensed consolidated financial statements.
10

Altria Group, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 1. Background and Basis of Presentation
When used in these notes, the term “Altria,” refers to Altria Group, Inc. and its subsidiaries, unless the context requires otherwise.
▪Background: At September 30, 2021, Altria’s wholly owned subsidiaries included Philip Morris USA Inc. (“PM USA”), which is engaged in the manufacture and sale of cigarettes in the United States; John Middleton Co. (“Middleton”), which is engaged in the manufacture and sale of machine-made large cigars and pipe tobacco and is a wholly owned subsidiary of PM USA; UST LLC (“UST”), which through its wholly owned subsidiaries, including U.S. Smokeless Tobacco Company LLC (“USSTC”) and Ste. Michelle Wine Estates Ltd. (“Ste. Michelle”), is engaged in the manufacture and sale of moist smokeless tobacco products (“MST”), snus products and wine; Helix Innovations LLC (“Helix”), which operates in the United States and Canada, and Helix Innovations GmbH and its subsidiaries (“Helix ROW”), which operate internationally in the rest-of-world, are engaged in the manufacture and sale of on! oral nicotine pouches; and Philip Morris Capital Corporation (“PMCC”), which maintains a portfolio of finance assets, substantially all of which are leveraged leases.
On July 8, 2021, UST entered into a share purchase agreement pursuant to which it agreed to sell its subsidiary, International Wine & Spirits Ltd. (“IWS”), which includes Ste. Michelle. The sale was completed on October 1, 2021. At September 30, 2021, the assets and liabilities associated with the pending sale of IWS were classified as assets held for sale on Altria’s condensed consolidated balance sheet. For further discussion, see Note 3. Assets Held for Sale.
Altria owns 100% of the global on! business as a result of transactions in December 2020 and April 2021 to purchase the remaining 20% interest in (i) Helix ROW and (ii) Helix, respectively. The total purchase price of the December 2020 and April 2021 transactions was approximately $250 million.
Other Altria wholly owned subsidiaries included Altria Group Distribution Company, which provides sales and distribution services to certain Altria operating subsidiaries, and Altria Client Services LLC, which provides various support services in areas such as legal, regulatory, consumer engagement, finance, human resources and external affairs to Altria and its subsidiaries. Altria’s access to the operating cash flows of its wholly owned subsidiaries consists of cash received from the payment of dividends and distributions, and the payment of interest on intercompany loans by its subsidiaries. At September 30, 2021, Altria’s significant wholly owned subsidiaries were not limited by contractual obligations in their ability to pay cash dividends or make other distributions with respect to their equity interests.
At September 30, 2021, Altria’s investments in equity securities consisted of Anheuser-Busch InBev SA/NV (“ABI”), Cronos Group Inc. (“Cronos”) and JUUL Labs, Inc. (“JUUL”). Altria accounts for its investments in ABI and Cronos under the equity method of accounting using a one-quarter lag. Altria accounts for its equity investment in JUUL under the fair value option.
For further discussion of Altria’s investments in equity securities, see Note 4. Investments in Equity Securities.
▪Dividends and Share Repurchases: In August 2021, Altria’s Board of Directors (the “Board of Directors” or “Board”) approved a 4.7% increase in the quarterly dividend rate to $0.90 per share of Altria common stock versus the previous rate of $0.86 per share. The current annualized dividend rate is $3.60. Future dividend payments remain subject to the discretion of the Board.
In July 2019, the Board of Directors authorized a $1.0 billion share repurchase program. In April 2020, the Board rescinded the $500 million remaining in this program as part of Altria’s efforts to enhance its liquidity position in response to the COVID-19 pandemic. Altria did not repurchase any shares in 2020.
In January 2021, the Board authorized a new $2.0 billion share repurchase program, of which $1,028 million was remaining at September 30, 2021. In October 2021, the Board authorized a $1.5 billion expansion of this program to $3.5 billion. The timing of share repurchases under this program depends upon marketplace conditions and other factors, and the program remains subject to the discretion of the Board.
Altria’s share repurchase activity for the nine and three months ended September 30, 2021 was as follows:
(in millions, except per share data)For the Nine Months Ended September 30, 2021For the Three Months Ended September 30, 2021
Total number of shares repurchased
20.2 6.7 
Aggregate cost of shares repurchased
$972 $322 
Average price per share of shares repurchased
$48.17 $48.35 
11
▪Basis of Presentation: The interim condensed consolidated financial statements of Altria are unaudited. It is the opinion of Altria’s management that all adjustments necessary for a fair statement of the interim results presented have been reflected in the interim condensed consolidated financial statements. All such adjustments were of a normal recurring nature. Net revenues and net earnings for any interim period are not necessarily indicative of results that may be expected for the entire year.
Certain immaterial prior year amounts have been reclassified to conform with the current year’s presentation.
These statements should be read in conjunction with Altria’s audited consolidated financial statements and related notes, which appear in Altria’s Annual Report on Form 10-K for the year ended December 31, 2020 (the “2020 Form 10-K”).
On January 1, 2021, Altria adopted Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU No. 2019-12”). This guidance removes certain exceptions for investments, intraperiod allocations and interim calculations, and adds guidance to reduce complexity in accounting for income taxes. The adoption of ASU No. 2019-12 did not have a material impact on Altria’s condensed consolidated financial statements.
Additionally, on January 1, 2021, Altria adopted ASU No. 2020-01, Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (“ASU No. 2020-01”). This guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The adoption of ASU No. 2020-01 did not have a material impact on Altria’s condensed consolidated financial statements.
For a description of issued accounting guidance applicable to, but not yet adopted by, Altria, see Note 13. New Accounting Guidance Not Yet Adopted.

Note 2. Revenues from Contracts with Customers
Altria disaggregates net revenues based on product type. For further discussion, see Note 9. Segment Reporting.
In 2020, a majority of Altria’s businesses offered cash discounts to customers for prompt payment and calculated cash discounts as a percentage of the list price based on historical experience and agreed-upon payment terms. Beginning in the first quarter of 2021 for USSTC and the third quarter of 2021 for PM USA, cash discounts were calculated as a flat rate per unit, based on agreed-upon payment terms. Altria’s businesses record receivables net of the cash discounts on Altria’s condensed consolidated balance sheets.
Altria’s businesses that receive payments in advance of product shipment record such payments as deferred revenue. These payments are included in other accrued liabilities on Altria’s condensed consolidated balance sheets until control of such products is obtained by the customer. Deferred revenue was $260 million and $301 million at September 30, 2021 and December 31, 2020, respectively. When cash is received in advance of product shipment, Altria’s businesses satisfy their performance obligations within three days of receiving payment. At September 30, 2021 and December 31, 2020, there were no differences between amounts recorded as deferred revenue and amounts subsequently recognized as revenue.
Receivables were $144 million (including $108 million in assets held for sale) and $137 million at September 30, 2021 and December 31, 2020, respectively. At September 30, 2021 and December 31, 2020, there were no expected differences between amounts recorded and subsequently received, and Altria’s businesses did not record an allowance for doubtful accounts against these receivables.
Altria’s businesses record an allowance for returned goods, which is included in other accrued liabilities on Altria’s condensed consolidated balance sheets. While all of Altria’s tobacco operating companies sell tobacco products with dates relative to freshness as printed on product packaging, it is USSTC’s policy to accept authorized sales returns from its customers for products that have passed such dates due to the limited shelf life of USSTC’s MST and snus products. Altria’s businesses record estimated sales returns, which are based principally on historical volume and return rates, as a reduction to revenues. Actual sales returns will differ from estimated sales returns to the extent actual results differ from estimated assumptions. Altria’s businesses reflect differences between actual and estimated sales returns in the period in which the actual amounts become known. These differences, if any, have not had a material impact on Altria’s condensed consolidated financial statements. All returned goods are destroyed upon return and not included in inventory. Consequently, Altria’s businesses do not record an asset for their right to recover goods from customers upon return.
Sales incentives include variable payments related to goods sold by Altria’s businesses. Altria’s businesses include estimates of variable consideration as a reduction to revenues upon shipment of goods to customers. The sales incentives that require significant estimates and judgments are as follows:
Price promotion payments- Altria’s businesses make price promotion payments, substantially all of which are made to their retail partners, to incent the promotion of certain product offerings in select geographic areas.
12
Wholesale and retail participation payments- Altria’s businesses make payments to their wholesale and retail partners to incent merchandising and sharing of sales data in accordance with each business’s trade agreements.
These estimates primarily include estimated wholesale to retail sales volume and historical acceptance rates. Actual payments will differ from estimated payments to the extent actual results differ from estimated assumptions. Differences between actual and estimated payments are reflected in the period such information becomes available. These differences, if any, have not had a material impact on Altria’s condensed consolidated financial statements.

Note 3. Assets Held for Sale
On July 8, 2021, UST entered into a share purchase agreement pursuant to which it agreed to sell its subsidiary, IWS, which includes Ste. Michelle, to an entity controlled by investment funds managed by Sycamore Partners Management, L.P. in an all-cash transaction with a purchase price of approximately $1.2 billion and the assumption of certain liabilities of IWS and its subsidiaries (the “Ste. Michelle Transaction”).
At September 30, 2021, the assets and liabilities associated with the Ste. Michelle Transaction were classified as assets held for sale and were measured at their fair value less costs to sell, resulting in a pre-tax charge of $41 million. A reserve (as shown below), representing the adjustment to record the assets and liabilities at their fair value less costs to sell, was included as a component of assets held for sale in Altria’s condensed consolidated balance sheets at September 30, 2021. Altria recorded an additional pre-tax charge of $10 million for disposition-related costs related to the Ste. Michelle Transaction. The total pre-tax charges of $51 million were included in the wine segment and recorded in marketing, administration and research costs in Altria’s condensed consolidated statements of earnings (losses) for the nine and three months ended September 30, 2021.
On October 1, 2021, UST completed the sale of IWS and received approximately $1.2 billion in net cash proceeds. Altria expects to record additional adjustments related to the Ste. Michelle Transaction in the fourth quarter of 2021 and does not expect these adjustments to be material.
The major classes of assets and liabilities of IWS classified as held for sale at September 30, 2021 were as follows:
(in millions)September 30, 2021
Assets held for sale
Cash and cash equivalents$36 
Receivables108 
Inventories715 
Property, plant and equipment, net of accumulated depreciation407 
Other intangible assets, net236 
Other assets29 
Total assets1,531 
Reserve(41)
Total assets held for sale1,490 
Liabilities held for sale
Accounts payable114 
Accrued liabilities83 
Accrued pension costs49 
Other liabilities49 
Total liabilities held for sale295 
Assets and liabilities held for sale, net$1,195 

13
Note 4. Investments in Equity Securities
The carrying amount of Altria’s investments consisted of the following:
(in millions)September 30, 2021December 31, 2020
ABI$11,237 $16,651 
JUUL
1,705 1,705 
Cronos (1)
932 1,173 
Total
$13,874 $19,529 
(1) Atria’s investment in Cronos at September 30, 2021 consisted of Altria’s equity method investment in Cronos ($897 million), the Cronos warrant ($32 million) and the Fixed-price Preemptive Rights ($3 million), (collectively, “Investment in Cronos”). The Investment in Cronos at December 31, 2020 consisted of Altria’s equity method investment in Cronos ($1,010 million), the Cronos warrant ($139 million) and the Fixed-price Preemptive Rights ($24 million). See below for further discussion.
Income (losses) from equity investments accounted for under the equity method of accounting and fair value option consisted of the following:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
ABI (1)
$(5,644)$(306)$(6,036)$(418)
Cronos(145)— 21 (54)
Income (losses) from investments under equity method of accounting(5,789)(306)$(6,015)$(472)
JUUL— — 100 — 
Income (losses) from equity investments$(5,789)$(306)$(5,915)$(472)
(1) For the nine and three months ended September 30, 2021, Altria recorded a non-cash, pre-tax impairment charge of $6,157 million related to its equity investment in ABI. See below for further discussion.
Investment in ABI
At September 30, 2021, Altria had an approximate 10% ownership interest in ABI, consisting of 185 million restricted shares of ABI (the “Restricted Shares”) and 12 million ordinary shares of ABI. The Restricted Shares:
▪are unlisted and not admitted to trading on any stock exchange;
▪are convertible by Altria into ordinary shares of ABI on a one-for-one basis;
▪rank equally with ordinary shares of ABI with regards to dividends and voting rights; and
▪have director nomination rights with respect to ABI.
The Restricted Shares were subject to a five-year lock-up period that ended October 10, 2021. As of this filing, Altria has not elected to convert its Restricted Shares into ordinary shares of ABI.
Altria accounts for its investment in ABI under the equity method of accounting because Altria has the ability to exercise significant influence over the operating and financial policies of ABI, including having active representation on ABI’s board of directors and certain ABI board committees. Through this representation, Altria participates in ABI policy making processes.
Altria reports its share of ABI’s results using a one-quarter lag because ABI’s results are not available in time for Altria to record them in the concurrent period.
The fair value of Altria’s equity investment in ABI is based on (i) unadjusted quoted prices in active markets for ABI’s ordinary shares and was classified in Level 1 of the fair value hierarchy and (ii) observable inputs other than Level 1 prices, such as quoted prices for similar assets for the Restricted Shares, and was classified in Level 2 of the fair value hierarchy. Altria can convert its Restricted Shares to ordinary shares at its discretion. Therefore, the fair value of each Restricted Share is based on the value of an ordinary share.
In October 2019, the fair value of Altria’s equity investment in ABI declined below its carrying value and has not recovered. At December 31, 2020, the fair value of Altria’s equity investment in ABI was $13.8 billion (carrying value of $16.7 billion), which was less than its carrying value by approximately 17%. In preparing its financial statements for the period ended December 31, 2020, Altria evaluated the factors related to the fair value decline, including the impact on the fair value of ABI’s shares during the COVID-19 pandemic, which has negatively impacted ABI’s business. Altria evaluated the duration and magnitude of the fair value decline, ABI’s financial condition and near-term prospects and Altria’s intent and ability to hold its
14
investment in ABI until recovery. Altria concluded that the decline in fair value of its investment in ABI at December 31, 2020 below its carrying value was temporary and, therefore, no impairment was recorded at that time.
Following the consideration of the same factors, Altria, in preparing its financial statements for the period ended September 30, 2021, concluded that the decline in fair value of its investment in ABI at September 30, 2021 was other than temporary. As a result, Altria recorded a non-cash, pre-tax impairment charge of $6.2 billion for the nine and three months ended September 30, 2021, which was recorded to income (losses) from equity investments in its condensed consolidated statements of earnings (losses). This impairment charge reflects the difference between the fair value of Altria’s investment in ABI using ABI’s share price at September 30, 2021 and the carrying value of Altria’s equity investment in ABI at September 30, 2021. Altria continues to have confidence in ABI’s (i) long-term strategies, (ii) premium global brands, (iii) experienced management team and (iv) capability to successfully navigate its near-term challenges. Altria further expects that the impacts related to the COVID-19 pandemic that have negatively impacted ABI’s global business are transitory, but now also anticipates that the full recovery to carrying value will take longer than previously expected. This is evidenced by the resumption of declines in fair value during the third quarter of 2021, following positive share price momentum during the first half of 2021. At September 30, 2021, prior to recording the impairment charge, the fair value of Altria’s investment in ABI was below the carrying value by approximately 35%, which represents an additional 18% reduction in ABI’s share price since December 31, 2020. After recording the impairment charge, the fair value and carrying value of Altria’s equity investment in ABI at September 30, 2021 were $11.2 billion.
At September 30, 2021, the carrying value of Altria’s equity investment in ABI exceeded its share of ABI’s net assets attributable to equity holders of ABI by approximately $5.1 billion. Substantially all of this difference is comprised of goodwill and other indefinite-lived intangible assets (consisting primarily of trademarks).
Investment in JUUL
In December 2018, Altria made an investment in JUUL and received a 35% economic interest in JUUL through non-voting shares, which were convertible at Altria’s election into voting shares (“Share Conversion”), and a security convertible into additional non-voting or voting shares, as applicable, upon settlement or exercise of certain JUUL convertible securities (the “JUUL Transaction”).
Altria received a broad preemptive right to purchase JUUL shares, exercisable each quarter upon dilution, to maintain its ownership percentage and is subject to a standstill restriction under which it may not acquire additional JUUL shares above its 35% interest. Furthermore, Altria agreed not to sell or transfer any of its JUUL shares until December 20, 2024.
On April 1, 2020, the U.S. Federal Trade Commission (“FTC”) issued an administrative complaint challenging Altria’s investment in JUUL. For further discussion, see Note 12. Contingencies - Antitrust Litigation.
In November 2020, Altria exercised its rights to convert its non-voting JUUL shares into voting shares. Altria does not currently intend to exercise its additional governance rights obtained upon Share Conversion, including the right to elect directors to JUUL’s board or to vote its JUUL shares other than as a passive investor, pending the outcome of the FTC administrative complaint. At September 30, 2021, Altria had a 35% ownership interest in JUUL, consisting of 42 million voting shares.
Following Share Conversion in the fourth quarter of 2020, Altria elected to account for its equity method investment in JUUL under the fair value option. Under this option, Altria’s condensed consolidated statements of earnings (losses) include any cash dividends received from its investment in JUUL and any changes in the estimated fair value of its investment, which is calculated quarterly. Altria believes the fair value option provides quarterly transparency to investors as to the fair market value of Altria’s investment in JUUL, given the changes and volatility in the e-vapor category since Altria’s initial investment, as well as the lack of publicly available information regarding JUUL’s business or a market-derived valuation.
The following table provides a reconciliation of the beginning and ending balance of Altria’s investment in JUUL, which is classified in Level 3 of the fair value hierarchy:
Investment
(in millions)Balance
Balance at December 31, 2020$1,705 
Unrealized gains (losses) included in income (losses) from equity investments— 
Balance at September 30, 2021$1,705 
For the three months ended September 30, 2021, Altria recorded a non-cash, pre-tax unrealized gain of $100 million, as a result of changes in the estimated fair value of its investment in JUUL. At September 30, 2021, the estimated fair value of Altria’s JUUL investment was $1.7 billion, unchanged from its December 31, 2020 estimated fair value. There were no material
15
changes to the significant assumptions used in the valuations, as described below, during the nine and three months ended September 30, 2021.
Prior to Share Conversion, Altria accounted for its investment in JUUL as an investment in an equity security. Since the JUUL shares do not have a readily determinable fair value, Altria elected to measure its investment in JUUL at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There were no upward or downward adjustments to the carrying value of Altria’s investment in JUUL resulting from observable price changes in orderly transactions since the JUUL Transaction through the date of Share Conversion. In addition, prior to Share Conversion, Altria reviewed its investment in JUUL for impairment by performing a qualitative assessment of impairment indicators on a quarterly basis in connection with the preparation of its financial statements. If this qualitative assessment indicated that Altria’s investment in JUUL may be impaired, a quantitative assessment was performed. If the quantitative assessment indicated the estimated fair value of the investment was less than its carrying value, the investment was written down to its fair value.
In September 2020, JUUL announced a strategic update, which included its plans for a significant global workforce reduction, its evaluation of its resource allocation and the possibility of exiting various international markets. As part of the preparation of Altria’s financial statements for the period ended September 30, 2020, Altria performed a qualitative assessment of impairment indicators for its investment in JUUL and determined that JUUL’s strategic update was an indicator of impairment at September 30, 2020, given the significant deterioration in JUUL’s business prospects.
Given the existence of this impairment indicator, Altria performed a quantitative valuation of its investment in JUUL during the third quarter of 2020 and recorded a non-cash, pre-tax charge of $2.6 billion for the nine and three months ended September 30, 2020, reported as impairment of JUUL equity securities in its condensed consolidated statements of earnings (losses). The impairment charge was driven by Altria’s projections of lower JUUL revenues over time due to lower pricing assumptions and delays in JUUL achieving previously forecasted operating margin performance. These drivers were the result of (i) JUUL’s revised international expansion plans and (ii) the evolving U.S. e-vapor category and associated competitive dynamics.
Altria uses an income approach to estimate the fair value of its investment in JUUL. The income approach reflects the discounting of future cash flows for the U.S. and international markets at a rate of return that incorporates the risk-free rate for the use of those funds, the expected rate of inflation and the risks associated with realizing future cash flows. Future cash flows were based on a range of scenarios that consider various potential regulatory and market outcomes.
In determining the estimated fair value of its investment in JUUL, as of September 30, 2021 and December 31, 2020, Altria made various judgments, estimates and assumptions, the most significant of which were sales volume, operating margins, discount rates and perpetual growth rates. All significant inputs used in the valuation are classified in Level 3 of the fair value hierarchy. Additionally, in determining these significant assumptions, Altria made judgments regarding the (i) likelihood and extent of various potential regulatory actions and the continued adverse public perception impacting the e-vapor category and specifically JUUL, (ii) risk created by the number and types of legal cases pending against JUUL and (iii) expectations for the future state of the e-vapor category, including competitive dynamics.
Investment in Cronos
At September 30, 2021, Altria had a 41.9% ownership interest in Cronos, consisting of 156.6 million shares, which Altria accounts for under the equity method of accounting. Altria’s ownership percentage decreased from 43.5% at December 31, 2020 due to the issuance of additional shares by Cronos. Altria reports its share of Cronos’s results using a one-quarter lag because Cronos’s results are not available in time for Altria to record them in the concurrent period.
As part of its Investment in Cronos, at September 30, 2021, Altria owned:
▪anti-dilution protections to purchase Cronos common shares, exercisable each quarter upon dilution, to maintain its ownership percentage. Certain of the anti-dilution protections provide Altria the ability to purchase additional Cronos common shares at a per share exercise price of Canadian dollar (“CAD”) $16.25 upon the occurrence of specified events (“Fixed-price Preemptive Rights”). Based on Altria’s assumptions as of September 30, 2021, Altria estimates the Fixed-price Preemptive Rights allows Altria to purchase up to an additional approximately 14 million common shares of Cronos; and
▪a warrant providing Altria the ability to purchase an additional approximate 10% of common shares of Cronos (approximately 83 million common shares at September 30, 2021) at a per share exercise price of CAD $19.00, which expires on March 8, 2023.
If exercised in full, the exercise prices for the warrant and Fixed-price Preemptive Rights are approximately CAD $1.6 billion and CAD $0.2 billion, respectively (approximately USD $1.3 billion and $0.2 billion, respectively, based on the CAD to USD exchange rate on October 25, 2021). At September 30, 2021, upon full exercise of the Fixed-price Preemptive Rights, to the
16
extent such rights become available, and the warrant, Altria would own approximately 53% of the outstanding common shares of Cronos.
For a discussion of derivatives related to the Investment in Cronos, including Altria’s accounting for changes in the fair value of these derivatives, see Note 5. Financial Instruments.
The fair value of Altria’s equity method investment in Cronos is based on unadjusted quoted prices in active markets for Cronos’s common shares and was classified in Level 1 of the fair value hierarchy. In September 2021, the fair value of Altria’s equity method investment in Cronos declined below its carrying value. At September 30, 2021, the fair value of Altria’s equity method investment in Cronos was less than its carrying value by $14 million or approximately 2%. The fair value of Altria’s equity method investment in Cronos exceeded its carrying value by $77 million or approximately 8% at December 31, 2020. Based on Altria’s evaluation of the duration and magnitude of the fair value decline at September 30, 2021, Altria concluded that the decline in fair value of its equity method investment in Cronos below its carrying value is temporary and, therefore, no impairment was recorded.

Note 5. Financial Instruments
Altria enters into derivative financial instruments to mitigate the potential impact of certain market risks, including foreign currency exchange rate risk. Altria uses various types of derivative financial instruments, including forward contracts, options and swaps. Altria does not enter into or hold derivative financial instruments for trading or speculative purposes.
Altria’s investment in ABI, whose functional currency is the Euro, exposes Altria to foreign currency exchange risk on the carrying value of its investment. To manage this risk, Altria designates certain foreign exchange contracts, including cross-currency swap contracts and forward contracts (collectively, “foreign currency contracts”), and Euro denominated unsecured long-term notes (“foreign currency denominated debt”) as net investment hedges of Altria’s investment in ABI.
In May 2021, all outstanding foreign currency contracts matured. When Altria has foreign currency contracts in effect, counterparties are domestic and international financial institutions. Under these contracts, Altria is exposed to potential losses due to non-performance by these counterparties. Altria manages its credit risk by entering into transactions with counterparties with investment grade credit ratings, limiting the amount of exposure Altria has with each counterparty and monitoring the financial condition of each counterparty. The counterparty agreements contain provisions that require Altria to maintain an investment grade credit rating. In the event Altria’s credit rating falls below investment grade, counterparties to Altria’s foreign currency contracts can require Altria to post collateral. No collateral was received or posted related to derivative assets and liabilities at December 31, 2020.
The following table provides (i) the aggregate notional amounts of foreign currency contracts and (ii) the aggregate carrying value and fair value of foreign currency denominated debt:
(in millions)September 30, 2021December 31, 2020
Foreign currency contracts (notional amounts)$— $1,066 
Foreign currency denominated debt
Carrying value4,905 5,171 
Fair value5,288 5,687 
Altria’s estimates of the fair values of its foreign currency contracts are determined using valuation models with significant inputs that are readily available in public markets, or can be derived from observable market transactions, and therefore are classified in Level 2 of the fair value hierarchy. An adjustment for credit risk and non-performance risk is included in the fair values of foreign currency contracts.
The following table provides the aggregate carrying value and fair value of Altria’s total long-term debt:
(in millions)September 30, 2021December 31, 2020
Carrying value$28,127 $29,471 
Fair value31,037 34,682 
Altria’s estimate of the fair value of its total long-term debt is based on observable market information derived from a third-party pricing source and is classified in Level 2 of the fair value hierarchy.
The Fixed-price Preemptive Rights and Cronos warrant, which are further discussed in Note 4. Investments in Equity Securities, are derivative financial instruments, which are required to be recorded at fair value. The fair values of the Fixed-price Preemptive Rights and Cronos warrant are estimated using Black-Scholes option-pricing models, adjusted for observable inputs (which are classified in Level 1 of the fair value hierarchy), including share price, and unobservable inputs, including
17
probability factors and weighting of expected life, volatility levels and risk-free interest rates (which are classified in Level 3 of the fair value hierarchy) based on the following assumptions at:
Fixed-price Preemptive RightsCronos Warrant
September 30, 2021December 31, 2020September 30, 2021December 31, 2020
Share price (1)
C$7.15C$8.84C$7.15C$8.84
Expected life (2)
0.81 year1.05 years1.43 years2.18 years
Expected volatility (3)
67.32%80.68%67.32%80.68%
Risk-free interest rate (4)(5)
0.24%0.13%0.39%0.21%
Expected dividend yield (6)
—%—%—%—%
(1) Based on the closing market price for Cronos common stock on the Toronto Stock Exchange on the date indicated.
(2) Based on the weighted-average expected life of the Fixed-price Preemptive Rights (with a range from approximately 0.25 year to 4.00 years at September 30, 2021 and 0.25 year to 5 years at December 31, 2020) and the March 8, 2023 expiration date of the Cronos warrant.
(3) Based on a blend of historical volatility of the underlying equity security and implied volatility from traded options on the underlying equity security at September 30, 2021. Based on a blend of historical volatility levels of the underlying equity security and peer companies at December 31, 2020.
(4) Based on the implied yield currently available on Canadian Treasury zero coupon issues (with a range from approximately 0.12% to 0.89% at September 30, 2021 and 0.06% to 0.39% at December 31, 2020) weighted for the remaining expected life of the Fixed-price Preemptive Rights.
(5) Based on the implied yield currently available on Canadian Treasury zero coupon issues and the expected life of the Cronos warrant.
(6) Based on Cronos’s expected dividend payments.
The following table provides a reconciliation of the beginning and ending balance of the Fixed-price Preemptive Rights and Cronos warrant, which are classified in Level 3 of the fair value hierarchy:
(in millions)
Balance at December 31, 2019$303 
Pre-tax earnings (losses) recognized in net earnings (losses)(140)
Balance at December 31, 2020163 
Pre-tax earnings (losses) recognized in net earnings (losses)(128)
Balance at September 30, 2021$35 
Altria elects to record the gross assets and liabilities of derivative financial instruments executed with the same counterparty on its condensed consolidated balance sheets. The fair values of Altria’s derivative financial instruments on a gross basis included on the condensed consolidated balance sheets were as follows:
Fair Value of AssetsFair Value of Liabilities
(in millions)
Balance Sheet ClassificationSeptember 30, 2021December 31, 2020Balance Sheet ClassificationSeptember 30, 2021December 31, 2020
Derivatives designated as hedging instruments:
    Foreign currency contracts
Other current assets
$— $— 
Other accrued liabilities
$— $87 
    Foreign currency contracts
Other assets
— — 
Other liabilities
— — 
Total
$— $— $— $87 
Derivatives not designated as hedging instruments:
Cronos warrant
Investments in equity securities
$32 $139 
Fixed-price Preemptive Rights
Investments in equity securities
3 24 
Total
$35 $163 
Total derivatives
$35 $163 $— $87 
18
Altria records in its condensed consolidated statements of earnings (losses) any changes in the fair values of the Fixed-price Preemptive Rights and Cronos warrant as gains or losses on Cronos-related financial instruments in the periods in which the changes occur. For the nine and three months ended September 30, 2021 and 2020, Altria recorded non-cash, pre-tax unrealized gains (losses), representing the changes in the fair values of the Fixed-price Preemptive Rights and Cronos warrant, as follows:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Fixed-price Preemptive Rights$(21)$(54)$(17)$(25)
Cronos warrant(107)(148)(118)(80)
Total$(128)$(202)$(135)$(105)
Net Investment Hedging
The pre-tax effects of Altria’s net investment hedges on accumulated other comprehensive losses and the condensed consolidated statements of earnings (losses) were as follows:
Gain (Loss) Recognized in Accumulated Other Comprehensive LossesGain (Loss) Recognized in
Net Earnings (Losses)		Gain (Loss) Recognized in Accumulated Other Comprehensive LossesGain (Loss) Recognized in
Net Earnings (Losses)
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)20212020202120202021202020212020
Foreign currency contracts$16 $(28)$7 $33 $— $(66)$— $8 
Foreign currency denominated debt270 (215)— — 118 (206)— — 
Total$286 $(243)$7 $33 $118 $(272)$— $8 
The changes in the fair value of the foreign currency contracts and in the carrying value of the foreign currency denominated debt due to changes in the Euro to USD exchange rate were recognized in accumulated other comprehensive losses related to ABI. Gains on the foreign currency contracts arising from components excluded from effectiveness testing were recognized in interest and other debt expense, net in the condensed consolidated statements of earnings (losses) based on an amortization approach.

19
Note 6. Benefit Plans
Components of Net Periodic Benefit (Income) Cost
Net periodic benefit (income) cost consisted of the following:
PensionPostretirementPensionPostretirement
For the Nine Months Ended
September 30,		For the Three Months Ended
September 30,
 (in millions)20212020202120202021202020212020
Service cost$51 $55 $15 $13 $17 $18 $5 $5 
Interest cost139 188 29 44 46 62 8 14 
Expected return on plan assets
(393)(376)(10)(11)(131)(125)(2)(4)
Amortization:
Net loss99 108 16 7 33 55 2 — 
Prior service cost (credit)
3 4 (35)(22)1 2 (20)(7)
Net periodic benefit
(income) cost
$(101)$(21)$15 $31 $(34)$12 $(7)$8 
Employer Contributions
Altria makes contributions to the pension plans to the extent that the contributions are tax deductible and pays benefits that relate to plans for salaried employees that cannot be funded under Internal Revenue Service regulations. Altria made employer contributions of $23 million to its pension plans and did not make any contributions to its postretirement plans during the nine months ended September 30, 2021. Currently, Altria anticipates making additional employer contributions to its pension plans of up to approximately $5 million and no additional contributions to its postretirement plans for the remainder of 2021. However, the foregoing estimates of 2021 contributions to the pension and postretirement plans are subject to change as a result of changes in tax and other benefit laws, changes in interest rates, as well as asset performance significantly above or below the assumed long-term rate of return for each respective plan.
During the second quarter of 2021, Altria announced several amendments to its salaried retiree healthcare plans, primarily changing its post-age 65 coverage to a private medicare marketplace. These amendments triggered a plan remeasurement as of May 31, 2021 and resulted in Altria recording a reduction of $432 million to its accrued postretirement health care costs liability and a corresponding reduction to its accumulated other comprehensive losses on its condensed consolidated balance sheet. Ongoing amortization has been adjusted to reflect these changes as of June 1, 2021 and is reflected in the amounts shown above.

Note 7. Earnings (Losses) per Share
Basic and diluted earnings (losses) per share (“EPS”) were calculated using the following:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Net earnings (losses) attributable to Altria$851 $2,543 $(2,722)$(952)
Less: Distributed and undistributed earnings attributable to share-based awards
(8)(6)(2)(1)
Earnings (losses) for basic and diluted EPS$843 $2,537 $(2,724)$(953)
Weighted-average shares for basic EPS1,849 1,858 1,842 1,858 
Plus: contingently issuable performance stock units— 1 — 1 
Weighted-average shares for diluted EPS1,849 1,859 1,842 1,859 

20
Note 8. Other Comprehensive Earnings/Losses
The following tables set forth the changes in each component of accumulated other comprehensive losses, net of deferred income taxes, attributable to Altria:
For the Nine Months Ended September 30, 2021
(in millions)Benefit PlansABICurrency
Translation
Adjustments and Other		Accumulated
Other
Comprehensive
Losses
Balances, December 31, 2020$(2,420)$(1,938)$17 $(4,341)
Other comprehensive earnings (losses) before reclassifications
432 
(1)
685 35 1,152 
Deferred income taxes(118)(151)— (269)
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes
314 534 35 883 
Amounts reclassified to net earnings (losses) 92 (49)(2)41 
Deferred income taxes(23)10 — (13)
Amounts reclassified to net earnings (losses), net of deferred income taxes69 (39)(2)28 
Other comprehensive earnings (losses), net of deferred income taxes
383 495 
(2)
33 911 
Balances, September 30, 2021$(2,037)$(1,443)$50 $(3,430)

For the Three Months Ended September 30, 2021
(in millions)Benefit PlansABICurrency
Translation
Adjustments and Other 		Accumulated
Other
Comprehensive
Losses
Balances, June 30, 2021$(2,043)$(1,604)$45 $(3,602)
Other comprehensive earnings (losses) before reclassifications
— 

215 6 221 
Deferred income taxes(9)(48)— (57)
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes
(9)167 6 164 
Amounts reclassified to net earnings (losses)20 (7)(1)12 
Deferred income taxes(5)1 — (4)
Amounts reclassified to net earnings (losses), net of deferred income taxes15 (6)(1)8 
Other comprehensive earnings (losses), net of deferred income taxes
6 161 
(2)
5 172 
Balances, September 30, 2021$(2,037)$(1,443)$50 $(3,430)

21
For the Nine Months Ended September 30, 2020
(in millions)Benefit PlansABICurrency
Translation
Adjustments and Other		Accumulated
Other
Comprehensive
Losses
Balances, December 31, 2019$(2,192)$(693)$21 $(2,864)
Other comprehensive earnings (losses) before reclassifications
(75)(1,211)(16)(1,302)
Deferred income taxes19 260 — 279 
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes
(56)(951)(16)(1,023)
Amounts reclassified to net earnings (losses)111 29 — 140 
Deferred income taxes(28)(6)— (34)
Amounts reclassified to net earnings (losses), net of deferred income taxes83 23 — 106 
Other comprehensive earnings (losses), net of deferred income taxes
27 (928)
(2)
(16)(917)
Balances, September 30, 2020$(2,165)$(1,621)$5 $(3,781)


For the Three Months Ended September 30, 2020
(in millions)Benefit PlansABICurrency
Translation
Adjustments and Other		Accumulated
Other
Comprehensive
Losses
Balances, June 30, 2020$(2,150)$(1,606)$(18)$(3,774)
Other comprehensive earnings (losses) before reclassifications
(75)(71)23 (123)
Deferred income taxes19 22 — 41 
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes
(56)(49)23 (82)
Amounts reclassified to net earnings (losses)55 44 — 99 
Deferred income taxes(14)(10)— (24)
Amounts reclassified to net earnings (losses), net of deferred income taxes41 34 — 75 
Other comprehensive earnings (losses), net of deferred income taxes
(15)(15)
(2)
23 (7)
Balances, September 30, 2020$(2,165)$(1,621)$5 $(3,781)
(1) Reflects the remeasurement impact of salaried retiree healthcare plan amendments. For further discussion, see Note 6. Benefit Plans.
(2) Primarily reflects Altria’s share of ABI’s currency translation adjustments and the impact of Altria’s designated net investment hedges. For further discussion of designated net investment hedges, see Note 5. Financial Instruments.

22
The following table sets forth pre-tax amounts by component, reclassified from accumulated other comprehensive losses to net earnings (losses):
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Benefit Plans: (1)
Net loss$124 $129 $39 $60 
Prior service cost/credit(32)(18)(19)(5)
92 111 20 55 
ABI (2)
(49)29 (7)44 
Currency Translation Adjustments and Other (2)
(2)— (1)— 
Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings (losses)$41 $140 $12 $99 
(1) Amounts are included in net defined benefit plan costs. For further information related to defined benefit plans, see Note 6. Benefit Plans.
(2) Amounts are included in (income) losses from equity investments. For further information related to equity investments, see Note 4. Investments in Equity Securities.

Note 9. Segment Reporting
The products of Altria’s subsidiaries include smokeable tobacco products, consisting of combustible cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton; oral tobacco products, consisting of MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix; and wine produced and/or distributed by Ste. Michelle. The products and services of these subsidiaries constitute Altria’s reportable segments of smokeable products, oral tobacco products and wine. The financial services and the innovative tobacco products businesses, which include the heated tobacco business and Helix ROW, are included in all other.
Altria’s chief operating decision maker (the “CODM”) reviews operating companies income (loss) (“OCI”) to evaluate the performance of, and allocate resources to, the segments. OCI for the segments is defined as operating income before general corporate expenses and amortization of intangibles. Interest and other debt expense, net, along with net periodic benefit income/cost, excluding service cost, and provision (benefit) for income taxes are centrally managed at the corporate level and, accordingly, such items are not presented by segment since they are excluded from the measure of segment profitability reviewed by the CODM.
23
Segment data were as follows:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Net revenues:
Smokeable products$17,275 $17,522 $5,975 $6,313 
Oral tobacco products1,945 1,901 626 640 
Wine494 434 177 157 
All other44 (8)8 13 
Net revenues$19,758 $19,849 $6,786 $7,123 
Earnings (losses) before income taxes:
OCI:
Smokeable products$7,901 $7,609 $2,753 $2,789 
Oral tobacco products1,269 1,297 405 436 
Wine21 (347)(24)19 
All other(56)(63)(30)(7)
Amortization of intangibles(53)(54)(18)(17)
General corporate expenses(255)(150)(135)(60)
Operating income8,827 8,292 2,951 3,160 
Interest and other debt expense, net(869)(893)(266)(310)
Loss on early extinguishment of debt(649)— — — 
Net periodic benefit income, excluding
service cost
152 58 63 3 
Income (losses) from equity investments(5,789)(306)(5,915)(472)
Impairment of JUUL equity securities— (2,600)— (2,600)
Gain (loss) on Cronos-related financial instruments(128)(202)(135)(105)
Earnings (losses) before income taxes$1,544 $4,349 $(3,302)$(324)
The comparability of OCI for the reportable segments was affected by the following:
▪Non-Participating Manufacturer (“NPM”) Adjustment Items: Pre-tax (income) for NPM adjustment items was recorded to Altria’s condensed consolidated statements of earnings (losses) as follows:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)20212021
Smokeable products segment$(53)$(21)
Interest and other debt expense, net(23)(23)
Total$(76)$(44)
NPM adjustment items result from the resolutions of certain disputes with states and territories related to the NPM adjustment provision under the 1998 Master Settlement Agreement (such dispute resolutions are referred to as “NPM Adjustment Items” and are more fully described in Health Care Cost Recovery Litigation in Note 12. Contingencies). The amounts shown in the table above for the smokeable products segment were recorded as reductions to cost of sales, which increased OCI in the smokeable products segment.
24
▪Tobacco and Health and Certain Other Litigation Items: Pre-tax charges related to tobacco and health and certain other litigation items were recorded in Altria’s condensed consolidated statements of earnings (losses) as follows:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Smokeable products segment$72 $73 $29 $34 
General corporate70 — 70 — 
Interest and other debt expense, net6 3 6 — 
Total$148 $76 $105 $34 
The amounts shown in the table above for the smokeable products segment and general corporate were recorded in marketing, administration and research costs. For further discussion, see Note 12. Contingencies.
▪COVID-19 Special Items: Net pre-tax charges of $50 million ($41 million in the smokeable products segment and $9 million in the oral tobacco products segment) related to the COVID-19 pandemic were recorded in Altria’s condensed consolidated statements of earnings (losses) for the nine months ended September 30, 2020. The net pre-tax charges, which were directly related to disruptions caused by or efforts to mitigate the impact of the COVID-19 pandemic, were all recorded in costs of sales and included premium pay, personal protective equipment and health screenings, which were partially offset by certain employment tax credits. The COVID-19 special items do not include the inventory-related implementation costs associated with the wine business strategic reset discussed below. These implementation costs were due to increased inventory levels, which were further negatively impacted by the COVID-19 pandemic, including economic uncertainty and government restrictions.
▪Implementation, Acquisition and Disposition-Related Costs:
Ste. Michelle Transaction: For the nine and three months ended September 30, 2021, pre-tax disposition-related costs of $51 million were recorded in the wine segment, which consisted of a pre-tax charge of $41 million to record the assets and liabilities associated with the Ste. Michelle Transaction at their fair value less costs to sell and $10 million of other disposition-related costs. For further discussion, see Note 3. Assets Held for Sale.
Wine Business Strategic Reset: During the nine months ended September 30, 2020, Ste. Michelle recorded pre-tax implementation costs of $395 million associated with a strategic reset initiated in the first quarter of 2020 to maximize Ste. Michelle’s profitability and achieve improved long-term cash flow generation. Substantially all of the charges consisted of the following: (i) write-off of inventory ($292 million) as Ste. Michelle no longer believed that the benefit of the blending and production plans for its inventory outweighed inventory carrying cost given the reduced product volume demand; and (ii) estimated losses on future non-cancelable grape purchase commitments that Ste. Michelle believed no longer had a future economic benefit ($100 million). These charges were included in cost of sales in Altria’s condensed consolidated statements of earnings (losses).
Acquisition-Related Costs: For the nine months ended September 30, 2021, Altria recorded pre-tax acquisition-related costs of $37 million in the oral tobacco products segment primarily for the settlement of an arbitration related to the 2019 on! transaction. These costs were included in marketing, administration and research costs in Altria’s condensed consolidated statements of earnings (losses).

Note 10. Debt
Short-term Borrowings and Borrowing Arrangements
At September 30, 2021 and December 31, 2020, Altria had no short-term borrowings.
On August 18, 2021, Altria entered into an extension and amendment (the “Extension and Amendment”) to its $3.0 billion senior unsecured 5-year revolving credit agreement (as amended, the “Credit Agreement”). The Extension and Amendment extends the maturity date of the Credit Agreement from August 1, 2023 to August 1, 2024 and amends the Credit Agreement to update certain provisions regarding a successor interest rate to the London Interbank Offered Rate (“LIBOR”) and make certain other market updates. All other terms and conditions of the Credit Agreement remain in full force and effect. The Credit Agreement, which is used for general corporate purposes, includes an additional option, subject to certain conditions, for Altria to extend the expiration date for an additional one-year period.
At September 30, 2021, the Credit Agreement had available borrowings up to an aggregate principal amount of $3.0 billion.
25
Pricing for interest and fees under the Credit Agreement may be modified in the event of a change in the rating of Altria’s long-term senior unsecured debt. Interest rates on borrowings under the Credit Agreement are expected to be based on LIBOR, or a fallback benchmark rate determined based on prevailing market convention, plus a percentage based on the higher of the ratings of Altria’s long-term senior unsecured debt from Moody’s Investors Service, Inc. (“Moody’s”) and Standard & Poor’s Financial Services LLC (“S&P”). The applicable percentage based on Altria’s long-term senior unsecured debt ratings at September 30, 2021 for borrowings under the Credit Agreement was 1.0%. The Credit Agreement does not include any other rating triggers, or any provisions that could require the posting of collateral.
The Credit Agreement includes various covenants, one of which requires Altria to maintain a ratio of consolidated earnings before interest, taxes, depreciation and amortization (“EBITDA”) to Consolidated Interest Expense of not less than 4.0 to 1.0, calculated as of the end of the applicable quarter on a rolling four quarters basis. At September 30, 2021, the ratio of consolidated EBITDA to Consolidated Interest Expense, calculated in accordance with the Credit Agreement, was 9.8 to 1.0. At September 30, 2021, Altria was in compliance with its covenants in the Credit Agreement. The terms “Consolidated EBITDA” and “Consolidated Interest Expense,” each as defined in the Credit Agreement, include certain adjustments.
In March 2020, due to the uncertainty at that time in the global capital markets, including the commercial paper markets, resulting from the COVID-19 pandemic, Altria elected to borrow the full $3.0 billion available under the Credit Agreement as a precautionary measure to increase its cash position and preserve financial flexibility. In June 2020, Altria repaid the full amount outstanding under the Credit Agreement using the net proceeds from the issuance of long-term senior unsecured notes issued in May 2020 and available cash.
Any commercial paper issued by Altria and borrowings under the Credit Agreement are guaranteed by PM USA.
Long-term Debt
The aggregate carrying value of Altria’s total long-term debt at September 30, 2021 and December 31, 2020 was $28.1 billion and $29.5 billion, respectively.
In May 2021, Altria repaid in full senior unsecured notes in the aggregate principal amount of $1.5 billion at maturity.
In February 2021, Altria issued long-term senior unsecured notes in the aggregate principal amount of $5.5 billion (the “Notes”). The net proceeds from the Notes were used (i) to fund the purchase and redemption of certain unsecured notes and payment of related fees and expenses, as described below, and (ii) for other general corporate purposes. The Notes contain the following terms:
▪$1.75 billion at 2.450%, due 2032, interest payable semiannually beginning August 4, 2021;
▪$1.50 billion at 3.400%, due 2041, interest payable semiannually beginning August 4, 2021;
▪$1.25 billion at 3.700%, due 2051, interest payable semiannually beginning August 4, 2021; and
▪$1.00 billion at 4.000%, due 2061, interest payable semiannually beginning August 4, 2021.
The Notes are Altria’s senior unsecured obligations and rank equally in right of payment with all of Altria’s existing and future senior unsecured indebtedness. Upon the occurrence of both (i) a change of control of Altria and (ii) the Notes ceasing to be rated investment grade by each of Moody’s, S&P and Fitch Ratings, Inc. within a specified time period, Altria will be required to make an offer to purchase the Notes at a price equal to 101% of the aggregate principal amount of such Notes, plus accrued and unpaid interest to the date of repurchase as and to the extent set forth in the terms of the Notes.
The obligations of Altria under the Notes are guaranteed by PM USA.
26
During the first quarter of 2021, Altria completed debt tender offers to purchase for cash certain of its long-term senior unsecured notes in an aggregate principal amount of $4,042 million. Details of the debt tender offers are as follows:
(in millions)Principal Amount of Notes Purchased
2.850% Notes due 2022
$795 
2.950% Notes due 2023
132 
4.000% Notes due 2024
624 
3.800% Notes due 2024
655 
4.400% Notes due 2026
430 
4.800% Notes due 2029
1,094 
9.950% Notes due 2038
65 
10.200% Notes due 2039
18 
6.200% Notes due 2059
229 
$4,042 
During the first quarter of 2021, Altria also redeemed all of its outstanding 3.490% Notes due 2022 in an aggregate principal amount of $1.0 billion.
As a result of the debt tender offers and redemption, during the first quarter of 2021, Altria recorded pre-tax losses on early extinguishment of debt of $649 million, which included premiums and fees of $623 million and the write-off of related unamortized debt discounts and debt issuance costs of $26 million.
At September 30, 2021 and December 31, 2020, accrued interest on long-term debt of $206 million and $458 million, respectively, was included in other accrued liabilities on Altria’s condensed consolidated balance sheets.
For a discussion of the fair value of Altria’s long-term debt and the designation of its Euro denominated senior unsecured notes as a net investment hedge of its investment in ABI, see Note 5. Financial Instruments.

Note 11. Income Taxes
Earnings (losses) before income taxes, provision (benefit) for income taxes and income tax rates consisted of the following:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Earnings (losses) before income taxes$1,544$4,349$(3,302)$(324)
Provision (benefit) for income taxes6931,817(582)632
Income tax rate44.9 %41.8 %17.6 %(195.1)%
Altria’s income tax rates for the nine and three months ended September 30, 2021 and 2020 are not comparable in a meaningful way due to the following significant pre-tax charges and valuation allowances:
▪the $6,157 million impairment of Altria’s equity investment in ABI during the nine and three months ended September 30, 2021; and
▪the $2,600 million impairment of Altria’s investment in JUUL during the nine and three months ended September 30, 2020 and valuation allowances associated with Altria’s investments in JUUL and Altria’s Investment in Cronos.
Altria’s income tax rates for the nine and three months ended September 30, 2021 differ from the U.S. federal statutory rate of 21%, due primarily to the state tax treatment of the impairment charge on Altria’s equity investment in ABI.
Altria’s income tax rates for the nine and three months ended September 30, 2020 differ from the U.S. federal statutory rate of 21%, due primarily to valuation allowances primarily attributable to deferred tax assets recorded in connection with the impairment of Altria’s investment in JUUL, and Altria’s Investment in Cronos.
For further information on the impairments of Altria’s equity investment in ABI and investment in JUUL, see Note 4. Investments in Equity Securities.
27
The following chart provides a reconciliation of the beginning and ending valuation allowances for the period ended September 30, 2021:
(in millions)
Balance at beginning of year$2,817 
Additions to valuation allowance charged to income tax expense264 
Reductions to valuation allowance credited to income tax benefit(73)
Foreign currency translation(4)
Balance at end of period$3,004 
Altria determines the realizability of deferred tax assets based on the weight of available evidence, that it is more-likely-than-not that the deferred tax asset will not be realized. In reaching this determination, Altria considers all available positive and negative evidence, including the character of the loss, carryback and carryforward considerations, future reversals of temporary differences and available tax planning strategies.
The current changes in valuation allowances were due to deferred tax assets recorded in connection with Altria’s Investment in Cronos and changes in the estimated fair value of its investment in JUUL. The valuation allowance at the end of the period is primarily attributable to deferred tax assets recorded in connection with Altria’s investment in JUUL and Investment in Cronos.

Note 12. Contingencies
Legal proceedings covering a wide range of matters are pending or threatened in various U.S. and foreign jurisdictions against Altria and its subsidiaries, including PM USA and USSTC, as well as their respective indemnitees and Altria’s investees. Various types of claims may be raised in these proceedings, including product liability, unfair trade practices, antitrust, tax, contraband shipments, patent infringement, employment matters, claims alleging violation of the Racketeer Influenced and Corrupt Organizations Act (“RICO”), claims for contribution and claims of competitors, shareholders or distributors. Legislative action, such as changes to tort law, also may expand the types of claims and remedies available to plaintiffs.
Litigation is subject to uncertainty and it is possible that there could be adverse developments in pending or future cases. An unfavorable outcome or settlement of pending tobacco-related or other litigation could encourage the commencement of additional litigation. Damages claimed in some tobacco-related and other litigation are or can be significant and, in certain cases, have ranged in the billions of dollars. The variability in pleadings in multiple jurisdictions, together with the actual experience of management in litigating claims, demonstrate that the monetary relief that may be specified in a lawsuit bears little relevance to the ultimate outcome. In certain cases, plaintiffs claim that defendants’ liability is joint and several. In such cases, Altria or its subsidiaries may face the risk that one or more co-defendants decline or otherwise fail to participate in the bonding required for an appeal or to pay their proportionate or jury-allocated share of a judgment. As a result, Altria or its subsidiaries under certain circumstances may have to pay more than their proportionate share of any bonding- or judgment-related amounts. Furthermore, in those cases where plaintiffs are successful, Altria or its subsidiaries also may be required to pay interest and attorneys’ fees.
Although PM USA has historically been able to obtain required bonds or relief from bonding requirements in order to prevent plaintiffs from seeking to collect judgments while adverse verdicts have been appealed, there remains a risk that such relief may not be obtainable in all cases. This risk has been substantially reduced given that 47 states and Puerto Rico limit the dollar amount of bonds or require no bond at all. As discussed below, however, tobacco litigation plaintiffs have challenged the constitutionality of Florida’s bond cap statute in several cases and plaintiffs may challenge state bond cap statutes in other jurisdictions as well. Such challenges may include the applicability of state bond caps in federal court. States, including Florida, also may seek to repeal or alter bond cap statutes through legislation. Although Altria cannot predict the outcome of such challenges, it is possible that the consolidated results of operations, cash flows or financial position of Altria, or one or more of its subsidiaries, could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome of one or more such challenges.
Altria and its subsidiaries record provisions in the condensed consolidated financial statements for pending litigation when they determine that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. At the present time, while it is reasonably possible that an unfavorable outcome in a case may occur, except to the extent discussed elsewhere in this Note 12. Contingencies: (i) management has concluded that it is not probable that a loss has been incurred in any of the pending cases; (ii) management is unable to estimate the possible loss or range of loss that could result from an unfavorable outcome in any of the pending cases; and (iii) accordingly, management has not provided any amounts in the condensed consolidated financial statements for unfavorable outcomes, if any. Litigation defense costs are expensed as incurred.
28
Altria and its subsidiaries have achieved substantial success in managing litigation. Nevertheless, litigation is subject to uncertainty and significant challenges remain. It is possible that the consolidated results of operations, cash flows or financial position of Altria, or one or more of its subsidiaries, could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending litigation. Altria and each of its subsidiaries named as a defendant believe, and each has been so advised by counsel handling the respective cases, that it has valid defenses to the litigation pending against it, as well as valid bases for appeal of adverse verdicts. Each of the companies has defended, and will continue to defend, vigorously against litigation challenges. However, Altria and its subsidiaries may enter into settlement discussions in particular cases if they believe it is in the best interests of Altria to do so.
Judgments Paid and Provisions for Tobacco and Health and Certain Other Litigation Items (Including Engle Progeny Litigation): After exhausting all appeals in those cases resulting in adverse verdicts associated with tobacco-related litigation, since October 2004, PM USA has paid judgments and settlements (including related costs and fees) totaling approximately $865 million and interest totaling approximately $218 million as of September 30, 2021. These amounts include payments for Engle progeny judgments (and related costs and fees) totaling approximately $410 million and related interest totaling approximately $56 million.
The changes in Altria’s accrued liability for tobacco and health and certain other litigation items, including related interest costs, for the periods specified below are as follows:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Accrued liability for tobacco and health and certain other litigation items at beginning of period$9 $14 $— $22 
Pre-tax charges for:
Tobacco and health and certain other litigation (1)
142 73 99 34 
Related interest costs
6 3 6 — 
Payments (1)
(60)(81)(8)(47)
Accrued liability for tobacco and health and certain other litigation items at end of period$97 $9 $97 $9 
(1) Includes amounts related to certain other litigation and pre-trial resolution of certain tobacco and health cases.
The accrued liability for tobacco and health and certain other litigation items, including related interest costs, was included in accrued liabilities on Altria’s condensed consolidated balance sheets. Pre-tax charges for tobacco and health and certain other litigation were included in marketing, administration and research costs on Altria’s condensed consolidated statements of earnings (losses). Pre-tax charges for related interest costs were included in interest and other debt expense, net on Altria’s condensed consolidated statements of earnings (losses).
Security for Judgments: To obtain stays of judgments pending appeal, PM USA has posted various forms of security. As of September 30, 2021, PM USA has posted appeal bonds totaling approximately $45 million, which have been collateralized with restricted cash that are included in assets on the condensed consolidated balance sheets.
Overview of Altria and/or PM USA Tobacco-Related Litigation
Types and Number of U.S. Cases: Claims related to tobacco products generally fall within the following categories: (i) smoking and health cases alleging personal injury brought on behalf of individual plaintiffs; (ii) health care cost recovery cases brought by governmental (both domestic and foreign) plaintiffs seeking reimbursement for health care expenditures allegedly caused by cigarette smoking and/or disgorgement of profits; (iii) e-vapor cases alleging violation of RICO, fraud, failure to warn, design defect, negligence, antitrust and unfair trade practices; and (iv) other tobacco-related litigation described below. Plaintiffs’ theories of recovery and the defenses raised in tobacco-related litigation are discussed below.
29
The table below lists the number of certain tobacco-related cases pending in the U.S. against PM USA and/or Altria as of October 25, 2021, October 27, 2020 and October 28, 2019:
October 25, 2021October 27, 2020October 28, 2019
Individual Smoking and Health Cases (1)
17914295
Health Care Cost Recovery Actions (2)
111
E-vapor Cases (3)
2,9511,145—
Other Tobacco-Related Cases (4)
344
(1) Includes 18 cases filed in Illinois, 17 cases filed in New Mexico, 40 cases filed in Massachusetts and 70 non-Engle cases filed in Florida. Does not include individual smoking and health cases brought by or on behalf of plaintiffs in Florida state and federal courts following the decertification of the Engle case (these Engle progeny cases are discussed below in Smoking and Health Litigation - Engle Class Action). Also does not include 1,471 cases brought by flight attendants seeking compensatory damages for personal injuries allegedly caused by exposure to environmental tobacco smoke (“ETS”). The flight attendants allege that they are members of an ETS smoking and health class action in Florida, which was settled in 1997 (Broin). The terms of the court-approved settlement in that case allowed class members to file individual lawsuits seeking compensatory damages, but prohibited them from seeking punitive damages. Class members were prohibited from filing individual lawsuits after 2000 under the court-approved settlement.
(2) See Health Care Cost Recovery Litigation - Federal Government’s Lawsuit below.
(3) Includes 53 class action lawsuits, 2,548 individual lawsuits and 350 “third party” lawsuits relating to JUUL e-vapor products, which include school districts, state and local government, tribal and healthcare organization lawsuits. JUUL is an additional named defendant in each of these lawsuits. The 53 class action lawsuits include 28 cases in the Northern District of California (“Multidistrict Litigation” or “MDL”) involving plaintiffs whose claims were previously included in other class action complaints but were refiled as separate stand-alone class actions for procedural and other reasons.
(4) Includes one inactive smoking and health case alleging personal injury and purporting to be brought on behalf of a class of individual plaintiffs and two inactive class action lawsuits alleging that use of the terms “Lights” and “Ultra Lights” constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment, breach of warranty or violations of RICO.
International Tobacco-Related Cases: As of October 25, 2021, (i) Altria is named as a defendant in three e-vapor class action lawsuits in Canada; (ii) PM USA is a named defendant in 10 health care cost recovery actions in Canada, eight of which also name Altria as a defendant; and (iii) PM USA and Altria are named as defendants in seven smoking and health class actions filed in various Canadian provinces. See Guarantees and Other Similar Matters below for a discussion of the Distribution Agreement between Altria and Philip Morris International Inc. (“PMI”) that provides for indemnities for certain liabilities concerning tobacco products.
Tobacco-Related Cases Set for Trial: As of October 25, 2021, no Engle progeny or individual smoking and health cases against PM USA are set for trial through December 31, 2021. Trial dates are subject to change and many of the trials were postponed due to the COVID-19 pandemic; however, the courts are reopening and additional trials may be scheduled for the remainder of 2021.
Trial Results: Since January 1999, excluding the Engle progeny cases (separately discussed below), verdicts have been returned in 69 tobacco-related cases in which PM USA was a defendant. Verdicts in favor of PM USA and other defendants were returned in 44 of the 69 cases. These 44 cases were tried in Alaska (1), California (7), Connecticut (1), Florida (10), Louisiana (1), Massachusetts (4), Mississippi (1), Missouri (4), New Hampshire (1), New Jersey (1), New York (5), Ohio (2), Pennsylvania (1), Rhode Island (1), Tennessee (2) and West Virginia (2).
Of the 25 non-Engle progeny cases in which verdicts were returned in favor of plaintiffs, 20 have reached final resolution, and two cases (Gentile and Principe) that were initially returned in favor of plaintiffs were reversed post-trial and remain pending.
See Smoking and Health Litigation - Engle Progeny Trial Results below for a discussion of verdicts in state and federal Engle progeny cases involving PM USA as of October 25, 2021.
Smoking and Health Litigation
Overview: Plaintiffs’ allegations of liability in smoking and health cases are based on various theories of recovery, including negligence, gross negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, nuisance, breach of express and implied warranties, breach of special duty, conspiracy, concert of action, violations of unfair trade practice laws and consumer protection statutes, and claims under the federal and state anti-racketeering statutes. Plaintiffs in the smoking and health cases seek various forms of relief, including compensatory and punitive damages, treble/multiple damages and other statutory damages and penalties, creation of medical monitoring and smoking cessation funds, disgorgement of profits, and injunctive and equitable relief. Defenses raised in these cases include lack of proximate cause, assumption of the risk, comparative fault and/or contributory negligence, statutes of limitations and preemption by the Federal Cigarette Labeling and Advertising Act.
30
Non-Engle Progeny Litigation: Summarized below are the non-Engle progeny smoking and health cases pending during 2021 in which a verdict was returned in favor of plaintiff and against PM USA. Charts listing certain verdicts for plaintiffs in the Engle progeny cases can be found in Smoking and Health Litigation - Engle Progeny Trial Results below.
Principe: In February 2020, a jury in a Florida state court returned a verdict in favor of plaintiff and against PM USA, awarding approximately $11 million in compensatory damages. There was no claim for punitive damages. PM USA appealed the trial court verdict to the Third District Court of Appeal and, in September 2021, the appellate court reversed the trial court’s decision and found in favor of PM USA.
Greene: In September 2019, a jury in a Massachusetts state court returned a verdict in favor of plaintiffs and against PM USA, awarding approximately $10 million in compensatory damages. In May 2020, the court ruled on plaintiffs’ remaining claim and trebled the compensatory damages award to approximately $30 million. In February 2021, the trial court awarded plaintiffs attorneys’ fees and costs in the amount of approximately $2.3 million. Also in February 2021, PM USA served its post-trial motions to reverse the judgment or for a new trial. The trial court denied the post-trial motions in June 2021. In July 2021, PM USA appealed the judgment to the Appeals Court of Massachusetts.
Laramie: In August 2019, a jury in a Massachusetts state court returned a verdict in favor of plaintiff and against PM USA, awarding $11 million in compensatory damages and $10 million in punitive damages. PM USA appealed and, in February 2021, the Massachusetts Supreme Judicial Court asserted jurisdiction over the appeal. In September 2021, the Massachusetts Supreme Judicial Court affirmed the trial court award of $21 million in compensatory and punitive damages. PM USA recorded a pre-tax provision of approximately $27.1 million for the judgment, including interest, in the third quarter of 2021.
Gentile: In October 2017, a jury in a Florida state court returned a verdict in favor of plaintiff and against PM USA, awarding approximately $7.1 million in compensatory damages and allocating 75% of the fault to PM USA. PM USA appealed. In September 2019, the Florida Fourth District Court of Appeal reversed the judgment entered by the trial court, granted PM USA judgment on certain claims and remanded for a new trial on the remaining claims. Plaintiff petitioned the Florida Supreme Court for further review, which the court denied in January 2021.
Federal Government’s Lawsuit: See Health Care Cost Recovery Litigation - Federal Government’s Lawsuit below for a discussion of the verdict and post-trial developments in the United States of America health care cost recovery case.
Engle Class Action: In July 2000, in the second phase of the Engle smoking and health class action in Florida, a jury returned a verdict assessing punitive damages totaling approximately $145 billion against various defendants, including $74 billion against PM USA. Following entry of judgment, PM USA appealed. In May 2003, the Florida Third District Court of Appeal reversed the judgment entered by the trial court and instructed the trial court to order the decertification of the class. Plaintiffs petitioned the Florida Supreme Court for further review.
In July 2006, the Florida Supreme Court ordered that the punitive damages award be vacated, that the class approved by the trial court be decertified and that members of the decertified class could file individual actions against defendants within one year of issuance of the mandate. The court further declared the following Phase I findings are entitled to res judicata effect in such individual actions brought within one year of the issuance of the mandate: (i) that smoking causes various diseases; (ii) that nicotine in cigarettes is addictive; (iii) that defendants’ cigarettes were defective and unreasonably dangerous; (iv) that defendants concealed or omitted material information not otherwise known or available knowing that the material was false or misleading or failed to disclose a material fact concerning the health effects or addictive nature of smoking; (v) that defendants agreed to misrepresent information regarding the health effects or addictive nature of cigarettes with the intention of causing the public to rely on this information to their detriment; (vi) that defendants agreed to conceal or omit information regarding the health effects of cigarettes or their addictive nature with the intention that smokers would rely on the information to their detriment; (vii) that all defendants sold or supplied cigarettes that were defective; and (viii) that defendants were negligent.
In August 2006, PM USA and plaintiffs sought rehearing from the Florida Supreme Court on parts of its July 2006 opinion. In December 2006, the Florida Supreme Court refused to revise its July 2006 ruling, except that it revised the set of Phase I findings entitled to res judicata effect by excluding finding (v) listed above (relating to agreement to misrepresent information), and added the finding that defendants sold or supplied cigarettes that, at the time of sale or supply, did not conform to the representations of fact made by defendants. In February 2008, the trial court decertified the class.
Pending Engle Progeny Cases: The deadline for filing Engle progeny cases expired in January 2008, at which point a total of approximately 9,300 federal and state claims were pending. As of October 25, 2021, approximately 1,026 state court cases were pending against PM USA or Altria asserting individual claims by or on behalf of approximately 1,285 state court plaintiffs.  Because of a number of factors, including docketing delays, duplicated filings and overlapping dismissal orders, these numbers are estimates. While the Federal Engle Agreement (discussed below) resolved nearly all Engle progeny cases pending in federal court, as of October 25, 2021, two cases were pending against PM USA in federal court representing the cases excluded from that agreement.
31
Engle Progeny Trial Results: As of October 25, 2021, 137 federal and state Engle progeny cases involving PM USA have resulted in verdicts since the Florida Supreme Court Engle decision. Seventy-six verdicts were returned in favor of plaintiffs and seven verdicts (Skolnick, Calloway, Oshinsky-Blacker, McCoy, Mahfuz, Neff and Frogel) that were initially returned in favor of plaintiffs were reversed post-trial or on appeal and remain pending.
Fifty-four verdicts were returned in favor of PM USA, of which 44 were state cases. In addition, there have been a number of mistrials, only some of which have resulted in new trials as of October 25, 2021. The jury in one case, Garcia, awarded plaintiff compensatory damages and found plaintiff was entitled to punitive damages; however, the court declared a mistrial in the second phase of the trial regarding punitive damages because the jury was unable to determine the amount of the punitive damages. Four verdicts (Pearson, D. Cohen, Collar and Chacon) that were returned in favor of PM USA were subsequently reversed for new trials. Juries in two cases (Reider and Banks) returned zero damages verdicts in favor of PM USA. Juries in two other cases (Weingart and Hancock) returned verdicts against PM USA awarding no damages, but the trial court in each case decided to award plaintiffs damages. One case, Pollari, resulted in a verdict in favor of PM USA following a retrial of an initial verdict returned in favor of plaintiff. Plaintiff and defendants appealed the verdict and the appellate court affirmed the judgement in favor of the defendants. Three cases, Gloger, Rintoul (Caprio) and Duignan, resulted in verdicts in favor of plaintiffs following retrial of initial verdicts returned in favor of plaintiffs. Post-trial appeals are pending in those three cases. Two cases, Freeman and Harris, resulted in an appellate reversal of a jury verdict in favor of plaintiff, and a judgment in favor of PM USA.
The charts below list the verdicts and post-trial developments in certain Engle progeny cases in which verdicts were returned in favor of plaintiffs. The first chart lists cases that are pending as of October 25, 2021 but where PM USA has determined an unfavorable outcome is not probable and the amount of loss cannot be reasonably estimated. The second chart lists cases that have concluded within the previous 12 months. Unless otherwise noted for a particular case, the jury’s award for compensatory damages will not be reduced by any finding of plaintiff’s comparative fault. Further, the damages noted reflect adjustments based on post-trial or appellate rulings. As of October 25, 2021, there are no Engle progeny cases where PM USA has recorded a provision in its condensed consolidated financial statements because PM USA has not determined for any currently pending case that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated.
References below to “R.J. Reynolds,” “Lorillard” and “Liggett Group” are to R.J. Reynolds Tobacco Company, Lorillard Tobacco Company and Liggett Group, LLC, respectively.
Currently Pending Engle Cases with Verdicts Against PM USA
(rounded to nearest $ million)
PlaintiffVerdict DateDefendant(s)Court
Compensatory Damages (1)
Punitive Damages
(PM USA)		Appeal Status
LippSeptember 2021PM USAMiami-Dade
$15 million
$28 million
Defendant’s post-trial motions denied. Defendant plans to appeal.
Garcia
May 2021
PM USAMiami-Dade
$3 million
MistrialAppeal by defendant to Third District Court of Appeal pending.
Duignan
February 2020 (2)
PM USA and R.J. ReynoldsPinellas
$3 million
$12 million
Appeal by defendants to Second District Court of Appeal pending.
CuddiheeJanuary 2020PM USADuval
$3 million
$0
Appeal by defendant to First District Court of Appeal pending.
Rintoul (Caprio)
November 2019 (2)
PM USA and R.J. ReynoldsBroward
$9 million
$74 million
Appeal by plaintiff and defendants to Fourth District Court of Appeal pending.
Gloger
November 2019 (2)
PM USA and R.J. ReynoldsMiami-Dade
$15 million
$11 million
Appeal by defendants to Third District Court of Appeal pending.
McCallMarch 2019PM USABroward
<$1 million (<$1 million PM USA)
$0
New trial ordered on punitive damages.
NeffMarch 2019PM USA and R.J. ReynoldsBroward
$4 million
$2 million
Fourth District Court of Appeal reversed the judgment against defendants and remanded for a new trial. Plaintiff's motion for rehearing was denied.
32
PlaintiffVerdict DateDefendant(s)Court
Compensatory Damages (1)
Punitive Damages
(PM USA)		Appeal Status
MahfuzFebruary 2019PM USA and R.J. ReynoldsBroward
$12 million
$10 million
Fourth District Court of Appeal reversed the judgment against defendants and remanded for a new trial. Plaintiff's motion for rehearing was denied.
HollimanFebruary 2019PM USAMiami-Dade
$3 million
$0
Defendant’s appeal to Third District Court of Appeal pending.
ChadwellSeptember 2018PM USAMiami-Dade
$2 million
$0
Third District Court of Appeal affirmed the compensatory damages award. PM USA petitioned Florida Supreme Court for review. Case stayed pending Florida Supreme Court decision in Prentice.(3)
KaplanJuly 2018PM USA and R.J. ReynoldsBroward
$2 million
$2 million
Fourth District Court of Appeal affirmed the verdict and reaffirmed the verdict on rehearing. Defendants sought review of the decision before the Florida Supreme Court and the court stayed the case pending its decision in Sheffield.(3)
R. DouglasNovember 2017PM USADuval
<$1 million
$0
Awaiting entry of final judgment by the trial court.
SommersApril 2017PM USAMiami-Dade
$1 million
$0
Third District Court of Appeal affirmed compensatory damages award and granted new trial on punitive damages. Florida Supreme Court denied PM USA’s petition for review of the Third District Court of Appeal’s decision. PM USA paid approximately $1 million for the compensatory damages award and awaits the new trial on punitive damages.(4) The trial court stayed the new trial on punitive damages pending Florida Supreme Court’s decision in Sheffield.(3)
Cooper (Blackwood)September 2015PM USA and R.J. ReynoldsBroward
$5 million
(<$1 million PM USA)
$0
Fourth District Court of Appeal affirmed judgment and granted a new trial on punitive damages.
D. BrownJanuary 2015PM USAFederal Court - Middle District of Florida
$8 million
$9 million
Appeal by defendant to U.S. Court of Appeals for the Eleventh Circuit stayed pending Florida Supreme Court decision in Prentice.(3)
(1) PM USA’s portion of the compensatory damages award is noted parenthetically where the court has ruled that comparative fault applies.
(2) Plaintiff’s verdict following a retrial of an initial verdict in favor of plaintiff.
(3) PM USA is not a defendant in Prentice or Sheffield. Prentice and Sheffield are discussed below in Engle Progeny Appellate Issues.
(4) Plaintiff was granted an award of approximately $3 million in fees, costs and interest that PM USA appealed. The Florida Third District Court of Appeals affirmed the award and PM USA paid the award amount in March 2021.
33
Engle Cases Concluded Within Past 12 Months (1)
(rounded to nearest $ million)
PlaintiffVerdict DateDefendant(s)CourtAccrual DatePayment Amount
(if any)		Payment Date
Berger (Cote)September 2014PM USAFederal Court - Middle District of FloridaFourth quarter of 2018 and first quarter of 2021
$29 million
February 2021
SantoroMarch 2017PM USA, R.J. Reynolds and Liggett GroupBrowardSecond quarter of 2020 and first quarter of 2021
$1 million
January 2021
(1) In six cases in which PM USA paid the judgments more than a year ago, Naugle, Gore, M. Brown, Jordan, Theis and Landi, plaintiffs were awarded approximately $8 million, $2 million, $8 million, $4 million, $1 million and $3 million in fees and costs, respectively. PM USA has appealed in all of these cases, except Theis and Landi. In M. Brown, in March 2021 the Florida First District Court of Appeals affirmed the fee award and reversed the pre-judgment interest award and, in April 2021, PM USA paid $8.2 million in satisfaction of the fee award and post-judgment interest. In Theis, PM USA paid $1 million in satisfaction of fees and costs in May 2021 and, in Landi, PM USA paid approximately $1.5 million in satisfaction of fees, costs and interest in July 2021 (R.J. Reynolds paid approximately $1.5 million of the approximately $3 million award).

Engle Progeny Appellate Issues: The Florida appellate courts are considering the following appeals which may have wide application to other Engle progeny cases:
In Mary Sheffield v. R.J. Reynolds Tobacco Company, an Engle progeny case against R.J. Reynolds only, the Florida Supreme Court has taken jurisdiction to resolve the conflict among Florida’s District Courts of Appeal over whether the 1999 amendments to Florida’s punitive damages statute (including its caps and bar on multiple punitive damages awards for the same course of conduct) apply in wrongful death cases where the decedent was injured prior to the October 1, 1999 effective date of the amendments but died from his or her injuries after such effective date. Oral argument was held before the Florida Supreme Court in April 2021; a decision has not yet been issued.
In Linda Prentice v. R.J. Reynolds Tobacco Company, an Engle progeny case against R.J. Reynolds only, the Florida First District Court of Appeal in January 2020 reversed a judgment in favor of the plaintiff and remanded for a new trial. The court held that the trial court had erred by failing to instruct the jury that in order to prevail on her claim for conspiracy to commit fraudulent concealment, the plaintiff was required to prove that her decedent relied to his detriment on a statement that concealed or omitted material information about the health risks of smoking. That holding conflicts with decisions from the Second, Third, and Fourth District Courts of Appeal, which have each held that Engle plaintiffs do not need to prove reliance on a statement, and instead can prevail by proving reliance on the Engle defendants’ concealment of information. In August 2020, the Florida Supreme Court accepted jurisdiction in the case. As an alternative ground to approve the First District Court of Appeal’s decision in its favor in Prentice, R.J. Reynolds has asked the Florida Supreme Court to reconsider its prior decisions giving the Engle Phase I findings preclusive effect in Engle progeny cases, as described more fully in the section Engle Class Action above. Oral argument was held before the Florida Supreme Court in June 2021; a decision has not yet been issued.
Florida Bond Statute: In June 2009, Florida amended its existing bond cap statute by adding a $200 million bond cap that applies to all state Engle progeny lawsuits in the aggregate and establishes individual bond caps for individual Engle progeny cases in amounts that vary depending on the number of judgments in effect at a given time. Plaintiffs have been unsuccessful in various challenges to the bond cap statute in Florida state court.
No federal court has yet addressed the constitutionality of the bond cap statute or the applicability of the bond cap to Engle progeny cases tried in federal court.
From time to time, legislation has been presented to the Florida legislature that would repeal the bond cap statute; however to date, no legislation repealing the statute has passed.
Other Smoking and Health Class Actions: Since the dismissal in May 1996 of a purported nationwide class action brought on behalf of allegedly addicted smokers, plaintiffs have filed numerous putative smoking and health class action suits in various state and federal courts. In general, these cases purport to be brought on behalf of residents of a particular state or states (although a few cases purport to be nationwide in scope) and raise addiction claims and, in many cases, claims of physical injury as well.
Class certification has been denied or reversed by courts in 61 smoking and health class actions involving PM USA in Arkansas (1), California (1), Delaware (1), the District of Columbia (2), Florida (2), Illinois (3), Iowa (1), Kansas (1), Louisiana (1), Maryland (1), Michigan (1), Minnesota (1), Nevada (29), New Jersey (6), New York (2), Ohio (1), Oklahoma (1), Oregon (1), Pennsylvania (1), Puerto Rico (1), South Carolina (1), Texas (1) and Wisconsin (1). See Certain Other Tobacco-Related
34
Litigation below for a discussion of “Lights” and “Ultra Lights” class action cases and medical monitoring class action cases pending against PM USA.
As of October 25, 2021, PM USA and Altria are named as defendants, along with other cigarette manufacturers, in seven class actions filed in the Canadian provinces of Alberta, Manitoba, Nova Scotia, Saskatchewan, British Columbia and Ontario. In Saskatchewan, British Columbia (two separate cases) and Ontario, plaintiffs seek class certification on behalf of individuals who suffer or have suffered from various diseases, including chronic obstructive pulmonary disease, emphysema, heart disease or cancer, after smoking defendants’ cigarettes. In the actions filed in Alberta, Manitoba and Nova Scotia, plaintiffs seek certification of classes of all individuals who smoked defendants’ cigarettes. In March 2019, all of these class actions were stayed as a result of three Canadian tobacco manufacturers (none of which is related to Altria or its subsidiaries) seeking protection under Canada’s Companies’ Creditors Arrangement Act (which is similar to Chapter 11 bankruptcy in the U.S.). The companies entered into these proceedings following a Canadian appellate court upholding two smoking and health class action verdicts against those companies totaling approximately CAD $13 billion. See Guarantees and Other Similar Matters below for a discussion of the Distribution Agreement between Altria and PMI, which provides for indemnities for certain liabilities concerning tobacco products.
Health Care Cost Recovery Litigation
Overview: In the health care cost recovery litigation, governmental entities seek reimbursement of health care cost expenditures allegedly caused by tobacco products and, in some cases, of future expenditures and damages. Relief sought by some but not all plaintiffs includes punitive damages, multiple damages and other statutory damages and penalties, injunctions prohibiting alleged marketing and sales to minors, disclosure of research, disgorgement of profits, funding of anti-smoking programs, additional disclosure of nicotine yields, and payment of attorney and expert witness fees.
Although there have been some decisions to the contrary, most judicial decisions in the U.S. have dismissed all or most health care cost recovery claims against cigarette manufacturers. Nine federal circuit courts of appeals and eight state appellate courts, relying primarily on grounds that plaintiffs’ claims were too remote, have ordered or affirmed dismissals of health care cost recovery actions. The United States Supreme Court has refused to consider plaintiffs’ appeals from the cases decided by five federal circuit courts of appeal.
In addition to the cases brought in the U.S., health care cost recovery actions have also been brought against tobacco industry participants, including PM USA and Altria, in Canada (10 cases), and other entities have stated that they are considering filing such actions.
Since the beginning of 2008, the Canadian Provinces of British Columbia, New Brunswick, Ontario, Newfoundland and Labrador, Quebec, Alberta, Manitoba, Saskatchewan, Prince Edward Island and Nova Scotia have brought health care reimbursement claims against cigarette manufacturers. PM USA is named as a defendant in the British Columbia and Quebec cases, while both Altria and PM USA are named as defendants in the New Brunswick, Ontario, Newfoundland and Labrador, Alberta, Manitoba, Saskatchewan, Prince Edward Island and Nova Scotia cases. The Nunavut Territory and Northwest Territory have passed legislation permitting similar claims, but lawsuits based on this legislation have not been filed. All of these cases have been stayed pending resolution of proceedings in Canada involving three tobacco manufacturers (none of which are affiliated with Altria or its subsidiaries) under the Companies’ Creditors Arrangement Act discussed above. See Smoking and Health Litigation - Other Smoking and Health Class Actions above for a discussion of these proceedings. See Guarantees and Other Similar Matters below for a discussion of the Distribution Agreement between Altria and PMI that provides for indemnities for certain liabilities concerning tobacco products.
Settlements of Health Care Cost Recovery Litigation: In November 1998, PM USA and certain other tobacco product manufacturers entered into the 1998 Master Settlement Agreement (the “MSA”) with 46 states, the District of Columbia and certain U.S. territories to settle asserted and unasserted health care cost recovery and other claims. PM USA and certain other tobacco product manufacturers had previously entered into agreements to settle similar claims brought by Mississippi, Florida, Texas and Minnesota (together with the MSA, the “State Settlement Agreements”). The State Settlement Agreements require that the original participating manufacturers or “OPMs” (now PM USA, R.J. Reynolds and, with respect to certain brands, ITG Brands, LLC (“ITG”)) make annual payments of approximately $9.4 billion, subject to adjustments for several factors, including inflation, market share and industry volume. In addition, the OPMs are required to pay settling plaintiffs’ attorneys’ fees, subject to an annual cap of $500 million. For the three months ended September 30, 2021 and 2020, the aggregate amount recorded in cost of sales with respect to the State Settlement Agreements was approximately $1.1 billion and $1.2 billion, respectively. For the nine months ended September 30, 2021 and 2020, the aggregate amount recorded in cost of sales with respect to the State Settlement Agreements was approximately $3.2 billion and $3.3 billion, respectively. These amounts include PM USA’s estimate of amounts related to NPM Adjustments discussed below.
NPM Adjustment Disputes: The “NPM Adjustment” is a reduction in MSA payments made by the OPMs and those manufacturers that are subsequent signatories to the MSA (collectively, the “participating manufacturers” or “PMs”) that
35
applies if the PMs collectively lose at least a specified level of market share to non-participating manufacturers since 1997, subject to certain conditions and defenses.
The independent auditor (“IA”) appointed under the MSA has calculated that PM USA’s share of the maximum potential NPM Adjustments for 2004-2020 is (exclusive of interest or earnings): $388 million for 2004; $181 million for 2005; $154 million for 2006; $185 million for 2007; $250 million for 2008; $211 million for 2009; $218 million for 2010; $166 million for 2011; $214 million for 2012; $224 million for 2013; $258 million for 2014; $313 million for 2015; $292 million for 2016; $302 million for 2017; $325 million for 2018; $444 million for 2019; and $572 million for 2020. These maximum amounts will be reduced, likely substantially, to reflect the NPM Adjustment settlements discussed below, and potentially for current and future calculation disputes and other developments. In addition, PM USA’s recovery of these amounts, even as reduced, is dependent upon subsequent determinations regarding state-specific defenses and disputes with other PMs.
Settlements of NPM Adjustment Disputes.
▪Multi-State Settlement. By the end of 2018, PM USA entered into a multi-state settlement of NPM Adjustment disputes with a total of 36 MSA states and territories in which PM USA settled the NPM Adjustment disputes through 2022 with 35 of the 36 states, and through 2024 with one state. Pursuant to the multi-state settlement, PM USA received $1.03 billion and expects to receive approximately $320 million in credits to offset PM USA’s MSA payments through 2029.
▪New York Settlement. In 2015, PM USA entered into a separate NPM Adjustment settlement with New York in which PM USA settled the NPM Adjustment disputes with New York in perpetuity. PM USA received $373 million pursuant to the New York settlement and expects to receive annual credits applied against the MSA payments due to New York going forward.
▪Montana Settlement. In 2020, PM USA entered into a separate NPM Adjustment settlement with Montana in which PM USA settled the NPM Adjustment disputes with Montana through 2030. This settlement resulted in a payment by PM USA of $4 million.
Continuing NPM Adjustment Disputes with States That Have Not Settled.
▪2004 NPM Adjustment. The PMs and the 10 states that have not settled the NPM Adjustment disputes are currently arbitrating NPM Adjustment disputes for 2004 in a multi-state arbitration. Hearings for 9 of the 10 states have concluded. In September 2021, the arbitration panels issued decisions finding that two states, Missouri and Washington, were not diligent in their enforcement of their escrow statutes in 2004 and, therefore, are subject to the NPM adjustment for 2004. The arbitration panels further found that the remaining seven states were diligent in their enforcement and, therefore, are not subject to the NPM adjustment for 2004. The hearing for one remaining state is currently scheduled for February 2022. Several issues remain to be resolved by the arbitration panels that will affect the final amount of the 2004 NPM adjustment PM USA and other PMs will receive. PM USA recorded $21 million as a reduction to cost of sales in the third quarter of 2021 for its estimate of the minimum amount of the 2004 NPM adjustment it will receive. PM USA estimates it is entitled to interest of approximately $23 million in connection with the 2004 NPM adjustment, which it recorded as interest income in the third quarter of 2021.
▪2005-2007 NPM Adjustments. The PMs and the 10 states that have not settled the NPM Adjustment disputes are currently arbitrating NPM Adjustment disputes before a single arbitration panel. The arbitration encompasses three years, 2005-2007, for nine of the 10 states, and one year, 2005, for one state. As of October 25, 2021, no decisions have resulted from the arbitration.
▪Subsequent Years. No assurance can be given as to when proceedings for 2008 and subsequent years will be scheduled or the precise form those proceedings will take.
Other Disputes Under the State Settlement Agreements: The payment obligations of the tobacco product manufacturers that are parties to the State Settlement Agreements, as well as the allocations of any NPM Adjustments and related settlements, have been and may continue to be affected by R.J. Reynolds’s acquisition of Lorillard in 2015 and its related sale of certain cigarette brands to ITG (the “ITG transferred brands”). PM USA filed motions to enforce the state settlement agreements in Florida, Minnesota, Texas and Mississippi in connection with various positions that R.J. Reynolds and ITG took with regard to the ITG transferred brands. After various court decisions in each of those states that were favorable to PM USA, those motions to enforce have now been resolved either through settlement or exhaustion of appeals. Despite these resolutions, PM USA continues to dispute the accuracy of certain submissions made by R.J. Reynolds and ITG concerning the calculation of certain payments relating to the ITG transferred brands and may pursue such claims.
In December 2019, the State of Mississippi filed a motion in Mississippi state court seeking to enforce the Mississippi State Settlement Agreement against PM USA, R.J. Reynolds and ITG concerning the tax rates used in the annual calculation of the net operating profit adjustment payments starting in 2018. The Mississippi state court held a hearing in October 2021 and has not yet issued a decision.
36
In January 2021, PM USA and other PMs reached an agreement with several MSA states to waive the PMs’ claim under the most favored nation provision of the MSA in connection with a settlement between those MSA states and a non-participating manufacturer, S&M Brands, Inc. (“S&M Brands”), under which the states released certain claims against S&M Brands in exchange for receiving a portion of the funds S&M Brands deposited into escrow accounts in those states pursuant to the states’ escrow statutes. In consideration for waiving its most favored nation claim, PM USA received approximately $32 million from the escrow funds paid to those MSA states under their settlement with S&M Brands. These funds were received in January 2021 and were recorded in Altria’s condensed consolidated statement of earnings for the first quarter of 2021 as a reduction to cost of sales.
Federal Government’s Lawsuit: In 1999, the United States government filed a lawsuit in the U.S. District Court for the District of Columbia against various cigarette manufacturers, including PM USA, and others, including Altria, asserting claims under three federal statutes. The case ultimately proceeded only under the civil provisions of RICO. In August 2006, the district court held that certain defendants, including Altria and PM USA, violated RICO and engaged in seven of the eight “sub-schemes” to defraud that the government had alleged. Specifically, the court found that:
▪defendants falsely denied, distorted and minimized the significant adverse health consequences of smoking;
▪defendants hid from the public that cigarette smoking and nicotine are addictive;
▪defendants falsely denied that they control the level of nicotine delivered to create and sustain addiction;
▪defendants falsely marketed and promoted “low tar/light” cigarettes as less harmful than full-flavor cigarettes;
▪defendants falsely denied that they intentionally marketed to youth;
▪defendants publicly and falsely denied that ETS is hazardous to non-smokers; and
▪defendants suppressed scientific research.
The court did not impose monetary penalties on defendants, but ordered the following relief: (i) an injunction against “committing any act of racketeering” relating to the manufacturing, marketing, promotion, health consequences or sale of cigarettes in the United States; (ii) an injunction against participating directly or indirectly in the management or control of the Council for Tobacco Research, the Tobacco Institute, or the Center for Indoor Air Research, or any successor or affiliated entities of each; (iii) an injunction against “making, or causing to be made in any way, any material false, misleading, or deceptive statement or representation or engaging in any public relations or marketing endeavor that is disseminated to the United States public and that misrepresents or suppresses information concerning cigarettes;” (iv) an injunction against conveying any express or implied health message or health descriptors on cigarette packaging or in cigarette advertising or promotional material, including “lights,” “ultra lights” and “low tar,” which the court found could cause consumers to believe one cigarette brand is less hazardous than another brand; (v) the issuance of “corrective statements” in various media regarding the adverse health effects of smoking, the addictiveness of smoking and nicotine, the lack of any significant health benefit from smoking “low tar” or “light” cigarettes, defendants’ manipulation of cigarette design to ensure optimum nicotine delivery and the adverse health effects of exposure to ETS; (vi) the disclosure on defendants’ public document websites and in the Minnesota document repository of all documents produced to the government in the lawsuit or produced in any future court or administrative action concerning smoking and health until the third quarter of 2021, with certain additional requirements as to documents withheld from production under a claim of privilege or confidentiality; (vii) the disclosure of disaggregated marketing data to the government in the same form and on the same schedule as defendants now follow in disclosing such data to the FTC for a period of 10 years; (viii) certain restrictions on the sale or transfer by defendants of any cigarette brands, brand names, formulas or cigarette businesses within the U.S.; and (ix) payment of the government’s costs in bringing the action.
Following several years of appeals relating to the content of the corrective statements remedy described above, in October 2017, the district court approved the parties’ proposed consent order implementing corrective statements in newspapers and on television. The corrective statements began appearing in newspapers and on television in the fourth quarter of 2017. In April 2018, the parties reached agreement on the implementation details of the corrective statements on websites and onserts. The corrective statements began appearing on websites in the second quarter of 2018 and the onserts began appearing in the fourth quarter of 2018.
In 2014 and 2019, Altria and PM USA recorded provisions totaling approximately $36 million for the estimated costs of implementing the corrective communications remedy.
The requirements related to corrective statements at point-of-sale remain outstanding. In May 2014, the district court ordered further briefing on the issue, which was completed in June 2014. In May 2018, the parties submitted a joint status report and additional briefing on point-of-sale signage to the district court. In May 2019, the district court ordered a hearing on the point-of-sale signage issue. The hearing is currently scheduled for June 2022.
In June 2020, the United States government filed a motion with the district court asking for clarification as to whether the court-ordered injunction that applies to cigarettes also applies to HeatSticks, a heated tobacco product used with the IQOS electronic device. In August 2020, Altria and PM USA filed an opposition to the government’s motion and, in the alternative, a motion to
37
modify the injunction to make clear it does not apply to HeatSticks. Regardless of the district court’s decisions on the pending motions, the government has indicated it will not oppose a modification to the injunction that permits PM USA to use the Modified Risk Tobacco Product claim authorized by the United States Food and Drug Administration for HeatSticks.
E-vapor Product Litigation
As of October 25, 2021, Altria and/or its subsidiaries, including PM USA, were named as defendants in 53 class action lawsuits relating to JUUL e-vapor products. JUUL is an additional named defendant in each of these lawsuits. The theories of recovery include violation of RICO, fraud, failure to warn, design defect, negligence and unfair trade practices. Plaintiffs seek various remedies, including compensatory and punitive damages and an injunction prohibiting product sales. The 53 class action lawsuits include 28 cases involving plaintiffs whose claims were previously included in other class action complaints but were refiled as separate stand-alone class actions for procedural and other reasons.
Altria and/or its subsidiaries, including PM USA, also have been named as defendants in other lawsuits involving JUUL e-vapor products, including 2,548 individual lawsuits, 350 “third party” lawsuits, which include school districts, state and local governments and tribal and healthcare organization lawsuits. JUUL is an additional named defendant in each of these lawsuits.
The majority of the individual and class action lawsuits mentioned above were filed in federal court. In October 2019, the United States Judicial Panel on Multidistrict Litigation ordered the coordination or consolidation of these lawsuits in the U.S. District Court for the Northern District of California for pretrial purposes.
Altria and its subsidiaries filed motions to dismiss certain claims in the class action and school district cases, including the federal RICO claim. In October 2020, the U.S. District Court for the Northern District of California granted the motion to dismiss the RICO class action claim without prejudice. Although it otherwise denied the motion, the court found that plaintiffs had not sufficiently alleged standing or causation with respect to their claim under California law. The court also granted the motion to dismiss the RICO claim in the cases filed by various school districts, but denied the motion in all other respects. The court gave plaintiffs the opportunity to amend their complaints to attempt to cure the deficiencies the court identified and plaintiffs filed their amended complaints in November 2020. In January 2021, Altria and its subsidiaries filed a renewed motion to dismiss the RICO claim, which the court denied in April 2021. In December 2020, the U.S. District Court for the Northern District of California and the parties selected 20 personal injury plaintiffs to be adjudicated as bellwether cases and in July 2021, the court set dates for the first four of such cases to commence in 2022.
An additional group of cases is pending in California state courts. In January 2020, the Judicial Council of California determined that this group of cases was appropriate for coordination and assigned the group to the Superior Court of California, Los Angeles County, for pretrial purposes.
JUUL also is named in a significant number of additional individual and class action lawsuits to which neither Altria nor any of its subsidiaries is currently named.
Three of the “third party” lawsuits noted above against Altria and/or its subsidiaries and JUUL, as an additional named defendant, were initiated, individually, by the attorneys general of Alaska, Hawaii and Minnesota alleging violations of state consumer protection and other similar laws. JUUL is also named in other attorneys general lawsuits to which neither Altria nor any of its subsidiaries is currently named. JUUL settled one such lawsuit by agreeing to (i) pay approximately $40 million and (ii) certain restrictions on its sales and marketing activities.
IQOS Litigation
In April 2020, RAI Strategic Holdings, Inc. and R.J. Reynolds Vapor Co., which are affiliates of R.J. Reynolds, filed a lawsuit against Altria, PM USA, Altria Client Services LLC, PMI and its affiliate, Philip Morris Products S.A., in the United States District Court for the Eastern District of Virginia. The lawsuit asserts claims of patent infringement based on the sale of the IQOS electronic device and HeatSticks in the United States. Plaintiffs seek various remedies, including preliminary and permanent injunctive relief, treble damages and attorneys’ fees. Altria and PMI have been dismissed from the lawsuit. In June 2020, the remaining defendants filed a motion to dismiss certain of plaintiffs’ claims and also filed counterclaims against the plaintiffs for infringement of various patents owned by the remaining defendants. The case was stayed in December 2020 due to the COVID-19 pandemic; however, the stay was lifted with respect to defendants’ counterclaims in February 2021 and a trial is currently scheduled for April 2022.
Also in April 2020, a related action was filed against the same defendants by the same plaintiffs, as well as R.J. Reynolds, with the United States International Trade Commission (“ITC”). There, the plaintiffs also allege patent infringement, but the remedies sought include a prohibition on the importation of the IQOS electronic device, HeatSticks and component parts into the United States and on the sale of any such products previously imported into the United States. No damages are recoverable in the proceedings before the ITC. In May 2021, an administrative law judge found that the IQOS electronic device and HeatSticks infringe plaintiffs’ patents and recommended to the ITC a ban on the importation of the IQOS electronic device, HeatSticks and the infringing components into the United States. In September 2021, the ITC affirmed the administrative law judge’s initial determination and issued a limited exclusion order barring the importation of the IQOS electronic device,
38
HeatSticks and the infringing components into the United States and a cease and desist order barring domestic sales, marketing and distribution of these imported products. The orders will become effective on November 29, 2021 unless rejected by the Biden Administration prior to that date. Defendants may appeal the orders to the United States Court of Appeals for the Federal Circuit; however, any ban on importation or on the sale, marketing and distribution of previously imported product is unlikely to be stayed pending the conclusion of the appeal. Due to this litigation, in October 2021, PM USA announced plans to begin removing the IQOS electronic device and HeatSticks from the marketplace as it awaits the outcome of administrative review.
An additional unrelated patent infringement case regarding the IQOS electronic device was filed in November 2020 in the United States District Court for the Northern District of Georgia against PM USA and Philip Morris Products S.A. seeking damages and equitable relief. In February 2021, defendants filed a motion to dismiss the lawsuit, which the court granted in July 2021. In August 2021, plaintiff filed a motion to amend the complaint.
Antitrust Litigation
In April 2020, the FTC issued an administrative complaint against Altria and JUUL alleging that Altria’s 35% investment in JUUL and the associated agreements constitute an unreasonable restraint of trade in violation of Section 1 of the Sherman Antitrust Act of 1890 (“Sherman Act”) and Section 5 of the Federal Trade Commission Act of 1914, and substantially lessened competition in violation of Section 7 of the Clayton Antitrust Act (“Clayton Act”). If the FTC’s challenge is successful, the FTC may order a broad range of remedies, including divestiture of Altria’s minority investment in JUUL, rescission of the transaction and all associated agreements, a requirement of FTC approval of future agreements related to the development, manufacture, distribution or sale of e-vapor products and prohibition against any officer or director of either Altria or JUUL serving on the other party’s board of directors or attending meetings of the other party’s board of directors. The administrative trial was held before an FTC administrative law judge in June 2021. The post-trial briefing was completed in October 2021. The administrative law judge’s decision is subject to review by the FTC on its own motion or at the request of any party. The FTC then issues its ruling, which may be appealed to any United States Court of Appeals.
Also as of October 25, 2021, 16 putative class action lawsuits have been filed against Altria and JUUL in the United States District Court for the Northern District of California. The lawsuits initially named, in addition to the two companies, certain senior executives and certain members of the board of directors of both companies as defendants; however, those individuals currently or formerly affiliated with Altria were later dismissed. In November 2020 these lawsuits were consolidated into three complaints (one on behalf of direct purchasers, one on behalf of indirect purchasers and one on behalf of indirect resellers). The consolidated lawsuits, as amended, cite the FTC administrative complaint and allege that Altria and JUUL violated Sections 1, 2 and/or 3 of the Sherman Act and Section 7 of the Clayton Act and various state antitrust, consumer protection and unjust enrichment laws by restraining trade and/or substantially lessening competition in the U.S. closed-system electronic cigarette market. Plaintiffs seek various remedies, including treble damages, attorneys’ fees, a declaration that the agreements between Altria and JUUL are invalid, divestiture of Altria’s minority investment in JUUL and rescission of the transaction. Altria filed a motion to dismiss these lawsuits in January 2021. In August 2021, the United States District Court for the Northern District of California denied Altria’s motion to dismiss except with respect to plaintiffs’ claims for injunctive and equitable relief. However, plaintiffs were granted the opportunity to replead such claims by the trial court, which plaintiffs did in September 2021.
In November 2020, Altria exercised its rights to convert its non-voting JUUL shares to voting shares. However, pending the outcome of the FTC administrative complaint, Altria currently does not intend to exercise its additional governance rights obtained upon the conversion, including the right to elect directors to JUUL’s board or to vote its JUUL shares other than as a passive investor. For further discussion of Altria’s rights in the event of share conversion, see Note 4. Investments in Equity Securities - Investment in JUUL.
Shareholder Class Action and Shareholder Derivative Lawsuits
Shareholder Class Action: In October and December 2019, two purported Altria shareholders filed putative class action lawsuits against Altria, Howard A. Willard III, Altria’s former Chairman and Chief Executive Officer, and William F. Gifford, Jr., Altria’s former Vice Chairman and Chief Financial Officer and current Chief Executive Officer, in the United States District Court for the Eastern District of New York. In December 2019, the court consolidated the two lawsuits into a single proceeding. The consolidated lawsuit was subsequently transferred to the United States District Court for the Eastern District of Virginia. The lawsuit asserts claims under Sections 10(b) and 20(a) and under Rule 10b-5 of the Exchange Act. In April 2020, JUUL, its founders and some of its current and former executives were added to the lawsuit. The claims allege false and misleading statements and omissions relating to Altria’s investment in JUUL. Plaintiffs seek various remedies, including damages and attorneys’ fees. In July 2020, the defendants filed motions to dismiss plaintiffs’ claims, which the district court denied in March 2021.
Federal Shareholder Derivative Lawsuits: In August 2020, two purported Altria shareholders filed separate derivative lawsuits in the United States District Court for the Northern District of California on behalf of themselves and Altria, against Mr. Willard, Mr. Gifford, JUUL and certain of its executives and officers. These derivative lawsuits relate to Altria’s
39
investment in JUUL, and assert claims of breach of fiduciary duty by the Altria defendants and aiding and abetting in that alleged breach of fiduciary duty by the remaining defendants. In March 2021, the United States District Court for the Northern District of California granted defendants’ motion to transfer both lawsuits to the United States District Court for the Eastern District of Virginia. Three additional federal derivative lawsuits were filed in October 2020, January 2021 and March 2021, respectively, in the United States District Court for the Eastern District of Virginia against Mr. Willard, Mr. Gifford, Mr. Crosthwaite, certain members of Altria’s Board of Directors, JUUL, its founders and some of its current and former executives. These suits assert various claims, including breach of fiduciary duty, unjust enrichment, waste of corporate assets and violations of certain federal securities laws. The remedies sought in these lawsuits include damages, disgorgement of profits, reformation of Altria’s corporate governance and internal procedures, and attorneys’ fees. In April 2021, the court consolidated the five cases pending in the Eastern District of Virginia into a single action.
State Shareholder Derivative Lawsuits: Six derivative lawsuits have been filed in Virginia state courts against Mr. Willard, Mr. Gifford, Mr. Crosthwaite (Altria’s former Chief Growth Officer and JUUL’s current Chief Executive Officer), certain members of Altria’s Board of Directors, JUUL, its founders and some of its current and former executives. The lawsuits were filed in September 2020, May 2021, June 2021, July 2021, August 2021 and August 2021, respectively. The lawsuits assert various claims, including breach of fiduciary duty, and seek remedies similar to those sought by plaintiffs in the cases pending in federal court in the Eastern District of Virginia. In July 2021 and September 2021, the court consolidated the first four of these state derivative cases into a single action.
Certain Other Tobacco-Related Litigation
“Lights/Ultra Lights” Cases and Other Smoking and Health Class Actions: Plaintiffs have sought certification of their cases as class actions, alleging among other things, that the uses of the terms “Lights” and/or “Ultra Lights” constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment or breach of warranty, and have sought injunctive and equitable relief, including restitution and, in certain cases, punitive damages. These class actions have been brought against PM USA and, in certain instances, Altria or its other subsidiaries, on behalf of individuals who purchased and consumed various brands of cigarettes. Defenses raised in these cases include lack of misrepresentation, lack of causation, injury and damages, the statute of limitations, non-liability under state statutory provisions exempting conduct that complies with federal regulatory directives, and the First Amendment. Twenty-one state courts in 23 “Lights” cases have refused to certify class actions, dismissed class action allegations, reversed prior class certification decisions or have entered judgment in favor of PM USA. As of October 25, 2021, two “Lights/Ultra Lights” class actions are pending in U.S. state court. Neither case is active.
As of October 25, 2021, one smoking and health case alleging personal injury or seeking court-supervised programs or ongoing medical monitoring and purporting to be brought on behalf of a class of individual plaintiffs, is pending in a U.S. state court. The case is currently inactive.
UST Litigation: UST and/or its tobacco subsidiaries have been named in a number of individual tobacco and health lawsuits over time. Plaintiffs’ allegations of liability in these cases have been based on various theories of recovery, such as negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, breach of implied warranty, addiction and breach of consumer protection statutes. Plaintiffs have typically sought various forms of relief, including compensatory and punitive damages, and certain equitable relief, including but not limited to disgorgement. Defenses raised in these cases include lack of causation, assumption of the risk, comparative fault and/or contributory negligence, and statutes of limitations. As of October 25, 2021, there is one case pending against USSTC.
Environmental Regulation
Altria and its subsidiaries (and former subsidiaries) are subject to various federal, state and local laws and regulations concerning the discharge of materials into the environment, or otherwise related to environmental protection, including, in the U.S.: the Clean Air Act, the Clean Water Act, the Resource Conservation and Recovery Act and the Comprehensive Environmental Response, Compensation and Liability Act (commonly known as “Superfund”), which can impose joint and several liability on each responsible party. Subsidiaries (and former subsidiaries) of Altria are involved in several matters subjecting them to potential costs of remediation and natural resource damages under Superfund or other laws and regulations. Altria’s subsidiaries expect to continue to make capital and other expenditures in connection with environmental laws and regulations.
Altria provides for expenses associated with environmental remediation obligations on an undiscounted basis when such amounts are probable and can be reasonably estimated. Such accruals are adjusted as new information develops or circumstances change. Other than those amounts, it is not possible to reasonably estimate the cost of any environmental remediation and compliance efforts that subsidiaries of Altria may undertake in the future. In the opinion of management, however, compliance with environmental laws and regulations, including the payment of any remediation costs or damages and the making of related expenditures, has not had, and is not expected to have, a material adverse effect on Altria’s consolidated results of operations, capital expenditures, financial position or cash flows.
40
Guarantees and Other Similar Matters
In the ordinary course of business, certain subsidiaries of Altria have agreed to indemnify a limited number of third parties in the event of future litigation. At September 30, 2021, Altria and certain of its subsidiaries (i) had $48 million of unused letters of credit obtained in the ordinary course of business; (ii) were contingently liable for guarantees related to their own performance, including $24 million for surety bonds; and (iii) had a redeemable noncontrolling interest of $39 million recorded on its condensed consolidated balance sheet. In addition, from time to time, subsidiaries of Altria issue lines of credit to affiliated entities. These items have not had, and are not expected to have, a significant impact on Altria’s liquidity.
Under the terms of a distribution agreement between Altria and PMI (the “Distribution Agreement”), entered into as a result of Altria’s 2008 spin-off of its former subsidiary PMI, liabilities concerning tobacco products will be allocated based in substantial part on the manufacturer. PMI will indemnify Altria and PM USA for liabilities related to tobacco products manufactured by PMI or contract manufactured for PMI by PM USA, and PM USA will indemnify PMI for liabilities related to tobacco products manufactured by PM USA, excluding tobacco products contract manufactured for PMI. Altria does not have a related liability recorded on its condensed consolidated balance sheet at September 30, 2021 as the fair value of this indemnification is insignificant. PMI has agreed not to seek indemnification with respect to the IQOS patent litigation discussed above under Certain Other Tobacco-Related Litigation - IQOS Litigation, excluding the patent infringement case filed with the United States District Court for the Northern District of Georgia.
PM USA has issued guarantees relating to Altria’s obligations under its outstanding debt securities, borrowings under its $3.0 billion Credit Agreement and amounts outstanding under its commercial paper program.

Note 13. New Accounting Guidance Not Yet Adopted
The following table provides a description of issued accounting guidance applicable to, but not yet adopted by, Altria:
StandardsDescriptionEffective Date for Public EntityEffect on Financial Statements
ASU 2020-06 Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity
The guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity.  Key provisions of the guidance include reducing the number of accounting models, simplifying the earnings per share calculations and expanding the disclosures related to convertible instruments.The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. Altria’s adoption of this guidance is not expected to have a material impact on its consolidated financial statements and related disclosures.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Description of the Company
When used in this Quarterly Report on Form 10-Q (“Form 10-Q”), the terms “Altria,” “we” and “our” refer to Altria Group, Inc. and its subsidiaries, unless the context requires otherwise.
Altria’s Vision by 2030 is to responsibly lead the transition of adult smokers to a smoke-free future (“Vision”). Altria is focused on moving adult smokers away from cigarettes by taking action to transition adult smokers to potentially less harmful choices.
For a description of Altria, see Background in Note 1. Background and Basis of Presentation to the condensed consolidated financial statements in Part I, Item 1. Financial Statements of this Form 10-Q (“Item 1”).
For a detailed description of Altria’s reportable segments, see Note 9. Segment Reporting to the condensed consolidated financial statements in Item 1 (“Note 9”).
Executive Summary
In this Management’s Discussion and Analysis of Financial Condition and Results of Operations section, Altria refers to the following “adjusted” financial measures: adjusted operating companies income (loss) (“OCI”); adjusted OCI margins; adjusted net earnings attributable to Altria; adjusted diluted earnings per share attributable to Altria; and adjusted effective tax rates. These adjusted financial measures are not required by, or calculated in accordance with, United States generally accepted accounting principles (“GAAP”) and may not be calculated the same as similarly titled measures used by other companies. These adjusted financial measures should thus be considered as supplemental in nature and not considered in isolation or as a
41
substitute for the related financial information prepared in accordance with GAAP. Except as noted in the 2021 Forecasted Results section below, when Altria provides a non-GAAP measure in this Form 10-Q, it also provides a reconciliation of that non-GAAP financial measure to the most directly comparable GAAP financial measure. OCI for the segments is defined as operating income before general corporate expenses and amortization of intangibles. For a further description of these non-GAAP financial measures, see the Non-GAAP Financial Measures section below.
Ste. Michelle Transaction
On July 8, 2021, UST LLC (“UST”) entered into a share purchase agreement pursuant to which it agreed to sell its subsidiary, International Wine & Spirits Ltd. (“IWS”), which includes Ste. Michelle Wine Estates Ltd. (“Ste. Michelle”), to an entity controlled by investment funds managed by Sycamore Partners Management, L.P. in an all-cash transaction with a purchase price of approximately $1.2 billion and the assumption of certain liabilities of IWS and its subsidiaries (the “Ste. Michelle Transaction”). UST completed the sale of IWS on October 1, 2021. For further discussion, see Note 3. Assets Held for Sale to the condensed consolidated financial statements in Item 1 (“Note 3”).
COVID-19 Pandemic
The COVID-19 pandemic has led to adverse impacts on the U.S. and global economies and continues to create economic uncertainty even as COVID-19 vaccines have been and continue to be administered in 2021 and the U.S. and global economies have begun to operate with reduced restrictions on consumer movements and business operations. Although much uncertainty still surrounds the pandemic (including its duration, the impact of COVID-19 variants and ultimate overall impact on U.S and global economies, Altria and its subsidiaries’ operations and those of its investees), Altria continues to monitor the macroeconomic risks of the COVID-19 pandemic (including labor shortages and inflation) and continues to carefully evaluate potential outcomes and work to mitigate risks. Specifically, Altria remains focused on any potential impact to its liquidity, operations, supply and distribution chains and on economic conditions. In terms of Altria’s liquidity, despite some volatility in commercial paper markets in 2020, Altria has not experienced a material adverse impact to its liquidity.
As with so many other companies throughout the U.S. and globally, Altria’s operations have been affected by the COVID-19 pandemic. To date, Altria believes its tobacco businesses have not experienced any material adverse effects associated with governmental actions to restrict consumer movement or business operations, but continues to monitor these factors. Altria has implemented remote working for many employees and aligned with the social distancing protocols recommended by public health authorities for employees working at Altria facilities. Altria continues to believe that remote working due to the COVID-19 pandemic has had minimal impact on productivity. Also, Altria’s critical information technology systems have remained operational. Although Altria’s tobacco businesses previously suspended operations temporarily at several of their manufacturing facilities in March 2020, the businesses resumed operations at those facilities under enhanced safety protocols in April 2020 and all manufacturing facilities are currently operational under enhanced safety protocols. Altria continues to monitor the risks associated with facility disruptions and workforce availability as a result of uncertainty related to the COVID-19 pandemic.
Altria’s suppliers and those within its distribution chain continue to be subject to potential facility closures, remote working protocols and labor shortages. To date, Altria has not experienced any material disruptions to its supply chains or distribution systems, but is continuing to monitor these factors. Altria continues to monitor the risk that the business of one or more suppliers, distributors or any other entities within its supply and distribution chains may be disrupted.
In September 2021, the President of the United States issued an Executive Order charging the Occupational Safety and Health Administration (“OSHA”) with developing an emergency temporary standard requiring almost all employers mandate certain COVID-19 vaccination and testing requirements in the workplace. This mandate could have an adverse impact on worker availability at Altria’s subsidiaries’ or investees’ manufacturing, salesforce and administrative operations, or in their distribution and supply chains.
Altria believes that the COVID-19 pandemic altered adult tobacco consumer behaviors and purchasing patterns, particularly in the earlier stages of the pandemic. While the number of adult tobacco consumer trips to the store remain below pre-pandemic levels and tobacco expenditures per trip remain elevated, the environment continues to evolve as the effects of government stimulus have lessened and consumer mobility returns to more normal levels. Although Altria’s tobacco businesses have not experienced a material adverse impact to date by the COVID-19 pandemic, there is continued uncertainty as to how the COVID-19 pandemic (including changes in COVID-19-related restrictions and guidelines) may impact adult tobacco consumers in the future. Altria continues to monitor the macroeconomic risks of the COVID-19 pandemic (including risks associated with the timing and extent of vaccine administration and the impact of COVID-19 variants), and their effect on adult tobacco consumers, including stay-at-home practices and disposable income, which may be further impacted by unemployment rates and inflation. Altria also continues to monitor adult tobacco consumers’ purchasing behaviors, including overall tobacco product expenditures, mix between premium and discount brand purchases and adoption of smoke-free products.
42
Anheuser-Busch InBev SA/NV (“ABI”) continued to be impacted by the COVID-19 pandemic, including the effects of COVID-19 variants, supply-chain constraints across certain markets, transactional foreign exchange and commodity cost headwinds. During the first nine months of 2021, ABI’s share price continued to fluctuate, ultimately resulting in a lower share price at September 30, 2021 compared to December 31, 2020. As discussed in Note 4. Investment in Equity Securities to the condensed consolidated financial statements in Item 1 (“Note 4”), in preparing Altria’s financial statements for the period ended September 30, 2021, Altria concluded that the full recovery to the carrying value will take longer than previously expected, therefore, the decline in fair value of its investment in ABI at September 30, 2021 was other than temporary. In determining that the decline in fair value was other than temporary, Altria considered the continued impact of the COVID-19 pandemic on ABI’s global business along with several other factors. As a result, Altria recorded to income (losses) from equity investments in its condensed consolidated statements of earnings (losses) a non-cash, pre-tax impairment charge of $6.2 billion for the nine and three months ended September 30, 2021. Altria will continue to monitor its investment in ABI, including the impact of the COVID-19 pandemic on ABI’s business and market valuation.
Altria has considered the impact of the COVID-19 pandemic on the business of JUUL Labs, Inc. (“JUUL”), including its sales, distribution, operations, supply chain and liquidity, in conducting its periodic impairment assessment and quantitative valuations. JUUL’s operations were negatively impacted in 2020 by the COVID-19 pandemic due to stay-at-home practices and government-mandated restrictions. While the impact was considered in Altria’s quantitative valuations conducted in connection with the preparation of its financial statements for the nine months ended September 30, 2021 and during 2020, Altria does not believe the COVID-19 pandemic was a primary driver of the non-cash, pre-tax impairment charge recorded during 2020 or any quarterly changes in fair value recorded since the fourth quarter of 2020. Altria will continue to monitor the impact of the COVID-19 pandemic on JUUL’s business, including near-term supply chain constraints and component part shortages, in Altria’s quarterly quantitative valuations of JUUL.
Altria has considered the impact of the COVID-19 pandemic on the business of Cronos Group Inc. (“Cronos”), including its sales, distribution, operations, supply chain and liquidity. During 2020 and the first nine months of 2021, Cronos has been adversely impacted by the COVID-19 pandemic, due in part to government actions limiting access to retail stores in the United States and Canada, including the recording in 2020 of an impairment charge on certain goodwill and intangible assets. However, the continued rollout of vaccines in the United States and Canada has resulted in the easing of COVID-19 related restrictions in most of the United States and Canada during the third quarter of 2021. Altria will continue to monitor the impact of COVID-19 pandemic on Cronos’ business, including near-term supply chain challenges, and market valuation.
43
Consolidated Results of Operations for the Nine Months Ended September 30, 2021
The changes in net earnings (losses) attributable to Altria and diluted earnings (losses) per share (“EPS”) attributable to Altria for the nine months ended September 30, 2021, from the nine months ended September 30, 2020, were due primarily to the following:
(in millions, except per share data)Net Earnings (Losses)Diluted EPS
For the nine months ended September 30, 2020$2,543 $1.36 
2020 Implementation and acquisition-related costs314 0.17 
2020 Tobacco and health and certain other litigation items57 0.03 
2020 Impairment of JUUL equity securities2,600 1.40 
2020 ABI-related special items544 0.29 
2020 Cronos-related special items143 0.08 
2020 COVID-19 special items37 0.02 
2020 Tax items38 0.02 
Subtotal 2020 special items3,733 2.01 
2021 NPM Adjustment Items57 0.03 
2021 Implementation, acquisition and disposition-related costs(95)(0.05)
2021 Tobacco and health and certain other litigation items(113)(0.06)
2021 ABI-related special items(4,828)(2.60)
2021 Cronos-related special items(205)(0.11)
2021 Loss on early extinguishment of debt(496)(0.27)
2021 Tax items5 — 
Subtotal 2021 special items(5,675)(3.06)
Fewer shares outstanding— 0.02 
Change in tax rate(18)(0.01)
Operations268 0.14 
For the nine months ended September 30, 2021$851 $0.46 
2021 Reported Net Earnings (Losses)$851 $0.46 
2020 Reported Net Earnings (Losses)$2,543 $1.36 
% Change(66.5)%(66.2)%
2021 Adjusted Net Earnings and Adjusted Diluted EPS$6,526 $3.52 
2020 Adjusted Net Earnings and Adjusted Diluted EPS
$6,276 $3.37 
% Change4.0 %4.5 %
For a discussion of special items and other business drivers affecting the comparability of statements of earnings (losses) amounts and reconciliations of adjusted earnings attributable to Altria and adjusted diluted EPS attributable to Altria, see the Consolidated Operating Results section below.
▪Fewer Shares Outstanding: Fewer shares outstanding were due primarily to shares repurchased by Altria under its share repurchase program in 2021.
▪Change in Tax Rate: The change in the tax rate (which excludes the impact of special items shown in the table above) was driven primarily by higher state tax expense and foreign tax rate differential.
▪Operations: The increase of $268 million in operations (which excludes the impact of special items shown in the table above) was due primarily to the following:
•higher OCI from the smokeable products segment;
•favorable net periodic benefit income, excluding service cost; and
•higher income from Altria’s equity investment in ABI.
For further details, see the Consolidated Operating Results and Operating Results by Business Segment sections below.
44
Consolidated Results of Operations for the Three Months Ended September 30, 2021
The changes in net earnings (losses) attributable to Altria and diluted EPS attributable to Altria for the three months ended September 30, 2021, from the three months ended September 30, 2020, were due primarily to the following:
(in millions, except per share data)Net Earnings (Losses)Diluted EPS
For the three months ended September 30, 2020$(952)$(0.51)
2020 Implementation and acquisition-related costs8 — 
2020 Tobacco and health and certain other litigation items25 0.01 
2020 Impairment of JUUL equity securities2,600 1.40 
2020 ABI-related special items405 0.22 
2020 Cronos-related special items142 0.08 
2020 Tax items(13)(0.01)
Subtotal 2020 special items3,167 1.70 
2021 NPM Adjustment Items33 0.02 
2021 Implementation, acquisition and disposition-related costs(52)(0.03)
2021 Tobacco and health and certain other litigation items(80)(0.04)
2021 JUUL changes in fair value100 0.05 
2021 ABI-related special items(4,899)(2.65)
2021 Cronos-related special items(89)(0.05)
2021 Tax items8 — 
Subtotal 2021 special items(4,979)(2.70)
Fewer shares outstanding— 0.01 
Change in tax rate26 0.01 
Operations16 0.01 
For the three months ended September 30, 2021$(2,722)$(1.48)
2021 Reported Net Earnings (Losses)$(2,722)$(1.48)
2020 Reported Net Earnings (Losses)$(952)$(0.51)
% Change(100)%+(100)%+
2021 Adjusted Net Earnings and Adjusted Diluted EPS$2,257 $1.22 
2020 Adjusted Net Earnings and Adjusted Diluted EPS
$2,215 $1.19 
% Change1.9 %2.5 %
For a discussion of special items and other business drivers affecting the comparability of statements of earnings (losses) amounts and reconciliations of adjusted earnings attributable to Altria and adjusted diluted EPS attributable to Altria, see the Consolidated Operating Results section below.
▪Fewer Shares Outstanding: Fewer shares outstanding were due primarily to shares repurchased by Altria under its share repurchase program in 2021.
▪Change in Tax Rate: The change in the tax rate (which excludes the impact of special items shown in the table above) was driven primarily by dividends associated with Altria’s equity investment in ABI.
▪Operations: The increase of $16 million in operations (which excludes the impact of special items shown in the table above) was due primarily to the following:
•higher income from Altria’s equity investment in ABI;
•favorable net periodic benefit income, excluding service cost; and
•lower interest and other debt expense, net;
partially offset by:
▪lower OCI.
For further details, see the Consolidated Operating Results and Operating Results by Business Segment sections below.
45
2021 Forecasted Results
Altria narrows its guidance for 2021 full-year adjusted diluted EPS to be in a range of $4.58 to $4.62, representing a growth rate of 5% to 6% over its 2020 full-year adjusted diluted EPS base of $4.36, as shown in the first table below. While the 2021 full-year adjusted diluted EPS guidance accounts for a range of scenarios, the external environment remains dynamic. Altria will continue to monitor conditions related to (i) the economy (including unemployment rates and the impact of increased inflation), (ii) adult tobacco consumer dynamics, including stay-at-home practices, disposable income, purchasing patterns and adoption of smoke-free products, (iii) regulatory and legislative (including excise tax) developments and (iv) the timing and extent of COVID-19 vaccine administration and the impact of COVID-19 variants.
Altria’s 2021 full-year adjusted diluted EPS guidance range includes planned investments in support of its Vision to responsibly lead the transition of adult smokers to a smoke-free future, such as (i) marketplace investments to expand the availability and awareness of Altria’s smoke-free products, (ii) costs associated with building an industry-leading consumer engagement platform that enhances data collection and insights in support of adult tobacco consumer transition to smoke-free products and (iii) increased smoke-free product research and development expense. This forecasted growth rate excludes the (income) expense items in the second table below.
Altria continues to expect its 2021 full-year adjusted effective tax rate will be in a range of 24.5% to 25.5%.
Reconciliation of 2020 Reported Diluted EPS to 2020 Adjusted Diluted EPS
2020 Reported diluted EPS$2.40 
Asset impairment, exit, implementation and acquisition-related costs 0.18 
Tobacco and health and certain other litigation items0.03 
Impairment of JUUL equity securities1.40 
JUUL changes in fair value(0.05)
ABI-related special items0.32 
Cronos-related special items0.03 
COVID-19 special items0.02 
Tax items 0.03 
2020 Adjusted diluted EPS$4.36 
The following (income) expense items are excluded from Altria’s 2021 forecasted adjusted diluted EPS growth rate:
(Income) Expense Excluded from 2021 Forecasted Adjusted Diluted EPS
NPM Adjustment Items$(0.03)
Implementation, acquisition and disposition-related costs0.05 
Tobacco and health and certain other litigation items0.06 
ABI-related special items 2.60 
Cronos-related special items0.11 
Loss on early extinguishment of debt0.27 
$3.06 
For a discussion of certain income and expense items excluded from the forecasted results above, see the Consolidated Operating Results section below.
Altria’s full-year adjusted diluted EPS guidance and full-year forecast for its adjusted effective tax rate exclude the impact of certain income and expense items, including those items noted in the Non-GAAP Financial Measures section below, that management believes are not part of underlying operations. Altria’s management cannot estimate on a forward-looking basis the impact of these items on its reported diluted EPS or its reported effective tax rate because these items, which could be significant, may be unusual or infrequent, are difficult to predict and may be highly variable. As a result, Altria does not provide a corresponding GAAP measure for, or reconciliation to, its adjusted diluted EPS guidance or its adjusted effective tax rate forecast.
Non-GAAP Financial Measures
While Altria reports its financial results in accordance with GAAP, its management also reviews certain financial results, including OCI, OCI margins, net earnings (losses) attributable to Altria and diluted EPS, on an adjusted basis, which excludes certain income and expense items that management believes are not part of underlying operations. These items may include,
46
for example, loss on early extinguishment of debt, restructuring charges, asset impairment charges, acquisition-related and disposition-related costs, COVID-19 special items, equity investment-related special items (including any changes in fair value of the equity investment and any related warrants and preemptive rights), certain tax items, charges associated with tobacco and health and certain other litigation items, and resolutions of certain non-participating manufacturer (“NPM”) adjustment disputes under the 1998 Master Settlement Agreement (such dispute resolutions are referred to as “NPM Adjustment Items”). Altria’s management does not view any of these special items to be part of Altria’s underlying results as they may be highly variable, may be unusual or infrequent, are difficult to predict and can distort underlying business trends and results. Altria’s management also reviews income tax rates on an adjusted basis. Altria’s adjusted effective tax rate may exclude certain tax items from its reported effective tax rate.
Altria’s management believes that adjusted financial measures provide useful additional insight into underlying business trends and results, and provide a more meaningful comparison of year-over-year results. Adjusted financial measures are used by management and regularly provided to Altria’s chief operating decision maker (the “CODM”) for planning, forecasting and evaluating business and financial performance, including allocating resources and evaluating results relative to employee compensation targets. These adjusted financial measures are not required by, or calculated in accordance with GAAP and may not be calculated the same as similarly titled measures used by other companies. These adjusted financial measures should thus be considered as supplemental in nature and not considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP.
Discussion and Analysis
Critical Accounting Policies and Estimates
Altria’s critical accounting policies and estimates are discussed in its Annual Report on Form 10-K for the year ended December 31, 2020 (the “2020 Form 10-K”); there have been no material changes to these critical accounting policies and estimates, except as noted below.
Investment in ABI
At September 30, 2021, Altria’s investment in ABI consisted of 185 million restricted shares (the “Restricted Shares”) and 12 million ordinary shares of ABI. The fair value of Altria’s equity investment in ABI is based on (i) unadjusted quoted prices in active markets for ABI’s ordinary shares and, at September 30, 2021, was classified in Level 1 of the fair value hierarchy and (ii) observable inputs other than Level 1 prices, such as quoted prices for similar assets, for the Restricted Shares, and was classified in Level 2 of the fair value hierarchy.
In October 2019, the fair value of Altria’s equity investment in ABI declined below its carrying value and at September 30, 2021 had not recovered. In preparing its financial statements for the period ended September 30, 2021, Altria evaluated the factors related to the fair value decline, including the impact on the fair value of ABI’s shares during the COVID-19 pandemic, which has negatively impacted ABI’s business. Altria evaluated the duration and magnitude of the fair value decline at September 30, 2021, ABI’s financial condition and near-term prospects, and Altria’s intent and ability to hold its investment in ABI until recovery. In preparing its financial statements for the period ended September 30, 2021, Altria concluded that the decline in fair value of its investment in ABI at September 30, 2021 was other than temporary. As a result, Altria recorded a non-cash, pre-tax impairment charge of $6.2 billion for the nine and three months ended September 30, 2021 to income (losses) from equity investments in its condensed consolidated statements of earnings (losses). This impairment charge reflected the difference between the fair value using ABI’s share price at September 30, 2021 and the carrying value of Altria’s equity investment in ABI at September 30, 2021, prior to recording the impairment charge. This conclusion was based on the following factors:
▪the fair value of Altria’s investment in ABI had been below its carrying value since October 2019 and had not fully recovered. At its lowest point in March 2020, the fair value of Altria’s investment in ABI was below its carrying value by approximately 52% and at December 31, 2020 had recovered to approximately 17%. During the first nine months of 2021, ABI’s share price continued to fluctuate, ultimately resulting in a share price decline of 18% since December 31, 2020. At September 30, 2021, prior to recording the impairment charge, the fair value of Altria’s investment in ABI was below its carrying value by approximately 35%;
▪the fair value of Altria’s investment in ABI historically exceeded its carrying value since October 2016 (when Altria obtained its ownership interest in ABI) with the exception of certain periods starting in September 2018 and since October 2019. Altria was optimistic about a near-term recovery because ABI’s share price demonstrated significant recovery, including during 2019, the second half of 2020 and the first half of 2021. However, during the third quarter of 2021, the decline in ABI’s share price resumed and, at September 30, 2021, the share price was lower than at December 31, 2020, erasing much of the recovery experienced in the second half of 2020 and first half of 2021;
▪ABI’s share price continued to decline following the release of ABI’s second quarter of 2021 earnings report in which ABI’s performance in the first half of 2021 improved meaningfully versus the same period in 2020. Despite ABI’s
47
second quarter of 2021 results, which also included top-line growth ahead of the pre-pandemic levels from the second quarter of 2019 as well as the reaffirmation of its 2021 outlook, ABI’s income growth was impacted by, among other things, transactional foreign exchange and commodity cost headwinds; and
▪the industry disruption and volatility associated with the COVID-19 pandemic, including the impact of COVID-19 variants and related cost headwinds, have continued. While Altria continues to believe that ABI’s share price performance is not reflective of its underlying long-term equity value, and ABI’s share price will recover, Altria now believes that it will take longer than previously expected as Altria believes that COVID-19 variants, supply-chain constraints across certain markets, transactional foreign exchange and commodity cost headwinds may continue to impact ABI’s near-term financial results and share price performance.
Although Altria recorded an impairment charge on its investment in ABI during the nine and three months ended September 30, 2021, Altria continues to have confidence in ABI’s (i) long-term strategies, (ii) premium global brands, (iii) experienced management team and (iv) capability to successfully navigate its near-term challenges. Altria further expects that the adverse impacts related to the COVID-19 pandemic that have negatively impacted ABI’s global business are transitory, but now also anticipates that the full recovery to the carrying value will take longer than previously expected. During October 2021, ABI’s share price continued to fluctuate and at October 25, 2021, the fair value of Altria’s investment in ABI approximated its carrying value. Altria will continue to monitor its investment in ABI, including the impact of the COVID-19 pandemic and subsequent recovery on ABI’s business and market valuation. For further discussion of Altria’s investment in ABI, see Note 4.
Investment in Cronos
The fair value of Altria’s equity method investment in Cronos is based on unadjusted quoted prices in active markets for Cronos’s common shares and was classified in Level 1 of the fair value hierarchy. In September 2021, the fair value of Altria’s equity method investment in Cronos declined below its carrying value. At September 30 2021, the fair value of Altria’s equity method investment in Cronos was below its carrying value by $14 million or approximately 2%. Altria has evaluated the factors related to the fair value decline. Based on Altria’s evaluation of the duration and magnitude of the fair value decline at September 30, 2021, Altria concluded that the decline in fair value of its equity method investment in Cronos below its carrying value is temporary and, therefore, no impairment was recorded. At October 25, 2021, the fair value of Altria’s equity method investment in Cronos was below its carrying value by $26 million or approximately 3%.
Altria will continue to monitor its equity method investment in Cronos, including the impact of the COVID-19 pandemic on Cronos’s business and market valuation. If Altria were to conclude that the decline in fair value is other than temporary, Altria would determine and recognize, in the period identified, the impairment of its equity method investment, which could result in a material adverse effect on Altria’s consolidated financial position or earnings. For further discussion of Altria’s investment in Cronos, see Note 4.
Federal Excise Taxes
Congress is currently considering legislation that would significantly increase the federal excise tax for all tobacco products and create a new tax for e-vapor products and other products containing nicotine that are not currently subject to a tobacco federal excise tax. Additionally, e-vapor products and oral nicotine products not currently taxed would be subject to a federal excise tax that would vary based on the nicotine content.
Altria uses an income approach to estimate (i) the fair values of its goodwill and intangible assets when conducting its annual review of goodwill and indefinite-lived intangible assets for potential impairment (more frequently if events occur that would require an interim review) and (ii) the fair value of its investment in JUUL, when accounting for its equity method investment in JUUL under the fair value option. Altria believes that an excise tax on cigars, moist smokeless tobacco products (“MST”), e-vapor products and oral nicotine pouches at the current proposed rates could have a material adverse impact on the significant assumptions used in performing these valuations, including volume, operating margins and income.
At this time, it is unclear (i) whether proposed tobacco and nicotine taxes will be included in any final legislation and (ii) what the amounts of any such taxes that would be included, if enacted. If the proposed tobacco and nicotine federal excise taxes on cigars, MST and e-vapor products are included in any final legislation at the rates that are currently proposed, it could result in a material non-cash impairment of the Skoal trademark and a material decrease in the fair value of its investment in JUUL, either of which would have a material adverse effect on Altria’s consolidated financial position or earnings.
48
Consolidated Operating Results
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Net revenues:
Smokeable products$17,275 $17,522 $5,975 $6,313 
Oral tobacco products1,945 1,901 626 640 
Wine494 434 177 157 
All other44 (8)8 13 
Net revenues$19,758 $19,849 $6,786 $7,123 
Excise taxes on products:
Smokeable products$3,620 $3,950 $1,218 $1,407 
Oral tobacco products98 98 32 33 
Wine14 14 5 5 
All other1 1 — — 
Excise taxes on products$3,733 $4,063 $1,255 $1,445 
Operating income:
OCI:
Smokeable products$7,901 $7,609 $2,753 $2,789 
Oral tobacco products1,269 1,297 405 436 
Wine21 (347)(24)19 
All other(56)(63)(30)(7)
Amortization of intangibles
(53)(54)(18)(17)
General corporate expenses
(255)(150)(135)(60)
Operating income$8,827 $8,292 $2,951 $3,160 
As discussed further in Note 9, the CODM reviews OCI to evaluate the performance of, and allocate resources to, the segments. Management believes it is appropriate to disclose this measure to help investors analyze the business performance and trends of the various business segments.
49
The following table provides a reconciliation of adjusted net earnings (losses) attributable to Altria and adjusted diluted EPS attributable to Altria for the nine months ended September 30:
(in millions of dollars, except per share data)Earnings (Losses) before Income TaxesProvision (Benefit) for Income TaxesNet Earnings (Losses)Net Earnings (Losses) Attributable
to Altria		Diluted EPS
2021 Reported$1,544 $693 $851 $851 $0.46 
NPM Adjustment Items(76)(19)(57)(57)(0.03)
Implementation, acquisition and disposition-related costs 117 22 95 95 0.05 
Tobacco and health and certain other
litigation items
148 35 113 113 0.06 
ABI-related special items6,111 1,283 4,828 4,828 2.60 
Cronos-related special items200 (5)205 205 0.11 
Loss on early extinguishment of debt649 153 496 496 0.27 
Tax items— 5 (5)(5)— 
2021 Adjusted for Special Items$8,693 $2,167 $6,526 $6,526 $3.52 
2020 Reported$4,349 $1,817 $2,532 $2,543 $1.36 
Implementation and acquisition-related costs
415 101 314 314 0.17 
Tobacco and health and certain other
litigation items
76 19 57 57 0.03 
Impairment of JUUL equity securities2,600 — 2,600 2,600 1.40 
ABI-related special items689 145 544 544 0.29 
Cronos-related special items144 1 143 143 0.08 
COVID-19 special items50 13 37 37 0.02 
Tax items— (38)38 38 0.02 
2020 Adjusted for Special Items$8,323 $2,058 $6,265 $6,276 $3.37 

50
The following table provides a reconciliation of adjusted net earnings (losses) attributable to Altria and adjusted diluted EPS attributable to Altria for the three months ended September 30:
(in millions of dollars, except per share data)Earnings (Losses) before Income TaxesProvision (Benefit) for Income TaxesNet Earnings (Losses)Net Earnings (Losses) Attributable
to Altria		Diluted EPS
2021 Reported$(3,302)$(582)$(2,720)$(2,722)$(1.48)
NPM Adjustment Items(44)(11)(33)(33)(0.02)
Implementation, acquisition and disposition-related costs 61 9 52 52 0.03 
Tobacco and health and certain other
litigation items
105 25 80 80 0.04 
JUUL changes in fair value(100)— (100)(100)(0.05)
ABI-related special items6,200 1,301 4,899 4,899 2.65 
Cronos-related special items89 — 89 89 0.05 
Tax items— 8 (8)(8)— 
2021 Adjusted for Special Items$3,009 $750 $2,259 $2,257 $1.22 
2020 Reported$(324)$632 $(956)$(952)$(0.51)
Implementation and acquisition-related costs
12 4 8 8 — 
Tobacco and health and certain other
litigation items
34 9 25 25 0.01 
Impairment of JUUL equity securities2,600 — 2,600 2,600 1.40 
ABI-related special items513 108 405 405 0.22 
Cronos-related special items143 1 142 142 0.08 
Tax items— 13 (13)(13)(0.01)
2020 Adjusted for Special Items$2,978 $767 $2,211 $2,215 $1.19 
The following special items affected the comparability of statements of earnings (losses) amounts for the nine and three months ended September 30, 2021 and 2020:
▪NPM Adjustment Items: For a discussion of NPM Adjustment Items and a breakdown of these items by segment, see Health Care Cost Recovery Litigation in Note 12. Contingencies to the condensed consolidated financial statements in Item 1 (“Note 12”) and NPM Adjustment Items in Note 9, respectively.
▪Implementation, Acquisition and Disposition-Related Costs: Pre-tax implementation, acquisition and disposition-related charges were $117 million and $61 million for the nine and three months ended September 30, 2021, respectively. Pre-tax implementation and acquisition-related costs were $415 million and $12 million for the nine and three months ended September 30, 2020, respectively. For a discussion of implementation, acquisition and disposition-related costs, see Note 9.
▪Tobacco and Health and Certain Other Litigation Items: For a discussion of tobacco and health and certain other litigation items and a breakdown of these costs by segment, see Note 12 and Tobacco and Health and Certain Other Litigation Items in Note 9, respectively.
▪Impairment of JUUL Equity Securities: For the nine and three months ended September 30, 2020, Altria recorded a non-cash, pre-tax impairment charge of $2,600 million, reported as impairment of JUUL equity securities in its condensed consolidated statements of earnings (losses). A full tax valuation allowance was recorded in 2020 attributable to the tax benefit associated with the impairment charge. For further discussion, see Note 4 and Note 11. Income Taxes to the condensed consolidated financial statements in Item 1 (“Note 11”).
▪JUUL Changes in Fair Value: For the three months ended September 30, 2021, Altria recorded a non-cash, pre-tax unrealized gain of $100 million, reported as (income) losses from equity investments in its condensed consolidated statements of earnings (losses) as a result of changes in the estimated fair value of Altria’s investment in JUUL. A corresponding adjustment was made to the JUUL tax valuation allowance. At September 30, 2021, the estimated fair value of Altria’s investment in JUUL was $1,705 million, unchanged from its December 31, 2020 estimated fair value. For further discussion, see Note 4.
51
▪ABI-Related Special Items: Altria’s losses from its equity investment in ABI for the nine and three months ended September 30, 2021 included net pre-tax charges of $6,111 million and $6,200 million, respectively, substantially all of which related to an impairment of Altria’s equity investment in ABI. For further discussion, see Note 4.
Altria’s losses from its equity investment in ABI for the nine months ended September 30, 2020 included net pre-tax charges of $689 million, consisting primarily of (i) mark-to-market losses on certain ABI financial instruments associated with its share commitments, (ii) completion of the sale of its Australia subsidiary and (iii) goodwill impairment charges associated with its Africa businesses.
Altria’s losses from its equity investment in ABI for the three months ended September 30, 2020 included net pre-tax charges of $513 million, consisting primarily of ABI’s completion of the sale of its Australia subsidiary and goodwill impairment charges associated with its Africa businesses.
These amounts include Altria’s respective share of amounts recorded by ABI and may also include additional adjustments related to (i) conversion from international financial reporting standards to GAAP and (ii) adjustments to Altria’s investment required under the equity method of accounting.
▪Cronos-Related Special Items: For the nine and three months ended September 30, 2021 and 2020, Altria recorded net pre-tax (income) expense consisting of the following:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
(Gain) loss on Cronos-related financial instruments (1)
$128 $202 $135 $105 
(Income) losses from equity investments (2)
72 (58)(46)38 
Total Cronos-related special items - (income) expense$200 $144 $89 $143 
(1)Amounts are related to the non-cash change in the fair value of the warrant and certain anti-dilution protections (the “Fixed-price Preemptive Rights”) acquired in the Cronos transaction.
(2)Amounts include Altria’s share of special items recorded by Cronos and may also include adjustments to Altria’s investment required under the equity method of accounting.
For further discussion, see Note 4 and Note 5. Financial Instruments to the condensed consolidated financial statements in Item 1.
▪Loss on Early Extinguishment of Debt: During the first quarter of 2021, Altria recorded pre-tax losses of $649 million as a result of the completed debt tender offers and redemption of certain long-term senior unsecured notes. For further discussion, see Note 10. Debt to the condensed consolidated financial statements in Item 1 (“Note 10”).
▪COVID-19 Special Items: For the nine months ended September 30, 2020, Altria recorded net pre-tax charges totaling $50 million directly related to disruptions caused by or efforts to mitigate the impact of the COVID-19 pandemic. For further discussion and a breakdown of these costs by segment, see COVID-19 Special Items in Note 9.
▪Tax Items: Tax items for the nine months ended September 30, 2020 included net tax expense of $38 million, due primarily to tax expense of $17 million for a tax basis adjustment to Altria’s investment in ABI and net tax expense of $12 million for adjustments resulting from amended returns and audit adjustments related to prior years. Tax items for the three months ended September 30, 2020 included tax benefits of $13 million, due primarily to tax benefits of $17 million for a tax basis adjustment of Altria’s investment in ABI.
Nine Months Ended September 30, 2021 Compared with Nine Months Ended September 30, 2020
Net revenues, which include excise taxes billed to customers, decreased $91 million (0.5%), due primarily to lower net revenues in the smokeable products segment, partially offset by higher net revenues in the wine and oral tobacco products segments and the financial services business.
Cost of sales decreased $561 million (9.5.%), due primarily to the inventory-related charges in the wine segment in 2020 (as discussed in Note 9), lower shipment volume in the smokeable products segment, NPM Adjustment Items in 2021 and COVID-19 special items in 2020, partially offset by higher per unit settlement charges, higher manufacturing costs and higher shipment volume in the wine segment.
Excise taxes on products decreased $330 million (8.1%), due primarily to lower shipment volume in the smokeable products segment.
Marketing, administration and research costs increased $265 million (16.7%), due primarily to higher general corporate expenses, higher spending in the oral tobacco products (including higher acquisition-related costs - as discussed in Note 9) and
52
smokeable products segments, the charge associated with the Ste. Michelle Transaction and higher spending associated with the retail expansion of IQOS and Marlboro HeatSticks.
Operating income increased $535 million (6.5%), due primarily to higher operating results in the wine and smokeable products segments, partially offset by higher general corporate expenses and lower operating results in the oral tobacco products segment.
Net periodic benefit income, excluding service cost, increased by $94 million (100.0%+), due primarily to lower interest cost resulting from a decrease in discount rates and amendments to its salaried retiree healthcare plans during the second quarter of 2021. For further discussion, see Note 6. Benefit Plans to the condensed consolidated financial statements in Item 1 (“Note 6”).
Income (losses) from equity investments, which decreased $5,483 million (100.0%+), were negatively impacted by unfavorable special items from Altria’s equity investments in ABI (primarily due to the impairment of Altria’s equity investment in ABI in 2021) and Cronos (as shown above).
Altria’s income tax rate increased 3.1 percentage points to 44.9%. For further discussion, see Note 11.
Reported net earnings (losses) attributable to Altria of $851 million decreased $1,692 million (66.5%), due primarily to higher losses from equity investments and the loss on early extinguishment of debt, partially offset by the 2020 impairment of JUUL equity securities, higher operating income, lower loss on Cronos-related financial instruments and favorable net periodic benefit income, excluding service cost. Reported basic and diluted EPS attributable to Altria of $0.46, decreased by 66.4% and 66.2%, respectively, due to lower reported net earnings (losses) attributable to Altria, partially offset by fewer shares outstanding.
Adjusted net earnings attributable to Altria of $6,526 million increased $250 million (4.0%), due primarily to higher smokeable products segment OCI, favorable net periodic benefit income, excluding service cost, and higher income from Altria’s investment in ABI, partially offset by a higher income tax rate. Adjusted diluted EPS attributable to Altria of $3.52 increased by 4.5%, due to higher adjusted net earnings attributable to Altria and fewer shares outstanding.
Three Months Ended September 30, 2021 Compared with Three Months Ended September 30, 2020
Net revenues, which include excise taxes billed to customers, decreased $337 million (4.7%), due primarily to lower net revenues in the smokeable products segment.
Cost of sales decreased $103 million (5.3%), due primarily to lower shipment volume in the smokeable products segment and NPM Adjustment Items in 2021, partially offset by higher per unit settlement charges and higher manufacturing costs.
Excise taxes on products decreased $190 million (13.1%), due primarily to lower shipment volume in the smokeable products segment.
Marketing, administration and research costs increased $165 million (29.6%), due primarily to higher general corporate expenses, the charge associated with the Ste. Michelle Transaction, higher spending associated with the retail expansion of IQOS and Marlboro HeatSticks and higher spending in the oral tobacco products segment.
Operating income decreased $209 million (6.6%), due primarily to lower operating results in all reportable segments and higher general corporate expenses.
Interest and other debt expense, net decreased $44 million (14.2%), due primarily to lower interest costs in 2021 as a result of debt refinancing activities and interest income associated with NPM Adjustment Items in 2021.
Net periodic benefit income, excluding service cost, increased by $60 million (100.0%+), due primarily to lower interest cost resulting from a decrease in discount rates and amendments to its salaried retiree healthcare plans during the second quarter of 2021. For further discussion, see Note 6.
Income (losses) from equity investments, which decreased $5,443 million (100.0%+), were negatively impacted by unfavorable special items from Altria’s equity investment in ABI (primarily due to the impairment of Altria’s equity investment in ABI in 2021), partially offset by an increase in the estimated fair value of Altria’s investment in JUUL and Cronos’s special items (as shown above).
Altria’s income tax rate increased 212.7 percentage points to 17.6%. For further discussion, see Note 11.
Reported net earnings (losses) attributable to Altria of $(2,722) million decreased $1,770 million (100.0%+), due primarily to higher losses from equity investments and lower operating income, partially offset by the 2020 impairment of JUUL equity securities, favorable net periodic benefit income, excluding service cost, and lower interest and other debt expense, net. Reported basic and diluted EPS attributable to Altria of $(1.48), each decreased by 100.0%+, due to lower reported net earnings (losses) attributable to Altria, partially offset by fewer shares outstanding.
Adjusted net earnings attributable to Altria of $2,257 million increased $42 million (1.9%), due primarily to higher income from Altria’s equity investment in ABI, favorable net periodic income, excluding service cost, a lower income tax rate and
53
lower interest and other debt expense, net, partially offset by lower OCI. Adjusted diluted EPS attributable to Altria of $1.22 increased by 2.5%, due to higher adjusted net earnings attributable to Altria and fewer shares outstanding.

Operating Results by Business Segment
Tobacco Space
Business Environment
Summary
The U.S. tobacco industry faces a number of business and legal challenges that have adversely affected and may adversely affect the business and sales volume of Altria’s tobacco subsidiaries and investees and Altria’s consolidated results of operations, cash flows or financial position. These challenges, some of which are discussed in more detail in Note 12, in Part I, Item 1A. Risk Factors of our 2020 Form 10-K, in Part II, Item 1A. Risk Factors of our Quarterly Report on Form 10-Q for the period ended June 30, 2021 (“Second Quarter 2021 Form 10-Q”) and in Part II, Item 1A. Risk Factors of this Form 10-Q, include:
▪pending and threatened litigation and bonding requirements;
▪restrictions and requirements imposed by the Family Smoking Prevention and Tobacco Control Act (the “FSPTCA”), and restrictions and requirements (and related enforcement actions) that have been, and in the future will be, imposed by the United States Food and Drug Administration (the “FDA”);
▪actual and proposed excise tax increases, as well as changes in tax structures and tax stamping requirements;
▪bans and restrictions on tobacco use imposed by governmental entities and private establishments and employers;
▪other federal, state and local government actions, including:
▪restrictions on the sale of certain tobacco products, the sale of tobacco products by certain retail establishments, the sale of tobacco products with characterizing flavors and the sale of tobacco products in certain package sizes;
▪additional restrictions on the advertising and promotion of tobacco products;
▪other actual and proposed tobacco-related legislation and regulation; and
▪governmental investigations;
▪reductions in cigarette and MST consumption levels due to growth of innovative tobacco products;
▪increased efforts by tobacco control advocates and other private sector entities (including retail establishments) to further restrict the availability and use of tobacco products;
▪changes in adult tobacco consumer purchase behavior, which is influenced by various factors such as economic conditions, excise taxes and price gap relationships, may result in adult tobacco consumers switching to discount products or other lower-priced tobacco products;
▪the highly competitive nature of all tobacco categories, including, without limitation, competitive disadvantages related to cigarette price increases attributable to the settlement of certain litigation and the proliferation of innovative tobacco products, including e-vapor and oral nicotine pouch products;
▪illicit trade in tobacco products;
▪potential adverse changes in prices, availability and quality of tobacco, other raw materials and components; and
▪the COVID-19 pandemic.
In addition to and in connection with the foregoing, evolving adult tobacco consumer preferences are continuing to impact the tobacco industry. Altria’s tobacco subsidiaries believe that a significant number of adult tobacco consumers switch among tobacco categories, use multiple forms of tobacco products and try innovative tobacco products, such as e-vapor products and oral nicotine pouches. Adult smokers continue to transition from cigarettes to exclusive use of smoke-free tobacco product alternatives, which aligns with Altria’s Vision.
Until the second half of 2019, the e-vapor category experienced significant growth, and the number of adults who exclusively used e-vapor products also increased during that time, which, along with growth in oral nicotine pouches, negatively impacted consumption levels and sales volume of cigarettes and MST. Over the past two years, the legislative and regulatory activities discussed below negatively impacted growth in the e-vapor category. While these activities continue to impact the e-vapor category, the category has recently been experiencing a moderate rate of growth and has become increasingly competitive.
Oral nicotine pouch retail share of the total oral tobacco category has grown significantly over the past year from 7.7% year to date as of September 30, 2020 to 14.5% year to date as of September 30, 2021. The oral nicotine pouch category is also becoming increasingly competitive.
54
We are monitoring the introduction of unregulated synthetic nicotine products, which may lead to further competition for regulated tobacco products, including oral nicotine pouches and e-vapor products, and may result in underage use of these unregulated products.
Altria and its tobacco subsidiaries believe the innovative tobacco products categories (in particular, e-vapor) will continue to be dynamic due to adult tobacco consumer exploration of a variety of tobacco product options, adult consumer perceptions of the relative risks of smoke-free products compared to cigarettes, FDA determinations on product applications and legislative actions.
In the nine months ended September 30, 2021, we estimate that, when adjusted for trade inventory movements, calendar differences and other factors, domestic cigarette industry volume declined by 5%. Altria expects 2021 cigarette industry volume trends to continue to be most influenced by (i) changes to adult smoker stay-at-home practices, disposable income, purchasing patterns and adoption of smoke-free products, (ii) the economy (including unemployment rates, the impact of increased inflation and gasoline prices), (iii) fiscal stimulus, (iv) cross-category movement, (v) the timing and extent of COVID-19 vaccine administration and the impact of COVID-19 variants, (vi) adult smoker purchasing behavior of those who receive the vaccine and (vii) regulatory and legislative (including excise tax) developments.
Economic conditions also impact adult tobacco consumer purchase behavior. Prior economic downturns have resulted in adult tobacco consumers choosing discount products and other lower-priced tobacco products. Although the economic impact resulting from the COVID-19 pandemic has not meaningfully increased the growth of discount and lower priced tobacco products, in part due to stimulus payments, adult tobacco consumers may increasingly choose these products if economic conditions do not continue to improve. See Executive Summary in Item 7 above for further discussion.
Altria and its tobacco subsidiaries work to meet these evolving adult tobacco consumer preferences over time by developing, manufacturing, marketing and distributing products both within and outside the U.S. through innovation and adjacency growth strategies (including, where appropriate, arrangements with, or investments in, third parties).
FSPTCA and FDA Regulation
▪The Regulatory Framework: The FSPTCA, its implementing regulations and its 2016 deeming regulations establish broad FDA regulatory authority over all tobacco products and, among other provisions:
▪impose restrictions on the advertising, promotion, sale and distribution of tobacco products (see Final Tobacco Marketing Rule below);
▪establish pre-market review pathways for new and modified tobacco products (see Pre-Market Review Pathways for Tobacco Products and Market Authorization Enforcement below);
▪prohibit any express or implied claims that a tobacco product is or may be less harmful than other tobacco products without FDA authorization;
▪authorize the FDA to impose tobacco product standards that are appropriate for the protection of the public health; and
▪equip the FDA with a variety of investigatory and enforcement tools, including the authority to inspect product manufacturing and other facilities.
The FSPTCA also bans descriptors such as “light,” “low” or “mild” when used as descriptors of modified risk, unless expressly authorized by the FDA. In connection with a 2016 lawsuit initiated by John Middleton Co. (“Middleton”), the Department of Justice, on behalf of the FDA, informed Middleton that the FDA does not intend to bring an enforcement action against Middleton for the use of the term “mild” in the trademark “Black & Mild.” Consequently, Middleton dismissed its lawsuit without prejudice. If the FDA were to change its position at some later date, Middleton would have the opportunity to bring another lawsuit.
▪Final Tobacco Marketing Rule: As required by the FSPTCA, in March 2010 the FDA promulgated a wide range of advertising and promotion restrictions for cigarettes and smokeless tobacco (1) products (the “Final Tobacco Marketing Rule”). The May 2016 deeming regulations amended the Final Tobacco Marketing Rule to expand specific provisions to all tobacco products, including cigars, pipe tobacco and e-vapor and oral nicotine products containing tobacco-derived nicotine or other tobacco derivatives, but do not include any component or part that is not made or derived from tobacco.
The Final Tobacco Marketing Rule, as amended, among other things:
▪restricts the use of non-tobacco trade and brand names on cigarettes and smokeless tobacco products;
▪prohibits sampling of all tobacco products except that sampling of smokeless tobacco products is permitted in qualified adult-only facilities;
(1)“Smokeless tobacco,” as used in this section of this Form 10-Q, refers to smokeless tobacco products first regulated by the FDA in 2009, including MST. It excludes oral nicotine pouches, which were first regulated by the FDA in 2016.
55
▪prohibits the sale or distribution of items such as hats and tee shirts with cigarette or smokeless tobacco brands or logos;
▪prohibits cigarettes and smokeless tobacco brand name sponsorship of any athletic, musical, artistic or other social or cultural event, or any entry or team in any event; and
▪requires the development by the FDA of graphic warnings for cigarettes, establishes warning requirements for other tobacco products, and gives the FDA the authority to require new warnings for any type of tobacco product (see FDA Regulatory Actions - Graphic Warnings below).
Subject to certain limitations arising from legal challenges, the Final Tobacco Marketing Rule took effect in June 2010 for cigarettes and smokeless tobacco products and in August 2016 for all other tobacco products, including e-vapor and oral nicotine pouch products containing tobacco-derived nicotine.
▪Rulemaking and Guidance: From time to time, the FDA issues proposed regulations and guidance, which may be issued in draft or final form, generally involve public comment and may include scientific review. The FDA also may request comments on broad topics through an Advanced Notice of Proposed Rulemaking (“ANPRM”). Altria’s tobacco subsidiaries actively engage with the FDA to develop and implement the FSPTCA’s regulatory framework, including submission of comments to various FDA policies and proposals and participation in public hearings and engagement sessions.
The FDA’s implementation of the FSPTCA and related regulations and guidance also may have an impact on enforcement efforts by U.S. states, territories and localities of their laws and regulations as well as of the State Settlement Agreements discussed below (see State Settlement Agreements below).  Such enforcement efforts may adversely affect the ability of Altria’s tobacco subsidiaries and investees to market and sell regulated tobacco products in those states, territories and localities.
▪FDA’s Comprehensive Plan for Tobacco and Nicotine Regulation: In July 2017, the FDA announced a “Comprehensive Plan for Tobacco and Nicotine Regulation” (“Comprehensive Plan”) designed to strike a balance between regulation and encouraging the development of innovative tobacco products that may be less risky than cigarettes. Since then, the FDA has issued additional information about its Comprehensive Plan in response to concerns associated with the rise in the use of e-vapor products by youth and the potential youth appeal of flavored tobacco products (see Underage Access and Use of Certain Tobacco Products below). As part of the Comprehensive Plan, the FDA:
▪issued ANPRMs relating to potential product standards for nicotine in cigarettes, flavors in all tobacco products (including menthol in cigarettes and characterizing flavors in all cigars); and, for e-vapor products, to protect against known public health risks such as concerns about youth exposure to liquid nicotine;
▪took actions to restrict youth access to e-vapor products;
▪reconsidered the processes used by the FDA to review certain reports and new product applications; and
▪revisited the timelines (previously extended by the FDA) to submit applications for tobacco products first regulated by the FDA in 2016.
▪Pre-Market Review Pathways for Tobacco Products and Market Authorization Enforcement: The FSPTCA permits the sale of tobacco products commercially marketed as of February 15, 2007 and not subsequently modified (“Grandfathered Products”) and new or modified products authorized through the pre-market tobacco product application (“PMTA”), Substantial Equivalence (“SE”) or SE Exemption pathways. Subsequent FDA rules also provide a Supplemental PMTA pathway designed to increase the efficiency of submission and review for modified versions of previously authorized products.
The FDA pre-market authorization enforcement policy varies based on product type and date of availability in the market, specifically:
▪all tobacco products on the market as of February 15, 2007, and not subsequently modified, are Grandfathered Products and exempt from the pre-market authorization requirement;
▪cigarette and smokeless tobacco products that were modified or first introduced into the market between February 15, 2007 and March 22, 2011 are generally considered “Provisional Products” for which SE reports were required to be filed by March 22, 2011. These reports must demonstrate that the product has the same characteristics as a product on the market as of February 15, 2007 or to a product previously determined to be substantially equivalent, or has different characteristics but does not raise different questions of public health; and
▪tobacco products that were first regulated by the FDA in 2016, including cigars, e-vapor products and oral nicotine pouches that are not Grandfathered Products, are generally products for which either an SE report or PMTA needed to be filed by September 9, 2020.
Modifications to currently marketed products, including modifications that result from, for example, changes to the quantity of tobacco product(s) in a package, a manufacturer being unable to acquire ingredients or a supplier being unable to maintain the consistency required in ingredients, could trigger the FDA’s pre-market or SE review processes. Through these processes, a
56
manufacturer could receive (i) a “not substantially equivalent” determination, (ii) a denial of a PMTA or (iii) a marketing order withdrawal by the FDA on one or more products, which would require the removal of the product or products from the market. Such actions could have a material adverse impact on the business and consolidated results of operations of our tobacco subsidiaries and investees, and the cash flows or financial position of Altria and its tobacco subsidiaries, including adversely affecting the value of Altria’s investment in JUUL.
Provisional Products: Most cigarette and smokeless tobacco products currently marketed by Philip Morris USA Inc. (“PM USA”) and U.S. Smokeless Tobacco Company LLC (“USSTC”) are “Provisional Products”. Altria’s subsidiaries timely submitted SE reports for these Provisional Products. PM USA and USSTC have received SE determinations on certain Provisional Products. Those products that were found by the FDA to be not substantially equivalent (certain smokeless tobacco products) had been discontinued for business reasons prior to the FDA’s determinations; therefore, those determinations did not impact business results. PM USA and USSTC have other Provisional Products that continue to be subject to the FDA’s pre-market review process. In the meantime, they can continue marketing these products unless the FDA determines that a specific Provisional Product is not substantially equivalent.
In addition, the FDA has communicated that it will not review a certain subset of Provisional Product SE reports and that the products that are the subject of those reports can continue to be legally marketed without further FDA review. PM USA and USSTC have Provisional Products included in this subset of products.
While Altria’s cigarette and smokeless tobacco subsidiaries believe their current Provisional Products meet the statutory requirements of the FSPTCA, they cannot predict how the FDA will ultimately apply law, regulation and guidance to their various SE reports. Should Altria’s cigarette and smokeless tobacco subsidiaries receive unfavorable determinations on any SE reports currently pending with the FDA, they believe they can replace the vast majority of their respective product volumes with other FDA authorized products or with Grandfathered Products.
Non-Provisional Products: Cigarette and smokeless tobacco products introduced into the market or modified after March 22, 2011 are “Non-Provisional Products” and must receive a marketing order from the FDA prior to being offered for sale. Marketing orders for Non-Provisional Products may be obtained by filing an SE report, PMTA or using another pre-market pathway established by the FDA. Altria’s cigarette and smokeless tobacco subsidiaries may not be able to obtain a marketing order for non-provisional products because the FDA may determine that any such product does not meet the statutory requirements for approval.
Products Regulated in 2016: Manufacturers of products first regulated by the FDA in 2016, including cigars, oral nicotine pouches and e-vapor products, that were on the market as of August 8, 2016 and not subsequently modified must have filed an SE report or PMTA by the filing deadline of September 9, 2020 in order for their products to remain on the market. These products can remain on the market during FDA review through court-allowed, case-by-case discretion, so long as the report or application was timely filed with the FDA. Due to the large number of applications received by September 9, 2020, the FDA did not complete its review of all submitted applications by September 9, 2021; although it has issued various marketing denial orders on over 90% of the applications and issued marketing granted orders on a few applications for tobacco flavor e-vapor products. For those products still under FDA review, it is uncertain when and for how long the FDA may permit continued marketing and sale of those products pursuant to its case-by-case discretion. For products (new or modified) not on the market as of August 8, 2016, manufacturers must file an SE report or PMTA and receive FDA authorization prior to marketing and selling the product.
Helix Innovations LLC (“Helix”) submitted PMTAs for on! oral nicotine pouches in May 2020. JUUL submitted PMTAs to the FDA for its e-vapor device and the related tobacco and menthol flavors in July 2020. As of October 25, 2021, the FDA has not issued marketing order decisions for any on! or JUUL products. In addition, as of October 25, 2021, Middleton has received market orders or exemptions that cover over 98% of its cigar product volume and has pending timely filed SE reports for its remaining cigar product volume.
In December 2013, Altria’s subsidiaries entered into a series of agreements with Philip Morris International Inc. (“PMI”), including an agreement that grants Altria an exclusive right to commercialize certain of PMI’s heated tobacco products in the United States, subject to FDA authorization of the applicable products. PMI submitted a PMTA and a modified risk tobacco product application with the FDA for its electronically heated tobacco products comprising the IQOS Tobacco Heating System. In April 2019, the FDA authorized the PMTA for the IQOS Tobacco Heating System and in July 2020, the FDA authorized the marketing of this system as a modified risk tobacco product (“MRTP”) with a reduced exposure claim. The IQOS electronic device heats but does not burn tobacco. In December 2020, the FDA authorized the PMTA for IQOS 3, an updated version of the IQOS electronic device. The MRTP authorization for the original IQOS electronic device currently does not apply to the IQOS 3 device. PMI submitted an MRTP application for the IQOS 3 electronic device in March 2021, which is currently under review by the FDA.
In September 2021, in connection with a patent dispute, the United States International Trade Commission (“ITC”) issued a cease and desist order banning (i) the importation of the IQOS electronic device, HeatSticks and infringing components into the
57
United States and (ii) the sale, marketing and distribution of such imported products in the United States. As a result, PM USA announced plans to begin removing the product from the marketplace. For a further discussion of the ITC decision, see Note 12.
In October 2021, the FDA authorized the marketing and sale of four of USSTC’s Verve oral nicotine products, including Green Mint and Blue Mint varieties, representing the first flavored product authorizations issued by the FDA for newly deemed products. These products are not currently marketed or sold.
Post-Market Surveillance: Manufacturers that receive product authorizations through the PMTA process must submit to the FDA post-market records and reports, as detailed in market orders. This includes notification of all marketing activities. The IQOS Tobacco Heating System is subject to this post-market surveillance requirement. The FDA may amend requirements of a market order or withdraw the market order based on this information if, among other reasons, it determines that the continued marketing of the products is no longer appropriate for the protection of the public health.
Effect of Adverse FDA Determinations: FDA review time frames have varied. It is therefore difficult to predict the duration of FDA reviews of SE reports or PMTAs. Failure of manufacturers to submit applications by the applicable deadline, an unfavorable determination on an application or the withdrawal by the FDA of a prior marketing order could result in the removal of products from the market. These manufacturers would have the option of marketing products that have received FDA pre-market authorization or Grandfathered Products. A “not substantially equivalent” determination, a denial of a PMTA or a marketing order withdrawal by the FDA on one or more products (which would require the removal of the product or products from the market) could have a material adverse impact on the business and consolidated results of operations of our tobacco subsidiaries and investees, and the cash flows or financial position of Altria and its tobacco subsidiaries, including adversely affecting the value of Altria’s investment in JUUL. Also, an adverse FDA determination on one or more innovative tobacco products could impede our ability to achieve our Vision.
▪FDA Regulatory Actions
▪Graphic Warnings: In March 2020, the FDA issued a final rule requiring 11 textual warnings accompanied by color graphics depicting certain negative health consequences of smoking on cigarette packaging and advertising. As a result of a March 2021 court order related to the COVID-19 pandemic and subsequent court orders resulting from a lawsuit brought by R.J. Reynolds Tobacco Company and others against the FDA, the final rule will be effective October 11, 2022. PM USA and other cigarette manufacturers have filed lawsuits challenging the final rule on substantive and procedural grounds.
In the preamble to the final rule, the FDA stated that it would not exempt HeatSticks, a heated tobacco product used with the IQOS electronic device, as part of the rulemaking, but would consider the HeatSticks marketing order, and other marketing orders, on a case-by-case basis. To date, the FDA has not taken any action to exempt HeatSticks from the graphic health warnings requirements.
▪Underage Access and Use of Certain Tobacco Products: The FDA announced regulatory actions in September 2018 to address underage access and use of e-vapor products. Altria has engaged with the FDA on this topic and has reaffirmed to the FDA its ongoing and long-standing commitment to preventing underage use. For example, during 2019, Altria advocated raising the minimum legal age to purchase all tobacco products to 21 at the federal and state levels to further address underage use, which is now federal law. See Federal, State and Local Legislation to Increase the Legal Age to Purchase Tobacco Products below for further discussion.
Additionally, in March 2019, the FDA issued draft guidance further proposing restrictions to address underage e-vapor use. This guidance, which the FDA finalized in January 2020 and then revised in April 2020, states that the FDA intends to prioritize enforcement action against certain product categories, including cartridge-based, flavored e-vapor products and products targeted to minors.
▪Flavored Electronic Nicotine Delivery System (“ENDS”) Products: Some e-vapor product manufacturers filed PMTAs for flavored tobacco products. As of October 25, 2021, many of these manufacturers received marketing denial orders for failure to provide sufficiently strong product-specific scientific evidence to demonstrate that the benefit of their products to adult smokers overcomes the risk that their products pose to youth. FDA has communicated in these marketing denial orders that vapor products with non-tobacco flavors present unique questions relevant to the FDA’s “Appropriate for the Protection of Public Health” standard and that successful applications will require strong, product-specific evidence. A number of manufacturers are appealing the marketing denial orders for their products. If the FDA does not ultimately allow for the reintroduction of flavors other than tobacco, it could adversely affect the value of Altria’s investment in JUUL.
Some ENDS manufacturers, including some that have received marketing denial orders, have indicated their intention to market ENDS products containing synthetically-derived nicotine, which is not currently FDA-regulated. If these products are sold in higher volumes, and marketed outside of FDA oversight, it could adversely affect the value of
58
Altria’s investment in JUUL, have a material adverse effect on Altria’s consolidated financial position or earnings and impede our ability to achieve our Vision.
▪Potential Product Standards
▪Nicotine in Cigarettes and Other Combustible Tobacco Products: In March 2018, the FDA issued an ANPRM seeking comments on the potential public health benefits and any possible adverse effects of lowering nicotine in combustible cigarettes to non-addictive or minimally addictive levels. Among other issues, the FDA sought comments on (i) whether smokers would compensate by smoking more cigarettes to obtain the same level of nicotine as with their current product and (ii) whether the proposed rule would create an illicit trade of cigarettes containing nicotine at levels higher than a non-addictive threshold that may be established by the FDA. The FDA also sought comments on whether a nicotine product standard should apply to other combustible tobacco products, including cigars. Were the FDA to develop and finalize a product standard for nicotine in combustible products, and if the standard was appealed and upheld in the courts, it could have a material adverse effect on the business, consolidated results of operations, cash flows or financial position of Altria and its tobacco subsidiaries.
▪Flavors in Tobacco Products: As discussed above under FDA’s Comprehensive Plan for Tobacco and Nicotine Regulation, the FDA indicated that it is considering proposing rulemaking for a product standard that would seek to ban menthol in combustible tobacco products, including cigarettes and cigars, and that it intends to propose a product standard that would ban characterizing flavors in all cigars, including Grandfathered Products and those that have received SE determinations from the FDA - an intention reiterated in the FDA’s January 2020 guidance. In March 2018, the FDA issued an ANPRM seeking comments on the role, if any, that flavors (including menthol) in tobacco products may play in attracting youth and in helping some smokers switch to potentially less harmful forms of nicotine delivery. In the context of litigation, in April 2021, the FDA issued a response to a 2013 citizen petition requesting that the FDA prohibit menthol as a characterizing flavor in cigarettes. In the response, the FDA announced it intends to develop and propose two product standards within one year that would (i) ban menthol as a characterizing flavor in cigarettes and (ii) ban all characterizing flavors (including menthol) in cigars. While the FDA has yet to define “characterizing flavors” with respect to cigars, most of Middleton’s cigar products contain added flavors and may be subject to any action by the FDA to ban flavors in cigars.
If any such product standards become final and are appealed and upheld in the courts, it could have a material adverse effect on the business of our tobacco subsidiaries and investees, and the consolidated results of operations, cash flows or financial position of Altria and its tobacco subsidiaries, including adversely affecting the value of Altria’s investment in JUUL.
▪NNN in Smokeless Tobacco: In January 2017, the FDA proposed a product standard for N-nitrosonornicotine (“NNN”) levels in finished smokeless tobacco products.  If the proposed rule, in present form, were to become final and was appealed and upheld in the courts, it could have a material adverse effect on the business, consolidated results of operations, cash flows or financial position of Altria and USSTC.
▪Good Manufacturing Practices: The FSPTCA requires that the FDA promulgate good manufacturing practice regulations (referred to by the FDA as “Requirements for Tobacco Product Manufacturing Practice”) for tobacco product manufacturers, but does not specify a timeframe for such regulations. Compliance with any such regulations could result in increased costs, which could have a material adverse effect on the financial position of Altria, its tobacco subsidiaries and its investees, including adversely affecting the value of Altria’s investment in JUUL.
▪Impact on Our Business; Compliance Costs and User Fees: FDA regulatory actions under the FSPTCA could have a material adverse effect on the business, consolidated results of operations, cash flows or financial position of Altria and its tobacco subsidiaries in various ways. For example, actions by the FDA could:
▪impact the consumer acceptability of tobacco products;
▪delay, discontinue or prevent the sale or distribution of existing, new or modified tobacco products;
▪limit adult tobacco consumer choices;
▪impose restrictions on communications with adult tobacco consumers;
▪create a competitive advantage or disadvantage for certain tobacco companies;
▪impose additional manufacturing, labeling or packaging requirements;
▪impose additional restrictions at retail;
▪result in increased illicit trade in tobacco products; and/or
▪otherwise significantly increase the cost of doing business.
59
The failure to comply with FDA regulatory requirements, even inadvertently, and FDA enforcement actions also could have a material adverse effect on the business of our tobacco subsidiaries and investees, and the consolidated results of operations, cash flows or financial position of Altria and its tobacco subsidiaries, including adversely affecting the value of Altria’s investment in JUUL.
The FSPTCA imposes user fees on cigarette, cigarette tobacco, smokeless tobacco, cigar and pipe tobacco manufacturers and importers to pay for the cost of regulation and other matters. The FSPTCA does not impose user fees on e-vapor or oral nicotine pouch manufacturers. The cost of the FDA user fee is allocated first among tobacco product categories subject to FDA user fees and then among manufacturers and importers within each respective category based on their relative market shares, all as prescribed by the FSPTCA and FDA regulations. Payments for user fees are adjusted for several factors, including market share and industry volume. For a discussion of the impact of the FDA user fee payments on Altria, see Debt and Liquidity - Payments Under State Settlement Agreements and FDA Regulation below. In addition, compliance with the FSPTCA’s regulatory requirements has resulted, and will continue to result, in additional costs for Altria’s tobacco businesses. The amount of additional compliance and related costs has not been material in any given quarter or year to date period but could become material, either individually or in the aggregate, to one or more of Altria’s tobacco subsidiaries.
▪Investigation and Enforcement: The FDA has a number of investigatory and enforcement tools available to it, including document requests and other required information submissions, facility inspections, examinations and investigations, injunction proceedings, monetary penalties, product withdrawal and recall orders, and product seizures. Investigations or enforcement actions could result in significant costs or otherwise have a material adverse effect on the business of our tobacco subsidiaries and investees, and the consolidated results of operations, cash flows or financial position of Altria and its tobacco subsidiaries, including adversely affecting the value of Altria’s investment in JUUL.
Excise Taxes
Tobacco products are subject to substantial excise taxes in the U.S. Significant increases in tobacco-related taxes or fees have been proposed or enacted (including with respect to e-vapor products) and are likely to continue to be proposed or enacted at the federal, state and local levels within the U.S. The frequency and magnitude of excise tax increases can be influenced by various factors, including the composition of executive and legislative bodies.
Congress is currently considering legislation that would significantly increase the federal excise tax for all tobacco products and create a new tax for e-vapor products and other products containing nicotine that are not currently subject to a tobacco federal excise tax. Additionally, e-vapor products and oral nicotine products not currently taxed would be subject to a federal excise tax that would vary based on the nicotine content.
Federal, state and local cigarette excise taxes have increased substantially over the past two decades, far outpacing the rate of inflation. Between the end of 1998 and October 25, 2021, the weighted-average state cigarette excise tax increased from $0.36 to $1.89 per pack. As of October 25, 2021, one state, Maryland, has enacted new legislation increasing cigarette excise taxes in 2021.
A majority of states currently tax MST using an ad valorem method, which is calculated as a percentage of the price of the product, typically the wholesale price. This ad valorem method results in more tax being paid on premium products than is paid on lower-priced products of equal weight. Altria’s subsidiaries support legislation to convert ad valorem taxes on MST to a weight-based methodology because, unlike the ad valorem tax, a weight-based tax subjects cans of equal weight to the same tax. As of October 25, 2021, the federal government, 23 states, Puerto Rico, Philadelphia, Pennsylvania and Cook County, Illinois have adopted a weight-based tax methodology for MST.
An increasing number of states and localities also are imposing excise taxes on e-vapor and oral nicotine pouches. As of October 25, 2021, 30 states, the District of Columbia, Puerto Rico and a number of cities and counties have enacted legislation to tax e-vapor products. These taxes are calculated in varying ways and may differ based on the e-vapor product form. Similarly, 11 states and the District of Columbia have enacted legislation to tax oral nicotine pouches. Tax increases could have an adverse impact on the sales of these products.
Tax increases are expected to continue to have an adverse impact on product sales of Altria’s tobacco subsidiaries and JUUL through lower consumption levels and the potential shift in adult consumer purchases from the premium to the non-premium or discount segments, or to counterfeit and contraband products. Lower sales volume and reported share performance of Altria’s tobacco subsidiaries’ products could have a material adverse effect on Altria’s consolidated financial position or earnings. In addition, excise taxes on e-vapor and oral nicotine products may negatively impact adult smokers’ transition to these products, which could impede our ability to achieve our Vision.
60
International Treaty on Tobacco Control
The World Health Organization’s Framework Convention on Tobacco Control (the “FCTC”) entered into force in February 2005. As of October 25, 2021, 181 countries, as well as the European Community, have become parties to the FCTC. While the U.S. is a signatory of the FCTC, it is not currently a party to the agreement, as the agreement has not been submitted to, or ratified by, the United States Senate. The FCTC is the first international public health treaty and its objective is to establish a global agenda for tobacco regulation with the purpose of reducing initiation of tobacco use and encouraging cessation. The treaty recommends (and in certain instances, requires) signatory nations to enact legislation that would address various tobacco-related issues.
There are a number of proposals currently under consideration by the governing body of the FCTC, some of which call for substantial restrictions on the manufacture, marketing, distribution and sale of tobacco products. It is not possible to predict the outcome of these proposals or the impact of any FCTC actions on legislation or regulation in the U.S., either indirectly or as a result of the U.S. becoming a party to the FCTC, or whether or how these actions might indirectly influence FDA regulation and enforcement.
State Settlement Agreements
As discussed in Note 12, during 1997 and 1998, PM USA and other major domestic cigarette manufacturers entered into the State Settlement Agreements. These settlements require participating manufacturers to make substantial annual payments, which are adjusted for several factors, including inflation, operating income, market share and industry volume. Increases in inflation can increase our financial liability under the State Settlement Agreements. The State Settlement Agreements’ inflation calculations require us to apply the higher of 3% or the United States Bureau of Labor Statistics’ Consumer Price Index for All Urban Consumers (“CPI-U”) percentage rate as published in January of each year. For 2021, based on the latest CPI-U data, the inflation calculation may be above 3%, but Altria does not believe the increase would result in a material financial impact.
For a discussion of the impact of the State Settlement Agreements on Altria, see Debt and Liquidity - Payments Under State Settlement Agreements and FDA Regulation below and Note 12. The State Settlement Agreements also place numerous requirements and restrictions on participating manufacturers’ business operations, including prohibitions and restrictions on the advertising and marketing of cigarettes and smokeless tobacco products. Among these are prohibitions of outdoor and transit brand advertising, payments for product placement and free sampling (except in adult-only facilities). The State Settlement Agreements also place restrictions on the use of brand name sponsorships and brand name non-tobacco products and prohibitions on targeting youth and the use of cartoon characters. In addition, the State Settlement Agreements require companies to affirm corporate principles directed at reducing underage use of cigarettes; impose requirements regarding lobbying activities; mandate public disclosure of certain industry documents; limit the industry’s ability to challenge certain tobacco control and underage use laws; and provide for the dissolution of certain tobacco-related organizations and place restrictions on the establishment of any replacement organizations.
In November 1998, USSTC entered into the Smokeless Tobacco Master Settlement Agreement (the “STMSA”) with the attorneys general of various states and U.S. territories to resolve the remaining health care cost reimbursement cases initiated against USSTC. The STMSA required USSTC to adopt various marketing and advertising restrictions. USSTC is the only smokeless tobacco manufacturer to sign the STMSA.
Other International, Federal, State and Local Regulation and Governmental and Private Activity
▪International, Federal, State and Local Regulation: A number of states and localities have enacted or proposed legislation that imposes restrictions on tobacco products (including cigarettes, smokeless tobacco, cigars, e-vapor products and oral nicotine pouches), such as legislation that (i) prohibits the sale of all tobacco products or certain tobacco categories, such as e-vapor, (ii) prohibits the sale of tobacco products with characterizing flavors, such as menthol cigarettes and flavored e-vapor products, (iii) requires the disclosure of health information separate from or in addition to federally mandated health warnings and (iv) restricts commercial speech or imposes additional restrictions on the marketing or sale of tobacco products. The legislation varies in terms of the type of tobacco products, the conditions under which such products are or would be restricted or prohibited, and exceptions to the restrictions or prohibitions. For example, a number of proposals involving characterizing flavors would prohibit smokeless tobacco products with characterizing flavors without providing an exception for mint- or wintergreen-flavored products. As of October 25, 2021, three states are considering legislation to ban flavors in one or more tobacco products, and six states (California, Massachusetts, New Jersey, Utah, New York and Illinois) and the District of Columbia have passed such legislation. Some of these states, such as New York, Utah and Illinois, exempt certain products that have received FDA market authorization through the PMTA pathway.
The legislation in California bans the sale of most tobacco products with characterizing flavors, including menthol, mint and wintergreen. Following enactment of the flavor ban in August 2020, several registered California voters filed a referendum against the legislation. In January 2021 the requisite number of registered California voters signed a petition to place the question of whether the legislation should be affirmed or overturned on the next statewide general election ballot, which will
61
likely take place in 2022, unless a special statewide election is called earlier. As a result, the implementation of the legislation is delayed until after a vote on the referendum occurs.
Massachusetts passed legislation capping the amount of nicotine in e-vapor products. Similar legislation is pending in one other state.
Restrictions on e-vapor products also have been instituted or proposed internationally. For example, India and Singapore have instituted bans on e-vapor products.
Altria’s tobacco subsidiaries have challenged and will continue to challenge certain federal, state and local legislation and other governmental action, including through litigation. It is possible, however, that legislation, regulation or other governmental action could be enacted or implemented that could have a material adverse impact on the business and volume of our tobacco subsidiaries and investees, and the consolidated results of operations, cash flows or financial position of Altria and its tobacco subsidiaries, including adversely affecting the value of Altria’s investment in JUUL. Such action also could negatively impact adult smokers’ transition to these products, which could adversely affect our ability to achieve our Vision.
▪Federal, State and Local Legislation to Increase the Legal Age to Purchase Tobacco Products: After a number of states and localities proposed and enacted legislation to increase the minimum age to purchase all tobacco products, including e-vapor products, in December 2019, the federal government passed legislation increasing the minimum age to purchase all tobacco products, including e-vapor products, to 21 nationwide. As of October 25, 2021, 39 states, the District of Columbia and Puerto Rico have enacted laws increasing the legal age to purchase tobacco products to 21. Although an increase in the minimum age to purchase tobacco products may have a negative impact on sales volume of our tobacco businesses, as discussed above under Underage Access and Use of Certain Tobacco Products, Altria supported raising the minimum legal age to purchase all tobacco products to 21 at the federal and state levels, reflecting its longstanding commitment to combat underage tobacco use.
▪Health Effects of Tobacco Products, Including E-vapor Products: Reports with respect to the health effects of smoking have been publicized for many years, including various reports by the U.S. Surgeon General. In 2019, there were public health advisories concerning vaping-related lung injuries and deaths and, more recently, there have been health concerns raised about potential increased risks associated with COVID-19 among smokers and vapers. Altria and its tobacco subsidiaries believe that the public should be guided by the messages of the U.S. Surgeon General and public health authorities worldwide in making decisions concerning the use of tobacco products, including e-vapor products.
Most jurisdictions within the U.S. have restricted smoking in public places and some have restricted vaping in public places. Some public health groups have called for, and various jurisdictions have adopted or proposed, bans on smoking and vaping in outdoor places, in private apartments and in cars transporting children. It is not possible to predict the results of ongoing scientific research or the types of future scientific research into the health risks of tobacco exposure and the impact of such research on legislation and regulation.
▪Other Legislation or Governmental Initiatives: In addition to the actions discussed above, other regulatory initiatives affecting the tobacco industry have been adopted or are being considered at the federal level and in a number of state and local jurisdictions. For example, during the COVID-19 pandemic, state and local governments required additional health and safety requirements of all businesses, including tobacco manufacturing and other facilities. State and local governments also mandated the temporary closure of some businesses. While many restrictions have eased, it is possible that tobacco manufacturing and other facilities and the facilities of our suppliers, our suppliers’ suppliers and our trade partners could be subject to additional government-mandated temporary closures and restrictions. In September 2021, the President of the United States issued an Executive Order charging OSHA with developing an emergency temporary standard requiring almost all employers to mandate certain COVID-19 vaccination and testing requirements in the workplace. This mandate could have an adverse impact on worker availability at Altria’s subsidiaries’ or investees’ manufacturing, salesforce and administrative operations, or in their distribution and supply chains.
Additionally, in recent years, legislation has been introduced or enacted at the state or local level to subject tobacco products to various reporting requirements and performance standards; establish educational campaigns relating to tobacco consumption or tobacco control programs or provide additional funding for governmental tobacco control activities; restrict the sale of tobacco products in certain retail establishments and the sale of tobacco products in certain package sizes; require tax stamping of smokeless tobacco products; require the use of state tax stamps using data encryption technology; and further restrict the sale, marketing and advertising of cigarettes and other tobacco products. Such legislation may be subject to constitutional or other challenges on various grounds, which may or may not be successful.
It is not possible to predict what, if any, additional legislation, regulation or other governmental action will be enacted or implemented (and, if challenged, upheld) relating to the manufacturing, design, packaging, marketing, advertising, sale or use of tobacco products, or the tobacco industry generally. It is possible, however, that legislation, regulation or other governmental action could be enacted or implemented that could have a material adverse impact on the business and volume of
62
our tobacco subsidiaries and investees, and the consolidated results of operations, cash flows or financial position of Altria and its tobacco subsidiaries, including adversely affecting the value of Altria’s investment in JUUL.
▪Governmental Investigations: From time to time, Altria, its subsidiaries and investees are subject to governmental investigations on a range of matters.  For example: (i) the U.S. Federal Trade Commission (the “FTC”) issued a Civil Investigative Demand (“CID”) to Altria while conducting its antitrust review of Altria’s investment in JUUL seeking information regarding, among other things, Altria’s role in the resignation of JUUL’s former chief executive officer and the hiring by JUUL of any current or former Altria director, executive or employee (see Note 12 for a description of the FTC’s administrative complaint against Altria and JUUL); (ii) the U.S. Securities and Exchange Commission (“SEC”) commenced an investigation relating to Altria’s acquisition, disclosures and accounting controls in connection with the JUUL investment; and (iii) the New York State Office of the Attorney General issued a subpoena to Altria seeking documents relating to Altria’s investment in and provision of services to JUUL. Additionally, JUUL is currently under investigation by various federal and state agencies, including the SEC, the FDA and the FTC, and state attorneys general.  Such investigations vary in scope but at least some appear to include JUUL’s marketing practices, particularly as such practices relate to youth, and Altria may be asked in the context of those investigations to provide information concerning its investment in JUUL or relating to its marketing of Nu Mark LLC e-vapor products.
Private Sector Activity on E-Vapor
A number of retailers, including national chains, have discontinued the sale of e-vapor products. Reasons for the discontinuation include reported illnesses related to e-vapor product use and the uncertain regulatory environment. It is possible that this private sector activity could adversely affect the value of Altria’s investment in JUUL and have a material adverse effect on Altria’s consolidated financial position or earnings.
Illicit Trade in Tobacco Products
Illicit trade in tobacco products can have an adverse impact on the businesses of Altria, its tobacco subsidiaries and investees. Illicit trade can take many forms, including the sale of counterfeit tobacco products; the sale of tobacco products in the U.S. that are intended for sale outside the country; the sale of untaxed tobacco products over the Internet and by other means designed to avoid the collection of applicable taxes; and diversion into one taxing jurisdiction of tobacco products intended for sale in another. Counterfeit tobacco products, for example, are manufactured by unknown third parties in unregulated environments. Counterfeit versions of our tobacco subsidiaries’ and investees’ products can negatively affect adult tobacco consumer experiences with and opinions of those brands. Illicit trade in tobacco products also harms law-abiding wholesalers and retailers by depriving them of lawful sales and undermines the significant investment Altria’s tobacco subsidiaries and investees have made in legitimate distribution channels. Moreover, illicit trade in tobacco products results in federal, state and local governments losing tax revenues. Losses in tax revenues can cause such governments to take various actions, including increasing excise taxes; imposing legislative or regulatory requirements that may adversely impact Altria’s consolidated results of operations and cash flows, including adversely affecting the value of Altria’s investment in JUUL, and the businesses of its tobacco subsidiaries and investees; or asserting claims against manufacturers of tobacco products or members of the trade channels through which such tobacco products are distributed and sold.
Altria’s tobacco subsidiaries communicate with wholesale and retail trade members regarding illicit trade in tobacco products and how they can help prevent such activities, enforce wholesale and retail trade programs and policies that address illicit trade in tobacco products and, when necessary, litigate to protect their trademarks.
Price, Availability and Quality of Tobacco, Other Raw Materials, Ingredients and Component Parts
Shifts in crops (such as those driven by economic conditions and adverse weather patterns), government restrictions and mandated prices, production control programs, economic trade sanctions, import duties and tariffs, international trade disruptions, inflation, geopolitical instability, climate and environmental changes and disruptions due to man-made or natural disasters may increase the cost or reduce the supply or quality of tobacco or other raw materials or ingredients or component parts used to manufacture our companies’ and our investees’ products. Any significant change in the price, availability or quality of tobacco, other raw materials, ingredients or component parts used to manufacture our products and those of our investees could restrict our subsidiaries’ and investees’ ability to continue manufacturing and marketing existing products or impact adult consumer product acceptability and adversely affect our subsidiaries’ and investees’ profitability and businesses.
With respect to tobacco, as with other agricultural commodities, crop quality and availability can be influenced by variations in weather patterns, including those caused by climate change. Additionally, the price and availability of tobacco leaf can be influenced by economic conditions and imbalances in supply and demand. Economic conditions, including the economic effects of the COVID-19 pandemic, are unpredictable, which, among other factors, may result in changes in the patterns of demand for agricultural products and the cost of tobacco production which could impact tobacco leaf prices and tobacco supply. In addition, as consumer demand increases for smoke-free products and decreases for combustible products, the volume of
63
tobacco leaf required for production may decrease. The reduced demand for tobacco leaf may result in the reduced supply and availability of domestic tobacco as growers divert resources to other crops.
Tobacco production in certain countries also is subject to a variety of controls, including government-mandated prices and production control programs.  Moreover, certain types of tobacco are only available in limited geographies, including geographies experiencing political instability or government prohibitions on the import or export of tobacco, and loss of their availability could impair our subsidiaries’ ability to continue marketing existing products or impact adult tobacco consumer product acceptability.
The COVID-19 pandemic also may limit access to and increase the cost of raw materials, component parts and personal protective equipment as U.S. and global suppliers may temporarily shut down facilities or use different production schedules with lower productivity in order to address exposure to the virus or as a result of a government mandate. In addition, current labor market dynamics indicate labor shortages, with employers in a number of industries having difficulty employing workers. These shortages have led to certain increases in raw material, ingredient and component part prices and may lead to disruptions in the supply chain; however, to date, the impact has been immaterial. The effects of the COVID-19 pandemic and labor market dynamics outlined above may continue after the pandemic wanes as a result of the developing commercial and economic environment, including increased government spending. This environment has led to an increased rate of inflation that, to date, has not had a material impact on our businesses, revenues or profitability.
Timing of Sales
In the ordinary course of business, our tobacco subsidiaries are subject to many influences that can impact the timing of sales to customers, including the timing of holidays and other annual or special events, the timing of promotions, customer incentive programs and customer inventory programs, as well as the actual or speculated timing of pricing actions and tax-driven price increases.

Operating Results
Smokeable Products Segment
Financial Results
The following table summarizes operating results, includes reported and adjusted OCI margins, and provides a reconciliation of reported OCI to adjusted OCI for the smokeable products segment:
Operating Results
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)20212020Change20212020Change
Net revenues$17,275 $17,522 (1.4)%$5,975 $6,313 (5.4)%
Excise taxes(3,620)(3,950)(1,218)(1,407)
Revenues net of excise taxes$13,655 $13,572 $4,757 $4,906 
Reported OCI$7,901 $7,609 3.8 %$2,753 $2,789 (1.3)%
NPM Adjustment Items(53)— (21)— 
Tobacco and health and certain other litigation items72 73 29 34 
COVID-19 special items— 41 — — 
Adjusted OCI$7,920 $7,723 2.6 %$2,761 $2,823 (2.2)%
Reported OCI margins (1)
57.9 %56.1 %1.8 pp57.9 %56.8 %1.1 pp
Adjusted OCI margins (1)
58.0 %56.9 %1.1 pp58.0 %57.5 %0.5 pp
(1) Reported and adjusted OCI margins are calculated as reported and adjusted OCI, respectively, divided by revenues net of excise taxes.
Nine Months Ended September 30, 2021 Compared with Nine Months Ended September 30, 2020
Net revenues, which include excise taxes billed to customers, decreased $247 million (1.4%), due primarily to lower shipment volume ($1,539 million), partially offset by higher pricing ($1,284 million).
64
Reported OCI increased $292 million (3.8%), due primarily to higher pricing ($1,273 million), NPM Adjustment Items in 2021 ($53 million) and COVID-19 special items in 2020 ($41 million), partially offset by lower shipment volume ($923 million), higher per unit settlement charges and higher marketing, administration and research costs ($27 million).
Adjusted OCI increased $197 million (2.6%), due primarily to higher pricing, partially offset by lower shipment volume, higher per unit settlement charges and higher marketing, administration and research costs.
Three Months Ended September 30, 2021 Compared with Three Months Ended September 30, 2020
Net revenues, which include excise taxes billed to customers, decreased $338 million (5.4%), due primarily to lower shipment volume ($925 million), partially offset by higher pricing ($570 million), which includes lower promotional investments.
Reported OCI decreased $36 million (1.3%), due primarily to lower shipment volume ($546 million) and higher per unit settlement charges, partially offset by higher pricing ($567 million), which includes lower promotional investments and NPM Adjustment Items in 2021 ($21 million).
Adjusted OCI decreased $62 million (2.2%), due primarily to lower shipment volume and higher per unit settlement charges, partially offset by higher pricing, which includes lower promotional investments.
Shipment Volume and Retail Share Results
The following table summarizes the smokeable products segment shipment volume performance:
Shipment Volume
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(sticks in millions)20212020Change20212020 Change
Cigarettes:
     Marlboro63,122 67,890 (7.0)%21,368 24,258 (11.9)%
     Other premium3,180 3,496 (9.0)%1,042 1,231 (15.4)%
     Discount5,068 6,205 (18.3)%1,640 2,130 (23.0)%
Total cigarettes71,370 77,591 (8.0)%24,050 27,619 (12.9)%
Cigars:
     Black & Mild1,356 1,317 3.0 %424 468 (9.4)%
     Other5 8 (37.5)%1 3 (66.7)%
Total cigars1,361 1,325 2.7 %425 471 (9.8)%
Total smokeable products72,731 78,916 (7.8)%24,475 28,090 (12.9)%
Note: Cigarettes shipment volume includes Marlboro; Other premium brands, such as Virginia Slims, Parliament, Benson & Hedges and Nat’s; and Discount brands, which include L&M, Basic and Chesterfield. Cigarettes volume includes units sold as well as promotional units, but excludes units sold for distribution to Puerto Rico, and units sold in U.S. Territories, to overseas military and by Philip Morris Duty Free Inc., none of which, individually or in the aggregate, is material to the smokeable products segment.
The following table summarizes cigarettes retail share performance:
Retail Share
For the Nine Months Ended September 30,For the Three Months Ended September 30,
20212020Percentage Point Change20212020Percentage Point Change
Cigarettes:
     Marlboro43.2 %42.8 %0.4 43.2 %43.2 %— 
     Other premium2.3 2.3 — 2.3 2.3 — 
     Discount3.5 4.0 (0.5)3.4 3.8 (0.4)
Total cigarettes49.0 %49.1 %(0.1)48.9 %49.3 %(0.4)
Note: Retail share results for cigarettes are based on data from IRI/Management Science Associates, Inc., a tracking service that uses a sample of stores and certain wholesale shipments to project market share and depict share trends. This service tracks sales in the food, drug, mass merchandisers, convenience, military, dollar store and club trade classes. For other trade classes selling cigarettes, retail share is based on shipments from wholesalers to retailers through the Store Tracking Analytical Reporting System (“STARS”). This service is not designed to
65
capture sales through other channels, including the internet, direct mail and some illicitly tax-advantaged outlets. It is IRI’s standard practice to periodically refresh its services, which could restate retail share results that were previously released in this service.
For a discussion of volume trends and factors that impact volume and retail share performance, see Tobacco Space - Business Environment above.
Nine Months Ended September 30, 2021 Compared with the Nine Months Ended September 30, 2020
The smokeable products segment’s reported domestic cigarettes shipment volume decreased 8.0%, driven primarily by the industry’s rate of decline, trade inventory movements, calendar differences and other factors. When adjusted for trade inventory movements, calendar differences and other factors, the smokeable products segment’s reported domestic cigarettes shipment volume decreased by an estimated 5%. When adjusted for trade inventory movements, calendar differences and other factors, total estimated domestic cigarette industry volume decreased by an estimated 5%.
Shipments of premium cigarettes accounted for 92.9% and 92.0% of the smokeable products segment’s reported domestic cigarettes shipment volume for the nine months ended September 30, 2021 and 2020, respectively.
Total cigarettes industry discount category retail share increased 0.3 share points to 25.2%.
Three Months Ended September 30, 2021 Compared with the Three Months Ended September 30, 2020
The smokeable products segment’s reported domestic cigarettes shipment volume decreased 12.9%, driven primarily by the industry’s rate of decline and trade inventory movements. When adjusted for trade inventory movements, the smokeable products segment’s reported domestic cigarettes shipment volume decreased by an estimated 7%. When adjusted for trade inventory movements and other factors, total estimated domestic cigarette industry volume decreased by an estimated 6.5%.
Shipments of premium cigarettes accounted for 93.2% and 92.3% of the smokeable products segment’s reported domestic cigarettes shipment volume for the three months ended September 30, 2021 and 2020, respectively.
Total cigarettes industry discount category retail share increased 0.6 share points sequentially to 25.3%.
Pricing Actions
PM USA and Middleton executed the following pricing and promotional allowance actions during 2021 and 2020:
▪Effective August 15, 2021, PM USA increased the list price of Marlboro, L&M and Chesterfield by $0.14 per pack. In addition, PM USA increased the list price of all of its other cigarette brands by $0.17 per pack.
▪Effective January 24, 2021, PM USA increased the list price on all of its cigarette brands by $0.14 per pack.
▪Effective January 10, 2021, Middleton increased various list prices across substantially all of its cigar brands resulting in a weighted-average increase of approximately $0.07 per five-pack.
▪Effective November 1, 2020, PM USA increased the list price on all of its cigarette brands by $0.13 per pack.
▪Effective June 21, 2020, PM USA increased the list price on all of its cigarette brands by $0.11 per pack.
▪Effective February 16, 2020, PM USA increased the list price on all of its cigarette brands by $0.08 per pack.
▪Effective January 12, 2020, Middleton increased various list prices across substantially all of its cigar brands resulting in a weighted-average increase of approximately $0.08 per five-pack.
66
Oral Tobacco Products Segment
Financial Results
The following table summarizes operating results, includes reported and adjusted OCI margins, and provides a reconciliation of reported OCI to adjusted OCI for the oral tobacco products segment:
Operating Results
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)20212020Change20212020Change
Net revenues$1,945 $1,901 2.3 %$626 $640 (2.2)%
Excise taxes(98)(98)(32)(33)
Revenues net of excise taxes$1,847 $1,803 $594 $607 
Reported OCI$1,269 $1,297 (2.2)%$405 $436 (7.1)%
Acquisition-related costs37 6 — 4 
COVID-19 special items— 9 — — 
Adjusted OCI$1,306 $1,312 (0.5)%$405 $440 (8.0)%
Reported OCI margins (1)
68.7 %71.9 %(3.2) pp68.2 %71.8 %(3.6) pp
Adjusted OCI margins (1)
70.7 %72.8 %(2.1) pp68.2 %72.5 %(4.3) pp
(1) Reported and adjusted OCI margins are calculated as reported and adjusted OCI, respectively, divided by revenues net of excise taxes.
Nine Months Ended September 30, 2021 Compared with Nine Months Ended September 30, 2020
Net revenues, which include excise taxes billed to customers, increased $44 million (2.3%), due primarily to higher pricing ($72 million), which includes higher promotional investments in on!, partially offset by lower shipment volume ($29 million), including unfavorable shipment volume mix between the segment’s MST and oral nicotine pouch products.
Reported OCI decreased $28 million (2.2%) due primarily to higher costs ($51 million), which includes higher acquisition-related costs and COVID-19 special items in 2020, and lower shipment volume ($45 million), including unfavorable shipment volume mix), partially offset by higher pricing ($72 million), which includes higher promotional investments in on!.
Adjusted OCI was essentially unchanged as lower volume, including unfavorable shipment volume mix, and higher costs were mostly offset by higher pricing, which includes higher promotional investments in on!. Adjusted OCI margins declined by 2.1 percentage point to 70.7%, due to changes in shipment volume mix between the segment’s MST and oral nicotine pouch products.
Three Months Ended September 30, 2021 Compared with Three Months Ended September 30, 2020
Net revenues, which include excise taxes billed to customers, decreased $14 million (2.2%), due primarily to lower shipment volume ($33 million), including unfavorable shipment volume mix, partially offset by higher pricing ($20 million), which includes higher promotional investments in on!.
Reported OCI decreased $31 million (7.1%), due primarily to lower shipment volume ($35 million), including unfavorable shipment volume mix and higher costs ($13 million), including lower acquisition-related costs, partially offset by higher pricing, which includes higher promotional investments in on!.
Adjusted OCI decreased $35 million (8.0%), due primarily to lower shipment volume, including unfavorable shipment volume mix, and higher costs, partially offset by higher pricing, which includes higher promotional investments in on!. Adjusted OCI margins declined by 4.3 percentage points to 68.2%, due to changes in shipment volume mix between the segment’s MST and oral nicotine pouch products.
67
Shipment Volume and Retail Share Results
The following table summarizes oral tobacco products segment shipment volume performance:
Shipment Volume
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(cans and packs in millions)20212020Change20212020Change
Copenhagen378.4 395.0 (4.2)%121.4 131.1 (7.4)%
Skoal148.2 157.2 (5.7)%47.7 52.3 (8.8)%
Other (includes Red Seal and on!)
87.7 65.0 34.9 %29.7 23.3 27.5 %
Total oral tobacco products614.3 617.2 (0.5)%198.8 206.7 (3.8)%
Note: Oral tobacco products shipment volume includes cans and packs sold, as well as promotional units, but excludes international volume, which is currently not material to the oral tobacco products segment. New types of oral tobacco products, as well as new packaging configurations of existing oral tobacco products, may or may not be equivalent to existing MST products on a can-for-can basis. To calculate volumes of cans and packs shipped, one pack of snus or one can of oral nicotine pouches, irrespective of the number of pouches in the pack or can, is assumed to be equivalent to one can of MST.
The following table summarizes oral tobacco products segment retail share performance (excluding international volume):
Retail Share
For the Nine Months Ended September 30,For the Three Months Ended September 30,
20212020Percentage Point Change20212020Percentage Point Change
Copenhagen29.8 %32.1 %(2.3)29.2 %31.8 %(2.6)
Skoal12.7 14.1 (1.4)12.5 13.7 (1.2)
Other (includes Red Seal and on!)
5.4 3.9 1.5 6.1 4.5 1.6 
Total oral tobacco products47.9 %50.1 %(2.2)47.8 %50.0 %(2.2)
Note: Retail share results for oral tobacco products are based on data from IRI InfoScan, a tracking service that uses a sample of stores to project market share and depict share trends.  This service tracks sales in the food, drug, mass merchandisers, convenience, military, dollar store and club trade classes on the number of cans and packs sold.  Oral tobacco products is defined by IRI as MST, snus and oral nicotine pouches. New types of oral tobacco products, as well as new packaging configurations of existing oral tobacco products, may or may not be equivalent to existing MST products on a can-for-can basis. For example, one pack of snus or one can of oral nicotine pouches, irrespective of the number of pouches in the pack or can, is assumed to be equivalent to one can of MST. Because this service represents retail share performance only in key trade channels, it should not be considered a precise measurement of actual retail share.  It is IRI’s standard practice to periodically refresh its InfoScan services, which could restate retail share results that were previously released in this service.
For a discussion of volume trends and factors that impact volume and retail share performance, see Tobacco Space - Business Environment above.
Nine Months Ended September 30, 2021 Compared with the Nine Months Ended September 30, 2020
The oral tobacco products segment’s reported domestic shipment volume decreased 0.5%, driven primarily by retail share losses (primarily due to the growth of oral nicotine pouches) and calendar differences, partially offset by industry growth and trade inventory movements. When adjusted for trade inventory movements and calendar differences, the oral tobacco products segment’s reported domestic shipment volume decreased by an estimated 0.5%.
Total oral tobacco products category industry volume increased by an estimated 3% over the six months ended September 30, 2021, driven by growth in oral nicotine pouches.
Retail share losses in the oral tobacco products segment, including Copenhagen, were due to the growth of oral nicotine pouches.
Three Months Ended September 30, 2021 Compared with the Three Months Ended September 30, 2020
The oral tobacco products segment’s reported domestic shipment volume decreased 3.8%, driven primarily by retail share losses (primarily due to the growth of oral nicotine pouches) and trade inventory movements, partially offset by industry growth, calendar differences and other factors. When adjusted for trade inventory movements and calendar differences, the oral tobacco products segment’s reported domestic shipment volume decreased by an estimated 2.5%.
68
The oral tobacco products segment’s retail share was 47.8% and Copenhagen continued to be the leading oral tobacco brand with retail share of 29.2%. Share losses in the oral tobacco products segment, including Copenhagen, were due to the growth of oral nicotine pouches.
Total U.S. oral tobacco category share for on! was 3.0% in the third quarter, an increase of 1.0 percentage point sequentially and an increase of 1.9 percentage points from the end of 2020.
As of September 30, 2021, Helix had broadened the U.S. distribution of on! to over 110,000 stores.
Pricing Actions
USSTC executed the following pricing actions during 2021 and 2020:
▪Effective October 26, 2021, USSTC increased the list price on its Copenhagen and Skoal brands by $0.08 per can. USSTC also increased the list price on its Husky brand by $0.12 per can. In addition, USSTC decreased the price on its Red Seal brand by $0.17 per can.
▪Effective June 29, 2021, USSTC increased the list price on its Skoal Blend products by $0.46 per can. USSTC also increased the list price on its Red Seal and Copenhagen brands and the balance of its Skoal products by $0.05 per can. In addition, USSTC decreased the price on its Husky brand by $1.65 per can.
▪Effective March 2, 2021, USSTC increased the list price on its Skoal Blend products by $0.16 per can. USSTC also increased the list price on its Husky, Red Seal and Copenhagen brands and the balance of its Skoal products by $0.08 per can.
▪Effective October 20, 2020, USSTC increased the list price on its Skoal Blend products by $0.15 per can. USSTC also increased the list price on its Husky and Red Seal brands and its Copenhagen and Skoal popular price products by $0.08 per can. In addition, USSTC increased the list price on the balance of its Copenhagen and Skoal products by $0.07 per can.
▪Effective July 21, 2020, USSTC increased the list price on its Skoal Blend products by $0.15 per can.  USSTC also increased the list price on its Husky, Red Seal and Copenhagen brands and the balance of its Skoal products by $0.07 per can.
▪Effective February 18, 2020, USSTC increased the list price on its Skoal X-TRA products by $0.56 per can. USSTC also increased the list price on its Skoal Blend products by $0.16 cents per can and increased the list price on its Husky, Red Seal and Copenhagen brands and the balance of its Skoal products by $0.07 per can.

Wine Segment
Operating Results
Financial Results and Shipment Volume
The following table summarizes operating results, includes reported and adjusted OCI margins, and provides a reconciliation of reported OCI to adjusted OCI for the wine segment:
Operating Results
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)20212020Change20212020Change
Net revenues$494 $434 13.8 %$177 $157 12.7 %
Excise taxes(14)(14)(5)(5)
Revenues net of excise taxes$480 $420 $172 $152 
Reported OCI (Loss)$21 $(347)100.0%+$(24)$19 (100.0)%+
Implementation and disposition-related costs52 395 51 1 
Adjusted OCI$73 $48 52.1 %$27 $20 35.0 %
Reported OCI margins (1)
4.4 %(82.6)%87.0 pp(14.0)%12.5 %(26.5) pp
Adjusted OCI margins (1)
15.2 %11.4 %3.8 pp15.7 %13.2 %2.5 pp
(1) Reported and adjusted OCI margins are calculated as reported and adjusted OCI, respectively, divided by revenues net of excise taxes.
69
Nine Months Ended September 30, 2021 Compared with Nine Months Ended September 30, 2020
Net revenues, which include excise taxes billed to customers, increased $60 million (13.8%), due to higher shipment volume, improved mix and higher pricing.
Reported OCI increased $368 million (100%+), due primarily to 2020 inventory-related charges discussed in Note 9 (included in implementation costs and charged to cost of sales), higher shipment volume, improved mix and higher pricing, partially offset by disposition-related charges recorded in the third quarter of 2021 related to the Ste. Michelle Transaction.
Adjusted OCI increased $25 million (52.1%), due primarily to higher shipment volume, improved mix and higher pricing.
For the nine months ended September 30, 2021, Ste. Michelle’s reported wine shipment volume increased 5.1% to 5,446 thousand cases.
Three Months Ended September 30, 2021 Compared with Three Months Ended September 30, 2020
Net revenues, which include excise taxes billed to customers, increased $20 million (12.7%), due primarily to improved mix and higher pricing.
Reported OCI decreased $43 million (100.0%+), due primarily to disposition-related charges related to the Ste. Michelle Transaction, partially offset by higher pricing and improved mix.
Adjusted OCI increased $7 million (35.0%), due primarily to higher pricing and improved mix.
For the three months ended September 30, 2021, Ste. Michelle’s reported wine shipment volume decreased 2.6% to 1,836 thousand cases.

Financial Review
Cash Provided by/Used in Operating Activities
During the first nine months of 2021, net cash provided by operating activities was $5,742 million compared with $5,844 million during the first nine months of 2020. This decrease was due primarily to higher settlement and income tax payments, partially offset by lower excise tax payments due to lower volume.
Altria had a working capital deficit at September 30, 2021 and December 31, 2020. Altria’s management believes that Altria has the ability to fund working capital deficits with cash provided by operating activities and borrowings through its access to credit and capital markets, as discussed in the Debt and Liquidity section below.
Cash Provided by/Used in Investing Activities
During the first nine months of 2021, net cash used in investing activities was $42 million compared with $107 million during the first nine months of 2020. This decrease was due primarily to lower capital expenditures.
Capital expenditures for 2021 are expected to be in the range of $150 million to $200 million, a reduction from the previous range of $200 million to $250 million, and are expected to be funded from operating cash flows.
Cash Provided by/Used in Financing Activities
During the first nine months of 2021, net cash used in financing activities was $7,668 million compared with $3,713 million during the first nine months of 2020. This change was due primarily to the following:
▪repayment of $5.0 billion of Altria senior unsecured notes in connection with the 2021 debt tender offers and redemption and the premiums and fees in connection with the debt tender offers described below and in Note 10;
▪proceeds of $2.0 billion from the issuance of long-term senior unsecured notes in 2020;
▪repayment of $1.5 billion in full of Altria senior unsecured notes at scheduled maturity in May 2021;
▪repurchases of common stock in 2021;
▪higher dividends paid in 2021; and
▪purchase of the remaining 20% interest in Helix;
partially offset by:
▪proceeds of $5.5 billion from the issuance of long-term senior unsecured notes used to repurchase and redeem senior unsecured notes in connection with the 2021 debt tender offers and redemption; and
▪repayment of $1.0 billion in full of Altria senior unsecured notes at scheduled maturity in January 2020.
70
Debt and Liquidity
Source of Funds - Altria is a holding company. As a result, its access to the operating cash flows of its wholly owned subsidiaries consists of cash received from the payment of dividends and distributions, and the payment of interest on intercompany loans by its subsidiaries. In addition, Altria receives cash dividends on its interest in ABI and will continue to do so as long as ABI pays dividends.
Credit Ratings - Altria’s cost and terms of financing and its access to commercial paper markets may be impacted by applicable credit ratings. The impact of credit ratings on the cost of borrowings under the Credit Agreement (as defined below) is discussed in Note 10.
At September 30, 2021, the credit ratings and outlook for Altria’s indebtedness by major credit rating agencies were:
Short-term DebtLong-term DebtOutlook
Moody’s Investors Service, Inc. (“Moody’s”) P-2 A3 Stable
Standard & Poor’s Financial Services LLC (“S&P”) A-2BBB Stable
Fitch Ratings Inc. F2BBB Stable
Credit Lines - From time to time, Altria has short-term borrowing needs to meet its working capital requirements and generally uses its commercial paper program to meet those needs.
In August 2021, Altria entered into an extension and amendment to its $3.0 billion senior unsecured 5-year revolving credit agreement (as amended, the “Credit Agreement”). For further discussion, see Note 10.
Any commercial paper issued by Altria and borrowings under the Credit Agreement are guaranteed by PM USA. For further discussion, see Supplemental Guarantor Financial Information below and Note 10.
Financial Market Environment - Altria believes it has adequate liquidity and access to financial resources to meet its anticipated obligations and ongoing business needs in the foreseeable future. Altria monitors the credit quality of its bank group and is not aware of any potential non-performing credit provider in that group.
Ste. Michelle Transaction - On October 1, 2021, UST received net cash proceeds of approximately $1.2 billion from the sale of its wine business.
Debt - At September 30, 2021 and December 31, 2020, Altria’s total debt was $28.1 billion and $29.5 billion, respectively.
In May 2021, Altria repaid in full senior unsecured notes in the aggregate principal amount of $1.5 billion at maturity.
In February 2021, Altria issued long-term senior unsecured notes in the aggregate principal amount of $5.5 billion (the “Notes”). The net proceeds from the Notes were used (i) to fund the purchase and redemption of certain unsecured notes and payment of related fees and expenses, as described below, and (ii) for other general corporate purposes.
During the first quarter of 2021, Altria (i) completed debt tender offers to purchase for cash certain of its long-term senior unsecured notes in the aggregate principal amount of $4,042 million and (ii) redeemed all of its outstanding 3.490% Notes due 2022 in an aggregate principal amount of $1.0 billion. As a result, for the nine months ended September 30, 2021, Altria recorded pre-tax losses on early extinguishment of debt of $649 million, which included premiums and fees of $623 million and the write-off of related unamortized debt discounts and debt issuance costs of $26 million.
As a result of the first quarter debt transactions, Altria reduced its near-term maturity towers and extended the weighted-average maturity of its debt. In addition, the weighted-average coupon interest rate on total long-term debt decreased to 4.0% at September 30, 2021 from 4.1% at December 31, 2020.
For further details on long-term debt, including the terms of the Notes, the debt tender offers and the redemption, see Note 10.
Guarantees and Other Similar Matters - As discussed in Note 12, Altria and certain of its subsidiaries had unused letters of credit obtained in the ordinary course of business, guarantees (including third-party guarantees) and a redeemable noncontrolling interest outstanding at September 30, 2021. From time to time, subsidiaries of Altria also issue lines of credit to affiliated entities. In addition, as discussed below in Supplemental Guarantor Financial Information and in Note 10, PM USA has issued guarantees relating to Altria’s obligations under its outstanding debt securities, borrowings under the Credit Agreement and amounts outstanding under the commercial paper program. These items have not had, and are not expected to have, a significant impact on Altria’s liquidity. For further discussion regarding Altria’s liquidity, see the Debt and Liquidity section above.
Payments Under State Settlement Agreements and FDA Regulation - As discussed previously and in Note 12, PM USA has entered into State Settlement Agreements with the states and territories of the United States that call for certain payments. In addition, PM USA, Middleton and USSTC are subject to quarterly user fees imposed by the FDA as a result of the FSPTCA. Altria’s subsidiaries recorded $3.4 billion and $3.6 billion of charges to cost of sales for the nine months ended September 30,
71
2021 and 2020, respectively, and $1.2 billion and $1.3 billion of charges to cost of sales for the three months ended September 30, 2021 and 2020, in connection with the State Settlement Agreements and FDA user fees. For further discussion of the resolutions of certain disputes with states and territories related to the NPM adjustment provision under the 1998 Master Settlement Agreement, see Health Care Cost Recovery Litigation - NPM Adjustment Disputes in Note 12.
Based on current agreements, 2020 market share and estimated annual industry volume decline rates, the estimated amounts that Altria’s subsidiaries may charge to cost of sales for payments related to State Settlement Agreements and FDA user fees are $4.5 billion on average for the next three years. These amounts exclude the potential impact of any NPM Adjustment Items.
The estimated amounts due under the State Settlement Agreements charged to cost of sales in each year would generally be paid in the following year. The amounts charged to cost of sales for FDA user fees are generally paid in the quarter in which the fees are incurred. As previously stated, the payments due under the terms of the State Settlement Agreements and FDA user fees are subject to adjustment for several factors, including volume, operating income, inflation and certain contingent events and, in general, are allocated based on each manufacturer’s market share. The future payment amounts discussed above are estimates, and actual payment amounts will differ to the extent underlying assumptions differ from actual future results.
Litigation-Related Deposits and Payments - With respect to certain adverse verdicts currently on appeal, to obtain stays of judgments pending appeals, as of September 30, 2021, PM USA had posted appeal bonds totaling $45 million, which have been collateralized with restricted cash that is included in assets on the condensed consolidated balance sheet.
Although litigation is subject to uncertainty and an adverse outcome or settlement of litigation could have a material adverse effect on the financial position, cash flows or results of operations of PM USA, UST or Altria in a particular fiscal quarter or fiscal year, as more fully disclosed in Note 12, management expects cash flow from operations, together with Altria’s access to capital markets, to provide sufficient liquidity to meet ongoing business needs.
Equity and Dividends
Dividends paid during the first nine months of 2021 and 2020 were $4,787 million and $4,690 million, respectively, an increase of 2.1%, reflecting a higher dividend rate, partially offset by fewer shares outstanding as a result of shares repurchased by Altria in 2021 under its share repurchase program.
In August 2021, the Board of Directors (the “Board of Directors” or “Board”) declared a 4.7% increase in the quarterly dividend rate to $0.90 per share of Altria common stock versus the previous rate of $0.86 per share. The current annualized dividend rate is $3.60 per share. Altria maintains its long-term objective of a dividend payout ratio target of approximately 80% of its adjusted diluted EPS. Future dividend payments remain subject to the discretion of the Board.
In October 2021, the Board authorized a $1.5 billion expansion of Altria’s existing share repurchase program from $2.0 billion to $3.5 billion, partially funded by the net cash proceeds from the Ste. Michelle Transaction. Altria expects to complete the expanded program by December 31, 2022. The timing of share repurchases under this program depends upon marketplace conditions and other factors, and the program remains subject to the discretion of the Board. For a discussion of Altria’s share repurchase programs, see Note 1. Background and Basis of Presentation to the condensed consolidated financial statements in Item 1 and Part II, Item 2. Unregistered Sales of Equity Securities and Use of Proceeds of this Form 10-Q.
New Accounting Guidance Not Yet Adopted
See Note 13. New Accounting Guidance Not Yet Adopted to the condensed consolidated financial statements in Item 1 for a discussion of issued accounting guidance applicable to, but not yet adopted by, Altria.
Contingencies
See Note 12 for a discussion of contingencies.
Supplemental Guarantor Financial Information
PM USA (the “Guarantor”), which is a 100% owned subsidiary of Altria Group, Inc. (the “Parent”), has guaranteed the Parent’s obligations under its outstanding debt securities, borrowings under its Credit Agreement and amounts outstanding under its commercial paper program (the “Guarantees”). Pursuant to the Guarantees, the Guarantor fully and unconditionally guarantees, as primary obligor, the payment and performance of the Parent’s obligations under the guaranteed debt instruments (the “Obligations”), subject to release under certain customary circumstances as noted below.
The Guarantees provide that the Guarantor guarantees the punctual payment when due, whether at stated maturity, by acceleration or otherwise, of the Obligations. The liability of the Guarantor under the Guarantees is absolute and unconditional irrespective of: any lack of validity, enforceability or genuineness of any provision of any agreement or instrument relating thereto; any change in the time, manner or place of payment of, or in any other term of, all or any of the Obligations, or any other amendment or waiver of or any consent to departure from any agreement or instrument relating thereto; any exchange, release or non-perfection of any collateral, or any release or amendment or waiver of or consent to departure from any other guarantee, for all or any of the Obligations; or any other circumstance that might otherwise constitute a defense available to, or
72
a discharge of, the Parent or the Guarantor.
Under applicable provisions of federal bankruptcy law or comparable provisions of state fraudulent transfer law, the Guarantees could be voided, or claims in respect of the Guarantees could be subordinated to the debts of the Guarantor, if, among other things, the Guarantor, at the time it incurred the Obligations evidenced by the Guarantees:
▪received less than reasonably equivalent value or fair consideration therefor; and
▪either:
▪was insolvent or rendered insolvent by reason of such occurrence;
▪was engaged in a business or transaction for which the assets of the Guarantor constituted unreasonably small capital; or
▪intended to incur, or believed that it would incur, debts beyond its ability to pay such debts as they mature.
In addition, under such circumstances, the payment of amounts by the Guarantor pursuant to the Guarantees could be voided and required to be returned to the Guarantor, or to a fund for the benefit of the Guarantor, as the case may be.
The measures of insolvency for purposes of the foregoing considerations will vary depending upon the law applied in any proceeding with respect to the foregoing. Generally, however, the Guarantor would be considered insolvent if:
▪the sum of its debts, including contingent liabilities, was greater than the saleable value of its assets, all at a fair valuation;
▪the present fair saleable value of its assets was less than the amount that would be required to pay its probable liability on its existing debts, including contingent liabilities, as they become absolute and mature; or
▪it could not pay its debts as they become due.
To the extent the Guarantees are voided as a fraudulent conveyance or held unenforceable for any other reason, the holders of the guaranteed debt obligations would not have any claim against the Guarantor and would be creditors solely of the Parent.
The obligations of the Guarantor under the Guarantees are limited to the maximum amount as will not result in the Guarantor’s obligations under the Guarantees constituting a fraudulent transfer or conveyance, after giving effect to such maximum amount and all other contingent and fixed liabilities of the Guarantor that are relevant under Bankruptcy Law, the Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act or any similar federal or state law to the extent applicable to the Guarantees. For this purpose, “Bankruptcy Law” means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.
The Guarantor will be unconditionally released and discharged from the Obligations upon the earliest to occur of:
▪the date, if any, on which the Guarantor consolidates with or merges into the Parent or any successor;
▪the date, if any, on which the Parent or any successor consolidates with or merges into the Guarantor;
▪the payment in full of the Obligations pertaining to such Guarantees; and
▪the rating of the Parent’s long-term senior unsecured debt by S&P of A or higher.
The Parent is a holding company; therefore, its access to the operating cash flows of its wholly owned subsidiaries consists of cash received from the payment of dividends and distributions, and the payment of interest on intercompany loans by its subsidiaries. Neither the Guarantor nor other 100% owned subsidiaries of the Parent that are not guarantors of the debt (“Non-Guarantor Subsidiaries”) are limited by contractual obligations on their ability to pay cash dividends or make other distributions with respect to their equity interests.
The following tables include summarized financial information for the Parent and the Guarantor. Transactions between the Parent and the Guarantor (including investment and intercompany balances as well as equity earnings) have been eliminated. The Parent’s and the Guarantor’s intercompany balances with Non-Guarantor Subsidiaries have been presented separately. This summarized financial information is not intended to present the financial position or results of operations of the Parent or the Guarantor in accordance with GAAP.
73
Summarized Balance Sheets
(in millions of dollars)
ParentGuarantor
 September 30, 2021December 31, 2020September 30, 2021December 31, 2020
Assets
Due from Non-Guarantor Subsidiaries
$81 $112 $199 $199 
Other current assets3,076 4,896 962 734 
Total current assets$3,157 $5,008 $1,161 $933 
Due from Non-Guarantor Subsidiaries
$4,790 $4,790 $— $— 
Other assets11,292 16,883 1,850 1,983 
Total non-current assets$16,082 $21,673 $1,850 $1,983 
Liabilities
Due to Non-Guarantor Subsidiaries
$1,232 $1,169 $756 $656 
Other current liabilities3,123 3,688 4,071 4,539 
Total current liabilities$4,355 $4,857 $4,827 $5,195 
Total non-current liabilities$28,923 $30,958 $1,052 $1,268 

Summarized Statements of Earnings (Losses)
(in millions of dollars)
For the Nine Months Ended
September 30, 2021
 
Parent (1)
Guarantor
Net revenues$— $16,517 
Gross profit— 8,425 
Net earnings (losses)(5,611)5,514 
(1) For the nine months ended September 30, 2021, net earnings (losses) include $174 million of intercompany interest income from non-guarantor subsidiaries.
Cautionary Factors That May Affect Future Results
Forward-Looking and Cautionary Statements
We may from time to time make written or oral forward-looking statements, including earnings guidance and other statements contained in filings with the SEC, reports to security holders, press releases and investor webcasts. You can identify these forward-looking statements by use of words such as “strategy,” “expects,” “continues,” “plans,” “anticipates,” “believes,” “will,” “estimates,” “forecasts,” “intends,” “projects,” “goals,” “objectives,” “guidance,” “targets” and other words of similar meaning. You can also identify them by the fact that they do not relate strictly to historical or current facts.
We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans, estimates and assumptions. Achievement of future results is subject to risks, uncertainties and assumptions that may prove to be inaccurate. Should known or unknown risks or uncertainties materialize, or should underlying estimates or assumptions prove inaccurate, actual results could differ materially from those anticipated, estimated or projected. You should bear this in mind as you consider forward-looking statements and whether to invest in or remain invested in Altria’s securities. In connection with the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, we are identifying important factors that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in, or implied by, any forward-looking statements made by Altria; any such statement is qualified by reference to the following cautionary statements. We elaborate on these important factors and the risks we face throughout this Form 10-Q, particularly in Item 1A and the “Business Environment” section preceding our discussion of the operating results of our
74
segments, and in our publicly filed reports, including our 2020 Form 10-K and our Second Quarter 2021 Form 10-Q. These factors include the following:
▪unfavorable litigation outcomes, including risks associated with adverse jury and judicial determinations, courts and arbitrators reaching conclusions at variance with our, our subsidiaries’ or our investees’ understanding of applicable law, bonding requirements in the jurisdictions that do not limit the dollar amount of appeal bonds, and certain challenges to bond cap statutes;
▪government (including the FDA) and private sector actions that impact adult tobacco consumer acceptability of, or access to, tobacco products;
▪tobacco product taxation, including lower tobacco product consumption levels and potential shifts in adult consumer purchases as a result of federal, state and local excise tax increases;
▪unfavorable outcomes of any government investigations of Altria, our subsidiaries or investees;
▪a successful challenge to our tax positions, an increase to the corporate income tax rate or other changes to federal or state tax laws;
▪the risks related to our and our investees’ international business operations, including failure to prevent violations of various U.S. and foreign laws and regulations such as foreign privacy laws and laws prohibiting bribery and corruption;
▪the risks associated with health epidemics and pandemics, including the COVID-19 pandemic and similar outbreaks, such as their impact on our financial performance and financial condition and on our subsidiaries’ and investees’ ability to continue manufacturing and distributing products, including as a result of labor shortages, and the impact of health epidemics and pandemics on general economic conditions (including any resulting recession or other economic crisis) and, in turn, adult consumer purchasing behavior, which may be further adversely impacted by any reductions in, or eliminations of, government stimulus or unemployment payments;
▪the failure of our tobacco subsidiaries and our investees to compete effectively in their respective markets;
▪the growth of the e-vapor category and other innovative tobacco products, including oral nicotine pouches, contributing to reductions in cigarette and MST consumption levels and sales volume;
▪our tobacco subsidiaries’ and our investees’ continued ability to promote brand equity successfully; to anticipate and respond to evolving adult consumer preferences; to develop, manufacture, market and distribute products that appeal to adult consumers (including, where appropriate, through arrangements with, and investments in third parties); to improve productivity; and to protect or enhance margins through cost savings and price increases;
▪changes, including in economic conditions (due to the COVID-19 pandemic or otherwise), that result in adult consumers choosing lower-priced brands, including discount brands;
▪the unsuccessful commercialization of adjacent products or processes by our tobacco subsidiaries and investees, including innovative tobacco products that may reduce the health risks associated with cigarettes and other traditional tobacco products, and that appeal to adult tobacco consumers;
▪significant changes in price, availability or quality of tobacco, other raw materials or component parts, including as a result of the COVID-19 pandemic;
▪the risks related to the reliance by our tobacco subsidiaries on a few significant facilities and a small number of key suppliers, distributors and distribution chain service providers, and the risk of an extended disruption at a facility of, or of service by, a supplier, distributor or distribution chain service provider of our tobacco subsidiaries or investees, including as a result of the COVID-19 pandemic;
▪required or voluntary product recalls as a result of various circumstances such as product contamination or FDA or other regulatory action;
▪the failure of our information systems or service providers’ information systems to function as intended, or cyber attacks or security breaches;
▪our inability to attract and retain the best talent due to the impact of decreasing social acceptance of tobacco usage, tobacco control actions and other factors;
▪impairment losses as a result of the write down of intangible assets, including goodwill;
▪the adverse effect of acquisitions, investments, dispositions or other events on our credit rating;
▪our inability to acquire attractive businesses or make attractive investments on favorable terms, or at all, or to realize the anticipated benefits from an acquisition or investment and our inability to dispose of businesses or investments on favorable terms or at all;
75
▪the risks related to disruption and uncertainty in the credit and capital markets, including risk of access to these markets both generally and at current prevailing rates, which may adversely affect our earnings or dividend rate or both;
▪our inability to attract and retain investors due to the impact of decreasing social acceptance of tobacco usage or unfavorable environmental, social and governance ratings;
▪the risk that any challenge to our investment in JUUL, if successful, could result in a broad range of resolutions, including divestiture of the investment or rescission of the transaction;
▪the risks generally related to our investments in JUUL and Cronos, including our inability to realize the expected benefits of our investments in the expected time frames, or at all, due to the risks encountered by our investees in their businesses, such as operational, competitive, compliance, legislative and regulatory risks at the international, federal, state and local levels, including actions by the FDA, and adverse publicity; potential disruptions to our investees’ management or current or future plans and operations; domestic or international litigation developments, government investigations, tax disputes or otherwise; and impairment of our investment in Cronos and changes in the fair value of our investment in JUUL;
▪the risks related to our inability to acquire a controlling interest in JUUL as a result of standstill restrictions or to control the material decisions of JUUL, restrictions on our ability to sell or otherwise transfer our shares of JUUL until December 20, 2024, and non-competition restrictions for the same time period subject to certain exceptions;
▪the adverse effects of risks encountered by ABI in its business, including effects of the COVID-19 pandemic, foreign currency exchange rates and the impact of movements in ABI’s stock price on our equity investment in ABI, including on our reported earnings from and carrying value of our investment in ABI, which could result in additional impairments of our investment, and the dividends paid by ABI on the shares we own;
▪the risks related to our ownership percentage in ABI decreasing below certain levels, including additional tax liabilities, a reduction in the number of directors that we have the right to have appointed to the ABI board of directors and our potential inability to use the equity method of accounting for our investment in ABI;
▪the risk of challenges to the tax treatment of the consideration we received in the ABI/SABMiller business combination and the tax treatment of our equity investment; and
▪the risks, including criminal, civil or tax liability for Altria, related to Altria’s or Cronos’s failure to comply with applicable laws, including cannabis laws.
You should understand that it is not possible to predict or identify all factors and risks. Consequently, you should not consider the foregoing list to be complete. We do not undertake to update any forward-looking statement that we may make from time to time except as required by applicable law.

Item 3. Quantitative and Qualitative Disclosures About Market Risk
Interest Rate Risk
The fair value of Altria’s long-term debt, all of which is fixed-rate debt, is subject to fluctuations resulting from changes in market interest rates. The following table provides the fair value of Altria’s long-term debt and the change in fair value based on a 1% increase or decrease in market interest rates at September 30, 2021 and December 31, 2020:
(in billions)September 30, 2021December 31, 2020
Fair value$31.0 $34.7 
Decrease in fair value from a 1% increase in market interest rates2.8 2.7 
Increase in fair value from a 1% decrease in market interest rates3.3 3.1 
Interest rates on borrowings under the Credit Agreement are expected to be based on the London Interbank Offered Rate, or a fallback benchmark rate determined based on prevailing market convention, plus a percentage based on the higher of the ratings of Altria’s long-term senior unsecured debt from Moody’s and S&P. The applicable percentage based on Altria’s long-term senior unsecured debt ratings at September 30, 2021 borrowings under the Credit Agreement was 1.0%. At September 30, 2021 and December 31, 2020, Altria had no borrowings under the Credit Agreement.
Equity Price Risk
The estimated fair values of the Fixed-price Preemptive Rights and the Cronos warrant are subject to equity price risk. The Fixed-price Preemptive Rights and warrant are recorded at fair value, which is estimated using Black-Scholes option-pricing models. The fair values of the Fixed-price Preemptive Rights and Cronos warrant are subject to fluctuations resulting from changes in the quoted market price of Cronos shares, the underlying equity security.
76
The following table provides (i) fair values of the Fixed-price Preemptive Rights and Cronos warrants and (ii) the change in fair value based on a 10% increase or decrease in the quoted market price of Cronos shares at September 30, 2021 and December 31, 2020:
Fixed-price Preemptive RightsCronos Warrant
(in millions)September 30, 2021December 31, 2020September 30, 2021December 31, 2020
Fair values$3 $24 $32 $139 
Change in fair value based on a 10% increase/decrease in the quoted market price of Cronos shares1 6 11 28 


Item 4. Controls and Procedures
Altria carried out an evaluation, with the participation of Altria’s management, including its Chief Executive Officer and Chief Financial Officer, of the effectiveness of its disclosure controls and procedures (as defined in Rule 13a-15(e)) under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this Form 10-Q. Based upon that evaluation, Altria’s Chief Executive Officer and Chief Financial Officer concluded that Altria’s disclosure controls and procedures are effective.
There have been no changes in Altria’s internal control over financial reporting during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, its internal control over financial reporting.

Part II – OTHER INFORMATION
Item 1. Legal Proceedings
See Note 12 for a discussion of legal proceedings pending against Altria and its subsidiaries. See also Exhibits 99.1 and 99.2 to this Form 10-Q.

Item 1A. Risk Factors
Information regarding Risk Factors appears in Part I, Item 1A. Risk Factors of our 2020 Form 10-K and in Part II, Item 1A. Risk Factors of our Second Quarter 2021 Form 10-Q. Except as set forth below, there have been no material changes to the risk factors previously disclosed in our 2020 Form 10-K and in our Second Quarter 2021 Form 10-Q.
Risks Related to Litigation, Legislative or Regulatory Action
A challenge to our tax positions, an increase in the income tax rate or other changes to federal or state tax laws could adversely affect our earnings or cash flow.
Tax laws and regulations, such as the 2017 Tax Cuts and Jobs Act, are complex and subject to varying interpretations. A successful challenge to one or more of Altria’s tax positions (which could give rise to additional liabilities, including interest and potential penalties), an increase in the corporate income tax rate or other changes to federal or state tax laws, including changes in how foreign investments are taxed, could adversely affect our earnings or cash flow.
Risks Related to Our Investments
Altria recorded an impairment charge of $6.2 billion on its investment in ABI for the nine and three months ended September 30, 2021. If the carrying value of our investment in ABI exceeds its fair value and the loss in value is other than temporary, the investment is considered impaired, which would result in additional impairment losses.
As discussed in Note 4, since October 2019, the carrying value of our investment in ABI has exceeded the fair value of our equity investment in ABI. In preparing our financial statements for the period ended September 30, 2021, we concluded that the decline in fair value of our investment in ABI below its carrying value was other than temporary at September 30, 2021. As a result, we recorded a non-cash, pre-tax impairment charge of $6.2 billion for the nine and three months ended September 30, 2021 to income (losses) from equity investments in Altria’s condensed consolidated statements of earnings (losses). This impairment charge reflects the difference between the fair value of our investment in ABI using ABI’s share price at September 30, 2021 and the carrying value of Altria’s equity investment in ABI at September 30, 2021. Additionally, if ABI is unable to successfully execute its business plans and strategies and the fair value of our investment in ABI continues to decrease, it could result in additional impairment losses, which could have a material adverse effect on our consolidated financial position or earnings.
77
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
In January 2021, the Board of Directors authorized a new $2.0 billion share repurchase program, which it expanded to $3.5 billion in October 2021. Altria expects to complete the expanded program by December 31, 2022. The timing of share repurchases under this program depends upon marketplace conditions and other factors, and the program remains subject to the discretion of the Board.
Altria’s share repurchase activity for each of the three months in the period ended September 30, was as follows:
Period
Total Number of Shares Purchased (1)
Average Price Paid Per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or Programs
Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs (2)
July 1-31, 20212,088,922 $47.30 2,088,922 $1,251,200,508 
August 1-31, 20212,381,498 $48.20 2,373,425 $1,136,801,113 
September 1-30, 20212,206,667 $49.51 2,205,774 $1,027,601,765 
6,677,087 $48.35 6,668,121 
(1) The total number of shares purchased includes (a) shares purchased under the January 2021 share repurchase program (which totaled 2,088,922 shares in July, 2,373,425 shares in August and 2,205,774 shares in September) and (b) shares withheld by Altria in an amount equal to the statutory withholding taxes for vested stock-based awards previously granted to eligible employees (which totaled 8,073 shares in August and 893 shares in September).
(2) This chart provides information for each of the three months in the period ended September 30. 2021; therefore, it does not reflect the October 2021 expansion of Altria’s share repurchase program discussed above.

78
Item 6. Exhibits
4.1
22
31.1
31.2
32.1
32.2
99.1
99.2
101.INS
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH
XBRL Taxonomy Extension Schema.
101.CAL
XBRL Taxonomy Extension Calculation Linkbase.
101.DEF
XBRL Taxonomy Extension Definition Linkbase.
101.LAB
XBRL Taxonomy Extension Label Linkbase.
101.PRE
Taxonomy Extension Presentation Linkbase.
104
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).


79


Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ALTRIA GROUP, INC.

/s/ SALVATORE MANCUSO
Salvatore Mancuso
Executive Vice President and
Chief Financial Officer
October 28, 2021
80
 EX-31.1 2 exhibit311q32021.htm CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13A-14(A)/15D-14(A) Document

Exhibit 31.1

Certifications
I, William F. Gifford, Jr., certify that:

1.I have reviewed this quarterly report on Form 10-Q of Altria Group, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 28, 2021
/s/ WILLIAM F. GIFFORD, JR.
William F. Gifford, Jr.
Chief Executive Officer
                                

 EX-31.2 3 exhibit312q32021.htm CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13A-14(A)/15D-14(A) Document

Exhibit 31.2

Certifications
I, Salvatore Mancuso, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Altria Group, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 28, 2021
/s/ SALVATORE MANCUSO
Salvatore Mancuso
Executive Vice President and
Chief Financial Officer

                                

 EX-32.1 4 exhibit321q32021.htm CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. 1350 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Altria Group, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, William F. Gifford, Jr., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

    (1)    the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

    (2)    the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ WILLIAM F. GIFFORD, JR.
William F. Gifford, Jr.
Chief Executive Officer
October 28, 2021





 EX-32.2 5 exhibit322q32021.htm CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. 1350 Document

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Altria Group, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Salvatore Mancuso, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

    (1)    the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

    (2)    the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ SALVATORE MANCUSO
Salvatore Mancuso
Executive Vice President and
Chief Financial Officer
October 28, 2021



 EX-99.1 6 exhibit991q32021.htm CERTAIN LITIGATION MATTERS Document

Exhibit 99.1


CERTAIN LITIGATION MATTERS

As described in Note 12. Contingencies to Altria Group, Inc.’s (“Altria”) condensed consolidated financial statements in Part 1, Item 1 of the Quarterly Report on Form 10-Q to which this Exhibit 99.1 is attached (“Note 12”), there are legal proceedings covering a wide range of matters pending or threatened in various United States and foreign jurisdictions against Altria, its subsidiaries, including Philip Morris USA Inc. (“PM USA”), and their respective indemnitees. Various types of claims may be raised in these proceedings, including product liability, unfair trade practices, antitrust, tax, contraband shipments, patent infringement, employment matters, claims alleging violation of the Racketeer Influenced and Corrupt Organizations Act, claims for contribution and claims of competitors, shareholders or distributors. Claims related to tobacco products generally fall within the following categories: (i) smoking and health cases alleging personal injury brought on behalf of individual plaintiffs, (ii) smoking and health cases primarily alleging personal injury or seeking court-supervised programs for ongoing medical monitoring and purporting to be brought on behalf of a class of individual plaintiffs, including cases in which the aggregated claims of a number of individual plaintiffs are to be tried in a single proceeding, (iii) health care cost recovery cases brought by governmental (both domestic and foreign) plaintiffs seeking reimbursement for health care expenditures allegedly caused by cigarette smoking and/or disgorgement of profits, (iv) class action suits alleging that the use of the terms “Lights” and “Ultra Lights” constitute deceptive and unfair trade practices, common law fraud or statutory fraud, unjust enrichment, breach of warranty, or violations of the Racketeer Influenced and Corrupt Organizations Act, (v) class action suits involving e-vapor products and (vi) international cases. The following lists certain of the pending claims against Altria and PM USA included in these and other categories.

SMOKING AND HEALTH LITIGATION
The following lists the consolidated individual smoking and health cases as well as smoking and health class actions pending against PM USA and, in some cases, Altria and/or its other subsidiaries and affiliates, as of October 25, 2021. See International Cases below for a list of smoking and health class actions pending in Canada.
Flight Attendant Litigation
The settlement agreement entered into in 1997 in the case of Broin, et al. v. Philip Morris Companies Inc., et al., which was brought by flight attendants seeking damages for personal injuries allegedly caused by environmental tobacco smoke, allowed members of the Broin class to file individual lawsuits seeking compensatory damages, but prohibited them from seeking punitive damages. See Note 12 for a discussion of this litigation.
Domestic Class Actions
Engle, et al. v. R.J. Reynolds Tobacco Co., et al., Circuit Court, Eleventh Judicial Circuit, Dade County, Florida, filed May 5, 1994. See Note 12 for a discussion of this case (which has concluded) and the Engle progeny litigation.
Young, et al. v. The American Tobacco Company, et al., Civil District Court, Orleans Parish, Louisiana, filed November 12, 1997.

HEALTH CARE COST RECOVERY LITIGATION
The following lists a health care cost recovery action pending against PM USA and Altria as of October 25, 2021. See International Cases below for a list of international health care cost recovery actions.
Department of Justice Case
The United States of America v. Philip Morris Incorporated, et al., United States District Court, District of Columbia, filed September 22, 1999. See Note 12 for a discussion of this case.

“LIGHTS/ULTRA LIGHTS” CASES
The following lists the “Lights/Ultra Lights” class actions pending against Altria and/or its various subsidiaries and others as of October 25, 2021.
Moore, et al. v. Philip Morris Incorporated, et al., Circuit Court, Marshall County, West Virginia, filed September 17, 2001.
Virden v. Altria Group, Inc., et al., Circuit Court, Hancock County, West Virginia, filed March 28, 2003.

1

CLASS ACTION LAWSUITS INVOLVING E-VAPOR PRODUCTS
The following lists class action lawsuits relating to e-vapor products that are pending against Altria and/or its various subsidiaries and others as of October 25, 2021.
NesSmith, et al. v. JUUL Labs Inc., et al., United States District Court, Middle District of Florida, filed April 15, 2019.
Peavy (formerly Swearingen), et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of Alabama, filed May 31, 2019.
R.E., et al. v. JUUL Labs, Inc., et al., United States District Court, Southern District of West Virginia, filed August 13, 2019.
M.D., et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of Mississippi, filed August 15, 2019.
Oberhauser, et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of California, filed September 12, 2019.
Hochhauser, et al. v. JUUL Labs, Inc., et al., United States District Court, Eastern District of New York, filed October 1, 2019.
Emidy et al. v. JUUL Labs, Inc., et al., United States District Court, Western District of Tennessee, filed October 2, 2019.
Montgomery County, Maryland, et al. v. JUUL Labs, Inc., et al., United States District Court, District of Maryland, filed October 11, 2019.
King County, Washington, et al. v. JUUL Labs, Inc., et al., United States District Court, Western District of Washington, filed October 16, 2019.
City of Rochester, et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of California, filed November 6, 2019.
Jefferson County School District, et al. v. JUUL Labs, Inc., et al., United States District Court, Southern District of Mississippi, filed December 5, 2019.
Ledbetter, et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of Alabama, filed December 12, 2019.
Escambia County School District, et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of Florida, filed December 18, 2019.
Unified School District No. 320, Pottawatomie County, KS, individually and On Behalf Of Others Similarly Situated, v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed December 18, 2019.
School Board of Miami-Dade County, et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of California, filed December 19, 2019.
The School Board of Broward County, et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of California, filed December 19, 2019.
Frederick County, et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of California, filed December 19, 2019.
Imani, et al. v. JUUL Labs, Inc., et al., United States District Court, District of Oregon, filed December 20, 2019.
Cooper, et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of Texas, filed January 9, 2020.
O’Reilly, et al. v. JUUL Labs, Inc., et al., United States District Court, Northern District of California, filed January 13, 2020.
Gabbard, et al. v. JUUL Labs, Inc., et al., United States District Court, Eastern District of Kentucky, filed February 21, 2020.
Peoria Public Schools v. JUUL Labs, Inc., et al., United States District Court, Northern District of California, filed May 15, 2020.
Montgomery County Public Schools, MD. v. JUUL Labs, Inc. et al., United States District Court, Northern District of California, filed December 21, 2020.
Ann Parker, On Behalf Of Her Daughter, S.P., Individually And On Behalf Of Others Similarly Situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 29, 2021.
Adam Jenkins, Individually And On Behalf Of Others Similarly Situated, On Behalf Of D.L.J. v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 30, 2021.
2

Charleen Richey, On Behalf Of Her Son, T.Y., Individually And On Behalf Of Others Similarly Situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.
Shayla Aceti, individually and on behalf of others similarly situated v. Juul Labs Inc et al., United States District Court, Northern District of California, filed March 30, 2021.
Timothy Critzer, individually and on behalf of others similarly situated v. Juul Labs Inc.., United States District Court, Northern District of California, filed March 31, 2021.
Robert Dyer, On Behalf Of His Son, B.D., individually and on behalf of others similarly situated v. Juul Labs Inc., United States District Court, Northern District of California, filed March 30, 2021.
Joan Eubanks, individually and on behalf of others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.
Bruce Gibson, on behalf of his son, K.G., individually and others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.
Jenika Ingram, individually and on behalf of others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.
Shirley Moses on behalf of her daughter, K.S.C., individually and on behalf of others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.
Katherine Dentler, individually and on behalf of others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.
Vickie Perry, On Behalf Of Her Daughter LP, individually and on behalf of others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.
Jessica Pierre, individually and on behalf of others similarly situated v. Juul Labs Inc.; Altria Group Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.
Lacretia Pulce, On Behalf Of Her Daughter, K.P., individually and on behalf of others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.
Charles Tippe, individually and on behalf of others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.
Janece Wilhelm, individually and on behalf of others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.
Janece Wilhelm, on behalf of her son. D.L., individually and on behalf of others similarly situated v. Juul Labs Inc.; et al., United States District Court, Northern District of California, filed April 1, 2021.
Tonya Williams-Walker, On Behalf Of Her Son, M.W., and on behalf of others similarly situated v. Juul Labs Inc.et al., United States District Court, Northern District of California, filed March 31, 2021.
Randi Lines, individually and on behalf of others similarly situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.
Adam Jenkins, On Behalf Of His Son, M.R.J., Individually And On Behalf Of Others Similarly Situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 30, 2021.
Ann Parker, On Behalf Of Her Daughter, S.P., Individually And On Behalf Of Others Similarly Situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 29, 2021.
Erin Puente, individually and On Behalf Of Others Similarly Situated, v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 30, 2021.
Shannon Kinnard, individually and On Behalf Of Others Similarly Situated, v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 30, 2021.
John Hollis, individually and On Behalf Of Others Similarly Situated, v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 30, 2021.
Coleman Holniker, individually and On Behalf of Others Similarly Situated, v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.
Addison Altizer, individually and On Behalf Of Others Similarly Situated, v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.
3

Charleen Richey, On Behalf Of Her Son, T.Y., Individually And On Behalf Of Others Similarly Situated v. Juul Labs Inc. et al., United States District Court, Northern District of California, filed March 31, 2021.
See Note 12 for a discussion of these cases.

IQOS LITIGATION
RAI Strategic Holdings, Inc., et al. v. Altria Client Services, LLC, et al., United States District Court, Eastern District of Virginia, filed April 9, 2020.
Certain Tobacco Heating Articles and Components Thereof, United States International Trade Commission, filed April 9, 2020.
Healthier Choices Management Corp. v. Philip Morris USA Inc., et al., United States District Court, Northern District of Georgia, filed December 4, 2020.
See Note 12 for a discussion of these cases.

ANTITRUST LITIGATION
In re Altria Group, Inc., et al., United States of America Before the Federal Trade Commission, filed April 1, 2020.
Reece, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed April 7, 2020.
Blomquist, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed April 13, 2020.
Martinez, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed April 14, 2020.
Deadwyler, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed April 20, 2020.
Licari, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed April 21, 2020.
Flannery, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed April 27, 2020.
Walsh, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed May 8, 2020.
Redfield, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed May 15, 2020.
Carlson, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed May 21, 2020.
B&C Retail, Inc., et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed June 11, 2020.
Sofijon, Inc., et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed June 11, 2020.
Noor Baig, Inc., et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed June 11, 2020.
Somerset Party Store, Inc., et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed June 18, 2020.
Jackson, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed June 25, 2020.
McGhee, et al. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed July 1, 2020.
Irwindale Fuel Station, Inc. v. Altria Group, Inc., et al., United States District Court, Northern District of California, filed July 15, 2020.

SHAREHOLDER CLASS ACTION
Klein, et al. v. Altria Group, Inc., et al., United States District Court, Eastern District of Virginia, filed October 2, 2019. See Note 12 for a discussion of this case.

SHAREHOLDER DERIVATIVE LAWSUITS
Sandys, et al. v. Willard, et al., United States District Court, Northern District of California, filed August 7, 2020.
Lorca, et al. v. Gifford, et al., United States District Court, Northern District of California, filed August 27, 2020.
Cohen, et al. v. Willard, et al., Circuit Court for Henrico County, Virginia, filed September 14, 2020.
4

Gilbert, et al. v. Gifford et al., United States District Court, Eastern District of Virginia, filed October 1, 2020.
Hamilton et al. v. Gifford et al., United States District Court, Eastern District of Virginia, filed January 25, 2021.
Randolph et al. v. Gifford et al., United States District Court, Eastern District of Virginia, filed March 28, 2021.
Braunstein et al. v. Gifford et al., Circuit Court for Henrico County, Virginia, filed May 18, 2021.
Lopez et al. v. Casteen et al., Circuit Court for Henrico County, Virginia, filed June 16, 2021.
Merritts et al. v. Casteen et al., Circuit Court for Albemarle County, Virginia, filed July 30, 2021.
Dalton et al. v. W. Hildebrandt Surgner et al., Circuit Court for Henrico County, Virginia, filed August 17, 2021.
McCollum et al. v. Gifford et al., Circuit Court for Henrico County, Virginia, filed August 26, 2021.
See Note 12 for a discussion of these cases.

INTERNATIONAL CASES
The following lists cases pending against Altria and/or its subsidiaries in foreign jurisdictions as of October 25, 2021.
Canada
O’Donnell, et. al. v. JUUL Labs, Canada, Ltd., et al., Ontario, Ontario Superior Court, filed April 17, 2020. E-vapor class action. See Note 12 for a discussion of this case.
Salvatore, et al. v. JUUL Labs Canada, Ltd., et al., Quebec, District of Montreal Superior Court, filed June 12, 2019. E-vapor class action. See Note 12 for a discussion of this case.
Stephens, et al. v. JUUL Labs, Inc., et al., British Columbia, Canada Supreme Court, filed October 1, 2019. E-vapor class action. See Note 12 for a discussion of this case.
Her Majesty the Queen in Right of British Columbia v. Imperial Tobacco Limited, et al., Supreme Court, British Columbia, Vancouver Registry, Canada, filed January 24, 2001. Health care cost recovery action. See Note 12 for a discussion of this case.
Her Majesty the Queen in Right of the Province of New Brunswick v. Rothmans, Inc., et al., Court of Queen’s Bench of New Brunswick Judicial District of Fredericton, Canada, filed March 13, 2008. Health care cost recovery action. See Note 12 for a discussion of this case.
Dorion v. Canadian Tobacco Manufacturers’ Council, et al., Court of Queen’s Bench of Alberta, Judicial District of Calgary, Canada, filed on or about June 17, 2009. Smoking and health class action. See Note 12 for a discussion of this case.
Semple v. Canadian Tobacco Manufacturers’ Council, et al., Supreme Court of Nova Scotia, Canada, filed on or about June 18, 2009. Smoking and health class action. See Note 12 for a discussion of this case.
Kunta v. Canadian Tobacco Manufacturers’ Council, et al., Court of Queen’s Bench of Manitoba, Winnipeg Judicial Centre, Canada, filed on an unknown date in June 2009. Smoking and health class action. See Note 12 for a discussion of this case.
Adams v. Canadian Tobacco Manufacturers’ Council, et al., Court of Queen’s Bench for Saskatchewan, Judicial Centre of Regina, Canada, filed on or about July 10, 2009. Smoking and health class action. See Note 12 for a discussion of this case.
Her Majesty the Queen in Right of Ontario v. Rothmans Inc., et al., Superior Court of Justice of Ontario, Canada, filed on or about September 30, 2009. Health care cost recovery action. See Note 12 for a discussion of this case.
Bourassa v. Imperial Tobacco Canada Limited, et al., Supreme Court of British Columbia, Victoria Registry, Canada, filed on or about June 25, 2010. Smoking and health class action. See Note 12 for a discussion of this case.
McDermid v. Imperial Tobacco Canada Limited, et al., Supreme Court of British Columbia, Victoria Registry, Canada, filed on or about June 25, 2010. Smoking and health class action. See Note 12 for a discussion of this case.
Attorney General of Newfoundland and Labrador v. Rothmans Inc., et al., Supreme Court of Newfoundland and Labrador, Trial Division, Canada, filed February 8, 2011. Health care cost recovery action. See Note 12 for a discussion of this case.
Attorney General of Quebec v. Imperial Tobacco Canada Limited, et al., Superior Court of Quebec, Montreal District, Canada, filed June 8, 2012. Health care cost recovery action. See Note 12 for a discussion of this case.
Her Majesty in Right of Alberta v. Altria Group, Inc., et al., Court of Queen’s Bench of Alberta, Judicial District of Calgary, Canada, filed June 8, 2012. Health care cost recovery action. See Note 12 for a discussion of this case.
5

Her Majesty the Queen in the Right of Manitoba v. Rothmans, Benson & Hedges Inc., et al., Court of Queen’s Bench of Manitoba, Winnipeg Judicial Centre, Canada, filed May 31, 2012. Health care cost recovery action. See Note 12 for a discussion of this case.
Her Majesty the Queen in Right of Saskatchewan v. Rothmans, Benson & Hedges Inc., et al., Court of Queen’s Bench of Saskatchewan, Judicial Centre of Saskatoon, Canada, filed on June 8, 2012. Health care cost recovery action. See Note 12 for a discussion of this case.
Her Majesty in the Right of the Province of Prince Edward Island v. Rothmans, Benson & Hedges, Inc., et al., Supreme Court of Prince Edward Island, filed on September 10, 2012. Health care cost recovery action. See Note 12 for a discussion of this case.
Her Majesty the Queen in Right of the Province of Nova Scotia v. Benson & Hedges, Inc., et al., Supreme Court of Nova Scotia, filed on January 2, 2015. Health care cost recovery action. See Note 12 for a discussion of this case.
Jacklin v. Canadian Tobacco Manufacturers’ Council et al., Ontario Superior Court of Justice, Case No. 5379412, Ontario, Canada, filed on or about June 27, 2012. Smoking and health class action. See Note 12 for a discussion of this case.
6
 EX-99.2 7 exhibit992q32021.htm TRIAL SCHEDULE FOR CERTAIN CASES Document

Exhibit 99.2


TRIAL SCHEDULE FOR CERTAIN CASES

Below is a schedule, as of October 25, 2021, setting forth by month the number of individual smoking and health cases against Philip Morris USA Inc. that are scheduled for but not in trial through December 31, 2021.

2021

Engle progeny                        
October0
November0
December0

As of October 25, 2021, there are no Engle progeny cases in trial.

Other Individual Smoking & Health
October0
November0
December0

As of October 25, 2021, there is one non-Engle progeny case in trial.





 EX-101.SCH 8 mo-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Earnings (Losses) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Earnings (Losses) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Stockholders' (Deficit) Equity link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1007008 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Background and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Background and Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Background and Basis of Presentation (Tables) link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Background and Basis of Presentation (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Background and Basis of Presentation (Share Repurchase Table) (Details) link:presentationLink link:calculationLink link:definitionLink 2106102 - Disclosure - Revenues from Contracts with Customers link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Revenues from Contracts with Customers (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2208202 - Disclosure - Revenue from Contract with Customer (Policies) link:presentationLink link:calculationLink link:definitionLink 2109103 - Disclosure - Assets Held for Sale link:presentationLink link:calculationLink link:definitionLink 2310302 - Disclosure - Assets Held for Sale (Tables) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Assets Held for Sale (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - Assets Held for Sale (Summary of Major Classes of Assets and Liabilities Classified as Held for Sale) (Details) link:presentationLink link:calculationLink link:definitionLink 2113104 - Disclosure - Investments in Equity Securities link:presentationLink link:calculationLink link:definitionLink 2314303 - Disclosure - Investments in Equity Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2415406 - Disclosure - Investments in Equity Securities (Summary of Investments) (Details) link:presentationLink link:calculationLink link:definitionLink 2416407 - Disclosure - Investments in Equity Securities (Earnings in Equity Securities) (Details) link:presentationLink link:calculationLink link:definitionLink 2417408 - Disclosure - Investments in Equity Securities (Investment in ABI Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2418409 - Disclosure - Investments in Equity Securities (Investment in JUUL Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2419410 - Disclosure - Investments in Equity Securities (JUUL Investment Classified as Level 3) (Details) link:presentationLink link:calculationLink link:definitionLink 2420411 - Disclosure - Investments in Equity Securities (Investment in Cronos Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2121105 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2322304 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2423412 - Disclosure - Financial Instruments (Aggregate Notional Amounts, Aggregate Fair Values and Carrying Values) (Details) link:presentationLink link:calculationLink link:definitionLink 2424413 - Disclosure - Financial Instruments (Aggregate Fair Value and Carrying Value) (Details) link:presentationLink link:calculationLink link:definitionLink 2425414 - Disclosure - Financial Instruments (Fair Value Using Black-Scholes Option-Pricing Model) (Details) link:presentationLink link:calculationLink link:definitionLink 2426415 - Disclosure - Financial Instruments (Beginning and Ending Balances of Fixed-price Preemptive Rights and Warrants) (Details) link:presentationLink link:calculationLink link:definitionLink 2427416 - Disclosure - Financial Instruments (Fair Value Derivative Financial Instruments) (Details) link:presentationLink link:calculationLink link:definitionLink 2428417 - Disclosure - Financial Instruments (Pre-tax Unrealized Gains (Losses)) (Details) link:presentationLink link:calculationLink link:definitionLink 2429418 - Disclosure - Financial Instruments (Effects of Net Investment Hedges on Accumulated Other Comprehensive Losses) (Details) link:presentationLink link:calculationLink link:definitionLink 2130106 - Disclosure - Benefit Plans link:presentationLink link:calculationLink link:definitionLink 2331305 - Disclosure - Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 2432419 - Disclosure - Benefit Plans (Schedule Of Components Of Net Periodic Benefit Cost (Income)) (Details) link:presentationLink link:calculationLink link:definitionLink 2433420 - Disclosure - Benefit Plans (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2134107 - Disclosure - Earnings (Losses) per Share link:presentationLink link:calculationLink link:definitionLink 2335306 - Disclosure - Earnings (Losses) per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2436421 - Disclosure - Earnings (Losses) per Share (Basic and Diluted Earnings Per Share) (Details) link:presentationLink link:calculationLink link:definitionLink 2137108 - Disclosure - Other Comprehensive Earnings/Losses link:presentationLink link:calculationLink link:definitionLink 2338307 - Disclosure - Other Comprehensive Earnings/Losses (Tables) link:presentationLink link:calculationLink link:definitionLink 2439422 - Disclosure - Other Comprehensive Earnings/Losses (Changes in Each Component of Accumulated Other Comprehensive Losses) (Details) link:presentationLink link:calculationLink link:definitionLink 2440423 - Disclosure - Other Comprehensive Earnings/Losses (Reclassifications) (Details) link:presentationLink link:calculationLink link:definitionLink 2141109 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 2342308 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 2443424 - Disclosure - Segment Reporting (Segment Data Schedule) (Details) link:presentationLink link:calculationLink link:definitionLink 2444425 - Disclosure - Segment Reporting (Non-Participating Manufacturer Adjustment Items) (Details) link:presentationLink link:calculationLink link:definitionLink 2445426 - Disclosure - Segment Reporting (Schedule of Tobacco and Health and Certain Other Litigation Items) (Details) link:presentationLink link:calculationLink link:definitionLink 2446427 - Disclosure - Segment Reporting (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2147110 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2348309 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2449428 - Disclosure - Debt (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2450429 - Disclosure - Debt (Tender Offers) (Details) link:presentationLink link:calculationLink link:definitionLink 2151111 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2352310 - Disclosure - Income Taxes update (Tables) link:presentationLink link:calculationLink link:definitionLink 2453430 - Disclosure - Income Taxes - Summary of Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2454431 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2455432 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2156112 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 2357311 - Disclosure - Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2458433 - Disclosure - Contingencies (General Information) (Details) link:presentationLink link:calculationLink link:definitionLink 2459434 - Disclosure - Contingencies (Judgments Paid and Provisions for Tobacco and Health Litigation) (Details) link:presentationLink link:calculationLink link:definitionLink 2460435 - Disclosure - Contingencies (Schedule of Pending Cases) (Details) link:presentationLink link:calculationLink link:definitionLink 2461436 - Disclosure - Contingencies (Overview of Altria and/or PM USA Tobacco-Related Litigation Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2462437 - Disclosure - Contingencies (Non-Engle Progeny Litigation) (Details) link:presentationLink link:calculationLink link:definitionLink 2463438 - Disclosure - Contingencies (Engle Class Action And Engle Progeny Trial Results) (Details) link:presentationLink link:calculationLink link:definitionLink 2464439 - Disclosure - Contingencies (Engle Progeny Cases Trial Results - Pending and Concluded) (Details) link:presentationLink link:calculationLink link:definitionLink 2465440 - Disclosure - Contingencies (Florida Bond Statute) (Details) link:presentationLink link:calculationLink link:definitionLink 2466441 - Disclosure - Contingencies (Other Smoking and Health Class Actions) (Details) link:presentationLink link:calculationLink link:definitionLink 2467442 - Disclosure - Contingencies (Health Care Cost Recovery Litigation) (Details) link:presentationLink link:calculationLink link:definitionLink 2468443 - Disclosure - Contingencies (NPM Adjustment Disputes) (Details) link:presentationLink link:calculationLink link:definitionLink 2469444 - Disclosure - Contingencies (Other Disputes Under the State Settlement Agreements) (Details) link:presentationLink link:calculationLink link:definitionLink 2470445 - Disclosure - Contingencies (Federal Government's Lawsuit) (Details) link:presentationLink link:calculationLink link:definitionLink 2471446 - Disclosure - Contingencies (E-vapor Product Litigation and IQOS Litigation) (Details) link:presentationLink link:calculationLink link:definitionLink 2472447 - Disclosure - Contingencies (Antitrust Litigation and Shareholder Class Action and Shareholder Derivative Lawsuits) (Details) link:presentationLink link:calculationLink link:definitionLink 2473448 - Disclosure - Contingencies (Lights/Ultra Lights Cases) (Details) link:presentationLink link:calculationLink link:definitionLink 2474449 - Disclosure - Contingencies (UST Litigations Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2475450 - Disclosure - Contingencies (Guarantees and Other Similar Matters Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2176113 - Disclosure - New Accounting Guidance Not Yet Adopted link:presentationLink link:calculationLink link:definitionLink 2377312 - Disclosure - New Accounting Guidance Not Yet Adopted (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 mo-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 mo-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 mo-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Investments [Line Items] Investments [Line Items] [Line Items] for Investments [Table] Debt instrument, consolidated EBITDA to interest expense ratio Debt Instrument, Consolidated EBITDA to Interest Expense Ratio Debt Instrument, Consolidated EBITDA to Interest Expense Ratio Health Care Cost Recovery Actions, 2009 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2009 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2009 NPM Adjustment [Member] Payments Loss Contingency Accrual, Payments Hedging Designation [Domain] Hedging Designation [Domain] Planned share repurchase program Stock Repurchase Program, Authorized Amount Cash Discounts Cash Discounts [Policy Text Block] Cash Discounts Contingencies Legal Matters and Contingencies [Text Block] Letter of Credit [Member] Letter of Credit [Member] Amounts reclassified to net earnings (losses) Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Schedule of Share Repurchase Activity Class of Treasury Stock [Table Text Block] Schedule of Non-Participating Manufacturer Adjustment Items Schedule of Non-Participating Manufacturer Adjustment Items [Table Text Block] Schedule of Non-Participating Manufacturer Adjustment Items Disposal group, including discontinued operation, accounts, notes and loans receivable, net Receivables Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Non-Participating Manufacturer Arbitration Panel Decision Non-Participating Manufacturer Arbitration Panel Decision [Member] Non-Participating Manufacturer Arbitration Panel Decision [Member] July 2019 Share Repurchase Program [Member] July 2019 Share Repurchase Program [Member] July 2019 Share Repurchase Program [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net earnings (losses) attributable to Altria Net earnings (losses) attributable to Altria Net Income (Loss) Attributable to Parent Emerging Growth Company Entity Emerging Growth Company Difference between carrying amount and fair value, percentage (approximately) Equity method investment, difference between carrying amount and fair value, percentage (approximately) Equity Method Investment, Difference Between Carrying Amount and Fair Value, Percentage Equity Method Investment, Difference Between Carrying Amount and Fair Value, Percentage Interest cost Defined Benefit Plan, Interest Cost Number of ordinary shares owned (in shares) Number of ordinary shares owned (approximately) (in shares) Equity Method Investment, Number of Shares Owned, Common Equity Method Investment, Number of Shares Owned, Common Income Statement Location [Axis] Income Statement Location [Axis] Business combination, acquisition related costs Business Combination, Acquisition Related Costs Statistical Measurement [Domain] Statistical Measurement [Domain] Entity Address, Address Line One Entity Address, Address Line One Disposal group disposition related costs Disposal Group, Including Discontinued Operations, Disposition Related Costs Disposal Group, Including Discontinued Operations, Disposition Related Costs Stock repurchase program, increase authorized amount Stock Repurchase Program, Increase Authorized Amount Stock Repurchase Program, Increase Authorized Amount Other liabilities Disposal Group, Including Discontinued Operation, Other Liabilities, Current Cash dividends declared Dividends, Common Stock, Cash Debt instrument, covenant, consolidated EBITDA to interest expense ratio, minimum Debt Instrument, Covenant, Consolidated EBITDA to Interest Expense Ratio, Minimum Debt Instrument, Covenant, Consolidated EBITDA to Interest Expense Ratio, Minimum Disposal group, including discontinued operation, consideration Disposal Group, Including Discontinued Operation, Consideration Fair value of equity investment Equity Method Investments, Fair Value Disclosure Health Care Cost Recovery Actions [Member] Health Care Cost Recovery Actions [Member] Health Care Cost Recovery Actions [Member] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Additional paid-in capital Additional Paid in Capital, Common Stock Entity Filer Category Entity Filer Category Restructuring Type [Axis] Restructuring Type [Axis] ABI [Member] Accumulated Equity Method Investments Attributable To Parent [Member] Accumulated Equity Method Investments Attributable To Parent [Member] Other assets Other Assets, Noncurrent Number of favorable verdicts Loss Contingency, Claims Decided Favorable, Number Loss Contingency, Claims Decided Favorable, Number Amortization: Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract] Impairment of JUUL equity securities Impairment of JUUL equity securities Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount Investment, Name [Axis] Investment, Name [Axis] Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Segments [Axis] Segments [Axis] Additions to valuation allowance charged to income tax expense Valuation Allowance, Deferred Tax Asset, Increase In Amount Valuation Allowance, Deferred Tax Asset, Increase In Amount Retirement Benefits [Abstract] Retirement Benefits [Abstract] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Increase (decrease) Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Loss contingency, number of inactive class action lawsuits Loss Contingency, Number Of Inactive Class Action Lawsuits Loss Contingency, Number Of Inactive Class Action Lawsuits Debt instrument, redemption price, percentage Debt Instrument, Redemption Price, Percentage Income taxes Increase (Decrease) in Income Taxes Payable Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Assets Held for Sale Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Pre-tax charge for adjustment to record the assets and liabilities at fair value less costs to sell Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down Document Fiscal Year Focus Document Fiscal Year Focus Estimate of possible gain Litigation Settlement, Estimate of Possible Gain Litigation Settlement, Estimate of Possible Gain Subsequent Event Type [Domain] Subsequent Event Type [Domain] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Amortization of intangibles Amortization of Intangible Assets Total assets Disposal Group, Including Discontinued Operation, Assets, Current, Gross Disposal Group, Including Discontinued Operation, Assets, Current, Gross Engle Progeny Cases, Sommers [Member] Engle Progeny Cases, Sommers [Member] Engle Progeny Cases, Sommers [Member] Stock repurchase program, remaining authorized repurchase amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Other Current Assets [Member] Other Current Assets [Member] Altria Group [Member] Altria Group [Member] Altria Group Equity method investment, percentage of shares eligible for purchase (approximately) Equity Method Investment, Percentage of Shares Eligible For Purchase Equity Method Investment, Percentage of Shares Eligible For Purchase Loss contingency, number of complaints Loss Contingency, Number Of Complaints Loss Contingency, Number Of Complaints Dividends payable Dividends Payable, Current Health Care Cost Recovery Actions, Transition Years 2004-2018 [Member] Health Care Cost Recovery Actions, Transition Years 2004-2020 [Member] Health Care Cost Recovery Actions, Transition Years 2004-2020 [Member] Business Acquisition [Axis] Business Acquisition [Axis] Engle Progeny Cases, Chadwell [Member] Engle Progeny Cases, Chadwell [Member] Engle Progeny Cases, Chadwell [Member] [Member] Disposal Group Name [Axis] Disposal Group Name [Axis] Unrealized gains (losses) included in income (losses) from equity investments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 2.850%, Notes Due 2022 [Member] USD Denominated Notes, 2.850 Percent, Due 2022 [Member] USD Denominated Notes, 2.850 Percent, Due 2022 Share Repurchase Program [Domain] Share Repurchase Program [Domain] Credit Facility [Domain] Credit Facility [Domain] Assets Assets [Abstract] Loss contingency, number of states in compliance with escrow statues Loss Contingency, Number Of States In Compliance With Escrow Statues Loss Contingency, Number Of States In Compliance With Escrow Statues Engle Progeny Cases, Holliman [Member] Engle Progeny Cases, Holliman [Member] Engle Progeny Cases, Holliman [Member] Net loss Defined Benefit Plan, Amortization of Gain (Loss) Other Liabilities [Member] Other Liabilities [Member] Interim Period, Costs Not Allocable [Domain] Interim Period, Costs Not Allocable [Domain] Equity investments, fair value option, voting shares (in shares) Equity Investments, Fair Value Option, Voting Shares Equity Investments, Fair Value Option, Voting Shares Financial Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Segment Reconciling Items [Member] Segment Reconciling Items [Member] Number of cases set for trial Loss Contingency, Number of Cases Set for Trial Loss Contingency, Number of Cases Set for Trial Number of state courts Loss Contingency, State Courts, Number Loss Contingency, State Courts, Number Tobacco and Health and Certain Other Litigation [Member] Litigation Cases Results [Member] Litigation Cases Results [Member] Period One Period One [Member] Period One Entity Address, City or Town Entity Address, City or Town Damages awarded, value Loss Contingency, Damages Awarded, Value Health Care Cost Recovery Actions, 2015 NPM Adjustments [Member] Health Care Cost Recovery Actions, 2015 NPM Adjustments [Member] Health Care Cost Recovery Actions, 2015 NPM Adjustments [Member] Earnings Reinvested in the Business [Member] Retained Earnings [Member] Debt Instrument [Axis] Debt Instrument [Axis] Fair value Debt Instrument, Fair Value Disclosure Foreign Currency Denominated Debt [Member] Foreign currency denominated debt [Member] Foreign Currency Denominated Debt [Member] Foreign Currency Denominated Debt [Member] Amount awarded to other party Amount Awarded to Other Party Amount Awarded to Other Party Number of pending claims, consolidated for pre-trial purposes Loss Contingency, Pending Claims, Consolidated For Pre-Trial Purposes, Number Loss Contingency, Pending Claims, Consolidated For Pre-Trial Purposes, Number Loss contingency, number of states not settled Loss Contingency, Number Of States Not Settled Loss Contingency, Number Of States Not Settled Loss contingency, number of pending cases consolidated Loss Contingency, Number Of Pending Cases Consolidated Loss Contingency, Number Of Pending Cases Consolidated Prior service cost (credit) Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Dividends from ABI Proceeds from Equity Method Investment, Distribution Reserve Disposal Group, Including Discontinued Operation, Assets, Current, Reserve Disposal Group, Including Discontinued Operation, Assets, Current, Reserve Valuation Allowance Rollforward [Roll Forward] Valuation Allowance Rollforward [Roll Forward] Valuation Allowance Rollforward [Roll Forward] Debt instrument, repurchased face amount Debt Instrument, Repurchased Face Amount Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Comprehensive earnings (losses) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Engle Progeny Cases, D. Brown [Member] Engle Progeny Cases, D. Brown [Member] Engle Progeny Cases, D. Brown [Member] Number of states that cap bond or require no bond Loss Contingency, Number of States That Cap Bond or Require No Bond Loss Contingency, Number of States That Cap Bond or Require No Bond IQOS IQOS [Member] IQOS Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Entity Interactive Data Current Entity Interactive Data Current Loss contingency, number of additional states extended with settled litigation Loss Contingency, Number of Additional States Extended with Settled Litigation Loss Contingency, Number of Additional States Extended with Settled Litigation Repayment of short-term borrowings Repayments of Short-term Debt Basic earnings (losses) per share attributable to Altria (in usd per share) Earnings Per Share, Basic Number of cases pending Claims filed, number Loss Contingency, Pending Claims, Number Benefit plans Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Arkansas [Member] ARKANSAS Revenues from Contracts with Customers Revenue from Contract with Customer [Text Block] 6.200%, Notes Due 2059 [Member] USD Denominated Debt, 6.200 Percent, Due 2059 [Member] USD Denominated Debt, 6.200 Percent, Due 2059 Document Type Document Type Alaska [Member] ALASKA Canada [Member] CANADA Unrealized gain (loss) on derivatives Unrealized Gain (Loss) on Derivatives Loss Contingency Accrual [Roll Forward] Loss Contingency Accrual [Roll Forward] Revolving Credit Facility Due August 2024 [Member] Revolving Credit Facility Due August 2024 [Member] Revolving Credit Facility Due August 2024 [Member] Entity Current Reporting Status Entity Current Reporting Status Engle Progeny Cases, State [Member] Engle Progeny Cases, State [Member] Engle Progeny Cases, State [Member] Accrued pension costs Liability, Defined Benefit Pension Plan, Noncurrent Number of manufacturers Loss Contingency, Number of Manufacturers Loss Contingency, Number of Manufacturers Credit Agreement [Member] Credit Agreement [Member] Credit Agreement [Member] Derivative asset, fair value, gross asset Fair Value of Assets Derivative Asset, Fair Value, Gross Asset Number of plaintiffs Loss Contingency, Number of Plaintiffs 3.125% Notes due 2031 [Member] Common Stock, 3.125% Notes Due 2031 [Member] Common Stock, 3.125% Notes Due 2031 [Member] Receivables Receivables, Net, Current Accounts payable Disposal Group, Including Discontinued Operation, Accounts Payable, Current Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Health Care Cost Recovery Actions, 2019 NPM Adjustments [Member] Health Care Cost Recovery Actions, 2019 NPM Adjustments [Member] Health Care Cost Recovery Actions, 2019 NPM Adjustments [Member] Carrying value Long-term Debt Health Care Cost Recovery Actions, 2020 NPM Adjustments [Member] Health Care Cost Recovery Actions, 2020 NPM Adjustments [Member] Health Care Cost Recovery Actions, 2020 NPM Adjustments Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] JUUL [Member] JUUL [Member] JUUL [Member] Other, net Other Operating Activities, Cash Flow Statement Document Transition Report Document Transition Report Class not certified Loss Contingency, Class Not Certified, Number Loss Contingency, Class Not Certified, Number Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Total Liabilities and Stockholders’ (Deficit) Equity Liabilities and Equity Other Other Accrued Liabilities, Current Pending Litigation [Member] Pending Litigation [Member] Canadian Tobacco Manufacturers [Member] Canadian Tobacco Manufacturers [Member] Canadian Tobacco Manufacturers [Member] Arbitration Period [Domain] Arbitration Period [Domain] Arbitration Period [Domain] Plus: contingently issuable performance stock units (in shares) Weighted Average Number of Shares, Contingently Issuable Investments [Table] Investments [Table] Investments [Table] Other Disputes Under the State Settlement Agreements [Member] Other Disputes Under the State Settlement Agreements [Member] Other Disputes Under the State Settlement Agreements [Member] Equity method investment, impairment Equity Method Investment, Impairment Equity Method Investment, Impairment Accounts payable Increase (Decrease) in Accounts Payable Engle Progeny Cases, Landi [Member] Engle Progeny Cases, Landi [Member] Engle Progeny Cases, Landi [Member] Derivative [Line Items] Derivative [Line Items] Hedging Relationship [Domain] Hedging Relationship [Domain] Health Care Cost Recovery Actions, 2016 NPM Adjustments [Member] Health Care Cost Recovery Actions, 2016 NPM Adjustments [Member] [Member] Health Care Cost Recovery Actions, 2016 NPM Adjustments [Member] Deferred income taxes Reclassification from AOCI, Current Period, Tax Earnings (Losses) per Share Earnings Per Share [Text Block] Repurchases of common stock Aggregate cost of shares repurchased Treasury Stock, Value, Acquired, Cost Method Health Care Cost Recovery Actions, 2005 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2005 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2005 NPM Adjustment [Member] Equity method investment, ownership percentage Ownership percentage Equity Method Investment, Ownership Percentage Average price per share of shares repurchased (usd per share) Treasury Stock Acquired, Average Cost Per Share Compensatory damages award, allocation percentage Loss Contingency, Compensatory Damages Awarded, Allocation Percentage Loss Contingency, Compensatory Damages Awarded, Allocation Percentage Minimum [Member] Minimum [Member] Engle Progeny Cases, Pearson, D Cohen, Collar, Chacon [Member] Engle Progeny Cases, Pearson, D Cohen, Collar, Chacon [Member] [Member] Engle Progeny Cases, Pearson, D Cohen, Collar, Chacon [Member] [Member] Background and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] 2.950%, Notes Due 2023 [Member] USD Denominated Notes, 2.950 Percent, Due 2023 [Member] USD Denominated Notes, 2.950 Percent, Due 2023 USD Denominated Notes Due 2032 [Member] USD Denominated Notes Due 2032 [Member] USD Denominated Notes Due 2032 Gross profit Gross Profit District of Columbia [Member] DISTRICT OF COLUMBIA Balance Sheet Location [Domain] Balance Sheet Location [Domain] Comprehensive (earnings) losses attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Delaware [Member] DELAWARE Number of verdicts upheld Loss Contingency, Verdicts Upheld Loss Contingency, Verdicts Upheld Net periodic benefit income, excluding service cost Net periodic benefit income, excluding service cost Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component Lights [Member] Lights [Member] Lights [Member] Environmental Regulation Environmental Costs, Policy [Policy Text Block] Equity method investment, warrant exercised, ownership percentage Equity Method Investment, Warrant Exercised, Ownership Percentage Equity Method Investment, Warrant Exercised, Ownership Percentage Other comprehensive earnings (losses) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, before Tax Trading Symbol Trading Symbol Loss contingency, damages sought, value Loss Contingency, Damages Sought, Value Marketing Accrued Marketing Costs, Current Cash, cash equivalents and restricted cash: Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] General corporate expenses General and Administrative Expense Accrued settlement charges Increase (Decrease) In Settlement Payable The net change during the period in Settlement payable. Debt Debt Disclosure [Text Block] Restructuring Plan [Domain] Restructuring Plan [Domain] Currency Translation Adjustments and Other [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Engle Progeny Cases, Neff [Member] Engle Progeny Cases, Neff [Member] Engle Progeny Cases, Neff [Member] Line of Credit [Member] Line of Credit [Member] Engle Progeny Cases, Cooper [Member] Engle Progeny Cases, Cooper [Member] Engle Progeny Cases, Cooper [Member] Senior Notes [Member] Senior Notes [Member] Interest and other debt expense, net [Member] Interest And Other Debt Expense, Net [Member] Interest And Other Debt Expense, Net [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Equity method investment, number of shares eligible for purchase (approximately) (in shares) Equity Method Investment, Number of Shares Eligible For Purchase Equity Method Investment, Number of Shares Eligible For Purchase Dividends paid on common stock Payments of Ordinary Dividends, Common Stock Equity method investment, difference between carrying amount and underlying equity Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Implementation of Corrective Communications [Member] Implementation of Corrective Communications [Member] Implementation of Corrective Communications [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Disclosure period Federal Trade Commission, Disclosure Period Federal Trade Commission, Disclosure Period Debt instrument, extension term Debt Instrument, Extension Term Debt Instrument, Extension Term Punitive damages awarded Loss Contingency, Punitive Damages Awarded, Value Loss Contingency, Punitive Damages Awarded, Value Redeemable noncontrolling interest Redeemable Noncontrolling Interest, Equity, Carrying Amount Number of third party lawsuits Number Of Third Party Lawsuits Number Of Third Party Lawsuits Common stock, par value $0.33 1/3 per share (2,805,961,317 shares issued) Common Stock, Value, Issued Inventories: Inventory, Net [Abstract] Equity Contract, Preemptive Rights [Member] Fixed-price Preemptive Rights [Member] Equity Contract, Preemptive RIghts [Member] Equity Contract, Preemptive RIghts [Member] Litigation settlement, amount expected to be awarded from other party Litigation Settlement, Amount Expected To Be Awarded from Other Party Litigation Settlement, Amount Expected To Be Awarded from Other Party Individual Smoking and Health Cases [Member] Individual Smoking And Health Cases [Member] Individual Smoking and Health Cases [Member] Engle Progeny Cases, Gloger, Rintoul and Duignam [Member] Engle Progeny Cases, Gloger, Rintoul and Duignam [Member] Engle Progeny Cases, Gloger, Rintoul and Duignam [Member] Basis of Presentation, Policy Basis of Accounting, Policy [Policy Text Block] Postretirement [Member] Other Postretirement Benefits Plan [Member] Other Accrued Liabilities [Member] Other Accrued Liabilities [Member] Other Accrued Liabilities [Member] Contingencies (Note 12) Commitments and Contingencies Accumulated other comprehensive losses Accumulated Other Comprehensive Income (Loss), Net of Tax Number of restricted shares owned (in shares) Equity Method Investment, Number of Shares Owned, Restricted Equity Method Investment, Number of Shares Owned, Restricted Class of Treasury Stock [Table] Class of Treasury Stock [Table] Balance at begging of period Balance at end of period Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs Provision related to litigation recorded Loss Contingency Accrual, Provision Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Proceeds from issuance of debt Proceeds from Issuance of Debt Inventory Disposal Costs and Other [Member] Inventory Disposal Costs and Other [Member] Inventory Disposal Costs and Other [Member] Connecticut [Member] CONNECTICUT Operating Income (Loss) [Member] Operating Income (Loss) [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Ownership [Axis] Ownership [Axis] Document Period End Date Document Period End Date Pension plan contributions Payment for Pension and Other Postretirement Benefits Loss contingency, claims settled, number Loss Contingency, Claims Settled, Number Claims not certified, number Loss Contingency, Claims Not Certified, Number Loss Contingency, Claims Not Certified, Number Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Class of Stock [Axis] Class of Stock [Axis] Entity Registrant Name Entity Registrant Name Interest and other debt expense, net Interest and other debt expense, net Interest Income (Expense), Net California [Member] CALIFORNIA Work in process Inventory, Work in Process, Net of Reserves Iowa [Member] IOWA Less: Distributed and undistributed earnings attributable to share-based awards Participating Securities, Distributed and Undistributed Earnings (Loss), Basic and Diluted Participating Securities, Distributed and Undistributed Earnings (Loss), Basic and Diluted Health Care Cost Recovery Actions, 2007 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2007 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2007 NPM Adjustment [Member] Subsidiary ownership percentage Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions January 2021 Share Repurchase Program [Member] January 2021 Share Repurchase Program [Member] January 2021 Share Repurchase Program Engle Progeny Cases, Garcia [Member] Engle Progeny Cases, Garcia [Member] Engle Progeny Cases, Garcia Deferred income taxes Other Comprehensive Income (Loss) before Reclassifications, Tax Pre-tax earnings (losses) recognized in net earnings (losses) Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Financial Instrument [Axis] Financial Instrument [Axis] USD Denominated Notes Due 2051 [Member] USD Denominated Notes Due 2051 [Member] USD Denominated Notes Due 2051 Dividends declared (usd per share) Common Stock, Dividends, Per Share, Declared Net revenues Revenue from Contract with Customer, Excluding Assessed Tax USD Denominated Notes Due 2041 [Member] USD Denominated Notes Due 2041 [Member] USD Denominated Notes Due 2041 Engle Progeny Cases, McCall [Member] Engle Progeny Cases, McCall [Member] Engle Progeny Cases, McCall [Member] Other raw materials Other Inventory, Raw Materials, Net of Reserves Other Inventory, Raw Materials, Net of Reserves Arbitration Period [Axis] Arbitration Period [Axis] Arbitration Period Common stock, dividend increase, percentage Common Stock, Dividend Increase, Percentage Common Stock, Dividend Increase, Percentage Number of claims with unfavorable verdicts pending/reversed Loss Contingency, Unfavorable Verdicts Pending/Reversed Loss Contingency, Unfavorable Verdicts Pending/Reversed Finished product Inventory, Finished Goods, Net of Reserves Number of cases Loss Contingency, Number Of Cases Loss Contingency, Number Of Cases Loss contingency, number of cases with set court dates Loss Contingency, Number of Cases With Court Dates Set Loss Contingency, Number of Cases With Court Dates Set Investments In Equity Securities [Member] Investments In Equity Securities [Member] Investments In Equity Securities [Member] Consolidation Items [Domain] Consolidation Items [Domain] Equity [Abstract] Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Engle Progeny Cases, Gloger [Member] Engle Progeny Cases, Gloger [Member] Engle Progeny Cases, Gloger [Member] Measurement Input Type [Domain] Measurement Input Type [Domain] Engle Progeny Cases, Freeman [Member] Engle Progeny Cases, Freeman [Member] Engle Progeny Cases, Freeman [Member] Loss contingency, number of cases with payments a year or more ago Loss Contingency, Number Of Cases With Payments A Year Or More Ago Loss Contingency, Number Of Cases With Payments A Year Or More Ago Gain (Loss) Recognized in Accumulated Other Comprehensive Losses Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Common Stock [Member] Common Stock [Member] Variable Rate [Axis] Variable Rate [Axis] Segment Reporting Segment Reporting Disclosure [Text Block] Operating income Operating income Operating Income (Loss) Non-Engle Progeny Smoking and Health Case, Greene [Member] Non-Engle Progeny Smoking and Health Case, Greene [Member] Non-Engle Progeny Smoking and Health Case, Greene [Member] Shares repurchased (in shares) Treasury Stock, Common, Shares Leaf tobacco Inventory, Raw Materials, Plant Material, Net of Reserves Carrying amount as of the balance sheet date of products consisting of plant matter that is not used in the growth of plant goods Hedging Designation [Axis] Hedging Designation [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Variable Rate [Domain] Variable Rate [Domain] Accumulated Other Comprehensive Income [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Inventories Disposal Group, Including Discontinued Operation, Inventory, Current Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Loss contingency, number of states with settled litigation including New York, subsequent expansion Loss Contingency, Number of States with Settled Litigation, Settlement One Loss Contingency, Number of States with Settled Litigation, Settlement One Illinois [Member] ILLINOIS Number of verdicts reversed Loss Contingency, Verdict Reversed, Number Loss Contingency, Verdict Reversed, Number Loss contingency, credits to offset payments Amount ordered to be paid from other party Litigation Settlement, Amount Awarded from Other Party Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Cost of Repurchased Stock [Member] Treasury Stock [Member] Accrued interest on long-term debt Interest Payable Loss contingency, number of shareholders filing class action lawsuits Loss Contingency, Number Of Shareholders Filing Class Action Lawsuits Loss Contingency, Number Of Shareholders Filing Class Action Lawsuits Net loss [Member] Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member] Equity Method Investments Equity Method Investments [Policy Text Block] Recent Accounting Guidance Not Yet Adopted Accounting Standards Update and Change in Accounting Principle [Table Text Block] Health Care Cost Recovery Actions, 2010 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2010 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2010 NPM Adjustment [Member] Foreign currency contracts (notional amounts) Derivative, Notional Amount Other Assets [Member] Other Assets [Member] Health Care Cost Recovery Actions, 2012 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2012 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2012 NPM Adjustment [Member] Fair value Long-term Debt, Fair Value Other, net Payments for (Proceeds from) Other Investing Activities Capital expenditures Payments to Acquire Property, Plant, and Equipment Defined benefit plan, plan assets, contributions by employer Defined Benefit Plan, Plan Assets, Contributions by Employer Maximum [Member] Maximum [Member] Entity Information [Line Items] Entity Information [Line Items] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Florida [Member] FLORIDA Total liabilities Liabilities Other Tabacco-Related Cases [Member] Other Tabacco-Related Cases [Member] Other Tabacco-Related Cases [Member] Legal Entity [Axis] Legal Entity [Axis] Premiums and fees related to early extinguishment of debt Payment for Debt Extinguishment or Debt Prepayment Cost Receivables Increase (Decrease) in Receivables Restricted shares, lock-up period Restricted Shares, Lock-up Period Restricted Shares, Lock-up Period Cash Provided by (Used in) Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Consolidation Items [Axis] Consolidation Items [Axis] Measurement Input Type [Axis] Measurement Input Type [Axis] Total stockholders’ (deficit) equity attributable to Altria Stockholders' Equity Attributable to Parent Settled Litigation [Member] Settled Litigation [Member] Reductions to valuation allowance credited to income tax benefit Valuation Allowance, Deferred Tax Asset, Decrease In Amount Valuation Allowance, Deferred Tax Asset, Decrease In Amount Common stock, shares issued (in shares) Common Stock, Shares, Issued Other assets Disposal Group, Including Discontinued Operation, Other Assets, Current Designated as Hedging Instrument [Member] Designated as Hedging Instrument [Member] Expected Life [Member] Measurement Input, Expected Term [Member] Loss on early extinguishment of debt Loss on early extinguishment of debt Loss on early extinguishment of debt Gain (Loss) on Extinguishment of Debt Health Care Cost Recovery Actions, 2014 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2014 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2014 NPM Adjustment [Member] Settlement charges Accrued Settlement Liability, Current Accrued Settlement Liability, Current Repurchases of common stock Payments for Repurchase of Common Stock Engle Progeny Cases, M. Brown [Member] Engle Progeny Cases, M. Brown [Member] Engle Progeny Cases, M. Brown [Member] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Equity securities, ownership percentage Equity Securities Without Readily Determinable Fair Value, Ownership Percentage Equity Securities Without Readily Determinable Fair Value, Ownership Percentage Engle Progeny Cases, R. Douglas [Member] Engle Progeny Cases, R. Douglas [Member] Engle Progeny Cases, R. Douglas [Member] Assets and liabilities held for sale, net Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Accrued postretirement health care costs Liability, Other Postretirement Defined Benefit Plan, Noncurrent Maryland [Member] MARYLAND Balance Sheet Location [Axis] Balance Sheet Location [Axis] Other Comprehensive Earnings/Losses Comprehensive Income (Loss) Note [Text Block] Massachusetts [Member] MASSACHUSETTS Weighted Average Expected Term [Member] Measurement Input, Weighted Average Expected Term [Member] Measurement Input, Weighted Average Expected Term [Member] Face amount Debt Instrument, Face Amount 1.700% Notes due 2025 [Member] Common Stock, 1.700% Notes Due 2025 [Member] Common Stock, 1.700% Notes Due 2025 [Member] Net periodic benefit (income) cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Proceeds from short-term borrowings Proceeds from Short-term Debt Engle Progeny Cases, Gore [Member] Engle Progeny Cases, Gore [Member] Engle Progeny Cases, Gore [Member] Discontinued Operations and Disposal Groups [Abstract] Engle Progeny Cases, R.J. Reynolds [Member] Engle Progeny Cases, R.J. Reynolds [Member] Engle Progeny Cases, R.J. Reynolds Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Noncontrolling interest, remaining interest purchased by parent Noncontrolling Interest, Remaining Interest Purchased By Parent Noncontrolling Interest, Remaining Interest Purchased By Parent Number of claims resolved Loss Contingency, Claims Resolved, Number Loss Contingency, Claims Resolved, Number City Area Code City Area Code Earnings reinvested in the business Retained Earnings (Accumulated Deficit) Operating Segments [Member] Operating Segments [Member] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Period Two Period Two [Member] Period Two Puerto Rico [Member] PUERTO RICO Litigation Case [Domain] Litigation Case [Domain] Litigation Case [Domain] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Accrued pension costs Disposal Group, Including Discontinued Operation, Pension Plan Benefit Obligation, Current Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Smokeable Products Segment [Member] Smokeable Products Segment [Member] Smokeable Products Segment [Member] Equity Method Investments Equity Method Investments [Table Text Block] NPM Adjustment to Cost Of Sales [Member] NPM Adjustment to Cost Of Sales [Member] NPM Adjustment to Cost Of Sales [Member] 4.400%, Notes Due 2026 [Member] USD Denominated Notes, 4.400 Percent, Due 2026 [Member] USD Denominated Notes, 4.400 Percent, Due 2026 Engle Progeny Cases, Santoro [Member] Engle Progeny Cases, Santoro [Member] Engle Progeny Cases, Santoro [Member] Assets held for sale Disposal Group, Including Discontinued Operation, Assets [Abstract] Pre-tax Effects of Net Investment Hedges on Accumulated Other Comprehensive Losses Derivative Instruments, Gain (Loss) [Table Text Block] Engle Progeny Cases, Cuddihee [Member] Engle Progeny Cases, Cuddihee [Member] Engle Progeny Cases, Cuddihee Share Repurchase Program [Axis] Share Repurchase Program [Axis] Investments in equity securities Equity Method Investments Income Statement [Abstract] Income Statement [Abstract] Amendment Flag Amendment Flag New Hampshire [Member] NEW HAMPSHIRE 9.950%, Notes Due 2038 [Member] USD Denominated Notes, 9.950 Percent, Due 2038 [Member] USD Denominated Notes, 9.950 Percent, Due 2038 Oral Tobacco Segment [Member] Oral Tobacco Segment [Member] Oral Tobacco Segment [Member] Oral Tobacco Segment [Member] Non-Engle Progeny Smoking And Health Case, Principe [Member] Non-Engle Progeny Smoking And Health Case, Principe [Member] Non-Engle Progeny Smoking And Health Case, Principe Loss contingency, number of states not settled, arbitration period Loss Contingency, Number Of States Not Settled, Arbitration Period Loss Contingency, Number Of States Not Settled, Arbitration Period Asset Class [Domain] Asset Class [Domain] Engle Progeny Cases, Naugle [Member] Engle Progeny Cases, Naugle [Member] Engle Progeny Cases, Naugle [Member] Liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities [Abstract] New Accounting Guidance Not Yet Adopted Accounting Standards Update and Change in Accounting Principle [Text Block] Engle Progeny Cases, Federal [Member] Engle Progeny Cases, Federal [Member] Engle Progeny Cases, Federal [Member] Loss contingency, period for decertified class members to file individual actions against defendants Loss Contingency, Period for Decertified Class Members to File Individual Actions Against Defendants Loss Contingency, Period for Decertified Class Members to File Individual Actions Against Defendants MONTANA MONTANA Marketing, administration and research costs Marketing, Administration and Research Costs The aggregate total costs related to selling a firm's product and services, as well as research and development costs and all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. Research and development costs represent the aggregate costs incurred during an accounting period to research and develop new products/technologies when the technological feasibility has not been reached. General and administrative expenses include salaries of nonsales personnel, rent, utilities, communication, etc. USD Denominated Notes [Member] USD Denominated Notes [Member] USD Denominated Notes [Member] Provision (benefit) for income taxes Income Tax Expense (Benefit) Total stockholders’ (deficit) equity Beginning balance Ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Purchase Commitment [Member] Purchase Commitment [Member] Mississippi [Member] MISSISSIPPI Equity Contract, Warrant And Equity Contract, Preemptive Rights [Member] Equity Contract, Warrant And Equity Contract, Preemptive Rights [Member] Equity Contract, Warrant And Equity Contract, Preemptive Rights Long-term debt issued Proceeds from Issuance of Long-term Debt Equity Components [Axis] Equity Components [Axis] Equity Components [Axis] Loss contingency, number of consolidated derivative lawsuits Loss Contingency, Number Of Consolidated Derivative Lawsuits Loss Contingency, Number Of Consolidated Derivative Lawsuits Missouri [Member] MISSOURI Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Stock repurchase program, rescinded authorized repurchase amount Stock Repurchase Program, Rescinded Authorized Repurchase Amount Stock Repurchase Program, Rescinded Authorized Repurchase Amount Minnesota [Member] MINNESOTA OCI Operating Income (Loss) Before General Corporate Expenses and Amortization Of Intangibles Operating Income (Loss) Before General Corporate Expenses and Amortization Of Intangibles Michigan [Member] MICHIGAN Total current assets Assets, Current Loss on extinguishment of debt, premiums and fees Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost Cronos [Member] Cronos Group Inc. [Member] Cronos Group Inc. [Member] Inventory, net Inventory, Net Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Entity File Number Entity File Number Tobacco and Health Litigation Cases [Member] Tobacco and Health Litigation Cases [Member] Tobacco and Health Litigation Cases [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Engle Progeny Cases, Lipp [Member] Engle Progeny Cases, Lipp [Member] Engle Progeny Cases, Lipp Marketing Administration And Research Costs [Member] Marketing Administration And Research Costs [Member] Marketing Administration And Research Costs [Member] Current portion of long-term debt Long-term Debt, Current Maturities Common stock, dividend rate, annual (in usd per share) Common Stock, Dividend Rate, Annual, Per Share Common Stock, Dividend Rate, Annual, Per Share Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Accrued liabilities Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current Entity Small Business Entity Small Business Restructuring Plan [Axis] Restructuring Plan [Axis] Accounting Standards Update and Change in Accounting Principle [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Federal Governments Lawsuit [Member] Federal Governments Lawsuit [Member] Federal Government's Lawsuit [Member] Number of states with settled litigation Loss Contingency, Number of States with Settled Litigation Loss Contingency, Number of States with Settled Litigation Provision recorded, number of cases Provision Recorded, Number Of Cases Provision Recorded, Number Of Cases Equity Component [Domain] Equity Component [Domain] Disposal group, total pre-tax charges Disposal Group, Including Discontinued Operations, Marketing, Administration And Research Costs Disposal Group, Including Discontinued Operations, Marketing, Administration And Research Costs E-vapor Litigation [Member] E-vapor Litigation [Member] E-vapor Litigation [Member] Other Stockholders' Equity, Other Foreign currency translation Valuation Allowance, Foreign Currency Translation Adjustment Valuation Allowance, Foreign Currency Translation Adjustment Currency translation adjustments and other Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Disposal Group Name [Domain] Disposal Group Name [Domain] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Louisiana [Member] LOUISIANA Investments [Abstract] Investments [Abstract] Number of verdicts returned Loss Contingency, Claims Decided Loss Contingency, Claims Decided JUUL Equity Investment, Fair Value Option Equity Investment, Fair Value Option Statement [Line Items] Statement [Line Items] Litigation Case [Axis] Litigation Case [Axis] Kansas [Member] KANSAS Litigation settlement Litigation Settlement, Amount Awarded to Other Party Restricted cash included in other assets Restricted Cash, Noncurrent Pending Lawsuit Filed By School District [Member] Pending Lawsuit Filed By School District [Member] Pending Lawsuit Filed By School District [Member] Assets [Member] Assets [Member] Investments in equity securities ($1,740 million and $1,868 million at September 30, 2021 and December 31, 2020, respectively, measured at fair value) Investments Investments COVID-19 [Member] COVID-19 [Member] COVID-19 [Member] Retirement Plan Type [Domain] Retirement Plan Type [Domain] JUUL Income (loss) from equity investments, fair value option Income (Loss) from Equity Investments, Fair Value Option Income (Loss) from Equity Investments, Fair Value Option Expected period for satisfaction of performance obligation Revenue, Performance Obligation, Description of Timing Liabilities Liabilities [Abstract] Loss contingency, number of states with concluded hearings Loss Contingency, Number Of States With Concluded Hearings Loss Contingency, Number Of States With Concluded Hearings Decrease in accrued postretirement health care cost liability Increase (Decrease) in Obligation, Pension and Other Postretirement Benefits Engle Progeny Cases, Theis [Member] Engle Progeny Cases, Theis [Member] Engle Progeny Cases, Theis [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Loss contingency, reduction to cost of sales Loss Contingency, Reduction To Cost Of Sales Loss Contingency, Reduction To Cost Of Sales Accrued liabilities: Accrued Liabilities, Current [Abstract] Entity Address, State or Province Entity Address, State or Province Engle Progeny Cases, Duignan [Member] Engle Progeny Cases, Duignan [Member] Engle Progeny Cases, Duignan [Member] Earnings (losses) before income taxes Earnings (losses) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Litigation settlement interest expense (income) Litigation Settlement Interest Schedule of Pre-tax Tobacco and Health Litigation Charges [Table] Schedule of Pre-tax Tobacco and Health Litigation Charges [Table] Schedule of Pre-tax Tobacco and Health Litigation Charges [Table] Equity method investment, reduction in share price, percentage Equity Method Investment, Reduction In Share Price, Percentage Equity Method Investment, Reduction In Share Price, Percentage Balance at beginning of year Balance at end of period Deferred Tax Assets, Valuation Allowance USD Denominated Notes Due 2061 [Member] USD Denominated Notes Due 2061 [Member] USD Denominated Notes Due 2061 Expected Dividend Yield [Member] Measurement Input, Expected Dividend Rate [Member] Common Stock, $0.33 1/3 par value [Member] Common Stock, 0.33 1/3 Par Value [Member] Common Stock, 0.33 1/3 Par Value [Member] 10.200%, Notes Due 2039 [Member] USD Denominated Debt, 10.200 Percent, Due 2039 [Member] USD Denominated Debt, 10.200 Percent, Due 2039 Liabilities held for sale Liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities, Current General corporate [Member] Corporate, Non-Segment [Member] Corporate, Non-Segment [Member] (Gain) loss on Cronos-related financial instruments Gain (loss) on Cronos-related financial instruments Derivative, Gain (Loss) on Derivative, Net Type of Restructuring [Domain] Type of Restructuring [Domain] Entity [Domain] Entity [Domain] Segment Reporting [Abstract] Segment Reporting [Abstract] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Benefit Plans Retirement Benefits [Text Block] Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Ste. Michelle Transaction [Member] Ste. Michelle Transactions [Member] Ste. Michelle Transactions Entity Shell Company Entity Shell Company Asset Class [Axis] Asset Class [Axis] Local Phone Number Local Phone Number Rhode Island [Member] RHODE ISLAND Total Assets Assets Loss (gain) related to litigation settlement Gain (Loss) Related to Litigation Settlement Investment, Name [Domain] Investment, Name [Domain] Equity securities without readily determinable fair value, downward price adjustment, cumulative amount Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount Engle Progeny Cases, Pollari [Member] Engle Progeny Cases, Pollari [Member] Engle Progeny Cases, Pollari [Member] Geographical [Domain] Geographical [Domain] Earnings (losses) for diluted EPS Net Income (Loss) Available to Common Stockholders, Diluted PM USA [Member] Philip Morris USA [Member] Philip Morris USA [Member] Share price [Member] Measurement Input, Share Price [Member] Class Action Lawsuit [Member] Class Action Lawsuit [Member] Class Action Lawsuit [Member] Earnings (losses) for basic EPS Net Income (Loss) Available to Common Stockholders, Basic Non-controlling Interests [Member] Noncontrolling Interest [Member] Health Care Cost Recovery Actions, 2017 NPM Adjustments [Member] Health Care Cost Recovery Actions, 2017 NPM Adjustments [Member] Health Care Cost Recovery Actions, 2017 NPM Adjustments [Member] Non Engle Progeny Cases [Member] Non Engle Progeny Cases [Member] Non Engle Progeny Cases [Member] Health Care Cost Recovery Actions, 2018 NPM Adjustments [Member] Health Care Cost Recovery Actions, 2018 NPM Adjustments [Member] Health Care Cost Recovery Actions, 2018 NPM Adjustments [Member] Debt instrument, interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Derivative Contract [Domain] Derivative Contract [Domain] Receivables, Net Current, Including Assets Held For Sale Receivables, Net Current, Including Assets Held For Sale Receivables, Net Current, Including Assets Held For Sale ABI OCI, Equity Method Investment, after Tax UST Litigation [Member] UST Litigation [Member] UST Litigation [Member] Net (earnings) losses attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Equity method investment, shares purchased, (CAD per share) Equity Method Investment, Price Per Share If Exercised Equity Method Investment, Price Per Share If Exercised Revolving Credit Facility [Member] Revolving Credit Facility [Member] Short-term debt Short-term Debt Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities All Other [Member] Other Segments [Member] Litigation Status [Axis] Litigation Status [Axis] Ohio [Member] OHIO Schedule of Debt Schedule of Debt [Table Text Block] 2.200% Notes due 2027 [Member] Common Stock, 2.200% Notes Due 2027 [Member] Common Stock, 2.200% Notes Due 2027 [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Entity Tax Identification Number Entity Tax Identification Number Pending Individual Lawsuits [Member] Pending Individual Lawsuits [Member] Pending Individual Lawsuits [Member] Geographical [Axis] Geographical [Axis] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Weighted-average shares for basic EPS (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted earnings (losses) per share attributable to Altria (in usd per share) Earnings Per Share, Diluted New York [Member] NEW YORK Segments [Domain] Reporting Segment [Domain] Segments [Domain] Pending Lawsuits Filed By State Or Local Governments [Member] Pending Lawsuits Filed By State Or Local Governments [Member] Pending Lawsuits Filed By State Or Local Governments [Member] Nevada [Member] NEVADA Loss contingency, number of inactive cases Loss Contingency, Number Of Inactive Cases Loss Contingency, Number Of Inactive Cases Service cost Defined Benefit Plan, Service Cost Net Investment Hedging [Member] Net Investment Hedging [Member] Judgments paid (approximately) Loss Contingency, Damages Paid, Value Gain (Loss) Recognized in Net Earnings (Losses) Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax Hedging Relationship [Axis] Hedging Relationship [Axis] Net earnings attributable to noncontrolling interests Net Income (Loss) Attributable to Redeemable Noncontrolling Interest New Mexico [Member] NEW MEXICO New Jersey [Member] NEW JERSEY Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Comprehensive earnings (losses) attributable to Altria Comprehensive Income (Loss), Net of Tax, Attributable to Parent Other intangible assets, net Intangible Assets, Net (Excluding Goodwill) Summary of Income Taxes Summary of Income Taxes [Table Text Block] Summary of Income Taxes Deferred revenue Contract with Customer, Liability Investment, Policy Investment, Policy [Policy Text Block] Prior service cost/credit [Member] Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member] Engle Progeny Cases [Member] Engle Progeny Cases [Member] Engle Progeny Cases [Member] Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Other comprehensive earnings (losses), net of deferred income taxes: Other Comprehensive Income (Loss), Net of Tax [Abstract] Cost of repurchased stock (967,321,022 shares at September 30, 2021 and 947,542,152 shares at December 31, 2020) Treasury Stock, Value Deferred income taxes Deferred Income Tax Liabilities, Net Engle Progeny Cases, Naugle, Gore, M. Brown, Jordan, Theis and Landi [Member] Engle Progeny Cases, Naugle, Gore, M. Brown, Jordan, Theis, and Landi [Member] Engle Progeny Cases, Naugle, Gore, M. Brown, Jordan, Theis, and Landi Income (losses) from investments under equity method of accounting (Income) losses from equity investments Income (Loss) from Equity Method Investments Pennsylvania [Member] PENNSYLVANIA Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Restructuring charges Restructuring Charges Accounts payable Accounts Payable, Current Oregon [Member] OREGON Depreciation and amortization Depreciation, Depletion and Amortization Threatened Litigation [Member] Threatened Litigation [Member] Engle Progeny Cases, Weingart and Hancock [Member] Engle Progeny Cases, Weingart and Hancock [Member] Engle Progeny Cases, Weingart and Hancock [Member] Oklahoma [Member] OKLAHOMA Entities [Table] Entities [Table] British Columbia and Saskatchewan [Member] British Columbia, Saskatchewan [Member] British Columbia, Saskatchewan [Member] Helix Innovations LLC [Member] Helix Innovations LLC [Member] Helix Innovations LLC [Member] Zero damages verdicts Loss Contingency, Zero Damages Verdicts Loss Contingency, Zero Damages Verdicts Accumulated Other Comprehensive Losses [Member] AOCI Attributable to Parent [Member] Engle Progeny Cases, Jordan [Member] Engle Progeny Cases, Jordan [Member] Engle Progeny Cases, Jordan [Member] Inventories Increase (Decrease) in Inventories Health Care Cost Recovery Actions, 2011 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2011 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2011 NPM Adjustment [Member] Financial Instruments [Domain] Financial Instruments [Domain] Derivative [Table] Derivative [Table] Cost of sales Cost of Goods and Services Sold Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items] Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items] [Line Items] for Schedule of Pre-tax Tobacco and Health Litigation Charges [Table] State settlement agreements attorney fees annual cap Litigation Settlement, Annual Legal Fees Payable, Maximum Litigation Settlement, Annual Legal Fees Payable, Maximum Anticipated additional employer contributions Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year Schedule of Derivative Liabilities at Fair Value Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block] Excise taxes on products Other Cost of Operating Revenue Unusual or Infrequent Item, or Both [Domain] Unusual or Infrequent Item, or Both [Domain] Proceeds from divestiture of businesses Proceeds from Divestiture of Businesses Payments to acquire additional interest in subsidiaries Payments to Acquire Additional Interest in Subsidiaries Texas [Member] TEXAS Schedule of Contingencies Schedule of Loss Contingencies by Contingency [Table Text Block] 1.000% Notes due 2023 [Member] Common Stock, 1.000% Notes Due 2023 [Member] Common Stock, 1.000% Notes Due 2023 [Member] Loss contingency, number of states not in compliance with escrow statues Loss Contingency, Number Of States Not In Compliance With Escrow Statues Loss Contingency, Number Of States Not In Compliance With Escrow Statues Investments in Equity Securities Investment [Text Block] Health Care Cost Recovery Actions, 2005-2007 NPM Adjustment Health Care Cost Recovery Actions, 2005-2007 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2005-2007 NPM Adjustment Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Equity Method Investments, Fair Value Option [Member] Equity Method Investments, Fair Value Option [Member] Equity Method Investments, Fair Value Option Debt instrument, term Debt Instrument, Term Income Statement Location [Domain] Income Statement Location [Domain] Stockholders’ (Deficit) Equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Investments, fair value disclosure Investments, Fair Value Disclosure Disposal Group, Held-for-sale, Not Discontinued Operations [Member] Disposal Group, Held-for-sale, Not Discontinued Operations [Member] Repayments of senior unsecured debt Repayments of Unsecured Debt Philip Morris USA and Altria Group [Member] Philip Morris USA and Altria Group [Member] Philip Morris USA and Altria Group [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Property, plant and equipment, net Property, Plant and Equipment, Net Other liabilities Other Liabilities, Noncurrent Schedule of Long-term Debt Instruments Schedule of Long-term Debt Instruments [Table Text Block] Repurchase of common stock (shares) Total number of shares repurchased (shares) Treasury Stock, Shares, Acquired Debt Instrument [Line Items] Debt Instrument [Line Items] Long-term debt repaid Long-term debt repaid Repayments of Long-term Debt 4.000%, Notes Due 2024 [Member] USD Denominated Notes, 4.000 Percent, Due 2024 [Member] USD Denominated Notes, 4.000 Percent, Due 2024 Other intangible assets, net Disposal Group, Including Discontinued Operation, Intangible Assets, Current Allowance for doubtful accounts, receivables Allowance for Doubtful Accounts, Premiums and Other Receivables Per share data: Earnings Per Share [Abstract] Wine Segment [Member] Wine Segment [Member] Wine Segment [Member] Property, plant and equipment, at cost Property, Plant and Equipment, Gross Document Quarterly Report Document Quarterly Report Amounts reclassified to net earnings (losses), net of deferred income taxes Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax South Carolina [Member] SOUTH CAROLINA Engle Progeny Cases, Rintoul [Member] Engle Progeny Cases, Rintoul [Member] Engle Progeny Cases, Rintoul Foreign Currency Contract [Member] Foreign currency contracts [Member] Foreign Exchange Contract [Member] Accrued liability for tobacco and health litigation items at beginning of period Accrued liability for tobacco and health litigation items at end of period Loss Contingency Accrual Derivative asset, measurement input Derivative Asset, Measurement Input Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Non-Engle Progeny Smoking and Health Case, Laramie [Member] Non-Engle Progeny Smoking and Health Case, Laramie [Member] Non-Engle Progeny Smoking and Health Case, Laramie [Member] [Member] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Loss contingency, damages recoverable, value Loss Contingency, Damages Recoverable, Value Loss Contingency, Damages Recoverable, Value Stock award activity Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition and Income Tax Effect, Net Adjustment To Additional Paid In Capital, Share Based Compensation, Restricted And Deferred Stock Awards and the tax benefits associated with vestings of prior period restricted and deferred stock awards Long-term debt Long-term Debt, Excluding Current Maturities Unusual or Infrequent Item, or Both [Axis] Unusual or Infrequent Item, or Both [Axis] Equity method investment, aggregate exercise price Equity Method Investment, Aggregate Exercise Price Equity Method Investment, Aggregate Exercise Price Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] 4.800%, Notes Due 2029 [Member] USD Denominated Notes, 4.800 Percent, Due 2029 [Member] USD Denominated Notes, 4.800 Percent, Due 2029 Risk Free Interest Rate [Member] Measurement Input, Risk Free Interest Rate [Member] Document Fiscal Period Focus Document Fiscal Period Focus Tennessee [Member] TENNESSEE Income tax rate Effective Income Tax Rate Reconciliation, Percent Engle Progeny Cases, Kaplan [Member] Engle Progeny Cases, Kaplan [Member] Engle Progeny Cases, Kaplan [Member] Smoking and Health Class Actions and Aggregated Claims Litigation [Member] Smoking And Health Class Actions [Member] Smoking and Health Class Actions and Aggregated Claims Litigation [Member] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Net earnings (losses) Net earnings (losses) Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings (losses) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Related Interest Costs [Member] Interest Expense Related To Litigation [Member] Interest Expense Related To Litigation [Member] Restricted cash included in other current assets Restricted Cash, Current Loss contingency, number of shareholders filing derivative lawsuits Loss Contingency, Number Of Shareholders Filing Derivative Lawsuits Loss Contingency, Number Of Shareholders Filing Derivative Lawsuits Balance at beginning of period Balance at end of period Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Common stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Contingent liability related to performance surety bonds Guarantor Obligations, Maximum Exposure, Undiscounted Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Other, net Proceeds from (Payments for) Other Financing Activities Zero damages verdict modified Loss Contingency, Zero Damages Verdict Modified Loss Contingency, Zero Damages Verdict Modified Engle Progeny Cases, Reider and Banks [Member] Engle Progeny Cases, Reider and Banks [Member] Engle Progeny Cases, Reider and Banks [Member] Debt Instrument, Redemption, Period One [Member] Debt Instrument, Redemption, Period One [Member] Engle Progeny Cases, Berger [Member] Engle Progeny Cases, Berger [Member] Engle Progeny Cases, Berger [Member] State settlement agreements annual payments Litigation Settlement, Annual Payment Amount Litigation Settlement, Annual Payment Amount Cash and cash equivalents Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents Entity Central Index Key Entity Central Index Key Engle Progeny Cases, Mahfuz [Member] Engle Progeny Cases, Mahfuz [Member] Engle Progeny Cases, Mahfuz [Member] London Interbank Offered Rate (LIBOR) [Member] London Interbank Offered Rate (LIBOR) [Member] Security Exchange Name Security Exchange Name Non-Engle Progeny Smoking and Health Case, Gentile [Member] Non-Engle Progeny Smoking and Health Case, Gentile [Member] Non-Engle Progeny Smoking and Health Case, Gentile Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Revenue from Contract with Customer Revenue from Contract with Customer [Policy Text Block] Weighted-average shares for diluted EPS (in shares) Weighted Average Number of Shares Outstanding, Diluted Balance at beginning of period Balance at end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Other comprehensive earnings (losses), net of deferred income taxes Other comprehensive earnings (losses), net of deferred income taxes Other Comprehensive Income (Loss), Net of Tax Income Taxes Income Tax Disclosure [Text Block] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Debt instrument, basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Schedule of Net Periodic Benefit (Income) Cost Schedule of Net Benefit Costs [Table Text Block] Disposal Groups, Including Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Accrued liabilities and other current assets Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net Schedule of Tobacco and Health and Certain Other Litigation Items Schedule of Pre-tax Tobacco and Health Litigation Charges [Table Text Block] [Table Text Block] for Schedule of Pre-tax Tobacco and Health Litigation Charges [Table] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Credit Facility [Axis] Credit Facility [Axis] Not Designated as Hedging Instrument [Member] Not Designated as Hedging Instrument [Member] Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Cash effects of changes: Increase (Decrease) in Operating Capital [Abstract] (Income) losses from equity investments Income (losses) from equity investments Income (losses) from equity investments Income (Loss) from Equity Investments Income (Loss) from Equity Investments Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Equity Contract, Warrant [Member] Cronos Warrant [Member] Equity Contract, Warrant [Member] Equity Contract, Warrant [Member] Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Compensatory damages awarded Loss Contingency, Compensatory Damages Awarded, Value Loss Contingency, Compensatory Damages Awarded, Value USD Denominated Notes, 3.490 Percent, Due 2022 [Member] USD Denominated Notes, 3.490 Percent, Due 2022 [Member] USD Denominated Notes, 3.490 Percent, Due 2022 Total current liabilities Liabilities, Current Inventory Write-Off [Member] Inventory Write-Off [Member] Inventory Write-Off [Member] Class of Stock [Domain] Class of Stock [Domain] Number of unfavorable verdicts Loss Contingency, Claims Decided Unfavorable, Number Loss Contingency, Claims Decided Unfavorable, Number Maximum bond for all defendants Maximum Bond For All Defendants Maximum Bond For All Defendants Litigation Status [Domain] Litigation Status [Domain] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Credit line available under the agreement Line of Credit Facility, Maximum Borrowing Capacity Summary of Valuation Allowance Summary of Valuation Allowance [Table Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Reclassification out of Accumulated Other Comprehensive Income [Member] Reclassification out of Accumulated Other Comprehensive Income [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Ownership [Domain] Ownership [Domain] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restricted cash included in assets held for sale Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations Wine Business Strategic Reset [Member] Wine Business Strategic Reset [Member] Wine Business Strategic Reset [Member] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Health Care Cost Recovery Actions, 2008 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2008 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2008 NPM Adjustment [Member] Loss contingency, class action lawsuit Loss Contingency, Class Action Lawsuit Loss Contingency, Class Action Lawsuit Net earnings (losses) Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest Assets held for sale Assets held for sale Disposal Group, Including Discontinued Operation, Assets, Current Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Title of 12(b) Security Title of 12(b) Security Statement [Table] Statement [Table] Other current assets Other Assets, Current Wisconsin [Member] WISCONSIN Health Care Cost Recovery Actions, 2006 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2006 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2006 NPM Adjustment [Member] Investment Investment [Table Text Block] New Accounting Pronouncements, Policy New Accounting Pronouncements, Policy [Policy Text Block] Health Care Cost Recovery Actions, 2004 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2004 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2004 NPM Adjustment [Member] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Statistical Measurement [Axis] Statistical Measurement [Axis] ABI [Member] AB InBev [Member] AB InBev [Member] ETS Smoking and Health Case, Flight Attendants [Member] ETS Smoking and Health Case, Flight Attendants [Member] ETS Smoking and Health Case, Flight Attendants [Member] Property, plant and equipment, net of accumulated depreciation Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current Fair Value of Liabilities Derivative Liability, Fair Value, Gross Liability Subsequent Event [Member] Subsequent Event [Member] Cover [Abstract] Cover [Abstract] Goodwill Goodwill Tobacco and Health Judgment [Member] Tobacco and Health Judgment [Member] Tobacco and Health Judgment [Member] Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Expected Volatility [Member] Measurement Input, Price Volatility [Member] Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Cost of Sales [Member] Cost of Sales [Member] Equity Contract [Member] Equity Contract [Member] Write-off of amortized debt discounts and issuance costs, debt extinguishment Write off of Deferred Debt Issuance Cost Security posted for appeal of judgments Litigation Escrow Deposit Litigation Escrow Deposit Adjustments to reconcile net earnings (losses) to operating cash flows: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Pension [Member] Pension [Member] Pension Plan [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Pension provisions and postretirement, net Pension and Other Postretirement Benefits Expense (Reversal of Expense), Noncash Equity securities without readily determinable fair value, upward price adjustment, cumulative amount Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Health Care Cost Recovery Actions, 2013 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2013 NPM Adjustment [Member] Health Care Cost Recovery Actions, 2013 NPM Adjustment [Member] Benefit Plans [Member] Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Nature of Expense [Axis] Nature of Expense [Axis] West Virginia [Member] WEST VIRGINIA 3.800%, Notes Due 2024 [Member] USD Denominated Notes, 3.800 Percent, Due 2024 [Member] USD Denominated Notes, 3.800 Percent, Due 2024 Deferred income tax provision (benefit) Deferred Income Tax Expense (Benefit) Ste. Michelle Transaction [Member] Ste. Michelle Transaction [Member] Ste. Michelle Transaction EX-101.PRE 12 mo-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 13 mo-20210930_htm.xml IDEA: XBRL DOCUMENT 0000764180 2021-01-01 2021-09-30 0000764180 mo:CommonStock0.3313ParValueMember 2021-01-01 2021-09-30 0000764180 mo:CommonStock1.000NotesDue2023Member 2021-01-01 2021-09-30 0000764180 mo:CommonStock1.700NotesDue2025Member 2021-01-01 2021-09-30 0000764180 mo:CommonStock2.200NotesDue2027Member 2021-01-01 2021-09-30 0000764180 mo:CommonStock3.125NotesDue2031Member 2021-01-01 2021-09-30 0000764180 2021-10-21 0000764180 2021-09-30 0000764180 2020-12-31 0000764180 2020-01-01 2020-09-30 0000764180 2021-07-01 2021-09-30 0000764180 2020-07-01 2020-09-30 0000764180 us-gaap:CommonStockMember 2020-12-31 0000764180 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000764180 us-gaap:RetainedEarningsMember 2020-12-31 0000764180 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000764180 us-gaap:TreasuryStockMember 2020-12-31 0000764180 us-gaap:NoncontrollingInterestMember 2020-12-31 0000764180 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0000764180 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-09-30 0000764180 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0000764180 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0000764180 us-gaap:TreasuryStockMember 2021-01-01 2021-09-30 0000764180 us-gaap:CommonStockMember 2021-09-30 0000764180 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000764180 us-gaap:RetainedEarningsMember 2021-09-30 0000764180 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000764180 us-gaap:TreasuryStockMember 2021-09-30 0000764180 us-gaap:NoncontrollingInterestMember 2021-09-30 0000764180 us-gaap:CommonStockMember 2019-12-31 0000764180 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000764180 us-gaap:RetainedEarningsMember 2019-12-31 0000764180 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000764180 us-gaap:TreasuryStockMember 2019-12-31 0000764180 us-gaap:NoncontrollingInterestMember 2019-12-31 0000764180 2019-12-31 0000764180 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0000764180 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-09-30 0000764180 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000764180 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0000764180 us-gaap:TreasuryStockMember 2020-01-01 2020-09-30 0000764180 us-gaap:CommonStockMember 2020-09-30 0000764180 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000764180 us-gaap:RetainedEarningsMember 2020-09-30 0000764180 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000764180 us-gaap:TreasuryStockMember 2020-09-30 0000764180 us-gaap:NoncontrollingInterestMember 2020-09-30 0000764180 2020-09-30 0000764180 us-gaap:CommonStockMember 2021-06-30 0000764180 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000764180 us-gaap:RetainedEarningsMember 2021-06-30 0000764180 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000764180 us-gaap:TreasuryStockMember 2021-06-30 0000764180 us-gaap:NoncontrollingInterestMember 2021-06-30 0000764180 2021-06-30 0000764180 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000764180 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0000764180 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000764180 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000764180 us-gaap:TreasuryStockMember 2021-07-01 2021-09-30 0000764180 us-gaap:CommonStockMember 2020-06-30 0000764180 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000764180 us-gaap:RetainedEarningsMember 2020-06-30 0000764180 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000764180 us-gaap:TreasuryStockMember 2020-06-30 0000764180 us-gaap:NoncontrollingInterestMember 2020-06-30 0000764180 2020-06-30 0000764180 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000764180 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-09-30 0000764180 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000764180 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000764180 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0000764180 mo:HelixInnovationsLLCMember 2020-12-01 2021-04-29 0000764180 2020-12-01 2021-04-29 0000764180 2021-08-01 2021-08-31 0000764180 2021-04-01 2021-06-30 0000764180 mo:July2019ShareRepurchaseProgramMember 2019-07-31 0000764180 mo:July2019ShareRepurchaseProgramMember 2020-04-30 0000764180 mo:July2019ShareRepurchaseProgramMember 2020-01-01 2020-12-31 0000764180 mo:January2021ShareRepurchaseProgramMember 2021-01-31 0000764180 mo:January2021ShareRepurchaseProgramMember 2021-09-30 0000764180 mo:January2021ShareRepurchaseProgramMember us-gaap:SubsequentEventMember 2021-10-28 0000764180 mo:January2021ShareRepurchaseProgramMember 2021-01-01 2021-09-30 0000764180 mo:January2021ShareRepurchaseProgramMember 2021-07-01 2021-09-30 0000764180 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2021-09-30 0000764180 mo:SteMichelleTransactionMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember us-gaap:SubsequentEventMember 2021-10-01 0000764180 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember mo:SteMichelleTransactionMember 2021-01-01 2021-09-30 0000764180 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember mo:SteMichelleTransactionMember mo:MarketingAdministrationAndResearchCostsMember mo:WineSegmentMember 2021-01-01 2021-09-30 0000764180 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember mo:SteMichelleTransactionMember us-gaap:SubsequentEventMember 2021-10-01 2021-10-01 0000764180 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember mo:SteMichelleTransactionsMember 2021-09-30 0000764180 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember mo:SteMichelleTransactionsMember 2021-01-01 2021-09-30 0000764180 mo:ABInBevMember 2021-09-30 0000764180 mo:ABInBevMember 2020-12-31 0000764180 mo:JUULMember 2021-09-30 0000764180 mo:JUULMember 2020-12-31 0000764180 mo:CronosGroupInc.Member 2021-09-30 0000764180 mo:CronosGroupInc.Member 2020-12-31 0000764180 mo:CronosGroupInc.Member us-gaap:CommonStockMember 2021-09-30 0000764180 mo:CronosGroupInc.Member mo:EquityContractWarrantMember 2021-09-30 0000764180 mo:CronosGroupInc.Member mo:EquityContractPreemptiveRIghtsMember 2021-09-30 0000764180 mo:CronosGroupInc.Member us-gaap:CommonStockMember 2020-12-31 0000764180 mo:CronosGroupInc.Member mo:EquityContractWarrantMember 2020-12-31 0000764180 mo:CronosGroupInc.Member mo:EquityContractPreemptiveRIghtsMember 2020-12-31 0000764180 mo:ABInBevMember 2021-01-01 2021-09-30 0000764180 mo:ABInBevMember 2020-01-01 2020-09-30 0000764180 mo:ABInBevMember 2021-07-01 2021-09-30 0000764180 mo:ABInBevMember 2020-07-01 2020-09-30 0000764180 mo:CronosGroupInc.Member 2021-01-01 2021-09-30 0000764180 mo:CronosGroupInc.Member 2020-01-01 2020-09-30 0000764180 mo:CronosGroupInc.Member 2021-07-01 2021-09-30 0000764180 mo:CronosGroupInc.Member 2020-07-01 2020-09-30 0000764180 mo:JUULMember 2021-01-01 2021-09-30 0000764180 mo:JUULMember 2020-01-01 2020-09-30 0000764180 mo:JUULMember 2021-07-01 2021-09-30 0000764180 mo:JUULMember 2020-07-01 2020-09-30 0000764180 mo:ABInBevMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0000764180 mo:ABInBevMember 2020-01-01 2020-12-31 0000764180 mo:JUULMember 2018-12-31 0000764180 mo:JUULMember mo:EquityMethodInvestmentsFairValueOptionMember 2020-12-31 0000764180 mo:JUULMember mo:EquityMethodInvestmentsFairValueOptionMember 2021-01-01 2021-09-30 0000764180 mo:JUULMember mo:EquityMethodInvestmentsFairValueOptionMember 2021-09-30 0000764180 mo:JUULMember 2020-10-31 0000764180 2020-10-31 0000764180 mo:CronosGroupInc.Member mo:EquityContractWarrantMember 2021-01-01 2021-09-30 0000764180 mo:CronosGroupInc.Member mo:EquityContractPreemptiveRIghtsMember 2021-01-01 2021-09-30 0000764180 mo:CronosGroupInc.Member mo:EquityContractWarrantMember us-gaap:SubsequentEventMember 2021-10-25 2021-10-25 0000764180 mo:CronosGroupInc.Member mo:EquityContractPreemptiveRIghtsMember us-gaap:SubsequentEventMember 2021-10-25 2021-10-25 0000764180 mo:CronosGroupInc.Member mo:EquityContractWarrantAndEquityContractPreemptiveRightsMember 2021-01-01 2021-09-30 0000764180 mo:CronosGroupInc.Member 2020-01-01 2020-12-31 0000764180 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember 2021-09-30 0000764180 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember 2020-12-31 0000764180 mo:ForeignCurrencyDenominatedDebtMember 2021-09-30 0000764180 mo:ForeignCurrencyDenominatedDebtMember 2020-12-31 0000764180 mo:EquityContractPreemptiveRIghtsMember us-gaap:MeasurementInputSharePriceMember 2021-09-30 0000764180 mo:EquityContractPreemptiveRIghtsMember us-gaap:MeasurementInputSharePriceMember 2020-12-31 0000764180 mo:EquityContractWarrantMember us-gaap:MeasurementInputSharePriceMember 2021-09-30 0000764180 mo:EquityContractWarrantMember us-gaap:MeasurementInputSharePriceMember 2020-12-31 0000764180 mo:EquityContractPreemptiveRIghtsMember us-gaap:MeasurementInputExpectedTermMember 2021-09-30 0000764180 mo:EquityContractPreemptiveRIghtsMember us-gaap:MeasurementInputExpectedTermMember 2020-12-31 0000764180 mo:EquityContractWarrantMember us-gaap:MeasurementInputExpectedTermMember 2021-09-30 0000764180 mo:EquityContractWarrantMember us-gaap:MeasurementInputExpectedTermMember 2020-12-31 0000764180 mo:EquityContractPreemptiveRIghtsMember us-gaap:MeasurementInputPriceVolatilityMember 2021-09-30 0000764180 mo:EquityContractPreemptiveRIghtsMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0000764180 mo:EquityContractWarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2021-09-30 0000764180 mo:EquityContractWarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0000764180 mo:EquityContractPreemptiveRIghtsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-09-30 0000764180 mo:EquityContractPreemptiveRIghtsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0000764180 mo:EquityContractWarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-09-30 0000764180 mo:EquityContractWarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0000764180 mo:EquityContractPreemptiveRIghtsMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-09-30 0000764180 mo:EquityContractPreemptiveRIghtsMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-31 0000764180 mo:EquityContractWarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-09-30 0000764180 mo:EquityContractWarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-31 0000764180 srt:MinimumMember mo:EquityContractPreemptiveRIghtsMember mo:MeasurementInputWeightedAverageExpectedTermMember 2021-09-30 0000764180 srt:MaximumMember mo:EquityContractPreemptiveRIghtsMember mo:MeasurementInputWeightedAverageExpectedTermMember 2021-09-30 0000764180 srt:MinimumMember mo:EquityContractPreemptiveRIghtsMember mo:MeasurementInputWeightedAverageExpectedTermMember 2020-12-31 0000764180 srt:MaximumMember mo:EquityContractPreemptiveRIghtsMember mo:MeasurementInputWeightedAverageExpectedTermMember 2020-12-31 0000764180 srt:MinimumMember mo:EquityContractPreemptiveRIghtsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-09-30 0000764180 srt:MaximumMember mo:EquityContractPreemptiveRIghtsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-09-30 0000764180 srt:MinimumMember mo:EquityContractPreemptiveRIghtsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0000764180 srt:MaximumMember mo:EquityContractPreemptiveRIghtsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0000764180 us-gaap:EquityContractMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000764180 us-gaap:EquityContractMember us-gaap:FairValueInputsLevel3Member 2020-01-01 2020-12-31 0000764180 us-gaap:EquityContractMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0000764180 us-gaap:EquityContractMember us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-09-30 0000764180 us-gaap:EquityContractMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0000764180 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-09-30 0000764180 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000764180 mo:OtherAccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-09-30 0000764180 mo:OtherAccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000764180 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-09-30 0000764180 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000764180 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-09-30 0000764180 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000764180 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-09-30 0000764180 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000764180 mo:InvestmentsInEquitySecuritiesMember mo:EquityContractWarrantMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember 2021-09-30 0000764180 mo:InvestmentsInEquitySecuritiesMember mo:EquityContractWarrantMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember 2020-12-31 0000764180 mo:InvestmentsInEquitySecuritiesMember mo:EquityContractPreemptiveRIghtsMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember 2021-09-30 0000764180 mo:InvestmentsInEquitySecuritiesMember mo:EquityContractPreemptiveRIghtsMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember 2020-12-31 0000764180 us-gaap:EquityContractMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember 2021-09-30 0000764180 us-gaap:EquityContractMember us-gaap:NetInvestmentHedgingMember us-gaap:NondesignatedMember 2020-12-31 0000764180 us-gaap:NetInvestmentHedgingMember 2021-09-30 0000764180 us-gaap:NetInvestmentHedgingMember 2020-12-31 0000764180 mo:EquityContractPreemptiveRIghtsMember 2021-01-01 2021-09-30 0000764180 mo:EquityContractPreemptiveRIghtsMember 2020-01-01 2020-09-30 0000764180 mo:EquityContractPreemptiveRIghtsMember 2021-07-01 2021-09-30 0000764180 mo:EquityContractPreemptiveRIghtsMember 2020-07-01 2020-09-30 0000764180 mo:EquityContractWarrantMember 2021-01-01 2021-09-30 0000764180 mo:EquityContractWarrantMember 2020-01-01 2020-09-30 0000764180 mo:EquityContractWarrantMember 2021-07-01 2021-09-30 0000764180 mo:EquityContractWarrantMember 2020-07-01 2020-09-30 0000764180 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember 2021-01-01 2021-09-30 0000764180 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember 2020-01-01 2020-09-30 0000764180 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember 2021-07-01 2021-09-30 0000764180 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember 2020-07-01 2020-09-30 0000764180 mo:ForeignCurrencyDenominatedDebtMember us-gaap:NetInvestmentHedgingMember 2021-01-01 2021-09-30 0000764180 mo:ForeignCurrencyDenominatedDebtMember us-gaap:NetInvestmentHedgingMember 2020-01-01 2020-09-30 0000764180 mo:ForeignCurrencyDenominatedDebtMember us-gaap:NetInvestmentHedgingMember 2021-07-01 2021-09-30 0000764180 mo:ForeignCurrencyDenominatedDebtMember us-gaap:NetInvestmentHedgingMember 2020-07-01 2020-09-30 0000764180 us-gaap:NetInvestmentHedgingMember 2021-01-01 2021-09-30 0000764180 us-gaap:NetInvestmentHedgingMember 2020-01-01 2020-09-30 0000764180 us-gaap:NetInvestmentHedgingMember 2021-07-01 2021-09-30 0000764180 us-gaap:NetInvestmentHedgingMember 2020-07-01 2020-09-30 0000764180 us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-09-30 0000764180 us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000764180 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-09-30 0000764180 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000764180 us-gaap:PensionPlansDefinedBenefitMember 2021-07-01 2021-09-30 0000764180 us-gaap:PensionPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000764180 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-07-01 2021-09-30 0000764180 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000764180 srt:MaximumMember us-gaap:PensionPlansDefinedBenefitMember 2021-09-30 0000764180 srt:MaximumMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-09-30 0000764180 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-05-31 2021-05-31 0000764180 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0000764180 mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember 2020-12-31 0000764180 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0000764180 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-09-30 0000764180 mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember 2021-01-01 2021-09-30 0000764180 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-09-30 0000764180 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-09-30 0000764180 mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember 2021-09-30 0000764180 us-gaap:AccumulatedTranslationAdjustmentMember 2021-09-30 0000764180 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-06-30 0000764180 mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember 2021-06-30 0000764180 us-gaap:AccumulatedTranslationAdjustmentMember 2021-06-30 0000764180 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-07-01 2021-09-30 0000764180 mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember 2021-07-01 2021-09-30 0000764180 us-gaap:AccumulatedTranslationAdjustmentMember 2021-07-01 2021-09-30 0000764180 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000764180 mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember 2019-12-31 0000764180 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000764180 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-09-30 0000764180 mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember 2020-01-01 2020-09-30 0000764180 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-09-30 0000764180 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-09-30 0000764180 mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember 2020-09-30 0000764180 us-gaap:AccumulatedTranslationAdjustmentMember 2020-09-30 0000764180 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-06-30 0000764180 mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember 2020-06-30 0000764180 us-gaap:AccumulatedTranslationAdjustmentMember 2020-06-30 0000764180 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-07-01 2020-09-30 0000764180 mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember 2020-07-01 2020-09-30 0000764180 us-gaap:AccumulatedTranslationAdjustmentMember 2020-07-01 2020-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2021-01-01 2021-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2020-01-01 2020-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2021-07-01 2021-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2020-07-01 2020-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2021-01-01 2021-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2020-01-01 2020-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2021-07-01 2021-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2020-07-01 2020-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-07-01 2021-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-07-01 2020-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember 2021-01-01 2021-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember 2020-01-01 2020-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember 2021-07-01 2021-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember 2020-07-01 2020-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2021-07-01 2021-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2020-07-01 2020-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000764180 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000764180 mo:SmokeableProductsSegmentMember 2021-01-01 2021-09-30 0000764180 mo:SmokeableProductsSegmentMember 2020-01-01 2020-09-30 0000764180 mo:SmokeableProductsSegmentMember 2021-07-01 2021-09-30 0000764180 mo:SmokeableProductsSegmentMember 2020-07-01 2020-09-30 0000764180 mo:OralTobaccoSegmentMember 2021-01-01 2021-09-30 0000764180 mo:OralTobaccoSegmentMember 2020-01-01 2020-09-30 0000764180 mo:OralTobaccoSegmentMember 2021-07-01 2021-09-30 0000764180 mo:OralTobaccoSegmentMember 2020-07-01 2020-09-30 0000764180 mo:WineSegmentMember 2021-01-01 2021-09-30 0000764180 mo:WineSegmentMember 2020-01-01 2020-09-30 0000764180 mo:WineSegmentMember 2021-07-01 2021-09-30 0000764180 mo:WineSegmentMember 2020-07-01 2020-09-30 0000764180 us-gaap:AllOtherSegmentsMember 2021-01-01 2021-09-30 0000764180 us-gaap:AllOtherSegmentsMember 2020-01-01 2020-09-30 0000764180 us-gaap:AllOtherSegmentsMember 2021-07-01 2021-09-30 0000764180 us-gaap:AllOtherSegmentsMember 2020-07-01 2020-09-30 0000764180 us-gaap:MaterialReconcilingItemsMember 2021-01-01 2021-09-30 0000764180 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-09-30 0000764180 us-gaap:MaterialReconcilingItemsMember 2021-07-01 2021-09-30 0000764180 us-gaap:MaterialReconcilingItemsMember 2020-07-01 2020-09-30 0000764180 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-09-30 0000764180 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-09-30 0000764180 us-gaap:CorporateNonSegmentMember 2021-07-01 2021-09-30 0000764180 us-gaap:CorporateNonSegmentMember 2020-07-01 2020-09-30 0000764180 us-gaap:OperatingSegmentsMember mo:NonParticipatingManufacturerArbitrationPanelDecisionMember us-gaap:OperatingIncomeLossMember mo:NpmAdjustmentToCostOfSalesMember mo:SmokeableProductsSegmentMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 us-gaap:OperatingSegmentsMember mo:NonParticipatingManufacturerArbitrationPanelDecisionMember us-gaap:OperatingIncomeLossMember mo:NpmAdjustmentToCostOfSalesMember mo:SmokeableProductsSegmentMember mo:PhilipMorrisUSAMember 2021-07-01 2021-09-30 0000764180 us-gaap:MaterialReconcilingItemsMember mo:NonParticipatingManufacturerArbitrationPanelDecisionMember mo:InterestAndOtherDebtExpenseNetMember mo:NpmAdjustmentToCostOfSalesMember 2021-01-01 2021-09-30 0000764180 us-gaap:MaterialReconcilingItemsMember mo:NonParticipatingManufacturerArbitrationPanelDecisionMember mo:InterestAndOtherDebtExpenseNetMember mo:NpmAdjustmentToCostOfSalesMember 2021-07-01 2021-09-30 0000764180 mo:NonParticipatingManufacturerArbitrationPanelDecisionMember mo:NpmAdjustmentToCostOfSalesMember 2021-01-01 2021-09-30 0000764180 mo:NonParticipatingManufacturerArbitrationPanelDecisionMember mo:NpmAdjustmentToCostOfSalesMember 2021-07-01 2021-09-30 0000764180 us-gaap:OperatingSegmentsMember mo:TobaccoandHealthLitigationCasesMember mo:SmokeableProductsSegmentMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 us-gaap:OperatingSegmentsMember mo:TobaccoandHealthLitigationCasesMember mo:SmokeableProductsSegmentMember mo:PhilipMorrisUSAMember 2020-01-01 2020-09-30 0000764180 us-gaap:OperatingSegmentsMember mo:TobaccoandHealthLitigationCasesMember mo:SmokeableProductsSegmentMember mo:PhilipMorrisUSAMember 2021-07-01 2021-09-30 0000764180 us-gaap:OperatingSegmentsMember mo:TobaccoandHealthLitigationCasesMember mo:SmokeableProductsSegmentMember mo:PhilipMorrisUSAMember 2020-07-01 2020-09-30 0000764180 us-gaap:CorporateNonSegmentMember mo:TobaccoandHealthLitigationCasesMember 2021-01-01 2021-09-30 0000764180 us-gaap:CorporateNonSegmentMember mo:TobaccoandHealthLitigationCasesMember 2020-01-01 2020-09-30 0000764180 us-gaap:CorporateNonSegmentMember mo:TobaccoandHealthLitigationCasesMember 2021-07-01 2021-09-30 0000764180 us-gaap:CorporateNonSegmentMember mo:TobaccoandHealthLitigationCasesMember 2020-07-01 2020-09-30 0000764180 us-gaap:MaterialReconcilingItemsMember mo:TobaccoandHealthLitigationCasesMember 2021-01-01 2021-09-30 0000764180 us-gaap:MaterialReconcilingItemsMember mo:TobaccoandHealthLitigationCasesMember 2020-01-01 2020-09-30 0000764180 us-gaap:MaterialReconcilingItemsMember mo:TobaccoandHealthLitigationCasesMember 2021-07-01 2021-09-30 0000764180 us-gaap:MaterialReconcilingItemsMember mo:TobaccoandHealthLitigationCasesMember 2020-07-01 2020-09-30 0000764180 mo:TobaccoandHealthLitigationCasesMember 2021-01-01 2021-09-30 0000764180 mo:TobaccoandHealthLitigationCasesMember 2020-01-01 2020-09-30 0000764180 mo:TobaccoandHealthLitigationCasesMember 2021-07-01 2021-09-30 0000764180 mo:TobaccoandHealthLitigationCasesMember 2020-07-01 2020-09-30 0000764180 mo:COVID19Member 2020-01-01 2020-09-30 0000764180 mo:COVID19Member 2020-07-01 2020-09-30 0000764180 mo:SmokeableProductsSegmentMember mo:COVID19Member 2020-01-01 2020-09-30 0000764180 mo:SmokeableProductsSegmentMember mo:COVID19Member 2020-07-01 2020-09-30 0000764180 mo:OralTobaccoSegmentMember mo:COVID19Member 2020-01-01 2020-09-30 0000764180 mo:OralTobaccoSegmentMember mo:COVID19Member 2020-07-01 2020-09-30 0000764180 mo:InventoryDisposalCostsandOtherMember mo:WineBusinessStrategicResetMember 2020-01-01 2020-09-30 0000764180 mo:InventoryWriteOffMember mo:WineBusinessStrategicResetMember 2020-01-01 2020-09-30 0000764180 us-gaap:PurchaseCommitmentMember mo:WineBusinessStrategicResetMember 2020-01-01 2020-09-30 0000764180 us-gaap:RevolvingCreditFacilityMember mo:RevolvingCreditFacilityDueAugust2024Member us-gaap:LineOfCreditMember 2021-09-30 0000764180 us-gaap:RevolvingCreditFacilityMember mo:RevolvingCreditFacilityDueAugust2024Member us-gaap:LineOfCreditMember 2021-01-01 2021-09-30 0000764180 us-gaap:RevolvingCreditFacilityMember mo:RevolvingCreditFacilityDueAugust2024Member us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-01-01 2021-09-30 0000764180 us-gaap:RevolvingCreditFacilityMember 2021-01-01 2021-09-30 0000764180 us-gaap:RevolvingCreditFacilityMember mo:RevolvingCreditFacilityDueAugust2024Member us-gaap:LineOfCreditMember 2020-03-01 2020-03-31 0000764180 mo:USDDenominatedNotesMember us-gaap:SeniorNotesMember 2021-05-01 2021-05-31 0000764180 mo:USDDenominatedNotesMember us-gaap:SeniorNotesMember 2021-02-28 0000764180 mo:USDDenominatedNotesDue2032Member us-gaap:SeniorNotesMember 2021-02-28 0000764180 mo:USDDenominatedNotesDue2041Member us-gaap:SeniorNotesMember 2021-02-28 0000764180 mo:USDDenominatedNotesDue2051Member us-gaap:SeniorNotesMember 2021-02-28 0000764180 mo:USDDenominatedNotesDue2061Member us-gaap:SeniorNotesMember 2021-02-28 0000764180 us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:SeniorNotesMember 2021-02-01 2021-02-28 0000764180 us-gaap:SeniorNotesMember 2021-09-30 0000764180 mo:USDDenominatedNotes2850PercentDue2022Member us-gaap:SeniorNotesMember 2021-09-30 0000764180 mo:USDDenominatedNotes2950PercentDue2023Member us-gaap:SeniorNotesMember 2021-09-30 0000764180 mo:USDDenominatedNotes4000PercentDue2024Member us-gaap:SeniorNotesMember 2021-09-30 0000764180 mo:USDDenominatedNotes3800PercentDue2024Member us-gaap:SeniorNotesMember 2021-09-30 0000764180 mo:USDDenominatedNotes4400PercentDue2026Member us-gaap:SeniorNotesMember 2021-09-30 0000764180 mo:USDDenominatedNotes4800PercentDue2029Member us-gaap:SeniorNotesMember 2021-09-30 0000764180 mo:USDDenominatedNotes9950PercentDue2038Member us-gaap:SeniorNotesMember 2021-09-30 0000764180 mo:USDDenominatedDebt10200PercentDue2039Member us-gaap:SeniorNotesMember 2021-09-30 0000764180 mo:USDDenominatedDebt6200PercentDue2059Member us-gaap:SeniorNotesMember 2021-09-30 0000764180 mo:USDDenominatedNotes3490PercentDue2022Member us-gaap:SeniorNotesMember 2021-03-31 0000764180 mo:USDDenominatedNotes3490PercentDue2022Member us-gaap:SeniorNotesMember 2021-01-01 2021-03-31 0000764180 2021-01-01 2021-03-31 0000764180 mo:TobaccoandHealthJudgmentMember 2004-10-01 2021-09-30 0000764180 mo:EngleProgenyCasesMember 2004-10-01 2021-09-30 0000764180 mo:TobaccoandHealthJudgmentMember mo:LitigationCasesResultsMember 2021-01-01 2021-09-30 0000764180 mo:TobaccoandHealthJudgmentMember mo:LitigationCasesResultsMember 2020-01-01 2020-09-30 0000764180 mo:TobaccoandHealthJudgmentMember mo:LitigationCasesResultsMember 2021-07-01 2021-09-30 0000764180 mo:TobaccoandHealthJudgmentMember mo:LitigationCasesResultsMember 2020-07-01 2020-09-30 0000764180 mo:InterestExpenseRelatedToLitigationMember 2021-01-01 2021-09-30 0000764180 mo:InterestExpenseRelatedToLitigationMember 2020-01-01 2020-09-30 0000764180 mo:InterestExpenseRelatedToLitigationMember 2021-07-01 2021-09-30 0000764180 mo:InterestExpenseRelatedToLitigationMember 2020-07-01 2020-09-30 0000764180 us-gaap:AssetsMember us-gaap:PendingLitigationMember mo:PhilipMorrisUSAMember 2021-09-30 0000764180 mo:IndividualSmokingAndHealthCasesMember us-gaap:SubsequentEventMember 2021-10-25 0000764180 mo:IndividualSmokingAndHealthCasesMember 2020-10-27 0000764180 mo:IndividualSmokingAndHealthCasesMember 2019-10-28 0000764180 mo:HealthCareCostRecoveryActionsMember us-gaap:SubsequentEventMember 2021-10-25 0000764180 mo:HealthCareCostRecoveryActionsMember 2020-10-27 0000764180 mo:HealthCareCostRecoveryActionsMember 2019-10-28 0000764180 mo:EvaporLitigationMember us-gaap:SubsequentEventMember 2021-10-25 0000764180 mo:EvaporLitigationMember 2020-10-27 0000764180 mo:EvaporLitigationMember 2019-10-28 0000764180 mo:OtherTabaccoRelatedCasesMember us-gaap:SubsequentEventMember 2021-10-25 0000764180 mo:OtherTabaccoRelatedCasesMember 2020-10-27 0000764180 mo:OtherTabaccoRelatedCasesMember 2019-10-28 0000764180 mo:IndividualSmokingAndHealthCasesMember stpr:IL us-gaap:PendingLitigationMember us-gaap:SubsequentEventMember 2021-10-25 0000764180 mo:IndividualSmokingAndHealthCasesMember stpr:NM us-gaap:PendingLitigationMember us-gaap:SubsequentEventMember 2021-10-25 0000764180 mo:IndividualSmokingAndHealthCasesMember stpr:MA us-gaap:PendingLitigationMember us-gaap:SubsequentEventMember 2021-10-25 0000764180 mo:IndividualSmokingAndHealthCasesMember stpr:FL us-gaap:PendingLitigationMember us-gaap:SubsequentEventMember 2021-10-25 0000764180 mo:ETSSmokingandHealthCaseFlightAttendantsMember us-gaap:PendingLitigationMember us-gaap:SubsequentEventMember 2021-10-25 2021-10-25 0000764180 mo:EvaporLitigationMember mo:PendingIndividualLawsuitsMember us-gaap:SubsequentEventMember 2021-10-25 0000764180 mo:EvaporLitigationMember mo:PendingLawsuitsFiledByStateOrLocalGovernmentsMember us-gaap:SubsequentEventMember 2021-10-25 0000764180 mo:EvaporLitigationMember mo:ClassActionLawsuitMember us-gaap:SubsequentEventMember 2021-10-25 0000764180 mo:HealthCareCostRecoveryActionsMember country:CA us-gaap:SubsequentEventMember 2021-10-25 0000764180 mo:HealthCareCostRecoveryActionsMember country:CA us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 2021-10-25 0000764180 mo:HealthCareCostRecoveryActionsMember country:CA us-gaap:SubsequentEventMember mo:PhilipMorrisUSAandAltriaGroupMember 2021-10-25 0000764180 mo:SmokingAndHealthClassActionsMember country:CA us-gaap:SubsequentEventMember mo:PhilipMorrisUSAandAltriaGroupMember 2021-10-25 0000764180 mo:EngleProgenyCasesMember us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 2021-10-25 0000764180 mo:NonEngleProgenyCasesMember us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 1999-01-01 2021-10-25 0000764180 mo:NonEngleProgenyCasesMember stpr:AK us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 1999-01-01 2021-10-25 0000764180 mo:NonEngleProgenyCasesMember stpr:CA us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 1999-01-01 2021-10-25 0000764180 mo:NonEngleProgenyCasesMember stpr:CT us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 1999-01-01 2021-10-25 0000764180 mo:NonEngleProgenyCasesMember stpr:FL us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 1999-01-01 2021-10-25 0000764180 mo:NonEngleProgenyCasesMember stpr:LA us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 1999-01-01 2021-10-25 0000764180 mo:NonEngleProgenyCasesMember stpr:MA us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 1999-01-01 2021-10-25 0000764180 mo:NonEngleProgenyCasesMember stpr:MS us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 1999-01-01 2021-10-25 0000764180 mo:NonEngleProgenyCasesMember stpr:MO us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 1999-01-01 2021-10-25 0000764180 mo:NonEngleProgenyCasesMember stpr:NH us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 1999-01-01 2021-10-25 0000764180 mo:NonEngleProgenyCasesMember stpr:NJ us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 1999-01-01 2021-10-25 0000764180 mo:NonEngleProgenyCasesMember stpr:NY us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 1999-01-01 2021-10-25 0000764180 mo:NonEngleProgenyCasesMember stpr:OH us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 1999-01-01 2021-10-25 0000764180 mo:NonEngleProgenyCasesMember stpr:PA us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 1999-01-01 2021-10-25 0000764180 mo:NonEngleProgenyCasesMember stpr:RI us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 1999-01-01 2021-10-25 0000764180 mo:NonEngleProgenyCasesMember stpr:TN us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 1999-01-01 2021-10-25 0000764180 mo:NonEngleProgenyCasesMember stpr:WV us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 1999-01-01 2021-10-25 0000764180 mo:NonEngleProgenySmokingAndHealthCasePrincipeMember 2020-02-29 0000764180 mo:NonEngleProgenySmokingandHealthCaseGreeneMember 2019-09-30 0000764180 mo:NonEngleProgenySmokingandHealthCaseGreeneMember 2020-05-31 0000764180 mo:NonEngleProgenySmokingandHealthCaseGreeneMember 2021-02-28 0000764180 mo:NonEngleProgenySmokingandHealthCaseLaramieMember 2019-08-31 0000764180 mo:NonEngleProgenySmokingandHealthCaseLaramieMember 2021-09-01 2021-09-30 0000764180 mo:NonEngleProgenySmokingandHealthCaseGentileMember 2017-10-31 0000764180 mo:NonEngleProgenySmokingandHealthCaseGentileMember mo:PhilipMorrisUSAMember 2017-10-31 0000764180 mo:EngleProgenyCasesMember 2000-07-31 0000764180 mo:EngleProgenyCasesMember mo:PhilipMorrisUSAMember 2000-07-31 0000764180 mo:EngleProgenyCasesMember mo:PhilipMorrisUSAMember 2006-07-01 2006-07-31 0000764180 mo:EngleProgenyCasesMember 2008-01-31 0000764180 mo:EngleProgenyCasesStateMember us-gaap:SubsequentEventMember 2021-10-25 0000764180 mo:EngleProgenyCasesStateMember us-gaap:SubsequentEventMember 2021-10-25 2021-10-25 0000764180 mo:EngleProgenyCasesFederalMember us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 2021-10-25 0000764180 mo:EngleProgenyCasesMember us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 2021-10-25 2021-10-25 0000764180 mo:EngleProgenyCasesStateMember us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 2021-10-25 2021-10-25 0000764180 mo:EngleProgenyCasesPearsonDCohenCollarChaconMemberMember us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 2021-10-25 2021-10-25 0000764180 mo:EngleProgenyCasesReiderandBanksMember us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 2021-10-25 2021-10-25 0000764180 mo:EngleProgenyCasesWeingartandHancockMember us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 2021-10-25 2021-10-25 0000764180 mo:EngleProgenyCasesPollariMember us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 2021-10-25 2021-10-25 0000764180 mo:EngleProgenyCasesGlogerRintoulandDuignamMember us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 2021-10-25 2021-10-25 0000764180 mo:EngleProgenyCasesFreemanMember us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 2021-10-25 2021-10-25 0000764180 us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 2021-10-25 0000764180 mo:EngleProgenyCasesLippMember us-gaap:PendingLitigationMember 2021-09-30 0000764180 mo:EngleProgenyCasesLippMember us-gaap:PendingLitigationMember mo:PhilipMorrisUSAMember 2021-09-30 0000764180 mo:EngleProgenyCasesGarciaMember us-gaap:PendingLitigationMember 2021-05-31 0000764180 mo:EngleProgenyCasesDuignanMember us-gaap:PendingLitigationMember 2020-02-29 0000764180 mo:EngleProgenyCasesDuignanMember us-gaap:PendingLitigationMember mo:PhilipMorrisUSAMember 2020-02-29 0000764180 mo:EngleProgenyCasesCuddiheeMember us-gaap:PendingLitigationMember 2020-01-31 0000764180 mo:EngleProgenyCasesCuddiheeMember us-gaap:PendingLitigationMember mo:PhilipMorrisUSAMember 2020-01-31 0000764180 mo:EngleProgenyCasesRintoulMember us-gaap:PendingLitigationMember 2019-11-30 0000764180 mo:EngleProgenyCasesRintoulMember us-gaap:PendingLitigationMember mo:PhilipMorrisUSAMember 2019-11-30 0000764180 mo:EngleProgenyCasesGlogerMember us-gaap:PendingLitigationMember 2019-11-30 0000764180 mo:EngleProgenyCasesGlogerMember us-gaap:PendingLitigationMember mo:PhilipMorrisUSAMember 2019-11-30 0000764180 mo:EngleProgenyCasesMcCallMember us-gaap:PendingLitigationMember 2019-03-31 0000764180 mo:EngleProgenyCasesMcCallMember us-gaap:PendingLitigationMember mo:PhilipMorrisUSAMember 2019-03-31 0000764180 mo:EngleProgenyCasesNeffMember us-gaap:PendingLitigationMember 2019-03-31 0000764180 mo:EngleProgenyCasesNeffMember us-gaap:PendingLitigationMember mo:PhilipMorrisUSAMember 2019-03-31 0000764180 mo:EngleProgenyCasesMahfuzMember us-gaap:PendingLitigationMember 2019-02-28 0000764180 mo:EngleProgenyCasesMahfuzMember us-gaap:PendingLitigationMember mo:PhilipMorrisUSAMember 2019-02-28 0000764180 mo:EngleProgenyCasesHollimanMember us-gaap:PendingLitigationMember 2019-02-28 0000764180 mo:EngleProgenyCasesHollimanMember us-gaap:PendingLitigationMember mo:PhilipMorrisUSAMember 2019-02-28 0000764180 mo:EngleProgenyCasesChadwellMember us-gaap:PendingLitigationMember 2018-09-30 0000764180 mo:EngleProgenyCasesChadwellMember us-gaap:PendingLitigationMember mo:PhilipMorrisUSAMember 2018-09-30 0000764180 mo:EngleProgenyCasesKaplanMember us-gaap:PendingLitigationMember 2018-07-31 0000764180 mo:EngleProgenyCasesKaplanMember us-gaap:PendingLitigationMember mo:PhilipMorrisUSAMember 2018-07-31 0000764180 mo:EngleProgenyCasesR.DouglasMember us-gaap:PendingLitigationMember 2017-11-30 0000764180 mo:EngleProgenyCasesR.DouglasMember us-gaap:PendingLitigationMember mo:PhilipMorrisUSAMember 2017-11-30 0000764180 mo:EngleProgenyCasesSommersMember us-gaap:PendingLitigationMember 2017-04-30 0000764180 mo:EngleProgenyCasesSommersMember us-gaap:PendingLitigationMember mo:PhilipMorrisUSAMember 2017-04-30 0000764180 mo:EngleProgenyCasesSommersMember us-gaap:PendingLitigationMember 2021-01-01 2021-09-30 0000764180 mo:EngleProgenyCasesCooperMember us-gaap:PendingLitigationMember 2015-09-30 0000764180 mo:EngleProgenyCasesCooperMember us-gaap:PendingLitigationMember mo:PhilipMorrisUSAMember 2015-09-30 0000764180 mo:EngleProgenyCasesD.BrownMember us-gaap:PendingLitigationMember 2015-01-31 0000764180 mo:EngleProgenyCasesD.BrownMember us-gaap:PendingLitigationMember mo:PhilipMorrisUSAMember 2015-01-31 0000764180 mo:EngleProgenyCasesBergerMember us-gaap:SettledLitigationMember 2018-10-01 2018-12-31 0000764180 mo:EngleProgenyCasesBergerMember us-gaap:SettledLitigationMember 2021-01-01 2021-03-31 0000764180 mo:EngleProgenyCasesSantoroMember us-gaap:SettledLitigationMember 2020-04-01 2020-06-30 0000764180 mo:EngleProgenyCasesSantoroMember us-gaap:SettledLitigationMember 2021-01-01 2021-03-31 0000764180 mo:EngleProgenyCasesNaugleGoreMBrownJordanTheisAndLandiMember mo:PhilipMorrisUSAMember 2021-09-30 0000764180 mo:EngleProgenyCasesNaugleMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:EngleProgenyCasesGoreMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:EngleProgenyCasesM.BrownMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:EngleProgenyCasesJordanMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:EngleProgenyCasesTheisMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:EngleProgenyCasesLandiMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:EngleProgenyCasesM.BrownMember mo:PhilipMorrisUSAMember 2021-04-01 2021-04-29 0000764180 mo:EngleProgenyCasesTheisMember mo:PhilipMorrisUSAMember 2021-05-01 2021-05-31 0000764180 mo:EngleProgenyCasesLandiMember mo:PhilipMorrisUSAMember 2021-07-01 2021-07-31 0000764180 mo:EngleProgenyCasesRJReynoldsMember mo:PhilipMorrisUSAMember 2021-07-01 2021-07-31 0000764180 mo:EngleProgenyCasesStateMember stpr:FL 2009-06-30 0000764180 mo:SmokingAndHealthClassActionsMember mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:AR mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:CA mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:DE mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:DC mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:FL mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:IL mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:IA mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:KS mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:LA mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:MD mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:MI mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:MN mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:NV mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:NJ mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:NY mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:OH mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:OK mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:OR mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:PA mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember country:PR mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:SC mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:TX mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember stpr:WI mo:PhilipMorrisUSAMember 1996-05-01 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember mo:BritishColumbiaSaskatchewanMember us-gaap:SubsequentEventMember mo:PhilipMorrisUSAandAltriaGroupMember 2021-10-25 0000764180 mo:SmokingAndHealthClassActionsMember country:CA mo:CanadianTobaccoManufacturersMember 2019-03-31 0000764180 mo:SmokingAndHealthClassActionsMember country:CA mo:AltriaGroupMember 2019-03-31 0000764180 mo:SmokingAndHealthClassActionsMember country:CA mo:CanadianTobaccoManufacturersMember 2019-03-01 2019-03-31 0000764180 mo:HealthCareCostRecoveryActionsMember country:CA us-gaap:ThreatenedLitigationMember 2021-09-30 0000764180 mo:SmokingAndHealthClassActionsMember country:CA mo:CanadianTobaccoManufacturersMember 2021-09-30 0000764180 mo:HealthCareCostRecoveryActionsMember 1998-11-01 1998-11-30 0000764180 mo:HealthCareCostRecoveryActionsMember 1998-11-30 0000764180 mo:HealthCareCostRecoveryActionsMember 2021-07-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActionsMember 2020-07-01 2020-09-30 0000764180 mo:HealthCareCostRecoveryActionsMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActionsMember 2020-01-01 2020-09-30 0000764180 mo:HealthCareCostRecoveryActions2004NPMAdjustmentMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActions2005NPMAdjustmentMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActions2006NPMAdjustmentMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActions2007NPMAdjustmentMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActions2008NPMAdjustmentMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActions2009NPMAdjustmentMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActions2010NPMAdjustmentMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActions2011NPMAdjustmentMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActions2012NPMAdjustmentMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActions2013NPMAdjustmentMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActions2014NPMAdjustmentMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActions2015NPMAdjustmentsMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActions2017NPMAdjustmentsMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActions2018NPMAdjustmentsMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActions2019NPMAdjustmentsMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActions2020NPMAdjustmentsMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActionsMember mo:PhilipMorrisUSAMember 2018-01-01 2018-12-31 0000764180 mo:HealthCareCostRecoveryActionsMember us-gaap:SettledLitigationMember mo:PhilipMorrisUSAMember 2018-01-01 2018-12-31 0000764180 mo:HealthCareCostRecoveryActionsMember us-gaap:PendingLitigationMember mo:PhilipMorrisUSAMember 2018-01-01 2018-12-31 0000764180 mo:HealthCareCostRecoveryActionsMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActionsTransitionYears20042020Member stpr:NY us-gaap:SettledLitigationMember mo:PhilipMorrisUSAMember 2015-01-01 2015-12-31 0000764180 stpr:MT us-gaap:SettledLitigationMember mo:PhilipMorrisUSAMember 2020-01-01 2020-12-31 0000764180 mo:HealthCareCostRecoveryActions2004NPMAdjustmentMember us-gaap:PendingLitigationMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActions2004NPMAdjustmentMember us-gaap:CostOfSalesMember us-gaap:PendingLitigationMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActions2004NPMAdjustmentMember us-gaap:PendingLitigationMember mo:PhilipMorrisUSAMember 2021-07-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActions20052007NPMAdjustmentMember us-gaap:PendingLitigationMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActions20052007NPMAdjustmentMember us-gaap:PendingLitigationMember mo:PeriodOneMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:HealthCareCostRecoveryActions20052007NPMAdjustmentMember us-gaap:PendingLitigationMember mo:PeriodTwoMember mo:PhilipMorrisUSAMember 2021-01-01 2021-09-30 0000764180 mo:OtherDisputesUndertheStateSettlementAgreementsMember mo:PhilipMorrisUSAMember 2021-01-01 2021-01-31 0000764180 mo:FederalGovernmentsLawsuitMember 2006-08-01 2006-08-31 0000764180 mo:FederalGovernmentsLawsuitMember mo:ImplementationofCorrectiveCommunicationsMember mo:PhilipMorrisUSAMember 2019-01-01 2019-12-31 0000764180 mo:FederalGovernmentsLawsuitMember mo:ImplementationofCorrectiveCommunicationsMember mo:PhilipMorrisUSAMember 2014-01-01 2014-12-31 0000764180 mo:FederalGovernmentsLawsuitMember mo:ImplementationofCorrectiveCommunicationsMember mo:AltriaGroupMember 2019-01-01 2019-12-31 0000764180 mo:FederalGovernmentsLawsuitMember mo:ImplementationofCorrectiveCommunicationsMember mo:AltriaGroupMember 2014-01-01 2014-12-31 0000764180 mo:EvaporLitigationMember mo:PendingLawsuitFiledBySchoolDistrictMember us-gaap:SubsequentEventMember 2021-10-25 0000764180 mo:EvaporLitigationMember 2020-12-01 2020-12-31 0000764180 mo:EvaporLitigationMember 2021-09-30 0000764180 mo:EvaporLitigationMember us-gaap:SettledLitigationMember 2021-01-01 2021-09-30 0000764180 mo:IQOSMember 2020-04-01 2020-04-30 0000764180 mo:JUULMember 2020-04-30 0000764180 us-gaap:SubsequentEventMember 2021-10-25 0000764180 2020-11-30 0000764180 2019-10-01 2019-12-31 0000764180 2020-08-01 2020-08-31 0000764180 2020-10-01 2021-03-31 0000764180 2021-04-01 2021-04-30 0000764180 2020-09-01 2021-08-31 0000764180 mo:LightsMember us-gaap:SubsequentEventMember 2021-10-25 0000764180 mo:SmokingAndHealthClassActionsMember us-gaap:SubsequentEventMember 2021-10-25 0000764180 mo:USTLitigationMember mo:PendingIndividualLawsuitsMember us-gaap:SubsequentEventMember 2021-10-25 0000764180 us-gaap:LetterOfCreditMember 2021-09-30 0000764180 mo:CreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2021-09-30 0000764180 mo:LightsMember us-gaap:SubsequentEventMember mo:PhilipMorrisUSAMember 2021-10-25 shares iso4217:USD iso4217:USD shares pure iso4217:CAD shares iso4217:CAD mo:year mo:state mo:claim mo:case mo:lawsuit mo:plantiff mo:manufacture mo:ruling mo:complaint mo:shareholder mo:court false 2021 Q3 0000764180 --12-31 0.3333 0.3333 P5Y P3Y P1Y 21 10-Q true 2021-09-30 false 1-08940 Altria Group, Inc. VA 13-3260245 6601 West Broad Street, Richmond, VA 23230 804 274-2200 Common Stock, $0.33 1/3 par value MO NYSE 1.000% Notes due 2023 MO23A NYSE 1.700% Notes due 2025 MO25 NYSE 2.200% Notes due 2027 MO27 NYSE 3.125% Notes due 2031 MO31 NYSE Yes Yes Large Accelerated Filer false false false 1836988822 2957000000 4945000000 36000000 137000000 644000000 844000000 159000000 200000000 30000000 502000000 300000000 420000000 1133000000 1966000000 1490000000 0 404000000 69000000 6020000000 7117000000 4418000000 5150000000 2900000000 3138000000 1518000000 2012000000 5177000000 5177000000 12326000000 12615000000 1740000000 1868000000 13874000000 19529000000 649000000 964000000 39564000000 47414000000 1105000000 1500000000 266000000 380000000 680000000 523000000 2996000000 3564000000 1109000000 1494000000 1661000000 1602000000 295000000 0 8112000000 9063000000 27022000000 27971000000 3557000000 4532000000 280000000 551000000 1512000000 1951000000 307000000 381000000 40790000000 44449000000 39000000 40000000 2805961317 2805961317 935000000 935000000 5846000000 5910000000 30685000000 34679000000 -3430000000 -4341000000 967321022 947542152 35303000000 34344000000 -1267000000 2839000000 2000000 86000000 -1265000000 2925000000 39564000000 47414000000 19758000000 19849000000 6786000000 7123000000 5348000000 5909000000 1858000000 1961000000 3733000000 4063000000 1255000000 1445000000 10677000000 9877000000 3673000000 3717000000 1850000000 1585000000 722000000 557000000 8827000000 8292000000 2951000000 3160000000 -869000000 -893000000 -266000000 -310000000 -649000000 0 0 0 -152000000 -58000000 -63000000 -3000000 -5789000000 -306000000 -5915000000 -472000000 0 2600000000 0 2600000000 -128000000 -202000000 -135000000 -105000000 1544000000 4349000000 -3302000000 -324000000 693000000 1817000000 -582000000 632000000 851000000 2532000000 -2720000000 -956000000 0 -11000000 2000000 -4000000 851000000 2543000000 -2722000000 -952000000 0.46 1.37 -1.48 -0.51 0.46 1.36 -1.48 -0.51 851000000 2532000000 -2720000000 -956000000 -383000000 -27000000 -6000000 15000000 495000000 -928000000 161000000 -15000000 33000000 -16000000 5000000 23000000 911000000 -917000000 172000000 -7000000 1762000000 1615000000 -2548000000 -963000000 0 -11000000 2000000 -4000000 1762000000 1626000000 -2550000000 -959000000 935000000 5910000000 34679000000 -4341000000 -34344000000 86000000 2925000000 851000000 -4000000 847000000 911000000 911000000 13000000 13000000 26000000 2.62 4845000000 4845000000 972000000 972000000 77000000 80000000 157000000 935000000 5846000000 30685000000 -3430000000 -35303000000 2000000 -1265000000 935000000 5970000000 36539000000 -2864000000 -34358000000 97000000 6319000000 2543000000 -13000000 2530000000 -917000000 -917000000 3000000 14000000 17000000 2.54 4726000000 4726000000 -9000000 -9000000 935000000 5973000000 34356000000 -3781000000 -34344000000 93000000 3232000000 4000000 2000000 935000000 5840000000 35065000000 -3602000000 -34981000000 2000000 3259000000 -2722000000 0 -2722000000 172000000 172000000 6000000 0 6000000 0.90 1658000000 1658000000 322000000 322000000 935000000 5846000000 30685000000 -3430000000 -35303000000 2000000 -1265000000 935000000 5964000000 36908000000 -3774000000 -34345000000 98000000 5786000000 -952000000 -5000000 -957000000 -7000000 -7000000 9000000 1000000 10000000 0.86 1600000000 1600000000 935000000 5973000000 34356000000 -3781000000 -34344000000 93000000 3232000000 2000000 1000000 851000000 2532000000 190000000 192000000 -1180000000 -111000000 -5789000000 -306000000 119000000 108000000 -128000000 -202000000 0 0 2600000000 -649000000 0 7000000 -1000000 -118000000 -136000000 3000000 24000000 -200000000 0 104000000 504000000 -568000000 -140000000 23000000 16000000 -127000000 -35000000 104000000 549000000 5742000000 5844000000 102000000 162000000 -60000000 -55000000 -42000000 -107000000 0 3000000000 0 3000000000 5472000000 1993000000 6542000000 1000000000 972000000 0 4787000000 4690000000 623000000 0 -216000000 -16000000 -7668000000 -3713000000 -1968000000 2024000000 5006000000 2160000000 3038000000 4184000000 2957000000 4945000000 0 1000000 45000000 60000000 36000000 0 3038000000 5006000000 Background and Basis of Presentation<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">When used in these notes, the term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Altria,” refers to Altria Group, Inc. and its subsidiaries, unless the context requires otherwise.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Background: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, Altria’s wholly owned subsidiaries included Philip Morris USA Inc. (“PM USA”), which is engaged in the manufacture and sale of cigarettes in the United States; John Middleton Co. (“Middleton”), which is engaged in the manufacture and sale of machine-made large cigars and pipe tobacco and is a wholly owned subsidiary of PM USA; UST LLC (“UST”), which through its wholly owned subsidiaries, including U.S. Smokeless Tobacco Company LLC (“USSTC”) and Ste. Michelle Wine Estates Ltd. (“Ste. Michelle”), is engaged in the manufacture and sale of moist smokeless tobacco products (“MST”), snus products and wine; Helix Innovations LLC (“Helix”), which operates in the United States and Canada, and Helix Innovations GmbH and its subsidiaries (“Helix ROW”), which operate internationally in the rest-of-world, are engaged in the manufacture and sale of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">on! </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oral nicotine pouches; and Philip Morris Capital Corporation (“PMCC”), which maintains a portfolio of finance assets, substantially all of which are leveraged leases.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 8, 2021, UST entered into a share purchase agreement pursuant to which it agreed to sell its subsidiary, International Wine &amp; Spirits Ltd. (“IWS”), which includes Ste. Michelle. The sale was completed on October 1, 2021. At September 30, 2021, the assets and liabilities associated with the pending sale of IWS were classified as assets held for sale on Altria’s condensed consolidated balance sheet. For further discussion, see Note 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Altria owns 100% of the global </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">on!</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> business as a result of transactions in December 2020 and April 2021 to purchase the remaining 20% interest in (i) Helix ROW and (ii) Helix, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The total purchase price of the December 2020 and April 2021 transactions was approximately $250 million.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Altria wholly owned subsidiaries included Altria Group Distribution Company, which provides sales and distribution services to certain Altria operating subsidiaries, and Altria Client Services LLC, which provides various support services in areas such as legal, regulatory, consumer engagement, finance, human resources and external affairs to Altria and its subsidiaries. Altria’s access to the operating cash flows of its wholly owned subsidiaries consists of cash received from the payment of dividends and distributions, and the payment of interest on intercompany loans by its subsidiaries. At September 30, 2021, Altria’s significant wholly owned subsidiaries were not limited by contractual obligations in their ability to pay cash dividends or make other distributions with respect to their equity interests.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, Altria’s investments in equity securities consisted of Anheuser-Busch InBev SA/NV (“ABI”), Cronos Group Inc. (“Cronos”) and JUUL Labs, Inc. (“JUUL”). Altria accounts for its investments in ABI and Cronos under the equity method of accounting using a one-quarter lag. Altria accounts for its equity investment in JUUL under the fair value option.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further discussion of Altria’s investments in equity securities, see Note 4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Dividends and Share Repurchases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Altria’s Board of Directors (the “Board of Directors” or “Board”) approved a 4.7% increase in the quarterly dividend rate to $0.90 per share of Altria common stock versus the previous rate of $0.86 per share. The current annualized dividend rate is $3.60. Future dividend payments remain subject to the discretion of the Board.</span></div><div style="margin-bottom:5pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Board of Directors authorized a $1.0 billion share repurchase program. In April 2020, the Board rescinded the $500 million remaining in this program as part of Altria’s efforts to enhance its liquidity position in response to the COVID-19 pandemic. Altria did not repurchase any shares in 2020.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Board authorized a new $2.0 billion share repurchase program, of which $1,028 million was remaining at September 30, 2021. In October 2021, the Board authorized a $1.5 billion expansion of this program to $3.5 billion. The timing of share repurchases under this program depends upon marketplace conditions and other factors, and the program remains subject to the discretion of the Board.</span></div><div style="padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Altria’s share repurchase activity for the nine and three months ended September 30, 2021 was as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of shares repurchased</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate cost of shares repurchased</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">972</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share of shares repurchased</span></div></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48.17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48.35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Basis of Presentation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim condensed consolidated financial statements of Altria are unaudited. It is the opinion of Altria’s management that all adjustments necessary for a fair statement of the interim results presented have been reflected in the interim condensed consolidated financial statements. All such adjustments were of a normal recurring nature. Net revenues and net earnings for any interim period are not necessarily indicative of results that may be expected for the entire year.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain immaterial prior year amounts have been reclassified to conform with the current year’s presentation.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These statements should be read in conjunction with Altria’s audited consolidated financial statements and related notes, which appear in Altria’s Annual Report on Form 10-K for the year ended December 31, 2020 (the “2020 Form 10-K”).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, Altria adopted Accounting Standards Update (“ASU”) 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU No. 2019-12”). This guidance removes certain exceptions for investments, intraperiod allocations and interim calculations, and adds guidance to reduce complexity in accounting for income taxes. The adoption of ASU No. 2019-12 did not have a material impact on Altria’s condensed consolidated financial statements.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on January 1, 2021, Altria adopted ASU No. 2020-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clarifying the Interactions between Topic 321, Topic 323, and Topic 815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU No. 2020-01”). This guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The adoption of ASU No. 2020-01 did not have a material impact on Altria’s condensed consolidated financial statements.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of issued accounting guidance applicable to, but not yet adopted by, Altria, see Note 13. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Guidance Not Yet Adopted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> 1 0.20 250000000 Altria accounts for its investments in ABI and Cronos under the equity method of accounting using a one-quarter lag. Altria accounts for its equity investment in JUUL under the fair value option. 0.047 0.90 0.86 3.60 1000000000 500000000 0 2000000000 1028000000 1500000000 3500000000 <div style="padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Altria’s share repurchase activity for the nine and three months ended September 30, 2021 was as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of shares repurchased</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate cost of shares repurchased</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">972</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share of shares repurchased</span></div></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48.17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48.35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 20200000 6700000 972000000 322000000 48.17 48.35 The interim condensed consolidated financial statements of Altria are unaudited. It is the opinion of Altria’s management that all adjustments necessary for a fair statement of the interim results presented have been reflected in the interim condensed consolidated financial statements. All such adjustments were of a normal recurring nature. Net revenues and net earnings for any interim period are not necessarily indicative of results that may be expected for the entire year. <div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, Altria adopted Accounting Standards Update (“ASU”) 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU No. 2019-12”). This guidance removes certain exceptions for investments, intraperiod allocations and interim calculations, and adds guidance to reduce complexity in accounting for income taxes. The adoption of ASU No. 2019-12 did not have a material impact on Altria’s condensed consolidated financial statements.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on January 1, 2021, Altria adopted ASU No. 2020-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clarifying the Interactions between Topic 321, Topic 323, and Topic 815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU No. 2020-01”). This guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The adoption of ASU No. 2020-01 did not have a material impact on Altria’s condensed consolidated financial statements.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of issued accounting guidance applicable to, but not yet adopted by, Altria, see Note 13. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Guidance Not Yet Adopted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:16.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standards</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective Date for Public Entity</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect on Financial Statements </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU 2020-06 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accounting for Convertible Instruments and Contracts in an Entity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">s Own Equity</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity.  Key provisions of the guidance include reducing the number of accounting models, simplifying the earnings per share calculations and expanding the disclosures related to convertible instruments.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Altria’s adoption of this guidance is not expected to have a material impact on its consolidated financial statements and related disclosures. </span></td></tr></table> Revenues from Contracts with Customers<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria disaggregates net revenues based on product type. For further discussion, see Note 9. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, a majority of Altria’s businesses offered cash discounts to customers for prompt payment and calculated cash discounts as a percentage of the list price based on historical experience and agreed-upon payment terms. Beginning in the first quarter of 2021 for USSTC and the third quarter of 2021 for PM USA, cash discounts were calculated as a flat rate per unit, based on agreed-upon payment terms. Altria’s businesses record receivables net of the cash discounts on Altria’s condensed consolidated balance sheets.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria’s businesses that receive payments in advance of product shipment record such payments as deferred revenue. These payments are included in other accrued liabilities on Altria’s condensed consolidated balance sheets until control of such products is obtained by the customer. Deferred revenue was $260 million and $301 million at September 30, 2021 and December 31, 2020, respectively. When cash is received in advance of product shipment, Altria’s businesses satisfy their performance obligations within three days of receiving payment. At September 30, 2021 and December 31, 2020, there were no differences between amounts recorded as deferred revenue and amounts subsequently recognized as revenue.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables were $144 million (including $108 million in assets held for sale) and $137 million at September 30, 2021 and December 31, 2020, respectively. At September 30, 2021 and December 31, 2020, there were no expected differences between amounts recorded and subsequently received, and Altria’s businesses did not record an allowance for doubtful accounts against these receivables.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria’s businesses record an allowance for returned goods, which is included in other accrued liabilities on Altria’s condensed consolidated balance sheets. While all of Altria’s tobacco operating companies sell tobacco products with dates relative to freshness as printed on product packaging, it is USSTC’s policy to accept authorized sales returns from its customers for products that have passed such dates due to the limited shelf life of USSTC’s MST and snus products. Altria’s businesses record estimated sales returns, which are based principally on historical volume and return rates, as a reduction to revenues. Actual sales returns will differ from estimated sales returns to the extent actual results differ from estimated assumptions. Altria’s businesses reflect differences between actual and estimated sales returns in the period in which the actual amounts become known. These differences, if any, have not had a material impact on Altria’s condensed consolidated financial statements. All returned goods are destroyed upon return and not included in inventory. Consequently, Altria’s businesses do not record an asset for their right to recover goods from customers upon return.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales incentives include variable payments related to goods sold by Altria’s businesses. Altria’s businesses include estimates of variable consideration as a reduction to revenues upon shipment of goods to customers. The sales incentives that require significant estimates and judgments are as follows:</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Price promotion payments- </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria’s businesses make price promotion payments, substantially all of which are made to their retail partners, to incent the promotion of certain product offerings in select geographic areas.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wholesale and retail participation payments-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Altria’s businesses make payments to their wholesale and retail partners to incent merchandising and sharing of sales data in accordance with each business’s trade agreements.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These estimates primarily include estimated wholesale to retail sales volume and historical acceptance rates. Actual payments will differ from estimated payments to the extent actual results differ from estimated assumptions. Differences between actual and estimated payments are reflected in the period such information becomes available. These differences, if any, have not had a material impact on Altria’s condensed consolidated financial statements.</span></div> In 2020, a majority of Altria’s businesses offered cash discounts to customers for prompt payment and calculated cash discounts as a percentage of the list price based on historical experience and agreed-upon payment terms. Beginning in the first quarter of 2021 for USSTC and the third quarter of 2021 for PM USA, cash discounts were calculated as a flat rate per unit, based on agreed-upon payment terms. Altria’s businesses record receivables net of the cash discounts on Altria’s condensed consolidated balance sheets. 260000000 301000000 three days 144000000 108000000 137000000 0 0 Altria’s businesses record an allowance for returned goods, which is included in other accrued liabilities on Altria’s condensed consolidated balance sheets. While all of Altria’s tobacco operating companies sell tobacco products with dates relative to freshness as printed on product packaging, it is USSTC’s policy to accept authorized sales returns from its customers for products that have passed such dates due to the limited shelf life of USSTC’s MST and snus products. Altria’s businesses record estimated sales returns, which are based principally on historical volume and return rates, as a reduction to revenues. Actual sales returns will differ from estimated sales returns to the extent actual results differ from estimated assumptions. Altria’s businesses reflect differences between actual and estimated sales returns in the period in which the actual amounts become known. These differences, if any, have not had a material impact on Altria’s condensed consolidated financial statements. All returned goods are destroyed upon return and not included in inventory. Consequently, Altria’s businesses do not record an asset for their right to recover goods from customers upon return. Assets Held for Sale<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 8, 2021, UST entered into a share purchase agreement pursuant to which it agreed to sell its subsidiary, IWS, which includes Ste. Michelle, to an entity controlled by investment funds managed by Sycamore Partners Management, L.P. in an all-cash transaction with a purchase price of approximately $1.2 billion and the assumption of certain liabilities of IWS and its subsidiaries (the “Ste. Michelle Transaction”).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, the assets and liabilities associated with the Ste. Michelle Transaction were classified as assets held for sale and were measured at their fair value less costs to sell, resulting in a pre-tax charge of $41 million. A reserve (as shown below), representing the adjustment to record the assets and liabilities at their fair value less costs to sell, was included as a component of assets held for sale in Altria’s condensed consolidated balance sheets at September 30, 2021. Altria recorded an additional pre-tax charge of $10 million for disposition-related costs related to the Ste. Michelle Transaction. The total pre-tax charges of $51 million were included in the wine segment and recorded in marketing, administration and research costs in Altria’s condensed consolidated statements of earnings (losses) for the nine and three months ended September 30, 2021.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, UST completed the sale of IWS and received approximately $1.2 billion in net cash proceeds. Altria expects to record additional adjustments related to the Ste. Michelle Transaction in the fourth quarter of 2021 and does not expect these adjustments to be material.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major classes of assets and liabilities of IWS classified as held for sale at September 30, 2021 were as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net of accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,531 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,490 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued pension costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities held for sale</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets and liabilities held for sale, net</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1200000000 41000000 10000000 51000000 1200000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major classes of assets and liabilities of IWS classified as held for sale at September 30, 2021 were as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net of accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,531 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,490 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued pension costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities held for sale</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets and liabilities held for sale, net</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 36000000 108000000 715000000 407000000 236000000 29000000 1531000000 41000000 1490000000 114000000 83000000 49000000 49000000 295000000 1195000000 Investments in Equity Securities<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of Altria’s investments consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABI</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,651 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JUUL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,705</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cronos</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">932</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,874</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,529 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Atria’s investment in Cronos at September 30, 2021 consisted of Altria’s equity method investment in Cronos ($897 million), the Cronos warrant ($32 million) and the Fixed-price Preemptive Rights ($3 million), (collectively, “Investment in Cronos”). The Investment in Cronos at December 31, 2020 consisted of Altria’s equity method investment in Cronos ($1,010 million), the Cronos warrant ($139 million) and the Fixed-price Preemptive Rights ($24 million). See below for further discussion.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (losses) from equity investments accounted for under the equity method of accounting and fair value option consisted of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABI </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,644)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,036)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(418)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cronos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(145)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (losses) from investments under equity method of accounting</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,789)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,015)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(472)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JUUL</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (losses) from equity investments</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,789)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,915)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(472)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the nine and three months ended September 30, 2021, Altria recorded a non-cash, pre-tax impairment charge of $6,157 million related to its equity investment in ABI. See below for further discussion.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in ABI</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, Altria had an approximate 10% ownership interest in ABI, consisting of 185 million restricted shares of ABI (the “Restricted Shares”) and 12 million ordinary shares of ABI. The Restricted Shares:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">are unlisted and not admitted to trading on any stock exchange;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">are convertible by Altria into ordinary shares of ABI on a one-for-one basis;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">rank equally with ordinary shares of ABI with regards to dividends and voting rights; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">have director nomination rights with respect to ABI.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restricted Shares were subject to a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI5NWU1NmZiMTZmOTRkYWU5ZWFjYzYzMWM1NmQ0NjZjL3NlYzoyOTVlNTZmYjE2Zjk0ZGFlOWVhY2M2MzFjNTZkNDY2Y181Mi9mcmFnOmEyMmNlMjI5NGFiNDRlYjJiNTg3OGRiMjY3NzY2MjgyL3RleHRyZWdpb246YTIyY2UyMjk0YWI0NGViMmI1ODc4ZGIyNjc3NjYyODJfMzkwMzI2NjI3OTEyMjM_deac5b80-5cfb-43db-b6ef-127a6fca35e3">five</span>-year lock-up period that ended October 10, 2021. As of this filing, Altria has not elected to convert its Restricted Shares into ordinary shares of ABI.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria accounts for its investment in ABI under the equity method of accounting because Altria has the ability to exercise significant influence over the operating and financial policies of ABI, including having active representation on ABI’s board of directors and certain ABI board committees. Through this representation, Altria participates in ABI policy making processes.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria reports its share of ABI’s results using a one-quarter lag because ABI’s results are not available in time for Altria to record them in the concurrent period.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Altria’s equity investment in ABI is based on (i) unadjusted quoted prices in active markets for ABI’s ordinary shares and was classified in Level 1 of the fair value hierarchy and (ii) observable inputs other than Level 1 prices, such as quoted prices for similar assets for the Restricted Shares, and was classified in Level 2 of the fair value hierarchy. Altria can convert its Restricted Shares to ordinary shares at its discretion. Therefore, the fair value of each Restricted Share is based on the value of an ordinary share.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the fair value of Altria’s equity investment in ABI declined below its carrying value and has not recovered. At December 31, 2020, the fair value of Altria’s equity investment in ABI was $13.8 billion (carrying value of $16.7 billion), which was less than its carrying value by approximately 17%. In preparing its financial statements for the period ended December 31, 2020, Altria evaluated the factors related to the fair value decline, including the impact on the fair value of ABI’s shares during the COVID-19 pandemic, which has negatively impacted ABI’s business. Altria evaluated the duration and magnitude of the fair value decline, ABI’s financial condition and near-term prospects and Altria’s intent and ability to hold its </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment in ABI until recovery. Altria concluded that the decline in fair value of its investment in ABI at December 31, 2020 below its carrying value was temporary and, therefore, no impairment was recorded at that time.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the consideration of the same factors, Altria, in preparing its financial statements for the period ended September 30, 2021, concluded that the decline in fair value of its investment in ABI at September 30, 2021 was other than temporary. As a result, Altria recorded a non-cash, pre-tax impairment charge of $6.2 billion for the nine and three months ended September 30, 2021, which was recorded to income (losses) from equity investments in its condensed consolidated statements of earnings (losses). This impairment charge reflects the difference between the fair value of Altria’s investment in ABI using ABI’s share price at September 30, 2021 and the carrying value of Altria’s equity investment in ABI at September 30, 2021. Altria continues to have confidence in ABI’s (i) long-term strategies, (ii) premium global brands, (iii) experienced management team and (iv) capability to successfully navigate its near-term challenges. Altria further expects that the impacts related to the COVID-19 pandemic that have negatively impacted ABI’s global business are transitory, but now also anticipates that the full recovery to carrying value will take longer than previously expected. This is evidenced by the resumption of declines in fair value during the third quarter of 2021, following positive share price momentum during the first half of 2021. At September 30, 2021, prior to recording the impairment charge, the fair value of Altria’s investment in ABI was below the carrying value by approximately 35%, which represents an additional 18% reduction in ABI’s share price since December 31, 2020. After recording the impairment charge, the fair value and carrying value of Altria’s equity investment in ABI at September 30, 2021 were $11.2 billion.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, the carrying value of Altria’s equity investment in ABI exceeded its share of ABI’s net assets attributable to equity holders of ABI by approximately $5.1 billion. Substantially all of this difference is comprised of goodwill and other indefinite-lived intangible assets (consisting primarily of trademarks).</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in JUUL</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, Altria made an investment in JUUL and received a 35% economic interest in JUUL through non-voting shares, which were convertible at Altria’s election into voting shares (“Share Conversion”), and a security convertible into additional non-voting or voting shares, as applicable, upon settlement or exercise of certain JUUL convertible securities (the “JUUL Transaction”).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria received a broad preemptive right to purchase JUUL shares, exercisable each quarter upon dilution, to maintain its ownership percentage and is subject to a standstill restriction under which it may not acquire additional JUUL shares above its 35% interest. Furthermore, Altria agreed not to sell or transfer any of its JUUL shares until December 20, 2024.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2020, the U.S. Federal Trade Commission (“FTC”) issued an administrative complaint challenging Altria’s investment in JUUL. For further discussion, see Note 12. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies - Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Altria exercised its rights to convert its non-voting JUUL shares into voting shares. Altria does not currently intend to exercise its additional governance rights obtained upon Share Conversion, including the right to elect directors to JUUL’s board or to vote its JUUL shares other than as a passive investor, pending the outcome of the FTC administrative complaint. At September 30, 2021, Altria had a 35% ownership interest in JUUL, consisting of 42 million voting shares.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following Share Conversion in the fourth quarter of 2020, Altria elected to account for its equity method investment in JUUL under the fair value option. Under this option, Altria’s condensed consolidated statements of earnings (losses) include any cash dividends received from its investment in JUUL and any changes in the estimated fair value of its investment, which is calculated quarterly. Altria believes the fair value option provides quarterly transparency to investors as to the fair market value of Altria’s investment in JUUL, given the changes and volatility in the e-vapor category since Altria’s initial investment, as well as the lack of publicly available information regarding JUUL’s business or a market-derived valuation.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balance of Altria’s investment in JUUL, which is classified in Level 3 of the fair value hierarchy:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investment </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses) included in income (losses) from equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,705</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2021, Altria recorded a non-cash, pre-tax unrealized gain of $100 million, as a result of changes in the estimated fair value of its investment in JUUL. At September 30, 2021, the estimated fair value of Altria’s JUUL investment was $1.7 billion, unchanged from its December 31, 2020 estimated fair value. There were no material </span></div><div style="margin-bottom:10pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">changes to the significant assumptions used in the valuations, as described below, during the nine and three months ended September 30, 2021.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to Share Conversion, Altria accounted for its investment in JUUL as an investment in an equity security. Since the JUUL shares do not have a readily determinable fair value, Altria elected to measure its investment in JUUL at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There were no upward or downward adjustments to the carrying value of Altria’s investment in JUUL resulting from observable price changes in orderly transactions since the JUUL Transaction through the date of Share Conversion. In addition, prior to Share Conversion, Altria reviewed its investment in JUUL for impairment by performing a qualitative assessment of impairment indicators on a quarterly basis in connection with the preparation of its financial statements. If this qualitative assessment indicated that Altria’s investment in JUUL may be impaired, a quantitative assessment was performed. If the quantitative assessment indicated the estimated fair value of the investment was less than its carrying value, the investment was written down to its fair value.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, JUUL announced a strategic update, which included its plans for a significant global workforce reduction, its evaluation of its resource allocation and the possibility of exiting various international markets. As part of the preparation of Altria’s financial statements for the period ended September 30, 2020, Altria performed a qualitative assessment of impairment indicators for its investment in JUUL and determined that JUUL’s strategic update was an indicator of impairment at September 30, 2020, given the significant deterioration in JUUL’s business prospects.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the existence of this impairment indicator, Altria performed a quantitative valuation of its investment in JUUL during the third quarter of 2020 and recorded a non-cash, pre-tax charge of $2.6 billion for the nine and three months ended September 30, 2020, reported as impairment of JUUL equity securities in its condensed consolidated statements of earnings (losses). The impairment charge was driven by Altria’s projections of lower JUUL revenues over time due to lower pricing assumptions and delays in JUUL achieving previously forecasted operating margin performance. These drivers were the result of (i) JUUL’s revised international expansion plans and (ii) the evolving U.S. e-vapor category and associated competitive dynamics.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria uses an income approach to estimate the fair value of its investment in JUUL. The income approach reflects the discounting of future cash flows for the U.S. and international markets at a rate of return that incorporates the risk-free rate for the use of those funds, the expected rate of inflation and the risks associated with realizing future cash flows. Future cash flows were based on a range of scenarios that consider various potential regulatory and market outcomes.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the estimated fair value of its investment in JUUL, as of September 30, 2021 and December 31, 2020, Altria made various judgments, estimates and assumptions, the most significant of which were sales volume, operating margins, discount rates and perpetual growth rates. All significant inputs used in the valuation are classified in Level 3 of the fair value hierarchy. Additionally, in determining these significant assumptions, Altria made judgments regarding the (i) likelihood and extent of various potential regulatory actions and the continued adverse public perception impacting the e-vapor category and specifically JUUL, (ii) risk created by the number and types of legal cases pending against JUUL and (iii) expectations for the future state of the e-vapor category, including competitive dynamics.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Cronos</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, Altria had a 41.9% ownership interest in Cronos, consisting of 156.6 million shares, which Altria accounts for under the equity method of accounting. Altria’s ownership percentage decreased from 43.5% at December 31, 2020 due to the issuance of additional shares by Cronos. Altria reports its share of Cronos’s results using a one-quarter lag because Cronos’s results are not available in time for Altria to record them in the concurrent period.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its Investment in Cronos, at September 30, 2021, Altria owned:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">anti-dilution protections to purchase Cronos common shares, exercisable each quarter upon dilution, to maintain its ownership percentage. Certain of the anti-dilution protections provide Altria the ability to purchase additional Cronos common shares at a per share exercise price of Canadian dollar (“CAD”) $16.25 upon the occurrence of specified events (“Fixed-price Preemptive Rights”). Based on Altria’s assumptions as of September 30, 2021, Altria estimates the Fixed-price Preemptive Rights allows Altria to purchase up to an additional approximately 14 million common shares of Cronos; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">a warrant providing Altria the ability to purchase an additional approximate 10% of common shares of Cronos (approximately 83 million common shares at September 30, 2021) at a per share exercise price of CAD $19.00, which expires on March 8, 2023.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If exercised in full, the exercise prices for the warrant and Fixed-price Preemptive Rights are approximately CAD $1.6 billion and CAD $0.2 billion, respectively (approximately USD $1.3 billion and $0.2 billion, respectively, based on the CAD to USD exchange rate on October 25, 2021). At September 30, 2021, upon full exercise of the Fixed-price Preemptive Rights, to the </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">extent such rights become available, and the warrant, Altria would own approximately 53% of the outstanding common shares of Cronos.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of derivatives related to the Investment in Cronos, including Altria’s accounting for changes in the fair value of these derivatives, see Note 5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Altria’s equity method investment in Cronos is based on unadjusted quoted prices in active markets for Cronos’s common shares and was classified in Level 1 of the fair value hierarchy. In September 2021, the fair value of Altria’s equity method investment in Cronos declined below its carrying value. At September 30, 2021, the fair value of Altria’s equity method investment in Cronos was less than its carrying value by $14 million or approximately 2%. The fair value of Altria’s equity method investment in Cronos exceeded its carrying value by $77 million or approximately 8% at December 31, 2020. Based on Altria’s evaluation of the duration and magnitude of the fair value decline at September 30, 2021, Altria concluded that the decline in fair value of its equity method investment in Cronos below its carrying value is temporary and, therefore, no impairment was recorded.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of Altria’s investments consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABI</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,651 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JUUL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,705</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cronos</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">932</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,874</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,529 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Atria’s investment in Cronos at September 30, 2021 consisted of Altria’s equity method investment in Cronos ($897 million), the Cronos warrant ($32 million) and the Fixed-price Preemptive Rights ($3 million), (collectively, “Investment in Cronos”). The Investment in Cronos at December 31, 2020 consisted of Altria’s equity method investment in Cronos ($1,010 million), the Cronos warrant ($139 million) and the Fixed-price Preemptive Rights ($24 million). See below for further discussion.</span></div> 11237000000 16651000000 1705000000 1705000000 932000000 1173000000 13874000000 19529000000 897000000 32000000 3000000 1010000000 139000000 24000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (losses) from equity investments accounted for under the equity method of accounting and fair value option consisted of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABI </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,644)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,036)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(418)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cronos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(145)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (losses) from investments under equity method of accounting</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,789)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,015)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(472)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JUUL</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (losses) from equity investments</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,789)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,915)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(472)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the nine and three months ended September 30, 2021, Altria recorded a non-cash, pre-tax impairment charge of $6,157 million related to its equity investment in ABI. See below for further discussion.</span></div> -5644000000 -306000000 -6036000000 -418000000 -145000000 0 21000000 21000000 -54000000 -5789000000 -306000000 -6015000000 -472000000 0 0 100000000 0 -5789000000 -306000000 -5915000000 -472000000 6157000000 6157000000 0.10 185000000 12000000 <div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria accounts for its investment in ABI under the equity method of accounting because Altria has the ability to exercise significant influence over the operating and financial policies of ABI, including having active representation on ABI’s board of directors and certain ABI board committees. Through this representation, Altria participates in ABI policy making processes.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria reports its share of ABI’s results using a one-quarter lag because ABI’s results are not available in time for Altria to record them in the concurrent period.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Altria’s equity investment in ABI is based on (i) unadjusted quoted prices in active markets for ABI’s ordinary shares and was classified in Level 1 of the fair value hierarchy and (ii) observable inputs other than Level 1 prices, such as quoted prices for similar assets for the Restricted Shares, and was classified in Level 2 of the fair value hierarchy. Altria can convert its Restricted Shares to ordinary shares at its discretion. Therefore, the fair value of each Restricted Share is based on the value of an ordinary share.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the fair value of Altria’s equity investment in ABI declined below its carrying value and has not recovered. At December 31, 2020, the fair value of Altria’s equity investment in ABI was $13.8 billion (carrying value of $16.7 billion), which was less than its carrying value by approximately 17%. In preparing its financial statements for the period ended December 31, 2020, Altria evaluated the factors related to the fair value decline, including the impact on the fair value of ABI’s shares during the COVID-19 pandemic, which has negatively impacted ABI’s business. Altria evaluated the duration and magnitude of the fair value decline, ABI’s financial condition and near-term prospects and Altria’s intent and ability to hold its </span></div>investment in ABI until recovery. Altria concluded that the decline in fair value of its investment in ABI at December 31, 2020 below its carrying value was temporary and, therefore, no impairment was recorded at that time.Following the consideration of the same factors, Altria, in preparing its financial statements for the period ended September 30, 2021, concluded that the decline in fair value of its investment in ABI at September 30, 2021 was other than temporary. As a result, Altria recorded a non-cash, pre-tax impairment charge of $6.2 billion for the nine and three months ended September 30, 2021, which was recorded to income (losses) from equity investments in its condensed consolidated statements of earnings (losses). This impairment charge reflects the difference between the fair value of Altria’s investment in ABI using ABI’s share price at September 30, 2021 and the carrying value of Altria’s equity investment in ABI at September 30, 2021. Altria continues to have confidence in ABI’s (i) long-term strategies, (ii) premium global brands, (iii) experienced management team and (iv) capability to successfully navigate its near-term challenges. Altria further expects that the impacts related to the COVID-19 pandemic that have negatively impacted ABI’s global business are transitory, but now also anticipates that the full recovery to carrying value will take longer than previously expected. This is evidenced by the resumption of declines in fair value during the third quarter of 2021, following positive share price momentum during the first half of 2021. At September 30, 2021, prior to recording the impairment charge, the fair value of Altria’s investment in ABI was below the carrying value by approximately 35%, which represents an additional 18% reduction in ABI’s share price since December 31, 2020. The fair value of Altria’s equity method investment in Cronos is based on unadjusted quoted prices in active markets for Cronos’s common shares and was classified in Level 1 of the fair value hierarchy. In September 2021, the fair value of Altria’s equity method investment in Cronos declined below its carrying value. 13800000000 16700000000 -0.17 0 6200000000 6200000000 -0.35 0.18 11200000000 11200000000 5100000000 0.35 0.35 0.35 42000000 <div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balance of Altria’s investment in JUUL, which is classified in Level 3 of the fair value hierarchy:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investment </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses) included in income (losses) from equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,705</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1705000000 0 1705000000 100000000 1700000000 0 0 2600000000 2600000000 0.419 156600000 0.435 16.25 14000000 0.10 83000000 19.00 1600000000 200000000 1300000000 200000000 0.53 14000000 0.02 77000000 0.08 Financial Instruments<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria enters into derivative financial instruments to mitigate the potential impact of certain market risks, including foreign currency exchange rate risk. Altria uses various types of derivative financial instruments, including forward contracts, options and swaps. Altria does not enter into or hold derivative financial instruments for trading or speculative purposes.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria’s investment in ABI, whose functional currency is the Euro, exposes Altria to foreign currency exchange risk on the carrying value of its investment. To manage this risk, Altria designates certain foreign exchange contracts, including cross-currency swap contracts and forward contracts (collectively, “foreign currency contracts”), and Euro denominated unsecured long-term notes (“foreign currency denominated debt”) as net investment hedges of Altria’s investment in ABI.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, all outstanding foreign currency contracts matured. When Altria has foreign currency contracts in effect, counterparties are domestic and international financial institutions. Under these contracts, Altria is exposed to potential losses due to non-performance by these counterparties. Altria manages its credit risk by entering into transactions with counterparties with investment grade credit ratings, limiting the amount of exposure Altria has with each counterparty and monitoring the financial condition of each counterparty. The counterparty agreements contain provisions that require Altria to maintain an investment grade credit rating. In the event Altria’s credit rating falls below investment grade, counterparties to Altria’s foreign currency contracts can require Altria to post collateral. No collateral was received or posted related to derivative assets and liabilities at December 31, 2020.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides (i) the aggregate notional amounts of foreign currency contracts and (ii) the aggregate carrying value and fair value of foreign currency denominated debt:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts (notional amounts)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,905</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,288</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,687 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria’s estimates of the fair values of its foreign currency contracts are determined using valuation models with significant inputs that are readily available in public markets, or can be derived from observable market transactions, and therefore are classified in Level 2 of the fair value hierarchy. An adjustment for credit risk and non-performance risk is included in the fair values of foreign currency contracts.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the aggregate carrying value and fair value of Altria’s total long-term debt:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,471 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,037</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,682 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria’s estimate of the fair value of its total long-term debt is based on observable market information derived from a third-party pricing source and is classified in Level 2 of the fair value hierarchy.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Fixed-price Preemptive Rights and Cronos warrant, which are further discussed in Note 4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, are derivative financial instruments, which are required to be recorded at fair value. The fair values of the Fixed-price Preemptive Rights and Cronos warrant are estimated using Black-Scholes option-pricing models, adjusted for observable inputs (which are classified in Level 1 of the fair value hierarchy), including share price, and unobservable inputs, including </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">probability factors and weighting of expected life, volatility levels and risk-free interest rates (which are classified in Level 3 of the fair value hierarchy) based on the following assumptions at:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.448%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fixed-price Preemptive Rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cronos Warrant</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">C$7.15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$8.84</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">C$7.15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$8.84</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.81 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.05 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.43 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.18 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67.32%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.68%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67.32%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.68%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.24%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.39%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Based on the closing market price for Cronos common stock on the Toronto Stock Exchange on the date indicated.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Based on the weighted-average expected life of the Fixed-price Preemptive Rights (with a range from approximately 0.25 year to 4.00 years at September 30, 2021 and 0.25 year to 5 years at December 31, 2020) and the March 8, 2023 expiration date of the Cronos warrant.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Based on a blend of historical volatility of the underlying equity security and implied volatility from traded options on the underlying equity security at September 30, 2021. Based on a blend of historical volatility levels of the underlying equity security and peer companies at December 31, 2020.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Based on the implied yield currently available on Canadian Treasury zero coupon issues (with a range from approximately 0.12% to 0.89% at September 30, 2021 and 0.06% to 0.39% at December 31, 2020) weighted for the remaining expected life of the Fixed-price Preemptive Rights.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Based on the implied yield currently available on Canadian Treasury zero coupon issues and the expected life of the Cronos warrant.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Based on Cronos’s expected dividend payments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balance of the Fixed-price Preemptive Rights and Cronos warrant, which are classified in Level 3 of the fair value hierarchy:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax earnings (losses) recognized in net earnings (losses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax earnings (losses) recognized in net earnings (losses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria elects to record the gross assets and liabilities of derivative financial instruments executed with the same counterparty on its condensed consolidated balance sheets. The fair values of Altria’s derivative financial instruments on a gross basis included on the condensed consolidated balance sheets were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments:</span></div></td><td colspan="30" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cronos warrant</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in equity securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed-price Preemptive Rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in equity securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivatives</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria records in its condensed consolidated statements of earnings (losses) any changes in the fair values of the Fixed-price Preemptive Rights and Cronos warrant as gains or losses on Cronos-related financial instruments in the periods in which the changes occur. For the nine and three months ended September 30, 2021 and 2020, Altria recorded non-cash, pre-tax unrealized gains (losses), representing the changes in the fair values of the Fixed-price Preemptive Rights and Cronos warrant, as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed-price Preemptive Rights</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cronos warrant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(128)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(135)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Investment Hedging</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax effects of Altria’s net investment hedges on accumulated other comprehensive losses and the condensed consolidated statements of earnings (losses) were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.391%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (Loss) Recognized in Accumulated Other Comprehensive Losses</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (Loss) Recognized in <br/>Net Earnings (Losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (Loss) Recognized in Accumulated Other Comprehensive Losses</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (Loss) Recognized in <br/>Net Earnings (Losses)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">270</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(243)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the fair value of the foreign currency contracts and in the carrying value of the foreign currency denominated debt due to changes in the Euro to USD exchange rate were recognized in accumulated other comprehensive losses related to ABI. Gains on the foreign currency contracts arising from components excluded from effectiveness testing were recognized in interest and other debt expense, net in the condensed consolidated statements of earnings (losses) based on an amortization approach.</span></div> <div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides (i) the aggregate notional amounts of foreign currency contracts and (ii) the aggregate carrying value and fair value of foreign currency denominated debt:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts (notional amounts)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,905</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,288</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,687 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>For the nine and three months ended September 30, 2021 and 2020, Altria recorded non-cash, pre-tax unrealized gains (losses), representing the changes in the fair values of the Fixed-price Preemptive Rights and Cronos warrant, as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed-price Preemptive Rights</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cronos warrant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(128)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(135)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax effects of Altria’s net investment hedges on accumulated other comprehensive losses and the condensed consolidated statements of earnings (losses) were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.391%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (Loss) Recognized in Accumulated Other Comprehensive Losses</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (Loss) Recognized in <br/>Net Earnings (Losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (Loss) Recognized in Accumulated Other Comprehensive Losses</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (Loss) Recognized in <br/>Net Earnings (Losses)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">270</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(243)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 1066000000 4905000000 5171000000 5288000000 5687000000 <div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the aggregate carrying value and fair value of Altria’s total long-term debt:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,471 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,037</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,682 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 28127000000 29471000000 31037000000 34682000000 The fair values of the Fixed-price Preemptive Rights and Cronos warrant are estimated using Black-Scholes option-pricing models, adjusted for observable inputs (which are classified in Level 1 of the fair value hierarchy), including share price, and unobservable inputs, including <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">probability factors and weighting of expected life, volatility levels and risk-free interest rates (which are classified in Level 3 of the fair value hierarchy) based on the following assumptions at:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.448%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fixed-price Preemptive Rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cronos Warrant</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">C$7.15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$8.84</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">C$7.15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$8.84</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.81 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.05 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.43 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.18 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67.32%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.68%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67.32%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.68%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.24%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.39%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Based on the closing market price for Cronos common stock on the Toronto Stock Exchange on the date indicated.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Based on the weighted-average expected life of the Fixed-price Preemptive Rights (with a range from approximately 0.25 year to 4.00 years at September 30, 2021 and 0.25 year to 5 years at December 31, 2020) and the March 8, 2023 expiration date of the Cronos warrant.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Based on a blend of historical volatility of the underlying equity security and implied volatility from traded options on the underlying equity security at September 30, 2021. Based on a blend of historical volatility levels of the underlying equity security and peer companies at December 31, 2020.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Based on the implied yield currently available on Canadian Treasury zero coupon issues (with a range from approximately 0.12% to 0.89% at September 30, 2021 and 0.06% to 0.39% at December 31, 2020) weighted for the remaining expected life of the Fixed-price Preemptive Rights.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Based on the implied yield currently available on Canadian Treasury zero coupon issues and the expected life of the Cronos warrant.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Based on Cronos’s expected dividend payments.</span></div> 7.15 8.84 7.15 8.84 0.81 1.05 1.43 2.18 0.6732 0.8068 0.6732 0.8068 0.0024 0.0013 0.0039 0.0021 0 0 0 0 0.25 4.00 0.25 5 0.0012 0.0089 0.0006 0.0039 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balance of the Fixed-price Preemptive Rights and Cronos warrant, which are classified in Level 3 of the fair value hierarchy:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax earnings (losses) recognized in net earnings (losses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax earnings (losses) recognized in net earnings (losses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 303000000 -140000000 163000000 -128000000 35000000 The fair values of Altria’s derivative financial instruments on a gross basis included on the condensed consolidated balance sheets were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments:</span></div></td><td colspan="30" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cronos warrant</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in equity securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed-price Preemptive Rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in equity securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivatives</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0 0 0 87000000 0 0 0 0 0 0 0 87000000 32000000 139000000 3000000 24000000 35000000 163000000 35000000 163000000 0 87000000 -21000000 -54000000 -17000000 -25000000 -107000000 -148000000 -118000000 -80000000 -128000000 -202000000 -135000000 -105000000 16000000 -28000000 7000000 33000000 0 -66000000 0 8000000 270000000 -215000000 0 0 118000000 -206000000 0 0 286000000 -243000000 7000000 33000000 118000000 -272000000 0 8000000 Benefit Plans<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Components of Net Periodic Benefit (Income) Cost</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit (income) cost consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.094%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Postretirement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Postretirement</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended <br/>September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">139</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(393)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(131)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">99</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(income) cost</span></div></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employer Contributions</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria makes contributions to the pension plans to the extent that the contributions are tax deductible and pays benefits that relate to plans for salaried employees that cannot be funded under Internal Revenue Service regulations. Altria made employer contributions of $23 million to its pension plans and did not make any contributions to its postretirement plans during the nine months ended September 30, 2021. Currently, Altria anticipates making additional employer contributions to its pension plans of up to approximately $5 million and no additional contributions to its postretirement plans for the remainder of 2021. However, the foregoing estimates of 2021 contributions to the pension and postretirement plans are subject to change as a result of changes in tax and other benefit laws, changes in interest rates, as well as asset performance significantly above or below the assumed long-term rate of return for each respective plan.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, Altria announced several amendments to its salaried retiree healthcare plans, primarily changing its post-age 65 coverage to a private medicare marketplace. These amendments triggered a plan remeasurement as of May 31, 2021 and resulted in Altria recording a reduction of $432 million to its accrued postretirement health care costs liability and a corresponding reduction to its accumulated other comprehensive losses on its condensed consolidated balance sheet. Ongoing amortization has been adjusted to reflect these changes as of June 1, 2021 and is reflected in the amounts shown above.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit (income) cost consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.094%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Postretirement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Postretirement</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended <br/>September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">139</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(393)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(131)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">99</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(income) cost</span></div></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 51000000 55000000 15000000 13000000 17000000 18000000 5000000 5000000 139000000 188000000 29000000 44000000 46000000 62000000 8000000 14000000 393000000 376000000 10000000 11000000 131000000 125000000 2000000 4000000 -99000000 -108000000 -16000000 -7000000 -33000000 -55000000 -2000000 0 3000000 4000000 -35000000 -22000000 1000000 2000000 -20000000 -7000000 -101000000 -21000000 15000000 31000000 -34000000 12000000 -7000000 8000000 23000000 0 5000000 0 -432000000 Earnings (Losses) per Share<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings (losses) per share (“EPS”) were calculated using the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings (losses) attributable to Altria</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">851</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,543 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,722)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(952)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Distributed and undistributed earnings attributable to share-based awards</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (losses) for basic and diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">843</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,537 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,724)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(953)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for basic EPS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,849</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,842</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: contingently issuable performance stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,849</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,859 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,842</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,859 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings (losses) per share (“EPS”) were calculated using the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings (losses) attributable to Altria</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">851</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,543 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,722)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(952)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Distributed and undistributed earnings attributable to share-based awards</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (losses) for basic and diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">843</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,537 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,724)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(953)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for basic EPS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,849</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,842</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: contingently issuable performance stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,849</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,859 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,842</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,859 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 851000000 2543000000 -2722000000 -952000000 8000000 6000000 2000000 1000000 843000000 843000000 2537000000 2537000000 -2724000000 -2724000000 -953000000 -953000000 1849000000 1858000000 1842000000 1858000000 0 1000000 0 1000000 1849000000 1859000000 1842000000 1859000000 Other Comprehensive Earnings/Losses<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the changes in each component of accumulated other comprehensive losses, net of deferred income taxes, attributable to Altria:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ABI</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency<br/>Translation<br/>Adjustments and Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,420)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,938)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,341)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">432</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">685</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,152</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(151)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">314</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">534</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings (losses) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings (losses), net of deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(39)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses), net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">383</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">495</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">911</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,037)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,443)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,430)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ABI</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency<br/>Translation<br/>Adjustments and Other </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,043)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,604)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,602)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">167</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">164</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings (losses), net of deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses), net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">161</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">172</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,037)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,443)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,430)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ABI</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency<br/>Translation<br/>Adjustments and Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,192)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(693)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,864)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,302)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(951)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,023)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings (losses), net of deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses), net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(928)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(917)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,165)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,621)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,781)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ABI</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency<br/>Translation<br/>Adjustments and Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,150)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,606)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,774)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings (losses), net of deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses), net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,165)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,621)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,781)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Reflects the remeasurement impact of salaried retiree healthcare plan amendments. For further discussion, see Note 6. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Benefit Plans.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Primarily reflects Altria’s share of ABI’s currency translation adjustments and the impact of Altria’s designated net investment hedges. For further discussion of designated net investment hedges, see Note 5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth pre-tax amounts by component, reclassified from accumulated other comprehensive losses to net earnings (losses):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit Plans: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">124</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost/credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABI </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency Translation Adjustments and Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings (losses)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Amounts are included in net defined benefit plan costs. For further information related to defined benefit plans, see Note 6. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Benefit Plans.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Amounts are included in (income) losses from equity investments. For further information related to equity investments, see Note 4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Investments in Equity Securities.</span></div> <div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the changes in each component of accumulated other comprehensive losses, net of deferred income taxes, attributable to Altria:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ABI</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency<br/>Translation<br/>Adjustments and Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,420)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,938)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,341)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">432</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">685</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,152</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(151)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">314</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">534</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings (losses) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings (losses), net of deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(39)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses), net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">383</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">495</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">911</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,037)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,443)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,430)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ABI</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency<br/>Translation<br/>Adjustments and Other </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,043)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,604)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,602)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">167</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">164</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings (losses), net of deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses), net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">161</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">172</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,037)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,443)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,430)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ABI</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency<br/>Translation<br/>Adjustments and Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,192)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(693)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,864)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,302)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(951)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,023)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings (losses), net of deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses), net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(928)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(917)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,165)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,621)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,781)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ABI</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency<br/>Translation<br/>Adjustments and Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,150)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,606)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,774)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net earnings (losses), net of deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (losses), net of deferred income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,165)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,621)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,781)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Reflects the remeasurement impact of salaried retiree healthcare plan amendments. For further discussion, see Note 6. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Benefit Plans.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Primarily reflects Altria’s share of ABI’s currency translation adjustments and the impact of Altria’s designated net investment hedges. For further discussion of designated net investment hedges, see Note 5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments.</span></div> -2420000000 -1938000000 17000000 -4341000000 432000000 685000000 35000000 1152000000 118000000 151000000 0 269000000 314000000 534000000 35000000 883000000 -92000000 49000000 2000000 -41000000 -23000000 10000000 0 -13000000 -69000000 39000000 2000000 -28000000 383000000 495000000 33000000 911000000 -2037000000 -1443000000 50000000 -3430000000 -2043000000 -1604000000 45000000 -3602000000 0 215000000 6000000 221000000 9000000 48000000 0 57000000 -9000000 167000000 6000000 164000000 -20000000 7000000 1000000 -12000000 -5000000 1000000 0 -4000000 -15000000 6000000 1000000 -8000000 6000000 161000000 5000000 172000000 -2037000000 -1443000000 50000000 -3430000000 -2192000000 -693000000 21000000 -2864000000 -75000000 -1211000000 -16000000 -1302000000 -19000000 -260000000 0 -279000000 -56000000 -951000000 -16000000 -1023000000 -111000000 -29000000 0 -140000000 -28000000 -6000000 0 -34000000 -83000000 -23000000 0 -106000000 27000000 -928000000 -16000000 -917000000 -2165000000 -1621000000 5000000 -3781000000 -2150000000 -1606000000 -18000000 -3774000000 -75000000 -71000000 23000000 -123000000 -19000000 -22000000 0 -41000000 -56000000 -49000000 23000000 -82000000 -55000000 -44000000 0 -99000000 -14000000 -10000000 0 -24000000 -41000000 -34000000 0 -75000000 -15000000 -15000000 23000000 -7000000 -2165000000 -1621000000 5000000 -3781000000 <div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth pre-tax amounts by component, reclassified from accumulated other comprehensive losses to net earnings (losses):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit Plans: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">124</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost/credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABI </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency Translation Adjustments and Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings (losses)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Amounts are included in net defined benefit plan costs. For further information related to defined benefit plans, see Note 6. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Benefit Plans.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Amounts are included in (income) losses from equity investments. For further information related to equity investments, see Note 4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Investments in Equity Securities.</span></div> 124000000 129000000 39000000 60000000 -32000000 -18000000 -19000000 -5000000 92000000 111000000 20000000 55000000 49000000 -29000000 7000000 -44000000 2000000 0 1000000 0 -41000000 -140000000 -12000000 -99000000 Segment Reporting<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products of Altria’s subsidiaries include smokeable tobacco products, consisting of combustible cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton; oral tobacco products, consisting of MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix; and wine produced and/or distributed by Ste. Michelle. The products and services of these subsidiaries constitute Altria’s reportable segments of smokeable products, oral tobacco products and wine. The financial services and the innovative tobacco products businesses, which include the heated tobacco business and Helix ROW, are included in all other.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria’s chief operating decision maker (the “CODM”) reviews operating companies income (loss) (“OCI”) to evaluate the performance of, and allocate resources to, the segments. OCI for the segments is defined as operating income before general corporate expenses and amortization of intangibles. Interest and other debt expense, net, along with net periodic benefit income/cost, excluding service cost, and provision (benefit) for income taxes are centrally managed at the corporate level and, accordingly, such items are not presented by segment since they are excluded from the measure of segment profitability reviewed by the CODM.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment data were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smokeable products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,275</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,522 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,975</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral tobacco products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,945</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">626</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wine</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">494</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,758</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,849 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,786</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,123 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings (losses) before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OCI:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smokeable products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,901</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,609 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,753</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral tobacco products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">405</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wine</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,827</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,292 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,160 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other debt expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(869)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(893)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(649)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit income, excluding </span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">service cost</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">152</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (losses) from equity investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,915)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(472)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of JUUL equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on Cronos-related financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (losses) before income taxes</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,544</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,349 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,302)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(324)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The comparability of OCI for the reportable segments was affected by the following:</span></div><div style="margin-bottom:5pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Non-Participating Manufacturer (“NPM”) Adjustment Items:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-tax (income) for NPM adjustment items was recorded to Altria’s condensed consolidated statements of earnings (losses) as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.903%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smokeable products segment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other debt expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(76)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(44)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NPM adjustment items result from the resolutions of certain disputes with states and territories related to the NPM adjustment provision under the 1998 Master Settlement Agreement (such dispute resolutions are referred to as “NPM Adjustment Items” and are more fully described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Cost Recovery Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Note 12. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The amounts shown in the table above for the smokeable products segment were recorded as reductions to cost of sales, which increased OCI in the smokeable products segment.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Tobacco and Health and Certain Other Litigation Items:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax charges related to tobacco and health and certain other litigation items were recorded in Altria’s condensed consolidated statements of earnings (losses) as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smokeable products segment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other debt expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">148</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts shown in the table above for the smokeable products segment and general corporate were recorded in marketing, administration and research costs. For further discussion, see Note 12. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">COVID-19 Special Items: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pre-tax charges of $50 million ($41 million in the smokeable products segment and $9 million in the oral tobacco products segment) related to the COVID-19 pandemic were recorded in Altria’s condensed consolidated statements of earnings (losses) for the nine months ended September 30, 2020. The net pre-tax charges, which were directly related to disruptions caused by or efforts to mitigate the impact of the COVID-19 pandemic, were all recorded in costs of sales and included premium pay, personal protective equipment and health screenings, which were partially offset by certain employment tax credits. The COVID-19 special items do not include the inventory-related implementation costs associated with the wine business strategic reset discussed below. These implementation costs were due to increased inventory levels, which were further negatively impacted by the COVID-19 pandemic, including economic uncertainty and government restrictions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Implementation, Acquisition and Disposition-Related Costs:</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ste. Michelle Transaction:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine and three months ended September 30, 2021, pre-tax disposition-related costs of $51 million were recorded in the wine segment, which consisted of a pre-tax charge of $41 million to record the assets and liabilities associated with the Ste. Michelle Transaction at their fair value less costs to sell and $10 million of other disposition-related costs. For further discussion, see Note 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wine Business Strategic Reset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: During the nine months ended September 30, 2020, Ste. Michelle recorded pre-tax implementation costs of $395 million associated with a strategic reset initiated in the first quarter of 2020 to maximize Ste. Michelle’s profitability and achieve improved long-term cash flow generation. Substantially all of the charges consisted of the following: (i) write-off of inventory ($292 million) as Ste. Michelle no longer believed that the benefit of the blending and production plans for its inventory outweighed inventory carrying cost given the reduced product volume demand; and (ii) estimated losses on future non-cancelable grape purchase commitments that Ste. Michelle believed no longer had a future economic benefit ($100 million). These charges were included in cost of sales in Altria’s condensed consolidated statements of earnings (losses).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition-Related Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For the nine months ended September 30, 2021, Altria recorded pre-tax acquisition-related costs of $37 million in the oral tobacco products segment primarily for the settlement of an arbitration related to the 2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">on!</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transaction. These costs were included in marketing, administration and research costs in Altria’s condensed consolidated statements of earnings (losses).</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment data were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smokeable products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,275</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,522 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,975</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral tobacco products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,945</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">626</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wine</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">494</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,758</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,849 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,786</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,123 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings (losses) before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OCI:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smokeable products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,901</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,609 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,753</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral tobacco products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">405</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wine</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,827</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,292 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,160 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other debt expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(869)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(893)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(649)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit income, excluding </span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">service cost</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">152</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (losses) from equity investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,915)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(472)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of JUUL equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on Cronos-related financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (losses) before income taxes</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,544</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,349 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,302)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(324)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 17275000000 17522000000 5975000000 6313000000 1945000000 1901000000 626000000 640000000 494000000 434000000 177000000 157000000 44000000 -8000000 8000000 13000000 19758000000 19849000000 6786000000 7123000000 7901000000 7609000000 2753000000 2789000000 1269000000 1297000000 405000000 436000000 21000000 -347000000 -24000000 19000000 -56000000 -63000000 -30000000 -7000000 53000000 54000000 18000000 17000000 255000000 150000000 135000000 60000000 8827000000 8292000000 2951000000 3160000000 -869000000 -893000000 -266000000 -310000000 -649000000 0 0 0 -152000000 -58000000 -63000000 -3000000 -5789000000 -306000000 -5915000000 -472000000 0 2600000000 0 2600000000 -128000000 -202000000 -135000000 -105000000 1544000000 4349000000 -3302000000 -324000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Non-Participating Manufacturer (“NPM”) Adjustment Items:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-tax (income) for NPM adjustment items was recorded to Altria’s condensed consolidated statements of earnings (losses) as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.903%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smokeable products segment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other debt expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(76)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(44)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 53000000 21000000 23000000 23000000 76000000 44000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.46pt">Tobacco and Health and Certain Other Litigation Items:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax charges related to tobacco and health and certain other litigation items were recorded in Altria’s condensed consolidated statements of earnings (losses) as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smokeable products segment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other debt expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">148</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 72000000 73000000 29000000 34000000 70000000 0 70000000 0 6000000 3000000 6000000 0 148000000 76000000 105000000 34000000 50000000 50000000 41000000 41000000 9000000 9000000 51000000 51000000 41000000 10000000 395000000 292000000 100000000 37000000 Debt<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term Borrowings and Borrowing Arrangements</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021 and December 31, 2020, Altria had no short-term borrowings.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 18, 2021, Altria entered into an extension and amendment (the “Extension and Amendment”) to its $3.0 billion senior unsecured 5-year revolving credit agreement (as amended, the “Credit Agreement”). The Extension and Amendment extends the maturity date of the Credit Agreement from August 1, 2023 to August 1, 2024 and amends the Credit Agreement to update certain provisions regarding a successor interest rate to the London Interbank Offered Rate (“LIBOR”) and make certain other market updates. All other terms and conditions of the Credit Agreement remain in full force and effect. The Credit Agreement, which is used for general corporate purposes, includes an additional option, subject to certain conditions, for Altria to extend the expiration date for an additional one-year period.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, the Credit Agreement had available borrowings up to an aggregate principal amount of $3.0 billion.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing for interest and fees under the Credit Agreement may be modified in the event of a change in the rating of Altria’s long-term senior unsecured debt. Interest rates on borrowings under the Credit Agreement are expected to be based on LIBOR, or a fallback benchmark rate determined based on prevailing market convention, plus a percentage based on the higher of the ratings of Altria’s long-term senior unsecured debt from Moody’s Investors Service, Inc. (“Moody’s”) and Standard &amp; Poor’s Financial Services LLC (“S&amp;P”). The applicable percentage based on Altria’s long-term senior unsecured debt ratings at September 30, 2021 for borrowings under the Credit Agreement was 1.0%. The Credit Agreement does not include any other rating triggers, or any provisions that could require the posting of collateral.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement includes various covenants, one of which requires Altria to maintain a ratio of consolidated earnings before interest, taxes, depreciation and amortization (“EBITDA”) to Consolidated Interest Expense of not less than 4.0 to 1.0, calculated as of the end of the applicable quarter on a rolling four quarters basis. At September 30, 2021, the ratio of consolidated EBITDA to Consolidated Interest Expense, calculated in accordance with the Credit Agreement, was 9.8 to 1.0. At September 30, 2021, Altria was in compliance with its covenants in the Credit Agreement. The terms “Consolidated EBITDA” and “Consolidated Interest Expense,” each as defined in the Credit Agreement, include certain adjustments.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, due to the uncertainty at that time in the global capital markets, including the commercial paper markets, resulting from the COVID-19 pandemic, Altria elected to borrow the full $3.0 billion available under the Credit Agreement as a precautionary measure to increase its cash position and preserve financial flexibility. In June 2020, Altria repaid the full amount outstanding under the Credit Agreement using the net proceeds from the issuance of long-term senior unsecured notes issued in May 2020 and available cash.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any commercial paper issued by Altria and borrowings under the Credit Agreement are guaranteed by PM USA.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate carrying value of Altria’s total long-term debt at September 30, 2021 and December 31, 2020 was $28.1 billion and $29.5 billion, respectively.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, Altria repaid in full senior unsecured notes in the aggregate principal amount of $1.5 billion at maturity.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Altria issued long-term senior unsecured notes in the aggregate principal amount of $5.5 billion (the “Notes”). The net proceeds from the Notes were used (i) to fund the purchase and redemption of certain unsecured notes and payment of related fees and expenses, as described below, and (ii) for other general corporate purposes. The Notes contain the following terms:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">$1.75 billion at 2.450%, due 2032, interest payable semiannually beginning August 4, 2021;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">$1.50 billion at 3.400%, due 2041, interest payable semiannually beginning August 4, 2021;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">$1.25 billion at 3.700%, due 2051, interest payable semiannually beginning August 4, 2021; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">$1.00 billion at 4.000%, due 2061, interest payable semiannually beginning August 4, 2021.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are Altria’s senior unsecured obligations and rank equally in right of payment with all of Altria’s existing and future senior unsecured indebtedness. Upon the occurrence of both (i) a change of control of Altria and (ii) the Notes ceasing to be rated investment grade by each of Moody’s, S&amp;P and Fitch Ratings, Inc. within a specified time period, Altria will be required to make an offer to purchase the Notes at a price equal to 101% of the aggregate principal amount of such Notes, plus accrued and unpaid interest to the date of repurchase as and to the extent set forth in the terms of the Notes.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations of Altria under the Notes are guaranteed by PM USA.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, Altria completed debt tender offers to purchase for cash certain of its long-term senior unsecured notes in an aggregate principal amount of $4,042 million. Details of the debt tender offers are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Amount of Notes Purchased</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.850% Notes due 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">795</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.950% Notes due 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">132</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000% Notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">624</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.800% Notes due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">655</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.400% Notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">430</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.800% Notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,094</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.950% Notes due 2038</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.200% Notes due 2039</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.200% Notes due 2059</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,042</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, Altria also redeemed all of its outstanding 3.490% Notes due 2022 in an aggregate principal amount of $1.0 billion.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the debt tender offers and redemption, during the first quarter of 2021, Altria recorded pre-tax losses on early extinguishment of debt of $649 million, which included premiums and fees of $623 million and the write-off of related unamortized debt discounts and debt issuance costs of $26 million.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021 and December 31, 2020, accrued interest on long-term debt of $206 million and $458 million, respectively, was included in other accrued liabilities on Altria’s condensed consolidated balance sheets.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of the fair value of Altria’s long-term debt and the designation of its Euro denominated senior unsecured notes as a net investment hedge of its investment in ABI, see Note 5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> 0 0 3000000000 P5Y P1Y 3000000000 0.010 4.0 9.8 3000000000 28100000000 29500000000 1500000000 5500000000 1750000000 0.02450 1500000000 0.03400 1250000000 0.03700 1000000000 0.04000 1.01 <div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, Altria completed debt tender offers to purchase for cash certain of its long-term senior unsecured notes in an aggregate principal amount of $4,042 million. Details of the debt tender offers are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Amount of Notes Purchased</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.850% Notes due 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">795</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.950% Notes due 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">132</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000% Notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">624</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.800% Notes due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">655</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.400% Notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">430</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.800% Notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,094</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.950% Notes due 2038</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.200% Notes due 2039</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.200% Notes due 2059</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,042</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div> 4042000000 0.02850 795000000 0.02950 132000000 0.04000 624000000 0.03800 655000000 0.04400 430000000 0.04800 1094000000 0.09950 65000000 0.10200 18000000 0.06200 229000000 4042000000 0.03490 1000000000 -649000000 -623000000 26000000 206000000 458000000 Income Taxes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Earnings (losses) before income taxes, provision (benefit) for income taxes and income tax rates consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (losses) before income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,544</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,349</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,302)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(324)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (benefit) for income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">693</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,817</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(582)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195.1)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria’s income tax rates for the nine and three months ended September 30, 2021 and 2020 are not comparable in a meaningful way due to the following significant pre-tax charges and valuation allowances:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the $6,157 million impairment of Altria’s equity investment in ABI during the nine and three months ended September 30, 2021;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the $2,600 million impairment of Altria’s investment in JUUL during the nine and three months ended September 30, 2020 and valuation allowances associated with Altria’s investments in JUUL and Altria’s Investment in Cronos.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria’s income tax rates for the nine and three months ended September 30, 2021 differ from the U.S. federal statutory rate of 21%, due primarily to the state tax treatment of the impairment charge on Altria’s equity investment in ABI.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria’s income tax rates for the nine and three months ended September 30, 2020 differ from the U.S. federal statutory rate of 21%, due primarily to valuation allowances primarily attributable to deferred tax assets recorded in connection with the impairment of Altria’s investment in JUUL, and Altria’s Investment in Cronos.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information on the impairments of Altria’s equity investment in ABI and investment in JUUL, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following chart provides a reconciliation of the beginning and ending valuation allowances for the period ended September 30, 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,817 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to valuation allowance charged to income tax expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">264</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions to valuation allowance credited to income tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,004</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria determines the realizability of deferred tax assets based on the weight of available evidence, that it is more-likely-than-not that the deferred tax asset will not be realized. In reaching this determination, Altria considers all available positive and negative evidence, including the character of the loss, carryback and carryforward considerations, future reversals of temporary differences and available tax planning strategies.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current changes in valuation allowances were due to deferred tax assets recorded in connection with Altria’s Investment in Cronos and changes in the estimated fair value of its investment in JUUL. The valuation allowance at the end of the period is primarily attributable to deferred tax assets recorded in connection with Altria’s investment in JUUL and Investment in Cronos.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Earnings (losses) before income taxes, provision (benefit) for income taxes and income tax rates consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (losses) before income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,544</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,349</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,302)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(324)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (benefit) for income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">693</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,817</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(582)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8 </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195.1)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 1544000000 4349000000 -3302000000 -324000000 693000000 1817000000 -582000000 632000000 0.449 0.418 0.176 -1.951 6157000000 6157000000 2600000000 2600000000 <div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following chart provides a reconciliation of the beginning and ending valuation allowances for the period ended September 30, 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,817 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to valuation allowance charged to income tax expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">264</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions to valuation allowance credited to income tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,004</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2817000000 264000000 73000000 -4000000 3004000000 Contingencies<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal proceedings covering a wide range of matters are pending or threatened in various U.S. and foreign jurisdictions against Altria and its subsidiaries, including PM USA and USSTC, as well as their respective indemnitees and Altria’s investees. Various types of claims may be raised in these proceedings, including product liability, unfair trade practices, antitrust, tax, contraband shipments, patent infringement, employment matters, claims alleging violation of the Racketeer Influenced and Corrupt Organizations Act (“RICO”), claims for contribution and claims of competitors, shareholders or distributors. Legislative action, such as changes to tort law, also may expand the types of claims and remedies available to plaintiffs.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation is subject to uncertainty and it is possible that there could be adverse developments in pending or future cases. An unfavorable outcome or settlement of pending tobacco-related or other litigation could encourage the commencement of additional litigation. Damages claimed in some tobacco-related and other litigation are or can be significant and, in certain cases, have ranged in the billions of dollars. The variability in pleadings in multiple jurisdictions, together with the actual experience of management in litigating claims, demonstrate that the monetary relief that may be specified in a lawsuit bears little relevance to the ultimate outcome. In certain cases, plaintiffs claim that defendants’ liability is joint and several. In such cases, Altria or its subsidiaries may face the risk that one or more co-defendants decline or otherwise fail to participate in the bonding required for an appeal or to pay their proportionate or jury-allocated share of a judgment. As a result, Altria or its subsidiaries under certain circumstances may have to pay more than their proportionate share of any bonding- or judgment-related amounts. Furthermore, in those cases where plaintiffs are successful, Altria or its subsidiaries also may be required to pay interest and attorneys’ fees.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although PM USA has historically been able to obtain required bonds or relief from bonding requirements in order to prevent plaintiffs from seeking to collect judgments while adverse verdicts have been appealed, there remains a risk that such relief may not be obtainable in all cases. This risk has been substantially reduced given that 47 states and Puerto Rico limit the dollar amount of bonds or require no bond at all. As discussed below, however, tobacco litigation plaintiffs have challenged the constitutionality of Florida’s bond cap statute in several cases and plaintiffs may challenge state bond cap statutes in other jurisdictions as well. Such challenges may include the applicability of state bond caps in federal court. States, including Florida, also may seek to repeal or alter bond cap statutes through legislation. Although Altria cannot predict the outcome of such challenges, it is possible that the consolidated results of operations, cash flows or financial position of Altria, or one or more of its subsidiaries, could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome of one or more such challenges.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria and its subsidiaries record provisions in the condensed consolidated financial statements for pending litigation when they determine that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. At the present time, while it is reasonably possible that an unfavorable outcome in a case may occur, except to the extent discussed elsewhere in this Note 12. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: (i) management has concluded that it is not probable that a loss has been incurred in any of the pending cases; (ii) management is unable to estimate the possible loss or range of loss that could result from an unfavorable outcome in any of the pending cases; and (iii) accordingly, management has not provided any amounts in the condensed consolidated financial statements for unfavorable outcomes, if any. Litigation defense costs are expensed as incurred.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria and its subsidiaries have achieved substantial success in managing litigation. Nevertheless, litigation is subject to uncertainty and significant challenges remain. It is possible that the consolidated results of operations, cash flows or financial position of Altria, or one or more of its subsidiaries, could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending litigation. Altria and each of its subsidiaries named as a defendant believe, and each has been so advised by counsel handling the respective cases, that it has valid defenses to the litigation pending against it, as well as valid bases for appeal of adverse verdicts. Each of the companies has defended, and will continue to defend, vigorously against litigation challenges. However, Altria and its subsidiaries may enter into settlement discussions in particular cases if they believe it is in the best interests of Altria to do so.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Judgments Paid and Provisions for Tobacco and Health and Certain Other Litigation Items (Including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Progeny Litigation): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After exhausting all appeals in those cases resulting in adverse verdicts associated with tobacco-related litigation, since October 2004, PM USA has paid judgments and settlements (including related costs and fees) totaling approximately $865 million and interest totaling approximately $218 million as of September 30, 2021. These amounts include payments for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny judgments (and related costs and fees) totaling approximately $410 million and related interest totaling approximately $56 million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Altria’s accrued liability for tobacco and health and certain other litigation items, including related interest costs, for the periods specified below are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liability for tobacco and health and certain other litigation items at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax charges for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tobacco and health and certain other litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">99</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related interest costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liability for tobacco and health and certain other litigation items at end of period</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes amounts related to certain other litigation and pre-trial resolution of certain tobacco and health cases.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accrued liability for tobacco and health and certain other litigation items, including related interest costs, was included in accrued liabilities on Altria’s condensed consolidated balance sheets. Pre-tax charges for tobacco and health and certain other litigation were included in marketing, administration and research costs on Altria’s condensed consolidated statements of earnings (losses). Pre-tax charges for related interest costs were included in interest and other debt expense, net on Altria’s condensed consolidated statements of earnings (losses).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Security for Judgments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain stays of judgments pending appeal, PM USA has posted various forms of security. As of September 30, 2021, PM USA has posted appeal bonds totaling approximately $45 million, which have been collateralized with restricted cash that are included in assets on the condensed consolidated balance sheets.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of Altria and/or PM USA Tobacco-Related Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Types and Number of U.S. Cases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims related to tobacco products generally fall within the following categories: (i) smoking and health cases alleging personal injury brought on behalf of individual plaintiffs; (ii) health care cost recovery cases brought by governmental (both domestic and foreign) plaintiffs seeking reimbursement for health care expenditures allegedly caused by cigarette smoking and/or disgorgement of profits; (iii) e-vapor cases alleging violation of RICO, fraud, failure to warn, design defect, negligence, antitrust and unfair trade practices; and (iv) other tobacco-related litigation described below. Plaintiffs’ theories of recovery and the defenses raised in tobacco-related litigation are discussed below.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below lists the number of certain tobacco-related cases pending in the U.S. against PM USA and/or Altria as of October 25, 2021, October 27, 2020 and October 28, 2019:</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">October 25, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">October 27, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">October 28, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Smoking and Health Cases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">179</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Care Cost Recovery Actions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E-vapor Cases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,951</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Tobacco-Related Cases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes 18 cases filed in Illinois, 17 cases filed in New Mexico, 40 cases filed in Massachusetts and 70 non-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">cases filed in Florida. Does not include individual smoking and health cases brought by or on behalf of plaintiffs in Florida state and federal courts following the decertification of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">case (these </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> progeny cases are discussed below in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Smoking and Health Litigation - Engle Class Action</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">). Also does not include 1,471 cases brought by flight attendants seeking compensatory damages for personal injuries allegedly caused by exposure to environmental tobacco smoke (“ETS”). The flight attendants allege that they are members of an ETS smoking and health class action in Florida, which was settled in 1997 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Broin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">). The terms of the court-approved settlement in that case allowed class members to file individual lawsuits seeking compensatory damages, but prohibited them from seeking punitive damages. Class members were prohibited from filing individual lawsuits after 2000 under the court-approved settlement.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Health Care Cost Recovery Litigation - Federal Government’s Lawsuit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> below.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes 53 class action lawsuits, 2,548 individual lawsuits and 350 “third party” lawsuits relating to JUUL e-vapor products, which include school districts, state and local government, tribal and healthcare organization lawsuits. JUUL is an additional named defendant in each of these lawsuits. The 53 class action lawsuits include 28 cases in the Northern District of California (“Multidistrict Litigation” or “MDL”) involving plaintiffs whose claims were previously included in other class action complaints but were refiled as separate stand-alone class actions for procedural and other reasons.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes one inactive smoking and health case alleging personal injury and purporting to be brought on behalf of a class of individual plaintiffs and two inactive class action lawsuits alleging that use of the terms “Lights” and “Ultra Lights” constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment, breach of warranty or violations of RICO.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">International Tobacco-Related Cases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 25, 2021, (i) Altria is named as a defendant in three e-vapor class action lawsuits in Canada; (ii) PM USA is a named defendant in 10 health care cost recovery actions in Canada, eight of which also name Altria as a defendant; and (iii) PM USA and Altria are named as defendants in seven smoking and health class actions filed in various Canadian provinces. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees and Other Similar Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the Distribution Agreement between Altria and Philip Morris International Inc. (“PMI”) that provides for indemnities for certain liabilities concerning tobacco products.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tobacco-Related Cases Set for Trial: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 25, 2021, no </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny or individual smoking and health cases against PM USA are set for trial through December 31, 2021. Trial dates are subject to change and many of the trials were postponed due to the COVID-19 pandemic; however, the courts are reopening and additional trials may be scheduled for the remainder of 2021.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trial Results: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since January 1999, excluding the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny cases (separately discussed below), verdicts have been returned in 69 tobacco-related cases in which PM USA was a defendant. Verdicts in favor of PM USA and other defendants were returned in 44 of the 69 cases. These 44 cases were tried in Alaska (1), California (7), Connecticut (1), Florida (10), Louisiana (1), Massachusetts (4), Mississippi (1), Missouri (4), New Hampshire (1), New Jersey (1), New York (5), Ohio (2), Pennsylvania (1), Rhode Island (1), Tennessee (2) and West Virginia (2).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the 25 non-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases in which verdicts were returned in favor of plaintiffs, 20 have reached final resolution, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and two cases (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gentile </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Principe</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) that were initially returned in favor of plaintiffs were reversed post-trial and remain pending.</span></div><div style="margin-bottom:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Smoking and Health Liti</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">gation - Engle Progeny Trial Results</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of verdicts in state and federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases involving PM USA as of October 25, 2021.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Smoking and Health Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs’ allegations of liability in smoking and health cases are based on various theories of recovery, including negligence, gross negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, nuisance, breach of express and implied warranties, breach of special duty, conspiracy, concert of action, violations of unfair trade practice laws and consumer protection statutes, and claims under the federal and state anti-racketeering statutes. Plaintiffs in the smoking and health cases seek various forms of relief, including compensatory and punitive damages, treble/multiple damages and other statutory damages and penalties, creation of medical monitoring and smoking cessation funds, disgorgement of profits, and injunctive and equitable relief. Defenses raised in these cases include lack of proximate cause, assumption of the risk, comparative fault and/or contributory negligence, statutes of limitations and preemption by the Federal Cigarette Labeling and Advertising Act.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Progeny Litigation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized below are the non-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny smoking and health cases pending during 2021 in which a verdict was returned in favor of plaintiff and against PM USA. Charts listing certain verdicts for plaintiffs in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny cases can be found in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Smoking and Health Litigation - Engle Progeny Trial Results</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In February 2020, a jury in a Florida state court returned a verdict in favor of plaintiff and against PM USA, awarding approximately $11 million in compensatory damages. There was no claim for punitive damages. PM USA appealed the trial court verdict to the Third District Court of Appeal and, in September 2021, the appellate court reversed the trial court’s decision and found in favor of PM USA.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Greene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In September 2019, a jury in a Massachusetts state court returned a verdict in favor of plaintiffs and against PM USA, awarding approximately $10 million in compensatory damages. In May 2020, the court ruled on plaintiffs’ remaining claim and trebled the compensatory damages award to approximately $30 million. In February 2021, the trial court awarded plaintiffs attorneys’ fees and costs in the amount of approximately $2.3 million. Also in February 2021, PM USA served its post-trial motions to reverse the judgment or for a new trial. The trial court denied the post-trial motions in June 2021. In July 2021, PM USA appealed the judgment to the Appeals Court of Massachusetts.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Laramie</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In August 2019, a jury in a Massachusetts state court returned a verdict in favor of plaintiff and against PM USA, awarding $11 million in compensatory damages and $10 million in punitive damages. PM USA appealed and, in February 2021, the Massachusetts Supreme Judicial Court asserted jurisdiction over the appeal. In September 2021, the Massachusetts Supreme Judicial Court affirmed the trial court award of $21 million in compensatory and punitive damages. PM USA recorded a pre-tax provision of approximately $27.1 million for the judgment, including interest, in the third quarter of 2021.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gentile</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In October 2017, a jury in a Florida state court returned a verdict in favor of plaintiff and against PM USA, awarding approximately $7.1 million in compensatory damages and allocating 75% of the fault to PM USA. PM USA appealed. In September 2019, the Florida Fourth District Court of Appeal reversed the judgment entered by the trial court, granted PM USA judgment on certain claims and remanded for a new trial on the remaining claims. Plaintiff petitioned the Florida Supreme Court for further review, which the court denied in January 2021.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Federal Government’s Lawsuit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Cost Recovery Litigation - Federal Government’s Lawsuit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the verdict and post-trial developments in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States of America</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> health care cost recovery case.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Class Action: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2000, in the second phase of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smoking and health class action in Florida, a jury returned a verdict assessing punitive damages totaling approximately $145 billion against various defendants, including $74 billion against PM USA. Following entry of judgment, PM USA appealed. In May 2003, the Florida Third District Court of Appeal reversed the judgment entered by the trial court and instructed the trial court to order the decertification of the class. Plaintiffs petitioned the Florida Supreme Court for further review.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2006, the Florida Supreme Court ordered that the punitive damages award be vacated, that the class approved by the trial court be decertified and that members of the decertified class could file individual actions against defendants within one year of issuance of the mandate. The court further declared the following Phase I findings are entitled to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">res judicata</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> effect in such individual actions brought within one year of the issuance of the mandate: (i) that smoking causes various diseases; (ii) that nicotine in cigarettes is addictive; (iii) that defendants’ cigarettes were defective and unreasonably dangerous; (iv) that defendants concealed or omitted material information not otherwise known or available knowing that the material was false or misleading or failed to disclose a material fact concerning the health effects or addictive nature of smoking; (v) that defendants agreed to misrepresent information regarding the health effects or addictive nature of cigarettes with the intention of causing the public to rely on this information to their detriment; (vi) that defendants agreed to conceal or omit information regarding the health effects of cigarettes or their addictive nature with the intention that smokers would rely on the information to their detriment; (vii) that all defendants sold or supplied cigarettes that were defective; and (viii) that defendants were negligent.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2006, PM USA and plaintiffs sought rehearing from the Florida Supreme Court on parts of its July 2006 opinion. In December 2006, the Florida Supreme Court refused to revise its July 2006 ruling, except that it revised the set of Phase I findings entitled to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">res judicata</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> effect by excluding finding (v) listed above (relating to agreement to misrepresent information), and added the finding that defendants sold or supplied cigarettes that, at the time of sale or supply, did not conform to the representations of fact made by defendants. In February 2008, the trial court decertified the class.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pending </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">e Progeny Cases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deadline for filing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases expired in January 2008, at which point a total of approximately 9,300 federal and state claims were pending. As of October 25, 2021, approximately 1,026 state court cases were pending against PM USA or Altria asserting individual claims by or on behalf of approximately 1,285 state court plaintiffs.  Because of a number of factors, including docketing delays, duplicated filings and overlapping dismissal orders, these numbers are estimates. While the Federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement (discussed below) resolved nearly all </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny cases pending in federal court, as of October 25, 2021, two cases were pending against PM USA in federal court representing the cases excluded from that agreement.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Progeny Trial Results: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 25, 2021, 137 federal and state </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases involving PM USA have resulted in verdicts since the Florida Supreme Court </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decision. Seventy-six verdicts were returned in favor of plaintiffs and seven verdicts (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Skolnick</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Calloway</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oshinsky-Blacker,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">McCoy, Mahfuz, Neff and Frogel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) that were initially returned in favor of plaintiffs were reversed post-trial or on appeal and remain pending.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fifty-four verdicts were returned in favor of PM USA, of which 44 were state cases. In addition, there have been a number of mistrials, only some of which have resulted in new trials as of October 25, 2021. The jury in one case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Garcia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, awarded plaintiff compensatory damages and found plaintiff was entitled to punitive damages; however, the court declared a mistrial in the second phase of the trial regarding punitive damages because the jury was unable to determine the amount of the punitive damages. Four verdicts (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pearson, D. Cohen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collar </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Chacon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) that were returned in favor of PM USA were subsequently reversed for new trials. Juries in two cases (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reider </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Banks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">returned zero damages verdicts in favor of PM USA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Juries in two other cases (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Weingart</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hancock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) returned verdicts against PM USA awarding no damages, but the trial court in each case decided to award plaintiffs damages. One case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pollari, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resulted in a verdict in favor of PM USA following a retrial of an initial verdict returned in favor of plaintiff. Plaintiff and defendants appealed the verdict and the appellate court affirmed the judgement in favor of the defendants. Three cases, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gloger,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rintoul </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Caprio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duignan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, resulted in verdicts in favor of plaintiffs following retrial of initial verdicts returned in favor of plaintiffs. Post-trial appeals are pending in those three cases. Two cases, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Freeman </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Harris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, resulted in an appellate reversal of a jury verdict in favor of plaintiff, and a judgment in favor of PM USA.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The charts below list the verdicts and post-trial developments in certain </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases in which verdicts were returned in favor of plaintiffs. The first chart lists cases that are pending as of October 25, 2021 but where PM USA has determined an unfavorable outcome is not probable and the amount of loss cannot be reasonably estimated. The second chart lists cases that have concluded within the previous 12 months. Unless otherwise noted for a particular case, the jury’s award for compensatory damages will not be reduced by any finding of plaintiff’s comparative fault. Further, the damages noted reflect adjustments based on post-trial or appellate rulings. As of October 25, 2021, there are no </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases where PM USA has recorded a provision in its condensed consolidated financial statements because PM USA has not determined for any currently pending case that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References below to “R.J. Reynolds,” “Lorillard” and “Liggett Group” are to R.J. Reynolds Tobacco Company, Lorillard Tobacco Company and Liggett Group, LLC, respectively.</span></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Currently Pending Engle Cases with Verdicts Against PM USA </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(rounded to nearest $ million)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.488%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plaintiff</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Verdict Date</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Defendant(s)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Court</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Compensatory Damages </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Punitive Damages <br/>(PM USA)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appeal Status</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lipp</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$15 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$28 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Defendant’s post-trial motions denied. Defendant plans to appeal.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Garcia</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2021</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mistrial</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appeal by defendant to Third District Court of Appeal pending.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Duignan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pinellas</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$12 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appeal by defendants to Second District Court of Appeal pending.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Cuddihee</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Duval</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appeal by defendant to First District Court of Appeal pending. </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Rintoul </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Caprio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$9 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$74 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appeal by plaintiff and defendants to Fourth District Court of Appeal pending.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Gloger</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$15 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$11 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appeal by defendants to Third District Court of Appeal pending.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">McCall</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&lt;$1 million (&lt;$1 million PM USA)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New trial ordered on punitive damages.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Neff</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2019</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$4 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fourth District Court of Appeal reversed the judgment against defendants and remanded for a new trial. Plaintiff's motion for rehearing was denied.</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.488%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plaintiff</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Verdict Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Defendant(s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Court</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Compensatory Damages </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Punitive Damages <br/>(PM USA)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appeal Status</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Mahfuz</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$12 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$10 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fourth District Court of Appeal reversed the judgment against defendants and remanded for a new trial. Plaintiff's motion for rehearing was denied.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Holliman</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Defendant’s appeal to Third District Court of Appeal pending.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Chadwell</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2018</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third District Court of Appeal affirmed the compensatory damages award. PM USA petitioned Florida Supreme Court for review. Case stayed pending Florida Supreme Court decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Prentice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Kaplan</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Fourth District Court of Appeal affirmed the verdict and reaffirmed the verdict on rehearing. Defendants sought review of the decision before the Florida Supreme Court and the court stayed the case pending its decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Sheffield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">R. Douglas</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2017</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Duval</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&lt;$1 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Awaiting entry of final judgment by the trial court.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Sommers</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2017</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third District Court of Appeal affirmed compensatory damages award and granted new trial on punitive damages. Florida Supreme Court denied PM USA’s petition for review of the Third District Court of Appeal’s decision. PM USA paid approximately $1 million for the compensatory damages award and awaits the new trial on punitive damages.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> The trial court stayed the new trial on punitive damages pending Florida Supreme Court’s decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Sheffield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Cooper (Blackwood)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5 million </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(&lt;$1 million PM USA)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fourth District Court of Appeal affirmed judgment and granted a new trial on punitive damages.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">D. Brown</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2015</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal Court - Middle District of Florida</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$8 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$9 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appeal by defendant to U.S. Court of Appeals for the Eleventh Circuit stayed pending Florida Supreme Court decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Prentice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PM USA’s portion of the compensatory damages award is noted parenthetically where the court has ruled that comparative fault applies. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Plaintiff’s verdict following a retrial of an initial verdict in favor of plaintiff.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> PM USA is not a defendant in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Prentice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Sheffield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Prentice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Sheffield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">are discussed below in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Engle Progeny Appellate Issues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Plaintiff was granted an award of approximately $3 million in fees, costs and interest that PM USA appealed. The Florida Third District Court of Appeals affirmed the award and PM USA paid the award amount in March 2021.</span></div><div style="margin-bottom:3pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engle Cases Concluded Within Past 12 Months </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(rounded to nearest $ million)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:14.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.346%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plaintiff</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Verdict Date</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Defendant(s)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Court</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accrual Date</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payment Amount<br/>(if any)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payment Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Berger (Cote)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2014</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal Court - Middle District of Florida</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fourth quarter of 2018 and first quarter of 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$29 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Santoro</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2017</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA, R.J. Reynolds and Liggett Group</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second quarter of 2020 and first quarter of 2021</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2021</span></td></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In six cases in which PM USA paid the judgments more than a year ago, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Naugle,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gore</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">M. Brown,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Jordan,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Theis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Landi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, plaintiffs were awarded approximately $8 million, $2 million, $8 million, $4 million, $1 million and $3 million in fees and costs, respectively. PM USA has appealed in all of these cases, except </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Theis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Landi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. In</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> M. Brown</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, in March 2021 the Florida First District Court of Appeals affirmed the fee award and reversed the pre-judgment interest award and, in April 2021, PM USA paid $8.2 million in satisfaction of the fee award and post-judgment interest. In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Theis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, PM USA paid $1 million in satisfaction of fees and costs in May 2021 and, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Landi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, PM USA paid approximately $1.5 million in satisfaction of fees, costs and interest in July 2021 (R.J. Reynolds paid approximately $1.5 million of the approximately $3 million award).</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Progeny Appellate Issues: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Florida appellate courts are considering the following appeals which may have wide application to other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases:</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mary Sheffield v. R.J. Reynolds Tobacco Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny case against R.J. Reynolds only, the Florida Supreme Court has taken jurisdiction to resolve the conflict among Florida’s District Courts of Appeal over whether the 1999 amendments to Florida’s punitive damages statute (including its caps and bar on multiple punitive damages awards for the same course of conduct) apply in wrongful death cases where the decedent was injured prior to the October 1, 1999 effective date of the amendments but died from his or her injuries after such effective date. Oral argument was held before the Florida Supreme Court in April 2021; a decision has not yet been issued.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Linda Prentice v. R.J. Reynolds Tobacco Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny case against R.J. Reynolds only, the Florida First District Court of Appeal in January 2020 reversed a judgment in favor of the plaintiff and remanded for a new trial. The court held that the trial court had erred by failing to instruct the jury that in order to prevail on her claim for conspiracy to commit fraudulent concealment, the plaintiff was required to prove that her decedent relied to his detriment on a statement that concealed or omitted material information about the health risks of smoking. That holding conflicts with decisions from the Second, Third, and Fourth District Courts of Appeal, which have each held that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plaintiffs do not need to prove reliance on a statement, and instead can prevail by proving reliance on the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> defendants’ concealment of information. In August 2020, the Florida Supreme Court accepted jurisdiction in the case. As an alternative ground to approve the First District Court of Appeal’s decision in its favor in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prentice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, R.J. Reynolds has asked the Florida Supreme Court to reconsider its prior decisions giving the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Phase I findings preclusive effect in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases, as described more fully in the section </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Class Action above. Oral argument was held before the Florida Supreme Court in June 2021; a decision has not yet been issued.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Florida Bond Statute: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2009, Florida amended its existing bond cap statute by adding a $200 million bond cap that applies to all state </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny lawsuits in the aggregate and establishes individual bond caps for individual </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> progeny cases in amounts that vary depending on the number of judgments in effect at a given time. Plaintiffs have been unsuccessful in various challenges to the bond cap statute in Florida state court.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No federal court has yet addressed the constitutionality of the bond cap statute or the applicability of the bond cap to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progeny cases tried in federal court.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, legislation has been presented to the Florida legislature that would repeal the bond cap statute; however to date, no legislation repealing the statute has passed.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Smoking and Health Class Actions: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the dismissal in May 1996 of a purported nationwide class action brought on behalf of allegedly addicted smokers, plaintiffs have filed numerous putative smoking and health class action suits in various state and federal courts. In general, these cases purport to be brought on behalf of residents of a particular state or states (although a few cases purport to be nationwide in scope) and raise addiction claims and, in many cases, claims of physical injury as well.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class certification has been denied or reversed by courts in 61 smoking and health class actions involving PM USA in Arkansas (1), California (1), Delaware (1), the District of Columbia (2), Florida (2), Illinois (3), Iowa (1), Kansas (1), Louisiana (1), Maryland (1), Michigan (1), Minnesota (1), Nevada (29), New Jersey (6), New York (2), Ohio (1), Oklahoma (1), Oregon (1), Pennsylvania (1), Puerto Rico (1), South Carolina (1), Texas (1) and Wisconsin (1). See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Other Tobacco-Related </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below for a discussion of “Lights” and “Ultra Lights” class action cases and medical monitoring class action cases pending against PM USA.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 25, 2021, PM USA and Altria are named as defendants, along with other cigarette manufacturers, in seven class actions filed in the Canadian provinces of Alberta, Manitoba, Nova Scotia, Saskatchewan, British Columbia and Ontario. In Saskatchewan, British Columbia (two separate cases) and Ontario, plaintiffs seek class certification on behalf of individuals who suffer or have suffered from various diseases, including chronic obstructive pulmonary disease, emphysema, heart disease or cancer, after smoking defendants’ cigarettes. In the actions filed in Alberta, Manitoba and Nova Scotia, plaintiffs seek certification of classes of all individuals who smoked defendants’ cigarettes. In March 2019, all of these class actions were stayed as a result of three Canadian tobacco manufacturers (none of which is related to Altria or its subsidiaries) seeking protection under Canada’s Companies’ Creditors Arrangement Act (which is similar to Chapter 11 bankruptcy in the U.S.). The companies entered into these proceedings following a Canadian appellate court upholding two smoking and health class action verdicts against those companies totaling approximately CAD $13 billion. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees and Other Similar Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the Distribution Agreement between Altria and PMI, which provides for indemnities for certain liabilities concerning tobacco products.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Health Care Cost Recovery Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the health care cost recovery litigation, governmental entities seek reimbursement of health care cost expenditures allegedly caused by tobacco products and, in some cases, of future expenditures and damages. Relief sought by some but not all plaintiffs includes punitive damages, multiple damages and other statutory damages and penalties, injunctions prohibiting alleged marketing and sales to minors, disclosure of research, disgorgement of profits, funding of anti-smoking programs, additional disclosure of nicotine yields, and payment of attorney and expert witness fees.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although there have been some decisions to the contrary, most judicial decisions in the U.S. have dismissed all or most health care cost recovery claims against cigarette manufacturers. Nine federal circuit courts of appeals and eight state appellate courts, relying primarily on grounds that plaintiffs’ claims were too remote, have ordered or affirmed dismissals of health care cost recovery actions. The United States Supreme Court has refused to consider plaintiffs’ appeals from the cases decided by five federal circuit courts of appeal.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the cases brought in the U.S., health care cost recovery actions have also been brought against tobacco industry participants, including PM USA and Altria, in Canada (10 cases), and other entities have stated that they are considering filing such actions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the beginning of 2008, the Canadian Provinces of British Columbia, New Brunswick, Ontario, Newfoundland and Labrador, Quebec, Alberta, Manitoba, Saskatchewan, Prince Edward Island and Nova Scotia have brought health care reimbursement claims against cigarette manufacturers. PM USA is named as a defendant in the British Columbia and Quebec cases, while both Altria and PM USA are named as defendants in the New Brunswick, Ontario, Newfoundland and Labrador, Alberta, Manitoba, Saskatchewan, Prince Edward Island and Nova Scotia cases. The Nunavut Territory and Northwest Territory have passed legislation permitting similar claims, but lawsuits based on this legislation have not been filed. All of these cases have been stayed pending resolution of proceedings in Canada involving three tobacco manufacturers (none of which are affiliated with Altria or its subsidiaries) under the Companies’ Creditors Arrangement Act discussed above. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Smoking and Health Litigation - Other Smoking and Health Class Actions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for a discussion of these proceedings. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees and Other Similar Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the Distribution Agreement between Altria and PMI that provides for indemnities for certain liabilities concerning tobacco products.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Settlements of Health Care Cost Recovery Litigation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 1998, PM USA and certain other tobacco product manufacturers entered into the 1998 Master Settlement Agreement (the “MSA”) with 46 states, the District of Columbia and certain U.S. territories to settle asserted and unasserted health care cost recovery and other claims. PM USA and certain other tobacco product manufacturers had previously entered into agreements to settle similar claims brought by Mississippi, Florida, Texas and Minnesota (together with the MSA, the “State Settlement Agreements”). The State Settlement Agreements require that the original participating manufacturers or “OPMs” (now PM USA, R.J. Reynolds and, with respect to certain brands, ITG Brands, LLC (“ITG”)) make annual payments of approximately $9.4 billion, subject to adjustments for several factors, including inflation, market share and industry volume. In addition, the OPMs are required to pay settling plaintiffs’ attorneys’ fees, subject to an annual cap of $500 million. For the three months ended September 30, 2021 and 2020, the aggregate amount recorded in cost of sales with respect to the State Settlement Agreements was approximately $1.1 billion and $1.2 billion, respectively. For the nine months ended September 30, 2021 and 2020, the aggregate amount recorded in cost of sales with respect to the State Settlement Agreements was approximately $3.2 billion and $3.3 billion, respectively. These amounts include PM USA’s estimate of amounts related to NPM Adjustments discussed below.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NPM Adjustment Disputes: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The “NPM Adjustment” is a reduction in MSA payments made by the OPMs and those manufacturers that are subsequent signatories to the MSA (collectively, the “participating manufacturers” or “PMs”) that </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applies if the PMs collectively lose at least a specified level of market share to non-participating manufacturers since 1997, subject to certain conditions and defenses.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The independent auditor (“IA”) appointed under the MSA has calculated that PM USA’s share of the maximum potential NPM Adjustments for 2004-2020 is (exclusive of interest or earnings): $388 million for 2004; $181 million for 2005; $154 million for 2006; $185 million for 2007; $250 million for 2008; $211 million for 2009; $218 million for 2010; $166 million for 2011; $214 million for 2012; $224 million for 2013; $258 million for 2014; $313 million for 2015; $292 million for 2016; $302 million for 2017; $325 million for 2018; $444 million for 2019; and $572 million for 2020. These maximum amounts will be reduced, likely substantially, to reflect the NPM Adjustment settlements discussed below, and potentially for current and future calculation disputes and other developments. In addition, PM USA’s recovery of these amounts, even as reduced, is dependent upon subsequent determinations regarding state-specific defenses and disputes with other PMs.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Settlements of NPM Adjustment Disputes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Multi-State Settlement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> By the end of 2018, PM USA entered into a multi-state settlement of NPM Adjustment disputes with a total of 36 MSA states and territories in which PM USA settled the NPM Adjustment disputes through 2022 with 35 of the 36 states, and through 2024 with one state. Pursuant to the multi-state settlement, PM USA received $1.03 billion and expects to receive approximately $320 million in credits to offset PM USA’s MSA payments through 2029.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">New York Settlement. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, PM USA entered into a separate NPM Adjustment settlement with New York in which PM USA settled the NPM Adjustment disputes with New York in perpetuity. PM USA received $373 million pursuant to the New York settlement and expects to receive annual credits applied against the MSA payments due to New York going forward.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Montana Settlement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In 2020, PM USA entered into a separate NPM Adjustment settlement with Montana in which PM USA settled the NPM Adjustment disputes with Montana through 2030. This settlement resulted in a payment by PM USA of $4 million.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Continuing NPM Adjustment Disputes with States That Have Not Settled</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">2004 NPM Adjustment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The PMs and the 10 states that have not settled the NPM Adjustment disputes are currently arbitrating NPM Adjustment disputes for 2004 in a multi-state arbitration. Hearings for 9 of the 10 states have concluded. In September 2021, the arbitration panels issued decisions finding that two states, Missouri and Washington, were not diligent in their enforcement of their escrow statutes in 2004 and, therefore, are subject to the NPM adjustment for 2004. The arbitration panels further found that the remaining seven states were diligent in their enforcement and, therefore, are not subject to the NPM adjustment for 2004. The hearing for one remaining state is currently scheduled for February 2022. Several issues remain to be resolved by the arbitration panels that will affect the final amount of the 2004 NPM adjustment PM USA and other PMs will receive. PM USA recorded $21 million as a reduction to cost of sales in the third quarter of 2021 for its estimate of the minimum amount of the 2004 NPM adjustment it will receive. PM USA estimates it is entitled to interest of approximately $23 million in connection with the 2004 NPM adjustment, which it recorded as interest income in the third quarter of 2021.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">2005-2007 NPM Adjustments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The PMs and the 10 states that have not settled the NPM Adjustment disputes are currently arbitrating NPM Adjustment disputes before a single arbitration panel. The arbitration encompasses <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI5NWU1NmZiMTZmOTRkYWU5ZWFjYzYzMWM1NmQ0NjZjL3NlYzoyOTVlNTZmYjE2Zjk0ZGFlOWVhY2M2MzFjNTZkNDY2Y18xMDAvZnJhZzozYWIwN2ZmOWI3YTc0MGJiODY1ZGFlNDhlYzQ4Nzc1Zi90ZXh0cmVnaW9uOjNhYjA3ZmY5YjdhNzQwYmI4NjVkYWU0OGVjNDg3NzVmXzM1NjYx_a644eea3-4823-4d15-b961-96400803386e">three</span> years, 2005-2007, for nine of the 10 states, and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI5NWU1NmZiMTZmOTRkYWU5ZWFjYzYzMWM1NmQ0NjZjL3NlYzoyOTVlNTZmYjE2Zjk0ZGFlOWVhY2M2MzFjNTZkNDY2Y18xMDAvZnJhZzozYWIwN2ZmOWI3YTc0MGJiODY1ZGFlNDhlYzQ4Nzc1Zi90ZXh0cmVnaW9uOjNhYjA3ZmY5YjdhNzQwYmI4NjVkYWU0OGVjNDg3NzVmXzM1NzEx_1f0bca57-bdd0-4faf-a0bb-bb958177008c">one</span> year, 2005, for one state. As of October 25, 2021, no decisions have resulted from the arbitration.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Subsequent Years. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No assurance can be given as to when proceedings for 2008 and subsequent years will be scheduled or the precise form those proceedings will take.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Disputes Under the State Settlement Agreements: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payment obligations of the tobacco product manufacturers that are parties to the State Settlement Agreements, as well as the allocations of any NPM Adjustments and related settlements, have been and may continue to be affected by R.J. Reynolds’s acquisition of Lorillard in 2015 and its related sale of certain cigarette brands to ITG (the “ITG transferred brands”). PM USA filed motions to enforce the state settlement agreements in Florida, Minnesota, Texas and Mississippi in connection with various positions that R.J. Reynolds and ITG took with regard to the ITG transferred brands. After various court decisions in each of those states that were favorable to PM USA, those motions to enforce have now been resolved either through settlement or exhaustion of appeals. Despite these resolutions, PM USA continues to dispute the accuracy of certain submissions made by R.J. Reynolds and ITG concerning the calculation of certain payments relating to the ITG transferred brands and may pursue such claims.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the State of Mississippi filed a motion in Mississippi state court seeking to enforce the Mississippi State Settlement Agreement against PM USA, R.J. Reynolds and ITG concerning the tax rates used in the annual calculation of the net operating profit adjustment payments starting in 2018. The Mississippi state court held a hearing in October 2021 and has not yet issued a decision.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, PM USA and other PMs reached an agreement with several MSA states to waive the PMs’ claim under the most favored nation provision of the MSA in connection with a settlement between those MSA states and a non-participating manufacturer, S&amp;M Brands, Inc. (“S&amp;M Brands”), under which the states released certain claims against S&amp;M Brands in exchange for receiving a portion of the funds S&amp;M Brands deposited into escrow accounts in those states pursuant to the states’ escrow statutes. In consideration for waiving its most favored nation claim, PM USA received approximately $32 million from the escrow funds paid to those MSA states under their settlement with S&amp;M Brands. These funds were received in January 2021 and were recorded in Altria’s condensed consolidated statement of earnings for the first quarter of 2021 as a reduction to cost of sales.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Federal Government’s Lawsuit: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1999, the United States government filed a lawsuit in the U.S. District Court for the District of Columbia against various cigarette manufacturers, including PM USA, and others, including Altria, asserting claims under three federal statutes. The case ultimately proceeded only under the civil provisions of RICO. In August 2006, the district court held that certain defendants, including Altria and PM USA, violated RICO and engaged in seven of the eight “sub-schemes” to defraud that the government had alleged. Specifically, the court found that:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">defendants falsely denied, distorted and minimized the significant adverse health consequences of smoking;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">defendants hid from the public that cigarette smoking and nicotine are addictive;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">defendants falsely denied that they control the level of nicotine delivered to create and sustain addiction;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">defendants falsely marketed and promoted “low tar/light” cigarettes as less harmful than full-flavor cigarettes;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">defendants falsely denied that they intentionally marketed to youth;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">defendants publicly and falsely denied that ETS is hazardous to non-smokers; and </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">defendants suppressed scientific research.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The court did not impose monetary penalties on defendants, but ordered the following relief: (i) an injunction against “committing any act of racketeering” relating to the manufacturing, marketing, promotion, health consequences or sale of cigarettes in the United States; (ii) an injunction against participating directly or indirectly in the management or control of the Council for Tobacco Research, the Tobacco Institute, or the Center for Indoor Air Research, or any successor or affiliated entities of each; (iii) an injunction against “making, or causing to be made in any way, any material false, misleading, or deceptive statement or representation or engaging in any public relations or marketing endeavor that is disseminated to the United States public and that misrepresents or suppresses information concerning cigarettes;” (iv) an injunction against conveying any express or implied health message or health descriptors on cigarette packaging or in cigarette advertising or promotional material, including “lights,” “ultra lights” and “low tar,” which the court found could cause consumers to believe one cigarette brand is less hazardous than another brand; (v) the issuance of “corrective statements” in various media regarding the adverse health effects of smoking, the addictiveness of smoking and nicotine, the lack of any significant health benefit from smoking “low tar” or “light” cigarettes, defendants’ manipulation of cigarette design to ensure optimum nicotine delivery and the adverse health effects of exposure to ETS; (vi) the disclosure on defendants’ public document websites and in the Minnesota document repository of all documents produced to the government in the lawsuit or produced in any future court or administrative action concerning smoking and health until the third quarter of 2021, with certain additional requirements as to documents withheld from production under a claim of privilege or confidentiality; (vii) the disclosure of disaggregated marketing data to the government in the same form and on the same schedule as defendants now follow in disclosing such data to the FTC for a period of 10 years; (viii) certain restrictions on the sale or transfer by defendants of any cigarette brands, brand names, formulas or cigarette businesses within the U.S.; and (ix) payment of the government’s costs in bringing the action.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following several years of appeals relating to the content of the corrective statements remedy described above, in October 2017, the district court approved the parties’ proposed consent order implementing corrective statements in newspapers and on television. The corrective statements began appearing in newspapers and on television in the fourth quarter of 2017. In April 2018, the parties reached agreement on the implementation details of the corrective statements on websites and onserts. The corrective statements began appearing on websites in the second quarter of 2018 and the onserts began appearing in the fourth quarter of 2018.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014 and 2019, Altria and PM USA recorded provisions totaling approximately $36 million for the estimated costs of implementing the corrective communications remedy.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirements related to corrective statements at point-of-sale remain outstanding. In May 2014, the district court ordered further briefing on the issue, which was completed in June 2014. In May 2018, the parties submitted a joint status report and additional briefing on point-of-sale signage to the district court. In May 2019, the district court ordered a hearing on the point-of-sale signage issue. The hearing is currently scheduled for June 2022.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the United States government filed a motion with the district court asking for clarification as to whether the court-ordered injunction that applies to cigarettes also applies to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HeatSticks,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a heated tobacco product used with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> electronic device. In August 2020, Altria and PM USA filed an opposition to the government’s motion and, in the alternative, a motion to </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">modify the injunction to make clear it does not apply to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HeatSticks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Regardless of the district court’s decisions on the pending motions, the government has indicated it will not oppose a modification to the injunction that permits PM USA to use the Modified Risk Tobacco Product claim authorized by the United States Food and Drug Administration for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HeatSticks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E-vapor Product Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 25, 2021, Altria and/or its subsidiaries, including PM USA, were named as defendants in 53 class action lawsuits relating to JUUL e-vapor products. JUUL is an additional named defendant in each of these lawsuits. The theories of recovery include violation of RICO, fraud, failure to warn, design defect, negligence and unfair trade practices. Plaintiffs seek various remedies, including compensatory and punitive damages and an injunction prohibiting product sales. The 53 class action lawsuits include 28 cases involving plaintiffs whose claims were previously included in other class action complaints but were refiled as separate stand-alone class actions for procedural and other reasons</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria and/or its subsidiaries, including PM USA, also have been named as defendants in other lawsuits involving JUUL e-vapor products, including 2,548 individual lawsuits, 350 “third party” lawsuits, which include school districts, state and local governments and tribal and healthcare organization lawsuits. JUUL is an additional named defendant in each of these lawsuits.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the individual and class action lawsuits mentioned above were filed in federal court. In October 2019, the United States Judicial Panel on Multidistrict Litigation ordered the coordination or consolidation of these lawsuits in the U.S. District Court for the Northern District of California for pretrial purposes.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria and its subsidiaries filed motions to dismiss certain claims in the class action and school district cases, including the federal RICO claim. In October 2020, the U.S. District Court for the Northern District of California granted the motion to dismiss the RICO class action claim without prejudice. Although it otherwise denied the motion, the court found that plaintiffs had not sufficiently alleged standing or causation with respect to their claim under California law. The court also granted the motion to dismiss the RICO claim in the cases filed by various school districts, but denied the motion in all other respects. The court gave plaintiffs the opportunity to amend their complaints to attempt to cure the deficiencies the court identified and plaintiffs filed their amended complaints in November 2020. In January 2021, Altria and its subsidiaries filed a renewed motion to dismiss the RICO claim, which the court denied in April 2021. In December 2020, the U.S. District Court for the Northern District of California and the parties selected 20 personal injury plaintiffs to be adjudicated as bellwether cases and in July 2021, the court set dates for the first four of such cases to commence in 2022.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An additional group of cases is pending in California state courts. In January 2020, the Judicial Council of California determined that this group of cases was appropriate for coordination and assigned the group to the Superior Court of California, Los Angeles County, for pretrial purposes.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JUUL also is named in a significant number of additional individual and class action lawsuits to which neither Altria nor any of its subsidiaries is currently named.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three of the “third party” lawsuits noted above against Altria and/or its subsidiaries and JUUL, as an additional named defendant, were initiated, individually, by the attorneys general of Alaska, Hawaii and Minnesota alleging violations of state consumer protection and other similar laws. JUUL is also named in other attorneys general lawsuits to which neither Altria nor any of its subsidiaries is currently named. JUUL settled one such lawsuit by agreeing to (i) pay approximately $40 million and (ii) certain restrictions on its sales and marketing activities.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IQOS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, RAI Strategic Holdings, Inc. and R.J. Reynolds Vapor Co., which are affiliates of R.J. Reynolds, filed a lawsuit against Altria, PM USA, Altria Client Services LLC, PMI and its affiliate, Philip Morris Products S.A., in the United States District Court for the Eastern District of Virginia. The lawsuit asserts claims of patent infringement based on the sale of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> electronic device and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HeatSticks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. Plaintiffs seek various remedies, including preliminary and permanent injunctive relief, treble damages and attorneys’ fees. Altria and PMI have been dismissed from the lawsuit. In June 2020, the remaining defendants filed a motion to dismiss certain of plaintiffs’ claims and also filed counterclaims against the plaintiffs for infringement of various patents owned by the remaining defendants. The case was stayed in December 2020 due to the COVID-19 pandemic; however, the stay was lifted with respect to defendants’ counterclaims in February 2021 and a trial is currently scheduled for April 2022.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in April 2020, a related action was filed against the same defendants by the same plaintiffs, as well as R.J. Reynolds, with the United States International Trade Commission (“ITC”). There, the plaintiffs also allege patent infringement, but the remedies sought include a prohibition on the importation of the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> electronic device, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HeatSticks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and component parts into the United States and on the sale of any such products previously imported into the United States. No damages are recoverable in the proceedings before the ITC. In May 2021, an administrative law judge found that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> electronic device and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HeatSticks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> infringe plaintiffs’ patents and recommended to the ITC a ban on the importation of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> electronic device, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HeatSticks </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the infringing components into the United States. In September 2021, the ITC affirmed the administrative law judge’s initial determination and issued a limited exclusion order barring the importation of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">electronic device,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HeatSticks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the infringing components into the United States and a cease and desist order barring domestic sales, marketing and distribution of these imported products. The orders will become effective on November 29, 2021 unless rejected by the Biden Administration prior to that date. Defendants may appeal the orders to the United States Court of Appeals for the Federal Circuit; however, any ban on importation or on the sale, marketing and distribution of previously imported product is unlikely to be stayed pending the conclusion of the appeal. Due to this litigation, in October 2021, PM USA announced plans to begin removing the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">electronic device and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> HeatSticks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the marketplace as it awaits the outcome of administrative review.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An additional unrelated patent infringement case regarding the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> electronic device was filed in November 2020 in the United States District Court for the Northern District of Georgia against PM USA and Philip Morris Products S.A. seeking damages and equitable relief. In February 2021, defendants filed a motion to dismiss the lawsuit, which the court granted in July 2021. In August 2021, plaintiff filed a motion to amend the complaint.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the FTC issued an administrative complaint against Altria and JUUL alleging that Altria’s 35% investment in JUUL and the associated agreements constitute an unreasonable restraint of trade in violation of Section 1 of the Sherman Antitrust Act of 1890 (“Sherman Act”) and Section 5 of the Federal Trade Commission Act of 1914, and substantially lessened competition in violation of Section 7 of the Clayton Antitrust Act (“Clayton Act”). If the FTC’s challenge is successful, the FTC may order a broad range of remedies, including divestiture of Altria’s minority investment in JUUL, rescission of the transaction and all associated agreements, a requirement of FTC approval of future agreements related to the development, manufacture, distribution or sale of e-vapor products and prohibition against any officer or director of either Altria or JUUL serving on the other party’s board of directors or attending meetings of the other party’s board of directors. The administrative trial was held before an FTC administrative law judge in June 2021. The post-trial briefing was completed in October 2021. The administrative law judge’s decision is subject to review by the FTC on its own motion or at the request of any party. The FTC then issues its ruling, which may be appealed to any United States Court of Appeals.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also as of October 25, 2021, 16 putative class action lawsuits have been filed against Altria and JUUL in the United States District Court for the Northern District of California. The lawsuits initially named, in addition to the two companies, certain senior executives and certain members of the board of directors of both companies as defendants; however, those individuals currently or formerly affiliated with Altria were later dismissed. In November 2020 these lawsuits were consolidated into three complaints (one on behalf of direct purchasers, one on behalf of indirect purchasers and one on behalf of indirect resellers). The consolidated lawsuits, as amended, cite the FTC administrative complaint and allege that Altria and JUUL violated Sections 1, 2 and/or 3 of the Sherman Act and Section 7 of the Clayton Act and various state antitrust, consumer protection and unjust enrichment laws by restraining trade and/or substantially lessening competition in the U.S. closed-system electronic cigarette market. Plaintiffs seek various remedies, including treble damages, attorneys’ fees, a declaration that the agreements between Altria and JUUL are invalid, divestiture of Altria’s minority investment in JUUL and rescission of the transaction. Altria filed a motion to dismiss these lawsuits in January 2021. In August 2021, the United States District Court for the Northern District of California denied Altria’s motion to dismiss except with respect to plaintiffs’ claims for injunctive and equitable relief. However, plaintiffs were granted the opportunity to replead such claims by the trial court, which plaintiffs did in September 2021.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Altria exercised its rights to convert its non-voting JUUL shares to voting shares. However, pending the outcome of the FTC administrative complaint, Altria currently does not intend to exercise its additional governance rights obtained upon the conversion, including the right to elect directors to JUUL’s board or to vote its JUUL shares other than as a passive investor. For further discussion of Altria’s rights in the event of share conversion, see Note 4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Equity Securities - Investment in JUUL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Class Action and Shareholder Derivative Lawsuits</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shareholder Class Action:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In October and December 2019, two purported Altria shareholders filed putative class action lawsuits against Altria, Howard A. Willard III, Altria’s former Chairman and Chief Executive Officer, and William F. Gifford, Jr., Altria’s former Vice Chairman and Chief Financial Officer and current Chief Executive Officer, in the United States District Court for the Eastern District of New York. In December 2019, the court consolidated the two lawsuits into a single proceeding. The consolidated lawsuit was subsequently transferred to the United States District Court for the Eastern District of Virginia. The lawsuit asserts claims under Sections 10(b) and 20(a) and under Rule 10b-5 of the Exchange Act. In April 2020, JUUL, its founders and some of its current and former executives were added to the lawsuit. The claims allege false and misleading statements and omissions relating to Altria’s investment in JUUL. Plaintiffs seek various remedies, including damages and attorneys’ fees. In July 2020, the defendants filed motions to dismiss plaintiffs’ claims, which the district court denied in March 2021.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal Shareholder Derivative Lawsuits: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, two purported Altria shareholders filed separate derivative lawsuits in the United States District Court for the Northern District of California on behalf of themselves and Altria, against Mr. Willard, Mr. Gifford, JUUL and certain of its executives and officers. These derivative lawsuits relate to Altria’s </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment in JUUL, and assert claims of breach of fiduciary duty by the Altria defendants and aiding and abetting in that alleged breach of fiduciary duty by the remaining defendants. In March 2021, the United States District Court for the Northern District of California granted defendants’ motion to transfer both lawsuits to the United States District Court for the Eastern District of Virginia. Three additional federal derivative lawsuits were filed in October 2020, January 2021 and March 2021, respectively, in the United States District Court for the Eastern District of Virginia against Mr. Willard, Mr. Gifford, Mr. Crosthwaite, certain members of Altria’s Board of Directors, JUUL, its founders and some of its current and former executives. These suits assert various claims, including breach of fiduciary duty, unjust enrichment, waste of corporate assets and violations of certain federal securities laws. The remedies sought in these lawsuits include damages, disgorgement of profits, reformation of Altria’s corporate governance and internal procedures, and attorneys’ fees. In April 2021, the court consolidated the five cases pending in the Eastern District of Virginia into a single action.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State Shareholder Derivative Lawsuits:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Six derivative lawsuits have been filed in Virginia state courts against Mr. Willard, Mr. Gifford, Mr. Crosthwaite (Altria’s former Chief Growth Officer and JUUL’s current Chief Executive Officer), certain members of Altria’s Board of Directors, JUUL, its founders and some of its current and former executives. The lawsuits were filed in September 2020, May 2021, June 2021, July 2021, August 2021 and August 2021, respectively. The lawsuits assert various claims, including breach of fiduciary duty, and seek remedies similar to those sought by plaintiffs in the cases pending in federal court in the Eastern District of Virginia. In July 2021 and September 2021, the court consolidated the first four of these state derivative cases into a single action.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Other Tobacco-Related Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">“Lights/Ultra Lights” Cases and Other Smoking and Health Class Actions: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs have sought certification of their cases as class actions, alleging among other things, that the uses of the terms “Lights” and/or “Ultra Lights” constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment or breach of warranty, and have sought injunctive and equitable relief, including restitution and, in certain cases, punitive damages. These class actions have been brought against PM USA and, in certain instances, Altria or its other subsidiaries, on behalf of individuals who purchased and consumed various brands of cigarettes. Defenses raised in these cases include lack of misrepresentation, lack of causation, injury and damages, the statute of limitations, non-liability under state statutory provisions exempting conduct that complies with federal regulatory directives, and the First Amendment. Twenty-one state courts in 23 “Lights” cases have refused to certify class actions, dismissed class action allegations, reversed prior class certification decisions or have entered judgment in favor of PM USA. As of October 25, 2021, two “Lights/Ultra Lights” class actions are pending in U.S. state court. Neither case is active.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 25, 2021, one smoking and health case alleging personal injury or seeking court-supervised programs or ongoing medical monitoring and purporting to be brought on behalf of a class of individual plaintiffs, is pending in a U.S. state court. The case is currently inactive.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UST Litigation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UST and/or its tobacco subsidiaries have been named in a number of individual tobacco and health lawsuits over time. Plaintiffs’ allegations of liability in these cases have been based on various theories of recovery, such as negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, breach of implied warranty, addiction and breach of consumer protection statutes. Plaintiffs have typically sought various forms of relief, including compensatory and punitive damages, and certain equitable relief, including but not limited to disgorgement. Defenses raised in these cases include lack of causation, assumption of the risk, comparative fault and/or contributory negligence, and statutes of limitations. As of October 25, 2021, there is one case pending against USSTC.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Regulation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria and its subsidiaries (and former subsidiaries) are subject to various federal, state and local laws and regulations concerning the discharge of materials into the environment, or otherwise related to environmental protection, including, in the U.S.: the Clean Air Act, the Clean Water Act, the Resource Conservation and Recovery Act and the Comprehensive Environmental Response, Compensation and Liability Act (commonly known as “Superfund”), which can impose joint and several liability on each responsible party. Subsidiaries (and former subsidiaries) of Altria are involved in several matters subjecting them to potential costs of remediation and natural resource damages under Superfund or other laws and regulations. Altria’s subsidiaries expect to continue to make capital and other expenditures in connection with environmental laws and regulations.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Altria provides for expenses associated with environmental remediation obligations on an undiscounted basis when such amounts are probable and can be reasonably estimated. Such accruals are adjusted as new information develops or circumstances change. Other than those amounts, it is not possible to reasonably estimate the cost of any environmental remediation and compliance efforts that subsidiaries of Altria may undertake in the future. In the opinion of management, however, compliance with environmental laws and regulations, including the payment of any remediation costs or damages and the making of related expenditures, has not had, and is not expected to have, a material adverse effect on Altria’s consolidated results of operations, capital expenditures, financial position or cash flows.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees and Other Similar Matters</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, certain subsidiaries of Altria have agreed to indemnify a limited number of third parties in the event of future litigation. At September 30, 2021, Altria and certain of its subsidiaries (i) had $48 million of unused letters of credit obtained in the ordinary course of business; (ii) were contingently liable for guarantees related to their own performance, including $24 million for surety bonds; and (iii) had a redeemable noncontrolling interest of $39 million recorded on its condensed consolidated balance sheet. In addition, from time to time, subsidiaries of Altria issue lines of credit to affiliated entities. These items have not had, and are not expected to have, a significant impact on Altria’s liquidity.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of a distribution agreement between Altria and PMI (the “Distribution Agreement”), entered into as a result of Altria’s 2008 spin-off of its former subsidiary PMI, liabilities concerning tobacco products will be allocated based in substantial part on the manufacturer. PMI will indemnify Altria and PM USA for liabilities related to tobacco products manufactured by PMI or contract manufactured for PMI by PM USA, and PM USA will indemnify PMI for liabilities related to tobacco products manufactured by PM USA, excluding tobacco products contract manufactured for PMI. Altria does not have a related liability recorded on its condensed consolidated balance sheet at September 30, 2021 as the fair value of this indemnification is insignificant. PMI has agreed not to seek indemnification with respect to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patent litigation discussed above under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Other Tobacco-Related Litigation - IQOS Litigation, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">excluding the patent infringement case filed with the United States District Court for the Northern District of Georgia.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PM USA has issued guarantees relating to Altria’s obligations under its outstanding debt securities, borrowings under its $3.0 billion Credit Agreement and amounts outstanding under its commercial paper program.</span></div> 47 865000000 218000000 410000000 56000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Altria’s accrued liability for tobacco and health and certain other litigation items, including related interest costs, for the periods specified below are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liability for tobacco and health and certain other litigation items at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax charges for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tobacco and health and certain other litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">99</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related interest costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liability for tobacco and health and certain other litigation items at end of period</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes amounts related to certain other litigation and pre-trial resolution of certain tobacco and health cases.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below lists the number of certain tobacco-related cases pending in the U.S. against PM USA and/or Altria as of October 25, 2021, October 27, 2020 and October 28, 2019:</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">October 25, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">October 27, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">October 28, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Smoking and Health Cases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">179</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Care Cost Recovery Actions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E-vapor Cases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,951</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Tobacco-Related Cases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes 18 cases filed in Illinois, 17 cases filed in New Mexico, 40 cases filed in Massachusetts and 70 non-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">cases filed in Florida. Does not include individual smoking and health cases brought by or on behalf of plaintiffs in Florida state and federal courts following the decertification of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Engle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">case (these </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Engle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> progeny cases are discussed below in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Smoking and Health Litigation - Engle Class Action</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">). Also does not include 1,471 cases brought by flight attendants seeking compensatory damages for personal injuries allegedly caused by exposure to environmental tobacco smoke (“ETS”). The flight attendants allege that they are members of an ETS smoking and health class action in Florida, which was settled in 1997 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Broin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">). The terms of the court-approved settlement in that case allowed class members to file individual lawsuits seeking compensatory damages, but prohibited them from seeking punitive damages. Class members were prohibited from filing individual lawsuits after 2000 under the court-approved settlement.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Health Care Cost Recovery Litigation - Federal Government’s Lawsuit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> below.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes 53 class action lawsuits, 2,548 individual lawsuits and 350 “third party” lawsuits relating to JUUL e-vapor products, which include school districts, state and local government, tribal and healthcare organization lawsuits. JUUL is an additional named defendant in each of these lawsuits. The 53 class action lawsuits include 28 cases in the Northern District of California (“Multidistrict Litigation” or “MDL”) involving plaintiffs whose claims were previously included in other class action complaints but were refiled as separate stand-alone class actions for procedural and other reasons.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes one inactive smoking and health case alleging personal injury and purporting to be brought on behalf of a class of individual plaintiffs and two inactive class action lawsuits alleging that use of the terms “Lights” and “Ultra Lights” constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment, breach of warranty or violations of RICO.</span></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Currently Pending Engle Cases with Verdicts Against PM USA </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(rounded to nearest $ million)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.488%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plaintiff</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Verdict Date</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Defendant(s)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Court</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Compensatory Damages </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Punitive Damages <br/>(PM USA)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appeal Status</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lipp</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$15 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$28 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Defendant’s post-trial motions denied. Defendant plans to appeal.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Garcia</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2021</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mistrial</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appeal by defendant to Third District Court of Appeal pending.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Duignan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pinellas</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$12 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appeal by defendants to Second District Court of Appeal pending.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Cuddihee</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Duval</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appeal by defendant to First District Court of Appeal pending. </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Rintoul </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Caprio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$9 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$74 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appeal by plaintiff and defendants to Fourth District Court of Appeal pending.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Gloger</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$15 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$11 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appeal by defendants to Third District Court of Appeal pending.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">McCall</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&lt;$1 million (&lt;$1 million PM USA)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New trial ordered on punitive damages.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Neff</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2019</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$4 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fourth District Court of Appeal reversed the judgment against defendants and remanded for a new trial. Plaintiff's motion for rehearing was denied.</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.488%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plaintiff</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Verdict Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Defendant(s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Court</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Compensatory Damages </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Punitive Damages <br/>(PM USA)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appeal Status</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Mahfuz</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$12 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$10 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fourth District Court of Appeal reversed the judgment against defendants and remanded for a new trial. Plaintiff's motion for rehearing was denied.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Holliman</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Defendant’s appeal to Third District Court of Appeal pending.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Chadwell</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2018</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third District Court of Appeal affirmed the compensatory damages award. PM USA petitioned Florida Supreme Court for review. Case stayed pending Florida Supreme Court decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Prentice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Kaplan</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Fourth District Court of Appeal affirmed the verdict and reaffirmed the verdict on rehearing. Defendants sought review of the decision before the Florida Supreme Court and the court stayed the case pending its decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Sheffield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">R. Douglas</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2017</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Duval</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&lt;$1 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Awaiting entry of final judgment by the trial court.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Sommers</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2017</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miami-Dade</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third District Court of Appeal affirmed compensatory damages award and granted new trial on punitive damages. Florida Supreme Court denied PM USA’s petition for review of the Third District Court of Appeal’s decision. PM USA paid approximately $1 million for the compensatory damages award and awaits the new trial on punitive damages.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> The trial court stayed the new trial on punitive damages pending Florida Supreme Court’s decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Sheffield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Cooper (Blackwood)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA and R.J. Reynolds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5 million </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(&lt;$1 million PM USA)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fourth District Court of Appeal affirmed judgment and granted a new trial on punitive damages.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">D. Brown</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2015</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal Court - Middle District of Florida</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$8 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$9 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appeal by defendant to U.S. Court of Appeals for the Eleventh Circuit stayed pending Florida Supreme Court decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Prentice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PM USA’s portion of the compensatory damages award is noted parenthetically where the court has ruled that comparative fault applies. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Plaintiff’s verdict following a retrial of an initial verdict in favor of plaintiff.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> PM USA is not a defendant in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Prentice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Sheffield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Prentice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Sheffield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">are discussed below in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Engle Progeny Appellate Issues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Plaintiff was granted an award of approximately $3 million in fees, costs and interest that PM USA appealed. The Florida Third District Court of Appeals affirmed the award and PM USA paid the award amount in March 2021.</span></div><div style="margin-bottom:3pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engle Cases Concluded Within Past 12 Months </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(rounded to nearest $ million)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:14.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.346%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plaintiff</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Verdict Date</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Defendant(s)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Court</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accrual Date</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payment Amount<br/>(if any)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payment Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Berger (Cote)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2014</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal Court - Middle District of Florida</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fourth quarter of 2018 and first quarter of 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$29 million</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Santoro</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2017</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM USA, R.J. Reynolds and Liggett Group</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Broward</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second quarter of 2020 and first quarter of 2021</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1 million</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2021</span></td></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In six cases in which PM USA paid the judgments more than a year ago, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Naugle,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gore</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">M. Brown,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Jordan,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Theis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Landi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, plaintiffs were awarded approximately $8 million, $2 million, $8 million, $4 million, $1 million and $3 million in fees and costs, respectively. PM USA has appealed in all of these cases, except </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Theis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Landi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. In</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> M. Brown</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, in March 2021 the Florida First District Court of Appeals affirmed the fee award and reversed the pre-judgment interest award and, in April 2021, PM USA paid $8.2 million in satisfaction of the fee award and post-judgment interest. In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Theis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, PM USA paid $1 million in satisfaction of fees and costs in May 2021 and, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Landi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, PM USA paid approximately $1.5 million in satisfaction of fees, costs and interest in July 2021 (R.J. Reynolds paid approximately $1.5 million of the approximately $3 million award).</span></div> 9000000 14000000 0 22000000 142000000 73000000 99000000 34000000 6000000 3000000 6000000 0 60000000 81000000 8000000 47000000 97000000 9000000 97000000 9000000 45000000 179 142 95 1 1 1 2951 1145 0 3 4 4 18 17 40 70 1471 53 2548 350 53 28 1 2 3 10 8 7 0 69 44 69 44 1 7 1 10 1 4 1 4 1 1 5 2 1 1 2 2 25 20 2 11000000 0 10000000 30000000 2300000 11000000 10000000 21000000 27100000 7100000 0.75 145000000000 74000000000 P1Y P1Y 9300 1026 1285 2 137 76 7 54 44 4 2 0 2 0 1 3 3 2 0 15000000 28000000 3000000 3000000 12000000 3000000 0 9000000 74000000 15000000 11000000 1000000 1000000 0 4000000 2000000 12000000 10000000 3000000 0 2000000 0 2000000 2000000 1000000 0 1000000 0 1000000 5000000 1000000 0 8000000 9000000 3000000 29000000 29000000 1000000 1000000 6 8000000 2000000 8000000 4000000 1000000 3000000 8200000 1000000 1500000 1500000 3000000 200000000 61 1 1 1 2 2 3 1 1 1 1 1 1 29 6 2 1 1 1 1 1 1 1 1 7 2 3 0 2 13000000000 10 3 46 9400000000 500000000 1100000000 1200000000 3200000000 3300000000 388000000 181000000 154000000 185000000 250000000 211000000 218000000 166000000 214000000 224000000 258000000 313000000 292000000 302000000 325000000 444000000 572000000 36 35 36 1 1030000000.00 320000000 373000000 4000000 10 9 10 2 7 21000000 23000000 10 9 10 1 32000000 P10Y 36000000 36000000 36000000 36000000 53 53 28 2548 350 20 4 3 1 40000000 0 0.35 16 3 2 2 2 3 5 6 4 23 2 1 1 Altria and its subsidiaries (and former subsidiaries) are subject to various federal, state and local laws and regulations concerning the discharge of materials into the environment, or otherwise related to environmental protection, including, in the U.S.: the Clean Air Act, the Clean Water Act, the Resource Conservation and Recovery Act and the Comprehensive Environmental Response, Compensation and Liability Act (commonly known as “Superfund”), which can impose joint and several liability on each responsible party. Subsidiaries (and former subsidiaries) of Altria are involved in several matters subjecting them to potential costs of remediation and natural resource damages under Superfund or other laws and regulations. Altria’s subsidiaries expect to continue to make capital and other expenditures in connection with environmental laws and regulations.Altria provides for expenses associated with environmental remediation obligations on an undiscounted basis when such amounts are probable and can be reasonably estimated. Such accruals are adjusted as new information develops or circumstances change. 48000000 24000000 39000000 3000000000 New Accounting Guidance Not Yet Adopted<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a description of issued accounting guidance applicable to, but not yet adopted by, Altria:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:16.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standards</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective Date for Public Entity</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect on Financial Statements </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU 2020-06 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accounting for Convertible Instruments and Contracts in an Entity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">s Own Equity</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity.  Key provisions of the guidance include reducing the number of accounting models, simplifying the earnings per share calculations and expanding the disclosures related to convertible instruments.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Altria’s adoption of this guidance is not expected to have a material impact on its consolidated financial statements and related disclosures. </span></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a description of issued accounting guidance applicable to, but not yet adopted by, Altria:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:16.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standards</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective Date for Public Entity</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect on Financial Statements </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU 2020-06 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accounting for Convertible Instruments and Contracts in an Entity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">s Own Equity</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity.  Key provisions of the guidance include reducing the number of accounting models, simplifying the earnings per share calculations and expanding the disclosures related to convertible instruments.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Altria’s adoption of this guidance is not expected to have a material impact on its consolidated financial statements and related disclosures. </span></td></tr></table></div> Amounts attributable to noncontrolling interests for the nine months ended September 30, 2021 and 2020 exclude net earnings of $4 million and $2 million, respectively, due to the redeemable noncontrolling interest related to Stag’s Leap Wine Cellars, which is reported in the mezzanine equity section on the condensed consolidated balance sheets. Represents the purchase of the remaining noncontrolling interests in Helix. For additional information, see Note 1. Background and Basis of Presentation. 2020 primarily reflects inventory-related amounts associated with the wine business strategic reset. For further discussion, see Note 9. Segment Reporting. Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 12. Contingencies. Amounts attributable to noncontrolling interests for the three months ended September 30, 2021 and 2020 exclude net earnings of $2 million and $1 million, respectively, due to the redeemable noncontrolling interest related to Stag’s Leap Wine Cellars, which is reported in the mezzanine equity section on the condensed consolidated balance sheets. Cash included in assets held for sale at September 30, 2021 is related to the Ste. Michelle Transaction. For further discussion, see Note 3. Assets Held for Sale. XML 14 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover Page - shares
 9 Months Ended
Sep. 30, 2021
Oct. 21, 2021
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2021  
Document Transition Report false  
Entity File Number 1-08940  
Entity Registrant Name Altria Group, Inc.  
Entity Incorporation, State or Country Code VA  
Entity Tax Identification Number 13-3260245  
Entity Address, Address Line One 6601 West Broad Street,  
Entity Address, City or Town Richmond,  
Entity Address, State or Province VA  
Entity Address, Postal Zip Code 23230  
City Area Code 804  
Local Phone Number 274-2200  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   1,836,988,822
Amendment Flag false  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0000764180  
Current Fiscal Year End Date --12-31  
Common Stock, $0.33 1/3 par value [Member]    
Entity Information [Line Items]    
Title of 12(b) Security Common Stock, $0.33 1/3 par value  
Trading Symbol MO  
Security Exchange Name NYSE  
1.000% Notes due 2023 [Member]    
Entity Information [Line Items]    
Title of 12(b) Security 1.000% Notes due 2023  
Trading Symbol MO23A  
Security Exchange Name NYSE  
1.700% Notes due 2025 [Member]    
Entity Information [Line Items]    
Title of 12(b) Security 1.700% Notes due 2025  
Trading Symbol MO25  
Security Exchange Name NYSE  
2.200% Notes due 2027 [Member]    
Entity Information [Line Items]    
Title of 12(b) Security 2.200% Notes due 2027  
Trading Symbol MO27  
Security Exchange Name NYSE  
3.125% Notes due 2031 [Member]    
Entity Information [Line Items]    
Title of 12(b) Security 3.125% Notes due 2031  
Trading Symbol MO31  
Security Exchange Name NYSE  
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Assets    
Cash and cash equivalents $ 2,957 $ 4,945
Receivables 36 137
Inventories:    
Leaf tobacco 644 844
Other raw materials 159 200
Work in process 30 502
Finished product 300 420
Inventory, net 1,133 1,966
Assets held for sale 1,490 0
Other current assets 404 69
Total current assets 6,020 7,117
Property, plant and equipment, at cost 4,418 5,150
Less accumulated depreciation 2,900 3,138
Property, plant and equipment, net 1,518 2,012
Goodwill 5,177 5,177
Other intangible assets, net 12,326 12,615
Investments in equity securities ($1,740 million and $1,868 million at September 30, 2021 and December 31, 2020, respectively, measured at fair value) 13,874 19,529
Other assets 649 964
Total Assets 39,564 47,414
Liabilities    
Current portion of long-term debt 1,105 1,500
Accounts payable 266 380
Accrued liabilities:    
Marketing 680 523
Settlement charges 2,996 3,564
Other 1,109 1,494
Dividends payable 1,661 1,602
Liabilities held for sale 295 0
Total current liabilities 8,112 9,063
Long-term debt 27,022 27,971
Deferred income taxes 3,557 4,532
Accrued pension costs 280 551
Accrued postretirement health care costs 1,512 1,951
Other liabilities 307 381
Total liabilities 40,790 44,449
Contingencies (Note 12)
Redeemable noncontrolling interest 39 40
Stockholders’ (Deficit) Equity    
Common stock, par value $0.33 1/3 per share (2,805,961,317 shares issued) 935 935
Additional paid-in capital 5,846 5,910
Earnings reinvested in the business 30,685 34,679
Accumulated other comprehensive losses (3,430) (4,341)
Cost of repurchased stock (967,321,022 shares at September 30, 2021 and 947,542,152 shares at December 31, 2020) (35,303) (34,344)
Total stockholders’ (deficit) equity attributable to Altria (1,267) 2,839
Noncontrolling interests 2 86
Total stockholders’ (deficit) equity (1,265) 2,925
Total Liabilities and Stockholders’ (Deficit) Equity $ 39,564 $ 47,414
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Stockholders’ (Deficit) Equity    
Investments, fair value disclosure $ 1,740 $ 1,868
Common stock, par value (usd per share) $ 0.3333 $ 0.3333
Common stock, shares issued (in shares) 2,805,961,317 2,805,961,317
Shares repurchased (in shares) 967,321,022 947,542,152
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Earnings (Losses) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]        
Net revenues $ 6,786 $ 7,123 $ 19,758 $ 19,849
Cost of sales 1,858 1,961 5,348 5,909
Excise taxes on products 1,255 1,445 3,733 4,063
Gross profit 3,673 3,717 10,677 9,877
Marketing, administration and research costs 722 557 1,850 1,585
Operating income 2,951 3,160 8,827 8,292
Interest and other debt expense, net 266 310 869 893
Loss on early extinguishment of debt 0 0 649 0
Net periodic benefit income, excluding service cost (63) (3) (152) (58)
(Income) losses from equity investments 5,915 472 5,789 306
Impairment of JUUL equity securities 0 2,600 0 2,600
(Gain) loss on Cronos-related financial instruments 135 105 128 202
Earnings (losses) before income taxes (3,302) (324) 1,544 4,349
Provision (benefit) for income taxes (582) 632 693 1,817
Net earnings (losses) (2,720) (956) 851 2,532
Net (earnings) losses attributable to noncontrolling interests (2) 4 0 11
Net earnings (losses) attributable to Altria $ (2,722) $ (952) $ 851 $ 2,543
Per share data:        
Basic earnings (losses) per share attributable to Altria (in usd per share) $ (1.48) $ (0.51) $ 0.46 $ 1.37
Diluted earnings (losses) per share attributable to Altria (in usd per share) $ (1.48) $ (0.51) $ 0.46 $ 1.36
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Comprehensive Earnings (Losses) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Statement of Comprehensive Income [Abstract]        
Net earnings (losses) $ (2,720) $ (956) $ 851 $ 2,532
Other comprehensive earnings (losses), net of deferred income taxes:        
Benefit plans 6 (15) 383 27
ABI 161 (15) 495 (928)
Currency translation adjustments and other 5 23 33 (16)
Other comprehensive earnings (losses), net of deferred income taxes 172 (7) 911 (917)
Comprehensive earnings (losses) (2,548) (963) 1,762 1,615
Comprehensive (earnings) losses attributable to noncontrolling interests (2) 4 0 11
Comprehensive earnings (losses) attributable to Altria $ (2,550) $ (959) $ 1,762 $ 1,626
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Stockholders' (Deficit) Equity - USD ($)
$ in Millions
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Earnings Reinvested in the Business [Member]
Accumulated Other Comprehensive Losses [Member]
Cost of Repurchased Stock [Member]
Non-controlling Interests [Member]
Beginning balance at Dec. 31, 2019 $ 6,319 $ 935 $ 5,970 $ 36,539 $ (2,864) $ (34,358) $ 97
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net earnings (losses) [1] 2,530     2,543     (13)
Other comprehensive earnings (losses), net of deferred income taxes (917)       (917)    
Stock award activity 17   3     14  
Cash dividends declared (4,726)     (4,726)      
Other 9           9
Ending balance at Sep. 30, 2020 3,232 935 5,973 34,356 (3,781) (34,344) 93
Beginning balance at Jun. 30, 2020 5,786 935 5,964 36,908 (3,774) (34,345) 98
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net earnings (losses) [2] (957)     (952)     (5)
Other comprehensive earnings (losses), net of deferred income taxes (7)       (7)    
Stock award activity 10   9     1  
Cash dividends declared (1,600)     (1,600)      
Ending balance at Sep. 30, 2020 3,232 935 5,973 34,356 (3,781) (34,344) 93
Beginning balance at Dec. 31, 2020 2,925 935 5,910 34,679 (4,341) (34,344) 86
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net earnings (losses) [1] 847     851     (4)
Other comprehensive earnings (losses), net of deferred income taxes 911       911    
Stock award activity 26   13     13  
Cash dividends declared (4,845)     (4,845)      
Repurchases of common stock (972)         (972)  
Other [3] (157)   (77)       (80)
Ending balance at Sep. 30, 2021 (1,265) 935 5,846 30,685 (3,430) (35,303) 2
Beginning balance at Jun. 30, 2021 3,259 935 5,840 35,065 (3,602) (34,981) 2
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net earnings (losses) [2] (2,722)     (2,722)     0
Other comprehensive earnings (losses), net of deferred income taxes 172       172    
Stock award activity 6   6     0  
Cash dividends declared (1,658)     (1,658)      
Repurchases of common stock (322)         (322)  
Ending balance at Sep. 30, 2021 $ (1,265) $ 935 $ 5,846 $ 30,685 $ (3,430) $ (35,303) $ 2
[1] Amounts attributable to noncontrolling interests for the nine months ended September 30, 2021 and 2020 exclude net earnings of $4 million and $2 million, respectively, due to the redeemable noncontrolling interest related to Stag’s Leap Wine Cellars, which is reported in the mezzanine equity section on the condensed consolidated balance sheets.
[2] Amounts attributable to noncontrolling interests for the three months ended September 30, 2021 and 2020 exclude net earnings of $2 million and $1 million, respectively, due to the redeemable noncontrolling interest related to Stag’s Leap Wine Cellars, which is reported in the mezzanine equity section on the condensed consolidated balance sheets.
[3] Represents the purchase of the remaining noncontrolling interests in Helix. For additional information, see Note 1. Background and Basis of Presentation.
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Statement of Stockholders' Equity [Abstract]        
Dividends declared (usd per share) $ 0.90 $ 0.86 $ 2.62 $ 2.54
Net earnings attributable to noncontrolling interests $ 2 $ 1 $ 4 $ 2
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Cash Provided by (Used in) Operating Activities      
Net earnings (losses) $ (2,720) $ 851 $ 2,532
Adjustments to reconcile net earnings (losses) to operating cash flows:      
Depreciation and amortization   190 192
Deferred income tax provision (benefit)   (1,180) (111)
(Income) losses from equity investments 5,915 5,789 306
Dividends from ABI   119 108
(Gain) loss on Cronos-related financial instruments 135 128 202
Impairment of JUUL equity securities 0 0 2,600
Loss on early extinguishment of debt 0 649 0
Cash effects of changes:      
Receivables   (7) 1
Inventories   118 136
Accounts payable   3 24
Income taxes   (200) 0
Accrued liabilities and other current assets   (104) (504)
Accrued settlement charges   (568) (140)
Pension plan contributions   (23) (16)
Pension provisions and postretirement, net   (127) (35)
Other, net   104 [1] 549 [1]
Net cash provided by (used in) operating activities   5,742 5,844
Cash Provided by (Used in) Investing Activities      
Capital expenditures   (102) (162)
Other, net   60 55
Net cash provided by (used in) investing activities   (42) (107)
Cash Provided by (Used in) Financing Activities      
Proceeds from short-term borrowings   0 3,000
Repayment of short-term borrowings   0 (3,000)
Long-term debt issued   5,472 1,993
Long-term debt repaid   (6,542) (1,000)
Repurchases of common stock   (972) 0
Dividends paid on common stock   (4,787) (4,690)
Premiums and fees related to early extinguishment of debt   (623) 0
Other, net   (216) (16)
Net cash provided by (used in) financing activities   (7,668) (3,713)
Cash, cash equivalents and restricted cash:      
Increase (decrease)   (1,968) 2,024
Balance at beginning of period   5,006 2,160
Balance at end of period 3,038 3,038 4,184
Cash and cash equivalents 2,957 2,957  
Restricted cash included in other current assets 0 [2] 0 [2]  
Restricted cash included in other assets 45 [2] 45 [2]  
Restricted cash included in assets held for sale 36 [3] 36 [3]  
Cash, cash equivalents and restricted cash $ 3,038 $ 3,038 $ 4,184
[1] 2020 primarily reflects inventory-related amounts associated with the wine business strategic reset. For further discussion, see Note 9. Segment Reporting.
[2] Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 12. Contingencies.
[3] Cash included in assets held for sale at September 30, 2021 is related to the Ste. Michelle Transaction. For further discussion, see Note 3. Assets Held for Sale.
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Background and Basis of Presentation
 9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Background and Basis of Presentation Background and Basis of Presentation
When used in these notes, the term “Altria,” refers to Altria Group, Inc. and its subsidiaries, unless the context requires otherwise.
▪Background: At September 30, 2021, Altria’s wholly owned subsidiaries included Philip Morris USA Inc. (“PM USA”), which is engaged in the manufacture and sale of cigarettes in the United States; John Middleton Co. (“Middleton”), which is engaged in the manufacture and sale of machine-made large cigars and pipe tobacco and is a wholly owned subsidiary of PM USA; UST LLC (“UST”), which through its wholly owned subsidiaries, including U.S. Smokeless Tobacco Company LLC (“USSTC”) and Ste. Michelle Wine Estates Ltd. (“Ste. Michelle”), is engaged in the manufacture and sale of moist smokeless tobacco products (“MST”), snus products and wine; Helix Innovations LLC (“Helix”), which operates in the United States and Canada, and Helix Innovations GmbH and its subsidiaries (“Helix ROW”), which operate internationally in the rest-of-world, are engaged in the manufacture and sale of on! oral nicotine pouches; and Philip Morris Capital Corporation (“PMCC”), which maintains a portfolio of finance assets, substantially all of which are leveraged leases.
On July 8, 2021, UST entered into a share purchase agreement pursuant to which it agreed to sell its subsidiary, International Wine & Spirits Ltd. (“IWS”), which includes Ste. Michelle. The sale was completed on October 1, 2021. At September 30, 2021, the assets and liabilities associated with the pending sale of IWS were classified as assets held for sale on Altria’s condensed consolidated balance sheet. For further discussion, see Note 3. Assets Held for Sale.
Altria owns 100% of the global on! business as a result of transactions in December 2020 and April 2021 to purchase the remaining 20% interest in (i) Helix ROW and (ii) Helix, respectively. The total purchase price of the December 2020 and April 2021 transactions was approximately $250 million.
Other Altria wholly owned subsidiaries included Altria Group Distribution Company, which provides sales and distribution services to certain Altria operating subsidiaries, and Altria Client Services LLC, which provides various support services in areas such as legal, regulatory, consumer engagement, finance, human resources and external affairs to Altria and its subsidiaries. Altria’s access to the operating cash flows of its wholly owned subsidiaries consists of cash received from the payment of dividends and distributions, and the payment of interest on intercompany loans by its subsidiaries. At September 30, 2021, Altria’s significant wholly owned subsidiaries were not limited by contractual obligations in their ability to pay cash dividends or make other distributions with respect to their equity interests.
At September 30, 2021, Altria’s investments in equity securities consisted of Anheuser-Busch InBev SA/NV (“ABI”), Cronos Group Inc. (“Cronos”) and JUUL Labs, Inc. (“JUUL”). Altria accounts for its investments in ABI and Cronos under the equity method of accounting using a one-quarter lag. Altria accounts for its equity investment in JUUL under the fair value option.
For further discussion of Altria’s investments in equity securities, see Note 4. Investments in Equity Securities.
▪Dividends and Share Repurchases: In August 2021, Altria’s Board of Directors (the “Board of Directors” or “Board”) approved a 4.7% increase in the quarterly dividend rate to $0.90 per share of Altria common stock versus the previous rate of $0.86 per share. The current annualized dividend rate is $3.60. Future dividend payments remain subject to the discretion of the Board.
In July 2019, the Board of Directors authorized a $1.0 billion share repurchase program. In April 2020, the Board rescinded the $500 million remaining in this program as part of Altria’s efforts to enhance its liquidity position in response to the COVID-19 pandemic. Altria did not repurchase any shares in 2020.
In January 2021, the Board authorized a new $2.0 billion share repurchase program, of which $1,028 million was remaining at September 30, 2021. In October 2021, the Board authorized a $1.5 billion expansion of this program to $3.5 billion. The timing of share repurchases under this program depends upon marketplace conditions and other factors, and the program remains subject to the discretion of the Board.
Altria’s share repurchase activity for the nine and three months ended September 30, 2021 was as follows:
(in millions, except per share data)For the Nine Months Ended September 30, 2021For the Three Months Ended September 30, 2021
Total number of shares repurchased
20.2 6.7 
Aggregate cost of shares repurchased
$972 $322 
Average price per share of shares repurchased
$48.17 $48.35 
▪Basis of Presentation: The interim condensed consolidated financial statements of Altria are unaudited. It is the opinion of Altria’s management that all adjustments necessary for a fair statement of the interim results presented have been reflected in the interim condensed consolidated financial statements. All such adjustments were of a normal recurring nature. Net revenues and net earnings for any interim period are not necessarily indicative of results that may be expected for the entire year.
Certain immaterial prior year amounts have been reclassified to conform with the current year’s presentation.
These statements should be read in conjunction with Altria’s audited consolidated financial statements and related notes, which appear in Altria’s Annual Report on Form 10-K for the year ended December 31, 2020 (the “2020 Form 10-K”).
On January 1, 2021, Altria adopted Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU No. 2019-12”). This guidance removes certain exceptions for investments, intraperiod allocations and interim calculations, and adds guidance to reduce complexity in accounting for income taxes. The adoption of ASU No. 2019-12 did not have a material impact on Altria’s condensed consolidated financial statements.
Additionally, on January 1, 2021, Altria adopted ASU No. 2020-01, Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (“ASU No. 2020-01”). This guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The adoption of ASU No. 2020-01 did not have a material impact on Altria’s condensed consolidated financial statements.
For a description of issued accounting guidance applicable to, but not yet adopted by, Altria, see Note 13. New Accounting Guidance Not Yet Adopted.
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Revenues from Contracts with Customers
 9 Months Ended
Sep. 30, 2021
Revenue from Contract with Customer [Abstract]  
Revenues from Contracts with Customers Revenues from Contracts with Customers
Altria disaggregates net revenues based on product type. For further discussion, see Note 9. Segment Reporting.
In 2020, a majority of Altria’s businesses offered cash discounts to customers for prompt payment and calculated cash discounts as a percentage of the list price based on historical experience and agreed-upon payment terms. Beginning in the first quarter of 2021 for USSTC and the third quarter of 2021 for PM USA, cash discounts were calculated as a flat rate per unit, based on agreed-upon payment terms. Altria’s businesses record receivables net of the cash discounts on Altria’s condensed consolidated balance sheets.
Altria’s businesses that receive payments in advance of product shipment record such payments as deferred revenue. These payments are included in other accrued liabilities on Altria’s condensed consolidated balance sheets until control of such products is obtained by the customer. Deferred revenue was $260 million and $301 million at September 30, 2021 and December 31, 2020, respectively. When cash is received in advance of product shipment, Altria’s businesses satisfy their performance obligations within three days of receiving payment. At September 30, 2021 and December 31, 2020, there were no differences between amounts recorded as deferred revenue and amounts subsequently recognized as revenue.
Receivables were $144 million (including $108 million in assets held for sale) and $137 million at September 30, 2021 and December 31, 2020, respectively. At September 30, 2021 and December 31, 2020, there were no expected differences between amounts recorded and subsequently received, and Altria’s businesses did not record an allowance for doubtful accounts against these receivables.
Altria’s businesses record an allowance for returned goods, which is included in other accrued liabilities on Altria’s condensed consolidated balance sheets. While all of Altria’s tobacco operating companies sell tobacco products with dates relative to freshness as printed on product packaging, it is USSTC’s policy to accept authorized sales returns from its customers for products that have passed such dates due to the limited shelf life of USSTC’s MST and snus products. Altria’s businesses record estimated sales returns, which are based principally on historical volume and return rates, as a reduction to revenues. Actual sales returns will differ from estimated sales returns to the extent actual results differ from estimated assumptions. Altria’s businesses reflect differences between actual and estimated sales returns in the period in which the actual amounts become known. These differences, if any, have not had a material impact on Altria’s condensed consolidated financial statements. All returned goods are destroyed upon return and not included in inventory. Consequently, Altria’s businesses do not record an asset for their right to recover goods from customers upon return.
Sales incentives include variable payments related to goods sold by Altria’s businesses. Altria’s businesses include estimates of variable consideration as a reduction to revenues upon shipment of goods to customers. The sales incentives that require significant estimates and judgments are as follows:
Price promotion payments- Altria’s businesses make price promotion payments, substantially all of which are made to their retail partners, to incent the promotion of certain product offerings in select geographic areas.
Wholesale and retail participation payments- Altria’s businesses make payments to their wholesale and retail partners to incent merchandising and sharing of sales data in accordance with each business’s trade agreements.
These estimates primarily include estimated wholesale to retail sales volume and historical acceptance rates. Actual payments will differ from estimated payments to the extent actual results differ from estimated assumptions. Differences between actual and estimated payments are reflected in the period such information becomes available. These differences, if any, have not had a material impact on Altria’s condensed consolidated financial statements.
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Assets Held for Sale
 9 Months Ended
Sep. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]  
Assets Held for Sale Assets Held for Sale
On July 8, 2021, UST entered into a share purchase agreement pursuant to which it agreed to sell its subsidiary, IWS, which includes Ste. Michelle, to an entity controlled by investment funds managed by Sycamore Partners Management, L.P. in an all-cash transaction with a purchase price of approximately $1.2 billion and the assumption of certain liabilities of IWS and its subsidiaries (the “Ste. Michelle Transaction”).
At September 30, 2021, the assets and liabilities associated with the Ste. Michelle Transaction were classified as assets held for sale and were measured at their fair value less costs to sell, resulting in a pre-tax charge of $41 million. A reserve (as shown below), representing the adjustment to record the assets and liabilities at their fair value less costs to sell, was included as a component of assets held for sale in Altria’s condensed consolidated balance sheets at September 30, 2021. Altria recorded an additional pre-tax charge of $10 million for disposition-related costs related to the Ste. Michelle Transaction. The total pre-tax charges of $51 million were included in the wine segment and recorded in marketing, administration and research costs in Altria’s condensed consolidated statements of earnings (losses) for the nine and three months ended September 30, 2021.
On October 1, 2021, UST completed the sale of IWS and received approximately $1.2 billion in net cash proceeds. Altria expects to record additional adjustments related to the Ste. Michelle Transaction in the fourth quarter of 2021 and does not expect these adjustments to be material.
The major classes of assets and liabilities of IWS classified as held for sale at September 30, 2021 were as follows:
(in millions)September 30, 2021
Assets held for sale
Cash and cash equivalents$36 
Receivables108 
Inventories715 
Property, plant and equipment, net of accumulated depreciation407 
Other intangible assets, net236 
Other assets29 
Total assets1,531 
Reserve(41)
Total assets held for sale1,490 
Liabilities held for sale
Accounts payable114 
Accrued liabilities83 
Accrued pension costs49 
Other liabilities49 
Total liabilities held for sale295 
Assets and liabilities held for sale, net$1,195 
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Investments in Equity Securities
 9 Months Ended
Sep. 30, 2021
Investments [Abstract]  
Investments in Equity Securities Investments in Equity Securities
The carrying amount of Altria’s investments consisted of the following:
(in millions)September 30, 2021December 31, 2020
ABI$11,237 $16,651 
JUUL
1,705 1,705 
Cronos (1)
932 1,173 
Total
$13,874 $19,529 
(1) Atria’s investment in Cronos at September 30, 2021 consisted of Altria’s equity method investment in Cronos ($897 million), the Cronos warrant ($32 million) and the Fixed-price Preemptive Rights ($3 million), (collectively, “Investment in Cronos”). The Investment in Cronos at December 31, 2020 consisted of Altria’s equity method investment in Cronos ($1,010 million), the Cronos warrant ($139 million) and the Fixed-price Preemptive Rights ($24 million). See below for further discussion.
Income (losses) from equity investments accounted for under the equity method of accounting and fair value option consisted of the following:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
ABI (1)
$(5,644)$(306)$(6,036)$(418)
Cronos(145)— 21 (54)
Income (losses) from investments under equity method of accounting(5,789)(306)$(6,015)$(472)
JUUL— — 100 — 
Income (losses) from equity investments$(5,789)$(306)$(5,915)$(472)
(1) For the nine and three months ended September 30, 2021, Altria recorded a non-cash, pre-tax impairment charge of $6,157 million related to its equity investment in ABI. See below for further discussion.
Investment in ABI
At September 30, 2021, Altria had an approximate 10% ownership interest in ABI, consisting of 185 million restricted shares of ABI (the “Restricted Shares”) and 12 million ordinary shares of ABI. The Restricted Shares:
▪are unlisted and not admitted to trading on any stock exchange;
▪are convertible by Altria into ordinary shares of ABI on a one-for-one basis;
▪rank equally with ordinary shares of ABI with regards to dividends and voting rights; and
▪have director nomination rights with respect to ABI.
The Restricted Shares were subject to a five-year lock-up period that ended October 10, 2021. As of this filing, Altria has not elected to convert its Restricted Shares into ordinary shares of ABI.
Altria accounts for its investment in ABI under the equity method of accounting because Altria has the ability to exercise significant influence over the operating and financial policies of ABI, including having active representation on ABI’s board of directors and certain ABI board committees. Through this representation, Altria participates in ABI policy making processes.
Altria reports its share of ABI’s results using a one-quarter lag because ABI’s results are not available in time for Altria to record them in the concurrent period.
The fair value of Altria’s equity investment in ABI is based on (i) unadjusted quoted prices in active markets for ABI’s ordinary shares and was classified in Level 1 of the fair value hierarchy and (ii) observable inputs other than Level 1 prices, such as quoted prices for similar assets for the Restricted Shares, and was classified in Level 2 of the fair value hierarchy. Altria can convert its Restricted Shares to ordinary shares at its discretion. Therefore, the fair value of each Restricted Share is based on the value of an ordinary share.
In October 2019, the fair value of Altria’s equity investment in ABI declined below its carrying value and has not recovered. At December 31, 2020, the fair value of Altria’s equity investment in ABI was $13.8 billion (carrying value of $16.7 billion), which was less than its carrying value by approximately 17%. In preparing its financial statements for the period ended December 31, 2020, Altria evaluated the factors related to the fair value decline, including the impact on the fair value of ABI’s shares during the COVID-19 pandemic, which has negatively impacted ABI’s business. Altria evaluated the duration and magnitude of the fair value decline, ABI’s financial condition and near-term prospects and Altria’s intent and ability to hold its
investment in ABI until recovery. Altria concluded that the decline in fair value of its investment in ABI at December 31, 2020 below its carrying value was temporary and, therefore, no impairment was recorded at that time.
Following the consideration of the same factors, Altria, in preparing its financial statements for the period ended September 30, 2021, concluded that the decline in fair value of its investment in ABI at September 30, 2021 was other than temporary. As a result, Altria recorded a non-cash, pre-tax impairment charge of $6.2 billion for the nine and three months ended September 30, 2021, which was recorded to income (losses) from equity investments in its condensed consolidated statements of earnings (losses). This impairment charge reflects the difference between the fair value of Altria’s investment in ABI using ABI’s share price at September 30, 2021 and the carrying value of Altria’s equity investment in ABI at September 30, 2021. Altria continues to have confidence in ABI’s (i) long-term strategies, (ii) premium global brands, (iii) experienced management team and (iv) capability to successfully navigate its near-term challenges. Altria further expects that the impacts related to the COVID-19 pandemic that have negatively impacted ABI’s global business are transitory, but now also anticipates that the full recovery to carrying value will take longer than previously expected. This is evidenced by the resumption of declines in fair value during the third quarter of 2021, following positive share price momentum during the first half of 2021. At September 30, 2021, prior to recording the impairment charge, the fair value of Altria’s investment in ABI was below the carrying value by approximately 35%, which represents an additional 18% reduction in ABI’s share price since December 31, 2020. After recording the impairment charge, the fair value and carrying value of Altria’s equity investment in ABI at September 30, 2021 were $11.2 billion.
At September 30, 2021, the carrying value of Altria’s equity investment in ABI exceeded its share of ABI’s net assets attributable to equity holders of ABI by approximately $5.1 billion. Substantially all of this difference is comprised of goodwill and other indefinite-lived intangible assets (consisting primarily of trademarks).
Investment in JUUL
In December 2018, Altria made an investment in JUUL and received a 35% economic interest in JUUL through non-voting shares, which were convertible at Altria’s election into voting shares (“Share Conversion”), and a security convertible into additional non-voting or voting shares, as applicable, upon settlement or exercise of certain JUUL convertible securities (the “JUUL Transaction”).
Altria received a broad preemptive right to purchase JUUL shares, exercisable each quarter upon dilution, to maintain its ownership percentage and is subject to a standstill restriction under which it may not acquire additional JUUL shares above its 35% interest. Furthermore, Altria agreed not to sell or transfer any of its JUUL shares until December 20, 2024.
On April 1, 2020, the U.S. Federal Trade Commission (“FTC”) issued an administrative complaint challenging Altria’s investment in JUUL. For further discussion, see Note 12. Contingencies - Antitrust Litigation.
In November 2020, Altria exercised its rights to convert its non-voting JUUL shares into voting shares. Altria does not currently intend to exercise its additional governance rights obtained upon Share Conversion, including the right to elect directors to JUUL’s board or to vote its JUUL shares other than as a passive investor, pending the outcome of the FTC administrative complaint. At September 30, 2021, Altria had a 35% ownership interest in JUUL, consisting of 42 million voting shares.
Following Share Conversion in the fourth quarter of 2020, Altria elected to account for its equity method investment in JUUL under the fair value option. Under this option, Altria’s condensed consolidated statements of earnings (losses) include any cash dividends received from its investment in JUUL and any changes in the estimated fair value of its investment, which is calculated quarterly. Altria believes the fair value option provides quarterly transparency to investors as to the fair market value of Altria’s investment in JUUL, given the changes and volatility in the e-vapor category since Altria’s initial investment, as well as the lack of publicly available information regarding JUUL’s business or a market-derived valuation.
The following table provides a reconciliation of the beginning and ending balance of Altria’s investment in JUUL, which is classified in Level 3 of the fair value hierarchy:
Investment
(in millions)Balance
Balance at December 31, 2020$1,705 
Unrealized gains (losses) included in income (losses) from equity investments— 
Balance at September 30, 2021$1,705 
For the three months ended September 30, 2021, Altria recorded a non-cash, pre-tax unrealized gain of $100 million, as a result of changes in the estimated fair value of its investment in JUUL. At September 30, 2021, the estimated fair value of Altria’s JUUL investment was $1.7 billion, unchanged from its December 31, 2020 estimated fair value. There were no material
changes to the significant assumptions used in the valuations, as described below, during the nine and three months ended September 30, 2021.
Prior to Share Conversion, Altria accounted for its investment in JUUL as an investment in an equity security. Since the JUUL shares do not have a readily determinable fair value, Altria elected to measure its investment in JUUL at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There were no upward or downward adjustments to the carrying value of Altria’s investment in JUUL resulting from observable price changes in orderly transactions since the JUUL Transaction through the date of Share Conversion. In addition, prior to Share Conversion, Altria reviewed its investment in JUUL for impairment by performing a qualitative assessment of impairment indicators on a quarterly basis in connection with the preparation of its financial statements. If this qualitative assessment indicated that Altria’s investment in JUUL may be impaired, a quantitative assessment was performed. If the quantitative assessment indicated the estimated fair value of the investment was less than its carrying value, the investment was written down to its fair value.
In September 2020, JUUL announced a strategic update, which included its plans for a significant global workforce reduction, its evaluation of its resource allocation and the possibility of exiting various international markets. As part of the preparation of Altria’s financial statements for the period ended September 30, 2020, Altria performed a qualitative assessment of impairment indicators for its investment in JUUL and determined that JUUL’s strategic update was an indicator of impairment at September 30, 2020, given the significant deterioration in JUUL’s business prospects.
Given the existence of this impairment indicator, Altria performed a quantitative valuation of its investment in JUUL during the third quarter of 2020 and recorded a non-cash, pre-tax charge of $2.6 billion for the nine and three months ended September 30, 2020, reported as impairment of JUUL equity securities in its condensed consolidated statements of earnings (losses). The impairment charge was driven by Altria’s projections of lower JUUL revenues over time due to lower pricing assumptions and delays in JUUL achieving previously forecasted operating margin performance. These drivers were the result of (i) JUUL’s revised international expansion plans and (ii) the evolving U.S. e-vapor category and associated competitive dynamics.
Altria uses an income approach to estimate the fair value of its investment in JUUL. The income approach reflects the discounting of future cash flows for the U.S. and international markets at a rate of return that incorporates the risk-free rate for the use of those funds, the expected rate of inflation and the risks associated with realizing future cash flows. Future cash flows were based on a range of scenarios that consider various potential regulatory and market outcomes.
In determining the estimated fair value of its investment in JUUL, as of September 30, 2021 and December 31, 2020, Altria made various judgments, estimates and assumptions, the most significant of which were sales volume, operating margins, discount rates and perpetual growth rates. All significant inputs used in the valuation are classified in Level 3 of the fair value hierarchy. Additionally, in determining these significant assumptions, Altria made judgments regarding the (i) likelihood and extent of various potential regulatory actions and the continued adverse public perception impacting the e-vapor category and specifically JUUL, (ii) risk created by the number and types of legal cases pending against JUUL and (iii) expectations for the future state of the e-vapor category, including competitive dynamics.
Investment in Cronos
At September 30, 2021, Altria had a 41.9% ownership interest in Cronos, consisting of 156.6 million shares, which Altria accounts for under the equity method of accounting. Altria’s ownership percentage decreased from 43.5% at December 31, 2020 due to the issuance of additional shares by Cronos. Altria reports its share of Cronos’s results using a one-quarter lag because Cronos’s results are not available in time for Altria to record them in the concurrent period.
As part of its Investment in Cronos, at September 30, 2021, Altria owned:
▪anti-dilution protections to purchase Cronos common shares, exercisable each quarter upon dilution, to maintain its ownership percentage. Certain of the anti-dilution protections provide Altria the ability to purchase additional Cronos common shares at a per share exercise price of Canadian dollar (“CAD”) $16.25 upon the occurrence of specified events (“Fixed-price Preemptive Rights”). Based on Altria’s assumptions as of September 30, 2021, Altria estimates the Fixed-price Preemptive Rights allows Altria to purchase up to an additional approximately 14 million common shares of Cronos; and
▪a warrant providing Altria the ability to purchase an additional approximate 10% of common shares of Cronos (approximately 83 million common shares at September 30, 2021) at a per share exercise price of CAD $19.00, which expires on March 8, 2023.
If exercised in full, the exercise prices for the warrant and Fixed-price Preemptive Rights are approximately CAD $1.6 billion and CAD $0.2 billion, respectively (approximately USD $1.3 billion and $0.2 billion, respectively, based on the CAD to USD exchange rate on October 25, 2021). At September 30, 2021, upon full exercise of the Fixed-price Preemptive Rights, to the
extent such rights become available, and the warrant, Altria would own approximately 53% of the outstanding common shares of Cronos.
For a discussion of derivatives related to the Investment in Cronos, including Altria’s accounting for changes in the fair value of these derivatives, see Note 5. Financial Instruments.
The fair value of Altria’s equity method investment in Cronos is based on unadjusted quoted prices in active markets for Cronos’s common shares and was classified in Level 1 of the fair value hierarchy. In September 2021, the fair value of Altria’s equity method investment in Cronos declined below its carrying value. At September 30, 2021, the fair value of Altria’s equity method investment in Cronos was less than its carrying value by $14 million or approximately 2%. The fair value of Altria’s equity method investment in Cronos exceeded its carrying value by $77 million or approximately 8% at December 31, 2020. Based on Altria’s evaluation of the duration and magnitude of the fair value decline at September 30, 2021, Altria concluded that the decline in fair value of its equity method investment in Cronos below its carrying value is temporary and, therefore, no impairment was recorded.
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments
 9 Months Ended
Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments Financial Instruments
Altria enters into derivative financial instruments to mitigate the potential impact of certain market risks, including foreign currency exchange rate risk. Altria uses various types of derivative financial instruments, including forward contracts, options and swaps. Altria does not enter into or hold derivative financial instruments for trading or speculative purposes.
Altria’s investment in ABI, whose functional currency is the Euro, exposes Altria to foreign currency exchange risk on the carrying value of its investment. To manage this risk, Altria designates certain foreign exchange contracts, including cross-currency swap contracts and forward contracts (collectively, “foreign currency contracts”), and Euro denominated unsecured long-term notes (“foreign currency denominated debt”) as net investment hedges of Altria’s investment in ABI.
In May 2021, all outstanding foreign currency contracts matured. When Altria has foreign currency contracts in effect, counterparties are domestic and international financial institutions. Under these contracts, Altria is exposed to potential losses due to non-performance by these counterparties. Altria manages its credit risk by entering into transactions with counterparties with investment grade credit ratings, limiting the amount of exposure Altria has with each counterparty and monitoring the financial condition of each counterparty. The counterparty agreements contain provisions that require Altria to maintain an investment grade credit rating. In the event Altria’s credit rating falls below investment grade, counterparties to Altria’s foreign currency contracts can require Altria to post collateral. No collateral was received or posted related to derivative assets and liabilities at December 31, 2020.
The following table provides (i) the aggregate notional amounts of foreign currency contracts and (ii) the aggregate carrying value and fair value of foreign currency denominated debt:
(in millions)September 30, 2021December 31, 2020
Foreign currency contracts (notional amounts)$— $1,066 
Foreign currency denominated debt
Carrying value4,905 5,171 
Fair value5,288 5,687 
Altria’s estimates of the fair values of its foreign currency contracts are determined using valuation models with significant inputs that are readily available in public markets, or can be derived from observable market transactions, and therefore are classified in Level 2 of the fair value hierarchy. An adjustment for credit risk and non-performance risk is included in the fair values of foreign currency contracts.
The following table provides the aggregate carrying value and fair value of Altria’s total long-term debt:
(in millions)September 30, 2021December 31, 2020
Carrying value$28,127 $29,471 
Fair value31,037 34,682 
Altria’s estimate of the fair value of its total long-term debt is based on observable market information derived from a third-party pricing source and is classified in Level 2 of the fair value hierarchy.
The Fixed-price Preemptive Rights and Cronos warrant, which are further discussed in Note 4. Investments in Equity Securities, are derivative financial instruments, which are required to be recorded at fair value. The fair values of the Fixed-price Preemptive Rights and Cronos warrant are estimated using Black-Scholes option-pricing models, adjusted for observable inputs (which are classified in Level 1 of the fair value hierarchy), including share price, and unobservable inputs, including
probability factors and weighting of expected life, volatility levels and risk-free interest rates (which are classified in Level 3 of the fair value hierarchy) based on the following assumptions at:
Fixed-price Preemptive RightsCronos Warrant
September 30, 2021December 31, 2020September 30, 2021December 31, 2020
Share price (1)
C$7.15C$8.84C$7.15C$8.84
Expected life (2)
0.81 year1.05 years1.43 years2.18 years
Expected volatility (3)
67.32%80.68%67.32%80.68%
Risk-free interest rate (4)(5)
0.24%0.13%0.39%0.21%
Expected dividend yield (6)
—%—%—%—%
(1) Based on the closing market price for Cronos common stock on the Toronto Stock Exchange on the date indicated.
(2) Based on the weighted-average expected life of the Fixed-price Preemptive Rights (with a range from approximately 0.25 year to 4.00 years at September 30, 2021 and 0.25 year to 5 years at December 31, 2020) and the March 8, 2023 expiration date of the Cronos warrant.
(3) Based on a blend of historical volatility of the underlying equity security and implied volatility from traded options on the underlying equity security at September 30, 2021. Based on a blend of historical volatility levels of the underlying equity security and peer companies at December 31, 2020.
(4) Based on the implied yield currently available on Canadian Treasury zero coupon issues (with a range from approximately 0.12% to 0.89% at September 30, 2021 and 0.06% to 0.39% at December 31, 2020) weighted for the remaining expected life of the Fixed-price Preemptive Rights.
(5) Based on the implied yield currently available on Canadian Treasury zero coupon issues and the expected life of the Cronos warrant.
(6) Based on Cronos’s expected dividend payments.
The following table provides a reconciliation of the beginning and ending balance of the Fixed-price Preemptive Rights and Cronos warrant, which are classified in Level 3 of the fair value hierarchy:
(in millions)
Balance at December 31, 2019$303 
Pre-tax earnings (losses) recognized in net earnings (losses)(140)
Balance at December 31, 2020163 
Pre-tax earnings (losses) recognized in net earnings (losses)(128)
Balance at September 30, 2021$35 
Altria elects to record the gross assets and liabilities of derivative financial instruments executed with the same counterparty on its condensed consolidated balance sheets. The fair values of Altria’s derivative financial instruments on a gross basis included on the condensed consolidated balance sheets were as follows:
Fair Value of AssetsFair Value of Liabilities
(in millions)
Balance Sheet ClassificationSeptember 30, 2021December 31, 2020Balance Sheet ClassificationSeptember 30, 2021December 31, 2020
Derivatives designated as hedging instruments:
    Foreign currency contracts
Other current assets
$— $— 
Other accrued liabilities
$— $87 
    Foreign currency contracts
Other assets
— — 
Other liabilities
— — 
Total
$— $— $— $87 
Derivatives not designated as hedging instruments:
Cronos warrant
Investments in equity securities
$32 $139 
Fixed-price Preemptive Rights
Investments in equity securities
3 24 
Total
$35 $163 
Total derivatives
$35 $163 $— $87 
Altria records in its condensed consolidated statements of earnings (losses) any changes in the fair values of the Fixed-price Preemptive Rights and Cronos warrant as gains or losses on Cronos-related financial instruments in the periods in which the changes occur. For the nine and three months ended September 30, 2021 and 2020, Altria recorded non-cash, pre-tax unrealized gains (losses), representing the changes in the fair values of the Fixed-price Preemptive Rights and Cronos warrant, as follows:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Fixed-price Preemptive Rights$(21)$(54)$(17)$(25)
Cronos warrant(107)(148)(118)(80)
Total$(128)$(202)$(135)$(105)
Net Investment Hedging
The pre-tax effects of Altria’s net investment hedges on accumulated other comprehensive losses and the condensed consolidated statements of earnings (losses) were as follows:
Gain (Loss) Recognized in Accumulated Other Comprehensive LossesGain (Loss) Recognized in
Net Earnings (Losses)		Gain (Loss) Recognized in Accumulated Other Comprehensive LossesGain (Loss) Recognized in
Net Earnings (Losses)
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)20212020202120202021202020212020
Foreign currency contracts$16 $(28)$7 $33 $— $(66)$— $8 
Foreign currency denominated debt270 (215)— — 118 (206)— — 
Total$286 $(243)$7 $33 $118 $(272)$— $8 
The changes in the fair value of the foreign currency contracts and in the carrying value of the foreign currency denominated debt due to changes in the Euro to USD exchange rate were recognized in accumulated other comprehensive losses related to ABI. Gains on the foreign currency contracts arising from components excluded from effectiveness testing were recognized in interest and other debt expense, net in the condensed consolidated statements of earnings (losses) based on an amortization approach.
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Benefit Plans
 9 Months Ended
Sep. 30, 2021
Retirement Benefits [Abstract]  
Benefit Plans Benefit Plans
Components of Net Periodic Benefit (Income) Cost
Net periodic benefit (income) cost consisted of the following:
PensionPostretirementPensionPostretirement
For the Nine Months Ended
September 30,		For the Three Months Ended
September 30,
 (in millions)20212020202120202021202020212020
Service cost$51 $55 $15 $13 $17 $18 $5 $5 
Interest cost139 188 29 44 46 62 8 14 
Expected return on plan assets
(393)(376)(10)(11)(131)(125)(2)(4)
Amortization:
Net loss99 108 16 7 33 55 2 — 
Prior service cost (credit)
3 4 (35)(22)1 2 (20)(7)
Net periodic benefit
(income) cost
$(101)$(21)$15 $31 $(34)$12 $(7)$8 
Employer Contributions
Altria makes contributions to the pension plans to the extent that the contributions are tax deductible and pays benefits that relate to plans for salaried employees that cannot be funded under Internal Revenue Service regulations. Altria made employer contributions of $23 million to its pension plans and did not make any contributions to its postretirement plans during the nine months ended September 30, 2021. Currently, Altria anticipates making additional employer contributions to its pension plans of up to approximately $5 million and no additional contributions to its postretirement plans for the remainder of 2021. However, the foregoing estimates of 2021 contributions to the pension and postretirement plans are subject to change as a result of changes in tax and other benefit laws, changes in interest rates, as well as asset performance significantly above or below the assumed long-term rate of return for each respective plan.
During the second quarter of 2021, Altria announced several amendments to its salaried retiree healthcare plans, primarily changing its post-age 65 coverage to a private medicare marketplace. These amendments triggered a plan remeasurement as of May 31, 2021 and resulted in Altria recording a reduction of $432 million to its accrued postretirement health care costs liability and a corresponding reduction to its accumulated other comprehensive losses on its condensed consolidated balance sheet. Ongoing amortization has been adjusted to reflect these changes as of June 1, 2021 and is reflected in the amounts shown above.
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Earnings (Losses) per Share
 9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Earnings (Losses) per Share Earnings (Losses) per Share
Basic and diluted earnings (losses) per share (“EPS”) were calculated using the following:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Net earnings (losses) attributable to Altria$851 $2,543 $(2,722)$(952)
Less: Distributed and undistributed earnings attributable to share-based awards
(8)(6)(2)(1)
Earnings (losses) for basic and diluted EPS$843 $2,537 $(2,724)$(953)
Weighted-average shares for basic EPS1,849 1,858 1,842 1,858 
Plus: contingently issuable performance stock units— 1 — 1 
Weighted-average shares for diluted EPS1,849 1,859 1,842 1,859 
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Other Comprehensive Earnings/Losses
 9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Other Comprehensive Earnings/Losses Other Comprehensive Earnings/Losses
The following tables set forth the changes in each component of accumulated other comprehensive losses, net of deferred income taxes, attributable to Altria:
For the Nine Months Ended September 30, 2021
(in millions)Benefit PlansABICurrency
Translation
Adjustments and Other		Accumulated
Other
Comprehensive
Losses
Balances, December 31, 2020$(2,420)$(1,938)$17 $(4,341)
Other comprehensive earnings (losses) before reclassifications
432 
(1)
685 35 1,152 
Deferred income taxes(118)(151)— (269)
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes
314 534 35 883 
Amounts reclassified to net earnings (losses) 92 (49)(2)41 
Deferred income taxes(23)10 — (13)
Amounts reclassified to net earnings (losses), net of deferred income taxes69 (39)(2)28 
Other comprehensive earnings (losses), net of deferred income taxes
383 495 
(2)
33 911 
Balances, September 30, 2021$(2,037)$(1,443)$50 $(3,430)
For the Three Months Ended September 30, 2021
(in millions)Benefit PlansABICurrency
Translation
Adjustments and Other 		Accumulated
Other
Comprehensive
Losses
Balances, June 30, 2021$(2,043)$(1,604)$45 $(3,602)
Other comprehensive earnings (losses) before reclassifications
— 

215 6 221 
Deferred income taxes(9)(48)— (57)
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes
(9)167 6 164 
Amounts reclassified to net earnings (losses)20 (7)(1)12 
Deferred income taxes(5)1 — (4)
Amounts reclassified to net earnings (losses), net of deferred income taxes15 (6)(1)8 
Other comprehensive earnings (losses), net of deferred income taxes
6 161 
(2)
5 172 
Balances, September 30, 2021$(2,037)$(1,443)$50 $(3,430)
For the Nine Months Ended September 30, 2020
(in millions)Benefit PlansABICurrency
Translation
Adjustments and Other		Accumulated
Other
Comprehensive
Losses
Balances, December 31, 2019$(2,192)$(693)$21 $(2,864)
Other comprehensive earnings (losses) before reclassifications
(75)(1,211)(16)(1,302)
Deferred income taxes19 260 — 279 
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes
(56)(951)(16)(1,023)
Amounts reclassified to net earnings (losses)111 29 — 140 
Deferred income taxes(28)(6)— (34)
Amounts reclassified to net earnings (losses), net of deferred income taxes83 23 — 106 
Other comprehensive earnings (losses), net of deferred income taxes
27 (928)
(2)
(16)(917)
Balances, September 30, 2020$(2,165)$(1,621)$5 $(3,781)
For the Three Months Ended September 30, 2020
(in millions)Benefit PlansABICurrency
Translation
Adjustments and Other		Accumulated
Other
Comprehensive
Losses
Balances, June 30, 2020$(2,150)$(1,606)$(18)$(3,774)
Other comprehensive earnings (losses) before reclassifications
(75)(71)23 (123)
Deferred income taxes19 22 — 41 
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes
(56)(49)23 (82)
Amounts reclassified to net earnings (losses)55 44 — 99 
Deferred income taxes(14)(10)— (24)
Amounts reclassified to net earnings (losses), net of deferred income taxes41 34 — 75 
Other comprehensive earnings (losses), net of deferred income taxes
(15)(15)
(2)
23 (7)
Balances, September 30, 2020$(2,165)$(1,621)$5 $(3,781)
(1) Reflects the remeasurement impact of salaried retiree healthcare plan amendments. For further discussion, see Note 6. Benefit Plans.
(2) Primarily reflects Altria’s share of ABI’s currency translation adjustments and the impact of Altria’s designated net investment hedges. For further discussion of designated net investment hedges, see Note 5. Financial Instruments.
The following table sets forth pre-tax amounts by component, reclassified from accumulated other comprehensive losses to net earnings (losses):
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Benefit Plans: (1)
Net loss$124 $129 $39 $60 
Prior service cost/credit(32)(18)(19)(5)
92 111 20 55 
ABI (2)
(49)29 (7)44 
Currency Translation Adjustments and Other (2)
(2)— (1)— 
Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings (losses)$41 $140 $12 $99 
(1) Amounts are included in net defined benefit plan costs. For further information related to defined benefit plans, see Note 6. Benefit Plans.
(2) Amounts are included in (income) losses from equity investments. For further information related to equity investments, see Note 4. Investments in Equity Securities.
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Reporting
 9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The products of Altria’s subsidiaries include smokeable tobacco products, consisting of combustible cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton; oral tobacco products, consisting of MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix; and wine produced and/or distributed by Ste. Michelle. The products and services of these subsidiaries constitute Altria’s reportable segments of smokeable products, oral tobacco products and wine. The financial services and the innovative tobacco products businesses, which include the heated tobacco business and Helix ROW, are included in all other.
Altria’s chief operating decision maker (the “CODM”) reviews operating companies income (loss) (“OCI”) to evaluate the performance of, and allocate resources to, the segments. OCI for the segments is defined as operating income before general corporate expenses and amortization of intangibles. Interest and other debt expense, net, along with net periodic benefit income/cost, excluding service cost, and provision (benefit) for income taxes are centrally managed at the corporate level and, accordingly, such items are not presented by segment since they are excluded from the measure of segment profitability reviewed by the CODM.
Segment data were as follows:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Net revenues:
Smokeable products$17,275 $17,522 $5,975 $6,313 
Oral tobacco products1,945 1,901 626 640 
Wine494 434 177 157 
All other44 (8)8 13 
Net revenues$19,758 $19,849 $6,786 $7,123 
Earnings (losses) before income taxes:
OCI:
Smokeable products$7,901 $7,609 $2,753 $2,789 
Oral tobacco products1,269 1,297 405 436 
Wine21 (347)(24)19 
All other(56)(63)(30)(7)
Amortization of intangibles(53)(54)(18)(17)
General corporate expenses(255)(150)(135)(60)
Operating income8,827 8,292 2,951 3,160 
Interest and other debt expense, net(869)(893)(266)(310)
Loss on early extinguishment of debt(649)— — — 
Net periodic benefit income, excluding
service cost
152 58 63 3 
Income (losses) from equity investments(5,789)(306)(5,915)(472)
Impairment of JUUL equity securities— (2,600)— (2,600)
Gain (loss) on Cronos-related financial instruments(128)(202)(135)(105)
Earnings (losses) before income taxes$1,544 $4,349 $(3,302)$(324)
The comparability of OCI for the reportable segments was affected by the following:
▪Non-Participating Manufacturer (“NPM”) Adjustment Items: Pre-tax (income) for NPM adjustment items was recorded to Altria’s condensed consolidated statements of earnings (losses) as follows:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)20212021
Smokeable products segment$(53)$(21)
Interest and other debt expense, net(23)(23)
Total$(76)$(44)
NPM adjustment items result from the resolutions of certain disputes with states and territories related to the NPM adjustment provision under the 1998 Master Settlement Agreement (such dispute resolutions are referred to as “NPM Adjustment Items” and are more fully described in Health Care Cost Recovery Litigation in Note 12. Contingencies). The amounts shown in the table above for the smokeable products segment were recorded as reductions to cost of sales, which increased OCI in the smokeable products segment.
▪Tobacco and Health and Certain Other Litigation Items: Pre-tax charges related to tobacco and health and certain other litigation items were recorded in Altria’s condensed consolidated statements of earnings (losses) as follows:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Smokeable products segment$72 $73 $29 $34 
General corporate70 — 70 — 
Interest and other debt expense, net6 3 6 — 
Total$148 $76 $105 $34 
The amounts shown in the table above for the smokeable products segment and general corporate were recorded in marketing, administration and research costs. For further discussion, see Note 12. Contingencies.
▪COVID-19 Special Items: Net pre-tax charges of $50 million ($41 million in the smokeable products segment and $9 million in the oral tobacco products segment) related to the COVID-19 pandemic were recorded in Altria’s condensed consolidated statements of earnings (losses) for the nine months ended September 30, 2020. The net pre-tax charges, which were directly related to disruptions caused by or efforts to mitigate the impact of the COVID-19 pandemic, were all recorded in costs of sales and included premium pay, personal protective equipment and health screenings, which were partially offset by certain employment tax credits. The COVID-19 special items do not include the inventory-related implementation costs associated with the wine business strategic reset discussed below. These implementation costs were due to increased inventory levels, which were further negatively impacted by the COVID-19 pandemic, including economic uncertainty and government restrictions.
▪Implementation, Acquisition and Disposition-Related Costs:
Ste. Michelle Transaction: For the nine and three months ended September 30, 2021, pre-tax disposition-related costs of $51 million were recorded in the wine segment, which consisted of a pre-tax charge of $41 million to record the assets and liabilities associated with the Ste. Michelle Transaction at their fair value less costs to sell and $10 million of other disposition-related costs. For further discussion, see Note 3. Assets Held for Sale.
Wine Business Strategic Reset: During the nine months ended September 30, 2020, Ste. Michelle recorded pre-tax implementation costs of $395 million associated with a strategic reset initiated in the first quarter of 2020 to maximize Ste. Michelle’s profitability and achieve improved long-term cash flow generation. Substantially all of the charges consisted of the following: (i) write-off of inventory ($292 million) as Ste. Michelle no longer believed that the benefit of the blending and production plans for its inventory outweighed inventory carrying cost given the reduced product volume demand; and (ii) estimated losses on future non-cancelable grape purchase commitments that Ste. Michelle believed no longer had a future economic benefit ($100 million). These charges were included in cost of sales in Altria’s condensed consolidated statements of earnings (losses).
Acquisition-Related Costs: For the nine months ended September 30, 2021, Altria recorded pre-tax acquisition-related costs of $37 million in the oral tobacco products segment primarily for the settlement of an arbitration related to the 2019 on! transaction. These costs were included in marketing, administration and research costs in Altria’s condensed consolidated statements of earnings (losses).
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Debt
 9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Debt Debt
Short-term Borrowings and Borrowing Arrangements
At September 30, 2021 and December 31, 2020, Altria had no short-term borrowings.
On August 18, 2021, Altria entered into an extension and amendment (the “Extension and Amendment”) to its $3.0 billion senior unsecured 5-year revolving credit agreement (as amended, the “Credit Agreement”). The Extension and Amendment extends the maturity date of the Credit Agreement from August 1, 2023 to August 1, 2024 and amends the Credit Agreement to update certain provisions regarding a successor interest rate to the London Interbank Offered Rate (“LIBOR”) and make certain other market updates. All other terms and conditions of the Credit Agreement remain in full force and effect. The Credit Agreement, which is used for general corporate purposes, includes an additional option, subject to certain conditions, for Altria to extend the expiration date for an additional one-year period.
At September 30, 2021, the Credit Agreement had available borrowings up to an aggregate principal amount of $3.0 billion.
Pricing for interest and fees under the Credit Agreement may be modified in the event of a change in the rating of Altria’s long-term senior unsecured debt. Interest rates on borrowings under the Credit Agreement are expected to be based on LIBOR, or a fallback benchmark rate determined based on prevailing market convention, plus a percentage based on the higher of the ratings of Altria’s long-term senior unsecured debt from Moody’s Investors Service, Inc. (“Moody’s”) and Standard & Poor’s Financial Services LLC (“S&P”). The applicable percentage based on Altria’s long-term senior unsecured debt ratings at September 30, 2021 for borrowings under the Credit Agreement was 1.0%. The Credit Agreement does not include any other rating triggers, or any provisions that could require the posting of collateral.
The Credit Agreement includes various covenants, one of which requires Altria to maintain a ratio of consolidated earnings before interest, taxes, depreciation and amortization (“EBITDA”) to Consolidated Interest Expense of not less than 4.0 to 1.0, calculated as of the end of the applicable quarter on a rolling four quarters basis. At September 30, 2021, the ratio of consolidated EBITDA to Consolidated Interest Expense, calculated in accordance with the Credit Agreement, was 9.8 to 1.0. At September 30, 2021, Altria was in compliance with its covenants in the Credit Agreement. The terms “Consolidated EBITDA” and “Consolidated Interest Expense,” each as defined in the Credit Agreement, include certain adjustments.
In March 2020, due to the uncertainty at that time in the global capital markets, including the commercial paper markets, resulting from the COVID-19 pandemic, Altria elected to borrow the full $3.0 billion available under the Credit Agreement as a precautionary measure to increase its cash position and preserve financial flexibility. In June 2020, Altria repaid the full amount outstanding under the Credit Agreement using the net proceeds from the issuance of long-term senior unsecured notes issued in May 2020 and available cash.
Any commercial paper issued by Altria and borrowings under the Credit Agreement are guaranteed by PM USA.
Long-term Debt
The aggregate carrying value of Altria’s total long-term debt at September 30, 2021 and December 31, 2020 was $28.1 billion and $29.5 billion, respectively.
In May 2021, Altria repaid in full senior unsecured notes in the aggregate principal amount of $1.5 billion at maturity.
In February 2021, Altria issued long-term senior unsecured notes in the aggregate principal amount of $5.5 billion (the “Notes”). The net proceeds from the Notes were used (i) to fund the purchase and redemption of certain unsecured notes and payment of related fees and expenses, as described below, and (ii) for other general corporate purposes. The Notes contain the following terms:
▪$1.75 billion at 2.450%, due 2032, interest payable semiannually beginning August 4, 2021;
▪$1.50 billion at 3.400%, due 2041, interest payable semiannually beginning August 4, 2021;
▪$1.25 billion at 3.700%, due 2051, interest payable semiannually beginning August 4, 2021; and
▪$1.00 billion at 4.000%, due 2061, interest payable semiannually beginning August 4, 2021.
The Notes are Altria’s senior unsecured obligations and rank equally in right of payment with all of Altria’s existing and future senior unsecured indebtedness. Upon the occurrence of both (i) a change of control of Altria and (ii) the Notes ceasing to be rated investment grade by each of Moody’s, S&P and Fitch Ratings, Inc. within a specified time period, Altria will be required to make an offer to purchase the Notes at a price equal to 101% of the aggregate principal amount of such Notes, plus accrued and unpaid interest to the date of repurchase as and to the extent set forth in the terms of the Notes.
The obligations of Altria under the Notes are guaranteed by PM USA.
During the first quarter of 2021, Altria completed debt tender offers to purchase for cash certain of its long-term senior unsecured notes in an aggregate principal amount of $4,042 million. Details of the debt tender offers are as follows:
(in millions)Principal Amount of Notes Purchased
2.850% Notes due 2022
$795 
2.950% Notes due 2023
132 
4.000% Notes due 2024
624 
3.800% Notes due 2024
655 
4.400% Notes due 2026
430 
4.800% Notes due 2029
1,094 
9.950% Notes due 2038
65 
10.200% Notes due 2039
18 
6.200% Notes due 2059
229 
$4,042 
During the first quarter of 2021, Altria also redeemed all of its outstanding 3.490% Notes due 2022 in an aggregate principal amount of $1.0 billion.
As a result of the debt tender offers and redemption, during the first quarter of 2021, Altria recorded pre-tax losses on early extinguishment of debt of $649 million, which included premiums and fees of $623 million and the write-off of related unamortized debt discounts and debt issuance costs of $26 million.
At September 30, 2021 and December 31, 2020, accrued interest on long-term debt of $206 million and $458 million, respectively, was included in other accrued liabilities on Altria’s condensed consolidated balance sheets.
For a discussion of the fair value of Altria’s long-term debt and the designation of its Euro denominated senior unsecured notes as a net investment hedge of its investment in ABI, see Note 5. Financial Instruments.
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes
 9 Months Ended
Sep. 30, 2021
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
Earnings (losses) before income taxes, provision (benefit) for income taxes and income tax rates consisted of the following:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Earnings (losses) before income taxes$1,544$4,349$(3,302)$(324)
Provision (benefit) for income taxes6931,817(582)632
Income tax rate44.9 %41.8 %17.6 %(195.1)%
Altria’s income tax rates for the nine and three months ended September 30, 2021 and 2020 are not comparable in a meaningful way due to the following significant pre-tax charges and valuation allowances:
▪the $6,157 million impairment of Altria’s equity investment in ABI during the nine and three months ended September 30, 2021; and
▪the $2,600 million impairment of Altria’s investment in JUUL during the nine and three months ended September 30, 2020 and valuation allowances associated with Altria’s investments in JUUL and Altria’s Investment in Cronos.
Altria’s income tax rates for the nine and three months ended September 30, 2021 differ from the U.S. federal statutory rate of 21%, due primarily to the state tax treatment of the impairment charge on Altria’s equity investment in ABI.
Altria’s income tax rates for the nine and three months ended September 30, 2020 differ from the U.S. federal statutory rate of 21%, due primarily to valuation allowances primarily attributable to deferred tax assets recorded in connection with the impairment of Altria’s investment in JUUL, and Altria’s Investment in Cronos.
For further information on the impairments of Altria’s equity investment in ABI and investment in JUUL, see Note 4. Investments in Equity Securities.
The following chart provides a reconciliation of the beginning and ending valuation allowances for the period ended September 30, 2021:
(in millions)
Balance at beginning of year$2,817 
Additions to valuation allowance charged to income tax expense264 
Reductions to valuation allowance credited to income tax benefit(73)
Foreign currency translation(4)
Balance at end of period$3,004 
Altria determines the realizability of deferred tax assets based on the weight of available evidence, that it is more-likely-than-not that the deferred tax asset will not be realized. In reaching this determination, Altria considers all available positive and negative evidence, including the character of the loss, carryback and carryforward considerations, future reversals of temporary differences and available tax planning strategies.
The current changes in valuation allowances were due to deferred tax assets recorded in connection with Altria’s Investment in Cronos and changes in the estimated fair value of its investment in JUUL. The valuation allowance at the end of the period is primarily attributable to deferred tax assets recorded in connection with Altria’s investment in JUUL and Investment in Cronos.
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Contingencies
 9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Contingencies Contingencies
Legal proceedings covering a wide range of matters are pending or threatened in various U.S. and foreign jurisdictions against Altria and its subsidiaries, including PM USA and USSTC, as well as their respective indemnitees and Altria’s investees. Various types of claims may be raised in these proceedings, including product liability, unfair trade practices, antitrust, tax, contraband shipments, patent infringement, employment matters, claims alleging violation of the Racketeer Influenced and Corrupt Organizations Act (“RICO”), claims for contribution and claims of competitors, shareholders or distributors. Legislative action, such as changes to tort law, also may expand the types of claims and remedies available to plaintiffs.
Litigation is subject to uncertainty and it is possible that there could be adverse developments in pending or future cases. An unfavorable outcome or settlement of pending tobacco-related or other litigation could encourage the commencement of additional litigation. Damages claimed in some tobacco-related and other litigation are or can be significant and, in certain cases, have ranged in the billions of dollars. The variability in pleadings in multiple jurisdictions, together with the actual experience of management in litigating claims, demonstrate that the monetary relief that may be specified in a lawsuit bears little relevance to the ultimate outcome. In certain cases, plaintiffs claim that defendants’ liability is joint and several. In such cases, Altria or its subsidiaries may face the risk that one or more co-defendants decline or otherwise fail to participate in the bonding required for an appeal or to pay their proportionate or jury-allocated share of a judgment. As a result, Altria or its subsidiaries under certain circumstances may have to pay more than their proportionate share of any bonding- or judgment-related amounts. Furthermore, in those cases where plaintiffs are successful, Altria or its subsidiaries also may be required to pay interest and attorneys’ fees.
Although PM USA has historically been able to obtain required bonds or relief from bonding requirements in order to prevent plaintiffs from seeking to collect judgments while adverse verdicts have been appealed, there remains a risk that such relief may not be obtainable in all cases. This risk has been substantially reduced given that 47 states and Puerto Rico limit the dollar amount of bonds or require no bond at all. As discussed below, however, tobacco litigation plaintiffs have challenged the constitutionality of Florida’s bond cap statute in several cases and plaintiffs may challenge state bond cap statutes in other jurisdictions as well. Such challenges may include the applicability of state bond caps in federal court. States, including Florida, also may seek to repeal or alter bond cap statutes through legislation. Although Altria cannot predict the outcome of such challenges, it is possible that the consolidated results of operations, cash flows or financial position of Altria, or one or more of its subsidiaries, could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome of one or more such challenges.
Altria and its subsidiaries record provisions in the condensed consolidated financial statements for pending litigation when they determine that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. At the present time, while it is reasonably possible that an unfavorable outcome in a case may occur, except to the extent discussed elsewhere in this Note 12. Contingencies: (i) management has concluded that it is not probable that a loss has been incurred in any of the pending cases; (ii) management is unable to estimate the possible loss or range of loss that could result from an unfavorable outcome in any of the pending cases; and (iii) accordingly, management has not provided any amounts in the condensed consolidated financial statements for unfavorable outcomes, if any. Litigation defense costs are expensed as incurred.
Altria and its subsidiaries have achieved substantial success in managing litigation. Nevertheless, litigation is subject to uncertainty and significant challenges remain. It is possible that the consolidated results of operations, cash flows or financial position of Altria, or one or more of its subsidiaries, could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending litigation. Altria and each of its subsidiaries named as a defendant believe, and each has been so advised by counsel handling the respective cases, that it has valid defenses to the litigation pending against it, as well as valid bases for appeal of adverse verdicts. Each of the companies has defended, and will continue to defend, vigorously against litigation challenges. However, Altria and its subsidiaries may enter into settlement discussions in particular cases if they believe it is in the best interests of Altria to do so.
Judgments Paid and Provisions for Tobacco and Health and Certain Other Litigation Items (Including Engle Progeny Litigation): After exhausting all appeals in those cases resulting in adverse verdicts associated with tobacco-related litigation, since October 2004, PM USA has paid judgments and settlements (including related costs and fees) totaling approximately $865 million and interest totaling approximately $218 million as of September 30, 2021. These amounts include payments for Engle progeny judgments (and related costs and fees) totaling approximately $410 million and related interest totaling approximately $56 million.
The changes in Altria’s accrued liability for tobacco and health and certain other litigation items, including related interest costs, for the periods specified below are as follows:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Accrued liability for tobacco and health and certain other litigation items at beginning of period$9 $14 $— $22 
Pre-tax charges for:
Tobacco and health and certain other litigation (1)
142 73 99 34 
Related interest costs
6 3 6 — 
Payments (1)
(60)(81)(8)(47)
Accrued liability for tobacco and health and certain other litigation items at end of period$97 $9 $97 $9 
(1) Includes amounts related to certain other litigation and pre-trial resolution of certain tobacco and health cases.
The accrued liability for tobacco and health and certain other litigation items, including related interest costs, was included in accrued liabilities on Altria’s condensed consolidated balance sheets. Pre-tax charges for tobacco and health and certain other litigation were included in marketing, administration and research costs on Altria’s condensed consolidated statements of earnings (losses). Pre-tax charges for related interest costs were included in interest and other debt expense, net on Altria’s condensed consolidated statements of earnings (losses).
Security for Judgments: To obtain stays of judgments pending appeal, PM USA has posted various forms of security. As of September 30, 2021, PM USA has posted appeal bonds totaling approximately $45 million, which have been collateralized with restricted cash that are included in assets on the condensed consolidated balance sheets.
Overview of Altria and/or PM USA Tobacco-Related Litigation
Types and Number of U.S. Cases: Claims related to tobacco products generally fall within the following categories: (i) smoking and health cases alleging personal injury brought on behalf of individual plaintiffs; (ii) health care cost recovery cases brought by governmental (both domestic and foreign) plaintiffs seeking reimbursement for health care expenditures allegedly caused by cigarette smoking and/or disgorgement of profits; (iii) e-vapor cases alleging violation of RICO, fraud, failure to warn, design defect, negligence, antitrust and unfair trade practices; and (iv) other tobacco-related litigation described below. Plaintiffs’ theories of recovery and the defenses raised in tobacco-related litigation are discussed below.
The table below lists the number of certain tobacco-related cases pending in the U.S. against PM USA and/or Altria as of October 25, 2021, October 27, 2020 and October 28, 2019:
October 25, 2021October 27, 2020October 28, 2019
Individual Smoking and Health Cases (1)
17914295
Health Care Cost Recovery Actions (2)
111
E-vapor Cases (3)
2,9511,145—
Other Tobacco-Related Cases (4)
344
(1) Includes 18 cases filed in Illinois, 17 cases filed in New Mexico, 40 cases filed in Massachusetts and 70 non-Engle cases filed in Florida. Does not include individual smoking and health cases brought by or on behalf of plaintiffs in Florida state and federal courts following the decertification of the Engle case (these Engle progeny cases are discussed below in Smoking and Health Litigation - Engle Class Action). Also does not include 1,471 cases brought by flight attendants seeking compensatory damages for personal injuries allegedly caused by exposure to environmental tobacco smoke (“ETS”). The flight attendants allege that they are members of an ETS smoking and health class action in Florida, which was settled in 1997 (Broin). The terms of the court-approved settlement in that case allowed class members to file individual lawsuits seeking compensatory damages, but prohibited them from seeking punitive damages. Class members were prohibited from filing individual lawsuits after 2000 under the court-approved settlement.
(2) See Health Care Cost Recovery Litigation - Federal Government’s Lawsuit below.
(3) Includes 53 class action lawsuits, 2,548 individual lawsuits and 350 “third party” lawsuits relating to JUUL e-vapor products, which include school districts, state and local government, tribal and healthcare organization lawsuits. JUUL is an additional named defendant in each of these lawsuits. The 53 class action lawsuits include 28 cases in the Northern District of California (“Multidistrict Litigation” or “MDL”) involving plaintiffs whose claims were previously included in other class action complaints but were refiled as separate stand-alone class actions for procedural and other reasons.
(4) Includes one inactive smoking and health case alleging personal injury and purporting to be brought on behalf of a class of individual plaintiffs and two inactive class action lawsuits alleging that use of the terms “Lights” and “Ultra Lights” constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment, breach of warranty or violations of RICO.
International Tobacco-Related Cases: As of October 25, 2021, (i) Altria is named as a defendant in three e-vapor class action lawsuits in Canada; (ii) PM USA is a named defendant in 10 health care cost recovery actions in Canada, eight of which also name Altria as a defendant; and (iii) PM USA and Altria are named as defendants in seven smoking and health class actions filed in various Canadian provinces. See Guarantees and Other Similar Matters below for a discussion of the Distribution Agreement between Altria and Philip Morris International Inc. (“PMI”) that provides for indemnities for certain liabilities concerning tobacco products.
Tobacco-Related Cases Set for Trial: As of October 25, 2021, no Engle progeny or individual smoking and health cases against PM USA are set for trial through December 31, 2021. Trial dates are subject to change and many of the trials were postponed due to the COVID-19 pandemic; however, the courts are reopening and additional trials may be scheduled for the remainder of 2021.
Trial Results: Since January 1999, excluding the Engle progeny cases (separately discussed below), verdicts have been returned in 69 tobacco-related cases in which PM USA was a defendant. Verdicts in favor of PM USA and other defendants were returned in 44 of the 69 cases. These 44 cases were tried in Alaska (1), California (7), Connecticut (1), Florida (10), Louisiana (1), Massachusetts (4), Mississippi (1), Missouri (4), New Hampshire (1), New Jersey (1), New York (5), Ohio (2), Pennsylvania (1), Rhode Island (1), Tennessee (2) and West Virginia (2).
Of the 25 non-Engle progeny cases in which verdicts were returned in favor of plaintiffs, 20 have reached final resolution, and two cases (Gentile and Principe) that were initially returned in favor of plaintiffs were reversed post-trial and remain pending.
See Smoking and Health Litigation - Engle Progeny Trial Results below for a discussion of verdicts in state and federal Engle progeny cases involving PM USA as of October 25, 2021.
Smoking and Health Litigation
Overview: Plaintiffs’ allegations of liability in smoking and health cases are based on various theories of recovery, including negligence, gross negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, nuisance, breach of express and implied warranties, breach of special duty, conspiracy, concert of action, violations of unfair trade practice laws and consumer protection statutes, and claims under the federal and state anti-racketeering statutes. Plaintiffs in the smoking and health cases seek various forms of relief, including compensatory and punitive damages, treble/multiple damages and other statutory damages and penalties, creation of medical monitoring and smoking cessation funds, disgorgement of profits, and injunctive and equitable relief. Defenses raised in these cases include lack of proximate cause, assumption of the risk, comparative fault and/or contributory negligence, statutes of limitations and preemption by the Federal Cigarette Labeling and Advertising Act.
Non-Engle Progeny Litigation: Summarized below are the non-Engle progeny smoking and health cases pending during 2021 in which a verdict was returned in favor of plaintiff and against PM USA. Charts listing certain verdicts for plaintiffs in the Engle progeny cases can be found in Smoking and Health Litigation - Engle Progeny Trial Results below.
Principe: In February 2020, a jury in a Florida state court returned a verdict in favor of plaintiff and against PM USA, awarding approximately $11 million in compensatory damages. There was no claim for punitive damages. PM USA appealed the trial court verdict to the Third District Court of Appeal and, in September 2021, the appellate court reversed the trial court’s decision and found in favor of PM USA.
Greene: In September 2019, a jury in a Massachusetts state court returned a verdict in favor of plaintiffs and against PM USA, awarding approximately $10 million in compensatory damages. In May 2020, the court ruled on plaintiffs’ remaining claim and trebled the compensatory damages award to approximately $30 million. In February 2021, the trial court awarded plaintiffs attorneys’ fees and costs in the amount of approximately $2.3 million. Also in February 2021, PM USA served its post-trial motions to reverse the judgment or for a new trial. The trial court denied the post-trial motions in June 2021. In July 2021, PM USA appealed the judgment to the Appeals Court of Massachusetts.
Laramie: In August 2019, a jury in a Massachusetts state court returned a verdict in favor of plaintiff and against PM USA, awarding $11 million in compensatory damages and $10 million in punitive damages. PM USA appealed and, in February 2021, the Massachusetts Supreme Judicial Court asserted jurisdiction over the appeal. In September 2021, the Massachusetts Supreme Judicial Court affirmed the trial court award of $21 million in compensatory and punitive damages. PM USA recorded a pre-tax provision of approximately $27.1 million for the judgment, including interest, in the third quarter of 2021.
Gentile: In October 2017, a jury in a Florida state court returned a verdict in favor of plaintiff and against PM USA, awarding approximately $7.1 million in compensatory damages and allocating 75% of the fault to PM USA. PM USA appealed. In September 2019, the Florida Fourth District Court of Appeal reversed the judgment entered by the trial court, granted PM USA judgment on certain claims and remanded for a new trial on the remaining claims. Plaintiff petitioned the Florida Supreme Court for further review, which the court denied in January 2021.
Federal Government’s Lawsuit: See Health Care Cost Recovery Litigation - Federal Government’s Lawsuit below for a discussion of the verdict and post-trial developments in the United States of America health care cost recovery case.
Engle Class Action: In July 2000, in the second phase of the Engle smoking and health class action in Florida, a jury returned a verdict assessing punitive damages totaling approximately $145 billion against various defendants, including $74 billion against PM USA. Following entry of judgment, PM USA appealed. In May 2003, the Florida Third District Court of Appeal reversed the judgment entered by the trial court and instructed the trial court to order the decertification of the class. Plaintiffs petitioned the Florida Supreme Court for further review.
In July 2006, the Florida Supreme Court ordered that the punitive damages award be vacated, that the class approved by the trial court be decertified and that members of the decertified class could file individual actions against defendants within one year of issuance of the mandate. The court further declared the following Phase I findings are entitled to res judicata effect in such individual actions brought within one year of the issuance of the mandate: (i) that smoking causes various diseases; (ii) that nicotine in cigarettes is addictive; (iii) that defendants’ cigarettes were defective and unreasonably dangerous; (iv) that defendants concealed or omitted material information not otherwise known or available knowing that the material was false or misleading or failed to disclose a material fact concerning the health effects or addictive nature of smoking; (v) that defendants agreed to misrepresent information regarding the health effects or addictive nature of cigarettes with the intention of causing the public to rely on this information to their detriment; (vi) that defendants agreed to conceal or omit information regarding the health effects of cigarettes or their addictive nature with the intention that smokers would rely on the information to their detriment; (vii) that all defendants sold or supplied cigarettes that were defective; and (viii) that defendants were negligent.
In August 2006, PM USA and plaintiffs sought rehearing from the Florida Supreme Court on parts of its July 2006 opinion. In December 2006, the Florida Supreme Court refused to revise its July 2006 ruling, except that it revised the set of Phase I findings entitled to res judicata effect by excluding finding (v) listed above (relating to agreement to misrepresent information), and added the finding that defendants sold or supplied cigarettes that, at the time of sale or supply, did not conform to the representations of fact made by defendants. In February 2008, the trial court decertified the class.
Pending Engle Progeny Cases: The deadline for filing Engle progeny cases expired in January 2008, at which point a total of approximately 9,300 federal and state claims were pending. As of October 25, 2021, approximately 1,026 state court cases were pending against PM USA or Altria asserting individual claims by or on behalf of approximately 1,285 state court plaintiffs.  Because of a number of factors, including docketing delays, duplicated filings and overlapping dismissal orders, these numbers are estimates. While the Federal Engle Agreement (discussed below) resolved nearly all Engle progeny cases pending in federal court, as of October 25, 2021, two cases were pending against PM USA in federal court representing the cases excluded from that agreement.
Engle Progeny Trial Results: As of October 25, 2021, 137 federal and state Engle progeny cases involving PM USA have resulted in verdicts since the Florida Supreme Court Engle decision. Seventy-six verdicts were returned in favor of plaintiffs and seven verdicts (Skolnick, Calloway, Oshinsky-Blacker, McCoy, Mahfuz, Neff and Frogel) that were initially returned in favor of plaintiffs were reversed post-trial or on appeal and remain pending.
Fifty-four verdicts were returned in favor of PM USA, of which 44 were state cases. In addition, there have been a number of mistrials, only some of which have resulted in new trials as of October 25, 2021. The jury in one case, Garcia, awarded plaintiff compensatory damages and found plaintiff was entitled to punitive damages; however, the court declared a mistrial in the second phase of the trial regarding punitive damages because the jury was unable to determine the amount of the punitive damages. Four verdicts (Pearson, D. Cohen, Collar and Chacon) that were returned in favor of PM USA were subsequently reversed for new trials. Juries in two cases (Reider and Banks) returned zero damages verdicts in favor of PM USA. Juries in two other cases (Weingart and Hancock) returned verdicts against PM USA awarding no damages, but the trial court in each case decided to award plaintiffs damages. One case, Pollari, resulted in a verdict in favor of PM USA following a retrial of an initial verdict returned in favor of plaintiff. Plaintiff and defendants appealed the verdict and the appellate court affirmed the judgement in favor of the defendants. Three cases, Gloger, Rintoul (Caprio) and Duignan, resulted in verdicts in favor of plaintiffs following retrial of initial verdicts returned in favor of plaintiffs. Post-trial appeals are pending in those three cases. Two cases, Freeman and Harris, resulted in an appellate reversal of a jury verdict in favor of plaintiff, and a judgment in favor of PM USA.
The charts below list the verdicts and post-trial developments in certain Engle progeny cases in which verdicts were returned in favor of plaintiffs. The first chart lists cases that are pending as of October 25, 2021 but where PM USA has determined an unfavorable outcome is not probable and the amount of loss cannot be reasonably estimated. The second chart lists cases that have concluded within the previous 12 months. Unless otherwise noted for a particular case, the jury’s award for compensatory damages will not be reduced by any finding of plaintiff’s comparative fault. Further, the damages noted reflect adjustments based on post-trial or appellate rulings. As of October 25, 2021, there are no Engle progeny cases where PM USA has recorded a provision in its condensed consolidated financial statements because PM USA has not determined for any currently pending case that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated.
References below to “R.J. Reynolds,” “Lorillard” and “Liggett Group” are to R.J. Reynolds Tobacco Company, Lorillard Tobacco Company and Liggett Group, LLC, respectively.
Currently Pending Engle Cases with Verdicts Against PM USA
(rounded to nearest $ million)
PlaintiffVerdict DateDefendant(s)Court
Compensatory Damages (1)
Punitive Damages
(PM USA)		Appeal Status
LippSeptember 2021PM USAMiami-Dade
$15 million
$28 million
Defendant’s post-trial motions denied. Defendant plans to appeal.
Garcia
May 2021
PM USAMiami-Dade
$3 million
MistrialAppeal by defendant to Third District Court of Appeal pending.
Duignan
February 2020 (2)
PM USA and R.J. ReynoldsPinellas
$3 million
$12 million
Appeal by defendants to Second District Court of Appeal pending.
CuddiheeJanuary 2020PM USADuval
$3 million
$0
Appeal by defendant to First District Court of Appeal pending.
Rintoul (Caprio)
November 2019 (2)
PM USA and R.J. ReynoldsBroward
$9 million
$74 million
Appeal by plaintiff and defendants to Fourth District Court of Appeal pending.
Gloger
November 2019 (2)
PM USA and R.J. ReynoldsMiami-Dade
$15 million
$11 million
Appeal by defendants to Third District Court of Appeal pending.
McCallMarch 2019PM USABroward
<$1 million (<$1 million PM USA)
$0
New trial ordered on punitive damages.
NeffMarch 2019PM USA and R.J. ReynoldsBroward
$4 million
$2 million
Fourth District Court of Appeal reversed the judgment against defendants and remanded for a new trial. Plaintiff's motion for rehearing was denied.
PlaintiffVerdict DateDefendant(s)Court
Compensatory Damages (1)
Punitive Damages
(PM USA)		Appeal Status
MahfuzFebruary 2019PM USA and R.J. ReynoldsBroward
$12 million
$10 million
Fourth District Court of Appeal reversed the judgment against defendants and remanded for a new trial. Plaintiff's motion for rehearing was denied.
HollimanFebruary 2019PM USAMiami-Dade
$3 million
$0
Defendant’s appeal to Third District Court of Appeal pending.
ChadwellSeptember 2018PM USAMiami-Dade
$2 million
$0
Third District Court of Appeal affirmed the compensatory damages award. PM USA petitioned Florida Supreme Court for review. Case stayed pending Florida Supreme Court decision in Prentice.(3)
KaplanJuly 2018PM USA and R.J. ReynoldsBroward
$2 million
$2 million
Fourth District Court of Appeal affirmed the verdict and reaffirmed the verdict on rehearing. Defendants sought review of the decision before the Florida Supreme Court and the court stayed the case pending its decision in Sheffield.(3)
R. DouglasNovember 2017PM USADuval
<$1 million
$0
Awaiting entry of final judgment by the trial court.
SommersApril 2017PM USAMiami-Dade
$1 million
$0
Third District Court of Appeal affirmed compensatory damages award and granted new trial on punitive damages. Florida Supreme Court denied PM USA’s petition for review of the Third District Court of Appeal’s decision. PM USA paid approximately $1 million for the compensatory damages award and awaits the new trial on punitive damages.(4) The trial court stayed the new trial on punitive damages pending Florida Supreme Court’s decision in Sheffield.(3)
Cooper (Blackwood)September 2015PM USA and R.J. ReynoldsBroward
$5 million
(<$1 million PM USA)
$0
Fourth District Court of Appeal affirmed judgment and granted a new trial on punitive damages.
D. BrownJanuary 2015PM USAFederal Court - Middle District of Florida
$8 million
$9 million
Appeal by defendant to U.S. Court of Appeals for the Eleventh Circuit stayed pending Florida Supreme Court decision in Prentice.(3)
(1) PM USA’s portion of the compensatory damages award is noted parenthetically where the court has ruled that comparative fault applies.
(2) Plaintiff’s verdict following a retrial of an initial verdict in favor of plaintiff.
(3) PM USA is not a defendant in Prentice or Sheffield. Prentice and Sheffield are discussed below in Engle Progeny Appellate Issues.
(4) Plaintiff was granted an award of approximately $3 million in fees, costs and interest that PM USA appealed. The Florida Third District Court of Appeals affirmed the award and PM USA paid the award amount in March 2021.
Engle Cases Concluded Within Past 12 Months (1)
(rounded to nearest $ million)
PlaintiffVerdict DateDefendant(s)CourtAccrual DatePayment Amount
(if any)		Payment Date
Berger (Cote)September 2014PM USAFederal Court - Middle District of FloridaFourth quarter of 2018 and first quarter of 2021
$29 million
February 2021
SantoroMarch 2017PM USA, R.J. Reynolds and Liggett GroupBrowardSecond quarter of 2020 and first quarter of 2021
$1 million
January 2021
(1) In six cases in which PM USA paid the judgments more than a year ago, Naugle, Gore, M. Brown, Jordan, Theis and Landi, plaintiffs were awarded approximately $8 million, $2 million, $8 million, $4 million, $1 million and $3 million in fees and costs, respectively. PM USA has appealed in all of these cases, except Theis and Landi. In M. Brown, in March 2021 the Florida First District Court of Appeals affirmed the fee award and reversed the pre-judgment interest award and, in April 2021, PM USA paid $8.2 million in satisfaction of the fee award and post-judgment interest. In Theis, PM USA paid $1 million in satisfaction of fees and costs in May 2021 and, in Landi, PM USA paid approximately $1.5 million in satisfaction of fees, costs and interest in July 2021 (R.J. Reynolds paid approximately $1.5 million of the approximately $3 million award).

Engle Progeny Appellate Issues: The Florida appellate courts are considering the following appeals which may have wide application to other Engle progeny cases:
In Mary Sheffield v. R.J. Reynolds Tobacco Company, an Engle progeny case against R.J. Reynolds only, the Florida Supreme Court has taken jurisdiction to resolve the conflict among Florida’s District Courts of Appeal over whether the 1999 amendments to Florida’s punitive damages statute (including its caps and bar on multiple punitive damages awards for the same course of conduct) apply in wrongful death cases where the decedent was injured prior to the October 1, 1999 effective date of the amendments but died from his or her injuries after such effective date. Oral argument was held before the Florida Supreme Court in April 2021; a decision has not yet been issued.
In Linda Prentice v. R.J. Reynolds Tobacco Company, an Engle progeny case against R.J. Reynolds only, the Florida First District Court of Appeal in January 2020 reversed a judgment in favor of the plaintiff and remanded for a new trial. The court held that the trial court had erred by failing to instruct the jury that in order to prevail on her claim for conspiracy to commit fraudulent concealment, the plaintiff was required to prove that her decedent relied to his detriment on a statement that concealed or omitted material information about the health risks of smoking. That holding conflicts with decisions from the Second, Third, and Fourth District Courts of Appeal, which have each held that Engle plaintiffs do not need to prove reliance on a statement, and instead can prevail by proving reliance on the Engle defendants’ concealment of information. In August 2020, the Florida Supreme Court accepted jurisdiction in the case. As an alternative ground to approve the First District Court of Appeal’s decision in its favor in Prentice, R.J. Reynolds has asked the Florida Supreme Court to reconsider its prior decisions giving the Engle Phase I findings preclusive effect in Engle progeny cases, as described more fully in the section Engle Class Action above. Oral argument was held before the Florida Supreme Court in June 2021; a decision has not yet been issued.
Florida Bond Statute: In June 2009, Florida amended its existing bond cap statute by adding a $200 million bond cap that applies to all state Engle progeny lawsuits in the aggregate and establishes individual bond caps for individual Engle progeny cases in amounts that vary depending on the number of judgments in effect at a given time. Plaintiffs have been unsuccessful in various challenges to the bond cap statute in Florida state court.
No federal court has yet addressed the constitutionality of the bond cap statute or the applicability of the bond cap to Engle progeny cases tried in federal court.
From time to time, legislation has been presented to the Florida legislature that would repeal the bond cap statute; however to date, no legislation repealing the statute has passed.
Other Smoking and Health Class Actions: Since the dismissal in May 1996 of a purported nationwide class action brought on behalf of allegedly addicted smokers, plaintiffs have filed numerous putative smoking and health class action suits in various state and federal courts. In general, these cases purport to be brought on behalf of residents of a particular state or states (although a few cases purport to be nationwide in scope) and raise addiction claims and, in many cases, claims of physical injury as well.
Class certification has been denied or reversed by courts in 61 smoking and health class actions involving PM USA in Arkansas (1), California (1), Delaware (1), the District of Columbia (2), Florida (2), Illinois (3), Iowa (1), Kansas (1), Louisiana (1), Maryland (1), Michigan (1), Minnesota (1), Nevada (29), New Jersey (6), New York (2), Ohio (1), Oklahoma (1), Oregon (1), Pennsylvania (1), Puerto Rico (1), South Carolina (1), Texas (1) and Wisconsin (1). See Certain Other Tobacco-Related
Litigation below for a discussion of “Lights” and “Ultra Lights” class action cases and medical monitoring class action cases pending against PM USA.
As of October 25, 2021, PM USA and Altria are named as defendants, along with other cigarette manufacturers, in seven class actions filed in the Canadian provinces of Alberta, Manitoba, Nova Scotia, Saskatchewan, British Columbia and Ontario. In Saskatchewan, British Columbia (two separate cases) and Ontario, plaintiffs seek class certification on behalf of individuals who suffer or have suffered from various diseases, including chronic obstructive pulmonary disease, emphysema, heart disease or cancer, after smoking defendants’ cigarettes. In the actions filed in Alberta, Manitoba and Nova Scotia, plaintiffs seek certification of classes of all individuals who smoked defendants’ cigarettes. In March 2019, all of these class actions were stayed as a result of three Canadian tobacco manufacturers (none of which is related to Altria or its subsidiaries) seeking protection under Canada’s Companies’ Creditors Arrangement Act (which is similar to Chapter 11 bankruptcy in the U.S.). The companies entered into these proceedings following a Canadian appellate court upholding two smoking and health class action verdicts against those companies totaling approximately CAD $13 billion. See Guarantees and Other Similar Matters below for a discussion of the Distribution Agreement between Altria and PMI, which provides for indemnities for certain liabilities concerning tobacco products.
Health Care Cost Recovery Litigation
Overview: In the health care cost recovery litigation, governmental entities seek reimbursement of health care cost expenditures allegedly caused by tobacco products and, in some cases, of future expenditures and damages. Relief sought by some but not all plaintiffs includes punitive damages, multiple damages and other statutory damages and penalties, injunctions prohibiting alleged marketing and sales to minors, disclosure of research, disgorgement of profits, funding of anti-smoking programs, additional disclosure of nicotine yields, and payment of attorney and expert witness fees.
Although there have been some decisions to the contrary, most judicial decisions in the U.S. have dismissed all or most health care cost recovery claims against cigarette manufacturers. Nine federal circuit courts of appeals and eight state appellate courts, relying primarily on grounds that plaintiffs’ claims were too remote, have ordered or affirmed dismissals of health care cost recovery actions. The United States Supreme Court has refused to consider plaintiffs’ appeals from the cases decided by five federal circuit courts of appeal.
In addition to the cases brought in the U.S., health care cost recovery actions have also been brought against tobacco industry participants, including PM USA and Altria, in Canada (10 cases), and other entities have stated that they are considering filing such actions.
Since the beginning of 2008, the Canadian Provinces of British Columbia, New Brunswick, Ontario, Newfoundland and Labrador, Quebec, Alberta, Manitoba, Saskatchewan, Prince Edward Island and Nova Scotia have brought health care reimbursement claims against cigarette manufacturers. PM USA is named as a defendant in the British Columbia and Quebec cases, while both Altria and PM USA are named as defendants in the New Brunswick, Ontario, Newfoundland and Labrador, Alberta, Manitoba, Saskatchewan, Prince Edward Island and Nova Scotia cases. The Nunavut Territory and Northwest Territory have passed legislation permitting similar claims, but lawsuits based on this legislation have not been filed. All of these cases have been stayed pending resolution of proceedings in Canada involving three tobacco manufacturers (none of which are affiliated with Altria or its subsidiaries) under the Companies’ Creditors Arrangement Act discussed above. See Smoking and Health Litigation - Other Smoking and Health Class Actions above for a discussion of these proceedings. See Guarantees and Other Similar Matters below for a discussion of the Distribution Agreement between Altria and PMI that provides for indemnities for certain liabilities concerning tobacco products.
Settlements of Health Care Cost Recovery Litigation: In November 1998, PM USA and certain other tobacco product manufacturers entered into the 1998 Master Settlement Agreement (the “MSA”) with 46 states, the District of Columbia and certain U.S. territories to settle asserted and unasserted health care cost recovery and other claims. PM USA and certain other tobacco product manufacturers had previously entered into agreements to settle similar claims brought by Mississippi, Florida, Texas and Minnesota (together with the MSA, the “State Settlement Agreements”). The State Settlement Agreements require that the original participating manufacturers or “OPMs” (now PM USA, R.J. Reynolds and, with respect to certain brands, ITG Brands, LLC (“ITG”)) make annual payments of approximately $9.4 billion, subject to adjustments for several factors, including inflation, market share and industry volume. In addition, the OPMs are required to pay settling plaintiffs’ attorneys’ fees, subject to an annual cap of $500 million. For the three months ended September 30, 2021 and 2020, the aggregate amount recorded in cost of sales with respect to the State Settlement Agreements was approximately $1.1 billion and $1.2 billion, respectively. For the nine months ended September 30, 2021 and 2020, the aggregate amount recorded in cost of sales with respect to the State Settlement Agreements was approximately $3.2 billion and $3.3 billion, respectively. These amounts include PM USA’s estimate of amounts related to NPM Adjustments discussed below.
NPM Adjustment Disputes: The “NPM Adjustment” is a reduction in MSA payments made by the OPMs and those manufacturers that are subsequent signatories to the MSA (collectively, the “participating manufacturers” or “PMs”) that
applies if the PMs collectively lose at least a specified level of market share to non-participating manufacturers since 1997, subject to certain conditions and defenses.
The independent auditor (“IA”) appointed under the MSA has calculated that PM USA’s share of the maximum potential NPM Adjustments for 2004-2020 is (exclusive of interest or earnings): $388 million for 2004; $181 million for 2005; $154 million for 2006; $185 million for 2007; $250 million for 2008; $211 million for 2009; $218 million for 2010; $166 million for 2011; $214 million for 2012; $224 million for 2013; $258 million for 2014; $313 million for 2015; $292 million for 2016; $302 million for 2017; $325 million for 2018; $444 million for 2019; and $572 million for 2020. These maximum amounts will be reduced, likely substantially, to reflect the NPM Adjustment settlements discussed below, and potentially for current and future calculation disputes and other developments. In addition, PM USA’s recovery of these amounts, even as reduced, is dependent upon subsequent determinations regarding state-specific defenses and disputes with other PMs.
Settlements of NPM Adjustment Disputes.
▪Multi-State Settlement. By the end of 2018, PM USA entered into a multi-state settlement of NPM Adjustment disputes with a total of 36 MSA states and territories in which PM USA settled the NPM Adjustment disputes through 2022 with 35 of the 36 states, and through 2024 with one state. Pursuant to the multi-state settlement, PM USA received $1.03 billion and expects to receive approximately $320 million in credits to offset PM USA’s MSA payments through 2029.
▪New York Settlement. In 2015, PM USA entered into a separate NPM Adjustment settlement with New York in which PM USA settled the NPM Adjustment disputes with New York in perpetuity. PM USA received $373 million pursuant to the New York settlement and expects to receive annual credits applied against the MSA payments due to New York going forward.
▪Montana Settlement. In 2020, PM USA entered into a separate NPM Adjustment settlement with Montana in which PM USA settled the NPM Adjustment disputes with Montana through 2030. This settlement resulted in a payment by PM USA of $4 million.
Continuing NPM Adjustment Disputes with States That Have Not Settled.
▪2004 NPM Adjustment. The PMs and the 10 states that have not settled the NPM Adjustment disputes are currently arbitrating NPM Adjustment disputes for 2004 in a multi-state arbitration. Hearings for 9 of the 10 states have concluded. In September 2021, the arbitration panels issued decisions finding that two states, Missouri and Washington, were not diligent in their enforcement of their escrow statutes in 2004 and, therefore, are subject to the NPM adjustment for 2004. The arbitration panels further found that the remaining seven states were diligent in their enforcement and, therefore, are not subject to the NPM adjustment for 2004. The hearing for one remaining state is currently scheduled for February 2022. Several issues remain to be resolved by the arbitration panels that will affect the final amount of the 2004 NPM adjustment PM USA and other PMs will receive. PM USA recorded $21 million as a reduction to cost of sales in the third quarter of 2021 for its estimate of the minimum amount of the 2004 NPM adjustment it will receive. PM USA estimates it is entitled to interest of approximately $23 million in connection with the 2004 NPM adjustment, which it recorded as interest income in the third quarter of 2021.
▪2005-2007 NPM Adjustments. The PMs and the 10 states that have not settled the NPM Adjustment disputes are currently arbitrating NPM Adjustment disputes before a single arbitration panel. The arbitration encompasses three years, 2005-2007, for nine of the 10 states, and one year, 2005, for one state. As of October 25, 2021, no decisions have resulted from the arbitration.
▪Subsequent Years. No assurance can be given as to when proceedings for 2008 and subsequent years will be scheduled or the precise form those proceedings will take.
Other Disputes Under the State Settlement Agreements: The payment obligations of the tobacco product manufacturers that are parties to the State Settlement Agreements, as well as the allocations of any NPM Adjustments and related settlements, have been and may continue to be affected by R.J. Reynolds’s acquisition of Lorillard in 2015 and its related sale of certain cigarette brands to ITG (the “ITG transferred brands”). PM USA filed motions to enforce the state settlement agreements in Florida, Minnesota, Texas and Mississippi in connection with various positions that R.J. Reynolds and ITG took with regard to the ITG transferred brands. After various court decisions in each of those states that were favorable to PM USA, those motions to enforce have now been resolved either through settlement or exhaustion of appeals. Despite these resolutions, PM USA continues to dispute the accuracy of certain submissions made by R.J. Reynolds and ITG concerning the calculation of certain payments relating to the ITG transferred brands and may pursue such claims.
In December 2019, the State of Mississippi filed a motion in Mississippi state court seeking to enforce the Mississippi State Settlement Agreement against PM USA, R.J. Reynolds and ITG concerning the tax rates used in the annual calculation of the net operating profit adjustment payments starting in 2018. The Mississippi state court held a hearing in October 2021 and has not yet issued a decision.
In January 2021, PM USA and other PMs reached an agreement with several MSA states to waive the PMs’ claim under the most favored nation provision of the MSA in connection with a settlement between those MSA states and a non-participating manufacturer, S&M Brands, Inc. (“S&M Brands”), under which the states released certain claims against S&M Brands in exchange for receiving a portion of the funds S&M Brands deposited into escrow accounts in those states pursuant to the states’ escrow statutes. In consideration for waiving its most favored nation claim, PM USA received approximately $32 million from the escrow funds paid to those MSA states under their settlement with S&M Brands. These funds were received in January 2021 and were recorded in Altria’s condensed consolidated statement of earnings for the first quarter of 2021 as a reduction to cost of sales.
Federal Government’s Lawsuit: In 1999, the United States government filed a lawsuit in the U.S. District Court for the District of Columbia against various cigarette manufacturers, including PM USA, and others, including Altria, asserting claims under three federal statutes. The case ultimately proceeded only under the civil provisions of RICO. In August 2006, the district court held that certain defendants, including Altria and PM USA, violated RICO and engaged in seven of the eight “sub-schemes” to defraud that the government had alleged. Specifically, the court found that:
▪defendants falsely denied, distorted and minimized the significant adverse health consequences of smoking;
▪defendants hid from the public that cigarette smoking and nicotine are addictive;
▪defendants falsely denied that they control the level of nicotine delivered to create and sustain addiction;
▪defendants falsely marketed and promoted “low tar/light” cigarettes as less harmful than full-flavor cigarettes;
▪defendants falsely denied that they intentionally marketed to youth;
▪defendants publicly and falsely denied that ETS is hazardous to non-smokers; and
▪defendants suppressed scientific research.
The court did not impose monetary penalties on defendants, but ordered the following relief: (i) an injunction against “committing any act of racketeering” relating to the manufacturing, marketing, promotion, health consequences or sale of cigarettes in the United States; (ii) an injunction against participating directly or indirectly in the management or control of the Council for Tobacco Research, the Tobacco Institute, or the Center for Indoor Air Research, or any successor or affiliated entities of each; (iii) an injunction against “making, or causing to be made in any way, any material false, misleading, or deceptive statement or representation or engaging in any public relations or marketing endeavor that is disseminated to the United States public and that misrepresents or suppresses information concerning cigarettes;” (iv) an injunction against conveying any express or implied health message or health descriptors on cigarette packaging or in cigarette advertising or promotional material, including “lights,” “ultra lights” and “low tar,” which the court found could cause consumers to believe one cigarette brand is less hazardous than another brand; (v) the issuance of “corrective statements” in various media regarding the adverse health effects of smoking, the addictiveness of smoking and nicotine, the lack of any significant health benefit from smoking “low tar” or “light” cigarettes, defendants’ manipulation of cigarette design to ensure optimum nicotine delivery and the adverse health effects of exposure to ETS; (vi) the disclosure on defendants’ public document websites and in the Minnesota document repository of all documents produced to the government in the lawsuit or produced in any future court or administrative action concerning smoking and health until the third quarter of 2021, with certain additional requirements as to documents withheld from production under a claim of privilege or confidentiality; (vii) the disclosure of disaggregated marketing data to the government in the same form and on the same schedule as defendants now follow in disclosing such data to the FTC for a period of 10 years; (viii) certain restrictions on the sale or transfer by defendants of any cigarette brands, brand names, formulas or cigarette businesses within the U.S.; and (ix) payment of the government’s costs in bringing the action.
Following several years of appeals relating to the content of the corrective statements remedy described above, in October 2017, the district court approved the parties’ proposed consent order implementing corrective statements in newspapers and on television. The corrective statements began appearing in newspapers and on television in the fourth quarter of 2017. In April 2018, the parties reached agreement on the implementation details of the corrective statements on websites and onserts. The corrective statements began appearing on websites in the second quarter of 2018 and the onserts began appearing in the fourth quarter of 2018.
In 2014 and 2019, Altria and PM USA recorded provisions totaling approximately $36 million for the estimated costs of implementing the corrective communications remedy.
The requirements related to corrective statements at point-of-sale remain outstanding. In May 2014, the district court ordered further briefing on the issue, which was completed in June 2014. In May 2018, the parties submitted a joint status report and additional briefing on point-of-sale signage to the district court. In May 2019, the district court ordered a hearing on the point-of-sale signage issue. The hearing is currently scheduled for June 2022.
In June 2020, the United States government filed a motion with the district court asking for clarification as to whether the court-ordered injunction that applies to cigarettes also applies to HeatSticks, a heated tobacco product used with the IQOS electronic device. In August 2020, Altria and PM USA filed an opposition to the government’s motion and, in the alternative, a motion to
modify the injunction to make clear it does not apply to HeatSticks. Regardless of the district court’s decisions on the pending motions, the government has indicated it will not oppose a modification to the injunction that permits PM USA to use the Modified Risk Tobacco Product claim authorized by the United States Food and Drug Administration for HeatSticks.
E-vapor Product Litigation
As of October 25, 2021, Altria and/or its subsidiaries, including PM USA, were named as defendants in 53 class action lawsuits relating to JUUL e-vapor products. JUUL is an additional named defendant in each of these lawsuits. The theories of recovery include violation of RICO, fraud, failure to warn, design defect, negligence and unfair trade practices. Plaintiffs seek various remedies, including compensatory and punitive damages and an injunction prohibiting product sales. The 53 class action lawsuits include 28 cases involving plaintiffs whose claims were previously included in other class action complaints but were refiled as separate stand-alone class actions for procedural and other reasons.
Altria and/or its subsidiaries, including PM USA, also have been named as defendants in other lawsuits involving JUUL e-vapor products, including 2,548 individual lawsuits, 350 “third party” lawsuits, which include school districts, state and local governments and tribal and healthcare organization lawsuits. JUUL is an additional named defendant in each of these lawsuits.
The majority of the individual and class action lawsuits mentioned above were filed in federal court. In October 2019, the United States Judicial Panel on Multidistrict Litigation ordered the coordination or consolidation of these lawsuits in the U.S. District Court for the Northern District of California for pretrial purposes.
Altria and its subsidiaries filed motions to dismiss certain claims in the class action and school district cases, including the federal RICO claim. In October 2020, the U.S. District Court for the Northern District of California granted the motion to dismiss the RICO class action claim without prejudice. Although it otherwise denied the motion, the court found that plaintiffs had not sufficiently alleged standing or causation with respect to their claim under California law. The court also granted the motion to dismiss the RICO claim in the cases filed by various school districts, but denied the motion in all other respects. The court gave plaintiffs the opportunity to amend their complaints to attempt to cure the deficiencies the court identified and plaintiffs filed their amended complaints in November 2020. In January 2021, Altria and its subsidiaries filed a renewed motion to dismiss the RICO claim, which the court denied in April 2021. In December 2020, the U.S. District Court for the Northern District of California and the parties selected 20 personal injury plaintiffs to be adjudicated as bellwether cases and in July 2021, the court set dates for the first four of such cases to commence in 2022.
An additional group of cases is pending in California state courts. In January 2020, the Judicial Council of California determined that this group of cases was appropriate for coordination and assigned the group to the Superior Court of California, Los Angeles County, for pretrial purposes.
JUUL also is named in a significant number of additional individual and class action lawsuits to which neither Altria nor any of its subsidiaries is currently named.
Three of the “third party” lawsuits noted above against Altria and/or its subsidiaries and JUUL, as an additional named defendant, were initiated, individually, by the attorneys general of Alaska, Hawaii and Minnesota alleging violations of state consumer protection and other similar laws. JUUL is also named in other attorneys general lawsuits to which neither Altria nor any of its subsidiaries is currently named. JUUL settled one such lawsuit by agreeing to (i) pay approximately $40 million and (ii) certain restrictions on its sales and marketing activities.
IQOS Litigation
In April 2020, RAI Strategic Holdings, Inc. and R.J. Reynolds Vapor Co., which are affiliates of R.J. Reynolds, filed a lawsuit against Altria, PM USA, Altria Client Services LLC, PMI and its affiliate, Philip Morris Products S.A., in the United States District Court for the Eastern District of Virginia. The lawsuit asserts claims of patent infringement based on the sale of the IQOS electronic device and HeatSticks in the United States. Plaintiffs seek various remedies, including preliminary and permanent injunctive relief, treble damages and attorneys’ fees. Altria and PMI have been dismissed from the lawsuit. In June 2020, the remaining defendants filed a motion to dismiss certain of plaintiffs’ claims and also filed counterclaims against the plaintiffs for infringement of various patents owned by the remaining defendants. The case was stayed in December 2020 due to the COVID-19 pandemic; however, the stay was lifted with respect to defendants’ counterclaims in February 2021 and a trial is currently scheduled for April 2022.
Also in April 2020, a related action was filed against the same defendants by the same plaintiffs, as well as R.J. Reynolds, with the United States International Trade Commission (“ITC”). There, the plaintiffs also allege patent infringement, but the remedies sought include a prohibition on the importation of the IQOS electronic device, HeatSticks and component parts into the United States and on the sale of any such products previously imported into the United States. No damages are recoverable in the proceedings before the ITC. In May 2021, an administrative law judge found that the IQOS electronic device and HeatSticks infringe plaintiffs’ patents and recommended to the ITC a ban on the importation of the IQOS electronic device, HeatSticks and the infringing components into the United States. In September 2021, the ITC affirmed the administrative law judge’s initial determination and issued a limited exclusion order barring the importation of the IQOS electronic device,
HeatSticks and the infringing components into the United States and a cease and desist order barring domestic sales, marketing and distribution of these imported products. The orders will become effective on November 29, 2021 unless rejected by the Biden Administration prior to that date. Defendants may appeal the orders to the United States Court of Appeals for the Federal Circuit; however, any ban on importation or on the sale, marketing and distribution of previously imported product is unlikely to be stayed pending the conclusion of the appeal. Due to this litigation, in October 2021, PM USA announced plans to begin removing the IQOS electronic device and HeatSticks from the marketplace as it awaits the outcome of administrative review.
An additional unrelated patent infringement case regarding the IQOS electronic device was filed in November 2020 in the United States District Court for the Northern District of Georgia against PM USA and Philip Morris Products S.A. seeking damages and equitable relief. In February 2021, defendants filed a motion to dismiss the lawsuit, which the court granted in July 2021. In August 2021, plaintiff filed a motion to amend the complaint.
Antitrust Litigation
In April 2020, the FTC issued an administrative complaint against Altria and JUUL alleging that Altria’s 35% investment in JUUL and the associated agreements constitute an unreasonable restraint of trade in violation of Section 1 of the Sherman Antitrust Act of 1890 (“Sherman Act”) and Section 5 of the Federal Trade Commission Act of 1914, and substantially lessened competition in violation of Section 7 of the Clayton Antitrust Act (“Clayton Act”). If the FTC’s challenge is successful, the FTC may order a broad range of remedies, including divestiture of Altria’s minority investment in JUUL, rescission of the transaction and all associated agreements, a requirement of FTC approval of future agreements related to the development, manufacture, distribution or sale of e-vapor products and prohibition against any officer or director of either Altria or JUUL serving on the other party’s board of directors or attending meetings of the other party’s board of directors. The administrative trial was held before an FTC administrative law judge in June 2021. The post-trial briefing was completed in October 2021. The administrative law judge’s decision is subject to review by the FTC on its own motion or at the request of any party. The FTC then issues its ruling, which may be appealed to any United States Court of Appeals.
Also as of October 25, 2021, 16 putative class action lawsuits have been filed against Altria and JUUL in the United States District Court for the Northern District of California. The lawsuits initially named, in addition to the two companies, certain senior executives and certain members of the board of directors of both companies as defendants; however, those individuals currently or formerly affiliated with Altria were later dismissed. In November 2020 these lawsuits were consolidated into three complaints (one on behalf of direct purchasers, one on behalf of indirect purchasers and one on behalf of indirect resellers). The consolidated lawsuits, as amended, cite the FTC administrative complaint and allege that Altria and JUUL violated Sections 1, 2 and/or 3 of the Sherman Act and Section 7 of the Clayton Act and various state antitrust, consumer protection and unjust enrichment laws by restraining trade and/or substantially lessening competition in the U.S. closed-system electronic cigarette market. Plaintiffs seek various remedies, including treble damages, attorneys’ fees, a declaration that the agreements between Altria and JUUL are invalid, divestiture of Altria’s minority investment in JUUL and rescission of the transaction. Altria filed a motion to dismiss these lawsuits in January 2021. In August 2021, the United States District Court for the Northern District of California denied Altria’s motion to dismiss except with respect to plaintiffs’ claims for injunctive and equitable relief. However, plaintiffs were granted the opportunity to replead such claims by the trial court, which plaintiffs did in September 2021.
In November 2020, Altria exercised its rights to convert its non-voting JUUL shares to voting shares. However, pending the outcome of the FTC administrative complaint, Altria currently does not intend to exercise its additional governance rights obtained upon the conversion, including the right to elect directors to JUUL’s board or to vote its JUUL shares other than as a passive investor. For further discussion of Altria’s rights in the event of share conversion, see Note 4. Investments in Equity Securities - Investment in JUUL.
Shareholder Class Action and Shareholder Derivative Lawsuits
Shareholder Class Action: In October and December 2019, two purported Altria shareholders filed putative class action lawsuits against Altria, Howard A. Willard III, Altria’s former Chairman and Chief Executive Officer, and William F. Gifford, Jr., Altria’s former Vice Chairman and Chief Financial Officer and current Chief Executive Officer, in the United States District Court for the Eastern District of New York. In December 2019, the court consolidated the two lawsuits into a single proceeding. The consolidated lawsuit was subsequently transferred to the United States District Court for the Eastern District of Virginia. The lawsuit asserts claims under Sections 10(b) and 20(a) and under Rule 10b-5 of the Exchange Act. In April 2020, JUUL, its founders and some of its current and former executives were added to the lawsuit. The claims allege false and misleading statements and omissions relating to Altria’s investment in JUUL. Plaintiffs seek various remedies, including damages and attorneys’ fees. In July 2020, the defendants filed motions to dismiss plaintiffs’ claims, which the district court denied in March 2021.
Federal Shareholder Derivative Lawsuits: In August 2020, two purported Altria shareholders filed separate derivative lawsuits in the United States District Court for the Northern District of California on behalf of themselves and Altria, against Mr. Willard, Mr. Gifford, JUUL and certain of its executives and officers. These derivative lawsuits relate to Altria’s
investment in JUUL, and assert claims of breach of fiduciary duty by the Altria defendants and aiding and abetting in that alleged breach of fiduciary duty by the remaining defendants. In March 2021, the United States District Court for the Northern District of California granted defendants’ motion to transfer both lawsuits to the United States District Court for the Eastern District of Virginia. Three additional federal derivative lawsuits were filed in October 2020, January 2021 and March 2021, respectively, in the United States District Court for the Eastern District of Virginia against Mr. Willard, Mr. Gifford, Mr. Crosthwaite, certain members of Altria’s Board of Directors, JUUL, its founders and some of its current and former executives. These suits assert various claims, including breach of fiduciary duty, unjust enrichment, waste of corporate assets and violations of certain federal securities laws. The remedies sought in these lawsuits include damages, disgorgement of profits, reformation of Altria’s corporate governance and internal procedures, and attorneys’ fees. In April 2021, the court consolidated the five cases pending in the Eastern District of Virginia into a single action.
State Shareholder Derivative Lawsuits: Six derivative lawsuits have been filed in Virginia state courts against Mr. Willard, Mr. Gifford, Mr. Crosthwaite (Altria’s former Chief Growth Officer and JUUL’s current Chief Executive Officer), certain members of Altria’s Board of Directors, JUUL, its founders and some of its current and former executives. The lawsuits were filed in September 2020, May 2021, June 2021, July 2021, August 2021 and August 2021, respectively. The lawsuits assert various claims, including breach of fiduciary duty, and seek remedies similar to those sought by plaintiffs in the cases pending in federal court in the Eastern District of Virginia. In July 2021 and September 2021, the court consolidated the first four of these state derivative cases into a single action.
Certain Other Tobacco-Related Litigation
“Lights/Ultra Lights” Cases and Other Smoking and Health Class Actions: Plaintiffs have sought certification of their cases as class actions, alleging among other things, that the uses of the terms “Lights” and/or “Ultra Lights” constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment or breach of warranty, and have sought injunctive and equitable relief, including restitution and, in certain cases, punitive damages. These class actions have been brought against PM USA and, in certain instances, Altria or its other subsidiaries, on behalf of individuals who purchased and consumed various brands of cigarettes. Defenses raised in these cases include lack of misrepresentation, lack of causation, injury and damages, the statute of limitations, non-liability under state statutory provisions exempting conduct that complies with federal regulatory directives, and the First Amendment. Twenty-one state courts in 23 “Lights” cases have refused to certify class actions, dismissed class action allegations, reversed prior class certification decisions or have entered judgment in favor of PM USA. As of October 25, 2021, two “Lights/Ultra Lights” class actions are pending in U.S. state court. Neither case is active.
As of October 25, 2021, one smoking and health case alleging personal injury or seeking court-supervised programs or ongoing medical monitoring and purporting to be brought on behalf of a class of individual plaintiffs, is pending in a U.S. state court. The case is currently inactive.
UST Litigation: UST and/or its tobacco subsidiaries have been named in a number of individual tobacco and health lawsuits over time. Plaintiffs’ allegations of liability in these cases have been based on various theories of recovery, such as negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, breach of implied warranty, addiction and breach of consumer protection statutes. Plaintiffs have typically sought various forms of relief, including compensatory and punitive damages, and certain equitable relief, including but not limited to disgorgement. Defenses raised in these cases include lack of causation, assumption of the risk, comparative fault and/or contributory negligence, and statutes of limitations. As of October 25, 2021, there is one case pending against USSTC.
Environmental Regulation
Altria and its subsidiaries (and former subsidiaries) are subject to various federal, state and local laws and regulations concerning the discharge of materials into the environment, or otherwise related to environmental protection, including, in the U.S.: the Clean Air Act, the Clean Water Act, the Resource Conservation and Recovery Act and the Comprehensive Environmental Response, Compensation and Liability Act (commonly known as “Superfund”), which can impose joint and several liability on each responsible party. Subsidiaries (and former subsidiaries) of Altria are involved in several matters subjecting them to potential costs of remediation and natural resource damages under Superfund or other laws and regulations. Altria’s subsidiaries expect to continue to make capital and other expenditures in connection with environmental laws and regulations.
Altria provides for expenses associated with environmental remediation obligations on an undiscounted basis when such amounts are probable and can be reasonably estimated. Such accruals are adjusted as new information develops or circumstances change. Other than those amounts, it is not possible to reasonably estimate the cost of any environmental remediation and compliance efforts that subsidiaries of Altria may undertake in the future. In the opinion of management, however, compliance with environmental laws and regulations, including the payment of any remediation costs or damages and the making of related expenditures, has not had, and is not expected to have, a material adverse effect on Altria’s consolidated results of operations, capital expenditures, financial position or cash flows.
Guarantees and Other Similar Matters
In the ordinary course of business, certain subsidiaries of Altria have agreed to indemnify a limited number of third parties in the event of future litigation. At September 30, 2021, Altria and certain of its subsidiaries (i) had $48 million of unused letters of credit obtained in the ordinary course of business; (ii) were contingently liable for guarantees related to their own performance, including $24 million for surety bonds; and (iii) had a redeemable noncontrolling interest of $39 million recorded on its condensed consolidated balance sheet. In addition, from time to time, subsidiaries of Altria issue lines of credit to affiliated entities. These items have not had, and are not expected to have, a significant impact on Altria’s liquidity.
Under the terms of a distribution agreement between Altria and PMI (the “Distribution Agreement”), entered into as a result of Altria’s 2008 spin-off of its former subsidiary PMI, liabilities concerning tobacco products will be allocated based in substantial part on the manufacturer. PMI will indemnify Altria and PM USA for liabilities related to tobacco products manufactured by PMI or contract manufactured for PMI by PM USA, and PM USA will indemnify PMI for liabilities related to tobacco products manufactured by PM USA, excluding tobacco products contract manufactured for PMI. Altria does not have a related liability recorded on its condensed consolidated balance sheet at September 30, 2021 as the fair value of this indemnification is insignificant. PMI has agreed not to seek indemnification with respect to the IQOS patent litigation discussed above under Certain Other Tobacco-Related Litigation - IQOS Litigation, excluding the patent infringement case filed with the United States District Court for the Northern District of Georgia.
PM USA has issued guarantees relating to Altria’s obligations under its outstanding debt securities, borrowings under its $3.0 billion Credit Agreement and amounts outstanding under its commercial paper program.
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.21.2
New Accounting Guidance Not Yet Adopted
 9 Months Ended
Sep. 30, 2021
Accounting Standards Update and Change in Accounting Principle [Abstract]  
New Accounting Guidance Not Yet Adopted New Accounting Guidance Not Yet Adopted
The following table provides a description of issued accounting guidance applicable to, but not yet adopted by, Altria:
StandardsDescriptionEffective Date for Public EntityEffect on Financial Statements
ASU 2020-06 Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity
The guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity.  Key provisions of the guidance include reducing the number of accounting models, simplifying the earnings per share calculations and expanding the disclosures related to convertible instruments.The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. Altria’s adoption of this guidance is not expected to have a material impact on its consolidated financial statements and related disclosures.
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Background and Basis of Presentation (Policies)
 9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Investment, Policy Altria accounts for its investments in ABI and Cronos under the equity method of accounting using a one-quarter lag. Altria accounts for its equity investment in JUUL under the fair value option.
Basis of Presentation, Policy The interim condensed consolidated financial statements of Altria are unaudited. It is the opinion of Altria’s management that all adjustments necessary for a fair statement of the interim results presented have been reflected in the interim condensed consolidated financial statements. All such adjustments were of a normal recurring nature. Net revenues and net earnings for any interim period are not necessarily indicative of results that may be expected for the entire year.
New Accounting Pronouncements, Policy
On January 1, 2021, Altria adopted Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU No. 2019-12”). This guidance removes certain exceptions for investments, intraperiod allocations and interim calculations, and adds guidance to reduce complexity in accounting for income taxes. The adoption of ASU No. 2019-12 did not have a material impact on Altria’s condensed consolidated financial statements.
Additionally, on January 1, 2021, Altria adopted ASU No. 2020-01, Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (“ASU No. 2020-01”). This guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The adoption of ASU No. 2020-01 did not have a material impact on Altria’s condensed consolidated financial statements.
For a description of issued accounting guidance applicable to, but not yet adopted by, Altria, see Note 13. New Accounting Guidance Not Yet Adopted.
StandardsDescriptionEffective Date for Public EntityEffect on Financial Statements
ASU 2020-06 Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity
The guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity.  Key provisions of the guidance include reducing the number of accounting models, simplifying the earnings per share calculations and expanding the disclosures related to convertible instruments.The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. Altria’s adoption of this guidance is not expected to have a material impact on its consolidated financial statements and related disclosures.
Cash Discounts In 2020, a majority of Altria’s businesses offered cash discounts to customers for prompt payment and calculated cash discounts as a percentage of the list price based on historical experience and agreed-upon payment terms. Beginning in the first quarter of 2021 for USSTC and the third quarter of 2021 for PM USA, cash discounts were calculated as a flat rate per unit, based on agreed-upon payment terms. Altria’s businesses record receivables net of the cash discounts on Altria’s condensed consolidated balance sheets.
Equity Method Investments
Altria accounts for its investment in ABI under the equity method of accounting because Altria has the ability to exercise significant influence over the operating and financial policies of ABI, including having active representation on ABI’s board of directors and certain ABI board committees. Through this representation, Altria participates in ABI policy making processes.
Altria reports its share of ABI’s results using a one-quarter lag because ABI’s results are not available in time for Altria to record them in the concurrent period.
The fair value of Altria’s equity investment in ABI is based on (i) unadjusted quoted prices in active markets for ABI’s ordinary shares and was classified in Level 1 of the fair value hierarchy and (ii) observable inputs other than Level 1 prices, such as quoted prices for similar assets for the Restricted Shares, and was classified in Level 2 of the fair value hierarchy. Altria can convert its Restricted Shares to ordinary shares at its discretion. Therefore, the fair value of each Restricted Share is based on the value of an ordinary share.
In October 2019, the fair value of Altria’s equity investment in ABI declined below its carrying value and has not recovered. At December 31, 2020, the fair value of Altria’s equity investment in ABI was $13.8 billion (carrying value of $16.7 billion), which was less than its carrying value by approximately 17%. In preparing its financial statements for the period ended December 31, 2020, Altria evaluated the factors related to the fair value decline, including the impact on the fair value of ABI’s shares during the COVID-19 pandemic, which has negatively impacted ABI’s business. Altria evaluated the duration and magnitude of the fair value decline, ABI’s financial condition and near-term prospects and Altria’s intent and ability to hold its
investment in ABI until recovery. Altria concluded that the decline in fair value of its investment in ABI at December 31, 2020 below its carrying value was temporary and, therefore, no impairment was recorded at that time.Following the consideration of the same factors, Altria, in preparing its financial statements for the period ended September 30, 2021, concluded that the decline in fair value of its investment in ABI at September 30, 2021 was other than temporary. As a result, Altria recorded a non-cash, pre-tax impairment charge of $6.2 billion for the nine and three months ended September 30, 2021, which was recorded to income (losses) from equity investments in its condensed consolidated statements of earnings (losses). This impairment charge reflects the difference between the fair value of Altria’s investment in ABI using ABI’s share price at September 30, 2021 and the carrying value of Altria’s equity investment in ABI at September 30, 2021. Altria continues to have confidence in ABI’s (i) long-term strategies, (ii) premium global brands, (iii) experienced management team and (iv) capability to successfully navigate its near-term challenges. Altria further expects that the impacts related to the COVID-19 pandemic that have negatively impacted ABI’s global business are transitory, but now also anticipates that the full recovery to carrying value will take longer than previously expected. This is evidenced by the resumption of declines in fair value during the third quarter of 2021, following positive share price momentum during the first half of 2021. At September 30, 2021, prior to recording the impairment charge, the fair value of Altria’s investment in ABI was below the carrying value by approximately 35%, which represents an additional 18% reduction in ABI’s share price since December 31, 2020. The fair value of Altria’s equity method investment in Cronos is based on unadjusted quoted prices in active markets for Cronos’s common shares and was classified in Level 1 of the fair value hierarchy. In September 2021, the fair value of Altria’s equity method investment in Cronos declined below its carrying value.
Environmental Regulation Altria and its subsidiaries (and former subsidiaries) are subject to various federal, state and local laws and regulations concerning the discharge of materials into the environment, or otherwise related to environmental protection, including, in the U.S.: the Clean Air Act, the Clean Water Act, the Resource Conservation and Recovery Act and the Comprehensive Environmental Response, Compensation and Liability Act (commonly known as “Superfund”), which can impose joint and several liability on each responsible party. Subsidiaries (and former subsidiaries) of Altria are involved in several matters subjecting them to potential costs of remediation and natural resource damages under Superfund or other laws and regulations. Altria’s subsidiaries expect to continue to make capital and other expenditures in connection with environmental laws and regulations.Altria provides for expenses associated with environmental remediation obligations on an undiscounted basis when such amounts are probable and can be reasonably estimated. Such accruals are adjusted as new information develops or circumstances change.
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue from Contract with Customer (Policies)
 9 Months Ended
Sep. 30, 2021
Revenue from Contract with Customer [Abstract]  
Revenue from Contract with Customer Altria’s businesses record an allowance for returned goods, which is included in other accrued liabilities on Altria’s condensed consolidated balance sheets. While all of Altria’s tobacco operating companies sell tobacco products with dates relative to freshness as printed on product packaging, it is USSTC’s policy to accept authorized sales returns from its customers for products that have passed such dates due to the limited shelf life of USSTC’s MST and snus products. Altria’s businesses record estimated sales returns, which are based principally on historical volume and return rates, as a reduction to revenues. Actual sales returns will differ from estimated sales returns to the extent actual results differ from estimated assumptions. Altria’s businesses reflect differences between actual and estimated sales returns in the period in which the actual amounts become known. These differences, if any, have not had a material impact on Altria’s condensed consolidated financial statements. All returned goods are destroyed upon return and not included in inventory. Consequently, Altria’s businesses do not record an asset for their right to recover goods from customers upon return.
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Background and Basis of Presentation (Tables)
 9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Share Repurchase Activity
Altria’s share repurchase activity for the nine and three months ended September 30, 2021 was as follows:
(in millions, except per share data)For the Nine Months Ended September 30, 2021For the Three Months Ended September 30, 2021
Total number of shares repurchased
20.2 6.7 
Aggregate cost of shares repurchased
$972 $322 
Average price per share of shares repurchased
$48.17 $48.35 
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Assets Held for Sale (Tables)
 9 Months Ended
Sep. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]  
Disposal Groups, Including Discontinued Operations
The major classes of assets and liabilities of IWS classified as held for sale at September 30, 2021 were as follows:
(in millions)September 30, 2021
Assets held for sale
Cash and cash equivalents$36 
Receivables108 
Inventories715 
Property, plant and equipment, net of accumulated depreciation407 
Other intangible assets, net236 
Other assets29 
Total assets1,531 
Reserve(41)
Total assets held for sale1,490 
Liabilities held for sale
Accounts payable114 
Accrued liabilities83 
Accrued pension costs49 
Other liabilities49 
Total liabilities held for sale295 
Assets and liabilities held for sale, net$1,195 
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Investments in Equity Securities (Tables)
 9 Months Ended
Sep. 30, 2021
Investments [Abstract]  
Investment
The carrying amount of Altria’s investments consisted of the following:
(in millions)September 30, 2021December 31, 2020
ABI$11,237 $16,651 
JUUL
1,705 1,705 
Cronos (1)
932 1,173 
Total
$13,874 $19,529 
(1) Atria’s investment in Cronos at September 30, 2021 consisted of Altria’s equity method investment in Cronos ($897 million), the Cronos warrant ($32 million) and the Fixed-price Preemptive Rights ($3 million), (collectively, “Investment in Cronos”). The Investment in Cronos at December 31, 2020 consisted of Altria’s equity method investment in Cronos ($1,010 million), the Cronos warrant ($139 million) and the Fixed-price Preemptive Rights ($24 million). See below for further discussion.
Equity Method Investments
Income (losses) from equity investments accounted for under the equity method of accounting and fair value option consisted of the following:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
ABI (1)
$(5,644)$(306)$(6,036)$(418)
Cronos(145)— 21 (54)
Income (losses) from investments under equity method of accounting(5,789)(306)$(6,015)$(472)
JUUL— — 100 — 
Income (losses) from equity investments$(5,789)$(306)$(5,915)$(472)
(1) For the nine and three months ended September 30, 2021, Altria recorded a non-cash, pre-tax impairment charge of $6,157 million related to its equity investment in ABI. See below for further discussion.
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation
The following table provides a reconciliation of the beginning and ending balance of Altria’s investment in JUUL, which is classified in Level 3 of the fair value hierarchy:
Investment
(in millions)Balance
Balance at December 31, 2020$1,705 
Unrealized gains (losses) included in income (losses) from equity investments— 
Balance at September 30, 2021$1,705 
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments (Tables)
 9 Months Ended
Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Pre-tax Effects of Net Investment Hedges on Accumulated Other Comprehensive Losses
The following table provides (i) the aggregate notional amounts of foreign currency contracts and (ii) the aggregate carrying value and fair value of foreign currency denominated debt:
(in millions)September 30, 2021December 31, 2020
Foreign currency contracts (notional amounts)$— $1,066 
Foreign currency denominated debt
Carrying value4,905 5,171 
Fair value5,288 5,687 
For the nine and three months ended September 30, 2021 and 2020, Altria recorded non-cash, pre-tax unrealized gains (losses), representing the changes in the fair values of the Fixed-price Preemptive Rights and Cronos warrant, as follows:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Fixed-price Preemptive Rights$(21)$(54)$(17)$(25)
Cronos warrant(107)(148)(118)(80)
Total$(128)$(202)$(135)$(105)
The pre-tax effects of Altria’s net investment hedges on accumulated other comprehensive losses and the condensed consolidated statements of earnings (losses) were as follows:
Gain (Loss) Recognized in Accumulated Other Comprehensive LossesGain (Loss) Recognized in
Net Earnings (Losses)		Gain (Loss) Recognized in Accumulated Other Comprehensive LossesGain (Loss) Recognized in
Net Earnings (Losses)
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)20212020202120202021202020212020
Foreign currency contracts$16 $(28)$7 $33 $— $(66)$— $8 
Foreign currency denominated debt270 (215)— — 118 (206)— — 
Total$286 $(243)$7 $33 $118 $(272)$— $8 
Schedule of Debt
The following table provides the aggregate carrying value and fair value of Altria’s total long-term debt:
(in millions)September 30, 2021December 31, 2020
Carrying value$28,127 $29,471 
Fair value31,037 34,682 
Fair Value Measurement Inputs and Valuation Techniques The fair values of the Fixed-price Preemptive Rights and Cronos warrant are estimated using Black-Scholes option-pricing models, adjusted for observable inputs (which are classified in Level 1 of the fair value hierarchy), including share price, and unobservable inputs, including
probability factors and weighting of expected life, volatility levels and risk-free interest rates (which are classified in Level 3 of the fair value hierarchy) based on the following assumptions at:
Fixed-price Preemptive RightsCronos Warrant
September 30, 2021December 31, 2020September 30, 2021December 31, 2020
Share price (1)
C$7.15C$8.84C$7.15C$8.84
Expected life (2)
0.81 year1.05 years1.43 years2.18 years
Expected volatility (3)
67.32%80.68%67.32%80.68%
Risk-free interest rate (4)(5)
0.24%0.13%0.39%0.21%
Expected dividend yield (6)
—%—%—%—%
(1) Based on the closing market price for Cronos common stock on the Toronto Stock Exchange on the date indicated.
(2) Based on the weighted-average expected life of the Fixed-price Preemptive Rights (with a range from approximately 0.25 year to 4.00 years at September 30, 2021 and 0.25 year to 5 years at December 31, 2020) and the March 8, 2023 expiration date of the Cronos warrant.
(3) Based on a blend of historical volatility of the underlying equity security and implied volatility from traded options on the underlying equity security at September 30, 2021. Based on a blend of historical volatility levels of the underlying equity security and peer companies at December 31, 2020.
(4) Based on the implied yield currently available on Canadian Treasury zero coupon issues (with a range from approximately 0.12% to 0.89% at September 30, 2021 and 0.06% to 0.39% at December 31, 2020) weighted for the remaining expected life of the Fixed-price Preemptive Rights.
(5) Based on the implied yield currently available on Canadian Treasury zero coupon issues and the expected life of the Cronos warrant.
(6) Based on Cronos’s expected dividend payments.
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation
The following table provides a reconciliation of the beginning and ending balance of the Fixed-price Preemptive Rights and Cronos warrant, which are classified in Level 3 of the fair value hierarchy:
(in millions)
Balance at December 31, 2019$303 
Pre-tax earnings (losses) recognized in net earnings (losses)(140)
Balance at December 31, 2020163 
Pre-tax earnings (losses) recognized in net earnings (losses)(128)
Balance at September 30, 2021$35 
Schedule of Derivative Liabilities at Fair Value The fair values of Altria’s derivative financial instruments on a gross basis included on the condensed consolidated balance sheets were as follows:
Fair Value of AssetsFair Value of Liabilities
(in millions)
Balance Sheet ClassificationSeptember 30, 2021December 31, 2020Balance Sheet ClassificationSeptember 30, 2021December 31, 2020
Derivatives designated as hedging instruments:
    Foreign currency contracts
Other current assets
$— $— 
Other accrued liabilities
$— $87 
    Foreign currency contracts
Other assets
— — 
Other liabilities
— — 
Total
$— $— $— $87 
Derivatives not designated as hedging instruments:
Cronos warrant
Investments in equity securities
$32 $139 
Fixed-price Preemptive Rights
Investments in equity securities
3 24 
Total
$35 $163 
Total derivatives
$35 $163 $— $87 
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Benefit Plans (Tables)
 9 Months Ended
Sep. 30, 2021
Retirement Benefits [Abstract]  
Schedule of Net Periodic Benefit (Income) Cost
Net periodic benefit (income) cost consisted of the following:
PensionPostretirementPensionPostretirement
For the Nine Months Ended
September 30,		For the Three Months Ended
September 30,
 (in millions)20212020202120202021202020212020
Service cost$51 $55 $15 $13 $17 $18 $5 $5 
Interest cost139 188 29 44 46 62 8 14 
Expected return on plan assets
(393)(376)(10)(11)(131)(125)(2)(4)
Amortization:
Net loss99 108 16 7 33 55 2 — 
Prior service cost (credit)
3 4 (35)(22)1 2 (20)(7)
Net periodic benefit
(income) cost
$(101)$(21)$15 $31 $(34)$12 $(7)$8 
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Earnings (Losses) per Share (Tables)
 9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Earnings Per Share
Basic and diluted earnings (losses) per share (“EPS”) were calculated using the following:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Net earnings (losses) attributable to Altria$851 $2,543 $(2,722)$(952)
Less: Distributed and undistributed earnings attributable to share-based awards
(8)(6)(2)(1)
Earnings (losses) for basic and diluted EPS$843 $2,537 $(2,724)$(953)
Weighted-average shares for basic EPS1,849 1,858 1,842 1,858 
Plus: contingently issuable performance stock units— 1 — 1 
Weighted-average shares for diluted EPS1,849 1,859 1,842 1,859 
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Other Comprehensive Earnings/Losses (Tables)
 9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
The following tables set forth the changes in each component of accumulated other comprehensive losses, net of deferred income taxes, attributable to Altria:
For the Nine Months Ended September 30, 2021
(in millions)Benefit PlansABICurrency
Translation
Adjustments and Other		Accumulated
Other
Comprehensive
Losses
Balances, December 31, 2020$(2,420)$(1,938)$17 $(4,341)
Other comprehensive earnings (losses) before reclassifications
432 
(1)
685 35 1,152 
Deferred income taxes(118)(151)— (269)
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes
314 534 35 883 
Amounts reclassified to net earnings (losses) 92 (49)(2)41 
Deferred income taxes(23)10 — (13)
Amounts reclassified to net earnings (losses), net of deferred income taxes69 (39)(2)28 
Other comprehensive earnings (losses), net of deferred income taxes
383 495 
(2)
33 911 
Balances, September 30, 2021$(2,037)$(1,443)$50 $(3,430)
For the Three Months Ended September 30, 2021
(in millions)Benefit PlansABICurrency
Translation
Adjustments and Other 		Accumulated
Other
Comprehensive
Losses
Balances, June 30, 2021$(2,043)$(1,604)$45 $(3,602)
Other comprehensive earnings (losses) before reclassifications
— 

215 6 221 
Deferred income taxes(9)(48)— (57)
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes
(9)167 6 164 
Amounts reclassified to net earnings (losses)20 (7)(1)12 
Deferred income taxes(5)1 — (4)
Amounts reclassified to net earnings (losses), net of deferred income taxes15 (6)(1)8 
Other comprehensive earnings (losses), net of deferred income taxes
6 161 
(2)
5 172 
Balances, September 30, 2021$(2,037)$(1,443)$50 $(3,430)
For the Nine Months Ended September 30, 2020
(in millions)Benefit PlansABICurrency
Translation
Adjustments and Other		Accumulated
Other
Comprehensive
Losses
Balances, December 31, 2019$(2,192)$(693)$21 $(2,864)
Other comprehensive earnings (losses) before reclassifications
(75)(1,211)(16)(1,302)
Deferred income taxes19 260 — 279 
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes
(56)(951)(16)(1,023)
Amounts reclassified to net earnings (losses)111 29 — 140 
Deferred income taxes(28)(6)— (34)
Amounts reclassified to net earnings (losses), net of deferred income taxes83 23 — 106 
Other comprehensive earnings (losses), net of deferred income taxes
27 (928)
(2)
(16)(917)
Balances, September 30, 2020$(2,165)$(1,621)$5 $(3,781)
For the Three Months Ended September 30, 2020
(in millions)Benefit PlansABICurrency
Translation
Adjustments and Other		Accumulated
Other
Comprehensive
Losses
Balances, June 30, 2020$(2,150)$(1,606)$(18)$(3,774)
Other comprehensive earnings (losses) before reclassifications
(75)(71)23 (123)
Deferred income taxes19 22 — 41 
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes
(56)(49)23 (82)
Amounts reclassified to net earnings (losses)55 44 — 99 
Deferred income taxes(14)(10)— (24)
Amounts reclassified to net earnings (losses), net of deferred income taxes41 34 — 75 
Other comprehensive earnings (losses), net of deferred income taxes
(15)(15)
(2)
23 (7)
Balances, September 30, 2020$(2,165)$(1,621)$5 $(3,781)
(1) Reflects the remeasurement impact of salaried retiree healthcare plan amendments. For further discussion, see Note 6. Benefit Plans.
(2) Primarily reflects Altria’s share of ABI’s currency translation adjustments and the impact of Altria’s designated net investment hedges. For further discussion of designated net investment hedges, see Note 5. Financial Instruments.
Reclassification out of Accumulated Other Comprehensive Income
The following table sets forth pre-tax amounts by component, reclassified from accumulated other comprehensive losses to net earnings (losses):
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Benefit Plans: (1)
Net loss$124 $129 $39 $60 
Prior service cost/credit(32)(18)(19)(5)
92 111 20 55 
ABI (2)
(49)29 (7)44 
Currency Translation Adjustments and Other (2)
(2)— (1)— 
Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings (losses)$41 $140 $12 $99 
(1) Amounts are included in net defined benefit plan costs. For further information related to defined benefit plans, see Note 6. Benefit Plans.
(2) Amounts are included in (income) losses from equity investments. For further information related to equity investments, see Note 4. Investments in Equity Securities.
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
Segment data were as follows:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Net revenues:
Smokeable products$17,275 $17,522 $5,975 $6,313 
Oral tobacco products1,945 1,901 626 640 
Wine494 434 177 157 
All other44 (8)8 13 
Net revenues$19,758 $19,849 $6,786 $7,123 
Earnings (losses) before income taxes:
OCI:
Smokeable products$7,901 $7,609 $2,753 $2,789 
Oral tobacco products1,269 1,297 405 436 
Wine21 (347)(24)19 
All other(56)(63)(30)(7)
Amortization of intangibles(53)(54)(18)(17)
General corporate expenses(255)(150)(135)(60)
Operating income8,827 8,292 2,951 3,160 
Interest and other debt expense, net(869)(893)(266)(310)
Loss on early extinguishment of debt(649)— — — 
Net periodic benefit income, excluding
service cost
152 58 63 3 
Income (losses) from equity investments(5,789)(306)(5,915)(472)
Impairment of JUUL equity securities— (2,600)— (2,600)
Gain (loss) on Cronos-related financial instruments(128)(202)(135)(105)
Earnings (losses) before income taxes$1,544 $4,349 $(3,302)$(324)
Schedule of Non-Participating Manufacturer Adjustment Items Non-Participating Manufacturer (“NPM”) Adjustment Items: Pre-tax (income) for NPM adjustment items was recorded to Altria’s condensed consolidated statements of earnings (losses) as follows:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)20212021
Smokeable products segment$(53)$(21)
Interest and other debt expense, net(23)(23)
Total$(76)$(44)
Schedule of Tobacco and Health and Certain Other Litigation Items Tobacco and Health and Certain Other Litigation Items: Pre-tax charges related to tobacco and health and certain other litigation items were recorded in Altria’s condensed consolidated statements of earnings (losses) as follows:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Smokeable products segment$72 $73 $29 $34 
General corporate70 — 70 — 
Interest and other debt expense, net6 3 6 — 
Total$148 $76 $105 $34 
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Debt (Tables)
 9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Instruments
During the first quarter of 2021, Altria completed debt tender offers to purchase for cash certain of its long-term senior unsecured notes in an aggregate principal amount of $4,042 million. Details of the debt tender offers are as follows:
(in millions)Principal Amount of Notes Purchased
2.850% Notes due 2022
$795 
2.950% Notes due 2023
132 
4.000% Notes due 2024
624 
3.800% Notes due 2024
655 
4.400% Notes due 2026
430 
4.800% Notes due 2029
1,094 
9.950% Notes due 2038
65 
10.200% Notes due 2039
18 
6.200% Notes due 2059
229 
$4,042 
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes update (Tables)
 9 Months Ended
Sep. 30, 2021
Income Tax Disclosure [Abstract]  
Summary of Income Taxes
Earnings (losses) before income taxes, provision (benefit) for income taxes and income tax rates consisted of the following:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Earnings (losses) before income taxes$1,544$4,349$(3,302)$(324)
Provision (benefit) for income taxes6931,817(582)632
Income tax rate44.9 %41.8 %17.6 %(195.1)%
Summary of Valuation Allowance
The following chart provides a reconciliation of the beginning and ending valuation allowances for the period ended September 30, 2021:
(in millions)
Balance at beginning of year$2,817 
Additions to valuation allowance charged to income tax expense264 
Reductions to valuation allowance credited to income tax benefit(73)
Foreign currency translation(4)
Balance at end of period$3,004 
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Contingencies (Tables)
 9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Contingencies
The changes in Altria’s accrued liability for tobacco and health and certain other litigation items, including related interest costs, for the periods specified below are as follows:
For the Nine Months Ended September 30,For the Three Months Ended September 30,
(in millions)2021202020212020
Accrued liability for tobacco and health and certain other litigation items at beginning of period$9 $14 $— $22 
Pre-tax charges for:
Tobacco and health and certain other litigation (1)
142 73 99 34 
Related interest costs
6 3 6 — 
Payments (1)
(60)(81)(8)(47)
Accrued liability for tobacco and health and certain other litigation items at end of period$97 $9 $97 $9 
(1) Includes amounts related to certain other litigation and pre-trial resolution of certain tobacco and health cases.
The table below lists the number of certain tobacco-related cases pending in the U.S. against PM USA and/or Altria as of October 25, 2021, October 27, 2020 and October 28, 2019:
October 25, 2021October 27, 2020October 28, 2019
Individual Smoking and Health Cases (1)
17914295
Health Care Cost Recovery Actions (2)
111
E-vapor Cases (3)
2,9511,145—
Other Tobacco-Related Cases (4)
344
(1) Includes 18 cases filed in Illinois, 17 cases filed in New Mexico, 40 cases filed in Massachusetts and 70 non-Engle cases filed in Florida. Does not include individual smoking and health cases brought by or on behalf of plaintiffs in Florida state and federal courts following the decertification of the Engle case (these Engle progeny cases are discussed below in Smoking and Health Litigation - Engle Class Action). Also does not include 1,471 cases brought by flight attendants seeking compensatory damages for personal injuries allegedly caused by exposure to environmental tobacco smoke (“ETS”). The flight attendants allege that they are members of an ETS smoking and health class action in Florida, which was settled in 1997 (Broin). The terms of the court-approved settlement in that case allowed class members to file individual lawsuits seeking compensatory damages, but prohibited them from seeking punitive damages. Class members were prohibited from filing individual lawsuits after 2000 under the court-approved settlement.
(2) See Health Care Cost Recovery Litigation - Federal Government’s Lawsuit below.
(3) Includes 53 class action lawsuits, 2,548 individual lawsuits and 350 “third party” lawsuits relating to JUUL e-vapor products, which include school districts, state and local government, tribal and healthcare organization lawsuits. JUUL is an additional named defendant in each of these lawsuits. The 53 class action lawsuits include 28 cases in the Northern District of California (“Multidistrict Litigation” or “MDL”) involving plaintiffs whose claims were previously included in other class action complaints but were refiled as separate stand-alone class actions for procedural and other reasons.
(4) Includes one inactive smoking and health case alleging personal injury and purporting to be brought on behalf of a class of individual plaintiffs and two inactive class action lawsuits alleging that use of the terms “Lights” and “Ultra Lights” constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment, breach of warranty or violations of RICO.
Currently Pending Engle Cases with Verdicts Against PM USA
(rounded to nearest $ million)
PlaintiffVerdict DateDefendant(s)Court
Compensatory Damages (1)
Punitive Damages
(PM USA)		Appeal Status
LippSeptember 2021PM USAMiami-Dade
$15 million
$28 million
Defendant’s post-trial motions denied. Defendant plans to appeal.
Garcia
May 2021
PM USAMiami-Dade
$3 million
MistrialAppeal by defendant to Third District Court of Appeal pending.
Duignan
February 2020 (2)
PM USA and R.J. ReynoldsPinellas
$3 million
$12 million
Appeal by defendants to Second District Court of Appeal pending.
CuddiheeJanuary 2020PM USADuval
$3 million
$0
Appeal by defendant to First District Court of Appeal pending.
Rintoul (Caprio)
November 2019 (2)
PM USA and R.J. ReynoldsBroward
$9 million
$74 million
Appeal by plaintiff and defendants to Fourth District Court of Appeal pending.
Gloger
November 2019 (2)
PM USA and R.J. ReynoldsMiami-Dade
$15 million
$11 million
Appeal by defendants to Third District Court of Appeal pending.
McCallMarch 2019PM USABroward
<$1 million (<$1 million PM USA)
$0
New trial ordered on punitive damages.
NeffMarch 2019PM USA and R.J. ReynoldsBroward
$4 million
$2 million
Fourth District Court of Appeal reversed the judgment against defendants and remanded for a new trial. Plaintiff's motion for rehearing was denied.
PlaintiffVerdict DateDefendant(s)Court
Compensatory Damages (1)
Punitive Damages
(PM USA)		Appeal Status
MahfuzFebruary 2019PM USA and R.J. ReynoldsBroward
$12 million
$10 million
Fourth District Court of Appeal reversed the judgment against defendants and remanded for a new trial. Plaintiff's motion for rehearing was denied.
HollimanFebruary 2019PM USAMiami-Dade
$3 million
$0
Defendant’s appeal to Third District Court of Appeal pending.
ChadwellSeptember 2018PM USAMiami-Dade
$2 million
$0
Third District Court of Appeal affirmed the compensatory damages award. PM USA petitioned Florida Supreme Court for review. Case stayed pending Florida Supreme Court decision in Prentice.(3)
KaplanJuly 2018PM USA and R.J. ReynoldsBroward
$2 million
$2 million
Fourth District Court of Appeal affirmed the verdict and reaffirmed the verdict on rehearing. Defendants sought review of the decision before the Florida Supreme Court and the court stayed the case pending its decision in Sheffield.(3)
R. DouglasNovember 2017PM USADuval
<$1 million
$0
Awaiting entry of final judgment by the trial court.
SommersApril 2017PM USAMiami-Dade
$1 million
$0
Third District Court of Appeal affirmed compensatory damages award and granted new trial on punitive damages. Florida Supreme Court denied PM USA’s petition for review of the Third District Court of Appeal’s decision. PM USA paid approximately $1 million for the compensatory damages award and awaits the new trial on punitive damages.(4) The trial court stayed the new trial on punitive damages pending Florida Supreme Court’s decision in Sheffield.(3)
Cooper (Blackwood)September 2015PM USA and R.J. ReynoldsBroward
$5 million
(<$1 million PM USA)
$0
Fourth District Court of Appeal affirmed judgment and granted a new trial on punitive damages.
D. BrownJanuary 2015PM USAFederal Court - Middle District of Florida
$8 million
$9 million
Appeal by defendant to U.S. Court of Appeals for the Eleventh Circuit stayed pending Florida Supreme Court decision in Prentice.(3)
(1) PM USA’s portion of the compensatory damages award is noted parenthetically where the court has ruled that comparative fault applies.
(2) Plaintiff’s verdict following a retrial of an initial verdict in favor of plaintiff.
(3) PM USA is not a defendant in Prentice or Sheffield. Prentice and Sheffield are discussed below in Engle Progeny Appellate Issues.
(4) Plaintiff was granted an award of approximately $3 million in fees, costs and interest that PM USA appealed. The Florida Third District Court of Appeals affirmed the award and PM USA paid the award amount in March 2021.
Engle Cases Concluded Within Past 12 Months (1)
(rounded to nearest $ million)
PlaintiffVerdict DateDefendant(s)CourtAccrual DatePayment Amount
(if any)		Payment Date
Berger (Cote)September 2014PM USAFederal Court - Middle District of FloridaFourth quarter of 2018 and first quarter of 2021
$29 million
February 2021
SantoroMarch 2017PM USA, R.J. Reynolds and Liggett GroupBrowardSecond quarter of 2020 and first quarter of 2021
$1 million
January 2021
(1) In six cases in which PM USA paid the judgments more than a year ago, Naugle, Gore, M. Brown, Jordan, Theis and Landi, plaintiffs were awarded approximately $8 million, $2 million, $8 million, $4 million, $1 million and $3 million in fees and costs, respectively. PM USA has appealed in all of these cases, except Theis and Landi. In M. Brown, in March 2021 the Florida First District Court of Appeals affirmed the fee award and reversed the pre-judgment interest award and, in April 2021, PM USA paid $8.2 million in satisfaction of the fee award and post-judgment interest. In Theis, PM USA paid $1 million in satisfaction of fees and costs in May 2021 and, in Landi, PM USA paid approximately $1.5 million in satisfaction of fees, costs and interest in July 2021 (R.J. Reynolds paid approximately $1.5 million of the approximately $3 million award).
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.21.2
New Accounting Guidance Not Yet Adopted (Tables)
 9 Months Ended
Sep. 30, 2021
Accounting Standards Update and Change in Accounting Principle [Abstract]  
Recent Accounting Guidance Not Yet Adopted
The following table provides a description of issued accounting guidance applicable to, but not yet adopted by, Altria:
StandardsDescriptionEffective Date for Public EntityEffect on Financial Statements
ASU 2020-06 Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity
The guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity.  Key provisions of the guidance include reducing the number of accounting models, simplifying the earnings per share calculations and expanding the disclosures related to convertible instruments.The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. Altria’s adoption of this guidance is not expected to have a material impact on its consolidated financial statements and related disclosures.
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Background and Basis of Presentation (Narrative) (Details) - USD ($)
 1 Months Ended 3 Months Ended 5 Months Ended 9 Months Ended 12 Months Ended
Aug. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Sep. 30, 2020
Apr. 29, 2021
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Oct. 28, 2021
Jan. 31, 2021
Apr. 30, 2020
Jul. 31, 2019
Equity, Class of Treasury Stock [Line Items]                        
Payments to acquire additional interest in subsidiaries         $ 250,000,000              
Common stock, dividend increase, percentage 4.70%                      
Dividends declared (usd per share) $ 0.90 $ 0.90 $ 0.86 $ 0.86   $ 2.62 $ 2.54          
Common stock, dividend rate, annual (in usd per share)   $ 3.60       $ 3.60            
July 2019 Share Repurchase Program [Member]                        
Equity, Class of Treasury Stock [Line Items]                        
Planned share repurchase program                       $ 1,000,000,000
Stock repurchase program, rescinded authorized repurchase amount                     $ 500,000,000  
Repurchase of common stock (shares)               0        
January 2021 Share Repurchase Program [Member]                        
Equity, Class of Treasury Stock [Line Items]                        
Planned share repurchase program                   $ 2,000,000,000    
Repurchase of common stock (shares)   6,700,000       20,200,000            
Stock repurchase program, remaining authorized repurchase amount   $ 1,028,000,000       $ 1,028,000,000            
January 2021 Share Repurchase Program [Member] | Subsequent Event [Member]                        
Equity, Class of Treasury Stock [Line Items]                        
Planned share repurchase program                 $ 3,500,000,000      
Stock repurchase program, increase authorized amount                 $ 1,500,000,000      
Helix Innovations LLC [Member]                        
Equity, Class of Treasury Stock [Line Items]                        
Subsidiary ownership percentage         100.00%              
Noncontrolling interest, remaining interest purchased by parent         20.00%              
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Background and Basis of Presentation (Share Repurchase Table) (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2021
Equity, Class of Treasury Stock [Line Items]    
Aggregate cost of shares repurchased $ 322 $ 972
January 2021 Share Repurchase Program [Member]    
Equity, Class of Treasury Stock [Line Items]    
Total number of shares repurchased (shares) 6.7 20.2
Aggregate cost of shares repurchased $ 322 $ 972
Average price per share of shares repurchased (usd per share) $ 48.35 $ 48.17
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Revenues from Contracts with Customers (Narrative) (Details) - USD ($)
 9 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Deferred revenue $ 260,000,000 $ 301,000,000
Expected period for satisfaction of performance obligation three days  
Receivables, Net Current, Including Assets Held For Sale $ 144,000,000  
Receivables 36,000,000 137,000,000
Allowance for doubtful accounts, receivables 0 $ 0
Disposal Group, Held-for-sale, Not Discontinued Operations [Member]    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Disposal group, including discontinued operation, accounts, notes and loans receivable, net $ 108,000,000  
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Assets Held for Sale (Narrative) (Details) - Disposal Group, Held-for-sale, Not Discontinued Operations [Member] - USD ($)
$ in Millions
 9 Months Ended
Oct. 01, 2021
Sep. 30, 2021
Ste. Michelle Transaction [Member] | Subsequent Event [Member]    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Disposal group, including discontinued operation, consideration $ 1,200  
Ste. Michelle Transaction [Member]    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Pre-tax charge for adjustment to record the assets and liabilities at fair value less costs to sell   $ 41
Disposal group disposition related costs   10
Disposal group, total pre-tax charges   41
Ste. Michelle Transaction [Member] | Wine Segment [Member] | Marketing Administration And Research Costs [Member]    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Disposal group, total pre-tax charges   $ 51
Ste. Michelle Transaction [Member] | Subsequent Event [Member]    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Proceeds from divestiture of businesses $ 1,200  
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Assets Held for Sale (Summary of Major Classes of Assets and Liabilities Classified as Held for Sale) (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Assets held for sale    
Assets held for sale $ 1,490 $ 0
Liabilities held for sale    
Liabilities held for sale 295 $ 0
Disposal Group, Held-for-sale, Not Discontinued Operations [Member]    
Assets held for sale    
Receivables 108  
Ste. Michelle Transaction [Member] | Disposal Group, Held-for-sale, Not Discontinued Operations [Member]    
Assets held for sale    
Cash and cash equivalents 36  
Receivables 108  
Inventories 715  
Property, plant and equipment, net of accumulated depreciation 407  
Other intangible assets, net 236  
Other assets 29  
Total assets 1,531  
Reserve (41)  
Assets held for sale 1,490  
Liabilities held for sale    
Accounts payable 114  
Accrued liabilities 83  
Accrued pension costs 49  
Other liabilities 49  
Liabilities held for sale 295  
Assets and liabilities held for sale, net $ 1,195  
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Investments in Equity Securities (Summary of Investments) (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Investments [Line Items]    
Investments $ 13,874 $ 19,529
ABI [Member]    
Investments [Line Items]    
Investments in equity securities 11,237 16,651
JUUL [Member]    
Investments [Line Items]    
JUUL 1,705 1,705
Cronos [Member]    
Investments [Line Items]    
Investments in equity securities 932 1,173
Equity Contract, Warrant [Member] | Cronos [Member]    
Investments [Line Items]    
Derivative asset, fair value, gross asset 32 139
Equity Contract, Preemptive Rights [Member] | Cronos [Member]    
Investments [Line Items]    
Derivative asset, fair value, gross asset 3 24
Common Stock [Member] | Cronos [Member]    
Investments [Line Items]    
Investments in equity securities $ 897 $ 1,010
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Investments in Equity Securities (Earnings in Equity Securities) (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]          
Income (losses) from investments under equity method of accounting $ (6,015,000,000) $ (472,000,000) $ (5,789,000,000) $ (306,000,000)  
Income (losses) from equity investments (5,915,000,000) (472,000,000) (5,789,000,000) (306,000,000)  
ABI [Member]          
Schedule of Equity Method Investments [Line Items]          
Income (losses) from investments under equity method of accounting (6,036,000,000) (418,000,000) (5,644,000,000) (306,000,000)  
Equity method investment, impairment 6,157,000,000   6,157,000,000   $ 0
Cronos [Member]          
Schedule of Equity Method Investments [Line Items]          
Income (losses) from investments under equity method of accounting 21,000,000 (54,000,000) (145,000,000) 0  
JUUL [Member]          
Schedule of Equity Method Investments [Line Items]          
JUUL $ 100,000,000 $ 0 $ 0 $ 0  
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Investments in Equity Securities (Investment in ABI Narrative) (Details) - USD ($)
shares in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2021
Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]      
Fair value of equity investment $ 11,200,000,000 $ 11,200,000,000  
Equity method investment, difference between carrying amount and underlying equity $ 14,000,000 $ 14,000,000 $ 77,000,000
ABI [Member]      
Schedule of Equity Method Investments [Line Items]      
Equity method investment, ownership percentage 10.00% 10.00%  
Number of restricted shares owned (in shares) 185 185  
Number of ordinary shares owned (in shares) 12 12  
Restricted shares, lock-up period   5 years  
Investments in equity securities $ 11,237,000,000 $ 11,237,000,000 $ 16,651,000,000
Difference between carrying amount and fair value, percentage (approximately)   35.00% 17.00%
Equity method investment, impairment $ 6,157,000,000 $ 6,157,000,000 $ 0
Equity method investment, reduction in share price, percentage 18.00% 18.00%  
Equity method investment, difference between carrying amount and underlying equity $ 5,100,000,000 $ 5,100,000,000  
Fair Value, Inputs, Level 1 [Member] | ABI [Member]      
Schedule of Equity Method Investments [Line Items]      
Fair value of equity investment     $ 13,800,000,000
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Investments in Equity Securities (Investment in JUUL Narrative) (Details) - USD ($)
shares in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Oct. 31, 2020
Apr. 30, 2020
Dec. 31, 2018
Schedule of Equity Method Investments [Line Items]              
Equity securities without readily determinable fair value, downward price adjustment, cumulative amount         $ 0    
Impairment of JUUL equity securities $ 0 $ 2,600,000,000 $ 0 $ 2,600,000,000      
JUUL [Member]              
Schedule of Equity Method Investments [Line Items]              
Equity securities, ownership percentage 35.00%   35.00%     35.00% 35.00%
Equity investments, fair value option, voting shares (in shares) 42   42        
Equity securities without readily determinable fair value, upward price adjustment, cumulative amount         $ 0    
Impairment of JUUL equity securities   2,600,000,000   2,600,000,000      
Income (loss) from equity investments, fair value option $ 100,000,000 $ 0 $ 0 $ 0      
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Investments in Equity Securities (JUUL Investment Classified as Level 3) (Details) - Equity Method Investments, Fair Value Option [Member] - JUUL [Member]
$ in Millions
 9 Months Ended
Sep. 30, 2021
USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Balance at beginning of period $ 1,705
Unrealized gains (losses) included in income (losses) from equity investments 0
Balance at end of period $ 1,705
XML 59 R46.htm IDEA: XBRL DOCUMENT v3.21.2
Investments in Equity Securities (Investment in Cronos Narrative) (Details)
$ / shares in Units, shares in Thousands, $ in Millions, $ in Billions
 9 Months Ended 12 Months Ended
Oct. 25, 2021
USD ($)
Sep. 30, 2021
CAD ($)
Dec. 31, 2020
USD ($)
Sep. 30, 2021
USD ($)
shares
Sep. 30, 2021
$ / shares
Investments [Line Items]          
Equity method investment, difference between carrying amount and underlying equity     $ 77 $ 14  
Cronos [Member]          
Investments [Line Items]          
Ownership percentage     43.50% 41.90%  
Number of ordinary shares owned (approximately) (in shares) | shares       156,600  
Equity method investment, difference between carrying amount and fair value, percentage (approximately)   2.00% 8.00%    
Equity Contract, Preemptive Rights [Member] | Cronos [Member]          
Investments [Line Items]          
Equity method investment, shares purchased, (CAD per share) | $ / shares         $ 16.25
Equity method investment, number of shares eligible for purchase (approximately) (in shares) | shares       14,000  
Equity method investment, aggregate exercise price   $ 0.2      
Equity Contract, Preemptive Rights [Member] | Cronos [Member] | Subsequent Event [Member]          
Investments [Line Items]          
Equity method investment, aggregate exercise price $ 200        
Equity Contract, Warrant [Member] | Cronos [Member]          
Investments [Line Items]          
Equity method investment, shares purchased, (CAD per share) | $ / shares         $ 19.00
Equity method investment, number of shares eligible for purchase (approximately) (in shares) | shares       83,000  
Equity method investment, percentage of shares eligible for purchase (approximately)       10.00%  
Equity method investment, aggregate exercise price   $ 1.6      
Equity Contract, Warrant [Member] | Cronos [Member] | Subsequent Event [Member]          
Investments [Line Items]          
Equity method investment, aggregate exercise price $ 1,300        
Equity Contract, Warrant And Equity Contract, Preemptive Rights [Member] | Cronos [Member]          
Investments [Line Items]          
Equity method investment, warrant exercised, ownership percentage   53.00%      
XML 60 R47.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments (Aggregate Notional Amounts, Aggregate Fair Values and Carrying Values) (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Derivative [Line Items]    
Carrying value $ 28,127 $ 29,471
Foreign Currency Denominated Debt [Member]    
Derivative [Line Items]    
Carrying value 4,905 5,171
Fair value 5,288 5,687
Foreign Currency Contract [Member] | Net Investment Hedging [Member]    
Derivative [Line Items]    
Foreign currency contracts (notional amounts) $ 0 $ 1,066
XML 61 R48.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments (Aggregate Fair Value and Carrying Value) (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Carrying value $ 28,127 $ 29,471
Fair value $ 31,037 $ 34,682
XML 62 R49.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments (Fair Value Using Black-Scholes Option-Pricing Model) (Details)
Sep. 30, 2021
year
$ / shares
Dec. 31, 2020
year
$ / shares
Share price [Member] | Fixed-price Preemptive Rights [Member]    
Derivative [Line Items]    
Derivative asset, measurement input | $ / shares 7.15 8.84
Share price [Member] | Cronos Warrant [Member]    
Derivative [Line Items]    
Derivative asset, measurement input | $ / shares 7.15 8.84
Expected Life [Member] | Fixed-price Preemptive Rights [Member]    
Derivative [Line Items]    
Derivative asset, measurement input 0.81 1.05
Expected Life [Member] | Cronos Warrant [Member]    
Derivative [Line Items]    
Derivative asset, measurement input 1.43 2.18
Expected Volatility [Member] | Fixed-price Preemptive Rights [Member]    
Derivative [Line Items]    
Derivative asset, measurement input 0.6732 0.8068
Expected Volatility [Member] | Cronos Warrant [Member]    
Derivative [Line Items]    
Derivative asset, measurement input 0.6732 0.8068
Risk Free Interest Rate [Member] | Fixed-price Preemptive Rights [Member]    
Derivative [Line Items]    
Derivative asset, measurement input 0.0024 0.0013
Risk Free Interest Rate [Member] | Fixed-price Preemptive Rights [Member] | Minimum [Member]    
Derivative [Line Items]    
Derivative asset, measurement input 0.0012 0.0006
Risk Free Interest Rate [Member] | Fixed-price Preemptive Rights [Member] | Maximum [Member]    
Derivative [Line Items]    
Derivative asset, measurement input 0.0089 0.0039
Risk Free Interest Rate [Member] | Cronos Warrant [Member]    
Derivative [Line Items]    
Derivative asset, measurement input 0.0039 0.0021
Expected Dividend Yield [Member] | Fixed-price Preemptive Rights [Member]    
Derivative [Line Items]    
Derivative asset, measurement input 0 0
Expected Dividend Yield [Member] | Cronos Warrant [Member]    
Derivative [Line Items]    
Derivative asset, measurement input 0 0
Weighted Average Expected Term [Member] | Fixed-price Preemptive Rights [Member] | Minimum [Member]    
Derivative [Line Items]    
Derivative asset, measurement input 0.25 0.25
Weighted Average Expected Term [Member] | Fixed-price Preemptive Rights [Member] | Maximum [Member]    
Derivative [Line Items]    
Derivative asset, measurement input 4.00 5
XML 63 R50.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments (Beginning and Ending Balances of Fixed-price Preemptive Rights and Warrants) (Details) - Fair Value, Inputs, Level 3 [Member] - Equity Contract [Member] - USD ($)
$ in Millions
 9 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Balance at begging of period $ 163 $ 303
Pre-tax earnings (losses) recognized in net earnings (losses) (128) (140)
Balance at end of period $ 35 $ 163
XML 64 R51.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments (Fair Value Derivative Financial Instruments) (Details) - Net Investment Hedging [Member] - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Derivatives, Fair Value [Line Items]    
Fair Value of Assets $ 35 $ 163
Fair Value of Liabilities 0 87
Foreign currency contracts [Member] | Designated as Hedging Instrument [Member]    
Derivatives, Fair Value [Line Items]    
Fair Value of Assets 0 0
Fair Value of Liabilities 0 87
Foreign currency contracts [Member] | Designated as Hedging Instrument [Member] | Other Current Assets [Member]    
Derivatives, Fair Value [Line Items]    
Fair Value of Assets 0 0
Foreign currency contracts [Member] | Designated as Hedging Instrument [Member] | Other Assets [Member]    
Derivatives, Fair Value [Line Items]    
Fair Value of Assets 0 0
Foreign currency contracts [Member] | Designated as Hedging Instrument [Member] | Other Accrued Liabilities [Member]    
Derivatives, Fair Value [Line Items]    
Fair Value of Liabilities 0 87
Foreign currency contracts [Member] | Designated as Hedging Instrument [Member] | Other Liabilities [Member]    
Derivatives, Fair Value [Line Items]    
Fair Value of Liabilities 0 0
Equity Contract [Member] | Not Designated as Hedging Instrument [Member]    
Derivatives, Fair Value [Line Items]    
Fair Value of Assets 35 163
Cronos Warrant [Member] | Not Designated as Hedging Instrument [Member] | Investments In Equity Securities [Member]    
Derivatives, Fair Value [Line Items]    
Fair Value of Assets 32 139
Fixed-price Preemptive Rights [Member] | Not Designated as Hedging Instrument [Member] | Investments In Equity Securities [Member]    
Derivatives, Fair Value [Line Items]    
Fair Value of Assets $ 3 $ 24
XML 65 R52.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments (Pre-tax Unrealized Gains (Losses)) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Derivative [Line Items]        
Unrealized gain (loss) on derivatives $ (135) $ (105) $ (128) $ (202)
Fixed-price Preemptive Rights [Member]        
Derivative [Line Items]        
Unrealized gain (loss) on derivatives (17) (25) (21) (54)
Cronos Warrant [Member]        
Derivative [Line Items]        
Unrealized gain (loss) on derivatives $ (118) $ (80) $ (107) $ (148)
XML 66 R53.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments (Effects of Net Investment Hedges on Accumulated Other Comprehensive Losses) (Details) - Net Investment Hedging [Member] - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (Loss) Recognized in Accumulated Other Comprehensive Losses $ 118 $ (272) $ 286 $ (243)
Gain (Loss) Recognized in Net Earnings (Losses) 0 8 7 33
Foreign currency contracts [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (Loss) Recognized in Accumulated Other Comprehensive Losses 0 (66) 16 (28)
Gain (Loss) Recognized in Net Earnings (Losses) 0 8 7 33
Foreign currency denominated debt [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (Loss) Recognized in Accumulated Other Comprehensive Losses 118 (206) 270 (215)
Gain (Loss) Recognized in Net Earnings (Losses) $ 0 $ 0 $ 0 $ 0
XML 67 R54.htm IDEA: XBRL DOCUMENT v3.21.2
Benefit Plans (Schedule Of Components Of Net Periodic Benefit Cost (Income)) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Pension [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Service cost $ 17 $ 18 $ 51 $ 55
Interest cost 46 62 139 188
Expected return on plan assets (131) (125) (393) (376)
Amortization:        
Net loss 33 55 99 108
Prior service cost (credit) 1 2 3 4
Net periodic benefit (income) cost (34) 12 (101) (21)
Postretirement [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Service cost 5 5 15 13
Interest cost 8 14 29 44
Expected return on plan assets (2) (4) (10) (11)
Amortization:        
Net loss 2 0 16 7
Prior service cost (credit) (20) (7) (35) (22)
Net periodic benefit (income) cost $ (7) $ 8 $ 15 $ 31
XML 68 R55.htm IDEA: XBRL DOCUMENT v3.21.2
Benefit Plans (Narrative) (Details) - USD ($)
 9 Months Ended
May 31, 2021
Sep. 30, 2021
Pension [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined benefit plan, plan assets, contributions by employer   $ 23,000,000
Pension [Member] | Maximum [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Anticipated additional employer contributions   5,000,000
Postretirement [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined benefit plan, plan assets, contributions by employer   0
Decrease in accrued postretirement health care cost liability $ 432,000,000  
Postretirement [Member] | Maximum [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Anticipated additional employer contributions   $ 0
XML 69 R56.htm IDEA: XBRL DOCUMENT v3.21.2
Earnings (Losses) per Share (Basic and Diluted Earnings Per Share) (Details) - USD ($)
shares in Thousands, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Earnings Per Share [Abstract]        
Net earnings (losses) attributable to Altria $ (2,722) $ (952) $ 851 $ 2,543
Less: Distributed and undistributed earnings attributable to share-based awards (2) (1) (8) (6)
Earnings (losses) for basic EPS (2,724) (953) 843 2,537
Earnings (losses) for diluted EPS $ (2,724) $ (953) $ 843 $ 2,537
Weighted-average shares for basic EPS (in shares) 1,842,000 1,858,000 1,849,000 1,858,000
Plus: contingently issuable performance stock units (in shares) 0 1,000 0 1,000
Weighted-average shares for diluted EPS (in shares) 1,842,000 1,859,000 1,849,000 1,859,000
XML 70 R57.htm IDEA: XBRL DOCUMENT v3.21.2
Other Comprehensive Earnings/Losses (Changes in Each Component of Accumulated Other Comprehensive Losses) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Accumulated Other Comprehensive Income [Roll Forward]        
Beginning balance $ 3,259 $ 5,786 $ 2,925 $ 6,319
Other comprehensive earnings (losses), net of deferred income taxes 172 (7) 911 (917)
Ending balance (1,265) 3,232 (1,265) 3,232
Accumulated Other Comprehensive Losses [Member]        
Accumulated Other Comprehensive Income [Roll Forward]        
Beginning balance (3,602) (3,774) (4,341) (2,864)
Other comprehensive earnings (losses) before reclassifications 221 (123) 1,152 (1,302)
Deferred income taxes (57) 41 (269) 279
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes 164 (82) 883 (1,023)
Amounts reclassified to net earnings (losses) 12 99 41 140
Deferred income taxes (4) (24) (13) (34)
Amounts reclassified to net earnings (losses), net of deferred income taxes 8 75 28 106
Other comprehensive earnings (losses), net of deferred income taxes 172 (7) 911 (917)
Ending balance (3,430) (3,781) (3,430) (3,781)
Benefit Plans [Member]        
Accumulated Other Comprehensive Income [Roll Forward]        
Beginning balance (2,043) (2,150) (2,420) (2,192)
Other comprehensive earnings (losses) before reclassifications 0 (75) 432 (75)
Deferred income taxes (9) 19 (118) 19
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes (9) (56) 314 (56)
Amounts reclassified to net earnings (losses) 20 55 92 111
Deferred income taxes (5) (14) (23) (28)
Amounts reclassified to net earnings (losses), net of deferred income taxes 15 41 69 83
Other comprehensive earnings (losses), net of deferred income taxes 6 (15) 383 27
Ending balance (2,037) (2,165) (2,037) (2,165)
ABI [Member]        
Accumulated Other Comprehensive Income [Roll Forward]        
Beginning balance (1,604) (1,606) (1,938) (693)
Other comprehensive earnings (losses) before reclassifications 215 (71) 685 (1,211)
Deferred income taxes (48) 22 (151) 260
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes 167 (49) 534 (951)
Amounts reclassified to net earnings (losses) (7) 44 (49) 29
Deferred income taxes 1 (10) 10 (6)
Amounts reclassified to net earnings (losses), net of deferred income taxes (6) 34 (39) 23
Other comprehensive earnings (losses), net of deferred income taxes 161 (15) 495 (928)
Ending balance (1,443) (1,621) (1,443) (1,621)
Currency Translation Adjustments and Other [Member]        
Accumulated Other Comprehensive Income [Roll Forward]        
Beginning balance 45 (18) 17 21
Other comprehensive earnings (losses) before reclassifications 6 23 35 (16)
Deferred income taxes 0 0 0 0
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes 6 23 35 (16)
Amounts reclassified to net earnings (losses) (1) 0 (2) 0
Deferred income taxes 0 0 0 0
Amounts reclassified to net earnings (losses), net of deferred income taxes (1) 0 (2) 0
Other comprehensive earnings (losses), net of deferred income taxes 5 23 33 (16)
Ending balance $ 50 $ 5 $ 50 $ 5
XML 71 R58.htm IDEA: XBRL DOCUMENT v3.21.2
Other Comprehensive Earnings/Losses (Reclassifications) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Net periodic benefit income, excluding service cost $ (63) $ (3) $ (152) $ (58)
(Income) losses from equity investments 6,015 472 5,789 306
Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings (losses) 2,720 956 (851) (2,532)
Reclassification out of Accumulated Other Comprehensive Income [Member]        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings (losses) 12 99 41 140
Benefit Plans [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Net periodic benefit income, excluding service cost 20 55 92 111
Net loss [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Net periodic benefit income, excluding service cost 39 60 124 129
Prior service cost/credit [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Net periodic benefit income, excluding service cost (19) (5) (32) (18)
ABI [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
(Income) losses from equity investments (7) 44 (49) 29
Currency Translation Adjustments and Other [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
(Income) losses from equity investments $ (1) $ 0 $ (2) $ 0
XML 72 R59.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Reporting (Segment Data Schedule) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Segment Reporting Information [Line Items]          
Net revenues $ 6,786   $ 7,123 $ 19,758 $ 19,849
Operating income 2,951   3,160 8,827 8,292
Interest and other debt expense, net (266)   (310) (869) (893)
Loss on early extinguishment of debt 0 $ (649) 0 (649) 0
Net periodic benefit income, excluding service cost 63   3 152 58
Income (losses) from equity investments (5,915)   (472) (5,789) (306)
Impairment of JUUL equity securities 0   (2,600) 0 (2,600)
Gain (loss) on Cronos-related financial instruments (135)   (105) (128) (202)
Earnings (losses) before income taxes (3,302)   (324) 1,544 4,349
Smokeable Products Segment [Member]          
Segment Reporting Information [Line Items]          
Net revenues 5,975   6,313 17,275 17,522
OCI 2,753   2,789 7,901 7,609
Oral Tobacco Segment [Member]          
Segment Reporting Information [Line Items]          
Net revenues 626   640 1,945 1,901
OCI 405   436 1,269 1,297
Wine Segment [Member]          
Segment Reporting Information [Line Items]          
Net revenues 177   157 494 434
OCI (24)   19 21 (347)
All Other [Member]          
Segment Reporting Information [Line Items]          
Net revenues 8   13 44 (8)
OCI (30)   (7) (56) (63)
Segment Reconciling Items [Member]          
Segment Reporting Information [Line Items]          
Amortization of intangibles (18)   (17) (53) (54)
General corporate [Member]          
Segment Reporting Information [Line Items]          
General corporate expenses $ (135)   $ (60) $ (255) $ (150)
XML 73 R60.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Reporting (Non-Participating Manufacturer Adjustment Items) (Details) - Non-Participating Manufacturer Arbitration Panel Decision - NPM Adjustment to Cost Of Sales [Member] - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2021
Segment Reporting Information [Line Items]    
Loss (gain) related to litigation settlement $ (44) $ (76)
Operating Income (Loss) [Member] | Smokeable Products Segment [Member] | PM USA [Member] | Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Loss (gain) related to litigation settlement (21) (53)
Interest and other debt expense, net [Member] | Segment Reconciling Items [Member]    
Segment Reporting Information [Line Items]    
Loss (gain) related to litigation settlement $ (23) $ (23)
XML 74 R61.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Reporting (Schedule of Tobacco and Health and Certain Other Litigation Items) (Details) - Tobacco and Health Litigation Cases [Member] - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]        
Provision related to litigation recorded $ 105 $ 34 $ 148 $ 76
Corporate, Non-Segment [Member]        
Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]        
Provision related to litigation recorded 70 0 70 0
Segment Reconciling Items [Member]        
Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]        
Provision related to litigation recorded 6 0 6 3
PM USA [Member] | Operating Segments [Member] | Smokeable Products Segment [Member]        
Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]        
Provision related to litigation recorded $ 29 $ 34 $ 72 $ 73
XML 75 R62.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Reporting (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Restructuring Cost and Reserve [Line Items]        
Cost of sales $ 1,858 $ 1,961 $ 5,348 $ 5,909
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | Ste. Michelle Transaction [Member]        
Restructuring Cost and Reserve [Line Items]        
Disposal group, total pre-tax charges     41  
Disposal group disposition related costs     10  
COVID-19 [Member]        
Restructuring Cost and Reserve [Line Items]        
Cost of sales   50   50
Oral Tobacco Segment [Member]        
Restructuring Cost and Reserve [Line Items]        
Business combination, acquisition related costs     37  
Oral Tobacco Segment [Member] | COVID-19 [Member]        
Restructuring Cost and Reserve [Line Items]        
Cost of sales   9   9
Smokeable Products Segment [Member] | COVID-19 [Member]        
Restructuring Cost and Reserve [Line Items]        
Cost of sales   $ 41   41
Wine Segment [Member] | Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | Ste. Michelle Transaction [Member] | Marketing Administration And Research Costs [Member]        
Restructuring Cost and Reserve [Line Items]        
Disposal group, total pre-tax charges     $ 51  
Wine Business Strategic Reset [Member] | Inventory Disposal Costs and Other [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges       395
Wine Business Strategic Reset [Member] | Inventory Write-Off [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges       292
Wine Business Strategic Reset [Member] | Purchase Commitment [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges       $ 100
XML 76 R63.htm IDEA: XBRL DOCUMENT v3.21.2
Debt (Narrative) (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
May 31, 2021
Feb. 28, 2021
Mar. 31, 2020
Sep. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Debt Instrument [Line Items]                  
Short-term debt       $ 0     $ 0   $ 0
Carrying value       28,127,000,000     28,127,000,000   29,471,000,000
Long-term debt repaid             6,542,000,000 $ 1,000,000,000  
Loss on early extinguishment of debt       0 $ 649,000,000 $ 0 649,000,000 $ 0  
Loss on extinguishment of debt, premiums and fees         623,000,000        
Write-off of amortized debt discounts and issuance costs, debt extinguishment         $ 26,000,000        
Accrued interest on long-term debt       206,000,000     $ 206,000,000   $ 458,000,000
Senior Notes [Member] | USD Denominated Notes [Member]                  
Debt Instrument [Line Items]                  
Face amount   $ 5,500,000,000              
Repayments of senior unsecured debt $ 1,500,000,000                
Senior Notes [Member] | USD Denominated Notes Due 2032 [Member]                  
Debt Instrument [Line Items]                  
Face amount   $ 1,750,000,000              
Debt instrument, interest rate, stated percentage   2.45%              
Senior Notes [Member] | USD Denominated Notes Due 2041 [Member]                  
Debt Instrument [Line Items]                  
Face amount   $ 1,500,000,000              
Debt instrument, interest rate, stated percentage   3.40%              
Senior Notes [Member] | USD Denominated Notes Due 2051 [Member]                  
Debt Instrument [Line Items]                  
Face amount   $ 1,250,000,000              
Debt instrument, interest rate, stated percentage   3.70%              
Senior Notes [Member] | USD Denominated Notes Due 2061 [Member]                  
Debt Instrument [Line Items]                  
Face amount   $ 1,000,000,000              
Debt instrument, interest rate, stated percentage   4.00%              
Senior Notes [Member] | USD Denominated Notes, 3.490 Percent, Due 2022 [Member]                  
Debt Instrument [Line Items]                  
Debt instrument, interest rate, stated percentage         3.49%        
Long-term debt repaid         $ 1,000,000,000        
Revolving Credit Facility [Member]                  
Debt Instrument [Line Items]                  
Debt instrument, covenant, consolidated EBITDA to interest expense ratio, minimum             4.0    
Debt instrument, consolidated EBITDA to interest expense ratio             9.8    
Revolving Credit Facility [Member] | Line of Credit [Member] | Revolving Credit Facility Due August 2024 [Member]                  
Debt Instrument [Line Items]                  
Face amount       $ 3,000,000,000     $ 3,000,000,000    
Debt instrument, term             5 years    
Debt instrument, extension term             1 year    
Proceeds from issuance of debt     $ 3,000,000,000            
London Interbank Offered Rate (LIBOR) [Member] | Revolving Credit Facility [Member] | Line of Credit [Member] | Revolving Credit Facility Due August 2024 [Member]                  
Debt Instrument [Line Items]                  
Debt instrument, basis spread on variable rate             1.00%    
Debt Instrument, Redemption, Period One [Member] | Senior Notes [Member]                  
Debt Instrument [Line Items]                  
Debt instrument, redemption price, percentage   101.00%              
XML 77 R64.htm IDEA: XBRL DOCUMENT v3.21.2
Debt (Tender Offers) (Details) - Senior Notes [Member]
$ in Millions
Sep. 30, 2021
USD ($)
Debt Instrument [Line Items]  
Debt instrument, repurchased face amount $ 4,042
2.850%, Notes Due 2022 [Member]  
Debt Instrument [Line Items]  
Debt instrument, repurchased face amount $ 795
Debt instrument, interest rate, stated percentage 2.85%
2.950%, Notes Due 2023 [Member]  
Debt Instrument [Line Items]  
Debt instrument, repurchased face amount $ 132
Debt instrument, interest rate, stated percentage 2.95%
4.000%, Notes Due 2024 [Member]  
Debt Instrument [Line Items]  
Debt instrument, repurchased face amount $ 624
Debt instrument, interest rate, stated percentage 4.00%
3.800%, Notes Due 2024 [Member]  
Debt Instrument [Line Items]  
Debt instrument, repurchased face amount $ 655
Debt instrument, interest rate, stated percentage 3.80%
4.400%, Notes Due 2026 [Member]  
Debt Instrument [Line Items]  
Debt instrument, repurchased face amount $ 430
Debt instrument, interest rate, stated percentage 4.40%
4.800%, Notes Due 2029 [Member]  
Debt Instrument [Line Items]  
Debt instrument, repurchased face amount $ 1,094
Debt instrument, interest rate, stated percentage 4.80%
9.950%, Notes Due 2038 [Member]  
Debt Instrument [Line Items]  
Debt instrument, repurchased face amount $ 65
Debt instrument, interest rate, stated percentage 9.95%
10.200%, Notes Due 2039 [Member]  
Debt Instrument [Line Items]  
Debt instrument, repurchased face amount $ 18
Debt instrument, interest rate, stated percentage 10.20%
6.200%, Notes Due 2059 [Member]  
Debt Instrument [Line Items]  
Debt instrument, repurchased face amount $ 229
Debt instrument, interest rate, stated percentage 6.20%
XML 78 R65.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes - Summary of Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Tax Disclosure [Abstract]        
Earnings (losses) before income taxes $ (3,302) $ (324) $ 1,544 $ 4,349
Provision (benefit) for income taxes $ (582) $ 632 $ 693 $ 1,817
Income tax rate 17.60% (195.10%) 44.90% 41.80%
XML 79 R66.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes - Narrative (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Investments [Line Items]          
Impairment of JUUL equity securities $ 0 $ 2,600,000,000 $ 0 $ 2,600,000,000  
ABI [Member]          
Investments [Line Items]          
Equity method investment, impairment $ 6,157,000,000   $ 6,157,000,000   $ 0
JUUL [Member]          
Investments [Line Items]          
Impairment of JUUL equity securities   $ 2,600,000,000   $ 2,600,000,000  
XML 80 R67.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2021
USD ($)
Valuation Allowance Rollforward [Roll Forward]  
Balance at beginning of year $ 2,817
Additions to valuation allowance charged to income tax expense 264
Reductions to valuation allowance credited to income tax benefit (73)
Foreign currency translation (4)
Balance at end of period $ 3,004
XML 81 R68.htm IDEA: XBRL DOCUMENT v3.21.2
Contingencies (General Information) (Details)
Sep. 30, 2021
state
Commitments and Contingencies Disclosure [Abstract]  
Number of states that cap bond or require no bond 47
XML 82 R69.htm IDEA: XBRL DOCUMENT v3.21.2
Contingencies (Judgments Paid and Provisions for Tobacco and Health Litigation) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended 204 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Loss Contingency Accrual [Roll Forward]          
Accrued liability for tobacco and health litigation items at beginning of period $ 0 $ 22 $ 9 $ 14  
Payments (8) (47) (60) (81)  
Accrued liability for tobacco and health litigation items at end of period 97 9 97 9 $ 97
Related Interest Costs [Member]          
Loss Contingency Accrual [Roll Forward]          
Provision related to litigation recorded 6 0 6 3  
Assets [Member] | Pending Litigation [Member] | PM USA [Member]          
Loss Contingency Accrual [Roll Forward]          
Security posted for appeal of judgments 45   45   45
Tobacco and Health Judgment [Member]          
Loss Contingencies [Line Items]          
Judgments paid (approximately)         865
Litigation settlement interest expense (income)         218
Tobacco and Health Judgment [Member] | Tobacco and Health and Certain Other Litigation [Member]          
Loss Contingency Accrual [Roll Forward]          
Provision related to litigation recorded $ 99 $ 34 $ 142 $ 73  
Engle Progeny Cases [Member]          
Loss Contingencies [Line Items]          
Judgments paid (approximately)         410
Litigation settlement interest expense (income)         $ 56
XML 83 R70.htm IDEA: XBRL DOCUMENT v3.21.2
Contingencies (Schedule of Pending Cases) (Details)
Oct. 25, 2021
claim
case
lawsuit
Oct. 27, 2020
claim
Oct. 28, 2019
claim
Individual Smoking and Health Cases [Member]      
Loss Contingencies [Line Items]      
Number of cases pending   142 95
Health Care Cost Recovery Actions [Member]      
Loss Contingencies [Line Items]      
Number of cases pending   1 1
E-vapor Litigation [Member]      
Loss Contingencies [Line Items]      
Number of cases pending   1,145 0
Other Tabacco-Related Cases [Member]      
Loss Contingencies [Line Items]      
Number of cases pending   4 4
Subsequent Event [Member]      
Loss Contingencies [Line Items]      
Loss contingency, class action lawsuit | lawsuit 16    
Subsequent Event [Member] | Individual Smoking and Health Cases [Member]      
Loss Contingencies [Line Items]      
Number of cases pending 179    
Subsequent Event [Member] | Individual Smoking and Health Cases [Member] | Pending Litigation [Member] | Illinois [Member]      
Loss Contingencies [Line Items]      
Number of cases pending 18    
Subsequent Event [Member] | Individual Smoking and Health Cases [Member] | Pending Litigation [Member] | New Mexico [Member]      
Loss Contingencies [Line Items]      
Number of cases pending 17    
Subsequent Event [Member] | Individual Smoking and Health Cases [Member] | Pending Litigation [Member] | Massachusetts [Member]      
Loss Contingencies [Line Items]      
Number of cases pending 40    
Subsequent Event [Member] | Individual Smoking and Health Cases [Member] | Pending Litigation [Member] | Florida [Member]      
Loss Contingencies [Line Items]      
Number of cases pending 70    
Subsequent Event [Member] | ETS Smoking and Health Case, Flight Attendants [Member] | Pending Litigation [Member]      
Loss Contingencies [Line Items]      
Number of cases | case 1,471    
Subsequent Event [Member] | Health Care Cost Recovery Actions [Member]      
Loss Contingencies [Line Items]      
Number of cases pending 1    
Subsequent Event [Member] | E-vapor Litigation [Member]      
Loss Contingencies [Line Items]      
Number of cases pending 2,951    
Loss contingency, class action lawsuit | lawsuit 53    
Subsequent Event [Member] | E-vapor Litigation [Member] | Pending Individual Lawsuits [Member]      
Loss Contingencies [Line Items]      
Number of cases pending 2,548    
Subsequent Event [Member] | E-vapor Litigation [Member] | Pending Lawsuits Filed By State Or Local Governments [Member]      
Loss Contingencies [Line Items]      
Number of cases pending 350    
Subsequent Event [Member] | Other Tabacco-Related Cases [Member]      
Loss Contingencies [Line Items]      
Number of cases pending 3    
Loss contingency, number of inactive cases | case 1    
Loss contingency, number of inactive class action lawsuits | case 2    
XML 84 R71.htm IDEA: XBRL DOCUMENT v3.21.2
Contingencies (Overview of Altria and/or PM USA Tobacco-Related Litigation Narrative) (Details)
 274 Months Ended
Oct. 25, 2021
claim
case
Oct. 25, 2021
case
claim
Oct. 27, 2020
claim
Oct. 28, 2019
claim
Jan. 31, 2008
claim
Health Care Cost Recovery Actions [Member]          
Loss Contingencies [Line Items]          
Number of cases pending | claim     1 1  
Engle Progeny Cases [Member]          
Loss Contingencies [Line Items]          
Number of cases pending | claim         9,300
Subsequent Event [Member] | Health Care Cost Recovery Actions [Member]          
Loss Contingencies [Line Items]          
Number of cases pending | claim 1 1      
Subsequent Event [Member] | Health Care Cost Recovery Actions [Member] | Canada [Member]          
Loss Contingencies [Line Items]          
Number of cases pending | claim 3 3      
Subsequent Event [Member] | Smoking and Health Class Actions and Aggregated Claims Litigation [Member]          
Loss Contingencies [Line Items]          
Number of cases pending | claim 1 1      
Subsequent Event [Member] | PM USA [Member] | Health Care Cost Recovery Actions [Member] | Canada [Member]          
Loss Contingencies [Line Items]          
Number of cases pending | claim 10 10      
Subsequent Event [Member] | PM USA [Member] | Engle Progeny Cases [Member]          
Loss Contingencies [Line Items]          
Number of cases set for trial 0 0      
Number of verdicts returned 137        
Number of favorable verdicts 54        
Number of unfavorable verdicts 76        
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member]          
Loss Contingencies [Line Items]          
Number of verdicts returned   69      
Number of favorable verdicts   44      
Number of unfavorable verdicts   25      
Number of claims resolved   20      
Number of verdicts reversed   2      
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Alaska [Member]          
Loss Contingencies [Line Items]          
Number of favorable verdicts   1      
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | California [Member]          
Loss Contingencies [Line Items]          
Number of favorable verdicts   7      
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Connecticut [Member]          
Loss Contingencies [Line Items]          
Number of favorable verdicts   1      
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Florida [Member]          
Loss Contingencies [Line Items]          
Number of favorable verdicts   10      
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Louisiana [Member]          
Loss Contingencies [Line Items]          
Number of favorable verdicts   1      
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Massachusetts [Member]          
Loss Contingencies [Line Items]          
Number of favorable verdicts   4      
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Mississippi [Member]          
Loss Contingencies [Line Items]          
Number of favorable verdicts   1      
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Missouri [Member]          
Loss Contingencies [Line Items]          
Number of favorable verdicts   4      
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | New Hampshire [Member]          
Loss Contingencies [Line Items]          
Number of favorable verdicts   1      
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | New Jersey [Member]          
Loss Contingencies [Line Items]          
Number of favorable verdicts   1      
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | New York [Member]          
Loss Contingencies [Line Items]          
Number of favorable verdicts   5      
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Ohio [Member]          
Loss Contingencies [Line Items]          
Number of favorable verdicts   2      
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Pennsylvania [Member]          
Loss Contingencies [Line Items]          
Number of favorable verdicts   1      
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Rhode Island [Member]          
Loss Contingencies [Line Items]          
Number of favorable verdicts   1      
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Tennessee [Member]          
Loss Contingencies [Line Items]          
Number of favorable verdicts   2      
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | West Virginia [Member]          
Loss Contingencies [Line Items]          
Number of favorable verdicts   2      
Subsequent Event [Member] | Philip Morris USA and Altria Group [Member] | Health Care Cost Recovery Actions [Member] | Canada [Member]          
Loss Contingencies [Line Items]          
Number of cases pending | claim 8 8      
Subsequent Event [Member] | Philip Morris USA and Altria Group [Member] | Smoking and Health Class Actions and Aggregated Claims Litigation [Member] | Canada [Member]          
Loss Contingencies [Line Items]          
Number of cases pending | claim 7 7      
XML 85 R72.htm IDEA: XBRL DOCUMENT v3.21.2
Contingencies (Non-Engle Progeny Litigation) (Details) - USD ($)
 1 Months Ended
Sep. 30, 2021
Feb. 28, 2021
May 31, 2020
Feb. 29, 2020
Sep. 30, 2019
Aug. 31, 2019
Oct. 31, 2017
Non-Engle Progeny Smoking And Health Case, Principe [Member]              
Loss Contingencies [Line Items]              
Compensatory damages awarded       $ 11,000,000      
Punitive damages awarded       $ 0      
Non-Engle Progeny Smoking and Health Case, Greene [Member]              
Loss Contingencies [Line Items]              
Compensatory damages awarded   $ 2,300,000 $ 30,000,000   $ 10,000,000    
Non-Engle Progeny Smoking and Health Case, Laramie [Member]              
Loss Contingencies [Line Items]              
Compensatory damages awarded           $ 11,000,000  
Punitive damages awarded           $ 10,000,000  
Damages awarded, value $ 21,000,000            
Provision related to litigation recorded $ 27,100,000            
Non-Engle Progeny Smoking and Health Case, Gentile [Member]              
Loss Contingencies [Line Items]              
Compensatory damages awarded             $ 7,100,000
Non-Engle Progeny Smoking and Health Case, Gentile [Member] | PM USA [Member]              
Loss Contingencies [Line Items]              
Compensatory damages award, allocation percentage             75.00%
XML 86 R73.htm IDEA: XBRL DOCUMENT v3.21.2
Contingencies (Engle Class Action And Engle Progeny Trial Results) (Details)
 1 Months Ended
Oct. 25, 2021
USD ($)
claim
case
plantiff
Jul. 31, 2006
Jan. 31, 2008
claim
Jul. 31, 2000
USD ($)
Engle Progeny Cases [Member]        
Loss Contingencies [Line Items]        
Punitive damages awarded | $       $ 145,000,000,000
Number of cases pending | claim     9,300  
Engle Progeny Cases [Member] | PM USA [Member]        
Loss Contingencies [Line Items]        
Punitive damages awarded | $       $ 74,000,000,000
Loss contingency, period for decertified class members to file individual actions against defendants   1 year    
Subsequent Event [Member] | PM USA [Member]        
Loss Contingencies [Line Items]        
Provision recorded, number of cases 0      
Subsequent Event [Member] | Engle Progeny Cases [Member] | PM USA [Member]        
Loss Contingencies [Line Items]        
Number of verdicts returned 137      
Number of unfavorable verdicts 76      
Number of claims with unfavorable verdicts pending/reversed 7      
Number of favorable verdicts 54      
Subsequent Event [Member] | Engle Progeny Cases, State [Member]        
Loss Contingencies [Line Items]        
Number of cases pending | claim 1,026      
Number of plaintiffs | plantiff 1,285      
Subsequent Event [Member] | Engle Progeny Cases, State [Member] | PM USA [Member]        
Loss Contingencies [Line Items]        
Number of favorable verdicts 44      
Subsequent Event [Member] | Engle Progeny Cases, Federal [Member] | PM USA [Member]        
Loss Contingencies [Line Items]        
Number of cases pending | claim 2      
Subsequent Event [Member] | Engle Progeny Cases, Pearson, D Cohen, Collar, Chacon [Member] | PM USA [Member]        
Loss Contingencies [Line Items]        
Number of verdicts reversed 4      
Subsequent Event [Member] | Engle Progeny Cases, Reider and Banks [Member] | PM USA [Member]        
Loss Contingencies [Line Items]        
Zero damages verdicts 2      
Damages awarded, value | $ $ 0      
Subsequent Event [Member] | Engle Progeny Cases, Weingart and Hancock [Member] | PM USA [Member]        
Loss Contingencies [Line Items]        
Damages awarded, value | $ $ 0      
Zero damages verdict modified 2      
Subsequent Event [Member] | Engle Progeny Cases, Pollari [Member] | PM USA [Member]        
Loss Contingencies [Line Items]        
Number of favorable verdicts 1      
Subsequent Event [Member] | Engle Progeny Cases, Gloger, Rintoul and Duignam [Member] | PM USA [Member]        
Loss Contingencies [Line Items]        
Number of favorable verdicts 3      
Subsequent Event [Member] | Engle Progeny Cases, Freeman [Member] | PM USA [Member]        
Loss Contingencies [Line Items]        
Number of favorable verdicts 2      
XML 87 R74.htm IDEA: XBRL DOCUMENT v3.21.2
Contingencies (Engle Progeny Cases Trial Results - Pending and Concluded) (Details)
$ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Jul. 31, 2021
USD ($)
May 31, 2021
USD ($)
Apr. 29, 2021
USD ($)
Mar. 31, 2021
USD ($)
Jun. 30, 2020
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2021
USD ($)
case
Feb. 29, 2020
USD ($)
Jan. 31, 2020
USD ($)
Nov. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Feb. 28, 2019
USD ($)
Sep. 30, 2018
USD ($)
Jul. 31, 2018
USD ($)
Nov. 30, 2017
USD ($)
Apr. 30, 2017
USD ($)
Sep. 30, 2015
USD ($)
Jan. 31, 2015
USD ($)
Engle Progeny Cases, Lipp [Member] | Pending Litigation [Member]                                    
Loss Contingencies [Line Items]                                    
Compensatory damages awarded             $ 15.0                      
Engle Progeny Cases, Lipp [Member] | Pending Litigation [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Punitive damages awarded             28.0                      
Engle Progeny Cases, Garcia [Member] | Pending Litigation [Member]                                    
Loss Contingencies [Line Items]                                    
Compensatory damages awarded   $ 3.0                                
Engle Progeny Cases, Duignan [Member] | Pending Litigation [Member]                                    
Loss Contingencies [Line Items]                                    
Compensatory damages awarded               $ 3.0                    
Engle Progeny Cases, Duignan [Member] | Pending Litigation [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Punitive damages awarded               $ 12.0                    
Engle Progeny Cases, Cuddihee [Member] | Pending Litigation [Member]                                    
Loss Contingencies [Line Items]                                    
Compensatory damages awarded                 $ 3.0                  
Engle Progeny Cases, Cuddihee [Member] | Pending Litigation [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Punitive damages awarded                 $ 0.0                  
Engle Progeny Cases, Rintoul [Member] | Pending Litigation [Member]                                    
Loss Contingencies [Line Items]                                    
Compensatory damages awarded                   $ 9.0                
Engle Progeny Cases, Rintoul [Member] | Pending Litigation [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Punitive damages awarded                   74.0                
Engle Progeny Cases, Gloger [Member] | Pending Litigation [Member]                                    
Loss Contingencies [Line Items]                                    
Compensatory damages awarded                   15.0                
Engle Progeny Cases, Gloger [Member] | Pending Litigation [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Punitive damages awarded                   $ 11.0                
Engle Progeny Cases, McCall [Member] | Pending Litigation [Member]                                    
Loss Contingencies [Line Items]                                    
Compensatory damages awarded                     $ 1.0              
Engle Progeny Cases, McCall [Member] | Pending Litigation [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Compensatory damages awarded                     1.0              
Punitive damages awarded                     0.0              
Engle Progeny Cases, Neff [Member] | Pending Litigation [Member]                                    
Loss Contingencies [Line Items]                                    
Compensatory damages awarded                     4.0              
Engle Progeny Cases, Neff [Member] | Pending Litigation [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Punitive damages awarded                     $ 2.0              
Engle Progeny Cases, Mahfuz [Member] | Pending Litigation [Member]                                    
Loss Contingencies [Line Items]                                    
Compensatory damages awarded                       $ 12.0            
Engle Progeny Cases, Mahfuz [Member] | Pending Litigation [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Punitive damages awarded                       10.0            
Engle Progeny Cases, Holliman [Member] | Pending Litigation [Member]                                    
Loss Contingencies [Line Items]                                    
Compensatory damages awarded                       3.0            
Engle Progeny Cases, Holliman [Member] | Pending Litigation [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Punitive damages awarded                       $ 0.0            
Engle Progeny Cases, Chadwell [Member] | Pending Litigation [Member]                                    
Loss Contingencies [Line Items]                                    
Compensatory damages awarded                         $ 2.0          
Engle Progeny Cases, Chadwell [Member] | Pending Litigation [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Punitive damages awarded                         $ 0.0          
Engle Progeny Cases, Kaplan [Member] | Pending Litigation [Member]                                    
Loss Contingencies [Line Items]                                    
Compensatory damages awarded                           $ 2.0        
Engle Progeny Cases, Kaplan [Member] | Pending Litigation [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Punitive damages awarded                           $ 2.0        
Engle Progeny Cases, R. Douglas [Member] | Pending Litigation [Member]                                    
Loss Contingencies [Line Items]                                    
Compensatory damages awarded                             $ 1.0      
Engle Progeny Cases, R. Douglas [Member] | Pending Litigation [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Punitive damages awarded                             $ 0.0      
Engle Progeny Cases, Sommers [Member] | Pending Litigation [Member]                                    
Loss Contingencies [Line Items]                                    
Compensatory damages awarded                               $ 1.0    
Provision related to litigation recorded             1.0                      
Damages awarded, value             $ 3.0                      
Engle Progeny Cases, Sommers [Member] | Pending Litigation [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Punitive damages awarded                               $ 0.0    
Engle Progeny Cases, Cooper [Member] | Pending Litigation [Member]                                    
Loss Contingencies [Line Items]                                    
Compensatory damages awarded                                 $ 5.0  
Engle Progeny Cases, Cooper [Member] | Pending Litigation [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Compensatory damages awarded                                 1.0  
Punitive damages awarded                                 $ 0.0  
Engle Progeny Cases, D. Brown [Member] | Pending Litigation [Member]                                    
Loss Contingencies [Line Items]                                    
Compensatory damages awarded                                   $ 8.0
Engle Progeny Cases, D. Brown [Member] | Pending Litigation [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Punitive damages awarded                                   $ 9.0
Engle Progeny Cases, Berger [Member] | Settled Litigation [Member]                                    
Loss Contingencies [Line Items]                                    
Damages awarded, value       $ 29.0   $ 29.0                        
Engle Progeny Cases, Santoro [Member] | Settled Litigation [Member]                                    
Loss Contingencies [Line Items]                                    
Damages awarded, value       $ 1.0 $ 1.0                          
Engle Progeny Cases, Naugle, Gore, M. Brown, Jordan, Theis and Landi [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Loss contingency, number of cases with payments a year or more ago | case             6                      
Engle Progeny Cases, Naugle [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Damages awarded, value             $ 8.0                      
Engle Progeny Cases, Gore [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Damages awarded, value             2.0                      
Engle Progeny Cases, M. Brown [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Damages awarded, value             8.0                      
Judgments paid (approximately)     $ 8.2                              
Engle Progeny Cases, Jordan [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Damages awarded, value             4.0                      
Engle Progeny Cases, Theis [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Damages awarded, value             1.0                      
Judgments paid (approximately)   $ 1.0                                
Engle Progeny Cases, Landi [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Damages awarded, value             $ 3.0                      
Judgments paid (approximately) $ 1.5                                  
Engle Progeny Cases, R.J. Reynolds [Member] | PM USA [Member]                                    
Loss Contingencies [Line Items]                                    
Damages awarded, value 3.0                                  
Judgments paid (approximately) $ 1.5                                  
XML 88 R75.htm IDEA: XBRL DOCUMENT v3.21.2
Contingencies (Florida Bond Statute) (Details)
Jun. 30, 2009
USD ($)
Florida [Member] | Engle Progeny Cases, State [Member]  
Loss Contingencies [Line Items]  
Maximum bond for all defendants $ 200,000,000
XML 89 R76.htm IDEA: XBRL DOCUMENT v3.21.2
Contingencies (Other Smoking and Health Class Actions) (Details) - Smoking and Health Class Actions and Aggregated Claims Litigation [Member]
$ in Billions
 1 Months Ended 305 Months Ended
Mar. 31, 2019
CAD ($)
manufacture
ruling
Sep. 30, 2021
case
manufacture
Oct. 25, 2021
claim
Subsequent Event [Member]      
Loss Contingencies [Line Items]      
Number of cases pending | claim     1
PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   61  
Arkansas [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   1  
California [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   1  
Delaware [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   1  
District of Columbia [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   2  
Florida [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   2  
Illinois [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   3  
Iowa [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   1  
Kansas [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   1  
Louisiana [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   1  
Maryland [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   1  
Michigan [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   1  
Minnesota [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   1  
Nevada [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   29  
New Jersey [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   6  
New York [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   2  
Ohio [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   1  
Oklahoma [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   1  
Oregon [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   1  
Pennsylvania [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   1  
Puerto Rico [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   1  
South Carolina [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   1  
Texas [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   1  
Wisconsin [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Class not certified   1  
Canada [Member] | Philip Morris USA and Altria Group [Member] | Subsequent Event [Member]      
Loss Contingencies [Line Items]      
Number of cases pending | claim     7
Canada [Member] | Canadian Tobacco Manufacturers [Member]      
Loss Contingencies [Line Items]      
Number of manufacturers | manufacture 3 3  
Number of verdicts upheld | ruling 2    
Amount awarded to other party | $ $ 13    
Canada [Member] | Altria Group [Member]      
Loss Contingencies [Line Items]      
Number of manufacturers | manufacture 0    
British Columbia and Saskatchewan [Member] | Philip Morris USA and Altria Group [Member] | Subsequent Event [Member]      
Loss Contingencies [Line Items]      
Number of cases pending | claim     2
XML 90 R77.htm IDEA: XBRL DOCUMENT v3.21.2
Contingencies (Health Care Cost Recovery Litigation) (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Nov. 30, 1998
USD ($)
state
Sep. 30, 2021
USD ($)
claim
manufacture
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
claim
manufacture
Sep. 30, 2020
USD ($)
Oct. 27, 2020
claim
Oct. 28, 2019
claim
Mar. 31, 2019
manufacture
Health Care Cost Recovery Actions [Member]                
Loss Contingencies [Line Items]                
Number of cases pending | claim           1 1  
Number of states with settled litigation | state 46              
State settlement agreements annual payments $ 9,400,000,000              
State settlement agreements attorney fees annual cap $ 500,000,000              
Litigation settlement   $ 1,100,000,000 $ 1,200,000,000 $ 3,200,000,000 $ 3,300,000,000      
Threatened Litigation [Member] | Canada [Member] | Health Care Cost Recovery Actions [Member]                
Loss Contingencies [Line Items]                
Number of cases pending | claim   10   10        
Canadian Tobacco Manufacturers [Member] | Canada [Member] | Smoking and Health Class Actions and Aggregated Claims Litigation [Member]                
Loss Contingencies [Line Items]                
Number of manufacturers | manufacture   3   3       3
XML 91 R78.htm IDEA: XBRL DOCUMENT v3.21.2
Contingencies (NPM Adjustment Disputes) (Details)
$ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
state
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2018
USD ($)
state
Dec. 31, 2015
USD ($)
Health Care Cost Recovery Actions [Member]              
Loss Contingencies [Line Items]              
Litigation settlement $ 1,100.0 $ 1,200.0 $ 3,200.0 $ 3,300.0      
PM USA [Member] | Health Care Cost Recovery Actions [Member]              
Loss Contingencies [Line Items]              
Loss contingency, number of states with settled litigation including New York, subsequent expansion | state           36  
Loss contingency, credits to offset payments           $ 1,030.0  
Litigation settlement, amount expected to be awarded from other party     320.0        
PM USA [Member] | Health Care Cost Recovery Actions [Member] | Settled Litigation [Member]              
Loss Contingencies [Line Items]              
Loss contingency, number of additional states extended with settled litigation | state           35  
PM USA [Member] | Health Care Cost Recovery Actions [Member] | Pending Litigation [Member]              
Loss Contingencies [Line Items]              
Loss contingency, number of additional states extended with settled litigation | state           1  
PM USA [Member] | Health Care Cost Recovery Actions, 2004 NPM Adjustment [Member]              
Loss Contingencies [Line Items]              
Estimate of possible gain     $ 388.0        
PM USA [Member] | Health Care Cost Recovery Actions, 2004 NPM Adjustment [Member] | Pending Litigation [Member]              
Loss Contingencies [Line Items]              
Loss contingency, number of states not settled | state     10        
Loss contingency, number of states with concluded hearings | state     9        
Loss contingency, number of states not in compliance with escrow statues | state     2        
Loss contingency, number of states in compliance with escrow statues | state     7        
Loss contingency, damages sought, value $ 23.0            
PM USA [Member] | Health Care Cost Recovery Actions, 2004 NPM Adjustment [Member] | Pending Litigation [Member] | Cost of Sales [Member]              
Loss Contingencies [Line Items]              
Loss contingency, reduction to cost of sales     $ 21.0        
PM USA [Member] | Health Care Cost Recovery Actions, 2005 NPM Adjustment [Member]              
Loss Contingencies [Line Items]              
Estimate of possible gain     181.0        
PM USA [Member] | Health Care Cost Recovery Actions, 2006 NPM Adjustment [Member]              
Loss Contingencies [Line Items]              
Estimate of possible gain     154.0        
PM USA [Member] | Health Care Cost Recovery Actions, 2007 NPM Adjustment [Member]              
Loss Contingencies [Line Items]              
Estimate of possible gain     185.0        
PM USA [Member] | Health Care Cost Recovery Actions, 2008 NPM Adjustment [Member]              
Loss Contingencies [Line Items]              
Estimate of possible gain     250.0        
PM USA [Member] | Health Care Cost Recovery Actions, 2009 NPM Adjustment [Member]              
Loss Contingencies [Line Items]              
Estimate of possible gain     211.0        
PM USA [Member] | Health Care Cost Recovery Actions, 2010 NPM Adjustment [Member]              
Loss Contingencies [Line Items]              
Estimate of possible gain     218.0        
PM USA [Member] | Health Care Cost Recovery Actions, 2011 NPM Adjustment [Member]              
Loss Contingencies [Line Items]              
Estimate of possible gain     166.0        
PM USA [Member] | Health Care Cost Recovery Actions, 2012 NPM Adjustment [Member]              
Loss Contingencies [Line Items]              
Estimate of possible gain     214.0        
PM USA [Member] | Health Care Cost Recovery Actions, 2013 NPM Adjustment [Member]              
Loss Contingencies [Line Items]              
Estimate of possible gain     224.0        
PM USA [Member] | Health Care Cost Recovery Actions, 2014 NPM Adjustment [Member]              
Loss Contingencies [Line Items]              
Estimate of possible gain     258.0        
PM USA [Member] | Health Care Cost Recovery Actions, 2015 NPM Adjustments [Member]              
Loss Contingencies [Line Items]              
Estimate of possible gain     313.0        
PM USA [Member] | Health Care Cost Recovery Actions, 2016 NPM Adjustments [Member]              
Loss Contingencies [Line Items]              
Estimate of possible gain     292.0        
PM USA [Member] | Health Care Cost Recovery Actions, 2017 NPM Adjustments [Member]              
Loss Contingencies [Line Items]              
Estimate of possible gain     302.0        
PM USA [Member] | Health Care Cost Recovery Actions, 2018 NPM Adjustments [Member]              
Loss Contingencies [Line Items]              
Estimate of possible gain     325.0        
PM USA [Member] | Health Care Cost Recovery Actions, 2019 NPM Adjustments [Member]              
Loss Contingencies [Line Items]              
Estimate of possible gain     444.0        
PM USA [Member] | Health Care Cost Recovery Actions, 2020 NPM Adjustments [Member]              
Loss Contingencies [Line Items]              
Estimate of possible gain     $ 572.0        
PM USA [Member] | Health Care Cost Recovery Actions, 2005-2007 NPM Adjustment | Pending Litigation [Member]              
Loss Contingencies [Line Items]              
Loss contingency, number of states not settled | state     10        
PM USA [Member] | Health Care Cost Recovery Actions, 2005-2007 NPM Adjustment | Pending Litigation [Member] | Period One              
Loss Contingencies [Line Items]              
Loss contingency, number of states not settled | state     9        
Loss contingency, number of states not settled, arbitration period     3 years        
PM USA [Member] | Health Care Cost Recovery Actions, 2005-2007 NPM Adjustment | Pending Litigation [Member] | Period Two              
Loss Contingencies [Line Items]              
Loss contingency, number of states not settled | state     1        
Loss contingency, number of states not settled, arbitration period     1 year        
New York [Member] | PM USA [Member] | Health Care Cost Recovery Actions, Transition Years 2004-2018 [Member] | Settled Litigation [Member]              
Loss Contingencies [Line Items]              
Litigation settlement             $ 373.0
MONTANA | PM USA [Member] | Settled Litigation [Member]              
Loss Contingencies [Line Items]              
Litigation settlement         $ 4.0    
XML 92 R79.htm IDEA: XBRL DOCUMENT v3.21.2
Contingencies (Other Disputes Under the State Settlement Agreements) (Details)
$ in Millions
 1 Months Ended
Jan. 31, 2021
USD ($)
PM USA [Member] | Other Disputes Under the State Settlement Agreements [Member]  
Loss Contingencies [Line Items]  
Amount ordered to be paid from other party $ 32
XML 93 R80.htm IDEA: XBRL DOCUMENT v3.21.2
Contingencies (Federal Government's Lawsuit) (Details) - Federal Governments Lawsuit [Member] - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Aug. 31, 2006
Dec. 31, 2019
Dec. 31, 2014
Loss Contingencies [Line Items]      
Disclosure period 10 years    
Implementation of Corrective Communications [Member] | PM USA [Member]      
Loss Contingencies [Line Items]      
Provision related to litigation recorded   $ 36 $ 36
Implementation of Corrective Communications [Member] | Altria Group [Member]      
Loss Contingencies [Line Items]      
Provision related to litigation recorded   $ 36 $ 36
XML 94 R81.htm IDEA: XBRL DOCUMENT v3.21.2
Contingencies (E-vapor Product Litigation and IQOS Litigation) (Details)
 1 Months Ended 9 Months Ended
Dec. 31, 2020
plantiff
case
Apr. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
claim
lawsuit
Oct. 25, 2021
claim
Oct. 27, 2020
claim
Oct. 28, 2019
claim
Loss Contingencies [Line Items]            
Loss contingency, number of cases with set court dates | case 4          
E-vapor Litigation [Member]            
Loss Contingencies [Line Items]            
Number of cases pending         1,145 0
Number of plaintiffs | plantiff 20          
Number of third party lawsuits | lawsuit     3      
IQOS            
Loss Contingencies [Line Items]            
Loss contingency, damages recoverable, value | $   $ 0        
Subsequent Event [Member] | E-vapor Litigation [Member]            
Loss Contingencies [Line Items]            
Number of cases pending       2,951    
Class Action Lawsuit [Member] | Subsequent Event [Member] | E-vapor Litigation [Member]            
Loss Contingencies [Line Items]            
Number of cases pending       53    
Number of pending claims, consolidated for pre-trial purposes       28    
Pending Individual Lawsuits [Member] | Subsequent Event [Member] | E-vapor Litigation [Member]            
Loss Contingencies [Line Items]            
Number of cases pending       2,548    
Pending Lawsuit Filed By School District [Member] | Subsequent Event [Member] | E-vapor Litigation [Member]            
Loss Contingencies [Line Items]            
Number of cases pending       350    
Settled Litigation [Member] | E-vapor Litigation [Member]            
Loss Contingencies [Line Items]            
Loss contingency, claims settled, number     1      
Litigation settlement | $     $ 40,000,000      
XML 95 R82.htm IDEA: XBRL DOCUMENT v3.21.2
Contingencies (Antitrust Litigation and Shareholder Class Action and Shareholder Derivative Lawsuits) (Details)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 30, 2021
claim
Aug. 31, 2020
shareholder
Sep. 30, 2021
claim
Dec. 31, 2019
shareholder
Mar. 31, 2021
shareholder
Aug. 31, 2021
shareholder
Oct. 25, 2021
lawsuit
Nov. 30, 2020
complaint
Apr. 30, 2020
Dec. 31, 2018
Loss Contingencies [Line Items]                    
Loss contingency, number of complaints | complaint               3    
Loss contingency, number of shareholders filing class action lawsuits | shareholder   2   2            
Loss contingency, number of pending cases consolidated | claim 5                  
Loss contingency, number of shareholders filing derivative lawsuits | shareholder         3 6        
Loss contingency, number of consolidated derivative lawsuits | claim     4              
JUUL [Member]                    
Loss Contingencies [Line Items]                    
Equity securities, ownership percentage     35.00%           35.00% 35.00%
Subsequent Event [Member]                    
Loss Contingencies [Line Items]                    
Loss contingency, class action lawsuit | lawsuit             16      
XML 96 R83.htm IDEA: XBRL DOCUMENT v3.21.2
Contingencies (Lights/Ultra Lights Cases) (Details) - Subsequent Event [Member]
Oct. 25, 2021
claim
case
court
Lights [Member]  
Loss Contingencies [Line Items]  
Claims not certified, number | case 23
Number of cases pending 2
Lights [Member] | PM USA [Member]  
Loss Contingencies [Line Items]  
Number of state courts | court 21
Smoking and Health Class Actions and Aggregated Claims Litigation [Member]  
Loss Contingencies [Line Items]  
Number of cases pending 1
XML 97 R84.htm IDEA: XBRL DOCUMENT v3.21.2
Contingencies (UST Litigations Narrative) (Details)
Oct. 25, 2021
claim
Pending Individual Lawsuits [Member] | Subsequent Event [Member] | UST Litigation [Member]  
Loss Contingencies [Line Items]  
Claims filed, number 1
XML 98 R85.htm IDEA: XBRL DOCUMENT v3.21.2
Contingencies (Guarantees and Other Similar Matters Narrative) (Details)
Sep. 30, 2021
USD ($)
Loss Contingencies [Line Items]  
Contingent liability related to performance surety bonds $ 24,000,000
Letter of Credit [Member]  
Loss Contingencies [Line Items]  
Credit line available under the agreement 48,000,000
Revolving Credit Facility [Member] | Credit Agreement [Member]  
Loss Contingencies [Line Items]  
Credit line available under the agreement $ 3,000,000,000
XML 99 R9999.htm IDEA: XBRL DOCUMENT v3.21.2
Label Element Value
Restricted Cash, Current us-gaap_RestrictedCashCurrent $ 1,000,000 [1]
Restricted Cash, Noncurrent us-gaap_RestrictedCashNoncurrent 60,000,000 [1]
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations $ 0 [2]
[1] Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 12. Contingencies.
[2] Cash included in assets held for sale at September 30, 2021 is related to the Ste. Michelle Transaction. For further discussion, see Note 3. Assets Held for Sale.
EXCEL 100 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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Ā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zMK R$HQ<4MQ:XR,X35/>;)(]L)F59<$;6.S.DKT[X'M]_^UJ-5GZK<,A5JUI>X]ZX%0-E%=<[V&TF1(<#T4 M:K6W$&H9K:/VJC._2\=E MLIVM%6OJ%NL]N!RP6*S$TK;[!]2J(WUW!Z$6Q.!M$"Z3[6RMWE*WWCX4W58# MXLL2))L!*LG\ S(Y]LZ!6G6E;;<5 BN=P5':"D%M6X'\TG%[RVP[:RO*@5N4 MCT%N_]U"8"4X:+OW$%A!#8[2>]A$K2ZDW4UZC.I0C%, MC8_?'1AGN7Z7L3[1(BM>!SP*K452',Z!12!S W-_*H1^/RQB$# "1!P &0 'AL+W=O.AJJS@$F\UF*HHF'Z9 MH%";4= +7A?N>+ZR;B$<#TN6XSW:A_)6TRQLO62\0&FXDJ!Q.0HN>M^F V?O M#7YRW)C.&)R2A5)/;G*=C8+($4*!J74>&/W6.$4AG".B\=SX#-HC'; [?O5^ MY;63E@4S.%7B%\_L:A2UHQ9-AYJM0'MK,F;&_C8 M>#2IX=)E\=YJVN6$L^,K+IE,.1-P+8W5%27(&CB<8,ZEY#(')C.XE)D;3I@@ M6S2@EG#%MYB=E)JG"+<:L2A=.L!7@?&@7TQK1LZ.X'"&EG%!HQ.X8ES#3R8J M/*83R\J:8[C!-0I(X/<A_? 9I@3O>7BTAT[25D;B_26?548G4S_H.IFAYFOF MLWQA#"TF[OXUN/>(!F&ZV[X/]HDT9O-/S3[+6;0&9=LU&C2<4Q98Z M15. ?/Y.R"ZCLVBWDD&K9/"_ 4=J_KW! M'GP,9/\=Q8\FW7S4#,/.K5>@SOUC8"!5E;3U!=BNMN_-A;]FPS?S^K&:,TTU M8D#@DJ#1Z1<*CJX?@'IB5>GOT(6R="/[X8K>3-3.@/:72MG7B3N@?87'?P%0 M2P,$% @ /5%<4Z7@ /'C P KA, !D !X;"]W;W)K&ULQ5C?;]H\%/U7K&@/G;0UL37,!: M8F>V@5;:'__9(8U#@0 3;"_%2W.MLS>^ MKZ(YI%1=BPRX>3(5,J7:7,J9KS()-,Z#TL0G0=#R4\JX-^CE]^[EH"<6.F$< M[B52BS2E\O$=)&+5][#W=.,SF\VUO>$/>AF=P1CTE^Q>FBN_S!*S%+AB@B,) MT[[W%K\9DJX-R!%?&:Q498SL4B9"_+07MW'?"RPC2"#2-@4U/TL80I+83(;' MKR*I5\YI ZOCI^PW^>+-8B94P5 DWUBLYWVOXZ$8IG21Z,]B]0&*!35MOD@D M*O^+5@4V\%"T4%JD1;!AD#*^_J4/12$J ;BQ)X 4 >38@+ ("/.%KIGERQI1 M30<]*59(6K3)9@=Y;?)HLQK&K8QC+H4KWO'PT0W6I(U8^: M:<)RFC"?IK%/+I=93-%;I4#OK-TZ2RO/8M_DY2!L]OQEM3[;$-P*2\P&NT;) MKG$"NX^,3EC"-(.=%->IFI7Y@V<,MQ&=]FZ"S9)@LYZ@D.:]YN;%DA)X](@B MP;4T5J)LZ5,?DGVIV@F;-V'%Y4,^?2^!2;KM'LL$770C;I.8_& M?]6DG691)!<&7K&8HP1T5HXOZN78F3D^Q3>I]^ZA%%PH](U*2?F?RV+P M[BM-F3$J!!^#>5^/?KF(,W72O*B$SH1)ZSP2MK8E),\EW,;@L+M'0N?>Y(![ MLP>(7V>218#N)4":Y1_7^0F*^N>*.G\GG8LJZGR9'-A_'ZMH=_NC][F@VQ#2 M>*:G7SE,L2=9=U2:FBN4P-0$!==MTPYR?3BTOM BR\]7)D)KD>;#.= 8I 68 MYU,A]-.%/;(IC^@&_P-02P,$% @ /5%<4UB5-CT* P *PH !D !X M;"]W;W)K&ULM59;;]HP&/TK5K0'D$9SX]8*D,JE M6Z4BH:*N#]4>3/(!5AT[LTUA^_6SG9!"%!#:VA>([7/.=_6EM^7B5:X!%-HE ME,F^LU8JO7%=&:TAP?**I\#TRI*+!"L]%"M7I@)P;$D)=0//:[L))LP9].S< M3 QZ?*,H83 32&Z2!(O?0Z!\VW=\9S_Q2%9K92;<02_%*YB#>DIG0H_<0B4F M"3!).$,"EGWGUK^9^)XA6,0/ EMY\(U,* O.7\W@/NX[GO$(*$3*2&#]]P8C MH-0H:3]^Y:).8=,0#[_WZG!W, DL8^?8[Y &U MC%[$J;2_:)MC/0=%&ZEXDI.U!PEAV3_>Y8DX(&B=:D*0$X(RH7F"$.:$\%(+ MS9S0O-1"*R?8T-TL=INX,59XT!-\BX1!:S7S8;-OV3I?A)E&F2NA5XGFJ<$= M89A%!%-TSZ02&]T#2J+:3$!#X1UZ8KK[*/D#,?JFNTZO/' I0=;KJ#8&A0F5 M==1 3_,QJGVIHR^(,#0EE.H>D#U7:0>-&3?*G1EFS@0GG G1E#.UEFC"8H@K M^./S_.LS?%5Q1X@5_AS^ARNE<5SO]9G_RS]:-D MA$6KA%8O/*$W!D'>L-G7Z.5!KZ%[!8G\>4:Y62@WK7+SA/)!EZUTEZ$:U4U6 M1_HV4R;:MK#D2WP8-/VSUW+?#&E6!O!)H7 4*NL>@205(Y[8 '<7> M*F)OG8W]CNP@;J2"1(#TKH,DM1FV)[9$+U-(%B#.);E=&&I_\4M[9%2%ZGJE@E5*>:723RI1S6ZI:.[!Y9> 6-E7 MAT01WS"5'6[%;/&RN;7W>6E^Z-^,_(KYL7D)V7G*O]P!@HWH>#OU!+ P04 M" ]45Q3,WN=Z)T# 6#@ &0 'AL+W=OB#[1T;1.52(^D[7:_ M?I>4K"B2K'@=FA=;),^YA_?RB"+'>R&_J36 )M^SE*N)L]9Z<^VZ*EY#1M6E MV #'D:60&=78E"M7;230Q)*RU T\;^!FE'%G.K9]#W(Z%EN=,@X/DJAMEE'Y MXQ92L9\XOG/H>&2KM38=[G2\H2MX OUY\R"QY991$I8!5TQP(F$Y<6[\Z[D? M&H)%_,E@KRK/Q*2R$.*;:=PE$\?Q=!'5*34.L M/A^B?[#)8S(+JF FTK]8HM<39^20!)9TF^I'L?\(14)]$R\6J;*_9%]@/8?$ M6Z5%5I!Q!AGC^3_]7A2B0L X[82@( 1U0N\((2P(X:D*O8+0.U6A7Q!LZFZ> MNRU<1#6=CJ78$VG0&,T\V.I;-M:+<6.4)RUQE"%/3S\P3GG,:$KNN-)RBQ[0 MBIS-ETM<247$DOR.;KWC.U#:C)&/D*P !SBYB>-MMDVIAH3\H=<@R4QDZ-:U ML=$.R">A%*AS$<7+/TA3M MI,:NQES-C-VXR.LVSRLXDE=([@77:T7F/(&DA1]U\Z\Z^"[6N"QT<"CT;= 9 M\ DVER3TWI/ "_R6^_(;[FSDS!CGG'SYA"1RIR%37SLD>Z5DSTKVCDA60S]"+%:<_8/&9:?ZN,V" MN>+ *IH=>3?U_='8W567M8FY"(;!2U#4! 6CP4O,O"U0+RQ!+XK2+XO2_\FB MF!=U3B7'MU/E"'R5VVJ0"_0KT_)J%6@B:C6*FHAA+?DF(CR2^J!,?="9.GYF M\"/"<8^5$GC\@\3XODMJ-KW#;M3ANF&I,GPKHX]*R=&;&WWTZB(W$1>#FH.C M)L:OF[PE3#!J7^BKLAY7O]KC5Z^FWT34/=Y$U#W>1!SSN.\]?]V]_^;R!+C M8X3U0 (+?8K9_/LK>\ MQ-S8HWNM_]:_GODM_9&Y]-AS]7/X_,9T3R6>5!5)88E2WN40ETKFEY"\H<7& MGK(70N.9W3ZN\>(&T@!P?"F$/C2,0'D5G/X+4$L#!!0 ( #U17%/I6&PO=V]R:W-H965T&9SCDL3@[4_:='P$$>HFCA,][1R'2J6'PX BQS^]I"HE\LZ#IPS\,"?%D6&9YM"(?9+T%K/\V88M9O0D(I+ AB%^BF.?_;V$B)[G/=R[ M//A,#D>1/3 6L]0_P!;$EW3#Y)U110E)# DG-$$,]O/> YZN+3,CY(BO!,[\ MZAIE4G:4?L]N'L-YS\Q&!!$$(@OARW_/X$$499'D./XJ@_:JG!GQ^OH2_==< MO!2S\SEX-/J#A.(X[XU[*(2]?XK$9WK^#4I!;A8OH!'/_Z)SB35[*#AQ0>.2 M+$<0DZ3X[[^4A;@BR#AZ@E42+)7@M!#LDF"_-8-3$IRW9G!+0B[=*+3GA5OY MPE_,&#TCEJ%EM.PBKW[.EO4B2=8H6\'D6R)Y8K&$!/9$H$WD)QSUM[(1PU,$ MZ-,>>31.:0*)X-G=[[)I-\ (#4F +BR/;.CD_EWW][NPWQ;"K[K'S M>$Y+O$VY8WQ[@G@'[,^.D$X5TLE#VBTA5[*Q$@C1=6.B%>%!1/F) ?KV4;Y& MCP)BWI7.K=*YG0JVP)Y) "B0G:SKSH(]S-G9ION\P*.9\7P]X1K(^!:R:D)< M? M9:R!N!;F1-JRD#3NE/28"&,@%VJ:MH+M7*9VAHJT)&5J*MB8$VQ-%G 8S M'NO5C2IUHTYUZY=4>HUL% ;BQ!(DNS#-6L7G'(1VHQDU!G&';64:/!W(V>23B5_#UVM;M0/&(1$#+0F9#8' MH8C50-2EH(&H7:&!."U:KRP%*[>N_C+H;8,ZJN@F"#=4 M:P)A4]W?="@+MTBW:NE6]S1+<7(#( SDCU?Q%A_"M;=A^_]P(EP['W9^RHM* M^LUZ4^?K5# M<=K68>VWN-MP?]R2<-,8[RQ5L@;3D*S!8%/5K .UK<#:AO'H/[$D7'L<'K_; ME$IJQR;L:2"F6JXF! _5:C4QHY9:U6Z+N^WV1TVIZ8QWEJG*U8!&JEX-QFZL M>5TV2R_9JGW8ZO;A]WE3&738("IOG7_8X*0>/\\@A^""P#R/=[2L7E)DM0'4$M_@502P,$% M @ /5%<4Q>NH4_E @ P D !D !X;"]W;W)K&ULO59=:]LP%/TKPNRAA:ZV["3]( FT#6.%982&;@]E#[)]DXA*EB?)30/[ M\9-DQW%7QVT9Q ^VOLZY]QY?76FX%O)1K0 T>N8L4R-OI75^Z?LJ60$GZE3D MD)F9A9"<:-.52U_E$DCJ0)SY81 ,?$YHYHV';FPFQT-1:$8SF$FD"LZ)W%P# M$^N1A[WMP!U=KK0=\,?#G"QA#OH^GTG3\VN6E'+(%!49DK 8>5?X\@;W+,"M M^$%AK1IM9$.)A7BTG=MTY 76(V"0:$M!S.<);H QRV3\^%V1>K5-"VRVM^Q? M7/ FF)@HN!'L)TWU:N2=>RB%!2F8OA/KKU %U+=\B6#*O=&Z7#L(/9042@M> M@8T'G&;EESQ70C0 )M!V0%@!PO<"H@H0N4!+SUQ8$Z+)>"C%&DF[VK#9AM/& MH4TT-+._<:ZEF:4&I\?7D,&":C1C)%/HZ#N1DEAAC]'1!#2A3!VCS^A^/D%' MGXZ'OC8F+=!/*OKKDC[<0S\E&Q3A$Q0&(6Y!WW2CYY"?HBAH@_LFSCK8L XV M='R]/7RS*OT>IL!CD+\Z**.:,G*4T1[*B5$O@Q0U=403JA(F5"$!/7PST^A6 M U==YGJUN5YG!%MS<64N-^9.W!L1I4"K$Y2(3$L:%W:7*!1O$/"[XIW$8!>X9^D\M?O9K/_L?4AK]05/R3'G!WR/^H+8R.(3X9[6YL\Z@ MKC)-$YH3;4R2-*568<)J?5\JWZ9V2=]OJ-WO$ON\]NN\6VRAM 1-)9CZJM\C M\$7-?'$(@7&PJT;!0?.[,M>4?(_8N%$Q\1L^)N; 5("H/84261A_\Y>_8 6$ MZ15*B-$H,5.(41)31O6FM83B5[NP%X5=F8%W%0^_4?+:<^-C^Q'OJB$^2#G$ MNWJ(NPOB?^])_+H$_BNZWSA>[=UF2N22FMQCL#"8X/3,I)&PO=V]R:W-H965T3 Q?/(0C\*5LJILU-J?^^Z+/AHL *AF+KRKT@ M.#=!!7,#SQNZ!::E,YN8N86837BE&"W)0B!9%046/^>$\ZW2D] MX[PE2Z*^[!<"1F[+DM."E)+R$@FRF3H/_GWF>SK (+Y2"6.:"?+XKR%UVC5UX.GSD?T/(Q[$K+ DCYQ] MH[G:39W$03G9X(JIS_SP)VD$Q9IOS9DT?]&AP7H.6E=2\:()A@P*6M;_\8_& MB), X+$'!$U T V(7@D(FX#PK2M$34#TUA7B)L!(=VOMQK@4*SR;"'Y 0J.! M33\8]TTT^$5+72A+)> MA3@UR[ H:;F5:/")2TGD#=H3@98[+ @:S+&D:X3+ M'*6458KDJ(4OCJ@;-$B)PI1!Z"WZLDS1X,,-DOJ51+1$_^QX)8%"?D0?]/B) M,@85(B>N@O1U$NZZ275>IQJ\DFJ(GGBI=A)E94YR2WQZ.7Y\(=X%VUKO@J-W M\^ BX9+L[U#H?42!%_B6?![?'N[9Y/R_U;-WKWYF1M@64FCXPFN%U%8&^OZP MDDK 4?#O!?ZHY8\,?_0*_]]P:)*V6%E3K%@I05>5PBM&D.+H@<$8VVJK9A\: M=GUZOLQN@U$03-R7TU_,@AK''5#:!R6Q?X[)^I@@CL(6=&9!W%H07[3@$Y'R M'K:BK#7#=M1;LRKSDYG6HJXS9D?>ZC,5P@Y8Y-8=6"<0G[G4L<@"Z8A/+9"D MXX\%,K2[,VS=&5YT)^L5!URC^A*!(RQ;+&UJAQ:UHR#J"+:@QG'8D=P')5$' MD_4Q01R.[*I'K>K1.U3GQ^/:KGMDW0M=W1947W1TG;+@XZ>%2*]^XA\NN M\YUY,FX]&5_T9,$J.!_6<,E!19!2L9^(2EF9$P!N==-5EFNP2O'U,YP;5,EK M#HU[F7:]Z2/\OC%7:;(K-&=^^-[OYL9[=Y6<[)%K+C2K7"\4*S#N5T!J9[24 MRAL8:V_\S=] M_37QA,66EA(QLH&EO+L19"OJ!KT>*+XW'>B**^AGS>,./FJ(T !XO^%<'0=Z M@?8S:?8+4$L#!!0 ( #U17%/^AJ[/U0< $HQ 9 >&PO=V]R:W-H M965TAV@=B3V*V7+* F_;;[X =CSGG,-"+\]+8^#__X9RY_6:@YT]%^:E:*U4[ M7[(TKRXFZ[I^/)M.J^5:97'UIGA4N?[EOBBSN-9?RX=I]5BJ>-46RM(I=UU_ MFL5)/KD\;Z_=E)?GQ:9.DUS=E$ZUR;*X_'JMTN+I8L(FSQ?>)P_KNKDPO3Q_ MC!_4K:H_/-Z4^MMT[[)*,I5729$[I;J_F%RQL\ASFP*MXJ]$/54'GYTFE+NB M^-1\>;NZF+C-':E4+>O&(M9_/JN%2M/&2=_'?SO3R;[.IN#AYV?W7]O@=3!W M<:461?IWLJK7%Y/YQ%FI^WB3UN^+I]_4+B"O\5L6:=7^ZSSMM.[$66ZJNLAV MA?4=9$F^_1M_V27BH(#VH0OP70$."\B> F)70(RM0>X*R+$U>+L";>C3;>QM MXL*XCB_/R^+)*1NU=FL^M-EO2^M\)7G346[K4O^:Z'+UY1_U6I7.HLAT-ULW M[?]9.5%9ZGQ:ZX":VYHN=S=_ MO;UYWG/SPGE7Y/6Z/K"4G^I$[K/)G[-YS:V&M^KQC2/R<98M^U1.LG>OR&.L;;?%EDROGXODA31X_ZI[A< M_6.I5^[KE6V]LJ?>:_60Y$T'UC-(&N=+176LK87?6C23Z>=+P;W@?/KYL+6P MR)O-_:XHQ"(><*\KBK#(%\Q4UXG3V\?I6>/BL^/NL M^-:LZ*$\T/0^KI5Q'[38 JL$%R /X2BK:,"J$^9L'^;,&N:X6=?Y^$YE=ZJT M#:OYOL;YBP[G8%]O\./#.< -(7P7=EM*-9M)T*B$2@H)^RZAXG-?TJW*7+,< MNS\^J)T[I1%1:5!;IG%5)??),JY[EU 7W2GG()H%(=(]68#,$"K&/)#EB/02 M;D^'9P>DPJRI"8P0U@R\V""L(;/87X(\'+]GOP8&F)V M'#H2)#+,-)@2"1'"1$*#.9$RZ@5%9A"*V1EJ&!5W!J#/"A<&2LEF<[2XG9>&D6'G" 2[DHP0RU( M&?- ^X2D3'+8C+1;T(-!W& 0MV/0SR=$C@$&]G!"B'L9!C>H$C?D%H/#1&L"9 0P1K&.N9_KDA)6XGI?%# MA#B6@:D82;<&0"8$/!\ M@90Q>#88CG.+!MVZX1IPX_;#M:OKMV-(4!@>$^Z+DJ P7"3L7#2*! 5!'\QW MX:ZW1P87-%(6"$@!E,P/>L:P,,PCCGE"1&8'XPI'\QHA.IW!B8T0^7-X+DXY M,=ZWTHF#YTYV0!J]T@F"-233W'/<(@S;"CC8OC8." MH!,?SGZ$Z%1"AB9$GH \2#D%7E\?,30D?N*Y$9F&X6=@"T(C(211/C!3$2'B M/?L(81A)V!EI_# A: =&2CT)@QMGR@?NFBFC'OH7AG;$P,.RX]*@() &8@^A M@5T]I'P$Z@H$]?0M)89ZA)UZCH2# E,+\U'7(= & 2$AD@%:3PBGH&\O(0PC M"3LC#2.A(!X&,HG.ETB9#Y_%A>/"'*7A-\E>E!RE 2EI!ZEQ+XQ@6)$0C0C-*3P3 M"@D1@[A/:'H;UF"1/.:Y$9D3##1PWB,DZ+$RH1'H!1J*L'H6!GGPIM!/>E0F M,87 TY]A23@LB:R2;I2&=:2==5Z:$"6F%=0M"*!!W0)K<+>@SJ'ZNH4A(_D3 M3X_(#% X!%. -:B_$#;PL-!JTXW?\)*T\]+X88%A! V+04DX+(FLDFZ4!GJD M'7J.3(62XAJ8'*Q!R:%.?F!V;#;=[!CJD7;J.1(22DPM:!7%$CPW8(V @$1H M>N<&S^"19\>C81K<&71>&X6C@M* $$?81%:;;8#3@W?#,U4^M"_E5[IA==_? MOLN[O[I_\?^J?=T=7+]F9PM&7 _96;1]K=_8;_^7P;NXU&!5.:FZUU6Y;V:Z M*C?[XNB?O[25+#_[Q.7_P-02P,$ M% @ /5%<4_);0'B?! ^18 !D !X;"]W;W)K&ULS5A;;]LV%/XKA-&'!&@BD9)\"1P#\658@*8+DG5[&/; 2,Q2C(5^KF*7P M*)!<)PD5;V.(^?:V@SN[A2>V6*ILP1D-5W0!SZ ^K1Z%?G,J+1%+()6,ITC M_+9SAV]FQ,\$!W,"Y4PX?'O+%++VTZ_@R*8TW6LGOCV9R@#"C)] M(8]E_A=M2ZS;0>%:*IZ4PMJ#A*7%?_I:)F)/0.NQ"Y!2@)@"_A$!KQ3POM6" M7PKXWVHA* 7RT)TB]CQQ4ZKH:"CX%HD,K;5E#WGV(I>B!Q7$&&3I*NY<9<<+2E7'A"CGBBH<>>*J6$LW2""*+ M_+1=?M B[^BT5+DAN]R,2:O"9UA=(\]]CXA+L,6?R;>+N[9POL_Z[#];/TB& M5Q'%R_5Y1_29'$!WT5^:GKIF**0+$.)S=!>&ZV0=4P41LO'J/@UY NB/#UHU MNE>0R#];'/,KQ_S<,?^(8Q]U-5V!8#QB(7J!%.9,:2)FIMXC> WC=:3)C"2( M#0L!A5PJ&S<+(]W<2%9=-Z.KKC=T-OO[;<$8D*D%@@-R")I90$&_PAQD(:BR M$+1FX:)([B6*BS,[%SQ!\&7-U)M.Q@:*G;*>RD)QL.=-U\6!$7H3Y/>,L*9- M3-#K#XS8FR#/[=IC[U:Q=UMC?Q1PI>@KH@E?ZQAU_]I151,Q3P3=8R;/F1D> M,+-,FN(HU6R"LOZABV+]TI:U;B,.TLL.VD'6FJ!!T#6RUL1<]0-L9,T"(H%' M['GK57GKM>:M<:3_Y3E^@.0%1-L9[E>>],^KN PJQP;G1ZU!8[.Q<=0F3\-_7@\R(<)K5K MY!3]K+1R4*#,\F3!!$;AGUHP [.?63 8XR-$J@<.['TU$=DI.3&'ZKD#^V?& MH7H8P.W3P/_%(4NS'I@:&$Q\DT0VT. (B>K1 ']M-F!<' 3JA (B MG8[3LJKNR;AW9JRJFS3NGX15_>8P@QNTLH :IW_Q&L8".52)2 M]W72WMI:JC\_BLN::K6ZI[W+;R>-]3&^ MF6#+^A3?S(I;V%I]<2G\0,6"Z9$]AKDVY5[W-/]%<<]:O"B^RB\27[A2/,D? MET C$!E _S[G7.U>,@/5;??H'U!+ P04 " ]45Q32D'Z>5,& #R' M&0 'AL+W=OS:#9!L]D>BCW(,FT+E427I)-T?_U2LFS9Y(AV=]%>$DE^,^0; M/LX,I8L7+K[*!6,*O19Y*2]["Z66Y_V^3!>L2.0[OF2E_F7&19$H?2OF?;D4 M+)G61D7>)YX7]HLD*WM7%_6S!W%UP5YL&G M;+Y0U8/^U<4RF;-'IIZ6#T+?];=>IEG!2IGQ$@DVN^Q=X_,Q]2N#&O%7QE[D MSC6JJ$PX_UK=W$XO>UXU(Y:S5%4N$OWOF=VP/*\\Z7E\:YSVMF-6AKO7&^_C MFKPF,TDDN^'YYVRJ%I>]00]-V2Q9Y>H3?_F--82"RE_*-L9Y!D97K_\EK$X@= ^T'-B"- 3$-_ X#VAC08PW\QL _=DI!8Q <.T+8 M&(1U[-?!JB,]3%1R=2'X"Q(56GNK+NKEJJUU@+.R4M:C$OK73-NIJTG*(W*"O179;G M6B3RHJ_TA"JW_;09_/UZ<-(Q.$5WO%0+B4;EE$T!^Y';/G;8]W4@MM$@FVB\ M)TZ'CVSY#E'O+2(>P#^1V#_:%SL&#/K%PQ4(=KZ["V MKI+M\U48#<*+_O/NZMB@"!.Z#QK9(!Q'P6 ?-890 S_>HO9(!EN2@9/D_9*) MI(YD5J:\8!#1M8=@9V 2!]@@:H,H#CV#J T:#$AD\ 1 )"8PS7!+,W32O"T5 M$TPJE)13Q-6""5TJ)@JQ5UU.)7N+2J8@ZJ$UES,2FFL,@"@VJ0.@01@;U"%0 M3&'JT99ZY*3^D4N)].Y@BWUG[&IUF*)JQDLTPU>^"MCE*:KZ;5KI!, M/&(?5MEZKL.Q+/>+95$P-07VTL6Q#@PB ,H/S)XC2!7T/&_Z2I2N1J0S._(U;AZB' $1G#L_4_F%/XX.> M]LGO-&G82?Z#/B*L%_^T2@\W@I= M]# UI0"BO,",!H0B9AV$4+J_Z(@':>-!G/$8):+4.UZV&V+"=&_!FJ2 5/+: MH08"B)-ZQ P!!".^&0(;A0/?-T-@HWS:U0K@MKO"U!F"QX)_9?6 M4N(NI9\K4?R &DE;E CY^6HD;0$@[@)P2(V-^7[:BLSU D!!9*Z7#?)CL\Q! M(.IWK%9;?8C[7-^E11]H*WR3FPW"9H($,,1,C]!@U.\28EOIB+O27>HL*TJ)/P%*FR3/'$G^8,JM ^# W.=;(A5J@&,U6@!F+..8Q=I2PQQ'SV[ M!&@?\?0AQR0&@*R]!6""T&0&@,*.5PVD+6?$7Z40;U2:%CC*E0$&2N) 0RV[8Q M".K(DK2M/-1]'/K 2E8U6RD7.L;Z3'C4"NZ\R/T%;W)IF_.I.^?;;)HW?_ " MVJ]:@3,MA++>>$(@$IA=%SA@8![Q^SN?9 HFYO7',ZDYK4JU?H>^?;K]0'== M?Y8RGK_'YT,,/!_A\_'Z\UOK?OTU\"X1\ZR4*&6")5,F*H#^?<:YVMQ4 VP_"I$-*,@A51^28,3;K"@IDS5:*T3Y9*%XSL5N>A M*36RS(,*$<91- @+QF4P'OJSF1X/U9H$ESC38-9%P?3/:Q1J,PJZP?;@CN%BR'.=(]^5,VUW8L&2\0&FXDJ!Q.0JNNF\FW<@!O,5GCAO36H-+9:'4 M@]O<9J,@-'31HT/AVPO=ZRO_/)VV06S.!$B2\\ MH]4HN @@PR5;"[I3F_=8)]1W?*D2QO_"IK:- DC7AE11@VT$!9?5/WNJ"]$" M6)[#@+@&Q,\%)#4@\8E6D?FT;ABQ\5"K#6AG;=G(RA\Y')4]GS&Y27C)_-&5RO;0%7VO4<)5]MV%YT"UA84Z@ M85G#&) FXPY;XG+'8V;;.3@HDR!)^6,&<"#7R=8K% M_6>]OSC[H(R!3FZOGA-[00A&F+D>$)QX7CDT M2"30171(ZHI]X-G=[?4X/NWUAN%CNWP';,X'CV/TF[/[1L#^5J%E=FU05 M"!V7R,FN6W_!O% /R!8"8:95MD[)P+:R+2O;_??SJ_;)CKHVW[T#1^H]: (? MO+RXYXVS\Q<5MV+OMX5S';XG[@&;?G)8W(LF[(NC8=]*0HWV$F(R T4K>X5E MN"# )SM'#;X&B7L:[FJ:*IERX:OJ:O@V;70U\JL-J=)/S84B.X/]&ULQ5?;;MLX$/T50NA#"C31S9
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

7\S6;?!NEK%E,8V2JP.V6':=&H[6VUZ_6@ TX4IC%[[>&C3>=+.C MN?*X?HPGPWCL8K_!\(OYY7&![=_G,+C[K7Y<;'37LGS9]8,PVG&#]6<#&N\ MK UF0NON)$CK(0+9WW*_>O,DQPR7,2MR5N2LEF-6Y*S(69&S>HX97H1%+EZ= M=ZU2AWZ,_7_;/E8['BNK3USKJ-+5'DA8E[#1Y7/[T. #(4$$P[AAQ#I!+!-. MF$0M7%DXM\].3-"?,-Y&S=O>8UG,.ZJUB?J\XV;J..K3P^=?^>'1>[K[Z3T[ MW/G0V=MOM0^/MOGN\1OH]QMRL.]_''[:I5>C/IL_\C-:Q[M'T/Y1^-I\][?8 M>_?'\>[.E[.#_:]PWS^MYH_\/H=5D?*+_ L2&^VCMH@$J1&/B2!' T9:XR@- M8X*8M+$ER-,Y$5"KD/_5Q_2O&;RN-FA_7>!U^:J#WA,%N&H2B9QP ?!)J%-$ M)JX297CA_#@%7E<(KS\F)4HSK"HID%/!YE(^%NG$&3)$8\FBT6 3 5YG2Q07 MB'LR$%<8Y-W.K(HHDE':":\Y,!2KL/+6B^@4TS05!OFH$$#(L,2$X0-PU5=@+@RSP6ACD8S%(RW BCE"!0^2,!>N\H]Y% MXZR%05H\PV*!UQ7"*YODSO5&!$M@;T*)PF_7P@*UM6%7SP!JEZ:5 MQ#GLH]2><<-A&0BT4AF< A:26.K-PNE""M2ND^E4C Y&UM/VDE9-Z!] MEEA;F.5=L39PQQ,AA#O@)SXQ0[2TW #A]%@%MW@BNH*UJ\3:YH191FF#T4*A MH%A$8!=E3B&'D?%A[4UQ;N%(SZOKV-?:P!Z?Y[3[+K SLEQLL5> M^EKL76N^]P!1C>2:= +J7<,XN(PTR(1ZN>I,H'N6XD<%2F(8$:V_K--(Z M4>1\2,Q0IS5AH'IR?6QTT>ZG$#=2M'L)S]I4X(@"%<:4$%K)CE;/G'HF-//EJAZ-@R.C8)5S!&PB(C6A2$P(C[I)#1R:,0B69$ MI\ ]N:X44S&A:ZO>Z[!!7M1["?6>VB'GL(:A2<-R5*@ZI8@CC)E#^_DMSWD8[%] :OD3F,8JL52KXYOM) M]+FN0S\.3_O=7);KI),+E8I"S\ ^R9 MG\_0AVJ"]KKYL^UJ=@I(+0)2'Z=VT TP?!^40BI*8"!*> 2+,XV<(Y('CZU( M=F.+F=F#APM7>7^$H,2E/-WKH+?70]DB>OL .]A%;U>EMY/];.ZH%=Q2Y$2@ ML#IG)NNM0E0G0U5(TDJ@%DS-NM^*WM9 ;Y>WMP^PEUWT=E5Z.[6SK07AR6O$ M% V(FY3C96'%CV.0 0N&-:&$RR0E5$B#,L>2H11) 707#I[O*QH;@TT=WF+^P"[V$5S5Z>YDSUM M+"FPHY@SC 2&.%-@ LBG';A>]K:/>+F]Q'V![NNCMRO1V:K/: M&!%XT@)%5L5[28F /$D4),&)X9"BM1M;LWO5CZ*WS^&P]O9Q#SKSP^91?CE/ M0:<[G_.9APV.KW!X$XI'M:!I]0AQ<, WA=^ MNIVO3 /Y7GIGV]W!?V%R8J$K"]&5Z7I6C&(9'=%YF^Y"]X: M 8L,L]8'1,LRI[Y!N"N(FBGP\=#P,8F>82I*H[Q (AF!> H":2H"8@XG3RSV M(I?#(WA565&+#M>0 JP@@J;H\$/K,)DZ?VJ-,9$@'+%%W B)C',!!:^I9UQ' M$[,.K]'YTP(?ZT0!5A#)4^#CH>%C*G.$ .E4G".P]B:?S8G(W*E$( "'_7(95'@X\%=B%,Q1L1)6J6,\C2?H7&!()@WC& 5P8Q@0A-" M5UBUN2AQ#3G "L*,BA(_O!)/PHVH,LI0FI"QAJ#,Z)"UE"$F') ZRWW*+& V MW*B0@((?],7WX^A/?QUB>P=ZY#OM@[1$(NA53574W5X?J_FJ0#7 L"U=ZD0!N 2MR:@ M:"DL99CPR$A)D;/& Y7%RHFXL;76KI"2+[N^+.@!DH@4_%@]?DP"(@S!@3E' M$4D< WY8!=!!(B(R!J>2MM1<&_Q==+@N.ER+C")W=(44;5Z%-D]"(S#U(FGE M4>!&(RY%0H:"7IOD:,(DQ$0=L(%ESDX63:[Q&:S'"TTHFKP*39Y$*0BLJ!74 M(!%( DU6"=E\K!)'B@5/*@5,-[;H,J_D);E\Y=X+M?#1!IN)9F/&(&D^MI_O\L&D2UFK&I"_6J13V> MN:D7Z..?8W4E8EYB'CDI?MZ=4GV+!'W>OOTS!&W%I64"N(^,.).I:WEA/G@,6)@ M-!$/6"$KM86?E,!$"!%D]B\5P"V 6RAN+;;3'Z "5H'9E<#LE!>1 HQBS1-B M0B3$H\SG:[1&"EMIM4OP5KDD[FQH6FWWT O.%YPOQ+K>B98*SC\,SD_HM U$ M@ST.*#H-..\#0P9'@0#ZL:7&!V-;[B MT2D @-KMSP2F+"G'$58:<-9:@C+"(A6B,39H)Y+-U0D+NRU@6]AM?=CM0P:$ M%]A=$>SN3F!7.#")7J'DDT9<"8!=+ .2QG >7(B)DT5"4 O@%L M[+;>V?$* MS#X0S/Y] ;/"86!.8TAM;JZJ-\ZA86\5E_S:T MKA,O@G%';]4\/0:Q\I]Y5Z.BK\2>Y=^(REAV=#H;M='9_.EJU M^+(]A,?YGVLMS5K[YOBDTSN+_<;O\-5^VYWF*1O<�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

:7E06:)^#%6)B.S,SF30N)]U%[G0:W5[P_%@ MZQ7H?H%']/JG:+R.L"9U1^I(WTXT&\)\!R%@. MT\1]D*$T5',&S3M?3L96ZL3O\3.^;49!WVZ M<;^TKH5%JG>SWO1+]K.>.BQT"_:SV\LB/^HV2SH\K6-4N5ESMRQLOF7;K^I> MO3<(ECQ**\?EC85LGMOQM=:Z!Q6HNPB7!=^H!N.NPNA=(X39=,ST)'S$);]A M<._],#YO;8&4Q@XPL9T^/+R&ZD=KC[E86!XU$O7GK#DH#>E+T[#%AJ&._#?6 M@:Q-C$*8$9LQ=DV0^29LUS!*B! <"+GD25KGL%#&!ZZ#8"'2:Z367H,4'?5> MU()N.V_ZO='QYAB)X*>3OK';8#&*E@RVQF'P]7-!<.!1[YH0>%&1GYA(>;R] MX=GVSCK\_SX#UXHG'2UF'@DOO10W\;DO\.0)(6JX]IBK9)H,FP0? E2R M=,$1*F"7)#:(2\>0CIR!-ZBH4D%)J_G"(-!$_H GU])7! _8>1S6CDBG MLJ[*[:/C8M)^*3]IV6'^0-5O)0M_?+$=H..=S.QKHPIO',!WRDN>OM#.<,Z& MZC(CQ%SDN-9.(&.Y,[1+"YD *Z]<8'\XNI MVG4.\-FRG=^OU]KVO[$32F#C/4C,$SG&7QHWZ6,VE7^,8P?O)[&#;#*&C[F8 M+UH;HWZ.#UPW7+4V!ZD34C V]0L#'J :-P)1FXP207L:I.+1,LU,8F KDA(^ M\43N-R+_+L<]1GY85N)5'7S[::%QZ^P#;J_OI1 (QTPC++E#W'F.',FQ>,9( MY%(1V(QG+YFYF)<\P<-Y>VPO!,V /PWK#S24,E7]P;#UGY'M#T'F0&KR[I8P MIOU:'8%^29SVN-]+H(R%"M1A+>L/JOBEQ-_ZO2_PADZONX_@J4!#>&DR8U,8$1KC2]WP@O1+\C_"X.'ENZTNO,SJ*($!@2,+OY96_5"#*(!<@ M+\.B-OE(HP4#2".0DSR5+O*VZX'7Y,/7_;X]CJWC$?@]=@"ZTCLZJH;UT4B9 MX?EUF,Q^NB '%I1U_/!)E'J\*#?+YE":Z!24$8ESH:D)Q"46@@%WV'C&5\KS M@(3Z-=Y:WW-.1*8-02[)?!E<).1R4@^7@0@=";:YO0+!E[/H7R>A>J;W&YX*"2_>!7E M&MC^\G]<_[>7%TU"T5-J1!0R.2*3X<%&$T'R)"->R,"E]'LF9R/?[):!? "S M0JYUCEY?&\'/6PVDMH$1]H&"G<^$UT"$-1,2&\)=;H!!'5>4&@GNH>5L(8:> M!\:-Z(8Y.@F[!%1O!Q[]1Z?G/S\N]HGV!/LVR>[A/MT]^[/@WJ>-M^S3X2[? M/=S$NT?PGJ-_.ML;!P>?=MX=SF/?UN$_U?;&I\.MCQGW\K/#4?OPH (LK."G M\+D/?!O&T'[33NV=3;Z]OB>]5C(Z@HRB%O&H*3+""<238-I:*Z4SM1DKD=SU M;'MBY!3,E3:P$]S19&0^_\MYE(HG^-]G0-L]L/'_]PQX:7SV,B_X&#N;39V3 MZ#G-J'?BVZ\Y/RPF&57@-3$7% ?NYU0N^^-],%&2$-RS)T*FWA_T^L,Z0O!' MK]\OCGU]R##Y9VN]#]BW7V//,O#%J]GA\+*L@CH/)?K97Y%Q?*_A8]DONU$F M/>.*!:MB(%Q'JK'(*;Y@WEGBF/B]S47<:K/]YW6+0Y;MV8'=F6[.A$"9GPQ$ M@%CMR0@:*CE!C+ARJ&:0#DJB)+V4DC%@M^1&Q_\8%!<+*:EWBO.D3;"&8$<) M\92R4.\@)I21U0[>RPXFX16P7(M\\#G21 1R6EGD"">: -*"M_+L9;=WC7/Z MP12[W&1QE\*CO1*AMH'QC?9'X,X3/><.QM+U(Y-((.(P,A!38()CY@ARU0V% MP/^227HFC!3__OK<9];'GRF_);__6K(M@3/>Z 9@ROV]J(H1O)7@L9-.>2L$ M-L8Z3,1B6$/Z1BYC-M2;W1Q-RL/]T_JX7BX@_[3:,9O4TCY[>[K]=@^VT()3 M8!"-Q"&N<4*P(1AIS:WA5HO@@&FPYPLB2Z[Q%@>Q6X$'. *'PH^R;%U%>+72 MU%HJ3<"26Y7@WY8&D;!52BN*%Q+>F3T'E? OPJA_TNL'>/'56YY!\:?;XM<" MMO>T]&L[V\W!0V^H52(PE%NW(4ZB0C8PAY(0D2CMHI'@5PET"A[?/*\%7_)+ MK_.EA+Q+:GC+[O=C[>/_8@\8Y\VY']/'UUG>A0N_?-L')VPWH^-2N_RK:H9L_9B:_J M2PJ7+5 _'N6'5OF0 9X :N3K1-D(0_/#<9;_W-?&.6?5H%7N/N3PSL6*"\^5I[>V";X1"T$93;Q MZW'5!#7*[N0/GG_#(^!,S@\Z!S$3:?X)L09\;K&5>Y[H3&<-DA@K!(MMD8Z" M(6TXETH2H7#*T;6X&&&.X3^]L/RDZG*W;VVQ]I43N"^VJ@_TIOP1]+I5DR^[ MOY\!)FM3'[2H.@:AKFNDW+BBPJWXU 4G8T6H;JH!;T7[[ /9WGB-VSN?>4X? M-Y;9(!P"7Q&L+55@;:7P*!&#+7;@1"9U-:&Z29RUD5">HY[CW+@7)=1>?8F_ MGU1A>#"N@S7SK4:7\/0KU@UZG='P\J_,U"SRQ8=X)"VD8FYU9OX\Z$^;NNY' MY/K1?D8VP6!?V,Z)/1T\^^T\L@"LS"[@_-POG6%*#S;#NCA4R(=V9;=?C(!? M]?.G8$QV:<;2.NAGW/FO;\?L0=AW"@ "HN62176(S[Y6RDK!'BYM>*==_@RW,-#/-TLM,U5*$EY2%7VQE MCNQIR^7CX%"E:IKQ%;^,C^'R@7]W/XY_D;<2W@._F3L4FB9R77#H"U?KK6M9#N=7(,M9ZGX@TR" M:X(=8AX6+%F8?N\8'!,PK7DJ#5L&*_7DV>_+Y\Y>\Y;\L> M'W3C1-P(B_E.4!'X-ES5(=GQ0>7-AIB M.5'2.:>MXY93RE2R\AMI!X7S7$5K_K"#:O >Y,N&[>X_%I8'%B_[<&1" P$O]G5/7KV^A :\8@ M!_B=\P[ =UU^#V/A DV\ZR\@BKU1/KP'F+-@16%!NL6LUNYZLP"#&6\Z>__% MX;9E,7OU@LR<^$_.^%T$E8T3R[.6BP%DWSY$4(2<;#R-$/?ZP^JL_L$8>E[_ ML;FSL3X;#WXU^Y:)W7A=MY;.P\A;7JX%P19V;X@ GE.00C#HT>3$(^T$L9&! MH7142]J4'[D6 EQPYU\UBSL[_GIVP]YX<LWN4UV*JZU='H:((,^*<#A@^Y MWEBTA!O*-:*4)\1M]$A[11"C3!/G>>1$/GO)%SD]("P &&LM6#\_JE.$["2B ME6-!S5]G#-DDC[T(-BAX39Q&_?%O!MG 525P]@VG?;%:U#O^33D^-^BL93ZG MVN45]^O)^4\LX%YLK>\E9S&)-**DJ4%FN<7NS$U OX-66PP.\M&B8\>@;!/!2F?KDU@?TSDYR6KL;!U@'@< MBK\HU0U*%S!?]*D+0C[^ CAV!UDU0TR%BE\RC$D\>!+MM>%P-*ASUY??!F]V M6ULE=ZY.VFB*R>2)GBOP,FSN&<"KQPNQW^FY'"&WQSDUIO%*!K.U8LJEE][1 M$?#PS.*/[?$DU@^?@T4?=0IM*6[%)95GQL>XG:DW57AV?7$F1_EO$C:4#%SI M1()QDO.HO1/>$!VU<38(.ZG3R,:9_>Q\DL(-SV/_[O=\C&'P)\QOM_3TK =MAQ9'"%.QGOA]KHN6(&<-$8#EOA'[C%'8::;[* M$Q_4Q0.\'94SE/YIZRC:G#^*(ID[\6M6W MPTI\H/77J!O/YSOUX[&MPE0\Q_'MT3#?"BMZ<<6 <])WDUCHQLW*^MXF&?&&5B+O7CY,_NHEZXQ[I3J50K)O!-7&A$A+!X-S1"HR -@JQ%!V% M/9 NY"3-J^1_-F4[7SX;S!T%+O:@RB?K&X8EVR]7W !?,(V:-+Q)"8+Z9F&( M1R6OK\1,FP#/O&@69[&&N?RQ\!O]Z*F.#&O4< F(8!Y"KY$B$A:J[P2P/65S69676UG;W9^<8>(=>Z$JS2R&@B6%C+Z"'R* M/N<+F@#]=QWWIIC1M6DR$B!Z"9(-XE%EN]U1*>?D(H!GMUSAK+/N>1UU^'V% MMTN"M\$I91+7,0G-%356)*ND\>#V.&.]7N'M ZGAUEEIO4*Q98$B9P%JN1($ M.4\U(M%BHXQP3K/BUEP5V;\IWMYARU=X>XN-SG7]&)@XI3Q%3!B>^3M#L.P1 M_C"816:M\"7MFR^HT33!6TY6>/O4\591!XH6J!<1W&A'7#0$IX1UR/T0)5WA M[0.IX=NOH(8J2<4(DTC2Y'+5#Z ]$?X6J4\T>,YL'4:B]\EO[[#E*[R]Q4:? M;JWO62U%;BF' C7%L.)<3E(CHQ)6DAA%2<%;=17>BMOC;0Y3W*#O\0IS'Y3C M!BP=YI+X8#@UR@ELA23226]!-5<<]\%4463JPSAS%CBNHC8B3FE 3D:!9'!! M&JJQD;ADA=\KQ[W]EJ\P]^8;_>$$,)=KHRPU'@5-)>($8V28B AXJ\,RA8AM M*EF^5V&NO#7F+O^ASC04G7-JYO(V+ISC]%PGMQ L%QE*<#T7#8C_J1>AZK;Z M^ANFGAP@^VCI=JUSQZC=IT?D^5!G^ M?M^&F-.+2B8I/.G<7:BU5G.!J3SYSVH(GWE77S=JKE#EZ9>[#*4;8;GL5O(O MZPODTQQ:@)3R_OH^1*@O0GS.!QBY_V'.@NI-3S6FHP<(RKEQE8_U)N2/W0R3 MDM><,J":(B0N8[0"O/N0"_P1[SD9%_.CXZ/DFX+3N\GI2[XM&%?(U$[MC?6O M^?Y!2$9%"3;'YK)_).=/)IZ0PT)SH:4W-M-^?#%-YK\G]PNN/$@=C$ %R[I!^G9VBUIC\)N21/^68%Z>>YV7@9PH+(P"-7 MHG\$6O;VM/UV+^8XG.42"9F;503/D;7,(!:Q)]+#=@0!#N,:YI=W?0%'92." M-'4FC&B!%&9.80=-TL^WDWUR87 QCL'5UCU?4:O2*>CBL/9(QY2A#Z]!Y1;Y M\2"^&/_E]]R+KF-/7U3=HEGE2[]?C/M] 4VH0 ::MY07UK^>FMWL+V?3.^S# M_X?QFYM?/R^_^FT8+OY.F>=S:E(R6P]X(>?VV1\\N=8WWSBU.OR_?O>EY6_Y=<5;^6N,&O$_EI%N!F MOSNO*O HAQ] M.CPXVJ7O/H^_ ^\:?:(?)! RNGOTEK?/X/,?_SIJ;VR>??KX^FM[IW/0?K/) M=S_"7-]\.OSTYEW:>H]/_K7S>EC^>Z''RKL#F-_1]D>P8QOM0Y@7AG=V/GW\ MZ^#3QW>=K;,_JNV=3=8^^RNUU_>P!Y;O5 YPZX"X]0%93#U2DO+H52X?7E*K M]*+4JD;MZE@HI7/NP'G O:.:X=93 -[_,P^V]S3YV4F72.I2S?HF>?FW@I9, M9G\ZOOJ]$>7K&%'V7,YHM2ZAJ)1!G"B+K,C)![!12CB*;=3/7JH%;3T?Z> 5 MUV>_^3KHPRA@_M4-%?%VU".5__G1"8;&.FGEO#$B'JKWQX63[XR;]!&/X=/3V[-/&7[ 6ZU]W#__) M!,,2*52B$E&C.>)&8J1MQ$AJXHEF1--H,\$PWR88;#'!F"@6O9EB+:043]JZ MWDZO5M;U.ZC3U+I:&2U0GYS&QSWB+@ED#0XHN2"9"]0J(IZ]).QB%.D)6=?% M=NS[V-#&LO_@-I0*3$-T-*60BRH8YSD.244:),5"QI4-?6RE/[WEO&2 M_#YPRF%>!]76F\W3[8\?V-;&N\];A_MBZ_"?SV!?LPWU$G/->$1.2W#2 R4 M&;DBH:/>VD (2?+27*7S-I3?P88N4*SKV]"C*H1.7'X;>CN]6MG0[Z!.4QN: MK%-<66"1'"?$L3#(,2E04H(QF8^*%=A0F:7]Z=K0Q7;LFC9THFXK/_1R&QH% M91Q$2/AHN*+$&:L3CS+7XR]H^_..@??;YM/WF4[:A(6GN)(XH@G>$N! .6<\)@ =Q MC";P197,=RSTP]K0._FA3\6&WDZO5C;T.ZC3U(;BF @3 HPF4Q(4@DKD9%*( M!D)CL%RZ2,"&BB<=Y;V3'WI'&_IS^*'>.J-I<+F@+F><6(L%9H3#W[!B[I+T MI)4-_7Y*?]5A\9NW8O<,Q@%CV3KL5.TW6R>[]#7>.FL?M#^^.X)Q'VWMO*9; M.YUL0X77A"CBD2"2 60HAK07&A'*(B;VH2(H MX,9.16(%Z+IS1'E*#5/42*OM*I;[Z$I_Q7GHIYT\_S:LR_H)K$FGO?$)G@=S M.?,$GOUYZ^PSC+_XH]F&JJBHQ=XC%44"R% 1:4DU8BH(+IE.)>&*7\E=NZD.;V)2$Z5,"PQ(R1>F=A'5_NKCDO/WIYM?]SB8$(/ MMS_N4G!;\:>-SU^WZ+O#]B&86;I[TJ:OO^Z>E90CXB@+20A$I3< &M(B9X)% M8%L=H;EIM>:YO]6W4XZ87KFI5YO8V^G5RDW]#NHT)62\ M56!%+>7*$9N"RZ'>IVQ"5U[J0YM0231C'DO.*>;)@>)[01V@J8^21+.*]#ZV MSF]?<5K:?O//X>[AIT[[;!VW/^ZR]IM=W(;W[N[\4653NOMQ5VR_>?OUTYMR M+2@0%Y*.'@GL'>*4.:2-5(AZFIP*-+!\!8#@Y_2;;BI;N:G?:EQX*\5:V=#O MH$]3&\J- )_YY_/VFW>'6V_@^QN? M84W^K';/UNGVQ[>L?;A+/FT<5+ &Q89B!B2;!11BBL"ZGEG+VD^UWBZ-G0)_-#F3FM3N84\%^I$;;4]?I _7NE4V,\R@5JZWK1N0Y?;S0<#&TWK_ -*QM[DH),*5@C M!:>2Y^,*X12VVC%B"&X@B)WOC?MS^V!W*)[W@0)D>$L$N$(.*8T=XHHJ9)P( M* %--[GYMQ2I=!0RWRXS=.\5%BF.A/L$Z(4#EXP9FR0C!'NE"8F,S]<797?J M%C[;-7G5.;R(R&[N=L,=R96M'7(^@7>0#%@5IQABEE%JL1,NZ=)YX=+&"\M? M6'I]T,J]P0>CSO"J I#GFM/F7@/7!,M^+O,; ">/^[F*X]=6IS<8P.A!_*/M M=TYSD6YXTJ@:'(S[V9;7W[0B:<2 F *S8"DGT6F.M;%2">-(%#A]2U^ <@W M!,'?;J0X;VS5'?RKS&B[^_K<3.JROD^=T]U!@SS;VM_CD22E@(U%Z1GBS.>4 M!X<1][D;F^)>"?_LI>07_>MQM6?@>HU[>LW!X.1[?KXJC?XF65J_RO(%$N2AL04LB1Z,-S, MY5I@#@7G )&)Q9B'?-.:72I3=9, P*Z3O-@(,&ZVC_8(]JT'!/AL7)$Y5 .? MC7@MI!98-5,1"N(]58.!-3$(PECJ\*B]] Y,>.S]]U_Z-7I?W. M<+T;VKUNW8OG9Y;YSP2XK<0R:NX48DQPL,Q.(L>U0$9*10"= N889!Y?+O1% M<&ZR]=@IAX64U#O%>=(&_%V"'27$4\I"O?68T#NAW6KKK]SZW*1>$.^CBQ0I MA7/].QK!P0D"@?T1^2)"C"8^>\G%Q<2!*2F#)3Z./K>#Z9P"1;.#*4'+C0G MN/8GX-&I++A#U;"J>?]<:RT0D1"[@Y@/%+HE5E6LL+.=8F '!S$.GT"#GC][ M,.%"%4:#05:$QIE*MNJWOMC.*"YH*S8'I6-:$F(FF'6SDB:V]'K4[\'/N[VC MJEO6YY)6#[D#4JL;A[.-P0YBJ+N,Y0?-_!PV:OV/S35X5-T[J"6>MQXX&%J> M^*(:VD[EK[.H,-FNKVRG-=,?Y?%::3Y[>9TF2O7(7OZ/Z__V\J+8%L#Y9GL; MHYY=J^_I3#!5/H#HDV^=M91%*;)#R//6 W?,V>SZWE'WNRF\NE'_U5M3?R\HM6/8XN!#I/R?>"_LL??MUYX?'#6:>D%R)%2;FC<6!AY2( M\9IHROR#]64ZZKUX/SH"A3K=3A-)BX/29>JG%;/#UV)[!YYYEJOSK_/B?1O+ MK<&(&B]R=7Z)#+!$%#634>6D0TH6M6?Z_N=K"J#IM>WG3J>#UB]UW/'7EBM1 MELQ6LE0/\Q:OM8[[O2]5L=J_N-B-J1K^6KHMS7ZJ6.?I#TK_S<)>!M4@&^2Q MO2\]_3O!+G_I MT@UVM;(P6,KOL]_2?"[2;3YJGFBGH^SFE%ZC\)O6%GS\ 'R3;G;[)N&E%L-K M-^CP],,NT _0T.WFURYN=Y"J)OWQ5CR'.]; MQ87N< :5%2'G>OS9[QV]JN-;L+C;Q[%N>3ZH\O73T9^?M\[^.-S>>'NRO?.: M;WW^+-JTUVQ]0:>L_$!SR>);[WYZ^C3X9]'NQ_?GFV]V>+MC76QM;/_ M=?=P,W^?P;A//FU\.&GOE"8WI\U5'[R]LW_2?KM'8->-X :YW/&)!MF6'MQN>(EW04I%C))8(XFC M(+:$&D-""L(DY5RD(11PPV-PPRMP^U' #<^!6Q+:, ';K(3SB$>:D/8>=ETP MK#@EPHI\L+_&%N1;/A'"MNS(]CTYV](CVR7QH9NT#U0^5\E,6A+/L=#.<,U- MI#1&G"(Q#6]35_"VV^3JKC!N:3".SF$<%I%Y)3&BRB;$!==($XI1(-HIYEC" M!#".K3%\\:;?=:*1*P:W8G#WLQ@WP3FL-*<2!Q4!X3C6-C'MJ0,A5@(;X1L* MIZZ@L3C@8RC3W]?(T+@5NL^MQ74BV]=9SS%&_4B]G.\AB'9)0M_KK\F=7N'(37#F]$.,*!#9#FH0,IAIQDSBRX!$B1[TQ@9) F'SV4IJ+%Z16&O3C M16I6ZG5']9J/LO#<6TKE:^!"6L0#$4@[FIL@1P*@B"U6*8>0-5&/I6!+KD?+ M%1=8*!"BL]Y@9H';N\PM5])*]<5G3J M*3F3F^>S^.\A*OBM5;D4?ZX?%[O.PE^_BNIR^IP+BV/=T>UD\_#T.J7ZYNH$ MIW)]K$61L26JD?4$(*O]:N*)PK/6R?;ZG@K.$:HPX@HGQ),@R()SBK"+GJ:D M#3>Y+!]__B/45[T90"Y7!'NQGO[W"AF7A;8M;M)YMW#""AF_'S+B&62D[?4] M)AV/X+$B22GX0QIKI$7PR.!@<*1 [$A&1O+\8A&&GP^=%NO*"IV6F[?=,4:S M0J?OATYT!IURV3ZB7,X74T#9'$$\,H:TY QY1[DS'H.-\<]>$O7\8G6@%6][ M?#U=(>/RY'HL=FGO%G)CET:O5QCY8!C)9S!2;+W=R_&V(%)"+O #,Y+Y$C$ MR&'+1* )B+D"C#3B.?EV3/M'QJCKL+=[+"J?W_]811;/5_>Z4"PD-3?#N_GR M?%WL*U\1/ZJOB,>+5\2G!1HS#+1L/^8R7X E1\>V7XJ&Y,+CK:-H\XV\-.JT M3NQIJ4H^[)VO1E( HTJP^]WAI!:S/X!E:RJ;Y!)E==D>F[^2:Z\-OEG"I-D! M!JO3B"#*P=X73(X!N\K%W88O$-$/N2LW+"OV?__+2$Y_?R2J D,XOUJ$/^>E M>E?>L9L45$S@029O5&[JQ67"AEK+@V;.6Q,4Q_=SJ^VH]^+U?T;5\'0K#@]Z M87-20&X3I+#J'RU51<7O7B#)X^T-S[9WP"9L?""YY#5STFBM2D6D?,.,(1.T M0 R[2!3FEDMZL_XTD@:>O*8J8$ZH-"*WK.*:R."I)>H:9]VK7;[O7;;,B6", M1 H8'.*24*2C,8CR$"F1TH:4"YNO$;$H">2RBJK59*T7%(N,97LN%G"<+<9_ M,\ORT AX0UA^Z.*35[X<%NWZ-48?U]K]'+8M*9=+&P;0*B#7R3E/+%,&AP@_ MC_I^4^5JZ'N?2ZF6.K4?*P#!$0S%!EB?C9AKM%;=S+C^! 7])Y=SG>)B3JY? M[W9'MK-LC;P>%R=IMH8J!6XT0U3ECJ,X$&2DH(AX[ZGRWBG);F0-J>2&.N.8 M3(P')HR+R0H3622):A&ND:VRDHO'EXN0J+)&&L0\(X@'"8ZSRY5+G0O$.\E2 MOH=/U^2"3K2WM)_G#>=?'S[\Z]:6$U_J,K7L8-#S52G1? +"4_D/DO]>*#WS83_:X5A.\J]F)*?VBA=4*K^,@/VD M&X/O9V,6:M'T$W8(0W>CND3J,-= KWN8E-&#LD50I$F3*=@/,!;=6%N1HG]S MFWL=6%C[<30RUR),HWXIQU]U:\-7JLIWYQ9FW'9YEJ3 M+77(^:.6AU^R^OF;YZU-S69:4SJS[*7TQV-JOLB+Z]4;5/D#+TJ_INI+G)8U M_N]GY[[5:!^>?L6Z0:\S&E[^E0N%Z!Y);ZF:6YV9/P_ZTVL>^Q$Y,&6?D4TP MV!>VGXKV\W;%#/7I9*\1E&\W%;W:C"OERTC0OKY#]:W?NQJS,I?O_/V""O MC^WQ3UO^/G=9 %_%!I9*;R184L1)"D@GG6]6"B\#QHQ;MJCD_;*1@9US!T*9 MY@[KRO$, MK@#0G$;;?R(%R'Z$JCSW-/GE3C!9ML:$X^:K._;K>@E;7.193SU W*1DK9_N M'GJ\=1@./^V\_;JU\U9LG1T<[)YU.NT-+[8^OJ5;1UMDZ\TNO9"2M0'$Z^SM M:9NVX;.OO[8W/I]MO_GS[9AY-/AY_2UOO)=:.3O10% M!:I+4<+8UX?NUG"'$O?,:4^LMR*'DQ?=R;]3UNBW ?FFR5A/U\(NUL-U&&K) M.+PDV-?$6T/^]4Q@,M9WA^_#)-.%Z[9TF:7+4Y_GJ/?B(CC-X]=FU_>C'<3- M[H]QNO5]P:N: 2_P];5,22%%641@(*E<-+\!C4P3M+J3Y/C+YGR"@WJ@LXW=%U(VX0M3; M(^KI#*(21Q/A02'J?.\S^&>W M57=:]Z>M81^>UBER_]-3N>^,/'-7A!9"4+-?KYKMVIGNUGHX'-5'ARL8N@$, MS13!.-D3#DB;5Q%YJ0GBB6ID1> H"D^D3=:1I)^]_%9YU^5@5=^X@73;=E]+ MAV S(>WENV4,\ZZO7<9 YS7;+'S/%5INVW.3(J68<<6" M53$0KB/56#@34Q",)8Y)'0V]:XNL533TGNW.;#24@GT)GHI\&\4C+I1"EG*/ M'/P\:14U)S[W2,#X"844OH<2W\FH_B#75T&GZZQV>' ^S@>7M%.=65=UVNSF?_B#.I4;GCN>0<&3M2:M M,8/< ;1'^3HRLS0ZNRP+W7B:S?NEZ2RF0%77=\9A7&>>(Y6@ZK$_CA!(C?! M7&MYV^^?9A$M3RG_ C0\L?TP>6]][WZME4;#43^/'T1J -A9'A2/CGM]VS]M M:;IOI>(V.WWIWI&/(&PH? 0N406[)5OPRKI'%5PT7)P<];K3R?1:&Z M1FX;VCB3"E/=9T+SMV\UY#E>(UUY8<9E+2$O_\?U?WMY4;"*&?YF+AR ^;-K MW:*;@3UYGEIFW[-*I_/O/D4V7PIW\?8'_T3]=^-",@3@>[A^L,WBAV#\,!D)J3W:--WC[\ M)X\5;[_YY["]L<_:9_\<_?ML][2]\QGO*>M\2$(A3*5&G'N+3" $Z1"%/\]U;KP_OU\K$/[]_OO%H# M, 5SDDU](3( [?TX.*[+X[3R3=TC\(%B8V87HBK\$N#^GV:XP]/C6(RU[]CJ M"-B+/2T\Q%:#>E[PDD&<7:?9X<&/\U%/JU,U5&H-?+!B<,"2A_RU3,!]GI,% MD0'Y' S7LDU8*S+4MRX/+MBIG'*UW_I2]3KG4CS? 6T!Q@249K.;P/B!+0ME45[U^OT14.+M_K[M M @>L]V4=9O%+7BF*?W^W^6J[_)7\_NOD33D1M(PYF[EB(K/1K7^7EZ]W=!QA MAKT\N '0J7C0ZQ1>!M\+U:#^'OP6UAY$KQK4:?ZMVD&!KXS\0=[3L1G/E[MZ M?5A9>P)KUQGTRL[$K\?U1:9X8>/RS_NP8*'*FS_E5[U,KRI8_)2> *OZ%Y#6 M_0:+BE8<@FCG28Q@__K#/)'31FD* 0&:6I5I-OP:--3W1IV09=B&S$4SY?X2 M.[WCR861&15N6*L'HI\W9KU;Q/=+KRY#TQL-R]$D?! (S+ 3QY>MQD\8]H < M^QXJES:RJP#\N=Q*ZDRG40\'Q*\WZMO]6-/MWM%1%LCQ\VR330* -/TFC&?# M'MDL#&6+:W4_EKKP'YI M0&^L^"W7))$6#RGG(!?YK:EB?ZSS94T[^?)P1M&<>CKJ#"OXR7GH [WO[<"V:VO5SP\;SR@G=Q=)7X,-/8+G%5]AZEC!C^(P M^QJP*%5,]2\:-,L "9.OYV6S3@U&5?:W8#[Y!;"U^6OQ2V&\S;W*/(FCQ5]2Z 6'W)UPKK1Q<(:)[; MF(?<"VS..I0Y)>MK28+U_5R_$Z:?/YZ]3Y O-!U"#F=E19M(YPE >_8*.@4< M;(X 5!EW)YO>JZ6[GZ_*90Z?H0^DR!X?@W=:+%_^WFEC?\ &@)=7Q'=87@*[ M?HJR ^&+5^SJM7)^0-8Y2MG6ZZM3%>]ZOO1T6!8NU5Y)8K0 M-N,I<\\N]\*13MDX(V M,P*0'P]["",;I%'GREE- +VX_,TR-[.HFD:$M:,,>-SOQM.)(*7X%)QCF/I! M;[1_,.8O!V#9#L (]OHYVM3)\XX@4(V!ZKFRN9.%R)M3[&:CRN4J[IQ43M"\ M1,'*VN780ZX#-MV1\L5!C)]KL,['&YUL3\8[GC>QZDPM!?R9T6I02U4]QB+T M,:PUU@7>G E<%MZ)ZA7%;<::-[6)Y=33FA0T \XVMC,[.9Y3OI\7IKPGB\

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�\5 MJZMKLXZ0FN) Q!'DRMQ+,&F,[UXZ%U?]Z*Z0&_#A?I\;^.WA/Q_.?C-7JV:I MN[XQ1:C_;&H_M X?_TO3 K6)5OL4'BG\>/C11$8,W.*5_5@KV+(6%@4+ 4;1 M;@^>'_]]]MUH?!_^#B)UU5G38DVNOS).C1K"LK9&KCAO_&[ C4).QFW4-; " M,+\_O" MT4ZVS-W'O4G3G,6)NH@,$T]]]UNB-L*1>?TS5+-IUR,U!,LQ0IUZBD/>'[O^ M+E=EQ=NF=3/?X$E^J^9QUN+UO0K1@DM/&'UVR-2.-V-9\ACTH9V9=Z<"R"T0 M@;BX,&#SUA'XIO/E[XY:0B_(])S=8&P#%'IA0@P+Y+"MU^,<3T\# M\%ZMN\9++N8K"/:]^:E9XA;%'"U\I[<6XZ1M'%J'4;_!6K[D4-';AH1N#14%WUIIFA.N346ML8+E(K45.-]<@ MN[N=0 M49#!_P0#,!1FD/GNVH@6U3D*B]5@HGA[H0ME'",8'70C!';#A2FEP3#S:FDT M1?,<\^;.$( [KT)POFW>.F$4927>=X=U(\;:7IKU)1H&WG[8 O01MPPYG<]> M_[MA/ IW^,=IW\_ :/A':FW).:QN!2J"W)9TN[O7* M]';.4'JG3L7JQ+E*(:N/2Q1@N+5CI6$W^(6M[VOC)&GL"0LU:VC>A^GD4_MK MN[/1?QS/9ZOBS==MPL9WM38A1X)KQ+-U^@5'9N\X0O?&U[$I/K[NH,@J5HF< M9Y81F@O-2\E$2BI.\C(S]EHXBWP5I(IOO0KAY?'C!8X,K!@E26X0^@3A*W@* MOYJL,%JRS!2\0.2!&T ^8\@J$*.G^@M1!Y=DB\%[85*WU]H>IZS2HX;Z.SHG MI*?->BH$G=R(5_CZ!KCB\7+=UJ+W,G'V,4)E:L=+XL)B)6DHM< PVU5!MY04W2=#?G>,Y&>CG1+X.X*5KO#M^VWZ15QVFWK]=2,B(,<( MY\&_^'WE!&;HSCOIE]S[&$N_Y&C'__[P]4.,_\#IJS68$FAJQ_/L/W9&QG)S M+FO1R_K>.^[#"9-0RQP+998;5]T>W8U>ZT[^ZBD/PRSP_DZ!!:T2R1\T\LR& M,QB)[V/G9@+-8R-.$+PA"H>1NA7\.FAC!5)].>A?%[GY[?F3EUX-/-Z<@'?B MYHCZ7=3QS4>^AW/OH^)S2+):N*#.]JNX]XSO_+9N?!@&G^8;ZU%J/4DX7&[FL M51 )O0 ,1^+.=56K!H29<=%FO+=RL8/#:7T-INL%IH^WM\W2G>(2H[=Z-K#P7YM#JU=-,LA MG]4.B%0PM MS.+4YQ<^8;HR:XQ=7!B0""YIWTS]+[G!E*CV:AO#$,T2% (:8BVH!R;4WFY4/1417-F@1U9R?U^NUM^" [+WCVPJ% LA@UBFJENWL MY>#YPH?S(+/$G.^WX=DC/#^HJNN9C5_Y'>(F;WV(:!-9U:Q06E&-/ MUJK_+=P:%@P^:$PF1YLH.*)/P$=4X"UC&. XE%/\%@C)^Y+QT^?PW!K]\7FL MC'GBLECNJ\]7NH%_/:[;T;?A ]S;;J/@]3OLLVRQYJ%>ULY)=FU=M7=P,"CO MWOJ##N]GE&IQ8W2V-T/$. MVBAS@?;Z.."%\6MD,?@EY#M;[\N'="3>-_@%GCY"$&XK8.0T+[5?AR2?R/9*-#P2[,/60PQW9-I%^OZO?WKBG M\.VWYBHR@GGGGN HZ=Q#_@5:!O[O@([P+^$3C9'-^@(<7,>F@V]T 6SDM\H1 MY.@OSL]=UUWX6\\Q<#KQF,8QEFCRH>SHYO&-PJ>;Y;H5,_^W^"?_5_MT!\F[<3>!V M8-+@(=6C4\(Q64M_P43OQ%4&#M6-VOCHO)&8L_+IN2!N^PJGX;+6Y[8:/_T* M3-W^3UVH71M$PBC*%VX8@[B>7_S%003%*5V.H%&Z:@PQ=:Y %C$\U;9\&)]_ MV)T-B.'E_O[&N4]!Q%BHZ!'TX:W^LP%5$ZK@?(E1_UKX)1=)=003"O1\=@S# MM"*D4.$A%RV&:XV7++!46VL_E:Q>7[GSV7= %G\3)R?(&2A%!]FKQ5KLW\]. MG(=J3A>C'GT8:S_Q;4;F%I9K>3L#;Q&6X'832Y3&#_OY^(E3AP(A>NM&CT;Q MO$#) K0S!;BHJK)03$NJ"L>KP._J=V&!??6L MW>*&4?:O\_EUB09MKV#4'4OLOY(K\7-O_\?R#5_./11*7C/@E2^AB5NR4PTC MB(?15\'$D1B*DK!U\VDI&JEV9I!@[0->CH^U>I-392':&NY M)SLC;N>*X,DK M<,9U22TM#66,YIQJ6PBXGQ'.CB$TGB\]G.^?>[Y4<6.(DDFE4Y-0DZ4)DT66 M&"88)ZI4%.>#?+WJ^P*QYGL/Y MEE*F"5453^!@69+G%5.""&%D=J?SS:LRI5H0(UE*658Q(JN"4BQV2RFOR(%_ MO^CYPH$6.JO2)"U4D5 B>,)U6B::DK24@I4J%3MG]7W$!Y.AY+Y 9 M@'TSL4ZWK#4,I -EQ28Y;S???V/HV*%2C@(8L8/.E2SNLBO%>G;1U'#?QB;. MM0LX?\UFC3/9,33G+>,C<>4,K9V^0]R>'(U ^J'(S=(?U MX&7;+F9W%L$KU1*VR@8&''J?0S]A" XF\2Q&"0#?'^OF^K@OC6LHEETS_M-] MZDY_\.@?1JQ?KVMUULV_*N:7HVLO,Z9]R*YWKC^Z^[5YSW]]^?JK[II9@FQM MFQ7&TN.:> +$+<7L>/N>H2WCVD%[G% L;&'<0G.^LK%Q><# M?XUH^] JN*-5L#JT"MZ#M7S!5L%;6_^V6P4Y,45*E,(6F;0D,B4%0\=!R*)2 MX";<2X5\WNC:>D#FL4)L9N?B##3F$JP/Q 35C?%-QJ@*K^ZS(OS*X]U^<\GI M94@R7[=7>L$\ "M$4]#XH0@!*F%^O=.A[O J:W&$_M MMY^;QM>J/FTW)[/'HR1L\*L.9//QL[N^7B_8L^2M (^I)X:AG_(>+7WWYNZ# MV!H,J[\%_&X$0JIU#3Z$V=G'Y8=-B'./C#S*7X)=M3?"Y-CFVL3M(F74RC)G M)3659I7,JB*M>,5*E:5Z\1R72-*LV(-\N"=\],I+D">NC\SCMGW#*&V_OC]Z M>D86A>&%TKI,A$AY0K4E"3=9GN!P+0,:N^2\?/"HV &B#4?7=;%R))2>3'.H M__S]]U]F)O!&<'DP)><^KSO763^$%SSI]'0S!=3!+M;XC.#YPX=-&ZH",1OE M"GL\69K08!=*A+#);CYS37+P+U$O0UW/I6A7\U@VA ]6Z_EL94[<2 GE>SPV M*_B"2\UKA//"UU6NT? 5D!'6T]K.P:_T15@NKK7%(AB:,:M.N,(>UZJ #(!A M(^TAWGVH95)U!_MU6LLZPJ4XN>);8_WK'UCJ'K(4_/QN <8PX9R21"AJ$EI6 M5<*$Y8G5.-@D-];-HO]PEHHT_65/_#K4Y>2PGXP:P']NVE>M.<::S%>;%HVM M RT +1P_2Q>VS(460B5ISFQ"*T(2IG*:,%JF*E=I5DKP(#.V@Q:$K]Y]VRP= M],3%(&\N'21 Z(=V:O>B-6]1^BQ[">BBP+[*=$)5+DJ,=^I/GW,GJ5(93JB@(I,LIY24''P@8Y5)%2TH?'2#5/GX MM-]!R4P%R\NGOU\N!(@551"=6)P81TN3)ZPH59(SP@U5I50"[+9L#L=R7;:@ MG_RVU@C5%DEF?D?UDALM4LT,49HJEDI6:LNYU(QDE9 '@^*SG;5*%VFE*JZ, M3"J<<4,SHQ(.!Y HY$21@Y4LZ8-'>;$#GCS4U_N";IMF"G$>(T^4HZ!*&F+2U#(K 5XHK[&YOVA.QJM^+B2WS&8S_ M>R_BCUTGU1OP3=97,<@U8CC'APK;E=A&HC"P=5'"JY+6K3(KVV$:^%9+GLCVRV^FZSL!,W#T[R$2!??=$RON_@ ^!?UFMS?N&V0[G " ;EC=]1Y=+Z_7-\PXT+@KLHQO!$ M_W+^]NY1KBJH?PR\P@L0:7$6#LS86_;RESV;+5_Y^?7FOC"MM9# M/7I&_"I&<+R?@UEB;7A?9./2V/#HO?85;)+;Q2T3BPG%"F(8U3RGBEAALLP8 MA@DWPDQ6.0C % 21@P!,MTOM;K>UXNB*(9+U+9M:!)X-9C7L-K<$>WRJ/*$Y ME0FW195D/!,I)U4)?\31SJRQ?.<%PAXOFY"UD[T.R_0J7;XXGY M?](VFPO7S>NC7EV?[H47&@G7$?1W=TV'!.'=6[T1L6 JG[598XIW-:#+P-.V MGH_EE*Z'!50%/M!5SXVM8A>N[S!O$%2UOT&<&[%Q39UMT!R3Y\]GP">SQ\ C M.#@7E[B^FO]5[5_GRSFS"/;0NW!HK$S:PE=.#K@VN^&\/\@?A! ML!!6 2X"ZXVW#85)&:A;T?W?Q;U"/.S$=@D^S5AN"BMM55)9I$RE*I>%+@J9 MJDPS'WKY^ %747 ?8\S X?T&/--OVCS(CIZJ?"%2JG*;DX1:4R64E221F4X3 ME1>:9I*E&;<8 7!3(?>, [P])(->31\%B.@;-T>.'1LA.[K!-#?&5D*FOL8, M)!HC\Q$W(BQHG#\/7-&NS!4(1S"ZTKOA+KZ_KPQZ'S4- ^@.P=/LQ?'C M?%%8L*68KA*2,Y-0C0,\=<&3*E.ZT#G+P;3?-X8.;:P(J@%LX3J50VW#=_7W M.+/D$UI=/Y%4/C?$^W%S '@/5 -^H*DJ1@S02DYR\ ,)YO!Y!2T1U^8.R2\N@*0"7[D!^<*,*"CC#/*&*2X(W>.KRK>V&Z["T9W%T*AUT# M7PCW?/<"_D*U=R-P!'1>?GO\?/8:BT%!BZK9/YJEFQL89G,@C4P',_W+I72? M- ]CL,MA"D?4-(]E/O["_!K8^]2TF/%[+/:$A4$I;C3)!&G%'KIM/J#;9@+4>3\VZ7[4 M(^^DYSM6!%X@""5B_,6"0 .:?.6)UY< NJ&V"%0YGZU;@YT:DUK!: 5'N!AK MW!HF_5#/1W4C(4X^GI ;^"C$4:9MA[YEU4%DC MWKV5MU[&# M;Y16NHX'-WU;G'-I9#L=OB)F/OQS0R=KKRW^"@$^%Q:::CC1-T\'\QCW,%#5 MB ];/OWI^_&0T MU!2(IPW0AR/*](VO+MFX2^WX7%Z@2,?]LPZ3GNN^SD(,%;Z85>^ACYIV/4ZT MWR\!/+M_:FI^T%$[6XY7/@';K/QTS=9E87>BR4[ #;U]%-!X3_N*P4F%J2/2 M.']MER:\$V ,I976HK"%H."7LY1;24M+2TD*RS.?Y4QIR'*F].: R0^V?F=T M\MZTS?[4U%.O2'_S30/8!?DOL=R8;]GKI4?'S]\MB!%$%J5):%%F"?DR Q"T8W0(S'FZT.4$ MFQ3,E-F;C7;3 OLRD(,!?S#@/\6 ]YIZA[$:K4H_K-WG5?4 N@L4"YI;BALT M]CW;\OM'E_=78W_5@7VQ<"@09^P;- C^T;2Q)_$LPQ%<]Z.L, M<;\VZ !T[66]I*-^<(8:A\%FX^3L'A5UP"0FZF M30^][SMJ9\?HHKMSYS%'))J-)@R3J-UDD%'U,_<("^ 3.Q24UKSQY<$AR/43 MUEAO(X-$R]QGO&3 MNE6;>CV*>&(P(%B\$^7>CJ,&MVW?KOA!;&NO<:KOLCXS'CI'FABCC46 OA!V MU1L=WJSP;XP[$2.W.&ZE3_]M0;"C811 7<1JA:6!QE6PKT)][HE+T9XW;^,# M[Y=2OG]6"Q[S_=JCV3T167V&Q;,$$)ERDT(P9WDI7*422$JXRO2+]/11/>+>.Z?GSS*CFSWS]PII;ZS8^7OI@$B M&@:W]Z)1WY3+=XE-/SAGR$4B..[:F5@^8>F=TDF":_YA:<115O)Z!T_LO!KW M2&PC0L*#^I#.CN?T35!#;])]XK+=!2V/( MKL H.ZTO7ID6/5A@GS[AD&3?7L:A>/GT^>5""5!<"$EUF'63QN&0TY I%Z'HF42S<_7IZYF8S;PYV,O6@GC:9]+[J]2<;[= M]VZ9\79%O%VTOZ]EI>-=.0*%^['C$KM;,5@'8A"]"+,*[99F7<>6T9V+K_II MGDMQM6ZV%Q\7W?]U6#1*6AOY>!@)=8ILN7*8W'%\I]TL!X9'S\1[76(FVT;H M&4CQ$^,QNZZ7Q8 D,^Z,_-BV+2X'EO)=]=>/?HY'J,*.A7=TX[1&'=7"E0KL MH Q?F-!#O./W<>U^.I,O? _S\T;4-(*!]QVS;\VRN?"Y_V'R*_A%4T]H&.VZ M#V-JZE9EKGCECGOG*]?3L"4?=U\WVG@=M* MV8 AYB?C^;NYN6'8"AQ0-HUSY7J4S@^[1W"&MV2[+VM!8\;-^0OY/^ )M\G[ MDGT#B+U3\\<.#;Y;)_YN/1;]->3[L<>W>SW70]\1;-13L7P3RGB\'1X]A07@5^&2E==_G;M'NUFZZ9O>S$$^D=&E M]52%-[G9=[]/MLL-14!B#\3D'?N>>*Y 'TC.,VS+K9BL#!.6Y+Q,032:]",0 MS9Y@W]EC]_1?XC._V7Z)WR]?'O_Q;J$-,[E.9<)X6294%"3ADA>)-#)EEJF, MY]F#1^3Z2)'9Q68=C+F=[7Q#+>*TXFO;T/MDUV9HMIP6#/$T*#!'=;>C)&I<#-FZ(]KEI$>EB&)#MRMW"/KKF+E1-[5#S^1"]I*D#N9YB MN+AOJ1&FGX^L[N]]BO;Z%I-:5G"=9J)BP*8JYXR#J6U-EI?"B#PGH8*NQK],48P)4@&WJEO-^5]$8?EFB.G,9!TG@3V?3&>#<#K93%%LO\ MFJ&OUA/3_;HQ'2[H 5X"<%8PL>=[FR WJS=H@IL5B+!39X+B:Z/A$1T3Y_@Z MSR"L;I<3T$/-#EY CV:" WV-3KJK;FW.Q[&F85:LCU;>L9!]6IL^WUV8C@8V ME65^B53##:SW_>/\@U//V@*_& M$#8[@E&?2Y%%^)KM%[ZV0O-.F8OUM8+TO47YOL"^[SC8$\[[1]1-8Q!2U!AC M-*0MP*'6@$TN= "J\$\+EK0WX5U4+]J_HQOKVMGQTZ*6^V_J;FO8OHT*3(86 MR,[XGJD6OQ(P.X!*$53)-7RODK?-N@?L[$Z![-U5X5/_P>0H1KFQ42KA-J'8 M+VLP*OKA%35FQYWO$=?LV[Q&.!T.^D\@TDAXD4:B 00OM[D([J9_KRYDX,9H M9>XK[O8H?D;&4< *W_8LV[ !?AGCC?'N*(@1-\=*@+,%;/W6!,9O6MBHG]%6 M"K/3!F0A'#&L!H>JW;/D12_PW(OX\.1L MB$_.DMGS:S+Q,-/AIK#[:SS_TV;I0.&<0_-X4-CC/SZ%^[_U7!:!,N[#R]VQ M;W??Z_[P57-B8RQ#-S9EZ-A"R,N][DDWO,TVJIJLRJK(+*6FHHQP2?/24)XQ MHFFA1.H'U))TSX#:3_941OO<_5PO/=;M5A#BFW9BKEX^5=E"9B(CM+3@OZ1I M0H6N$IG2+,EPYFQ&RJK*2W!B+G>T(CCX)%=?$C3=B!AB\O&64,5V8S0H751( MCQ_._ETOE_CC\^?/Y]N*Q'OFLR>GHG;^ A+LDU.PH&;/8M1@]M+'<7T@'V]6 MB_/9SP]G?P?3!TAH/OMG^W#?C?^%.>$==_^Y1HV,)E6XNP]->/V^?P6?VI6- M//Y'TYY=0U&,8+0^;3OQYES:_\"T_]SQ/'>((Z7?2Y_FR]#OQ?7#R\9+? M-O!:))5)G_A[]DZ=NIP8D%-P(4>9/T!@EHZDM"JZM HF4%D+S''YDI*@XXYD,;:4LMI6R@\;X MPAKCY;'*%R8M)"F)2"1/JX16(D^DTC0!)2\+'#_&"_()9EX_S48/-'X-MOYS MA.U@F<,1QEA6$T:P44H!ERU-9 M2&EH+K]><\^-=+VK7BI &&,$>@#00JKV4U=LK3?@4[97,[U97\7(?1"U(RO+ MW:;6L>U#2+->!]QFE^6)\QANN_-NX!Z/#1 MKL^83XF)B^M(/4-.)7H1/G$_ M1AG]7 [%1Q@VA'.M60J>%"DI,(945.5YFE::29;;(DP%2"-J9/ZG&S:#_7BP M:]X?P?I.R-'[7XL7;T[@^2<+$%J*%=PF96Y)0G69)< D*BEM:G1>6G"5B[V0 MP:/42QSULDO93R<%38>_C#.4'K!WQ$\A10@W0^3?SX73]P&F#O[RI&VZ]2DV MQ)CYKDJ:+BY-,K!6W"#[BP'XZ ZG!TSPOD[)0& 4L12+2LDC@LUR4I>0LRQ\\LL!^^X:>CF8_W"IJIO'" M4,KQ%XS,.&E[:USFZR;C/L)<424AO%*RE&E)::ZEU2E3A2R%LD H:8C#\,BF M?WX]8=#W.YN\DP^VY?^@WS77]OFTLPVL<)L4F%R2W9L>^_KD&RS[*; MU$2!;3? IO6M$O/Q *E1+9H/18UKT\:VW_9C/\$01>'N>^Y_/WKUX S^_/UJ BE2I M!J'&.9$)Y561R,)D24F5%40R(DM^P]0M;VU[P342=W%6^STU16XT/)X$.>>F M/\R.&RF4:I+?0G?;_6HYOJ--%;H9?W$%?G_[':2WF/E?XL2=)_WD/?_ZK\^; MLQC*^H>;93PIAOK*B;%1^M3IU2!'45.Y:5LCJ)JZGRK836I_[=KB4=+.R I;I MJ]HO')C6SK=CH'8XV7C6HHTO18F@O**+Q-MU2 MYCS6;JTO,H_E?BXRTH_M]7-X+U CX+V"I]U'$B:[/;)_9.N7<1UP87)[_!LZ MV]U\U-7I>@[=.8UG%\VO-U3$CJ'+TZ9OP- !"]BU'@S-"1*V2?O80^P Z"*J M$)Y]*WS-<@PQ1!GGXPM+H<[PN^=UUYH+;.%8K0/J3OQ3/W5W'D=B.ER@&)A8 M>QQU1QAPM8,6%(%$L1QZ60L)!OOZ*A1.>*$[D /VYM:^# ',I_.+M>]^6#E$ M(4?&KN89#1!7#1_MB-:<;$"VX2U\ 3*:7?.^=?QGI_X?8Z,)$M?#V?$E_.LJ MP?Z5B<$*&W.7Z9M5IG*E9:5RIBD7.;=E:H2P6EN5V:+XN.Y%L,I>-.LG7@ < M9CZ]_SU_/LORZCM\IY#SI M.U9NC=UTOI3&B]VK;?$Z#%J8CO1&J1OIN\42_LXA8&%3H;]P*L9C2[+KRW:/ M=HE1^ ZV+L=4CA5O?2.XER;8PW+79MM=!NTG$.M'#R^+ 35/U ="?O'^V>4" M#H!@IC/)J )SE61HKDJ2<$8JE?*T8HKNJ8^XW?B9:BKL=ABY7:YI;"3P@+1> M!+0!!^54^V^^-??)PMW3A/XY6$)IH3GX"Y2GFJ:<"L9(GFE*N)+65.6!)?Y\ MEGCY]#E=",NIHBI-B+$%MK?RA*DT2UB9"W2X)9-[Y_F-K/M3;]T[6NXMXNT9 MWFA_!L KQP1)AY-]W]9>=#-1,W# ]W(&]FL-%D9\5BA5"H62 MTO2VX,1^$X$A)Z;<9-[)="RRV,6CQW'2S62*3+VZ1[QZ1R?N]]?'(R_T"T7 M=R_EJSI_N ^CX:]K[ZA/AYD.WL9H&/,P@'E$5O'K(U;H@W^8\)NM8>V3BMV8 MUAL9,MYNCV;ZEJL!EC5NO0P%RPR+ 7W.-HN"NKLS)LD;Y9^ S M']WK'S*/7N .OP,Q7D]6KJ)#K>%"42^Q31B'PHH6_C[XB+7S"_385]2Z'KJ[ MABMW-6P'IV5KXI=[W?75!?(_SFWR#![?&%5 >-UM7],U;*\Z[Y%X:3'U+.>3 MDL";W%8<.81]G!&FW=<\]^G?NWMW(Q<.)-,&G:RA=[JMN[.YQ[,(3:96;);K M2*2H/1WL$;[7^$Q=@#CLX9;G=X/]BI:'DVIWTMI2@-JN;(9*F^8ZXU(:SF4I MI*YRSNU!:__I6IN^?*K>+RRI"C@%AJE@FM"29HFDLDHJ,*9R#GY%+O0>K>W4 M6=1[,7KR^^O7QT_NA3J[46,\6[VMVV:%W ="]SK@GP=0/F4G_ H4?@D1, MX!-9;@G+"X>[)$G)129IE66\+*D4--\YN'C*,I-]>=)TZ^Y5 ^; U3?''G]< MO3@^RQ9Y!@XV192EE!A@#YDG@J=%4E:\RBUL,C/72E$KBE@NI:9,$UI)BSZA MX:EB957H7.H',P-2YP++J]N-02RN'ECCVA3T[T;)R/$?OG=NX0@2K5=H/IHV M[S%.]&S9J#",/8!M1&)WR(N@OU81!P#;\4^!T%W@#R=G(Q[$",O=#-0Q=^8U M"O_+V@$(]Z![9L):@WX>*<2AH@T,Y1\"5(M!))>ZQ8C^?/31OQUB4O_A;P8T M>(O]EK!^,/F'82AA:MA5C_;B[@%:L#6GH%M1#VYS?7>!-YF[JYRJC_?ZI3>> M'/JBCWR#]7"V0H0YT' MQSF+IO5+J=%\B/ATKS^,#OKT=P1D:99OO0$1'W>.Z(%M#Z 7#OO@/PY;L0*#P(=GP\;'_J_061=WH*>'G936@[CT2?H)F9MW$1 ELA+^ M?"[.T "Z0)?$-UBX^^/%H'00:\9%>^$KJV "NH#RE !WKB8JLR!&'_TEQ/[U M(OE;)4V4+2XF#W:XJQ)U^^=34#WFYHZ-&Q-"(Y=U[UNL/$HK"@LW/%6C(U%C M;@-\"N\LN/GU(735@D>#=.V,98&.]:P'>+V:84(')8UV%(_?5:IUJ1(W-5MC M3@DS)>A^7")R>5\;&8 ]G9^O<#;">4C0S'S;YL/K/32SD$UT^"2^Y"$L%4M# MT(A%*QVXUG.B \NYMM)0HS 2N[?MCCK$1@>RS0-%LPXD'FQGM+_P,2(-^DX M:XW$'\2D!SGU]1,>T:=>!8,?*$O$R:8]4MWHF1_($=N(,!?B*A:FXBN.7RI( MBG;2"+IVH/HN(..=*>''40V<"LL3?G]/A9Z'\57N=\_\7GF@MX:@5%'Y 6X MB'P8VH'$=ZT@=E0G L\!3\?M9P-R*;Y;E"'3]=B^/3\V1#E2$MWIS"Z;RVT4 MST-'UE@@T?30D74/UO(%.[+N>X?5;D?O[QOA.HJFU22A\.W(6T;W7OM'L8\C M.K"@#X/*G3M)N>G@ZFZ,A[I;K[@PF$/U4SA%VQYLUFY7+YB^-=UTPY.FV?X"UJV_E MB1^!I("F(H*N#P-BU@7]KZ5QMO#)(!ZFN/'@B**KA\X-$HH+D XFTEUHM$AS M6N5:5 :,=&8RV 7)C=5%G@/-$K6;1I/R3B3:B[F7@Z4>2/39.[ N@&&_9.&\ FW,N2,PN(4+MC?+I4\-8IV(]QON'0']UB_[Q635S\.B/7+A M$]&V5_#I8^BHZZF/(\72>7;=J3$!ERAVH\[#A#.P/9P8@W_/ M]QD$;N+!#&V-L7C%0ND!OAQC0V@"]#648">*[ZPN\M@7-+J_F\Z)#XAY3:2NR=_QQGB!NPX?-1\_=FM=>.&GK<0_P8WA MUCOW\\95#E#7/?2OM]O[50RAXX^1%C@198^9CJ3E0DU8^OT6YV(%1Z#K]R=6 M0+J/1EP=SAC#.\'!P(7#?KENH^UO;R-@KP\#![>K6<*8QL'!BCC)& B5#1"$ MC[W?KVW[T'X5A#S&F:F_C ;"?M7YJ>^F@<\](S)]KY^CWD\#.PD#'N^_H@LR M$ODZC ?<]I9V(PR.DP6>4%WQTF:-VL)#"!JY'B$IS,&8#F[T^!MW"@3PBE56 MI*5@G/(2H8*RPF9""&93:ZJO& C@WYQQC+GS9^F"*&%*EI4)6+]I0G.;)ARA M1_.,RE2!K5)P 1;QP_2Z22R#2>RW>C"+O+$9LDMCBAJH!G.UB)'OC)(+7R&& M]:!WB>9?X\ ?1V%WS$B!L1"8\M'_R/9O._*'[LAO# .Y_3Q2C]QV;WN^6I\ M3;U2]<72=,>PCI_ 4CW[ZDSW1V2Z%)X#O_^T_"/[[>SHZ3/X_0_RQYN3=__[ MYB3]WS>_TO]]>O8>/$GZXAK3_4K^]_C9Y1$PU__^_=?+HV/X__\L?W&Y^/_9>]?FMHUD8?BOH++)4W(]%$/P)M'> M395B.[L^3QQ[(V>WWD];0W HXA@$&%PD:W_]V]USP0 $))(B18":4^?X1"0Q MF.GNZ?ME-N=3]V)Z<>[.L"QAS+QSQK&+HS?K#^>SV25S63E=9>Q=S"]F\_D% MZT^&K#>YO.C/+_B0S?B\=]GW>#E=!8DI![WS=[#;2,,$ZG#^/] QKV81:)BS MAT/LE1&&1W=RZ.RG:V_!9UD /-Z2X&XD^,__(-KFDS&P^RGEWBQK[-KU93D MG/IO%/6SU0K49";2!CHZX_<>C2YQ(2L]YTX8 UVW_M$'ENU?=-W1Q2&6'4W&^U]VV.T/^ALM^R,!6 9 MT(B$];?O!M_E(?@9:DBO^ZMOCEM%4F5<"C3N6\68/'8=>[+94CAC\2P/RT^9.9A>^0ZSH\B5E8$)Z#GOT7U\?YKG1;=;/M_C.F_$7SCN M(W=SRKRO-S'V(SJ7F_<\SN?S-Y(]2X8+(''(H^>HP\GO44RL?_D - ,^7^?= MT>H@$G@S:%Y=_T$]D\Y[X\-X@2;;N[/$QG(ACR3]5@R%H[S #V$">DL^=^&M M].E2J@1LO4CW1P"J=,4T"IZ)\^E.#4 KF>+UC*%!%^0(:$3E5"N8"17'S3$D M00,ZB^2IVY1JEN0;1$I>2\SL!R*%G21PND*-H"^SHZB&[;Y8!)>3O5\B>Z]$ M]A0MS*?08_J$6+ K0@W._^.%[B"R7$V?4!6YQ1P;ETE_;)Z49)QX&4'E&(]-0&/%C]U4JWHJB?35)>. KY,W%4%],W4[#R8+^./>=0Q9T.E$47JCID7 MKUNA,_U(AF>5FS9WWQ:<2U7NW+UX:-W^1A[:O;MD^QNY9#_@T.@^4/Y'70>@ MD?LN'ZY*/29#%MQCG49D3J8#W47DCL@:*IT__TGGS^\.NM'6SFURV]0ZVY_; MX?VNZ/Y1!64LO&]"\&[+^.R_L3PGT\7E0 C_S%@,=SFX![QC'PRR::)XZ;B] M\W\Z9S)!17^2YZ3DR2_'#-S*_34K"BZ'"JE6/G*/=]SHRZ<^C+)8?1IS'&>A M0ZG8)3=;=<#0\+J5=:'8;0]'RZNYSGAC8!'0MO009BS+;'Z,N22/_D6J(:;2 M]'N#'@HAJL%2Q9'W#DTNUP/B?74SV0PSHK"-#!=3JYGXXWP>$H77A>%XC'-.1K/7=6E3!DE+U7>3LU[8](!1)"(4R/#A&ZNH-!)TRCT M6NQ1JB[ ?5M(CH*>-'D)0#] 7IOJW9<[Z=U'4K+S'O_7V1*VU C=^O%R/& 0 M![2Y,#M.I$9*Y80T1#WC+ ]92])1A?)*HURQ4!3Y M>3@*X0QL\N25ILA/;S\HI:!_M X%7:D@E641E:>R;^$GE,W9/$RN MU@7TG5*ZYPT/L;,&Z&_P0T[!?<,[N=*I(!J.?[^Z^JP *88X@QZ)VYAR\\W4 M>IDM<1R5&LZ 0[/]E 8FJR.0A@I*I^B&H5&XT?&3190%^")L-"VF=OLSJB^@ M4=TKV+7L$N"'HO6':-R >S5^C/VP$SDF"Z%'=0FU]_;E%<>[MCB^ 7O97W'\ M<=P;_[>*M!HH)*DZ2(P74.GPROEK!JGR?BZK&(="5_)?!_DG\+?WWY#; M.J*/2%X#W"S%E*II0//F'B,N+.7[4=53J4T RP>UH2,Z]91; S'J[H^05N)" M.PJU)41ME0SJ!VE+,U76Q-#2HM98A,=T>L_N%<-*_$65C\& M!(":AZ(F9:2@WV;&YU04#I21*S=2I9GB/$6N9+8Q0#'O@R22RL&*^*\^@@]" M,+S! " *5F%(S3,JYRC;4:)19_UQI1G5/$K]36TY5TT_RBTWAUJ;;V5?IT": M'WUOP0.@W2_H^1..P,;O_),P\9""<'4XB&VD>C+]>O71!>(D<"C(9SZC"5YF0B1!S+80D& MA$>J"%L!F_U&7<< 2]^[W;ZNC%%-MXKM?U4:B)G8 1\#P&K:2QJ%R+5D;'C* MD3ZHN1C/S16A->$KHGS$L:M#\L@Z->/4UK'A61HTS;-T)68!_X,'HC#W&H]X M3(:X/^?2H#V^R[>?_O7AW;D[@2N%%<2^U_@=8^Z+WO5*[IK*)P/!^E0O.Y$X MD:AZ>9H6@-?S)HBFV*4.T!LM54Z6*M8AWX\'UB)J+N(7GH-%*73C@5MA?R94 M@/06;D&+IO8.><=WNBHD"J<)Z_T4@6,RXD5LK&"%T<:]]CF72?1K=.= 8F 3;%O MS0+=^ZIA(UA>PGWSJH+*&$Y30O<6QTX ")&\46R4I:A6BU7NHO@K[5+4 M\XB^ZQ7WJ.8_".X-'^82FX2;459L+IFO+>&-_I28#Y?N6"X M8O2K[K>6)U !+81X(2K:6M: M+II?$H-?D9=7Z%B59(Y.S\A!0:@A/\7Q"[?HTC:F<2@FPXWN-074P!%J>HZN M]\F]0?Z@NJFJ,4TB44%4^:]Q.AJ%N,[G1)U8W7W'#$A&XXOS' 4JQE]*+RWQ MV"7*=;R'*A68T,'A-]&]ZGI(+E&S>P&=)Z#[@[H#.:VC-,)T23+GESAF3X!] M)6HYY"P2E@'W$E7[HI>P?H_: EC^99=I-4"U3 ML=L62JYE(1-1]EGQ;WWJH7T5)-$:I7FX?Z_D?4JYMPCA[MR @+E/\C9'@F?E M01,T4$SQ5%J[@MY6,;_%UNPX?"1+5@*P!K7#N] A$?O(U%+=M5N/"\T;Q1"& M-5"1Y7QD8#)(QH.@,EZ+78*6Q3?1!-%(D)5:1!3.\W#!Z!XD;([-S7)J@)=< M@3T2T$LD,07U>Z*4:SW>R(#98R_J/BK]A+PKWT7Y;IP9F<39*I>R2$B 7BS- MO&5^H-KFE#HHF8I%L0%@!:]I/E,NMUC'HE0UZER@7B98DW*T)CW+NJ$Q7R 7 MTAKB*G^W4[Z[.?70^(&B]E'!L2MEIME+, MY5IP$V,Z])4T:P3_R0/:U_^XTAXM8B"RC;P8"0?RC,IAE3#%I;['@LO$.K@'F\ MH-#08E)R%9OBX0 ,\](VGW[+"J6^^NL:"="B,,$00F0G%@Z M^HA54@=J!!QU6\9$@#A0(]LP.0(Y"5+@#=>VGJ'[_GOA![Q<)U6]!3C*2N>/ M)"ER*J';"#<[JBGG^C@!7@HI-N1"A:D;*[F@6H+# R@[.^4Q,45FRFDXB6HU MI]1KV'.N4:-YO\R"3*I?F!_+P^*H;.2SN@D>[">4C)HR.V+4!\7VMU/3JLV" MARPVNI9UAHDQ&$VW6REH&XQVO0#(/VJ_BWD6Q"+4[\Z5LE)PLI"!!18DI[:> MKTADR/U64X5F.WK"Q*%\$-7:&V5R^TLUCY-_2Z58D+ZK J')>Z9'A MP('RJ1$UYS=K'>&6W9^S]'R!9K^>>Z_D\2I*F"@'1/>'BCM(H:P,F!30'52HC7[%IQ:8.1: YCGDCYL4I=*$MS,);^-]VH%+C MTL^6ZM"4TR0FTNOPA#0IC];FL9^XO+QFH;Y.!&K 7FPQT3$TJ7/ , MGCW_.4N :WX(?^:WSO75C[_]2VOF5S_K5%-#8@H[U&2K-=*V.+[(4"W6!(3R M()]KDQ?%BT]! )!M8- I!5[Z=CMFL!8-8- T<* M_R8$LQKSM(QF(FH,EL&" ML]F='\Y0"7DGO"0D9OT8O@Q1L@&+3Q>T0SDE0YQ?:.DBMDYAX (LY@$PUXQL M9Q6L".ZE.T-/GP9M3N?2BC7,MK^.[O@K$F[$PKJ8>B BM[TN#GS-V\["PL?I M9Y$W'APV*TK/TE+\$+P;6'/$8 M57=B?/)0U:^M6\<$C\H[5^6N@B'F5D"U^1&%!:XJ8[?:;\<0;#**I9SNM _M M$;S*G<5&$%/V7:IX88*2K]4"+]J10>J8+(O2J(C$3LX8Z M9*5CP0,>W8^%A:TGMGX_-A*$%!&2L!$6$2KH4NS4T:1VPQ-Q%89Q2I.DDD3* M\G=+S.0HH=((E+J.B#RCG=06/Q&ZL4NTN@$7?BAGC MYR9/,M,[18Z$$7-Y'*";\'V#"IC2(N)[L'\)V;X MT73X6YZC"K4=M<]R4)?&,(7\AAX)[G.=3D;.:W4[%0I\P#S/W4?GTEU:=(P4 M/&42)W=%;/EK(TEJCJB )9XISYXEMD_"(L\D3A\1$Z8Z6' M%)$'4ZM@>$=Q+] &L<#.F<5PIEB1Y2;<17,]8P\JHO&G;B-A.*H,!J^?!2+W MN*Q?0X>)>E(JP;W<(U++?3:\5 4BS&?DY;#4*QH *! M1=Z)]$3^A#HB4@B0JN'+5KDA-&%1-(CPJ&L'YHI@4;9PQ&LO;#$0 M1JT%6Q8V2!I^XBCBGMTHK"+4U>Q-%,[I7LN^6+&\@SIX"B_R'FAY< M5+(P 1JS>'*G[*/;)3@*M2DOTN'"3VE:Y)4^;+2[Y7#E!]\QRZUJ,:ZRR$S< MK9E))3'G)(K^UFTXR8(% 0^)5VRGU;P\!^G .D@;L!?K(#WBF.*WID%8W1% M#Q5" ?91"+#W->KB&G,Y7D:\H1,6.@3DYFUEN;^,0)6:!.B'\FX!2IEX_UD7 M!=4MN8W"K48I;O9S^)?L&U0%A)*-V7SE9@U/:OO_[.W[+WH7N[3O'X^[D\'^ MV_>[ ]C09*=E'_JNWW6'^^_>CYMUZ[_>3_?^JKZBA^F+_C@/(_EZAJJ;\#XE M- ,1:[7SBPJ\C;UJ3S/X#0_]&_"T]YH]_2K8TQ:G[.$9OSLA@+R3/!OX\3Y; MX:^WW=VVY^XS0:6Z[^XOFXN>7IEZ]@.AGM,&.'U_H,.;AX[Q?8TZ=;\S&@Y* M^NI>SX]?;0F')[30?F S979G:?O4:=OM#L9-).U'Y)%2I,.(S/0';L-S_7)K M 3JG_VF5F"1?Y@=5WY;G?#+OS\P7?BV=^8IY-O5SHOK; ::2@S3O,@W[:MFM8Q)ROCAQ!U6;B@$[&>P0B1S&!'4? MZ\%VXA85$&H)*8ZV)<1J8G@.S?%)S**]&.IU>SOJ_4=A%BW6*%1<5&78R"RM M9"U=\X6(J7YGW.M97:+92'*[PR/BZ,7H$E<_?]!618*-:[ WQ$O4%X;;6A=6 M87AVA:$_L0K#P3F"2/O9(U-HL0S:VC-MU83GMR(NK9IP>*:@$@1?LHXPL#Z% MAF,(N$'?J@B'=T!BG<0+U <&1Q0U5ATX$ -H@#JP>YX/_>UC:66*F7<5^8U' M1<=U-DTC[!1*;&-ONL,3,B.:1[*#SL7@92; O%B4][L]MXD8WU6!.8T\1:HU M_>WS1^>*ALA1R.3#4[6#!ZY\6:>HJ^=%*UA M>-A2VXMT-[FE-+B.F0-G]"3<5TY<&_P=-64GD]%:P87U1C4&.\##CH.?%^*) M94:%U61^ 2XZ/@Y]3* %JWX=-1V%Y>&E'-91YV+ON7 M5B=K+H+ZW7'/ZF2'Y 4O,H&HCMJV,0"LZO7\JI?K6M7+:C(&]\(V%C1$DX;1 MP&YA]YF?+%0%Q8Q/TQ>GU$RV,%"L2O/\7*Q_856:@[J93C[AJ2;@U[X(C-6> MGHLXJ#-H_S"3$AI/(@=/]1(T,.R.&LX?S10O]\6G>-5(Z%%G?+%])*@9J0LV MO6MK= ^V\NC;U*Z#,ZE?N!X+!<9=EM)86]B\S>QJNRQO!H^TZ5T[I'?U+;6] MO/2NMV)L( Y& )L:1\.^-&>::\.##<8.\*4M(@+6E[;5Y<\[^K\P/UI_?-D^ M86<]:<^G#+G'FO=YZFZT1O/#+3JCNX=Q)S2M>W3U_3CU[M'5I[X&';Q+9_<$3H^:6%F\?C[K/WH#C& M07_88/"LC7:O$T?_Y1%'M;O+'>[B[]J'3ZC1:[P$V2!:&%#7O[)*C]UD]#=U M\YVMA=XR"WW<&?5?J(EN/5(OD-X'W5&;LFU;[)&:^;?'G.:UDPS;ZW;'5+'V MV'[?J/:-KZE-B'_+WV!([+RZA3E+."[PW4^.)B&"L_5UM-'7,>[T+X[H[+#^ MM1=(^@P MEW0/U=$G1?AM:BWR0@C_U)J2G<2&Z9$?4S8-N#)[X!_UQ)+%-WZH2!)M)_D) M6E/XIR3*;%] M"-FMHH/W-$O@^21Q9C&8BC%\-9]S#UNS4?V$%RU7+&93/\"Y]KA.RE*:'Y#@ M7USG9P0B/\-A2[C>J7A#S+TH].!149F&#S!E+.LG69K&_C0C-#AIY%P%\#>C MY_6/9[EE7?/[CI-P3CM^"V]"SD$=,F59'!SF=YYD >PKP<,!2*8\B.ZZ1:/W M0>P7T.U>&I_$*J>W,#/L'']S..932Q)K[*@OV/)D/'RN+@156RC!;]@=CA$\ MHGW$M6@?\2EO'_'Z2#*,@.74-;5PX&/NS#+NK&(?2 1>C20H?QCS519["Y8 MX4WO%2&#L(.U?"0]_)GQ*U@DNHG9$DNV,4YBJ?'8U)B7T&-;NM^!A1R7#K\@ M!\[+^N$O5=KOG-TM?&_A\&]>D,W@E?BE#[S:2]>Y?;*([L)\!62<;!K=\E?. M'9.,/S0H&FAW ;O &X#,GM[)OZUX""2+;'D>Q;#+O,T L&>0&3&0&;SR%(FX M&CM-)>*\%/RU+U0R_FR.J )K_OCR\=>$] TT) *='[W" M!2#L3:FR+7&.AL!'W26B8U&#LXDWB\#\S--+\\);+&9O ):]^ M_K"+2-9H:8RX1:-VGL5DM,YXROP@V=CH0ZUE_5/0LP_E MUH8$L[6 ZYT_2Q?2$60^)0'=RQ]A4]@WV+:UCQA.+@\VR.,CW8KAL!0@-OY= MZ(2_%;OAYU,0^5_/V1PV^YH%=^P^^>['(MD!S9D +)^]]H3S^>$N'0%ZQKU( M*"6OR6X3L?&_LL;LQ5G$?/ZW[_[B]RN-QK/A M>.S]YP(T,&+OH$'!]4C19?/7']E/QU0)A7-X_=\JTFH*FWK0D"WP'<57 ."Y M#H[6$K&H+X Y[GR,J!7)^\=:D2@0'$]U%W9G@C($%80*3U^]X^YQ?YT&2TI@ M>:1#2R?7'S?Y/?Q;[:C9SAA0CMXJ%BR.H]DZ12\ .P%;)?RU^H\WRNOLAP1C M>NC-.C67XA;T/O&U9(V32?>B=X'<47JXY8LEX^P2XRS%6L1WXW%W,AC5?MWK MNK7?/;2L.X -379:]J'O^EUW.#[(9MWZK\UE'XDB-#,MH*8" 2ZNM+834N/A MEJ":+]V0P++86GW"=D<6EZ%1A]ZH9O2!4VZ0X]\N@-3EU=ON8!L+DY?1'NRI MB6OM;&14?>JSR6C[VBW;GLM2=;.INM<=;=^ ]ZA]N5N79G(Z;3@^+%Z4CN']F?G";Z5'D*(S^'1;#E?#Y[+U&?8GCB YFMXQ)?(CB+%Q%[ M6' 6I OZ3P_VR3#$2][Z %C&C6 CISVXO 90H]:7I)XXAG RP@25S]_T&;% MWH9=MI#8LZ=-(G:*&KK]] M_BC;WI$W]\-3M9N6TFU-1\A!:_NOM#5YZ<72&BAQ+>P^VC#^W$[WF%M*T>F8 M^3FR"B-1=68O)%^G)A-^FVQ.ZS9[;NP #]O"46 C:]LS"INELP$97O:LMZJY MV $F,6RBM^H$_.IM57\H@W$=O4 M$=8J>#L,6'IQJ5,U:L*P)U=I_DXOM=;YF9#_8#+$=K,F++:(V-COLX$RJ;G"&30YKNRQO!H^T M&6([>/]=2VTOSQ>8C[)18UI>F/.O/VX1V5OGHV6+S7!^GH0O,6^__L+\B&Z; MF)YU)%JF=RI>Q$:SPVW:7;N'<:;^BT: M!X2MQ[4T\OKL<=10@SQFEMI:16T[C0"R(=?-H/N#(X*N&\P;W.6\393]O=ZK M'_[O/LZ[DZ%W*C"K=@JXPUV\ ONPG!N]QDO@)**HDQJLE=4^;-RAOZF;[FFM MJ)994?U.?W31HM"<]1I8>G]2GD*WWZ:^=2WV6M!L^Z.Y+G:387O=[I@J>Q[; M[QO5*>\U%4[[M_P-!@[.J[M%LX3C M_]Y&@2(CA;J[B-5C$(7[?](WM19LWDQW2;@:$F&H-N=M$\MVXXJM[TPQT###T]Q MJ6T(CCU4D9X0X?>[+>R1=NJ$?VI]6DYBP_3(CRF;!ER9/?"/>F+)XAL_5"2) MMI/\!*TI_%,2Y3DJ!*^IZ\*^26VB*(T6?.VG0-?>PW>PK[*D&39-][(DP3;( MT;S89H'L5M$L>9HE\'R2.+,83,48OIK/N9?"P2C1VHN6*Q:SJ1_@=&-<)V4I MM6I/\"^N8_B!B.$[; G7.Q5OB+D7A1X\*BI8\ &FC&7])$O3V)]FA 8GC9RK M /YF]+S^\2RWK&M^WW$2SFG';^%-R#FH9Y@LGX'#_,Z3+(!])7@X ,F4!]%= MMVCT/HC] KK=2^.36&4^%L8SG>-OGI\BUKA17W#ER7CX7,7:55LH@6_8O229 M+:KLKT65_:>\RO[UD408 C10H?QCS519["Y8 MW4WO%1V#K(.U?*0\_)GQ*U@DNHG9$BM;,4S2.F+,P;DE?VH>-0['")Z\TAB[ M=_T.'.2X=/@%&7!>_8QU+[("VCF[6_C>PN'?O"";P2OQ2Q]8M9>N,_MD$=V% M^0K(-]DTNN6OG#LF^7YH4#30+M">#W0S ^Z<)!$LA;STSD\7DJJI]\/%FT1- MO??#6RXG*,%KKG[^8&GYV+2<%XZ^=HY)Q$C#?NC%'#D>D.;W[MB!UP0TG0$T M$[W-?9)TF4/CK^91 !+?E"V/T.:@3)NCX;%I\Q%*O.SWQ\=JR%)%B:02+^![ ME( AJ)* A3A:;LI$WEA$/2>BYNPVBNDJA3QUX%[ZT MI W%\9'0 (9H"B(@0#MTG@"-3N\WY>7MH[AGU"HVHCBA50B2^_1V)P7O&>AG M!T?)/(OEI4F9'R0;.Q+PNJU_"LKSS\JCG ^'>ADTA7[(:?3T&! M_'K.YK#9URRX8_?)=S\6R0YHS@1@^>RU)YS/#W>)"- S[D5"QWU-S@"1;_%7 MUIB].(N8S__VW5_\_F3$1^/YU!W/)\,9XQ/./&\\<+W1>#8*M)K"IA[TU5'*+' F[C%R?DK6TDR&^R!J MI LL9'$C_.\^"X/R>L[C:W0O6VY3<'\R)R1."-B0H M0)?X#?S'N-]!GQIH0$",R(F9G3( W M@P4;@4C"->'Z\C@$"YB'MWX+]!0 M7,6P-E@7\ LQ_95 K8P0Z4/%IU8L1< D,F(0K5(5\5A&7_GY'!O%K.)HEGEI M0GN"3<7\)H-M1O$]/17P&S\18M8\.E@Z?D(^MU>@'=P"EEFLS?BNBCZ574_IZ5@$+0R(?Y0.@07A)ML*"42(Q^.1?/D6S@&#ANJ^ E/PI M& ,!9P*8 -Q0#@VF2!,2'A%!G. SS*2(>99F,1!2DGD+O-QX P"N7WD*6_%X M82/P+!A3"F7L%M1$%1 CFKMC,2>%#]Y:@DD=#;X2XXO7W*O3S ]F@IQ@"S, M8'Q_C@?$S_3EX>$-Z$1T(V&W*?"-)6R-@$3]U,2SV3@ M!7?@F;C_K]2STALH>7*"[&M68,HMN4.:52MB [0I255YI[@(TMX:$0%B^6NB ML@^BDN1??P3_\2@\5&S;L!#PC?[\'NNW"+#:[*",#:0QMDKX:_4?;U2DW0_I MM/30FW4=I92K02\47^>J>[#VJ][7;?V MNX>6=0?=\?ABHV4KLQ'&W^4F36UZH3#(&I7*\GLAC$]452CF?U=4UXKI\G6% M77OO+E^1)]3HM,TB#&<[U+]M"Y$3S97>_/Q-R1BK(8CNL+?G'N,5=\+6O-> M_RI!ES(JY'Z,^@E&.GSX%SX)2-?*-7?F_9GY0CG2TPF%/G>RGA];J#?F,96H.+68ZY^$GP^;V/>6\OI[>: M[,&)38797C:K[S67U9\$3]/3WW?S"%D.UJAN$*,J(.4^3_#P)+'RKTKB[LGC^>*'R_)[HM9VU27(8&5IS*38E99@R,2 M#?(4C.KLG3PO8YO$>P.T@RI(VM2"YTDM>*R[WO'2PVL:#'^0M/Q>TO+[ @67 M\V2/V(>O:O][[,.W]UR)5NDMOWW^*'%+ 8@/50;;?B#1-)WDJ=U4MSM\4Y2. M&F: EL763G [?7T/H3\C_:%CYCZ(C$Y*SJ[(A3A9GTKM1-H6]MVR_AR;AK'' M&_!"9W:_H/A2"R58;8#W=+/UZCI#CGLMNJ!61-DPZJZ2R'5;1.@-"("TB=!Q M6J0#.A9G<7"/-9>P<3!)%BH]$;N?O##.WNOV7^C,G69I1T6OP^YACFTG(IQD M1&Z_WJ\3B!%&"[0J(9W14]YI9Q!,!WSC" M1L0.-DB(1<\/(G.BG:6@&(1:!_=2[#8/&^@4+USE;=W@5JHK7,'#_-G?OGN\ M:Y;;=[_;5L8@Q>Z=[[D;]9_:X'(VMIV&:,$DR4C0ON@[-==G4=(,^V1X0%:" M#JC["IY:$(UQ4UF08+^96Y_?)9H7KRUG,N%/;S]T\!]'0"6A%IQ5HQ+J)Q\8 MM-HAWA#F)$I<05U4W1[E41'_9&;VQ> \>)UE\YY.?=?7E]?0<%S*WK -#8^Q M%]O0\(@L&!5=_HUAVD#'"3;PU6'_OB2-,R_-8FISM8"38-\W5NK(8'Q3T8#A MP62$CE-=^-%9;SY>$RLR^L*Q\+ZZ+E7J9Q4-S:EK!#RFU@8U+V:JE1SH27RY M(J6#;)[D54>S\U05$G34Z==ZAJ6[Q*8[).)I?.1[0F8^>: MIZG(*'&N;O#D^%]GU(=-/EG8EIB9,N>@_E&K0I8X^>O7\L+4?A[4O;5ZB3*= MT*+UZB+.1>]))1=+"QIB4AO(I*S?URB[3]*?00%'\*38M,UXLY[>E,9B7$>H MS?4'05!0:J3*H!3>I%+A6%_N(9T93ZJLV352%DZ&1ZR3MK1NJX*N5JU(Y])P MRI5&:;HDVL !,VR>!0YZ/I#LD0)%MSYL[QYMB/&.Y";*9EJ"X8*O0K435Q>S MO/Q$^(30/7&.+5&%H\*@F@?VBS2:R0%')CG1)K"G)K)YN8-9KM-J('D+G\^5 M6@FG ?$M>CHNV5?D+,@LY/5^^^E=SEY0J%"/2'BHHRTRW7<3N:]84(.'W##Z M /!"[)*(JKZIJ;,@B#SQ(/*<+/9D>U-C176YE=Y*'?JH)2H7X]% QY86)_+G M-%>5'T*\4KKQ]OLQ 92,6(\%7B9D1(V!HLUI?!RXB?$$-4%DJ/TG8+@#R1,Z M4A_X[2Q_M<*?$ Q$%*'/-]MVLB#'0+K($GHW]N $TD3QFU!329DKB/3KA SE M!>T7]VK\&.T48/&RGUR,#X/VF$T!I6DF3&XZC!*7^4Z 82(>Z4'@CT#/]9!Z M@L$^W,E@+[DN^[UN_Q#L:3,S_EWN :8I]YIWF*3&2!UYTIT M2\:;^3D*0$.1-_:]]*0U[X [21-/G9?EYUV9YU6>PT3J#81L>;6 6UV%(:H8 MHK\@"O1?L$FLVSO_?_IR$=L'&8(5$]SCRREP@X';$?T;34Y,'^CG%4]^@XO MJQ?L%EV)'-5&!W<4XSU5^K$8O@1<9?,#T8@9ODJ1*P@?=G-ZN6[IY_Y0'FG4 MA#,\3(8I*.BK5%)#CZC![93%^-JH)L'<26J :N%>CO2,+[+M0(M%@TK,231) MZ_?\6S$$,C3V6[(&13SJ[6(Q\ %4T 2QT)I5!#Q5R/NM6QNMJ$VF>$5Q"Y\)#%;WJ MQEA@14IB@IB4,%4WX9A.-NEKEWJ^U)W1PQ'%A<67EL>I8EOG.'.5ZE(30\-&X;>2\ _L>DY7U<2^%B+@M\Q+%,#"%7!A&5I)4U MSV61PNAJ#L'Z0F,]QC(.ZT_Y\#B("#=TI3^]0[RY=YHS&HJRQ'2']:R20 M&FY1$EE;R+\:U@$O1;A'$GLFPRRH*K1. ZC'D"58JP,!:0(-FCJ7"%M(!0CSINY-->A*C,' L8-) M"O:B+U[VD0:*H%VZ@3FCW'@-_ **=VC*0:)Y+/17B6I[V'.:Y:BQJ'56Z6)ZO2YNGL+ MZCS(?YSXA=(_SZ/3*YA6A#0)"Q& MMRW1/2&M$0U6S%J*?51P=/)J'2S6X6#YPR'YPT822A%6KJ[)2 Z7$Q4+JPC, MEB@TUXY%@!CI0%C%YK-&3*\XE=$D"!14,1#6S B$8DP>V$N6Y $S:13!,E(: MON/)RD^+E]OFN>D\MPN;Y]: O=@\MVI&?J1;4N-KMTJT.B=V M*7OKL05.LY0R$9T;RB_H!.AP3_("G:JWH3F5.'<\"&0N$KRT+MC"* M(GDI6BZC&?H-,!D/D]1F(!AFR1O\=H=XK978VVCT:HXH!HGC;*4]MK>4@"'& MF)93"JL]T]5.[XK9M3(A*$_ S''>$0%CK3+HNS%FV"KS M1\8GGW0I*;?('!TM\6R")K>&UNLJR+ZJ1L^F <'CL7! R"+*;A;K/N>PRL4< MUCB]#1-L.W=SI_(:J!LS]V=<:KLF-C!XG1.UL#AO?*XF#0/M+?ULZ=P$T13P M- 72F.E)V*:U923TI9PM\S'7'EL9L9HD\SR>)$*1#MDMYA5S D1.%@"@(."8 M 9+'IN993()#7( DCRBP&:KCBJ&LA=_6&)%XDH#R6(1,G5EG!<9Z3'2$!O@4 MC'N\QB24X:Z)C&=N; Z/F1NG:^A^U=?\H;J=<8F=;XE@X< MP\56Y;?)T5<[4K[R"M0+BVJ4$M?(IHE(ALX!'H65$4\9T41NY\A4S2B$O6+Q MLZ*S8@GT8X 0=82,2%YZ4:B2: 37A&(_WKMX@W6+)@2W/2D@39RRD M\6R9PB-6R'/N4"*&1@[/;KDZ0(8?BE['C:[F!D=]-,=DW8V_Q[<_YJS_WAT: MZ5HEWWW_AYR38&K#CHD7L,C/"MGE$V@^H)"SM_2'W6+A&X"T%IQ8]JW"X<+_ M2LF6J,AU,,_2T$40+4I-$?C?02[L _W]<3WZ!X^/GC\Z,]I$SCT.IVT%7Q26 MV= C,N[#7$MD3+^%#2K"?(PN_>IT"TW@=Y3;/^.HP2FM%2D++LY_*>7)S!]! M530EMM@I!P0?H?]BCP%A-HBXI5AJA* NJN.R%S JCS$-Z4I$ E0^YNZM2 MH/")>L%!#/O)1F0I5))C.NH:<76W[8+#P=X'BGC_S?.!D+ZP;RWH7O 6K(<8 M;SYFPF1Q#(08W.NZ&?)=@&&7R+H9NNWBSAK1Q8 *\V,*MA#;EX#@ A"8*X6J M#T.+11:. J.>99XTW?%1-#' M+K3O^;GMVR%)5CF+P4OT1\ARV0^7CFP>;TH M10XBZM]DJ5-^(E#T_Q?O-:9+Z%VL;Y1JT51!7 !\JGH;^)!^H_ZJ^$98#7U; MNJN)N8$*"!F@O44)7,A#TN_RA".]$==C$\F6):36ZA81**&9MZ""-M6'!GT) M16TA4?S\)HIF)!P1ZCX@.[SQ,:0@4L@="N:C2QK KQ(1F:A"$86FN$YIC1D' MWNVG_#SP;WG5HE3W%R&4J?@KES%G5-RHBF>1Z.>@ 8KL.@_P;J)0UMB)HZ.$ M6MA%2O] 2RT"1*(#_/ MOV$QB*1EY">IDRRCKSR@6M#R358EVA^OOZB*BLVN3Y1Y"Z02H4?("X1/@&C% M5F#D'!&2FQPP%4*[F QM)CX 4K/E2M1U9[)82;H'I;H$CVM5IZ!*W49!M@0E M)"\=E/* MQ50%O,W:_IRKHC 3 M>NJ4YZ$D5*'">]*&@H*@T$1^ISUN2Z1>NMGX")6)B%6-:V.LW:'K%3+IP_J@ MPE,/[7*=K8K*.GPNY_AJ;P=&,QG?N2)A?#S0T7>,=+9I:.!QV00?<_]1"M^M> MUG_]T+(/OW+8N[2;/[#Z\J\WH:BMP;$MJ=D7V!=L\8(]#0P3HX,FC;FMU6-JKC%@0C:[N1>=_L4+G;J\XWW=>+)8"PB^&B6G0?#59P."'_7[EN@LEWW& MLXTZ$\MD7RR]OSPF.^X,W$%C)YIN-3ZX\1KY)\P0*6B%^7D^S=\ MLI,&L:DRWCS>,YP]NG MK9_FQ=I3#+YE%ZM&H$TZE\.))>Z3(6XK-^8TG58VMY']51WU 8CJ9KAO2\U!U(I8'NKI:H#SKZJ;.SZ=OV7E5]ABZC: MFNYJHL6-LX51C,%33G,9>7TL<=?@961>$+9HZI/+0 M(N9CK9;GUATL@IJ"H.K;2Q.D^F_L';8D4H\?(I'VN1].HX2J+CO0EE.=;@)O M79+2Q6#0(D[]+,G#-C'>)L8_M350IS=N9&*\I6TK,YZ>=#5JH7O0WJL&WBLK M,PK)7<,=/:NVF.J0#"\?6>N'7K3DMHC*KM^>]?>4:;'Q#2T/9??#&0_A*ET> M8/[TAIF<;S_D5U:,SCY$K,^NT9PU]ADF'/2Z_5%C1-3>BPC M-L4^++U;'ON4LP&]7QZ1Q^XSX[\-*OG^Z@?;D"A:&RH83UK$8FTF\;/[O/N3 M(Q8T6R1M-,.@U\)PGR6/9\MU&(Q/HQZ@#5K%SJ6$;4@6K;'3K"/,IA+7XN=L M,+RP0U0:@)[JRWO6'UKL- [=4W?K3_@N6#]M&*^-JB'-1Q@--Z< UCE_;G% MYWA@L=, [-35N;5?CZD3L%DS<*MG/S29&U@1J G9J[HYK9[ V 3LU=\<]CG/' M)DW_G8<<(]A>%*^BF*7)&+;H.O5^;%&(ZN*-P ]=7QB9"VE)J"G M3L@.[.UI GKJG$#'N3R/2-F9GZP"=O\ZC$+^,$+M+XN_?&+%IL#2>GW9:72_ M*9=S;JM?[@5(34N'W5/Z]WY@TQ1N60V4R\YE_Z)]*0G[NMO/8>T^>:_;9JJ? MY)W>4XK[:=WI:J!<=OJ3OKU7]EY96;GG&JO)J(7I>_9.O[0[;67E%H,^X4JU M\%Z14?QCBET2E//:<+LO67SCAVIKF$PF/\'=X)]R"^?TIM=]D7'V_"CH4P \ M<<#L][(DX3-GGL685@;6K/-;E')GTG'@;^?MIW"DD<-O M69"A+Q]_ &;P/(IA+QYWHGG'8>',84$0>?B#F"=1%GNPY302ZR7\9LG#-.DZ MSD<6LAN.?SE3'OC\%G[FIXZ?.&RUBJ-5[-,[(MID$&&KV05\N>0LR6+Z8L&# M%6P8'DRC&!X+67#_7[&M:9; >9.DL#_<6QKS<)9@O!]_=LMB/\J2_.=Z?\7X MA(%B"<(A83-*?$P?>!WS@*7^+7]SY\_2A21Q\RE)$;W\$38%RLS2^D<,NO1@ M2SP^$ID,)Z58C?'O(E:[60$NSZ['XOV JV "L'SV MVA/.YP<[H6 ,^YA@ HQ QR'Q_@KV!-KS%Z<13 MX8SQ"6>>-QZXWF@\&X['WG\NOOOI"W5Q 2)_"R]$>O[KC^RG(VE0_5R#6O^W MBK0>HH.#;O(+<(1Y!,SK#OUZJ>J$<^O/X!T,N)D7A9X?^#IEB,W^-TM2X)XA M3QW.XA">2YPS8%8)3UXY+$UC?YJ)A8!?707P-Q,L4CTY\Y$)S)SWGZ_K?@_\ MBY@5K,Z=)9QBD3C Q."A:[Y*^7(*;'O0>UW+L4HBJ(JOB%=J7D4"%* >L%7" M7ZO_>*.)K_/[WNV).R_=R_+-\NLN?552!\1W@\ON M9'19^W6OZ_ZPDTM\XPVX;G?L3C;=P.;+]KJ#WN 0RPZ'!]CMP8 P'/7WC-Q' MHAC-C#G4!$!!.8-E ^ ^I,',\&+&2TMW=:=;RC]URA]/ M6MC)S]*]I?NGYB*U.+IJZ=[2O:5[2_>6[C<_=:\['%O"WR1?9B]NA"=6]1T# M0[]]_NA<48B*XO,?4K[]&62\(,9G_=DXIDY^U%[7]OL7L M:6)VTJ96]Q:S%K,6LS^!RZ-N49611:U%K44OF M09MBYDUT?C>OPUU;?OG!7/W_0,8%DQ3V?!46SQ88&RNG*'==M80*; M=4=M./3XLDW*A$7N-K-P.Y?]-EGN%KD6N1:Y%+/MCGL6M\V*$AP##V_C*(R2 MHRBL[;6A^[TVW1WK'MDJZ_'HB7FG"=A^JZ+2%K46M1:UZ"UNE6?&>HM/Z9I=1S7.8[SEJXM8$[6/[&-VWAD MG<8GBMKAI$T!:(M:BUJ+6K0$VCCFJU&6P$DXC+^P;]8[_.!-^3]_N>R[_3JVOZT01:UW_%K#M JR5-+9?]J,8HG[95VI,"[;1OY9!_B=VP]H/ M^&Q_O>;RE\N.[21JWT(EK*=]2OJ5\ M2_F6\G?IT= =M;"%6\/Z:*N?R)-=4KN<+0-!YI'*X\#K!M0_*>WJT#NQZQ]W M_9>:5M?O]7O/,"2NR0*N&C!;"[A&BK'JLPT[@^'DJ'D"EE[:1"]NY]*]L/1B MZ653H=(9#?J67BR];$XOPX&E%TLOF\JC[F!\ FF.S2LD:LLOC]"66*U=;O6[ M-I_C2'>B.(F#FA<;PSCJAF^\]"Z[-?:1.VI&NLYI@M?MN1:\AP/OP!U:\%KP MMA2\O>[6KH96Y4K:R0C'.$1Y,L+S:$!M*&*KAM=%0^RKTX2N>USG^XE#=W1< M5[6%KH7N$[2?WG$=H0UUP!S)H\+\6/67^9\__OC5X7]F?GKO)-S+8M HN*WM MK7?ICWN]9NCQIPE@6=)F06QIV +8 K@N4#9L"'R;Y4PY!B[LN)-M(3:^M';R M(9G#<-LHEP7O-H;R<-LX@06O!6]3P-OK]AO"?*TCPHZ>V$FZV3#M(<%K@7M( MVMW6"6S!:\';%/#VNKW+9L#7.AW>?OK7AW?G[L1Z'#8S*K;UEEF;8AN^VY#0 MYFE"=V #\Q:Z+84NJ S'K1>TWH8\W]/V+;>A]V.#^&QP:5LA'T:0-<0VL]"U MT'T&-:%5G@79RTB\=KV=TX=L\WVTZ![HL7_^X%-L[G'96?0W]$#L:^+ M>>#.DI:T7RAI]SN]T;::AR5M2]HM(.UQIS_>,4_-DG9CL&A)NYJT=ZVSM:3= M&"Q:TJYLE+UKP.38E+T?$[]Y+;/:\DL+6 O8=OW2 M8"MEV_M("U0+! .#Q@ M?TS9-. _Y5VQA#+^TU^G\8\_U;;,DHKT$#3?-ZM(].]\3<4?_BU_<^?/TH74 MLLVGI,+,R_EWH<3$K=L//IS%G M7\_9'#;[F@5W[#[Y[L?"F99^>&X"L'SVVA/.YP<[H3!"9MR+8FI!]AJL'A[C MKV!/K#%[<18QG__MN[_X_3X8SQB><>=YXX'JC\6PX'GO_N< L M(:!L[(OR%EX(Q)/\]4>F2?H81"2LS?5_JTCK&+WT:)-?%MR91T$0W8&EZA!W M<%9Q=.O/X!W,B0$MH><'ONA4!]!E*DX:\M3A+ [AN<0Y"Z(DX9=N>K/*((2%#EG/_.0S_WT%V)\D:7ENXLW3T_W?4[%_V>I3Q+>4>A/,OS+.4]/^6YW>$6 MM9G/17B',N4>J!\C@)4)M#P-L%&FW&^?/\K**^IJ_\1Z*_W+MA<;UA#Z<&A+ MD _$0EP+V0.9X ,+60O9=D$6J[J/#MMG:1774K6A.%JX8\X5IE0#A%CT\)SA MPR@7;6AX5$WT8_=(N3*]/%?FV*V63A.S$XO8TT3LJ&\Q:S%K,=LFS.(X18O; M9O4TM(.L]SG(^B#4/<:JVT^UAMS=J M$(,5GTVIMC07O:H 5=:71TV#;+CWD, MSGRL&?+M5?+'G7[/6G GBERW,^BU*9'"(G<+Y X[EY,V)5-8Y%KD6N12F*,[ MMH$.ZUC[Z6T7(M9B]DV8A;=FA:WMD5T M$WMOGX3#V@X3/SVMT/I"MM$=+&)/$[%G=D"]!6RK &LEC>WV^BB&J-OK$:>S MV\Y@K>T,-NCT>BWTE-B>>);RGWCJBU&;4HPLW5NZWU.@O],?68YO*?]E4OZ% MI7Q+^2^.\MUNOX7MJ#M7#(^TKAG7HG=CU MC[O^2TU3[/?ZO6<8<-1D 5<-F*T%7"/%6/79S@;]+=I[[S?QPE)*FRAE/.@? M-4W'4DN;J.5L,AI;OF(I92-*V7Z CZ64ET@IO>YHBXD9-DOTE'YYA/:L:NUR MR].U*05'N@_%>034Q-4825 W@N"E=QNMAJ6[K7)K4ZZV@.[0 O=PP+VTP+7 M;25P929F,T#<+ >P[0Z_S^[PSZ/]M*'^KQI>@VT%M*VNW *Z$PO< T:M1A:Z M%KKMA&ZOVW.; =]F^5Z.Y$QA?DSSH*.Y0[VP^9^9G]X["?>R&!0*;HMW:]E$ M9]SK-4.-/TT -\I2.DT06QJV &XW@-WNL"'P;98OY1BX.%:'ZO8JPR-WT Q= M^#3!Z_:V=65;\&X3X>I92]F"MZW@[77[QTWNM(X(C8LC=@MNL>H[W%9YL);% M-N"UP#TD[=K<(PO>MH*WU]W:L&BBTZ%Y":]M^>5+\.8\5_O6]EH0NP4HK)&V MC2"S_K%#%I>X@Z.7EEC(6LAN61#5:WE!U&/-',1KU_LYG$R7T=[S=AG=)W1/ MK2)RK[!I-N?H=R87.YIM^[J8>Z_9M:1M21N;D(XO+&%;PCX]PNYW^NZ.CGA+ MVHW!HB7M&M+>-L!O2=N2=@M(V^VZV]9_-82R;6"ET8&5YFVX+;^T@+6 ;=,#B)]ROA8 M<&<>!4%T!YIT,0G78?,Y]S!@D\*/O&BY8C&;^@'6"D=SV"A+J2M;@G]Q%H>P M0N*!K3BU6TD7,N;.$K2T2AX,$U7\%:4QX[ M@U['H9ET^$L,&[VN[<&R#M)"5Q;WLMS!SKU\!C"O35'HB[21R7CX7+,8J[90 M@LVP.QPC,'[[_%'&Y:@BG*)QKYWGV68U0?X"Y,(EB38V :(JVJ7H@V@ M,XTY^SJ+[NAW0&8)E\0[Q8+V&_Q]!_Z#'_I,M.)K/P4;T]O@E/\0'8?>LI@[ M;Z,D=7[G7@2&ZKWSJV[IAW7.6L66#&OK=][)@95O05);[03 M]\TKNN#- E(5'VK$+9UTG)BC\$[]6Q[<=ZW,/*#,++:C[3A7>2]:HMEWH!Q& MLC?M[[*Z"7G\D07KYYB?IYC?6]H^*VU_9FQ?M]9= -W 5NXXR*OO7??"@0T& MZHGOQZ[^>S=MKT2^CE.]V4=:_XK=#=U1<7=N_VF[ZZWMKDI'V0FLN&VAGHAK M;"_N(2^NV?+Q'WG+Q[>RY>,G:OF8ZU]-U8;333I7KG6&K%67Q=TIJ\M2&#=0 M".^$12NE7]IEK^AS]E[T.;O6?5R4YU>R&X$PO?4F4@)0R1&,0/-88GY0&U;."1D'WA%C<'SB$,(Y.:5,\^" MP,$-WK(@DS(=G4]@*7'G#O:A3P7OHJQAEL)IIQGYU1QI<>$"4Q[RN9_"WI,( MK"S"[[G=AC&]#Z$7+;GSA7WCQ^5E M3[-YI94I@:PL/;P?XV-! VX7I9".I- M 'N8.3>D"LT=4/_K6-Z93Y?JE2,8E#./HZ5B>GYXRX65_T2NAR_"72=90)S5 MRQ&!AX>7^$MQ=1 MR!6)58O34K'AQ9O$V X^B!@E;@J@0(4"-H;.>Y9[)I"3 M+ME,,TRB@1JVBRNEE2!_T@9I#]^[G8O>* =_%HKSSP2P$:SON"??ZPH!5_G* MC1AX/1^1A#AQQ"MVP\_))#AG<]CL:Q;:#P;CL?>?RZP^!I5'+A;Z.%&AO+7']E/Q^30(IUO_=\JTK)" M>Z]"&]LJ*M]AH53NN#*[Q/5-P8F\?$UXHC" H^P: P8!'63X725+Y(L MFG''5;4"18]DIZ]ZL!JR/[>]06QD4Q#=80J0#>Y1&N)Z=PO?6SC*/9>BDZ%D M&94@4'?B)\JK#:[0D03+7BC@$1/W8;P3VB\GN5*!ZIB?8$P0?@N:0PRG)M7O MS'\%6E#\]3R-SO'_PV)ROT FREU&F]-FBQ\F:9P)=:YL6>+YD@5&;$%M7/I" M.^S 6^ UF!T1\%1YZ."@"1/,')^Z KTL!JV $=7Y,Y_%]T2G\"P\?!-%LSLX MS;K=6KV)JWGL>\R99@D $\_S$@EI(V?)XY0T<@>/4Q*\5V]T1TR_2!Q_(0>S M2@22N"BST)PMR]L%H%2/:&MO>D_(1T@N&;+K)-+KX6$1'W!] ]\66\,Q4C' M,>R"=$)A40G*7O)T$J-1)/R0X MT$-OULF[5+1#M"V^EO;GY*+;NQBC"2J36>6+I77:)>NT5((DOAL.NL.+R]JO M>UVW]KN'EG7[77%&RSZURV\/J]ZJ$I4G M3^H4+!Q71RHN7./G/9-!_H8,\J-@B^_7V>(&?60L4-> ^H6$S890?81FF]F4 MJ/K\(!B5ZI^L-9>J(IVZ0M3>>BUJPU&/ZL.^3EQ[84X5L)FR(#G-6_74-C;MO%6UK4@M99\,95MY8FVTKCKUQAW&J-MGZ54+:DN^BT25 >?XK1[2*+MU%%S MXT>7F\]ZL-AY[JC)<&RQTP#L5-^=P1%GU#W1*WW:$U"^1"D+RF[J8KNM\[54 MG1U5SM/JP;Q?$_]$>C#7!8IZ+5*L]GS]G]%!L/M>=_0?G-:-WJ][X41N=-U0 MWZ&]5?9663FY5Z!<3JR8M!>ZZ1?:BLDMQ.2.,X./>JNVZ1@]*':,7JO!Z%^4 M*X F^R\ VL0=WM]+KM->MSW9:,\%:';[5(4MR]"P*LTH)Z-2'=E\1#;T4/T\ MBDTR\),[%LPF[ MJV[VI6I95?L&; $QG.1M?HL]MM2XBH C+<[@O$[*B:]%\SF/!:\$9D<25=3Q M*\D<1 !/V,H2^$+H \O(0NI_B#6UP!F23?IZN+VFL0]$>8L[Y1>Z!O9:US6P M%EGMXBMO/_WKP[MS=]+8POFM&Z<:5?+'@S;(TF-"4/4@23$^B5SY^Y%NEPCL M#6"5@A0QC!]@>7&V$M:*Q[)$**& !S"GHUCHF4O1?9GK9JR>YLN:BN"LP(!] MKY:C;MFQNED(VA/FX>S,N5,)4'Q'4P@:7 M>?>D6<:-MDDH\DL_-L9&S*FO/?5Q9HF?F+U+'[1391,H9 U5VRF->BBV T+U M$#D<99"RI3APS-,L#F5[_&R&#:6K>PC!R6#%>\YB5 +78;EE/RJCA;709\T^ M5)60+/YZ(U ^UJ<5&]5MS@N.9&<]T/-!^'QU/YRW-*).==':]+G#I$R4'4*/ MB/X&0+]FY!%'Y] M#S.>=&1_1.5=XM\\/Z%N[/"^*9"CN"D@OV'/8&1'=P64+CESB".9= @^#9K" (]0L=:>:+$4QB&4U3*.\;"+[,''3.N'QK>_A6657MB9= MGFKTT6PY=!^R !8UT#$R9O:<3;JC;B5"2'\#EA&F47R_-@W(!*@$FV[;?P8V MN=3EA&]:J![P$H'D9.&OZ(';*,B6?!,\5TX!%.\3O;"TSE5TELHM/4@H*XZF M/G!_^#@5""649K"(KVM.9$*G^?3RWKS2(C8AL&"0 MSF"06PAGEUWW@:N\-9:;#Z&/U$@4** #DG;IASXV?-13GD#+ T!>*0@#^"4 M"FK]<3Z6ZLP==R\JP29IZ09D/7(G,%17V%6:*RTGIT:@<='V7<*TFIN="5Z- MOY//U8_/.G=J[FQA")#MK3[J%V%A>ZO;WNI;$]&^>JL?Z0[4<_!$S(V04X>J MIO-",]*#WZS_#\?_OGI^JC& M?O/FMH'@#*91'.'0MO0Z];VO1W6'-5_3^ 1**4N%B*?I3X8V,1H8VL2XQIR2 M5RG2ZP@?R+HE].!M?D!KKE=3:%FA ]:^_D'[J_GH0!? &X0+ST7L;4Y%,6HZ'B'H.B1KHV<9*?G8]74\RM?D^FRZ PO!U47 MAN;^AOR&B=D>,N(D[E@6SMDM$4_-$F"G-,-NBXR2K39P"9R5I$O MN=!PV)W\L%%&Q38I0T<"Q^]JLASZ'"O&P)7&6,I8-/KR+T>Y*\X@=[PS)"+2TA^(?>T:V#+Y5T5LJ_GHV"18 MY4X,<>$.;+1JLVB5:T:K^I/N>-=HU:Z^X/4XEW4$GZXC^.@0VBJHVIK;O^9! M-AACOS\E.=<;B\DG^7N'S^WO/:2[M\;NS[T;2NK \_!R_VNQ?5CF;W N2;=32?]3L7_?ZK:F?SQ<5F_')S=W-9>5#L M>P_.Y3TX[DI\_P$Q_R3G\9G;'5X"'#DK,#XJ$1 M07&[DX>LV =OMAASB2V^V7XDC]YXTC"9#_]-=I_.-/ZVS1G_WMN\=ITNU??+=MZZ/Q M =#M;A2IRCTVOTM7"T#]9UENY%P+)TN#Y'=-O$UZS*[!+N.-WZT&[_OPU@?C MJ14@OLZ6L)7[!NVSIN@8%/L_NM==[47UPQFPBQC44X:E=,P),RJ1!8:CRNJ$ M?@[V?8"A@R#@(74H6+#46;!;[&IUR^,$+7\VGW.R_'7WJ])79%@4UA6Q.QGA M63>JU3:3;)KX,Q^=.,K?ALH?EW^5GBHD[BDG*2PNC1_XMN-0M[@Y\.,$NR7D MB2Y*+\.J8M'>0)\9+--([%(X1]![5"C064;XB0B"J'H=MX^>,.>_"?PE<%[+6\VXP/DK'J3I5YAG[&SS>P4[W-] 1.LHQ VT!%#] >""Z@*A@XS02OY*M MYLA/\,;BY8!X08TQ]F5G21'OS4&/GI9(JG5X5W^A;3G7R^@K8NDSY6UHY"F) MCEI]' 7.%;#60J_*Z\]?WEZI^]I1T>4'7G\F/A%I?SP$EN&)[ 01_TU>&0Q_ MRGG844R :K*S-(NQ@"$(X,M.^2Q_A#ZN>IV2A_Z7*!("XEV1.!?D8:-N ?^8N.9ZYB_Y9" MQ G:C#(C67S%EZL@N@>]SN+RD+@4?H4YGV'0OB.J3J2KW -LY:A3+%JI5]@' M>U?,C(86,]L)\DAFI3'A9U.=*\M9*IW"K]9R6. NJB=5$E7AXCWR.*488%X7 M!EYC_[\4*P_0&9Z7&M0^#.]4[UXQ[RO&ZA!$NU]O2T2;"%WX$"F(!>O,>B&- MZM1/E"(/V%I&JCUJ&8464X=GQ%5*DL2#+I<)^(V?!&9"YTTF_GR#?ULL'1!+ M!55&>(>DN6OUE -+0^1!Q+M0D@#008))5>7C]1=RQF6RM7, 5FR0J(C%31S= M@=P"AN:'871+@=/]\3:+O V0EX>35+]8M-DE"CSI70!9!"JGRJX3[%#9!PE' M9U]N.Q@=CBH5F5>(>)7THP2?D'BW\&LV]0.,[>.+LJ127[$$<4B",,QZ-L/< M5X,8X!HCYK,8?I2@&VC!;OTHUN5+^-0\R'CH">OREL5^E"486B"'<)*ATSQQ MT,<<+7V/2NU]:;L4BIZD!>IQYX:MA%L*?[7P5_!+#"S(Q-S:7<++0"?V%I33 M&>5)HEKI!9H5A$P163'6969I[5EI#6\]1JV#>YH/P)&%@ 0(&7D3<<1)D*?[ M(P.ZB6+*-],\ID.63Y2E3N O_92)4A5S,< \L"]&*8B%!K*YH!*$IKU<:[%R MD1.LR[7,\01%ESK%6(!A^G,99GI$M!D'8H8116!HY-+S-=4_1!E_6$/\$NP__. M=86.Y.TQNW,P2(WL(B6^N\;K&Y(7M?GR_0^!2)#ZA3"+4$ MN;\,3#(3]7M'$J_(T3!3LAF[%$ M5>"*,H6U5*=" \KW37 ?TI:@)<[G6 %4VAGH&L G0MJUKGZAI%OI72UAX5]^ MLMTLOR-1\Q\ J\ L:UJP8"YJFMR)\"HK3$B,WU,:(R">U'B3DH2]WM&Z3HFR M % + ^:@U=$XDG5$RY%XTO#4E5= N:F/:=H$?'@-3G\2P)>> KB'E132J2P_ MJG \5&4<&20C719PYS[=RK%[*Y; MNXB,6I $R[^6ZYZ>9#T!E5@7EF$%S. MZ*YRB_FYJA !^_CWP@^XG+-BK&U> 8-YE!>0]=X*KV"UX;0=D%>P!PSBYY@F MUN4L(PPV@4I,_P!LY/ZHB)0AES$;'\(S1K2CX,+H12R4 M&Q>@B' )S;N!2;X%DD%R$2SIHGOQ@_@3#5$*XA'[K!A'@;51V!MFHY^[(D.M MTEK0F_7E=2/,R:J?+7'W\NH- _Z0;FZH_.C&%_4K M'D D[BBPOA(Y?J;Z,>7.[#YDZ,Z589T:$PATC2#*_6*,W,.\8+=K93Q:2:^P M6"LWH["<6$Z[DZ):22(G]I.O24G)SX^F^HB9GC]8_Y=W5YBPS6-@U$P'X+5- ML%H%(-[SE,F"YB>"7LTGD0_AIM/%7"SFU_7NI)+CW>5A7E5$N>32.R8'T<"B MMUQFJ7B@7(A2()HQ^T M'4PZ*Z*4^!%ENKXFZ-)P"; M1#1GM["K M -2*HHD[CO$3!JM#+1C/$E2].OAG?!4K"6:9"5;JT!V3SB] J( M#0RSB-J-M>!&OU\/H$FK6H!YT\@=7*K/-$=/1^1PLJ>8P$>9WD)FBN*6.N^1 MMX@BPM1ZD"V_^ ]&V<3=7D39S<*X!5BW+8Y3ZO]2Z5:M!VKV1D4X* F5=%/7!CZ\ETRO#C*H=13M+025,N?S_+MY M54044$'G*9GZ,=S++G!NWK N8N^_<2^C&R9+X8[:0TSU9;\0?55(:JUW&FG^ M1=]$N[N+XJ\TY9?S5)+6-MYHX;: 3:,@E&R07-J%'I3XIVQ=*-MM)")(2L). M9['"92>'G2\X/U83^S/!I475X2*F6ZZT4#56>/:_#$Q^[UY=49(?P+4+"26D MBH!1 EI9',%UA5_ W8MCE-LB.QU?W<'0?K%C/ I,/YX)A18$89/P7EU.*NIW M"#:HH?ZN\P@;M/,&!*,>'_H[Z*NAOT""O^=JP2\Q6W*\.:^/Q48;.'P<820H MKT/L!L2-R'D0V5R*!A/-C_H]=PP\@R_+/] Y7\XTCI@@8E,IRT#:QQ2S1>YC MIGF8ND-'AJ14QEET2T&7Q%8W'#0'@LJ#'DM*[^09Z1U16E 4"]6)ZLY9TCC- MY1A$YT+'P1[I/KP3 M;/@%NO1)>PSA _(D1C-_[E<8"DTD[<]P)D'0(/OH3)_-,RF:_VS::_+W5X)% M_U_S@F![)4[\2@!!+_RIC[8QI0+$V*H#=6K0!I#PO8#YRT1EFI0]MS[] M%BW?*0;*$W0DQ$NPQO&!4(KRROHUS.)$/8&9E&=1?= :- EJ8:$A\(63@9P4 M)<126R@6SQ3FBX98WF,DCE*N T3T208,UI,==Y^4=6=QNHE$^S/S5QJ?E#U3 M"+7DI5'*/6IV>TBC*"A$VDCMT^HZDD=(HY4T711'511<_9BBZ;>ANWAN^,AL M">H(S1,O]E>%R@79F2+ 9SNR.87^,+I3G\!=D!_"9F?J4PJD4$H4*ZX.6-%J M!4:Q.DX6$NN4W#?0%M-_C08A[ZZZCO-A/3.1";,L8'=)1LU7 0E,MF/^GV@1 M.A_]V2S@*4[[BKJZ\X_^-.\:@J]YQ]%KHAO 9ABTX1TT"-")+%+)Y':0;# Y M$%Z5OT*D=4EJG$5<.&FQ@5Y(P;BI))N*GB,.NV$X=LQ837&9/'#K8.RN"MHR MIXIB5:C7J=_\'# /_F#+U1M8.)AUU0.8.I# [:'TJ([Q4C!JEKYH\02B2L%5 MB2S T/_"5?%P,M2'>7[QT%.%P2<**]&3*A/& 8A0(RF,-<>4XV.^[B[*@IEP MO]/,@Q4V=,*9,?LJ6ZAAXR_UT=UQEPEJF]*?N65;R;$G0)' M@HO>TQ2']G@6W-!59T">,TSC0]JC_,RZ:O*"F8_7JY0.20$Y8D92(3@(3,;= MT482;RW]#-M#G@_H:3JAQP*90C9E"1@D^4N-0I[5[CA3%6 * ,G4/NK7#TT MK'NB1/K4V_4!G94^"U,B2FYJ2A@:(+ M.O!QBM.1Q/%E,! 3%:+84>\2\4.Q?/.9YI='4$K]F"3^B[Y2C,#<6#_ILW2! M24R-)(RP9:U EDB3H5Y[,?X;,MQ2%#[*8FU?CV=U=.!X&/1MX.V95PJ0 ZTPK2R5Z1-4I48J/@5ESZ,PN#>,I'I43Z,8V)="M;M"Y3'P M@:A0D7VS;C(;C9,).C+E>-0C B@UD2*;9$I5 \R=\'B&GNQS0'2>6GYC:@&&?3FYB"6I2P?$CEO -D.M55 M,R(METR5Q][@/C#;Z.55"(QLA4 #]F(K!*SD?Z+DSQOCQ6O!:S&B2[G^0/3+ M"E?.<31MK-ONZ13D**[@X:3[45 DB&XBJ](]$V(?U;%SG1SL8>P7'V-[&=( MP:QDZ2+ 8I:.L\P2U$DPTRSU*65=VZDTX1'+!!T/-+H,92QU::84-(J>A9B0 MCCY+SI:40XL?XD]L'.3PYADYS\05-]*[3KJAY83'+)7]6>31'9Q-? M8/05.[[A*W!8):D8XL/Z@FAC=$DR>!%N@5K.2WU M1A[ K#F=LL!F-,C7P)J)M)1XW&IHH1S)W760M>M!0125E$JES/B>=C M7BPZT46VF'354P(+AI!%Q>F?F1ABO!2B J.FE ^;1BO?2W0Z/$#X"IN480'* M;Q%&6)'I?U9G-'"DHK57OWW^_:,1)MAH;(XGVT\ E\#J5]W'1B9^2"$I;K5* M_34"3WIU(Y-WKO*HS9L-;\6 J52C]>GA%:HC(,6K(NRUI9O]X5E5ER91>>JO M1/(9%N#H'))8C#.CM 4\!>TQX?2VMF0:O,M!J>',S)09(_U?=:RKH_.Q'DORFM M*B\B.JYP_X#Z9D 1[8M8S3AV\!%- =#U M\Q4NBS-E ?'5*4_OL$52SO.DU/$BL/1O5&Z<:5D^W.U31(_,S%C,];H7>;&Y MS@W"_-K'#<#J80X?+&^52HPQ.4 D7,G=33$="7T?%8"CN1+DY^"R)-X3Y>D) M.3'P-FMU(,:J:)D^)<.::SV\0(S=]3W;I1?KY:9X:4?B'@,%;:8>5L^:;(!Q 4Q$]H.4Q>LDH$G)9@4)G911]DJ)KC@N[#JMBTT=$ N= B"HHKB+ZGU;-AY)HB ML^?5&U%TAYM9;Z.31BJW6^=E?@VQ"UHAOUMV85%.\YS/$',2K(%_ U4_$^F1 M@?\G*++Z[-8[?M"&K.CUD6UKA.M1MM^7+%NP/,P3*V'?HN6PGFHLS/=!\'#= M0QPQP642@>&P)J11(5<^+6I%ZC\%,[!HK:)UD0TV'!Z%F$>92ORAQPH?!-Z\ MPF^B#%/XJ6G.K(!/&H9!WI)2KRG*<]\V">2A% UK5#UL5!VB4O*X9I91TR+R MT,Q@=T5E-KGI8@QH JT*FU]4JL"/?^'3.,.>+NX(^X3U+@2[B5)R':B:B;R( M1=E>?\<8ZYQA* ^5< KC)%&GH4%@^K1/+:05[PH-ZG@C;I,=ZV#QF"Z#S0VIO9/1M(]B MIM2,0#8Q+@P,D':M>$E'I\(CU5O#Z*"UIE6V2V1BHX[9=![F-AVJ1:UF-;); M'5[BO'=8+9$987VK\1YTR%1A2-P# 69RF5%^JF9[%+F+J86C:$9+83TYID>B M5?GNJN66K)WJXT>N2]23Q_\,55R)$%4D@ZR\*,*((8LX(P@+I8K3?G7MEF@Z M.?<#H;$57RZBAM1M13R[Q$#ZC"]A%]0"*Z^?5.P-'8%"D"^Y8=9C9A(%95C> M1'63RT7929'QE"%*5&-4?8HDEY^HT"H)*A*><&.JZV>ZMC-1OB/+/V.&+L;\ MQQ0FU;+,UHL_KU.@]LX];G!4E8=M/M@C[R2 1%'-P3NE^YE;0_KJ<5\,: WS M2XCT2&I7R/EL_1+FC6\GHO-^\S6DC\3_E'V(+OPLCJ4@5,IZ59;-LO@< EPV MPD9Y*)U]W["DA7?,'KB(Z#\SO.N5'9K/DE?D/%03HSLX/4)W @# 3KEH7JN& MJ#%/I+G!IX!>7Z1#Q#BJ!E5EO^*))?-#,4I[P05;3E)2CS5K]4-S.9S[AI73 M:>S?W,A1#&:LS!#[0KE7;7Z4MX68L;8T$L,/@Z>SU0^Z^F%LJQ\:L!=;_7!$ M=ES@=8+OJ);4V$QF10P4\/\\LSDW"%:9:@CU3-Y0NIJE'F.B4T3@KV$:WD*$WQ M5Q9OD+22#ZCR6+)PYD%TEZB$OY R]G4G#IT3\V"+75.>EE-L5!X P"WC%3DV M>2=:2K3]XX]?&Z%K;-U(;MT&.B;W.%K7UIHP_#%A\1'G&6QL45>HC< R/B_\ MP%\Y'Z,8[#7GC^LKYT/H=0TO*GY6\-M2$F%> *L3VDMW'>*L-S+T F>P3"_98\@X#=5ZV/+>SJ-. 5N3;6Z)_9- M2ZU/!%'AMNHEOU#26Y4%%65A.8 WY\HU#EA?.M.S(++X2&&:^\,))-FZ\B-AU+61% M*4 5Y 2D2O,YDKSTX0$5OJB\BTY8))K +]MMZ395 MRN^ANQSJCBD5IU"]1NH0V@A^O^G$TV+"&<:$LO^?O3=O;AM)]D6_"IZG>T*. M2[&Y2[1F.L*MMF=\HMWVM=PS[_UU @2+(L8@P,8B6?/I7RY5A0((4"1%B0") M<^^X;6*KRLK*S,KEESZ>'BD*@[@J,7< (B\.+X&M-P>Y9V.9NKY")F.+LG[. M.K8,;P"YMR07Z*X?ZMG,BC+'4 &,*=$4-I>"_&?X:9FF7\RDA>PIL_V-.GX] MP_K$5KB%9$Z:/J8OROI'N:'2(,444TT(* ,XH1*!3+%<)L$]W:/(3DL\R*.# M,[@WX N!U[#W!]J2:',ME_"G9]^W\GF9.A^>Q0:,4]4:I'P'"FM.!NI3B*', M_,2?80X5G:M6]07J0(/A4ZV[%#[9D6;QA:2#06867/"T9SNJR4V$R:/_D;#I M*C4?DSH%U75HM)($B];5KZW)M$)NBA806HJ'I:I)O# MQWS*3L=1HF":8 T%^R1YQ$7DP@1.F.[2F&Z:+"T<.XE2D-V%;<16I-KS'SAI M4NUB'2MY3*)2P24"\8*U4<<=JYGBBXXSR.#"8??L1\/#$YD:?\>PR#8M*],# M1%$,3Y;;7K:XXG9]*@YM<[)P./I1&"61,Y![<"KL*?6-RW0=EI$2[L&M6)Z5 M4&K!87HB^NVSX]91SO042MIM]4[5##PUV'3R#Y9=H/L;NW5-L=%@),XG#^?X M7SH$P;;F7A2!17W#99@TG:F9'G1OZS,DD\54QS#<7Q-E2("Q$=YF6IV;>7KZ MT%@45$IM:75R0K!"3\0,!ROG)R''TJ-LY@,%[T7YK;JEN;%9&*(LGE0X*2&&_E7'G1V6(K72XE*]*7W$+MD%,<7?U#MN:H=E?EJ_(N>4K7 U4?4\< MDSDJ1S%9>.C4-A8=V\_@L0H+@OAHP4TH?=8Y:"'2&IL"E9/ MLM]?)F&$42Y*QR+&+&0K.?@TYSZ7MO::EO?QS=K*!,EDN!\YL'A?27E@"NA%];*VW^"[?L=SO"J+5B4\2#15>U!2K<*$HF8KUKN M0(YD!/[_DPUI'(*NQ5J' (0?./)MD5-ZA:BI]X6V'.X-M:.GL$<=H9WLJD+9 M1(15A2A&G8FL^:,OOJ6M\R!/4UX8L>:9"D>BUBJ#)6LN_X#/L:^!]CL.DK>0U)RT=I,(RA M(R/NJPWSX:)1E2&.'4.49D9O'W^%)C07:TK#A?6'3U42-[(^W/#UKNJWK(F" M)S##EH!OFC93JB_M;"^%M5GB&00,+>8\&%$8^)P47#HAM.4D"@^^H5H2Z,/_ M_72C8S+_%%R#>/,0@2%Y2,G$;OJW0#*2NVU=-@D-[J'->29Z[J$?"P^[9: M]#@H+?1FS)F_OMR9AFU;8>OIH-Q4L"&-?DIX#N;T2->,VK*#4GILC0!3'0Z@ MJ?^8I^<6M8Q;VI@5C![/91)+N,7,62UWROQ*O4VNX40HJU259?C!2/52>$5P M5D1W*M5D"DSCEWZW3V1XS9O&#V'DRS"+A58][JZ5,6A6C$!Z(;F+7^798 M6"0^#,TPED3.(]4D*DK#ZDT]AZ[GN&CJ.2HPEJ:>XX!Z,JOK4'Q0&89"S&CE M8FSY5A&4NL'JR\RO*G)Z$?+CV;*_PFXI8 ?A;!72Z>ER_# MH#2Q-H4H;9WT*"%7#64*NEG'3EH6@N_]'L3"ZO9VMV,FMO/M-L0LYW.Y5#/Z MOROYK]X _]_S&CB'9'L=1H;5+/!?G1Y/_O-JJ?-_B?!.'#B6 M5=1/T@QF_"/$//B/KD3I_@7K<.A?W/2:ZG="@8V4$7Y/;B3.X='0E#HX8+HV M=%Z%D>!#>5[BGHKCQ<+$6%G)<5%US045%Y@W%WC32AP?MDW7"J)8(27=), = MKD=XJ8=-ULIE:\DR9TZ<*%E;$U2($7JXE(!S,B0HEQ$%7^+$=?$!Z.^IPL2F MD&6+FWK'-H4R06YGPJ;$':Y.*">GCR[+5BE AIC C%Z&2:ZJ^[R"T26+$_33 MXA$WRJQ:9+"KF4-I0/<3B#8V5%W)6K),3%),4V[1Z$9IW14AHKC8 M2XK15KD> A=LFH1:5*1O)L8TLB9DVABEVH$490,YBXEL_J4574!$XA+6>C(GE-"3(KWNP\[]-* M9(I.+!7YTL]F"X^R18!KP&/90130QK$-\;2R< M;J>%:*A2R:#@['8MW $)7-&]#5&V(4B RR=K&K]JPXA'J*7+0EPE(IEPM)X9B2];+N-]:T:?"/JTRDFDT3FVFV MUY_^]>'7\^X8W@W[>0$L2MZ<% W6>%85Q>L>?38U44K [)K0L9/:4'YI_T\; M!,Z#'WC350@%@DU# R/2@/MFO:A)<"J3G0C9T0]II?Q2W2YE]_:R=<]\^$BI ME36=C&HA.>A(=Q=,_2?ZXX&?VCEW0G7S MR/J_[-3374#]CHP2>5+8: %*[-%JR9%J!.E:U2+*89,W2]*,&Q+ICU,K!)VP M72W"5#$OP,XV! IU#\D699FRB%)HMQ6D:36$5/[LW3+T9^X2UOAB<62FA'!B M1RXY<0."(U\M<8KM;X+A(AA#C=JO5%MI'%0,:(^$:MPMK4)M7IJ.VR=9'2]Y M=MNZP+ NI[F:]5-K#GSIQU5,),U,,/K^*L!'-YM?V+TDG]1T&N)B)VKQ[73Q M2QH*:J@.$HS@OYY#[AAL<8_!M-1.GCL?@M[K=J/?0,G.ES?H]Z0;BYNH:BTL1@+M[ MX_Y0+><4BOD*'RO!P#N0@N;YENXZ%P,/XI1D@XYWVZ>^!H11(L,#/L7)(KY! M51VB\XK;$Z=A5H9NP?9<$4L$%V&VL,K5[#LC#33EC%'^*14W04%P&^3#"0[8 MX*$[Q=Q)C JWTIR30IS\5"(@[(CT/H% "<+Z&#-'8KJ\5POU+CUMM".LF6(@\M^5!3 M$@6PL(O*1/ABYJI3<0Z[R)ZB2YA0P1#I -87+ 4A<82H'%:^QGQN&7!+9>JA MB49#$78FA[,C43I_>G-.'I#U@Z!B660=@D'%7#80FNZ?B3"ZIX0"+ 6)9A/G ML%,E@[XM2!#YG$D0^T_1 M05&;#_O4I5LN!*7K<% V'RW>-E1<0WN Q G*N>QJF4HOPEL*LBI*EJ_%MX%V MTE"SN)2DD945*!,QZ+M&8)PZA- G'WQX*F;0AG-X*WU0)8YF3&,S)1.8XUPC MN;4ER^2S.#%7$U=L#E0 5I F^P*2G,ZDQA=:2I#)Z "8Z#:QLS2%*3H@I3+ MIB"E F-I"E(J)7]ORGSWJPO32 ,V^#3V027@>+20*6-PJ^QHE=32>VD;74O5S- M6@*!^/OG+Q^Q%NZ;\@QSQK_,_="[,9,RKXZ1S UX[@6)&1$C9$4N'941L99\ MQ[[!48[!/$[*72!-\<2'#,F)/)@?BOYDRB!.?V:/,)Z>C&H"FE5D9*5PII$Y M*2RUOP<[&6]7!UT5"@;9[D=X+IP\Z*0JRDW-CD]B8'-IY$(.!>>IIV='VG-O M] O0=3BJN%*-0R8?XT%Z*O.9>$2A8,>P!4=*U\%R'$(=@$\9(S+. .D 8N4R MER8[G=[L'&ECL&^B.=KV=%21H.2E4.(Z'H*MO@M(JZ9CKY2KI:?GB/L/:+@7 MF8AE\$+>X;(*)0U#^;<(4S1QCX[ MZR<1,)F/XH)] ,ER+CSEV.#4M\@XZCQNB9@9XJT-TL-;^TKV;ORHA_"C4JBP MT9+5U))O(Q6CPMT]":B]":8%58M&ICL3LV1#,0>-A:+\LVY2;J23TF2-EHHU6[<-8'4#]IS!*$ 4U-8 MU#E]]ZBB3:22$;,"U&?,TO:B*C,Y M#HH[K/I85]O795JYG),]I3VKH7!CU+ Z1I&)&62"JBH,RR"N3[&JPP 3*L#$ M ,M9-KM0I#@S.E?SNE&?Z96$"4+\]^ /I%T<(U7Q&0K"R&(QL-6]I?9&*V,W M LL48\A!:MMC1RF,06Z4<:@GKR!>=9&2;+4+!EKMT M@6TW8?DU:GJVR=!*D (/;^ADDV/GV,%#KN&AD0>::QJ)^BT5%W**-8P>?9BM M]CI*N6DB,.(J2RSH;*U#@,]Q[MBIY/3E3BH'ZSO)!^?W<=^,PB (_"+6)H!* 8-5U_H_T00$3@ A@ MCU)Y[[\VAZ=4UD+&(4:&AWPFH]D1T9O#IYE3.UB5-12MV+V+Q+M%5_ MSF*1F<52SL+H!PN&82AF M(N3\-=.0LG4:U)=\"\6<:ZJ$5GIKFPW/"E/J6EDL?TY\ N5-:# $!L/M,]$. M,H8.5BMZ-CR7\F<9G%>92^8,\V IKDR21C]^A/N;\UVVV>+KMFFKU$;1!HQA M*C562UW$P@<-V/()S.!?I)"_,GGP&OE)U>V$UGMQ:('!^$$@OR6ZEZ>Q)1XWV[L#N24D MAI$ZZB4+#.DYCEC&*N,% M_9;'Y17?7?*DM:QF#&W'E->[RYD':(8V*_#,8@V=N)GZ MJ\ WJA1D\CX:G(7+U*S/LZZ/2G;A/!P,!=Q1,I'MQU@6Q[(M_3>>'50!6KI2 M#*O4K-1+["1;ET5F3Z0MR[,GPF-8" .'RL0E:!;H91,Y5 M*/)-9//X"N*Z5WA@^BGMY[WMH;]9F0U6AI(.[UW8(I%[ZQ,,.=5"N6:AO2/# MFU/"4%#GXW)OS.D5*8V;(J4*C*4I4CI@$0WZ[HVJ;31 08[0(2+GI3.MGY:% M!W<0-PS+2868'%_'AU81%R).N6X"_/MSE1^07Z1WEHVT"'$^@(!"1!G\UI8! M3JJ+KE=BI_(NSE)REVE.7ZZ,G O7L#<3 ^ O[0==]ZWT7!I51WE?&+MV0G=BU%0P,=6NSX; /ML/:63. TW_DT14K8C1,Q D2&6< M1)!-G33'(7?Z%!Z$D7/YMG2VVP5MLA2*?<&2+-7 ="DE]]&J5EK%KV+"93:_ MN2!UI^BS/D]I2I!L$G3I!G:8Q[+V[6TH9#Q4+4J:-WUX0"5.O51GNA;K&B-* MFO*4EI EZD?"AJ%<1SP>RIE S KM6X9MHYJSN;YYC*30*C%>3A:KO:C4CN[; M _LL\1EEVGR-'CHW$&*8:7Z[PH6<8%,KK>5'#_ M'=B&MH3.=F-3/$\#)Z$[9;9S9&A=N5FGF9#W'(IS?=9,]"L& M3G72>VK<2;*2=OA/XG-V+2&4"QP*I?+Z(L8\L*6 _<3FI/UT"B3M'\S0GYHI__G$_#R>WFN=0.ZYWP37VYHZ?B(* MOY %X918@1)$%-$I95*GM(_3Z=)9..3&% \RO1\($"=,%3T)E(PV!:"Z5\#4<1PH#$TB\-S&06 M@7DF(*A1Y%7NO538IP;5J6BL"'N5*KQ4] W3!-3=A0"-@0*T7$&@TD<]&N)J M]T^SS$./8G6@6-.?0=PL'D9A6]3<%W%C357Y6;;.I(A"!FGO[-P1+_V6PZZS MZO/5^[(=G+H6,L)+8I"I6$6V=QO">7%>MHU]6.ZQALBQIX*,D1#!O^#,J+8H M00Z2C31CKH4U_47$]RC4\#KVEX3+W?'XDN%$5K 4\2Z>G)B>VW<,CHQ24 A?)?9CMG*VYQXL^,.2H>MXZ>>!)RBGB>YN M,P[NRG>UC8;M9O&5TX)EO\7" M.,?T&?A^]&#=V?[T@Z^#H)O\$?BQR#1 M/WC A($K18X]#9;$+ZN3,>F!&@FH5H/ME!$.Z8E1;BPMAZF_,;OV45F2-Q6? MR @1PZ5:H/;0IRK68=+V.WJU<$%_=3D/@$- '@R-%BM=1S89C4$[$D[6$!.]EEK)%"G#"X#+().1_Q<$CN,([&J,@UW-N2F$I9QY!-KWU0+[55Z+>E1J5_ MR<8C*0@3LPE$!@'N[1DW\F4+^P^8 8(0L0UZ R9F+%3Z! P'A\*UIIC(X&9X M,8NP&3-GJAA"0*E7?_-I8*Q6OPCFA/5[F[%2-]U30<+/<70\11^DJ0Q(X)58M5Y9H4F0J-?0-$1^"-W^&(:'5[NHU= M=SR^H!5!)W1KM342M*;:_B4$HE[4*SZA'9)HU---ND$A?U=TZ6R#&=/4+Z.8 MGHY%X3$L/5YZKCJII<7JCQ)LW1WJU&A^G1U+LAT0$S?A[D8,.@QOE*#(( 3Z M/RJYDU7!)PMAI6TCO[DM7(M?"9_]@>8T'>9&N59?X03LFAD MY: &Q[G^_.'\#VU;&;YQBIA@GF"BH)>-EF[HQ,4T1$QVDFE[;%EE?&.H!L&F MH$]@/I3-!DDA:13R&D.=]G]DL Z9MJ#S.[&*2]P)^1JYHO>YI W#ZY N- OQ M*DFXDA#91AF0ZU(%LWF0U4J#M(XQ#Y*1;5F:/RX@V+V^]&S8HC[N130=,\F0 M[);+VD-KA+':_FF:D9$;E,I6A56I4[&*3"Y._WZ=&2YVHAVG;2&X.A 6HT=+JN\\ M$]\1%T+[6\\#'R2L3$Z#0]OK[1:HB$:R72Z/UL>P%4%X@BJ;NTLFC7'-;!:7 M;RMI4,27W26SB*G&Y[!I91 8>+4K7M#'Y()2/;HFF300=>J%W^ $1A)_";8( M\!EZB=E^Y/P;?2XSN]MFF>+*T@7M!C-C^FI(# A'P@G%5-!.O:/5N$).YD19 M/FFBW/."*.$$U_2\)A6]2E&$!QF^@/4 7]4>!L/W"M3R/.'#<%_PB;N7E_-%FZ4\>! M%B&J&"V]U6?DV%J,4%[\_I5WD](HQAE/WZQPTG.F;VG#LN]V0GPS+U[K9>>NQW#<9YR M$)9"P(3PS9)#RI XM.M5V_WA.O\TBAZV.U!))IA*5_B&EJIQF+HF M8B [CDP\GRIQ5H]9;@M9<58_Q*4!Y\5FEF[,,,^;W"LI?H1O<]>_ M0* M4XQ]SV/3/0'*ST?K>(^NP0% 6I\ROU'/AXS1!5A0YT0-"M>@A>2?:Y[< MH"\XMMD26MJ$HCRU>P7FWJQ!6UU..A>ZW]6KSZY!ALT0DMG&)-8HLIUY@KY& MN!7%Y_]@2LA#R_HCMN?\R_^'@4%\BTK(>[U!UM32CC@]&!C&&'U;]EG7GGV5 M=Z9VM_H@#R#S64PJ$0LPS93\,;,U\_T]T"$AO9,V'-U .OU7R3Q.%\+A8R=W M&&D\O['9@99LJ@D_>Z4JR H(] \!@B8^T7T0IG''/57"16S@9\GVH6,EB]< M>X$"5MBPFB)DBT1%O%LJKL&>GC37(Z]Z(HO09@4ZZF(7CO.XTRR6J+I_52K M \=)MFK$4U:,H.NS3(E54WVZ$VXYES.'9AUM/*#'O= MPDUG\:@,GA;FO*!U)QO5&=]IF=DMJE2_Z),:CL-TK&A9I)H?KD]ESU95Z/ ; M3E4FV)]4P3_('CI7,7T-?+"]Y]GG!_N4C/NJ;-"J.G=+O;F_9=T$'\Q:;[@& M=[R])8GQ61:ZK+0:/BR*REMI13SF?4U;3U&R7&%]5J;0G7K#TT&2MUNN.R$L@BX\&H]]OOH.!I./NR'D5[;UVIW_C14C^. MS1C5?MDR./L^RL_$(][*SV/%]T##Y"+9.2D4,P=,9F:6$:6PM:G4 DJ8&=(_ M4U.5$_DI_!0EAI?,?*AK^UG&4/ON#@_W74N7G=_)S]U%>GU,D59TL>4:U M:;LKC%_,-H51!^;P+.@(>S9)!'*E'UH:,T]J2M2P7N#?4D\ZU5[7C27N$O4X MAM?I- ,CF[U13+LJ)EEC\HXL !) *UR)2DG*L7=2CE5#]WRAHLMH!2^',D%Y M7B*=%]I)E(N0PO!0M@Q\D#-J%Y@U@JF8&=&MD@I"^3&9J$^Y#S=)>"M =/V# M?8+LW-0J)A3RXMJHY!? M_O7AU_/N6$)JJC;39)?;2\Z?AX M9L+MS6%)UYN&PM^H[,4\6OJWA"@?.2[NL!E,'?N:4C=YF?J& 5RZ=Y9@/E'A MK3JM2]*--Z?!H.+[DJ/@ZJR;YC3+9HKJH_Z*[R ]UE>?A:NJ,3FAZK=LO5(F M4>J#++J[.W1#P0_9! CR@,K-E3.A6QJA4B/+NNDL2(QW&XK28-*/#%YTPQJ%))K!D9^'YVF0D07B&"- M45,C"X;$<@:;E^MG%YP :SA\^4!HD_AT,WY J9@W'KF6.\9/\KB&9P>,4""F MAOE/Y9O2/_"+\8!'_5)0*OOXLU.$Z)8N34JA\Y0V>;JLIN6S778C@#.E$T#A M('V&V]RI$0G/%@M1Z2FZ+*QW&HSP4TC%FW.2DK?6IYM_OF5[:8J\'"Q5JLE" M@,6"@(GI '6O;68HNM.CF#]R%-SF!0^Z+(P3NI5W6//U':R2A(+EA1#4!C#+ MHU+-8WDX*4%*,7*C]*V/P-O@@^C5891;=@C:\3JD++7"E'4EO;'JMUP3*3KG M<\$YI^?BV1(6B_T!IH-6 SB[84&U:D)57[ 0;AU2NK/(AS MMM_5><-4U%B8 M+B,P,1F+-;@=P.\4T*8RIVS>A[/GF56V(:,:@.Y1O%K=&54I6,%@RIL M=T V^XM%>1Y7%.#:B;37V^I5&2^9 &=AO:"Y5&1C4"QEZ?)>P#P)-9)O*P M4GI@U$&H7;\^9]&H8>=^6=D"@E3";?(&[H.&'8?^RR/@\A!";(N!/K+JISR- MS7@F/8WPZNJ71!*C#ZO_L&H_?&"RQL*9^X2BQK46LR24:CQ'A]::I/C5FB06 M^06)BC>YW#!5;FB(:UQU"O3Q,NKHD8YXD>6N.!%/!?Y4!R;P=702?Y!UBFC2 MHOMLEGC5W^/KCPOWH&9AYU-Q2LOD])T";Q11+(^[G9&C #Z6!B);5K*<"V_Z M.KM9,P@!# P@,+NJE7;XR\ &9 K+5'?:TC.T.OCD+4:9147QXQJ')9M$+YWH MU6L2O2HPEB;1ZX#R_W22%"JOBJOJ/,KYBEX0^0 MI\K9.=]"(:..W5R[$'3RA+;/F-&J!QGO<=.E\X8JG+2G6B9/6%_)68!P8MPO M)0MN9F";Z8.[=0U'@PRA0=G_*A94YZ.@.S[\JA^$\\Y]6W(OA6..CK:'@B&VY-[' M+^C[\/UD:KO"[)\0S&:N(T(M=^;L>Y@\\/ADO;3$IR(QP^]1L"%4P(Z^>N.5 MH?)7".L,^X1)X 9N1H FI!.Z2S,75:X/EY9GS_S4-LJFJ@59-6!(-!SBZRNN M24O#03".,/5&O?L.9BYRER%%T'_O3.!I&S#,"\-_:LVF@:WV#=JF8WJ@8J4& Q0(L[U^&: M=IF7EW7A\*Q68=VR;&5V/5E)@4!GG*FR_-TUNR>Q(DIMVO>(668\FZ_1 M5V*4CN@YN4M-+[ /DP.F!2$"T<$*&SZ0!]E>+F6[-1Z(R(J5U'6PQ!HDEZ)J M#*62$#HWYN3(.D-Y7?9^PU<2#@-"Z5O$&:XP(VC+!S+[PGVA?AF_?;;=:7CO,4UUZH>_X8DM"[+ M1TW[[OQ?.)D*3>'QRFUVQXEL!H;&T61?KT01)1QO3JC..NL*LOF_ *LC$QD0 M)/)9G>5'7*]1O%W/XXB*[F&XVH9)HVB2V\Y//8HZ@B;\.S<,R!9:<7.H= C\ M2:YAQ&MHJS4LR=+=SE2G$3XKBGB%&*P$&-C#+)]8FH\%>7<5FD&)8U'.(%8S M6'%((S;?^G8%:90PY9M6>=9.QL9'[LT, 3]']4P4:$1QO*+$U'8T8?577=^/ M>=FUQ:=;3V']B3]5((CT:!)C$$^J$80C?LB^&'ZB?E&KP BJ]Q%C;P@NFP6= M+:$B!>:9L#N418!]%[CJ[.ZI BVTGS&NZ7!#2(3/9QL'. D6@@6,[#L*5Y% M9CB[9.KY69*10N."U;A>0]06M_C25?AA!MJ2II?XW_S@'JGKAE,-Q Q?2'PI MOK#:+)5>4>Z3TP1!5B%WO$\'M,2+5"]&X0,M, M38_83#3?0WU9O@EM)MNJZ:F)9ZI3U\T>%5=I9QVS.V"0R6+)!#A)B*#UF2I5 M*237Z;]"SQRW"-'.N?WZUU(7859J;R:MKQ@3.1(RGPV.UL#?ZFB=1: MDCT8 M@*-$B11XA(6^9"Q=7&8 C*SNK-!@2UGV 22=5LET3184F4]C5+ MY84DFZ)E"N'W^&8DHXT1J1]8MPMOB9%$1/J7P!LZ[-U2X-/K1J&C[732#7 M0FX(!<"^T; P4BM09A->? @'85EB*&.=02QM5%VJ"E)_A8#O3I_X!J[F?JX7)]!OU;?QKS! M!DOLPPF#962=*7@75JK3D#JT@_X3(!R#!4)GIX!#.J4 <80Q4YWZ,J)[UT<@ M*Z/&*I.4QMBH,I&+.O6E_:GEZ3Z3*M)*/\Y,"A/6ZF)!G?JF29JC!GMU-B/1 M;'9CX"=!-H7)4JL:#9A]*P+<'3'V+*2:9V$L0N9RG9/2!L$*HTC0"02W$48C%T5E"M\('Y&4&*;^L '!N4[PXY_,CNSK M,82WCH:'P)7JG!=Q!E7*EP@$IMD2S3[,*V'+UE +9-)I>%/3CL,+I;8<>LC@ M,)#I]66G'+WF+9;+*TBD9JJA5-)?6KC/)"%5F9FFVIH:5;E@N*^N2<'-; MUL1)517>JUF4J<])?'QV(KJ:S%G:Q%J: M@,#7>6&7/04CKY'92T\J <*[8L6AK+>(M3(08Z-[PIX5#HSG4":!2@$ M4^1Y)4^5W)"TQ<_Q<#G*9"ZMVDOI2J:B=,7$I>A$MN&<;61,$HE9&[',T!8@ M4BV/%VU'Z7Z5HTN;*]+I'3/_S@E?.R.*IL*\"XL;$Y +$\\LUZ=C0Y-MM)IM MU&^RC2HPEB;;Z( :,".N="&+@?"O\G.5H)% HVQ73DU1FGE55A;'QA.&VLBK M)]U/1[W*IMS>>[1PR0U*EC\8*3*D*G."\:11?5OCZZKZ,!+ =0<\]B:Z4:9X MA;%6RL3N9L/_AT,@YS7\S+'YV,D;*IG!SU2>I MHH8KI>9YH26^N=V]XG NM+]KP*]%-IDJ*7N0/1]LAJ6( \LT63)F4^[\E3]P MR7*1B'L*7L9IB5@.!15&^4B]/X\@>,[AB7,PC+. M+>>6X9*QU(:(G#D()D\% [B9M+I.$50L!J9R+2XC(R^7+I^5R>]PD$^B@BYR MMLG."]M;/-ZTWBM7^RB3 MY"66&"6TN)@4 P-[D$]1D(**M(SF8^K]'";P9#MOW?S#Z.EE+JQYKF:G=F:9 M36%$S"-L>J_IYY!JPJS(NC*R^ ,L6Q$:IQ#W6UKBM%#CD-KIL:,%"XI">@=) MC'M!@<+@:+488+!#/DW(%]W;&)\IZ!UH%/(9X-_D]M$'H-3_4Q"H0)F:\DXD M00-5$9[Q+-%!+I0!K#/EKF'$"JK'5TS5(YJ6JGGIW)Z:@?TTY(LRTJQ1U:$8 MM@_2DW^5Q%FQ:Q9>)G-U;C#"5J'QEE9=(QL%Z.RGNM0 &YU0LR.Y(*TU>';9 M;%J*K^MSOG384R,^>6;%Z(RF#T<@<=># D6N3R:[+USBF\]F 5?LO4@RBH) M1TKQ!GD.31\%_ED$*C]=?@F_@U@&=[E0@W$=WX4AN=2;F^L8C ZS]/LR#&U^ MUG54XR/EUXCM[^?2--'E6Z_\ZJ NU0^=T@K/09., [# MV)?1G3U(AOOY;Y/PIY]W_WZ_Z/LKW'TE?XF#Y9O1NN'LC_^[FW6I$.:-7.-(8].15! M4H+]$&+EK='I5,;KE>@349K7QZYSV47UT_4'BR6V0Y/V'!.0[&4DWJB_ M7(%)MO3LAS>N3\2CAZY6F9+*-^'T)C]"W^/+J>NKW6'W5QS"_Z;JR_)RFR[] M%$]7K_4[[7Z_5WJYT^Z67EOWVG&[=UE^==U;UU\;C\;-6/<^UFY[T+FLR5CK M1-?G&^M@H[?^1-* )0(('11G?W_5?Y4SD-YTK"[I"/6^]-;T7BG#I%2"^RU* MM[*4%E'OZBV_X]M6A6)>BO&;7MY6Z*PW>/9!MNXP3S94%76GV7NI,7]'#/Z/ MI^I0Y5&Y)W0T8MH #6N%9J_F>(^XCY M;'!.?+TO'JK'TB.XU;/OFF.E7*>AW"Z4NZ:$C:?0[D0)UVS69K-68+,^HODG MMO.-@;K.Y2 =1XC9[.KQ[5PM8V'%L40$^5W$.CR29ZG]4*!C58L.Q8SQPS-- MWIPT><\K->ON1:MW,3Q0'E(GS4-Z'N+CI2T789T4W'TP>1E[G!NK>(&/?6,5 MSQHVUK#7.TGFUF_O[4N'%C)Z]=;\K-L>K)RW#[;8AZ# CYL8I8T8;>R336<] M;(T;\Z0Q3QKS9,^S'K7ZW?Y)\O;I6B?#QCIYDMMG1O]7*^?..P,PI-0T6[<1 M"N9<.78O"8+U6Z->9W.&+U[=9Y5AN4_N)*GJL$ E\JC?&@^/8X&J\HZZ,TK) M3NZV>MW+HV"4NB]0F=^C->A<',4"[?J.TXXA?5'E-0@BB""D:\R.XSQ;-CX; MP_4-EM>P<=HT3IO&:;/GF%*_-;PX\9A2#=]^G!NST7CIK >MB^%%H_ :A=M :=T8GR=O/^'9Y5%6OE00?TPU;'H6?:5[-VYNW-V\_YK?OZBZKEU,L M+9G?5GM5V4#9D^%?23.D>&X78(9TZV?>'\#0V=54KS*_[\D@KR2_%\_MHC7J MC&O/<]LD^M0PZ-9O7QYDB0Z?N-/(I!/4P;W6Q;#?Z. 3Y??3T\' [Y>-#JZX M#C[KMOM;I]367O\^=YY"YO3OGS]:;PGDD*"*/\1B M<7(9U,,MA%N%<_KJOCIE]NAEK]O+-^VH\3)5Y1UU9Y>2S=SK-INY JO3;.9G MR:,NH@'1/F]CT+]=?XJ@Q.?C54#@@[*!:K5##7"%[/4RXZSU(=G M9ZND#F>NDF!,K_$"-2?RTM#%CD7-55RAJKRC[IQ2XE >-W*DX8[2Z-K@>%9H MUW><@IM'=]A2/7]V-ZF:TT=E3A_'N4R#[O&L4%7><9R7KJ]:B&Y4\UE^+'N:\:"\7<5Y>-A7):%LI9K]UK,)A74LG5 M(.2=HP:+HGE[\_;F[4>)13%U[PX/2&$M[/#6]2/K6>SZ8?MRN,&0KI9!Y&(B MXYM0>';LWHDK7+3S?KL[+,C,M".!;\"RJU2'$C6/+BFEI!G.1?OTDI8.0>AG MJ3<_&N8L9H[AJ+UM?D(=&.0% 0GVI'RJ1ZUN^]):+IL]U0C\JA*Z$?@["?P& M@:81^,4"OYL7^+LF$\O#'$\G?Y[;?_[/P0YG9A+0"1_.]K?JE9.B)2K^LEVG M[)^][LIJ"?Y]6@;[(=-3TF&/<0>5VB'; B4=,1?OTWQY9BX^B/:OWMH4&$L5 M6: 3%3.-HJZVB&L4==5W4(FBOF@/&RYN%'5=%76G/2ST:OP4VQ-/J.,N_*$& MQL=X110\-X4-[,M)UU;6RZUL/]KW7*L_3& M-VX,R^5L0,??X1?K(]PVCZQW/L[Y1BQCL9B(D(5SO].R>IU>U[H.%DL@Z=2Z M=^.YM>ESG/S$(KIK-L>_/@:+B?"6H8NS!4&CH]ZP;T(K6CN M+@E(\B[PDH6PSG[HMH;]L7H<'@12QZ[MP4/!;!;!$($5YS!J>!C>YX"4I(=Z MEP/]4#DWROD.D ]7=_N].XWG4JB93\F5Z:2/V!,0UDE<_H@AL!V8G@@/M*:C M0<[I:/PYU_F%2_M6G$]@^;Z=VS,8[!O;N["D*"_WH *%B'+Y;_9E1F+-0_%[.^O_N+VQD,Q',TFW=%L/)C:8BQL MQQGUN\YP-!V,1L[_7KSZ^2NJ392PU_!!8)[H;S_9/Q_HB-5+CUBK?Q:Q5@7E M6B:_"P2:%E/C7BJF^NW+0C%5)&HN^H9\*@+$A:^PJCC[89C>2\JV&%A%/M"! M!P;=1X1?F> <]\QAJ7'#_Q+?!>-2Q+$GZ EG#@L#Y"4T/;X-YOM-Q##!%E@# ML,_=*&8>IIO )!!V"-K ":(X@D_U+C:0M559_DP$R5C^[MC04KWV:(/EWV)! MGG,%CL#:^@H"<2=S:^,'3\C>ZO;FEOC7O#;:VMX47'>"0S\$A^9QD& MBP#9%R6MVZBGECX48]4\KWMEBX_:U4#3=)J3Q?\3(3]6\4[?Z5TNZ+B&W7LV[FZ'_X M(J+$BZ.5J1V&6;[.A34+/%@&W$?DI[*B9($<\5_X2@R7HT7P3= %6*9IXL"6 MB<0MS3'/*, =LR"$03GBS6-KERIB^55UQ"17(,S?LY>1>*/^ MNEI5\SGG%)U$^')Z3&MW^*@FLXWDE^7E-EW*.9[Y6K_3[O=[I9<[[6[IM76O M';=[E^57U[UU_;7Q:-R,=>]C[;8'GNLC^8>/QT",(,B: M6,C%<2 75FI'AR I[)GWSS'2KE. M0[E=*'<]M_U;\13:G2CAFLW:;-:7IAS[OPNV[&GC"%^[MW8HXEA$;W;*(GLZ MG%/S]N;MS=NK^_8CZ>BR>0S64!=E?WZT0P_(&!QMSY=B'3KJM[J].K72*V;% M2K0]J#N'%*_/Z*)U.>XTJU3M53J[:'=>NK%O[0HCCIXW2DZ8W59_=-G(^(9# M2B&(!ZW><%L4EV:57EK&=[OM\>D)^9<&YCR<@"S[\U/,R55BX2:+$^OS#>>3 MRSH57%>X 6S=&:2D16]K,-ZQWTNS2"^FNL;;'$\:?+CCY(UB"=]M=09U\D U MPN.%UZ?;ZO4/@RG<+-(6AY-A>W!Z(OY(0BE/.)S\ZD8.3# ^L<#)L-5I?&J- MMV9-W*35Z^R(<]0LTLMIKTYC5+UJB[;<>0 MTUOS&J[L6;>W39[=ZQXW)@01]/LO%)OK_X(F[=7B#.. M)!^8WKBOZL5?/)BU]5=[L;RR/KK>],22A+NM_G!4OZ-#DYWTY%LTC5 M7J1^>]M@VK&8[@U_;"+E![U!(^,;]BA;G\'H,'WHFR7:I@RDR1$^P1QA*F \ MM03A&NFJ)BGIA=>GJ;6O^ *=]2_:P]/+&FN88R-W4R/:&^8H]6(T"U3M!3H; MC=H7IR?:FX1@F1#<) ,;7O%1G739Z67?U)3=2H,PO6TK(D]OR6NXL+WV86)K MAU>JE>*F:LIL):&CBZ9$Y0CUTMFX?=F$F[9,Y5/]#-O# M+ \=TSEPM=GM4X)3>R%/]2D.O>-DYI+B MU,O6N+LM=FC#4'MEJ!JRS=G%-F;%]F2HI=5Q1"Q94QE76E8[N*C34;J1KPTS MESH:+UN=77L1-0QUN@I[NX+@$]'8Y"?X*<9C,/QWZM[]_#?X0XUI88>WKJ]F M#W._DK\@UPV)N?8ZA?%C,^CA#'X/8O'&2CN<6M'<72Z$'UMW@9:"!Z#,7O]RD=5@O?A26U?K?CO_[ELM>]N#HD MX:YH+ H;6G/;_=P%=I.;M%JT_8TH^1$(:T>N4J19KKN8AB$; M U#YD8!OP_2!Q.$#/3AYL#[/X8>E]3& ^R/KUR1^L-Z'0E@??*?=LOS %U8P MXRW2@K>#,G:GB>UY#Q:,#+X&\MNR;V]#<6O' NZ +\!?0A>F!I_%JZM^;2L2 MMR@OVEKU/ZKH7]XXH:7]"N.?!9X7W(-599%9 LII <.#ET0&EJ,%_[%=#U0_ M_& M@2^#$+[NB#>/S3$U7>3KI07(AAY,U+.7D7BC_G(%W+#T[(N M5@VCG(E')B!?OKIWI_$17Y:7VW0I9Y?RM7ZGW>_W2B]WVMW2 M:^M>.V[W+LNOKGOK^FOCT;@9Z]['VFT/.IA!AI9R67UC"WZ"$WR:V_2C%NL,\Q5:=*/4CUWNP#U#] M_PY7P+SPXWEDO?.G8FK=B&4L%A,X]_4[K4W\]9L0Y42I^W6.QMJ&Y'UJS>^S M8#+5C_:]3J^[AS#3COQ\F[[M^)9R-_0 MOI$IC4PY?EIO(E-.NP@P]1[NAA/[]#SKYNW-VYNW5_?M1P+5M'E\9P/PIGSP M^NA@ DH*T/KM.G4E+V;$:F6E%!.Z0:#9H6"MUSX,A-3ATY8:!MF$9IWVH,&A MJ80,TBB8_4F/RUZW=W4X)7,D;4">BJJK$GI/K.-' MK]VOD>YL@,9?>'V /9HEJO82[:9 FF5J!&W#'M79Q8V@K?P2'5S0'DE0Y0F6 MNJJ#.K$02K]=0^"!Q@'Z8CZFK?N]-4OTPDMTUGGY+AC-\FPA8.O4$:]ACQ=> MG_Z!@L3-$FTC8+?HB%?KQ5#P\LO8.%TMP9AKP587\-)+VQ= M7+;'C751Y15J)'*U]E&I=;%CT.XX>;FQ+NK+R]OY3ZI@73SB>%&88P@'M]X@ M:>ZLYYT- YSXG0T#G/B=#0.<^)WUA5[_8F*OAB)*O#@BY%P#GQ4O3>Q(3*W MMZ9V;%NS,%A8'[Y\^.FC[=NW@@#;;QQ7^(ZPWD91X+AVC.BYC(1K6W$(IAO" MP,)0[URX*9[;L95$^'(KLA=+CZ!RHS@()>JU R:7[?K6_3SP1&0CN*M$AH\0 M''<9!O\13FP!(;^)6 X?GYN*I>NH'^)0^-.H;5E?YVZ4?AL' _^$ET8*AG<6 M!-.6-0V3VQ:\,XJLA0B=.;S0A:=@(D[@WPF?)MC2.,#P "++ACQN'K:73/ # M4P%_A?<(_#H"S@54VY&Y @/R/"1*2NI6%@L7!JWIGDZ?B*_I$A(]^#'ZQQPL MY-LYS>J&QO55$?^M;WL/9,C"LB\#L&GAQYN'*!8+ZPRS"GN=JYNO;[_';LWHD41Q>Q,XVG MY![II(_8$[#7D[C\D140GY<_N=!^&@VSM##_G(=J-$O8+N>34-C?SNT9#/:- M[=W;#]&KG[(2 X2#2<#\W$MG.)L]VPSY6#053A#:M#)P#A,AW@5CLBLS%FL> MBMG?7_W%[8V'8CB:3;JCV7@PM<58V(XSZG>=X6@Z&(V<_[UX]?-7@HT&R7,- M'\3-];>?[)\/Y)+LK4L[+6*MRFL8QU[&"0@@EK1*,+$D1.'J"R]J2K-C^?FY/[VP"R ()F<2>B$': M?HA13(%N4DT38-+PN!U.06G83DP:($"8<3>8HBR$=P''@-Z96P0%S[).]S9P M@L2;HF:,0:5EQ;-2EZ3,[@6"EX?BS@V2B-[I"9+=I&%2(5I]X'945S8BYSM) M%"%N/NP/"<[/"I668P:T#$(Y>7>QA'^JN_!R&:9["^CP3(TB=H'+8:3Z8 *B M(;!N8!+".K=^22*X)T)0V#LW#'Q4NX<4"I8]">ZV89QGWOT[$WH-GC&+N7ZG M92&<(\ACX*@0;KAWX_EC6,B99SN5WU]?US9VT&(K)!,-YCD%P1>!W#)-\GR; M)%"%(8N;RW;G1[1DP4N]EL <31YD.)UFD1Q^)!^!:4:;'!X 8ZT)4U4 M%\U=V-\/U@)8C^Q.,()!CJ,D!=DPFX&X@^W,LH!%NI0(8#3^>P[?MJ?_@4\) M[L/QY+>V'NF'\52R3;"KAX4/8 ^.J37\\=GF0;EHZ9=6QZE7::-A5I[?;_3) M!?A,M:LRCY<.U=)("H][[?&/1#?X6^='?.8Y5GXF0S=5E*_K":YV%*3/+O.&+6/ M4&OT01HIK=%_=JT1T[YOU,9C:F.451N1^#,!:KITZ&8=TJ\&*Y8JC96\*.[; M&+H.>50=]#Y%59C!^CZ3'ZT_;MX2+WYTIU-/Q'"L%]^%DR#GQYE.;4LY-[S9 M[+9GXPUXA+=LGK4U34*\,"_?@@I(RK9;71<$0MRS9J?.YQ[=V-,"_U2*/93;I/*CW">R''SKM[@#= M>-;2=KZ!/?,!K9DI16@V8CT0'O@?=+!*_Z\V7+B5K/K*1?J51I*\B"3Y']M/ ML*EI;["Q*/'-]2Q;R<$^5Y+C>V@^N[.'9G&W7MQN1RUNJO_3];V#PUB01,8: MHWT=!A&8;,D$XR?29LLONUIRCH2@,> ";U@\8C$]M^]$B/U+U*=(%"S!JOA. M9Q&/.*7#>WX&XSUO-O[+\<;O>.+$7G?=ECRA[&?C]QL1_M*[//&%U=OS,G:; M97SA97PO)B%+Z]%>E[)SN?52#INEW(_>[:F5K*#>O=Q4[YY>+M>H/)<+A^M. M__[J\02C;G_TJLD :S+ #I,!MGIN>ODB4IK1I]#V+)5C\UGYX6_8#U\%U^F6 MSM_WKF_[CDM9M)0 MC*'PT7P4CNOS8>C9NQ[GVLW?:@V35YK[(%MWF"?;,32 ?B^5YIK45ZO?:6V":_"DMMO'3=UU.5PKY-V04:N% MB5@\_S/7QTHV#T/Y*X@+N_)0/98>(R'/OFN.E7*=AG*[4.YZ;ONWXBFT.U'" M-9NUV:P5V*Q/Q%>N.8#R[R*V0G$G_&05/'D_%"C$IZJ![[A MSOWU&BS.1I(V%DK9K$>]46.?-/9)8Y_L==:CP;8-_8Z#LT_6.CGKM7N[HB\? MHV5R"IUNWWUWW$@@GM:.?;'JT*RM) 0VOFR:859@=4J$T9&L3E7>47=J@457MA/4\.W'^>^;/1=.NOA>-!HNT;;-=INOS&) MSL5)4M5K);G'=,.6A^!GFE?S]N;MS=N/^>V[.LKJY0Y+*^2WU5Y5 M-D_V9/17T@@I> M0GKL6^?/Q&7\TG."/!4XUR@^M5S9?IU2-RJ<259W[BB)RAS/ E7E'75GE&(Q M0GW7#@;=W&8Q&'S='RA==G?#P+5)5WU)U1&EG2R)(=UX=8Y'B6:==W[.JY.HZZK+=& M:X9MS>QZ9M ^-42VW>2K(@3*DE?ZG3JAY6R[]5[BY+?'S/1:[ZNG!N/JN:_* MDF3ZW=Y)\O8V#JGCPLOIM(=;U["NYJ?I4F]>QWVJ/VT4:\=M*:T M;!5^;%E#)0CPE^W3RU ]!*&?Y/$YT92VBVY[VS2..C#(,[@$]YE25PO6..NW M>Z^MY;+95;N(_%XC\AN17\E]#2+_\@@9I!'Y>Q'YHQ61_T2D:)Y0_ABZ_W2E M@YTIS9RE8SE3[G! V]^J5TZ.%NN>BTZMSG5[W975$OW[M WV0Z8]]&TZJAU4 M8HGTMK9$CIB+GZ\AY=ZY^"#:OWIK<]9K=W<^(3>"ICF/GYZ0:U1UU7=0J:H> M-ES>4$=>^$,-C8_RBBQXS 1U_AU^LCW#;/++>^3CG&[&, MQ6(B0A;/_4[+ZG5Z7>LZ6"R!I%/KWHWGUJ;/=2I(HO4$@656:]ZR[N>N,[=< MW_&2J6 WP4+$0(]\.=H8 M,K5^& PL&)X'&\L"N[[_XVM@ MJT18R]"%><*X\=\>>-M6?T=DXC/W8%:(*(*E9"9)?&=N^[=L;S S,CMMP77,R9G= ^^!2_#7 M-7S8<-X3.<^R"D-O(/3P9K(&>^VNM12A P2T;U&8N[!R(.HP=O,C*W@T"(@% MB,('5AI5-3N_SD.QD]VY\8,G9G@:FKD[R&GF L.S3$WV^[NHR0VU9*_3&+K08SG-MO7?_Q1&WG0[J_8R!$R/T9-*V D MR^D,T/);]7W?N]-X+IW\YE-2['321^Q)!,.-RQ\Q AA(#!$>2&"-+K*T,/^< MZT+A)2S6^02$V;=S>P:#?6-[]_9#].JGK! &"6P2,#_WTAG.9L\V0XX4 0L" M/]#*)' N"#E*\3>[,F.QX.@R^_NKO[B]\5 ,1[-)=S0;#Z:V& O;<4;]KC,< M30>CD?._%W! (@T0S.#X YSC8Q,&^^=#[GL^7*W^6<1:AU':I5)T)4> )G2C MA,Z_6.B@0/DB8MOUK)LYQHZ^B"CQC.X7:FJ'H?]7D(.SP ,# LV$F V$9(&F MQ7_A*R0*XV "G!1H&:@$YXJ !?$\"T(8DR/>/&9OI:=B^5$E#RF."]/W[&4D MWJB_7$W=:.G9#V][EJ/0R7"V]MNZUXW;OLOSJNK>NOS8>C9NQ[GVLW?9P.*C)6.M$U^<; MZV:K]4CYR.,)+$8&RYI$E4.I'L?=! M2.>+-/YGCNUSX'II.]_HH"O] M0]$*7M6N+%4/3L XSK-OHF.E7*>AW"Z4NR;WTE-H=Z*$:S9KLUDKL%F?6"5> M_;X5FSO]F43!4OAS^U;XI2RV>8%)W6I(RAJU7K8'M2W#.C#0[--A X^7W8I7 MNS\>MK?%%FZ6O-9+?C9H][9N=M[4H#6 Z]H..V"!8;JX- MAQ?M'?O9-8OT8OIKV+[8NL]+[;54PQL;M5*[J!5T8B,[7GA]AKUVOUFC:J_1 MV67[\O3D^ZYAKMJA&G^*L>+H3)<@5::D1O;QP:2D]&1T" I1JE"UR'*X6D#Z M_![@HRLM"(N-FT):KN,+VGL_; MQ><0I/H:P/FJN"+W*9&WO="N+^%F?/)8G^*?/$Y> M+CFO=7>.+C;\M!]^JB'7G'7:PZW=X5N0H99FQQ&Q9$U%7$F&S?BR?=FHZU,5 MKS7EY9)376?4OFCXJ5'7VW:ZW3YZ?>SJ^@G]<)X!*6RSQC*_![%X8WTJAM/* MP6CI8'8.Z0'6<-I" /A[X7GX7Q-H,_%=1.V<)#'".O/S+E;D^K:\0Z&"2M!. M>'T2AO!9[\'R@]A:V'"S2^,C?(VUT%]MB^@2/RP1)&Q6?'-FK#[.(A@5(7*O MS-;X-,RW^N"V3X*9"QD^+R+X/ -CSCIC3L=7%K'ZZR,%H>OW>R MPX>0&G9[MHAEK]VO#AY0L]C/K4;KA(!3;[G6J-&#JM%N^_*DV*U1HP=6HZ.* MJ=$&V>[X,%/*4&-K547:8.J\\/IT!UL?*9LU>FD%TMT&E[59GI<7L<-&Q#;\ M48ZDO6NU0+-&+RABMVCCL,?E:=#=*G$T:-#="H?4H+L=P)X8UK'-1X,I\V+> MRP/AAC5+M+G%=R#4GV:)-H>/:7<;(=NP1]GZ#)H=7/4EZK9'AUNB!MULS+%D35#&+)"\"R\:V)'8HH8:%,[MJU9&"RL#U\^6!_\67!#*&.V%8>P3 B@ M!4.[@1<%L4!?!*1Q^ #_Q$.PL6%WT0LAX-!Z*E8 MNH[Z(0Z%/XW:+.>LKW,W2C\0,K*:[:709[,@F+:L:9C<(M!;%%D+$3IS>*L+ M3T4MA(N[$[XK?$? #:[GQG;X \@+E?(@Z,Q.%XRP0],!?P5WB,( 2Z+NE8 MJJ?&60S/!V.?BAFLRM2:/! ![0A1UUH,!(>O*H1_JSU&'N*"\42O@^/1.4@ (OHD'Q3K >;[PHC"B)SVA8("">)(M@@2'F)G\G"AS;F M#(@:A'+R[@(X3*-LXN4RIH"M+41UTFH80E%N]QN8A+#.K5^2".Z)$'GHS@T# M']GO0.>S'F YK%V[C?:5F(?6)=!\!1* ONW7C^&.!6 MYME.Y??7U\<@8+4( R$;A#%,=1K ]T&&K0#:3H43LICIM(<_HJ('=>##&UT$ M 4Q-'G(;D4O(-U]EMXQ380"I@6C\A[(7:9T7K,E@)H"!"M(B-D,A)Y/PA)6 M*W9)J@:S603FRP1%_S2)XO!!O1>?9CW@HM$!XN/!6@!GXX10*_Y[#D.WI_^! MAV!":("5WKUF)(\B[.Y$7I@.< K>A6B^3.[JB_(UH3^@7BQND:AZF5*0Y))) M]W^T8 $8HBURO\-RT'84Z[:RYLF)Y@/0B,5F7>7I^:5@*TD3:RW+M23R-%J( MU=)]&L'FD H.C%(RGS8714>@#-=A'#ZJ#3=^^%358;]]^3+JL%1%;:036X5* MC$^^E*$OS>R::6NTHEW^ FW,91"Z>PM_ >^D,9[-GFR%["H$= G:IO$E (H5X%XS)KLQ8+!":L[^_^HO;&P_% M<#2;=$>S\6!JB[& K3#J=YWA:#H8C9S_O0"Q1+#UL/>OX8.XJ?[VD_WS(94D MB_75/XM8J^9BWA#0]W9D87STQVJ5XV1M)_^@W@$';G']1+OS4,1[PIZNN#,G M(=*0;(@,C8')$6[H1U R-XUE6Q_+]J"'RC_:-^TL:^@#)7,56BC5XHC#E<_Q M1D59UF]W?E0;*YZ[X=3Z,P$S480MM*#4T1NYH]ONH.-48;(N"9,U$G\F\ -; ME;B;5QX:KSP4<7P*ORC0KIS1N:#Z?/:6(C,9W'?I4?BG\-SOUMP&PS,,P ;& M !).CWARZH)][4Z26+JN&QXT>1 #/.C"Z78[+?B4##]6@AE**;F2DT-3^1RZ M#FJ=MPY%\:HP@[6D_^/FYNNU);X+)XDEOZ9]FY9R,C9/!O1%B/^DTS]N<]RQ MC_9WDP,OSU+^/1H'=UN$V0I4UW MT!Z,D!COX)#,P=1/<.)&>=,;*7G#2Y?Z1U9V#'#B*#R0Z/T&GR0Z?=N42%C1%W,+^9T6PO"A[CMHH1]9])].WA M\$25-.WV#)I^0*_9E#Q&:B>GCBM*CJ@N60^,@U% V0M-V48;O8@V^I\$SH:] M\5:JJ&)U?AW:-0 MX0>7#ZV*<5LECCW5\UPT-DT-Y5;>IKELM.^!W+DR(:[&"OB@9[QB!3QL%/!Q M*IM*^!4,55.]+5D1=5P]UJF T@V6"=:OLLPI5\&%T8%ULJOR!D_#E-5ERAP; M-J&4%P^E> \6>F!J;@96T ^3FH&R'KN)9#?.F*/6)Q51M(TSYD55\+!1P4]2 MP>_%)$SL\,'J7M9>#1_T9/S_GG_]\C;/S\/=PB%5)&X%;9R1Y5!QI20Q>R5J M1=G&MJFH;5,MJC3),W446MO8-N[T[Z\>KX+M]L>O"BPBI>,)$Y" ]HPZ:RQ/ M=V?=_[^8%CT_;4(#Z-UP]G?FG1S:U)Y)1(O-PH9(-_$;)! M!:?Y:&UU6DM$$)Q6E"P0T>*_B)"HEU$BUJFB76&@/% QH4*7^'3]P>*9(8PB MVT)W[I2@*T/A!$!!S[55A9U^!SX6!]G7$% %C.\>]X(L&GZTDDEBM5P5 3C( MZ?']$M+40;C*923>J+]<3=UHZ=D/;UR?R$4/7:TN7P[1E+['EU-@A7:'P15D M?QGY97FY39=R *U\K=]I]_N]TLM@499>6_?:<;MW67YUW5O77QN/QLU8]S[6 M;GO0N:S)6.M$U^<;ZV"CMS[2<>I1N.N^ ;:=16W.(#.CWEC3:XJ%8J6@\LMM MAGV0K3O,DVT5S;I^-'LO=>0:C$NL?M\$N'T3HIPH===AIJV0=T-&K5;_M^+Y MG[D^(GM[6%B^ BF_*P_58^DQX?[9=\VQ4J[34&X7REW/;3\%'=IESB=*N&:S M-INU IMUZUZRLH_M<32+_5W$5BCNA)^(E>ZP^Z% 80.>RAE-/SS3Y*O2=:BD M$]UX4*-&=-MNO)?H_KV]4C_.756\P,>^JTJZU_<')\G9SB:]W9[.Y=5;\&Z_ M?5FQ%3\$&7;K--@(TL8\*9EU]^*B,4\:\Z0Q3_:KK887)\G9IVN>]-I56_'# MFR=;NWUDS]TZ.7?>?:>NFK']?=6YL]%N*)ASY7B^) C6'6S=3ODEI5CNDT]I MDUWIU2GI=GTDJU.5=]2=2TKV\/ HF*3NBU.RA8]C<79]QVE'C;[(B)'EBYC; MJ9<;&L=YH&S<-(:_^[+3N&D:-TWCIMEO%*G7.4G.KO/;CW-7-KK.#$GT&EW7 MZ+I&U^TY)-$[2D/+IXDKP[,;7O2*M5;&,(A^?'_/"6C]AAWZ.FIH[/>%JD2U=N@=6:VTU,' MW7'M[8^CU0AGI!)>YW3"GM(8>>=U"K9>!NMXO JA=5":?%@L/8$(8XQ-ALAE M" 061-3@XSP4GHU',R>(XE-+@!S6*4Y1X02ANG-'\?KTQ\/C6:*JO*/NK%(B M2.KD#ZDPE]:=.THLQN-9H"85=!<&>&N OS:IG\<;N"^>]46_1LKA.'(&CG-3 M-=DP9C[U23+V1I;2,=;G#GOM;1H8YP\-9+?H( ME7)JQDE_V*[:BA_>.&F2JYNW-V]OWGY*R=74NNO@&=:R2]FS&/:C]G"# 5VI M]((WE%[@WHDK7++S?KN@P=C$C@2^X-7/S]._Y M72RX2MMI)2 ,[1I">5?:$"RF\Y.\5/LX752:-TM2URY[[=%+9[$>_I309#2N MI];E1;MC+9?-AMH^*;P[:'>.:T,UTG:/<*_;)O?5@4$:B;L'1=P#R_MU7N;N MFD.^KI'I,V0W'>P ^K:@37:-CT4U/8#N<)K;'Y]63O27H!,-VS5,^]^/'*F6 MMMJG.;,?,CTE,?D8=U")\=1M;]N\Z8BY>)\VUS-S\4'LE>JM3;]]N>N1NA$S M+ZJHZY2<=,0BKE'45=]!I3WWML4,/&(N;A1UW11UKSTL],/\%-L33ZCC+ORA M!L:.!T64/GQ$_B(IL>]Y;'*R[U4OM#S>8,RO?K9T4@%B!M@%#A[+#H4% W<2 MQA"P(RLL>Z8%EZ*E<'#VWD/+@E5SIW!I\J![:Z_KE+#7^5^J^=,+W[@Q$-[9 M@"+MK)_%8#QYVP"7S9 M9LB"<2J<("3S27O?OZ*4A,WV#5\$)@'-I?]\X$L[%YJ8:_^6<1:I5)^ MF)7RP_U+^70V6\J+W^$7ZR/<-H^L=SY*NQNQC,5B(D*>:+_3LGJ=7A=69+$$ M83JU[MUX;FWZ7*=4'AV.1.L) @)>2?N6=3]WG;GE^HZ73$5&ZEL3U_-@VG%@ M.:!!@H4(X7ZX$T1)!+__,.I8,#P/ 6W.L+/TCZ]!HR0"'YC#]P1(H+F[1-0; MZPX$ZD+ TXME&-S!PPOW.VDG>>,R=!VPB,IE^PHM#T2\3(Z?08O^Z-(@!DC- M_R.) 3.#L<- D"S(+O 4T#X.PH<4]F<.LX,Q3MT(*(WO!'E"^1[8D(!K'C4K0LV NQ:WLP\F VBX!IP$HH!"V2 MHP]1-LJ!QG-@@[D;3JT_$W@-O!9&1)M,/04CQ9MN8M&V/@(+"N UZVL(2V,[ M^/KJLT(FVF:P0F^8<@)63/Y8Q E'NT'>!R$MK(_B<\'B4ZP3NZTL#_SU+Y>] M[L658<3>XYMRA#+H/00*(T6'K<%@!)\.DHAV!%R,MB!75=775S N=M)?&S]X MN@JL9RJP7ONB<*<^MB.MRF_)C,X""U9-?]#/J*QVB=):+_,WD^;%VB1+22*N M2>WJ"[LR%7"1$A;+TM9I@/I.7DGZF 3-\XGZE&-[[1&)^F[KLO\$42_I]?/? M)N%//Z\^YD[__NKQHUQWEZ_[6.2 E\_U;=^!+6E] M$7>NN-]""[S '!Z-?M U^%8YYJ=M2J\$OUZ(4!FO?,LDGPG/!2HI@0>'E>A 1+; -MI$; MTV+-$GA_R; B9I3-^ W'.0G", Q?HN?"8/D%DPS/*,ZCH@BLL2 ^USF!_4M M6*=O GG!SAV!<:#/[!K;TAK_54QX[+^Y?R8N3.3AD*X[V&!D7>%2!_=5V@A; MBNL//O#ID8OK1,[5U7/-B^IR.=WM7#R#E&8IJG:A^+X$X\V-DW 78^JEB7]= M,&IK!A8I2\Q0T!5'GDTF0HD3.)+"\A;^0:]-Y2CQR R6I%+$WW(?2YOR M)/;Q3,\UOX\O6B/#&YS;ROW61;>_TV:&,S>R7>%6IA<$GD>J]\V&),?0O$Q% M.,>"AC=]?4!1./K=RX,MRU__,AX->E>'TZ]9VG0'[<$(B0&'5;9&20# Z9[< M3+B8\&]I947"=T$6)3XHZ 37W@]B&):+W.#[4FD3/^#"D4S M$;(]!0^+Q5(W#9!B:.$F"[X^$^7O+7CE5$1.Z$YPUZ+)(,URCC5T\S&_AG'V MRCA@/SM"3"-6' ;?: 7C1E$",H54BQ? "V(1+M8P$TJ'9LU>;K-WVT.]:*@! M$L][?-/#V2MRYF!-H"MZ88.E@N/RC_4!;OUG!9U[!) 35&0G:>*"-0;O" MR +GF]Q"S0(\ZP)(7Q"GFOD@_I:V.]6D1PW4D/\YM8[D?F1^.@")A>WZ:'3" M,[ ,H&+@.(KK\4_AN=^WV L'(G2!P[ Q>%_,;AD:*G WNX7.3W!D206S-G3% M.F-G=\MY&R$S;%AD#V929X]FTO_8?F*'#WP4;G)_%2MV"KYZFUV#2>=*Z$M L"V9H'WI1K^V<$D9P=_E;,!0 M 4IA+!-'9PX(YOG!MU#/<>:2)(D<5<1C3(>![XVCC"7]]IXFK,Y>18Y!)5:*V$3(GO4(7)4G?WH:"H_EGZ/87,';ENWV-FW0U8[Q; M8"0=*.VA-*.AQ?//4@47(TAB+PB^42 OMXYH?4^ \CZN%%!_8?\';LJ\PP)C M!Q86PS"P%1\]%,HDUJLBBXYJ&U,KD0HY@6Z>O8S$&_67*\R,].R'-ZY/LZ>' MKE;/$[G20OH>7TXMK7:'K2V);B6_+"^WZ5*N;)BO#3OM8>>R]'*GW2V]MNZU M8-D/!_V=7KO^VK!?_M'3&>QHH]<^ G>V10%S10N.BR$-;N9!&+,+ 0V\#4K# MCY42OVE?RHD3XA/KA:>! 3[6[:.SOC*_L,[^AUKC)WTV_=JQ5@UI>@8_6XBXV3S^>]9R?'4_ [CXW>;_L-N5^0 MW#=DG>X%3K5.0A*F[4_M<&K]U5XLKZS/01!JD9E60$B1&5F__7:M)>8-/?+Y M2;+R<8I5E5_>[B@.GZ&)>2VH]LLOOS3T.HA4R@ILA<6$&,-U;57_WHV=N7*G MD1FW!U6Y V&JRC7O]V&I/4://1@/1T'R705;0^W]B\4-,=AO= OCN=!)/ACE0@'K27D!]]ZF]PF M46Q)W[XD(KG2*3 !TX)AP:X3?J02V6V@T)0"&PBQ $3YH6]DC:SDB S/'X0= M(NI#X-T1O649828^0B\54PXO2"L^'TA1YGS;LK" ?9:$,:*$&6/V7NJ;%/AM0"XS(?_, ML'O1GH@,8Q HEC(I5\1I5[4="0GYD:U(YB^_,A5%@&E! YJ8\18&E&RXQ"9=& MM0QVPGTZ>'UY#A)3,P82'K,3/8'$*BAK@%71BX&T(16BUD!JA3VQU:#5,> H M](IPE08BBW-./WXQ2.((HRPXR7Y[,.[\*%D*J]1A@CW\))#]T7VOSW_Y3-/9 M]IB2:=(F8Y(N0\S/^@[DB:@2$,ZC=@AJ%DZE,.[$C>8ZP13IC@,:#<8IED,& M97!:4(--3_3Z&9+AF.]!>(ES6$!S(R0^3#R,@8GD.N-Q"BDALUKQ)UU4PRBO M5#0\4J^O/M<;"ZA*S[+.DT/!UL MST$;N'\-E!,)W0$BEL)-)9A.E5_:C!] @/#Q:$-EZ=*2FT6)/IU^JU5.JPRD M0&V=5-=4SR>SI:G[#^51X=E](MK=N/!M.P1S*HYQW@<^*A=F$_=:I@LIIVLR M:?P(;Y;X9$& J,)I:G/P02?2U&]0"C#"3M$UU42 N%1.=JN'4BSGW80"2$IY+"P ,/65N44OM3G1QK?J$,Y-, MR]AL+PK8E+,\B[)>CR+QP5E!1FP,_8#N<]^<'U&/]I!V3>+ M8]*2/DOR]4ASVV J+@M$E@KR)SG3E\-.TKR%0_**+"I:U=:F;E7R>;.*-U^7 M/E(6%6#;'?8(V!$+W&9W@GP^L-]2B"G\P829PKL0Q2IR;WUWYCHP"PVWD 9<]BR+:'BN6AQLK=:('911%6*?/0GNJ@%=N25!/RLHSC^( MD4 M5*P\9/QQ<_/UFH0 :*K_ 'OA_I=&-D<=0XD2M< #,X5T<"2X,O:JD?[^YO/7 MZ[>KP*(9-:B/53_ @2_KZ>JW1R8@E@(*SS>FV.Y,UY1]Z[+O;E/V78&Q-&7? M!SQ_:O<\.^.S+>U(")FQ$_E#?RNIM#FFO3&0$I"2352DEM+E)IC&[R%)11:J MX8'%4L2$_+CXV1(=E.O6\#LH%.X.2,.BN"!]*C5*N^/Q)9Q/(W38%,V@BL'_ M?PK; QIW,R[43K-5F"B\G M\+2;O$8/.Q$I:5N_=K7("_(9Z3Q,%1L0'I*/8.Y2E-IQZASB)X^LH1A+&K// MJL8QEE] TO=H E8?-;Z5P@W# 1EGV73AZZ:9(7V ?)W2A1J+(/'T_+J12%O+ MY=KATM,R J;VLO8-"+U56&H->JW[@^$8;#P0S-VB#F+)/4 MC!3#(! "DB6XBR04H3:](.,8$F*< M(Y-&$U-D2NTXLJ2YS[9$.=D(!!K]U>,6Q(/KN1$$@T'EXV4 ?% M_A;R>"#+R'-' 5V2;VYDZ(,? 1^Q"TG:.01;T2'R8^\Y@@"J9G*5]2PAH/-P& M!W,#^P"&!:NGL?_T$Y1.A'RS(!24/T-C-FTO* 9BM-DN[.N-LBWFQ@E0,#4. M)H)L"$*R@KZD=;PI#F'!) /.$ 10C'$*#+XP2Y14:9#E:8Y50KORIF%OX2 2 MG]ZHIDL5VO2:'))\]]PMQ@9DABFG]OS:-2\'E[GT!/BH/]3F510-Z72B'2W9 M:/T-'QE[^ CR3:/0V9>T]O*!3F.QH&&G%D[IR,7A\@Y(^436&E3/89N*$@]2R7T+7ZM?R5^HX&0!IDT&X 9Z9:Z"-G#2)BL-18IZ-TFP, M^MD24IU+C44R #D!)O=RETI!^LW<+U5^-(H"^/^HD.D4D,0 O"6S*5L05#] M-NH.!8H>:OSQ:J+MH/DW%<^VU#A'QT5GL&.\_7*##AG6]O1EE?TX(^4BDUB4 MT0#,.Q2QYK,AL)P%4JJTY2)66@G(ZI# 9>53-$$26;YR4!6DC/CI\J2C=83* M4BLW# &1KZ,GRV;\1 [.D?&+U1SJ-*-Q_5#I%)64 .6>;Y1R)TT!. YG>/$. MX6TJ3\>0*3IMB#A%-\R]%;SRI9SHW0E1\R)@U-N$8O;N6?9K,ZY6OT M2>W40LO&?O RC'31MEC'_D2KX$DLND_6P"?2$V\:%?/SO4KK0>F.7EF1R_H8 M%EC($>DG-5\D9-9HZYG&20X!YB@X"PW^-EK2" MCX_U[DS\#M/ONAV+B1AR2 MO"&'!1Q8:C0W:5("QP59;G_1*@P('0$=8/WFQ1]58DCEJAHN16CIZT54%T:L7>)N7R:&7-^&3VR,%2__ 7.Z;^P4_8T[BV*T#)98E<:<^7 M),12 50%>2G\0?8DZ_$9YK"+"7>5^*GJ20KV1/N-%&3/\LII8 )LN( V;KNA MGO3Z*IN6-*Z<=M2F<))X,#4'WVWK+I!@MG=6XF+TL_ M9B..O1/P!95+A?S-RD6:Z5<,F[0U!GR\L. BJ%1,/H.ZCVR; 08E& CHFN#8 MU,XG%#_YC&9*2? K530NTUCDU66!BW2WVF_6;WGS=F5QGT(.KO3:>%=7^;O2 M*9PI8X84E"$N;2!V8\(V;*".&J1AW5JNERIYL&*=8)@F&+;K!,,*[*5.,#RA MY&6[@S.(D'MGBHT1A'D95WTU@O/T-;LV%8L\#4,XE!&"C47"9![;*&X7S+IQ M<'7)3TAS "9N)3BMRY=5G)@C ;\TB_*>H[ C8=P&+C5GPJ4]RYV1E:YB^WG= M(?<[4/BX7$Q+742U,5I1.$S#15D[P^$J4@!/43LWBX])#8H*O=PX3=4I"AM# MD,??SIS.V?[JF8/''2@G.Z5X%*8&+<7 T!6HB",LVOXK<4$71-2#?R6D@HPM ME[4-;&W#"BSI.J!1U$-&CPTNX>)=[TT2O6Y]QW?>,7:6<='O>2OE4$A%TY0C MHCX=+269$)M.[*D1V!QQM<7>4XYKZ&P)'>%/K(G,U\K28E!CT#I3H86398NJ MO*ZBY9Q9+6@@:ZPOFJ%Y))-VT!C:=ZYI#=4MH(JUX]Q?(F E@;07V4W.D9EZ MLE>"0%:-R,X=.DW. MSY9W$Z+[0/H^\RH4NE RO^4=2J-L/42M50D8(XQ6PZ7YF4JHJ7./A"_&;E'3##CWCN)+Z,S@.6_5!P5ZWF; %I*08\!*!H#Z/N:KI>Y(:>N5 M(!2T_#^%WE MS)O&-%A@WGG1$;U00%9[RLDR=URKV,?D;52KG,STYCBY>@ MOU^Y>"GH@9)N M A(I)O/*\M.^A&0I2GU"9JFO^U-7(IB3@2E-V="Q2P ME+R/SE/CS38Z3RRE+^8]*!CG]14)'2309FA,A8>*>!IV\KC.+PM$L(K.$@[G)LOV1V713CTFNDAOFLL4,-*"OC'# MFF"27S'01T.%4ZE)@69,$P8B$=XR'X(] \A@'RCM+K8+'R+(/'?F:L[ F?73 MG8$DDQS+DEH-WJI,+99;[< M#\HC^]UW,59OO,M.\#I#\6L[7OO8-W70:SM6T;=(MBY3WF,LPR&O,*J,^:JZ M7$95X7IE=BJGR;+*:J:Y[+E#J%QWT'D!5-_<&)9K85OEQDT##N((*/O;"=+%'&E;, MH<<(0^^U=G9D[AF7 NPFZDR97RCO"9*YCK*Y WPX$]2^@IH2Y8-31 $) M57<%8:U@GQ"$:V"R'4!3^-<@/+J-)#U5JGGY:LX)YKEA9IEL&4B2/)-ANT27 M:HMD7RC)E@3E688;>EZ3QCU:&G*8)V6.DD)/M8OG(?4E)Z%\6+0MV(">P6Z6 M5VF0$]E0K!?VXCUEO1ST6F8Y/@*60J,AGUOK2IW7E3VGZ7=I-#;5(C3WKI.6 MIDJ5(P[=42(3V]+BI>SYK!^K[+ LCP)01-5NM%QI+0M:XB>.,!9DHY_VAR]+ M$]949GF#J;Z,IL%$+9,^1;CR+.V?[U]D;[K1%DWK*W539$29>6 3<.9ESJXA M'X+H?=:%GHL-F?5EHF%W:YP"=D;!/ MJC',:CI(%-%S;]1N\P[-((]32[.8>EA+^5"C$N;)&QLC+ A;8K""38VD23SDX[W^_7U ME_4H_/02,3OYNZ@3,>M$S(=*Q'QX&EA7^Y0RK%>RNM;RI>O3-NA'5ZMV1V'* M+;V/O\[80:/)+$&.WY9OEE\WZ"LUH#?W7;O?&+0[:[]N-EI[?M?KK'_IIE]N MVFRKWV@/+\]GL\UF[WPV>U8WV^H-MEKVCI'T.\RPOO/1X0ZK:K8[OO1IV2(Z(/I%('+&@.]P"Q-M.=A1J56&\]M;V"P%\= M)K/%/=U]^"=T@\4F.\WZ FL4K!(*WL')1VDWH@NY7]L6 FS6O6ZG]A&U2K5Z]7/]'J.S. ,?W?WF2N.0=R<;'V93%F.#R%0Y]99B*K^=?[ MI@NNIEW@5+C (JQWN?BF<0Y<]MGP[A]/0%E[VX- M*XY%/*H\;=M^;S? G89;>[>++*7%ZK'GCMF\[)\1@]Z LL=BT$\%0JR#SV6G>SH0[>N>W#H^0;OJ7%9<7_F&<]@.H:]L M?3V[6A+;77C5;(P#6=1;'KXJ=+Y.F6OU+L]($.Q%Z4>VPVNZ.JCM?F9T57[J MGMEL#FKD1A#5>_GG,B4KUZO7JU5J]3X^K4N*I9#9748C!BLG:VY5<]E38_S3X[(2X^L\N0?, MDZOSX_9UC[?,]K!.KJDQ9'W*;]\<#';U]=90>O PUZ!W3J9LC2 /3<;F\)14 M7&?):5ER..J[SI2KJ&U]9M'9->*@;S8'YZ36U6D/U26L.NTA.W6[9?8O*YGY M4"-W+36>F!%1TU5UZ:H6&O>SO1X$M^M4K7KU>O5'F:IU"OWA0S8T\3X.C7M! MIU[C_-8X4,#RT:4QQL%QDACO\(3?V_M=.<:TO=I9=L2J*)?KC+9VYYP\?=6+ M_)PSOM_7S*HROJ\SIEK]79M0U3A7\]C[G.VR5_>0>JK8_O0X;+]WPH98![*3 MSREY4:4"> ]D/F]*<-DVH[AZ/+ICMMJ=,^+2!TSXK1%D&_ATS/Y@SRXG-9 > MBHJ[9O/R#-MUU CR4/#IFKW.&?8@?I1YC(=27/:.UQSFUJMF<1S(OCZST/DZ M>=#I]VRFNZ.J@E?V9TM;;M=>^RQNU'@]NUS,CA=ONO5[]R:Q^3_\'T^TC_=]U\U 7Q8Q7:+\U=%!I&N<,UC569QFIA4LS/[U=5EI U]R*V1IY0A21: M;8RVE@WVC0CE#?[V7Z/PQ6_Y^I,M?O: S*V-%W^3S&96"#]PC)O8BL4,-A,9 MP=AX:X4^W%QD//L01)&(GE?^*,](V)NOH!6]C[^^6KA./$7D;S2) )2[0+Y9 M?MV@KPJ4P-_U!HU>=[CVZV:CM>=WO<[ZEV[ZY:;-M@:-3K=[3IN]W';9$A%X MD,D@ZWZR@SOKSD>'*X^6"$DFC4II9.^"T(BGPO@$WQ@?X?%I9+SU'>!AQ'1O MQ!P8V4B$!M@H1KO9;FWA:7H0H%5+!UG7B[I,"M\/$[>.;.Q3G5H!^4,7]\5" M!^=1#(5^H[?%%J[F0>3&(/Y>AL*S8O=67.&-7W0:)<)H9$4"%_CE-^,H6^XU M!O?;"L!3J35Z+#*N+D=[8!09F-WV.=6G'!U!'I@CET=*T"MPMA:;2,,3 M7B$\OWGC[TSZY.6*_&J>5GTBC3&$!M[M,N^,G;]_*5'\?' M/]QBTUFTSL=HW8RC=8*B=6F@CHE91>M,PR^3\(;A^K:7.,+XM7795:%^C/2[ MZ&6W@QF<;WP;V&%SL6'(/@!]VY8OF-HY\[27JIPMHTG^3?0#P"&,#J&A;'W M+?U[9OT0QB)TXU@ 083P/\LSQO+?W8@@TY\%-C['KTDX4;3XFT;]Z^-HU0S(,0'H5-1<).8#=+8QIX(&_A MA7,@R0@>\02PI8C>X?JW0*:PVX48V5841PW#^)\@,6RX6!=YK3M>XNJ1V' 4 M8[0T$G@"N, "9'L$M&U/#2LRT"W1;EY%<0B/3I8F_7?K2GTN?LX!N:/BQWA, M%R-!Q2] QO@K'P(W<6UW#B]8^6H$O%? MYSNKFPR#/\M.-0DL;^7#8(3/NB5[5)A0_#P&,A!QI#[-\(1O'D 0N8#U5FC, MA(5(I0$4-A#DH#I#R"'NC('OP!\6_D,L#2< 9HT1.9!PF(@5NG;L+1&IIBYB M"THX1'%53X0_+V/BU2-=N 8\F11#0O"A462M16\#T<48";@.8';_*QP3+C*> M!LED"E1C2"3#/Z?6+?XWD/\\3/":D4Z#)#08<8T4QPAL5A0ELSER0"2Z:WN* MR] + 8AC9O@A,WS#19HB7$$@A&[T Y9+ #U"9 A8QU5/]!?@#L/7;H"$[^-^.>@WXO06Q(; M2\\7A+F]\!:RE\,-VG$".*3.9]-2C@O2+DQ?Y"DN.PTBY(B*SIWL)AU\DZ0X MX4A4EQL; 5>%W\+544XB78^Q1%* +0$5A)LX&M[F8BJ(LN#JF$T2.$/8] SN M1'[&S/C: QJQR M[>14IUHN:C?'>QQ?Z2.:@**7<6K%&:XQX$X)-I$@:+\N- M5 (E/OLE=&^1$&_298T/\*^)14M^%7".&2 0(4YK..R9B(P6H(^B=3R<.T/) M8$EJ124#,02E$%"JZR1TWW Z. V^TYI,0C$A6#%P; M9? %NQ'Z2&'4\DCD; M(:B++\(@V!+0#D!J:6XF040^4#F!6?%%7]'C)&4R,@5 _P5[<\>\).P1MB)0 MF**$1B87>%ZPP(7M3//(W@'8 PP"6![ F\[\*7@6[TY/#:NR)2R(/Z)K"1$ MI@#WP6CW#L'2:E[\ 9+70K,@ ;;LH7)LO(=W&JWK="&)#:^2".XGPD2Z6S<, M?-R70HM(8A (<5N0UH"P4D^ (?7)8_LHIZ\ M:MVD2;)_RV=\26[>S'YBC<"*3^+U/WGX)+%R.7#9+:0M:?^=D&@DV_P.+9UYYP/#[:"=E6=H2-B(R081Y-=NA_ M6979BS$%$OW[+_]QMYEW^Y__L>PWSU9 M.):\5/KMM :-81\O(_''UBT0(I*2EVD02H+K@&;1!DI<8+ND:)'F8CFW8$D* MX\\$1"<"_D]X&A[P#$< T($9THH1*0VA5!! NW'1 D2P SL%11=%<("O8C4' M%-5;"\0ZRFIZ#?S6))S2G412NR+3.@F5^I5]3HP%Q+G/B#HVK#FH%S8?UEJ8 MQBC@KT+Q5^*&4K&0Z@X#X!"%#+O\D@Y1L5,,#X]MC?C4/ M4,% IA9-W3'S",:%% ?F20@D3DXT^)_4M,EN%\"$+,]DNX*6\P+TEHB?M@N, M$S:'VPK) U=CQL.)N]1*1;X-QJ/&(EB22&%(#["5N2J"V#Z6&WG&A9Z&! MCUQUG'B90$5YBF!!0E*6)PG?E*R4N0\6QYPM>1F$PI^P91]*GRFLJF2T)%QR M;!'IXM.@-M1@/C;[3OTH[&YV%(257;&BZ%%PD15-U+Z4ST0Z/@@=,LX_MEP/ M/:DQLGVL, %=TPV\C-91\PR2R/C>N&G0.]'A[TY\ CY]$(I)HGZ@(AOJ(5(C M[&7V,/T! F;J@M*+&QB%[DA(;1E0,DQ(WM18]5!8531AI@*]]X:8NXZ8N;84 M^? /^B\==7"-UY__]?[-16N8/D&/JQ +"!5R$,'/%&+ C]Q0:9 !F]5C,(M\ MLI( 1=%9FX;XLF_0=B9FQGCOKS5_LJB=1A)*&XU)3Z7HF0%O2=#:!LM&!EP= M%T,YHX3P4JFG^HD+R@RY0M&=#D;-1$@3!V]%'6]\QVWB.2;")\:*WH$ +S ] M::0KYRB3^KL]P!7-R(MWB3S+0E!URM7T(@ Q=0"D@>+8>I:Q$8D4C HN7 MB9C-O6!)7\PM^GJ9F MP,LY?PK($_X0-2P? I:3,%B@+XC#&N+BUIICR!DS"0(I3YDSN+X?W%*P8L7V MSKDND0OYKAW$F ,U#X!A"W)4^1E3Q."J3O6E!*&)IRGV\^;;.:(PL#^[D M-O" _=38<5SL6$?:NH@LU1R5;'1T@0FX,@.+'Q0U_!WZ!N.E9GIXRRM\*@L_ M2YTPFJ-7#[X1 /1;$F$%$90&("-:P4%D">:F)IB%*1E*7CR+%']E>@+[&7$7 MN5?H A2E&[P-GPT#T$HIDTS!^1^F+[2 "R6C=4J:2=+O9HO: /!2E M2 -79X, Z%)5S$E2RWE5Z55:V,*-Q'.3L5+JB2O.L0C,ZB"(4K?;!<'<8?K* M;06#U^1+YZ]J9#B^4$U\W:D2S !>-N7TR$C0&(#YIV63WJIX$*?8X(\$I?IM MU*Q2GIO'N;42.LM3(L'+ 4%I590;<*E(CC0=( XMQF3BDT4E@.V6$DY:=.[7 M.'AD'(S^.71NS:93WS?59+ "<;D%_3R,K(>?S4)!%0/GH0["I2778Q%C0*V*,87LZ^H *)7O8 A'/D6%13*P>.D:3W7BX,' M!D";:R=@!>G/PQBVI;:41@4Q&U>N2#ENZ79RN\$GM]C+1J-6#TS4N%\MW)?Y M!I2KB@:B'V/BH0I"8G:YYZT$$I5;VG9#.YEA6@,(X-3+J$4P8TNYI'#]=V^N M,Y>9=%R3M6S77N>3N*!0Q/)3ZG?UJ1P84' MF :-691\CRK6I;:R'\$8 !68.!0!&2/DCY">@?"!$C!%F MD,>6ASJ*9FQEOG1'D%5,F<\!!05DJ@F*QTP%,I+(F@A3UUWC,/#2%)9,*9:Y M=C4"'!B+R^.@D"!VM.:K@= MGUNKA$;V^Y-^9X.T3O,*-!<9Z6QIRH$6F+KE=MT_4GA :J XAJ9K"0) MN+LOQBZL0@4O6&R7X5&FG1.3R-S3VLX9MXC/YW>\>8?9!M?CVM.K[^CE[Z*N M[ZCK._;@>0>H[Z@9^P'=1;JWQ7>TZE05JE?"U^)T>VQ.H +VQ=(&EO0R9UO6 M^!QH!A:K:ITQB\RBVGM*)HSTM)(LE\22^@2P^;2XG]P\:.VA M72#S$/%=M99P>@--]4&(#F":<090)JA%5LQ)F>%R 7@YIP_1(JPP1E?KRS1K M9#@D9\D*_U=2BS55#3#C']^_?P#N,=92 E1)M!8!-49A8"%9XSJ $/ 5ZDK% M;%3'I53S6#J(",FRMU%M>62[N7I>0%4_JMUW#RMU,NY?2$HNI$P@9<6A1I9YFF&@7E@$$B&--A*(V M)=/A3]EP@SIUL(66II-?&0Y6CL2J*&5^C_05K*TO,:FR ,V]1';* M2#,K9')OYDY:00J$'J,:*SE9!%6ZGD/CUO(24?Y+Q-::AYRHG*'<3Z&\MQZG M2:1=TR1GR?L1J;@5,,FC!AS4E4>YHN+,#XP[4*%Q5%RR7B(LRO(_9:^5MC50 M7[T<5K($PK8>E)(^M4*1K@9Z#FS'>"-LGO74YNYQ7:96&CFNF B\*??FL>Q( M%UE8FH.L#0C.#1R]T8TJIQ4_4=DB6JS1]X%]H@3K4KER_>H]8BI*+R5+! M\)N@3(1 M([@H-[UG;D:CJ&\!&UF5*#D9;E"QH4E1!'%\;G &%O(D)6HNFQB2J+>-H[@TS PS!$!DH2M C]R =!7P(L*4<2:,RH# M]2NB5L6V7$[$WU;\(@7&Y@7 1S&6#JK;"/5P-'_'4IT'(A^[/X5S0?$:?B#? MBW7L)=@2DVW:K("9Z$ASS\@RK]3")P.'FZ)I?2EY\+G,"8Q*?#H;]YY*9&E$ M89/H[-?8BM[A3.K6W[)F&1B4$O+O=?M$?]Z:-O'T3F7^RZ]:]%5S?3,W+4_@ MSR1"-ED/?:^'ON\T]/T<9GT7)S.L&>$#5#?B,0I;#5#:8_;\>0Q%WFMB_*.] MC=2EJMCI<4=%XV$J031WBW6ZGG>I8#N3<='%"WYJO_O_3MXXIU^LGK\\4-KZ8W. M&7'44X^_K7'OH!ILHU59^-]C]N[I(C7O\S&'P#?@ID(*C$06_\/XC#/*X/NOU",/$ZF!WWL> @SS ML>TI,G=#1GQXJ@D&/=6:6@&0E )VX&,-,,T"M9S MT LTY]@).;F/ZW9_.J+#"QI0=JR_>SX M2KE91OH-$:'MH+:P(@-C 3CZ<)_HDBFW;TPMC)EO]]8JY1R41UC?Z^L=PFHO]HFI'<"W<)34P]U!6;G4PW(!UCHC^;47/3U$E4&->7L OU]# M_TE ?PW?J1E/C7HG$R,J:@!M/ROB2>,5L>Z:/6>B>?/ MM>SY&\X,QO&R;U5CWFONP]L:=K#',ZP]DZ,HK30+$,>;R#]E1V<;>Z%SW[AX MZD;&NR"<@=EQ\0>@QRLR1)(YU4=8<>Z""]>XQV7A)>!]"]FWK[#B%K=%U27J MIM?UN3M!%3<_IND4 &Y,]L0& MXD%$HVFQ5&,,MP3/_94 FA-JP$72NU67\73>C9Q)RKGV5A3XP!27AN?^P)$X M<;#Z Y.0=NL='JG/8+^S%2>M1I_!+P %X_U[@^#;NC(^?_OOMU^-]Y_>??[Z M\?K;^\^?3LA9=Q -+:#]#V("T"69() E5E\HW AA? IB8)AMZIMJ$0M)TH$M M'IUHGIT(6*#/S9XGENM'B@/QH(-]+"Y!V6;9\#=28FM4PJ\+IG?IHU?(Q$CMH.V M0RW-J9*H*'_2B1-*$&D3:=(&N%@ZB5/-@?]+T;S-1N[6$>[TZ; M[ M4:=#=7$*0J[U#$\1LH,9MQE74_-X\*Z&:7*T$,T_I^%"U.+:6D1R(,.=@_EL M*YH:8T#N4Y8,5:D\=8WBJ:Y5&_O$@%,3I!!B[6;KTL!'7R>RQN'6\8S?4+' M!&DHI.DV@3Z((3>$0;/55&TZ60?IE 00[I:'SSXOQ5P@\'E .'LO',ZU4,_4 M_&FP2">HZ&/#\(;AIZB+[XK\Y\9,6^W=F.EG./C[[*HJ1&YK^"4KBUG=LJ]/ M!P-<"'G:X*]]T UE$UD,ZK%151C$D4Y< K@+67<="C3U_'B*PWWP#:N9PPWC MO9P9L=TD'&H8+YR(-J%%'%6A-PA]0E_^%'19)@2P*H%HQ P))ER:Q=&(;I0V MQ1=J1!IB.-/T8INI._1F<09S!ZXC956P=G04D50L$"G?"MDZW5/*1) L+LY' M_0P:)$\8:PW-G?!Q"E*)<5(X:\;DK1L5!;A/_3[F5JA&.F9>B72*0C;+3/J[ MUI&2B:,6"AXI&ODD;#QX(42_]D \5PC)JW %V%.CC)IR1:\:85]GX^5,.01& M\AD>W09BP<3C7Z DNIOQ[,=?D"]+\?B,*?0Y]SA8 4J9,A5YGM MF9]?=.F,' M]V0;^.YW/T2/#0_,O+$\[I0A6SQIT35DH]\C H%TAE?)-%GGS#3^8?D):A>L MVJ <>*5&"[[)1@LF\30(86'2*N#=O[8;S51E8*D("E82@@2.J,7()+1F:4^F M&%N[6:0Z@-CXM=/HI;\%29$IA2SGV%SB9G!1.IA,Q.G0;5Y)O@3CD<6JO;;L MYQ3CT+0)#=TM;#'K+^9&Z4J.F-/(3HICUUSE-Z4 M#RJPV6:C M-^R=RV:[C7;O\)UYCKC9[6[V''IG;)F2]H7XT8/-*-IX_FK9#W0]WX(8C*Q/ MZ=#B&^Z_]47R?NC!5 M.5RO83/81I9;E'[!&>5 "0S>IS&P:T]\!P6% O.HY2I2,Y7H.ZO)/ZM-JO$'-+33^I5Q/\M+)L_K16AK_(V+L M!YT!X7N:W;CVPL^''QG/VF4,2J0RARTN8Y]2)/:Y%]F]Z.M"N@_VZ[-4./9]YBQ4NK1CS5@DLSD8F,/V&5;EGZ#V?M\*^RK7T1^H.44E MJ^7+S]:];'3.<+YDA?"]9HHUDM1,\5$QQ9;9[L'_-YMFKWE.DQ(/B/>/R#UZ MG4R2*-Y--=Z!V9\E3^\,6F9W6%WN?40*QZ^/X$F&+/O+P\5;W9XT"2FBF> M$U-LF3$\?*E:KS&X,P6WO2D%M[5M33SN=ITC.W#Z+6K\]7O\T:ONH%G6M+,U4?)7HK_#S-5%$KN[Z!29&F MD48BM&]D5!@+'U-S3_LZ=2\^Y]'PHW2_V&QW*CQJ(BOK/+%5 /QO!GIIC$T1 MX!)DP22V?TBH,1K]+/"H=Q(V1>)>'=B;@+I$!/:/"QZ%82VLT,EUJ)O@X%^N M.P583UPL(!2SN1=\G,.AIW2$ZXOWWQT--(^,8U@]Z IUEX M#M^Z#D$BZ\5XK^+3!E'+%;=$Q'9 =?A"KAB*TAEZMS,7(47F_Z+6D ME[4%LD;!^G;$ZYI_Y@L"GE KBT'^+O9L97'9/EHK"_4G7R#3[+YQ6Z8L^<)=NA_T:<.LMS$>#M!Q_Q(?A+R M>KW&97FOP;Q([+;IN5_.J,[_2-7HS<:@W3EX@?>@WV@-VB@ M6(&R$[T0SL0*7SA6;+VX['=;@^8+V'6K->RTVKTV_'^SV^R]<%J7@T&GXPQ^ M-*8QP.3M3Y 4I+NA?G^-(S"H1=FG +1!98.\#H4#FN#U!)1)'OV1CI%0UD%K MH/H"@A&#_>+8KOD]#)*Y:;SW[0:WU?%0[<3VV:#"+EG3Q*ZUV%?WR\<@G !N MO"8]\97E_S"-3XWK!@_% #UME'[$\SH<4$5<:N&&&P'E!40>L&IXF6I62R86 M7*!L?0=O6MU7-I,C"4,\^E<:T8 =UZ@S]^#BG\;8]7C$8.&TQK-W\ U=5NNB M.1AVF\\;ABYU[RQE'6XH93UDN& ;5\@C8'59D0NV/>_O.?J/Q)?J,Z7S3)&4_.9T_&93JM".E7-:8[ :>1^.JW67QWJ MR4>,XC5"80QP4!WLU@WRFB=AE #/0+Z0C27K/K.>OVCU'/Y+<9A=AY-93C!' M_J._XT;0V Q@&.UT62L$C4E$%Y]_>F*I5@1.V*Y9QVE91ZVD/ W6T=Z"=:S. M^:M91\TZUK".=JUU/ W6T;Z_UM$:&-\;-XW78#%T>LT[J7_8[-?47W7JKQ6' MIT']]U<<:NH_"O6?M& 1YZ?6#. ),(#A<$7\6ZYO9/,SC8]6'(LPJBGRY!19 MB^2G09$YD?R-1C3=V%/AH(&._GM%I*\M'LSWU.F2]>35?&K,LAP6DZ>[S4:: M&Y,FPM!G)R+L5K/5>/_IYH%;I&]+X?FK/-$5_=]77S\8[_THMC#\]2:P$TH< MN)#C+N7GCOH\32/EN> J&?4]YE):G$KPQHHM@^)<(V%;2<1CV^@]L37A:;"8 MJ^I@> RSH=,U:.0@/:C>UWC:U%=9K$'"NGG]WS5AW4%8WZR?@1_,ED:6H(/B M9F;5B'T'U,KS+D^([J^O/YP%NE?JXM81P6O+L^6D=K"'_!]8F5&3Q.DL($3P M-V_?5@0G'A\5V):0WL ,K3K2)DAOPO.@%;W=/9(33 MUK]HF0+H: W%7XD;4@E8M'4&8KZ&PI@"HW)PT!AY>!V>/1YR402\9B2,""Z, MJZW0_3L24\L;8ZT%+D3Q&?D %8\E/OR(ULNFL]\Y3/QD7)TGB7_X]O7]M?'[ MU\_?OYC&^T^O=]SO'7B?9\P2@4H8\TE.ORDB^")Z8=Q'-D[3UI<^,XKM_G5^CE MR\Y6K3L^E*MK>K:KSL'._] M]=>??OKEOSJ=OYV.KJUSXL0S'$36&<4HPJ[UZD53ZW<7AS^L,24SZW="?W@O MJ-/YE0.=D?D[]2;3R.IW^[W57^GGONT<'IZ<=#M'V$4=VW7'G1/G"'6.QSU[ M,#CL'[E]_)?)9]1]1GAL/W?Z]C,TLWL'G>>QV^T!Y\(G>SWN]W>_M]NKA]XT[VTK>\% M/Y9:OSU3/VL_V&<_/Z,09\UG9*DQ\B/JH4\.F>VSH79/!MVL)]@%&? QX_)2@\+/$:(3'-VB&0[GR,'2>?CU)\MB MK/%F+M.^S/ M3J^O1[9.--5IPZ=.!K>)/N0+3Z\/&=R:?:A<;G42(8/DGT/%;E0O7\5)R #8 MZ ]T"(;8^30A+_L.B8.(OG-QEBR!*I#L Q?^)O1=[.G0SIJS/QK3#*,YU2&Z M:,__JB"+@H!$' /[)OUN/O>",4F^@*^8G'[.A'6$QYDN+^U'%1J!_^\SH@XE MOD1][,\IF6,:>3@L[F4]&>ED*OL?/GK^!/W(&I30+Z\W]O,^@&#_ M.A]'!LM$_LM>"!SP<3(S[1WVG&+=80-("'LE9_*_^>@=Y.N.'D"41C>%$<>='A3C%M&*N8B6_Q-N&C]O$3ES]O. MU<4$AF1\@6C@!9/PFH0A7F"RB(&:X#8>B)@Q?HKACOX@Y#Q%Q?DR)[V(:G@-EQXLN_AE[ MT?N&F%^/7\SZ@V[WL GKB_3^9/VLDYU@L=GX0QQ? A1VD!3HLC95PJHMWQ:3&B>Q!J MQU,UNY2QB?C6[\(_C?@&6C,EL$T*4S;IC^C9WQ0#4UPB]@VZ@T%3]B7H=\S+ M1W2+*(4_7O YCI#G;XB-):PBAMI=VV[*T 6A/S,3A]/:<3F9T9TB3]9H$V2X7[LVEYFYS,OMM':'88BC\!OVW3&A M#\A7#'V6P<3Z\J177F$)#HLAL0"+Q=!L\\SK'"SJ@(4G">!!>654<6$;3PZE M&6VV-\G1"+>B7L_F\2\%%FWYQE.:Z(=X-D/TG8QOT/\1>N8C%@08M*F)8C]&;HR^6$':84).0M$?L2,'[9*6=8E^D$.S<4>B8 ME??,0BOXME/,KH(7'$;<^>P%23#A 3LQY=.E)BEB%,)]LP2>=#93U40B?=6>U"V<&22<))5[D/WK!\/2J MF0V^%@6Q%!S9/&BM*05Y"]8 J%I;;KPK<^C[T]/U!PM!)0FQ%!S;W9-UI8"1 MW8F!@$=L@O(&Q2/3-7[!_F!STJ!*22P4)W:OJR\47 P*DK%\ ./TK<%..H0K M^(R2@#2,):Q+1"@3_:[=*T5Z=15%0GC;5<6E%Z# \9!_%801Y?=H%#E<"2D\ M=<.YN^QB6:"Q"GBVG $Z)VP!O/!@W>\/RBZ02F9LXVFZ:E:'DPG%$Q3A6\*H M('\X8Q> \^\OD4=_0WZ,F5OR#/3*.QQ1DB^T=.='$1?KU('=*P4Q:N1A0=3* M>F.EW?F+E?_&>F0E/>#^T*Q3Z7<[?5OB[8*'JRS/ M[JGN)P6!X.0M3K^3=L!*>M!)NV#Q/NS$))N^4SSQ N;\@K5T$; Z1ND]S)", M+[TW[,YAWO ]Q7@V9W;MB!4G8IO"[\S2U77\?F@/Q )U:/?4K$7KYT6/N()) M^I1=3^5A.=ZM#N^7E7?,2GK&@;*^[02MI"+.,?5>^!FIJMGF5)$:';'0'-F] M4D1!KH5RRM6-=T*1S00LG@B]/044(]_[ [M?D1>D%U+7%@0%W&+F']N]4BRA MAOE JP/$K)R:Q&W=**U;EB5X83NI %,>\E: M6YKT;70C%6>1E>)T8Q_?\:(.)&"*Y(YIM'LP/HCK.6GC,Q*"D@-&:%ZQV0@I MH8(LN*261$&>?F)[,Z"^@6 ^88Y[U84NWW"+C&EZC$V$0VOU22%G( M7TZ5NXY2NGGS^ZS5=JK,\BFL26TL*1:Q&CWJE3/*JDYA&=+]!.N.38L)UE&L MBKC$*O9X4-[Y%%BVC:I6-M]G4Q1,,$N]03\::]-?^"?HC5]HG=+T6M ME60F[1E/%8*^Y8<5?HMGY[II+'HC[*2Y=DEA\9@@-6:6H(1;MMWKE=-_4Q36 L<63[K.AEP#*]R 88V4 M;:82 [9QNUV=S?3S.8I0YO#2TG(:^,1Z#7A62KJHX%CV%2-@911VFHQ-SBT) M[A'\Y7ASQ#[?H" >(R>"N:1#]__B)*QS%>&9WD:V 3IBUMMVO^1PKV#]+^$@J_'=(F0\2-Y1HY#X)C_#0.+IRQM#E.8H(";#]?0@PGO M_/H2LBY1L;@[""TVYP'T?2D21_+^E*:C_EG=D)4&&U-W+D M2[&(67QH]TOGYRJ-L-T._7/\'*FQ@[<4FZQ'O?+E) :V9?.I8YD6VHNMT>-! M^3C @+?1 &7C;J93*B'%>N3$[I>. CF2'$"HV ]ZO:H;A@S:XN#;.EJ-76KPQ6/A8.J#A0+VR[ M#"+>T0][Y?NM2_#;.M4ZVWD5H'@K/QJ4#:DE+-NXB2]-P%<<8,KN.XP)G?&. M:2D?15QBA71L#TKQT14NI:BM N[M/'4LS0QQXWN*?DQ0M9H!AF M:=6/F_M*FW-X38)B,3BQ!Z5PTHH8+.A;K /<(9QW@1H9TTVXT\ D9?MBU!Z4@T@K#BQ&!E(#%*>Q8&=Z]8/KBX5G_S]#!,%\$(\R2B7/Z;V?R;)BH6BIX]*(6*5H0BZP-/EN*]8,M]'U;__8T% M/"4K93T3AK"(E?XMEED3;J?LO@^"1P_=K&[ID@TH"26 M"]L>E (0E7*1"0 GO2P& ))9#CR!(.O!3CS"2Y]0L.-/2< ?>XVC-0R#>EQB M%A_8=LF#N\+B%+7%<%LI\AWW0IX"\S C/Y*EE9QV"EIY#06OC%K,6UB_,O=+ MDL>3DBJ>VHJ:?J?*<9CR %',KBV/L$/ "MZ(S::*6SBMGS/.LAML M_.YU1FMGPBW9T/6(DS.<8X'+D*:9P9_AT;$QV: MS<<32Y> +_BKYP\XBGS^]OEPPLJ!:1>RV@ =,>-/;%OFBDL4=T;7XH0M^"YY MV-W*:5LY\9U4A)?898[LKTSO!7Q2KM%K&'O1&I:7#*60UT==VY9YX5(*5D[B M3Z&5$MGQ-+QX07-"X0CBQDZ4;V5@S%S]S]W#)K9H70IBCO=L6^9BN^APBE9* MLNA!8S8:H[K;M(M3-H2_(PK;X!)W^#W\*?%A^12LY^4?\O)_Z8I:8R_XB%Z( M9:EOVS*/W:)3JU)4(+_LV%G]L5 A,>O=3N3":UX_] GD 25_KAG*$>,3B\' MMF4.O 3G/L=O)1]VH9QT=IX>'O.UT3 U2P>AF)E@_,F\;H"_L)JW_B&+Y32( M&+%BOI@7PT\\*=[,\Q&]05'4^'WT]4B(&7Y@'\A\<#E%KIU3MTU"U$JI;KL4 MW.+7H>.PIPA@XK[&+$/"84\F_!U'0Y?,(^RJL5H!CS#;[.BP5RZ4#TBM'*N5 MH66/*%B V$HQ[]A5F&:=Y#1E;,*,M:.C03E14)%U_^&Y;+_LOX6?T7SN!6/" MODD^!P%)^LZ_@F]PZG5@')Z1?R0O,=W@:$K6C@#S_<9F[[L@4T,G]^> MJ>]]GO/:E&RP7_:\((Q U>Y980STO2AFP_M*23S_LI>T]B(\V[,BWMJ-:(?] M%3(<3GJ+FR':VZ^9DD+*#J]Y79^W=0;#F*2IEH_X+3KUB?.C=EK6QBN?&C>F M'('VW$09%>GLW,YGN3_SD3 _]=V8/94=WN#9,Z;%X2?=3$8OA_O X;EDAKQ M.K9J3W\:8^EWNR=+OF+Q>)OA:O\<'&YP#JIQF9^#]$K,7?&^C>HB5P!MQ3IF M-91R&_;]-F:3?[>4I0@_A\3WV&4NMW; VG@V/OKT&S"^)YC*]9>HU =]]J*$ M]CT*V-LZ#D^=E6BV-3":E_4[(,:[G0@L8^D_=FONPY%+N>JO&0?#,C >S7 M]%TZEV=D!FT?(EA_W4^LZCK(!7_#1"Q 4C#S4K*RR@MNTM3AJ*H?JB W;?+I M*83"[/<_P:8$IP8XW^T?*?.M%K)UK/L-4]=SHO!I/L6^LEI?A3++LNH# M1K+U;.[ HH#O8Z8AY 3EL[":4CCZ=$[B"2PPL=C*XC@_QP&9>0&S@W)=<=@3LTL.9YY=-Q@Q7PPO MDA;,X^AWS.(7V!V"O0\'?K:I,[8\8CH3#[8!(O.C3]1'KC@6;Z8E;R5*U(X M3D.]K%@Y+G[^*".G\)0W/]C4L;+<;@.<ST;8_K2HF0'$8&87X_+&I,5Y.EUP3Q+'9!< M>0Y.=)2N!(7Y$7_#OO=V%03D)8DW7E^?R3PSM0#F1U/C4N")<^'O7C1=W%'X MAA%;\?7GSB:H##LH:M/5Q!R5@IGGZRW,-=,9Q/>Y)R#"8*1%(\R "U]DYK5[ M^@X'81S4GRV;(_S R5 -,V2]&Z81:J9D4N_'+98P6PW6/,?SD$:>[WH!=&:P M_,CX'A8G.U*QMSWK5[ &BI;NL(P[^0.5%V\1JV=/ F;$U@Y;"&/Z*)/[[,.( M#%V71RN1SVH.>,$9FGL1\OD1[)FM.E;$'WK/48\PF ZAQW*OZ0M[AYKWF44& M)DG,DZ5L9I[SY!U/$.C:6?K7=Z2E(B:+M!QL,&I3CWTLA\K]/@;GK N/1\9EH_.%-"_',O\<&*1Z2! MP/QH14JBD68Q?L0L1P"^C_![0'Q7.W10 C3/KT)8;O"IUS_(7>8#B:M=!=+\ M^.H" H-^LT!"#F=^;-]C_QW4]0DWVD=XGI[]UE4=E& 0Q\J_Q M!/F7&(?WZ)WU\0:]>;.XWDG1 %/SD-9''I\K%Q%)W<2/4Q2=H3FKKD(H]QM0 M?$O81[U%J8+/[ GC.P+>45"B_5XC!:P*;GX-R*)UOQ'^Z!-/(U".WXJ1&,T5 MJ=C[;7LYGM4_U#8?ZE&8YS#WBS/>!!&A[R/T>@/=9G6OPEL%;&:1/W)EW@23SL-3,/-^N@L2QECO8\KTEW4Q$$7DY;#O]=*QB@"3F4VAA MGDTC[& P*EDZ+JR'LYA2GK+#8JF@\[B+-/R&??>24';)0Y"SI8FGEFP;]!S=+,0Z).T4XY*#X $Q_4DTW0HK4.;%7183L3<87ZG& M97X.LOMK=V.-YU(U[\:MA;L5]VH6)@,K_41"=K4AC!;7T&5A?158\Y)06J]G MA,QE@Y, F1]5G7_,;IB@:[?(9UAS($V4+8[8ZP3,MM4]T);AS1Y@A>E>P)G$ M''2+M[+$*>7-$9K.T2C?N_%FK,?L@6!O[(&@QJM"+;FW4P-OEN-#QP&J;F[G M7WOHV?-9>FIB2];GCL@AV^FL*H=TT70<_Z&I?9>!S&NHQ=[W.P4\=^.QXE:Y MVMS\2,I!,NRQW,S /47!#^T(6R6P^5&NY!:D%8J'BV+(W.OG!6#&27P0#1"9 M'WVE=F27>UWUJ](K0*8C,BA KH>"M"I%T>R6B*P*I'F.E1;65P3'::2Y&I>! M6C@JW5V@-2/)8TD7H4/)ZSF&$Y#H7G%=^U8ZB&3Y28,-YCI5XS+/X9JR0#3) MON5ADJMQYN6JUZ*Z:#ZTH%!"KNG)\J#AR?*@12?+)/UU^(HH[&(1X9X*YL!Y MKS>\ZR%:FETMJ-0DU[F*P.8Y62%M _MD.<"GGV)4C\+\B$O;X2V*X9NOA.*; M4]A3@N^$NF#83+$7@D%Z#3ST-#=8#8SFYT.:^0__'FWR)D$M/O-SH5VM[=H+ M^$X0ULW&.A@_Z'"@>&&ZS@N6EZ .+SUV!:]DTEO=ME5R^12,T0NAK#]9O9HTT7R$0?&(C,H&F,SZ/=/K MOH\4N9BE+7LANQZ8ET65^+55P4U[L:N-_;3BP,+(OWL-@"E3;Y[7&-4\/BAA M;,&EX6IG&2HZRZX113.OD=--A,>\MBK95O<8T1"D]HQ,<7!&H'\4=DXGJZZG M::DI8C,_#\WJR&[,*FE9,9#D!(7WC)4'9\8AX3M?MG,K!6Q>G/T0PVV# ]('*KBV51 MJUIKM> MS9&KM$#.O3&L21@./L71*X8M"$R2=Q8)XRL2]/$BN[RQE=.01@OL MGG*&(!BMTLB4#,K\ZI9Y2(XWZ&VIQF5^#F27\._1.S]V#O\.%MH=O2$4#R>D M\9W^.G2&->*R5SA]FUO,<#&,><:6WSQG;D_-);L$8WY,PIM=KR!>:498SIMF ME\1J4)FN30:+Q9L$28(4;+S+)?(D!.EI,)DI6='4_ A6!.M_0:I2 M$REU9MT0EZ?PJ8JF"(-AB91M>IL,5[0U5%&SXUT%,$+O!6_ *2]$9;@6>"FM M/'9=;XHE#C IF'FVRO(\EE]/"56<7FNA;/^,'%5UO^EJ9_]K- MZZ&O5?F^A,OH36991OY5P,K\^1X[QC-S/\D.8S_'^N5Z5+$:W@17>I\$;\:$ MGF,GR];GFCN1X3 BK.+25>!Z+YX;(S^5^>$$,;XQWV#@ O>49VMS]$R'FTK) MQ_E^)]$F*I#F54?IGLKPS:N-^-8TWHSCW_5F2473S3G^>9*-9CIO <0\=T3Y MX86(=).+._58VFV_]S9XL;8&EWF^EVW1*7)?L>_KFK K8.9'MKI1Q*RV[@M. MSY)I"JB6KU^(HI6IW\N5G,] )@/$_I_7Y[HXO7H\'T8DJ^J=5O(>,=;<>(&P M!-.&L'^0%IC'"MG1=RP1)8DZ*Q6GK6]O7N#+H=81\7TPC9B81<(?:F"-V"J%I:E8V5'@.Y I%3 ML/V%,*U4P$OE)!ZP$U/807"8%)I]CD%%H@ L(S?_?($H>S\BY,]4HM!SH,&Y MY\>BD_2&J;0S=+V:'/0]=A44M@S*O-I^B/"-YTS!=L*/% 4A>P\KJ2;2)',[\V$J3?QY[DT"; M92M0YL=56VQX!K+E:;@,JR#-QI%N$/V!6?>&[@Q.16'J^1H&S/6-$76FO!B3 MF(.:2,PSM"QRG_@U-5U!788R/Z[TMD;N<\["E4KO$M2#F1]95AHLNTZ4%$ID M-S?XZHJQF[ZU3H(P:7'MS MR-M9H^_[T].UY+&$0@OS[.7>ZM)[ M#9G;>AB#F%+O#^Q*;IKIHFDG\Q0NQWX%BTE67%\;C7DQJ'_0);TU(>&_,GQ+ MKQ>6$T1\^%OW)O$R4 NX6LH("=>K!%L-;GA73A["ANTD!@/B*7"A>U/,S8F" M+&9O2$G,SV:XS'.Z7#T49H_$NN;G"I3Y<676X>/4HRZO%2;-9!>!F/4T5EQ M[A\?K%MGJQZ%>?95=?=DI;L#_1'7HC _XIHZ8(V*A[5X5,E.EZH+%K[F 0O) M,V&Z6%HP[A\2?]A#3+SLZ#LYVZG5YM[M9BF8!U.BVH- W?Y M^WMF.,]9%N_(FTQEK%P/I_DY*:=TKMR$YME#?M)D(9(:Q7S4T+7UQ*UZ 2W) MJES_(EN&Q^@EMHO'ARIWT*7/9'<816E"I61AZ"$QOQ*26T2/KY+7X$K-S/>\ M6KI&V(WYCG(5< '+:I W*\XCQ?:AA<;#@IKR8$0, M*^F>^![H5^EC=F*@5KQ2US3L NW#C>2/5&%M9?;XLL"RZS:'_65Y/9 \ *^# MP;S$K^1/:"5;M&<4J]>BU*Y#*=^R4D5G\EI5N?@9.[7K%DPKPIAGJ^ANZ^4& M[L>6QE@/IWD9.&47:\+I&?&! M1QYZ0.$/%#E3_"I+>U, -#^ZZ@CZ"(>.%X" YB'TO$VCF+P2QG:&YPN2>A4D M(IS?MY+Y^11 S0M!.1" 9>\A"D',CZBFUMW0=7D&,?*3O*^+-W9JQ>Y&"NEI M(C>LZL%<)C/,AG))R2R1S8*XU@Y>"M=2QX_R\Q_GT-,7Q#Q[FWM2I JG8RXF^>-R\*(473RI-E.9^[P?M2+7M!:H4QZ8W^ M[-$4/T;(4[?2M[VS%[VE=J$$J"6C M>D3\'GUVW4J^+6HIV^WFC];*,OQ4(,V/3R9O!YO, M4JE!9GX6KA7R-JY;EH=1*F=YSN&4JU]FS?:K7 :$ MYI[LCH ^'O-C5_;6L91&)]MR91*_)E;S@IX6F\D\T*Q&NGN:Y-;?T6OHLO^5 M*;= 02LV0M4ZP4A'D=@DQ22+2T+O*2QL#_GW,9T3%M[2,G.:8#9K(BR=AHZ6 M3D,'&N>H&DCSK"^_)",956U[\V.IB3_>H" >PT!B"MNL;O!R!;AE]NHIIOK7 MHI>!S+.MHD[O"'1">E\=4QXVU*GR6P7]H=L,I[')7,]0L8#=1BJ(*=-JIQ>S M(I-9._6Y/8MA10TMDM$?"6/"W?@!^>J'[CKHEJ8B,-]YP.S&$7J] =XP:R"\ M!\)1]ND61V2,.> MM J5<[)R:WYPK*VUZE&8YVS-IH)4-S!E^'^;3?=Q>Z[J"!(5YAE_-YLD7 MG H9GQ%*<>+J!0LM#CP'*?B/=+&8'W=EJ26>M\NN(#C\^OHI3ET@+#60)P/P M0BAZY9M4<;9S00C]Q=Q5R'-$V5O@[(E7F[F0U_! 2S"V0&RT'YW.1>$N4/;& MZ>/]U^V4O^S#M(3.%,_0KS_]/U!+ P04 " ]45Q3'VB$Y48C #Z9P$ M$P &UO+3(P,C$P.3,P7V-A;"YX;6SE?6MSFS>2[O?Y%3[9K]LQ[I?4S&PY M=C+KJB1VV9XS^XV%2\/BAB)U2,J)]]>?!BG)DDQ)% F0K[Q5B2Q1%-\'Z ?H M"[H;?_V//T\GSS[A?#&>3?_V'?^>??<,IVF6Q]./?_ONGQ]^!O?=?_S]+W_Y MZ_\!^*\?W_WR[-4LG9_B=/GLY1S#$O.S/\;+DV?_RKCX_5F9STZ?_6LV_WW\ M*0#\??5'+V=GG^?CCR?+9X()?ONW\Q^$2L9XS\!B#J!R+N"3#> *5U(:8;/ M?__X0V Q8%$1A(KT-L4UQ)(9&/1.\B 4",?G\\MW?7;S]SZ_>_X=+99BF^H#%^(?%ZL5?9BDL5W/^(*YG M=[ZC_@27;X/Z$G !DG__YR)_]_>_/'NVGH[Y;(+OL#RK__[SW>L;CPR3Y7P< MOD^ST^?UU\]?SJ89IPO,],UB-AGG*N0?PZ3B?W^"N%S0*%:?NOQ\AG_[;C$^ M/9O@Y6LGCN?G>%\^?DM/6CY M8II_^G_GX[.Z0'[#Y4A:$077&3@Z!RHD"U%*!\FE9&7F+$9S<^KJ !OB+?S65X\8[GB_/3T]5GPGB)IY=_7W?%3IQ9SKJ)9LT&&MF^='F12&'4 MN<;\"L_FF,:K*:+O)[B:_VE^<3J;+\?_LWK]SB&,;!1>*LA9A5 M"X>(GENN2Q=BM1K!-A047R@(3Y.#1Y%W,[:^7\[2[R>S"0EC4:$L/X]8#L4Q M(R 516O%T(*)3%L(V97LD:9#ZBZ\^QK+OJ-[.3L]G4U7G_M_P^0<1T5&SF4* M8$7RH%Q&<$X)X"%I$0WC.=LN8[N-9$C;\YX8?+,)YB_BG,I^0,+F[LZV6-& MI2Z$>1C;-H213Y,PC073P]![LSS!.3&8U/\)^63C3_AZ2HX:_D)6*-D7;\J' M\.>(1Y,"#P9$0 E*%/K"&&J.DGD5>]MSVP#=ADKJ:5*II\B:\>K#',/B M?/[YF@85*IOBN*JV8" <9!5&'SE@]+;($IPT?4RRK[%LPPY]**.^,3WVG/EF M#/AE'.)X0EH2%Z/B,20I- 0;:#Q%2?".G!1,I!:=2@6]["+Z:R :CN?E^7Q> MG9W@,>KL:64QQ&H3.HB!.<@E)TN+RR@G>@_K LN03/%=)7^;R7O.>#LFSZ8? M/^#\]!7&Y6^S:;K PC#X8,G5Y9S6DBH^T;X:"A@A2U1>Q(B=I+\1SY"L[68, MV'_FF[& S#2DQ^>UAB7%>FV0J_"+Y"9*=."R9* 2"O#(+! Z\AASR,'WL8P> M #8DH[H5+UK*HB5!JH7_(T[IF^7;:H_-IC5"=AW<-1+3!!2K2,>K: @C)[1$ M7$"="HO)!_JI%U\>@7-(AG1#^O225#,VK4S[M[/%U=I,M)D%(5QE8O MDFGPJ11@D0D5;4PV8Q<2W("Q[YA>3S_1I\SFGZN=P%%DZV@,CA4:DDT*G-4: MHE*E1".X-'UT\'440W+==I?X;2[O/,^-V?NFO!HOSF:+,/G'?'9^1A;CY+SF M2=&K:39=CJ?GF-^]E^1(485BBZ,DQ_:D>J[ M8!Z2^]>.10>283/.O0R+DQ?37/^IH;Q/84)0%B^6+\-\_ID0K^-Q-GC!HW5@ M,_.@6(@0,LL@@B?4R")G?;)MMH(W)(>Q'9/:2Z:MX75SI$YH&4.T((6O!J#F MX%PNM&%&].BM\)GU,[CN4;C'=0#;T6'/.6]X8)N0R!@GJ\#%)1298\HA"S!2 MD,G'%(+/VH-1-DO%18BY3PKB1CA# M0D0>:!_22X MP/DG7S+4B$83T4B7&K2CA02YL^; A&3\>+$\S_F,WR+6 *G8N1S+/B>2'53YB M@Q5:E@;K68\A1$;1V')68 M-6 U8!7?LPK,AQ!7WXD S 32C1-U&_QA/)B-$ MS)*'!,%5PTS0B +:*BQ.IIFSB)T22"X1#,G(:2#JG2:VH0VS#-./XSC!]5"( M7S_]>1&WOD)6;%8)257R5&J-@!,0BDF0192^^)(SZZ.SMD$W)"NF 1V:"Z2I MN;M8UDUH,4+.O0C:0:Q9NDI$8BT-&8QC(<3 0NY4G7$-Q/#B?7L*?K?I[1'? MOW:BKWQQ:%P&5XP")66!R(T -!PUR[1II3YGC!OA#"F=HH',]Y_RCL6I5^>7 M;VM%+4WQ MTFRHXF4)0C'E^J30M\'?H<07D6?+:J8-$ZFFQ"3P(F>@V6!,69L+J@/-R) < MI2/P[?;JVU-8S9;>K^/I;+Z:@(M!*5:D#K2;^-6@BA40K8]0!)GX(EEG8I\\ MMMM(AN15#8 P>PFJ1\7299 @9T&Z@C2/=CR3QL $T2<&Z)&Y&"Q'V<0O9XOEM4([+ID4 ;+RM '[5,")1%NZ)%$ZSXFE M?8IU[T,UI !5>V*T$4:+X_H+,.]QN9RLZA8N!_OY$I%G6&I&#&BE:<_*0H#S MEKX+D6F979+NUHZQX:#^P<<,*0+52-[-9[=QE&*-;5/E;3+%64XFF/0<5$15 MB^L\,&9BCL(DC7T:>=V/:TBQJL9;0D.!M*MQ''\:9YSFVPK,%ZVUM1+4*J%( M9 7!*(14;,B2>S)M.A4S;@8TI'!68UJT$$$/EVFG)'V!Q6MK+.0@ VFV&IM3 M-@&ZJ*)VPG/?W;_J56UAGR:_#BG2'CQ\,QYDIPJCNT$-U*UOSXQ6@AG:$50MTS0YTGYN:D4=?4LL+V1Q1NE4]MQ& MT^=LNL<1U&"B!^WY=P1Q-ZR'RHBG%==F5.OQ7!;MO3BMT;01AA0=>4!@I#)D M^GI+_G(B^[?(:**1VK,^P:I=T XTJ-&>AMU%>8MT?WU^>T9_H9\;7JCP?DE? M5]OZK%SV\:R=%K'5[0KW/*#350O;#JG1O0N_X?)+@\I1DLX+KTD#\N1 D1$% MWM;6IUH%'UQAN=/ITPT8#5)ZRWBY&A#2:,C745"R*+7Y.;E=)1D0DDN>D+6[RQPWTTHW1K*5\E3D!:O %7#K:HLZ)B%@R&"\LCXZ M;KCN0X5'0QW4!0?M*--79 US/R\Q_DR3L?85S@G555AE\2.6V1RO.MWAXJ<_ ME_- @AE/P_SS:YK.Q1T#XMI+%1-YI5'5"R%(H7I1JYJ%B5D+P\A9[91+VFU0 M#5;R6YR/9WF<;C;C(@1G53V^PWJO5IB\*1C)76R[/IJMH MEV#>")9!AXSU=A8)-:$>BN(65CD7&:5^D2O'X0VI,C14&G75K[MLAK6TU('^<6LU,6YX@L8YABH M:%3MYQI LE@<4RZJTBF5X6LP0XH_:^\JP&9G6$:OWF,[GJYC9O\;+D]GY M\AUY">/)YU=(8SVEF2 GX^H-:WT7ZX7>S%5LTMH*:=4:.*-\Q"BYX )10DH-,8^RV@' ML$,ZE]B5.U\?K*O;K@\RB*0FX4.M"LWEQJ MI 6''"%+[YVE#9V5/OOI/: >&8)Y&J1H)826[:DNSUF3T%;4ZP+1N'HE*7(( MQ2E"@A&5T2GE/B2XZRQ[6&=KGC.4G$5@(4E0'!%\"@Y,<()FB$PBW>OFB .= MK1U71^_(Q*^-UF%0H/%Y,0&],, O#J!&*HN2-(KJT>EJS],D(<]D7.CLG'?: M=KIA\PY @U+B3Y;A%< MO*IX?I%/:V/9Y7I?#M-IJ.,:D:^N7D+F3V79J*M1I0(/*'6M.VSN< M]J.RHIT5F<;KPZ)?<7DRRU^.C%X4\G(J++)F@S;, &I68U*Z5H"P#,F)S)E3 M0G9*9'X0VI"2P?JSKJF@6H<1-X[[9_*KQQ\OZL+3YP]SXGU(R_7Z6/UT(:ZO MUX+WVI.M$2!C+3NJAU6Q]F;7.08;10SJ]HGR 7;(W<]<$5D*B#S5FG'%((J4(:J^D, 8QBUCMJ1>QR:/#F(= MU\L=$K.:2_:H@>RP./EY,ONC2]CZZK,/$:3>/)!&(>GZZ; M-I&#_VG=)XT%K[4F"\QS1]/*O8$@=+TM0&DRP5!GV:TKPI88!Z7)A\OW#:71 M/4C0LH/')GQ7AZO7\"DI76;<0;+UNCB& D*LTR R)B.\-*9/>>#V& =E%#QY MDNY+@MXD70?[;^+SKFB"PD$;5@_F:ZRV\ @R25NOD)"^D\^S/<8A1;V?/DGW M)4&[@,8^4SDJ7"K/-8?B6.V4ZA30-PR\YC0IJJ!*??JE[ 7[J'/VB![,Y&6[ M8DL1#(AXM:) !P@F)\A&%QNT3;GTR2TXV!"_&0/M46OAJUCH(!G5L WH=>C7 MKG!$:7W,/ &B)S3D!T.PA"MBE-88+A3ODW!T%Z)OQA3;BXY-Y-6)/5<7)!CO M6982A,1(4"H*32-U+.8DC$33R?G<".>;L8X:\F87236U:VJ[[INC>[&\;%"[ MZLHPJ@D0A1&T5!*K%=0:? B*2!T5"BM#-GWN$=@*WI"ZR1Q7-[:5Y#$\/$=_ M;05:T++Z$))F(-JDH-X-J)-/*%RW[K@[>7@[G.&%SZNX\<^S.3TM(>95F=8J MM+]I2H3D2J9ZL8TE?UR1+PY>80899$"1N-.]#OH>!W10";&=*/?525]'6;:K M;[T ^6'V(M'.,$>"2I;N\G--REW2GE'WB[/ZEA'M.Z%49]JHVJU,)UZ[6B 8 MVAN"9JO6C5VY]C#&025]')AFC25XC#BSLRH89A!*[>"D,DT#P2-\-70YQ4F_W$@XCY@(\DG^@ M'(G9<8G B\-DI"ZR4\K=O; &U1'E:-3954X]6J9HHQEJ94$J2<^W*D'DPH)0 M:(M3T6C11WT]+@_Q4 & W%B1P&T(\ 6-7]W]H>OD5*:HY&7SC >-&A1#>%B M1(UX.7!:Q&(T+PG[M')K@7Y(=S ?BG2'%GI'57=QQ?2U%C@7-PN/?'&1<<.A MY%";U1D/SGH/.5DAK? YRCZ'+8\ .:3&L$?3@FU$>(A>P5I:&ETFI8RUM40L M#$AI>R"]C4H63VOBUD;7IU>P_48LH\93?E"MN&J:>>4S*F^P*%+9.B5B:C8) M G,)&.;H,6@3L$^V[:.A;L,O]XWPZS#R;'BYS=D< +'SC[MAAZ/!ZTK83;,"^7%3M7 M53PC%DQ(O$;@HJV-1!29C-HZD"[[$'DTG/5)<=@:XE84_,8B\'WDUU#Q%IS/ MK[D@MWIDEL!B2)D#6A.KKZO)&K %I(]6\VH88"^=>R^PK:ATJ/R]@^G;=K)J MY#/>\F??XW(Y6;'YTH\MH2"+O&8/UC;;&A-X2_0.FIP;;T4NX>'VCUL\:"L^ M'"HO[R"^8].I[QBF6FV 7S)+ZZ4*R]I+_]H=]O4VDL*URE'52HA4R\"[*X5'8VUBD&)!4&@$N,(\:-*U*3OO M#.N36]SD[DI^L O:#D2OM@+K&WNO+L&7<"WCW+/"0;MZEU)R#'PT!5SPNDA# M_]L^/'H0VE8\^M\0:-]97H>\P5D7,O,Y \S5@N.ZWO"K%'!ELU I*<'Z5-DU MN<&9?RO!^3X"ZYVKN*EFWW.7 Z("'0KYE#S@NC5D,BX)J7WQHD],8-?&#;OG M!I."N$QK>SD[/9U-WR]GZ?<12XQ4@G* +#M0-6DY*%(8R3+A3 K:^#Y= >[' M]112S?2%%<+J!"":"=:A;N0O044@Y;,Z:)=%JFC%W51UPKFUAY0)M&;HN(.B4'SD9RP(OB M$*5F(&1A-"?G]R6R^O**_2^A\5+6ILB(X MEF=P$1/P&#,6[P7S?9AU)Z1')C!^<[O3[O)I7B2U]I1O>L_K^V$L5SG'58 X M5!8S#=9^37\]VS^K7XY+F/,X?HGO,)E&$]V MZ/O;$WJ-*6W='.NR7TWBOK@B$EC#*SUU(*]..I J^\AB M35;LHYGV!+[W0<3V3[QU<'(Y:7X.]-M.C0 H.=2W?XF34*)U)Y]4#0">M M*C($)*UW;.[>@7U(3>N>"'E;L. 8[+THW*CM42[R^][$R?CCC2DT/AKO>0U[ MUU!X]?B"I,D,S#DE+!EVKL_95MMQ#"G^_$18W9H=QV#X1?'C=1/R GGAGMP2 M(X$7G4 9R<%;9/0=3]*P$FWHT_.C!?HAE?(_$3:W84*+E.;'@%[Y0!= Z?T+ M\J9C+0%! R;5JUR#"816"9#.)%(VV1K-[_<.]X5P)/-J#63DDBI:R@#"56D5 M@:1.,0"6X)3++,I.W1#V@CT$C^"@U&MD3>T@]&.HF.,Q%XUI"B1U!) M6*B13<@^R.0#3Z5T*FS9%_H0G("GPM<&PC\&9U]/EV'Z<4S.]HVI&W'&F% \ M S)+2C#Q",$%!DDP;;)WM=+CV*2] _L0C/RGPMH6XC^21;\*%/TV6^*J!F06 MIHLOG;YJPFQ.7M5;[<%Y33.8:G//5 MIO2^Y6"XU[W.&TW080[#QGPJ9&Y/B M*+&8NWK57BY,'8KD*3-P.@=03!3P(G(H1GNI9=;1=,K;;S>((70#>RJ<;DJ( MXQ@8Z\Z=GZ^"^<6*Z',!IB2K-U]%B*40:I6TT(*<[G)T!M\&/83LGZ?"V+T$ MWHRAZ_'O%(K2CH5@R,U4"AVMJ'JW2#85O@G6JIR#Z&,X[([Y"'&H=[C ^2<< M1>Y5YJ)A]Z#1Z#@92S\B9+86_?#]@W]'GW>35>I2-?>M7,6ULY/VC_'JLT@&V507>\W&6-P+@D$6_E&]$NUVL5 KN71 M@JS7F'K5L-_1 O3QX]E\W\%BI'5DB!ZA&E1$\")I;/2=D9&S()3TH<_)Q!V MAG#FL"\'MKMKXG%SWT*1W>ZD>M7:[=UUB6/'/">&F6+ MAL:"R!<-1_)R=:V*]ID>]\PAZ*5.U.@[_QVUUD4"7XTE+]ZG$\SG MDW49S=ELNJX/_0V7;W$^GN5QNFK9O5BN1[NS\FKSV/UU6(?A-W*.7M&CIIBO M =R,A*PJP[.DW9JC(L[ZC.!U02A!B>AR0BM%G^#YE@@;=(F]]9SW./\T3K@> M?I A6"U !N] "=IK/5,,@B7S7EJOG>V4AGP?K"%HP:Y,VM >MI&06G87O@7I M]72)<]J05YB67;^\XDVYUI!TQ F&6)WI6T9&*5<9?,@LU/)@S ML.032T5*AX?2C=O@'4+VT*!XUT"L'7W.R]C@>F&S":V9 MQ06XD=3.9X\%=/:I[EP<(M*/0952;$K)QS[G5X^&ND?X[&V@]9/&9Z%VPKH6 MK;Z\HAPSB>N?T_SEY^N2O27/$4,EE:@*8N6[ DG:"\H=3ZHM&RY_F:M1R<981ZYS1JE!Z9HT)RQ9$38&:VW,NE/E MT T80W)2#\.E_:71AQ#W#GC%WY&U7*K()%A6%"C!$,@0-:"3XS9:YECI$R%[ M)-"V"X6&)GR-&P22=A4-!^_)P3/HG"$3G.70)Z'DT0OE@'>.=>/-_%TUH/K\D-VX^Y.JZ/*M*,G MM*YHGIV>S?&D-M7XA#?=A9H?IHE%=6@VYGA3?"VF]LB[29==1!%IO;\J'\.>H]N<- MT7-(JM:^YQ+ !\$ I3(J")\9ZY,'TG(4^[6L#=7!D>"B]?7RQ6)9XI:9 ^X,&Q .RH 9-D7WE6_;NZ WS$/5FE?# MQY)=L,:#IC5!EGX0$)--D%7(,B:)C/4Y"]T&W1!TS=5,)2Y-2.AKP24'%8DH M0?,".@IMR1+.&/OXI_VT]Y&#BLT)VD.%["3_@ZSAM7*[/<8O,\=8,HS3?D.X M)6TZWM'.%@N@]SPDHTPV??+,]@ ]I#AE=WH>2KC#8".7 @MR"&751,E%<#DX M")&L+S2%R=*G!W0S-AYDOKY8K,QRI[U2($MD]1(I1A-F)" )VT?'&.;#:^:' M4 _)DSD46QLLZ]VD?LQUO?*I(NT]6D7P1L;:[Y-THZ<]*'J,J<2,N9/7LAO> M0?DP3XBF?=D\PV?@I^X )C)U53&TBY2F$85HLVRR\I\Y$7U'<:^)O&_YK3\WI127RM(YGRNO[N\ MP6B5SH7:,4\;+,A,[KYBN8!+TM0L@>R\\*;$(\W1MD,8DK)MR\G;N]9QI-Y, MOVZ#RY-1;4EIKPXO7Z M)88%_OTO_Q]02P,$% @ /5%<4T'&UL[+U;EUM'7]TLOM610IV?2P11Y2[9Z9 M%ZR\1)*PJ@ :0%&B?_V)1-VK@ (VL',#52RW%\6Z$/O+^&)GQBTC_OE__GEZ M\MT7G,W'T\E?O^<_L.^_PTF:YO'DXU^___MOOX#[_G_^RS_]TS__/P#_^Z?W M;[Y[-4UGISA9?/=RAF&!^;L_QHM/W_TCX_SW[\IL>OK=/Z:SW\=? L"_+/_1 MR^GGK[/QQT^+[P03_.Y/9W\1*AGC/0.+.8#*N8!/-H K7$EIA,T"_]^/?PDL M!BPJ@E"1?DUQ#;%D!@:]DSP(A=PN/_1D//G]+_6/&.;X'2UN,E]^^=?O/RT6 MG__RXX]__/''#W_&VC4OX;NUOU*_@\M>@?@NX ,E_^'.>O_^7?_KNNW/)A5F:34_P M/9;O+O[Z]_>O[R,=3Q8_YO'ICQ>_\V,X.2'$RT]8?/V,?_U^/C[]?(*7W_LT MP[(6_>62*RA=X?R/^FD_[HWI$P&9I;.(0-_%257P'C&N^O3],5]]%F0LX>QD MT2/B^Y_=*][I:1CW*>![']T#VN4'P2F>1ISU"?76Y][ >0GR+L+ZD>%D,1N' M']+T],T)<7_[X^ M:1<4^.<")QGS]]^-\U^_'R,J)ZV+UI2HK,-8:$=6S&<,7)L41ME(WMND5$R>L6.,1 M#)=T&CAK(#IC(#EF-3KT4:;[7,XO=6..Z8>/TR\_TE-^K(*L?UE*])S-!Y]] M+N+=5G1Y=OY&OSN2PA?+A0>>G &E4X%@$QUK*2?.4#/C]%YKN/FTVZBO5>/% M[!+_Q3NRXTM43_[>F5M,>Q#=.2\$_OOOIK.,L[]^S_J@\/\["[,%SDZ^OL?/ MT]EBQ*,.(CD-I;@(RBH.9+!H,#I*G0L3+)=>V+SSX"=#[#X"O<\Q[X/C=S@; M3_//D_R*#-T1TT&;;!,43G:G\EF"#XY!M"(DYD,T4?3"\*W'/AE^=Q?F?79% M+YOP+)!Y41=YH7'!(YUFTH!1!(R.-0<^I@0V:HO@[?> DN*9>6B9L+U8#-TY>.R\2-L#KV M0.GMISX16O<0Y7UJ]?[4OIZDZ8PVC>4B/RSHD'@Y/9LL9E]?3C..A"CHK1&0 M+.TFRB@R]F(-_TA:5ZCWF7:] M,?V2_OIV]MOTC\G(,&=*X@)TC>JK<_N"CAXTUI-[X(2*K#^>KQ_\M%C>4:#W M.?:]<;P\7-[.WLVF7\:31$Y?\4IHP8D=J4!)3UHHM(>4;2 /4$1=>GRA[SS] M:;&]CVA71$OV"HG= O9N.E^$D_\[_KRT)I+B(54W00I#L**@M7I)6TX).2/G M@0??'^.WGOVT^-Y=K"O8WBLX5O>9%S,,2R#96LL9*K(6LP453 :O70)C&#D- M43@?]HN)W7S:HV=T9]&MX'"O$%A-*)^\^S2=7#KV:(TJBD4@,U""RM9!(!0@ M#+D"T2G"NM_.?/>)CY[+O42X@L^]8ET?,)W-:(5_1,[BZ\%33N%=BZU*F?_TR?PN0C M+@-M7"3I(^T.7(BJ5PQIWS>2S+5 7Q1/"/<+0Z]ZZJ,G=6]1KN"VAV#5R[/9 M#">+\VQ'53HRR\_FHX#1Z)K=RDZ2TLFD(,0BH6A7M#0FY-A'M'+UTQ\]U[V) M=@7G/82J7D\6. MI,?Z"K\(B7. 1(%=;D0D ,:D,2M,.Y'1BP#43 M2>2 DO<1BK[UT"?"\.Z"7$%L#Y&J#Z?AY.2GLSDM;SX?"=0L%^106%V;]884 MS7@H9/V5Q!AYW7V\P[<>^D2(W5V0*\H[>@A'_7R*LX]T;/SK;/K'XM/+Z>GG M,/DZ\L&5B!G)Z4YU)Q&[C8%[Y\"="]/Z"74'X7A&I"P7\ MA"R#X+"6&+BN8\7^<8SGPB].XMQ!:M[Q:@N MK,#IZ6G-4D_3[Q\^A1G.WYXMZEV*ZN&-.'EV1B<)F44)BDP$B!XM"!.CRQ9] MD/LYQILQ/!'6>Q/S"BW8*[+UXA0GN9:6_7(2/HZTY$9@00C!D\.7"H<@(@-T MKOALI61[VMBW'O?HN=U=>"MHW"N@=5D@^,MXGL+)_\$P^X6^,Q\Y(SW#S,#3 M?E(Q>0B>>=#9,1^2)3M"]5)R>>?!CY[:/@2Z@N2]PEVW,9W7^YZCLJ)8CYAI M62Z!BE:"X^2^1\YT0D&XRG['\=I'/S&B=Q7J"JK[B'X1KEDX>3W)^.?_PJ^C M>H\S(VTIUB(A2JB ''0+QCI!+EUF(O?A/MUY[*.G>']AKJ!WKT#71>#E>G.Y M+-OW.D8EDX6B2@2E0@#ZEPITD,96=8QBQ1VZ+OG>-4]^]"3W(M(5/.\?W!KC M_+<03W"DR-1':0N(%#0HSQP$51)$EK-V5FK#]B/WUN-Z9/3&Y>-A7M:=1+;J MDM)WYS=)_Y).IG/,?_U^,3O#ZV].)PO\<_'S"=8#X*_?S_'CZ;U8[_:$G\WA M8PB?1\O2H?I!+T_"?/ZV+*W^%W^.228A::VL!0R)MIQ"JW&D?5!B*&@Y_80] M5*U3PCPN^;EXTKD6X,EB?OF=I3H XQ?7SO_'1D@]*LD#M\%7*,UN#$];2+K' MRVV7P&[B>;7<#K="-+IS)[U7';B/J<\]?]VU^FOJ>R9MVD3B ^F"5V1OB.KP M)P=*!G(BI,\@%#+% F)XL-3^^'7@5JN"0ZI !T'W2/WI='0CX,-^D)++=V'V M'^'D#/^V-(M&07ACF4%87K-6627PQDDPB?;!Y+U!O%.3?;:'#&?3]47! MM(G\>KRA?AL9_X$Q]NMT@?-79TCDR MPF@MIM-(@4R:3,V0&06<-49F0A;)< M"]F%W#7/>2+\]B'%9B\O_\'> J@]6E5B/J"%&J#$'PF#1G6@7; MC>*5SWDR%.\OQ1YOJ=\&)WX0M\#9"W"E]KU@Q8,7M;(-LR#]*[K6Q 1A$D_: MA"X4KWG.$Z&X#RGV>$/]-CCY Q?Z&ISD%^"<5RQALJ E"E ""SAO,^1$!PC9 M(AR-ZT+QFN<\$8K[D.+:6^O__.,=X;RA+W=M]#3)9(EBIK_,IR?C7-OH7=F< M\^FY6#Y-3^CY\U?TP#1>_/Q?9^/%U]LHM^L,M?.S>F@EU<\Z[_2>RJ@TMYF9 ME*+RB7FK AW!GLEH4(H\VN.Y/456KL-,Q;A@T9ZWK:$3Q)%](,AA"-X:ZU)" MO&MJ]1U2N<*RKZ/X>I)F&.;X"L__^WIR4X[G GP_/3GY93K[(\SRR"BN3"V; M%Z$PLH^4!:]$ 5:"XQAK"Z>'[I3LOO2.0(??_?;4D[N.94MB>O1-KE=_%QPM MX.2LEAJ\JZ6^)/D%;23Q;%$#<+]-?YU.:B24!$R?^'%9(HKSQUW'4];8\>Y.5JWBX^X:Q6\\WP4PU^?L'KQ=%*WY;?PI^CS LJJ6K-B,%J'VMP/#)( MBGL1:G_E^% 1SNYZN0VZIZUMO?/3KXOZ(O_GV7RQM)H7TQNWNO*SV=22\<;4<* M0LI8 XHOV(-W/W?7E6W0/6V]Z9V?'AO,EC; *"OF-5F$ MX$0JH'*P$$V=T2 %DS+%A**-$;8&T-/6E#Y8Z+$/7M]NLXO+#;&6CG)023EP M2%^6+!-G+#KW8)^MXPJ-[!&&/:_@2L@=0\/)\:IYVD2'1C#T-Z.$H7?>E9@> M*FOL(00[2+UCH^#B'L(\NH+'YS;6V8 *L6U1Y$#ZT$7D M+M(OP7YC]QQ.@B=E;+0U[9-[N9! M6$]!$?J3>X-=X#TN:'V8?PZS"7DH\PM4O+#H5?00&6%10I#K*1PI+5-&B,"# M?;!/S.[:L!K/4U"#'B3=('_V(J6ST[.36D"T+E5S62HJ<]*"5LQ-G70CM 7G M> &1:?59&NY=F]-A:XA/04O:\-%CTFQE*/("$BN1(QUDP%U4-;O!R*TJ$D@, MF'C6)KLV@8@58)Z",NPKXP89I-4!K4ML,MEH;(%<^Y$JKSRX(C(D'67PQEC, M;3(##Z%Z"HK0F]37YHQZK/[]*:3?/\ZF9Y,<)OFG,!_/I^4=X251G$]D";,Z MFN<+OJHGXLF\>\UOYR?L7>F[WYKNU/<:IY23*7F,23&I8_1.&AE$KB,.E!IU M?EHO$8'SBO5;>\YUA-67D$2Q&G04]5Z@]^"=UU#J#7Z6Z'^-MO8MP.T=/CV+ M\W$>A]G7M[/SQYUGTEY/OM!;AOCR_$0F>;_#6:HD?,2W?TQP-O\T_ORBT,OX MXN1D.1FP=O:<3N8CE70B7T^ \RJ "CQ#-'0V$\?2VJ*"T0_-2MTCY-KW4@ZV M>_:FC?>BM@=EN]^KD*O/A?=8!7WC&^_.9NE3K6#YZ>N[<-YP-FI1?4M(WI(5 MX;@CKS,XX#[YJ*34V>2']^ ]GOYT=&HH"AHX_N_"UV7=TV_3BQ*"ZS#%)>;7 MDZMW98SS4>$HBS::' ["JH*H[=6X)#5W)7EF4(LVE^8[0WTZ"C8,6\UN=E[6 M.5U6/ESOJ"-41F9&NZ1&*4"A,1!"R(!D"'G,.9%WV^7FW_I'/1UM:"+._Q\X6A]&XV_3@+IR_.R#:?C?\;\XO3.L27 MCUPF+2UTDK%8$)0)#(+4)(V0@D7ID=\U7?NL_=H,\.EH3DMF>BP\)05?C? ] MSM.XQEVNH5[_SCGH$;.,15.E"7ERQF0[.D%FMMJ:?;]Q1=G[\T]&5 MP4AH4)1Z2PSGW<$ORZI'/&+$DFDS4*H&5T,@:,Y!RKX($95E^J'1O3VE-&Z# M>CI:TS<#/HU]H4BAH<0AZ3,UPTK%+> M"?/34ZV!^.MQRO3:K?32T;M[\HXPH7;T&M21YY;D(^IE#WI9$GUH8-E[8S=' M\[H]\^DH2EMQ]SF*^LJ56R&#\VKF; K7'A,8P0TH&RUY2\*%@ M,?:A"3-7&D.??$-;Z*N[FG+OT8>Z - 3D],^)-IC7/\6D(N2@VV@=*GV[T;R M(6K[]Z1C%:E[R+(QO44+FY5,4 Q&VL_H, H8R3QFJE:EYQSD5EGFXZ%U385^ M.U:[B+#?%J?_AB?C/U]/)M,ORY*.^9LW+R\K@D-1/M+AQ(L/9'::")[@@.?& M".VR9V9S9F3MQP]GN.TM[VG/PFK1ZJOZJO=#8U5%2Y2>28? UM&U*J-=C>AI';L^R;U!4O1K9Y2NP!;:F5_ >0G>@FW@],;F5@NQ! M0X,RC J0#H=M[N0,KR*;[N8=0$.Z2+]? MV^#?STZ^"L;]:G@7)Y\JVK!B! 11!&V=9 )%%0S4*?'"I3KR<'/F8ILG':!] M:&^T3-O)M-]*OG\/D[,P^UKY>1!A8(Q 9 E!D@B4SG1@:E)^[S(I/:+WUF]F M?;N'/1'B&TBVQ4%P%N?X7V?U^O&7VIV _MGY0!:;(MFV"825#)1("4)TOC8H MX(A!687M2HE7 'IB-F0/4F]00+4"UN4MDBV M;4>UT$[D.G8!X&;E6(/Z0^S M5UP 3"4:])J!5*%.LH[D#MM$/+I4C-)6B4;7- 96BTWFXJ!:T47H[;7A\GJH M\SEHY@&=272<^0+1& \IN&P,9S;'K0+[^VK"P4R)?NAZ6 EVD/5:LW' &WAW M[*#E,=KL,MY##VM^+V_KE=ZYHE=GL83$/$;GE!7,JYR4M*GDR%7@8>,5O8<> MW/ZV'J)2)?(()0H%BD4RE>O,].*2ET[P8GR;.:<#W-9[J%8H9Q>,DW6:M& 8T) MO)02=&+686 ILV^I@>V@ZM(')PULJ%L8+^&]^(*S\!$KRJLB^2)-UB(H,*96 M-O/:KL5+!85;*45&X>XFYUKHS@,(G[C^],5-@ZS/^@@%ZJB99!9$8+0I1N' MAU)[UGKMLX@EVS8QG$=1EK6/;O0C\T.796V3Y1 Z&&L*5">U7L[A$(4-8'/Q M1KH23&HTN?X199,[<=XAF]Q!]D.G"+?!]IQ-WHG)3MGD'6@86E6,MC;4>YU2 M1%MG_2IP-DJ(*LO I7!1-9HG]YBRR:TTI(OT>\XF;YD 8SX9SC*=P\S5!%@I M9(+3/BHS[9[(19%/-K78B9SNJ<4NDATB/O@>O^#D#.=52B]K\Y*0%O,_QHM/ M+\_FB^DISN;[]^C:X1E[1P/W7=>=(" QKVG++B%QK5CA4054/G-C-7(6XVB' MY^T]H98^]JI1]4_A)$P2?OB$N'@QR=<]05Z-Y]5N/9OA_*>O],7GZ3R<_.ML M>O;Y>N)?_1W"/*8%Y+=D?EU45EZ9Y:EX3V^"A:QYJ(T&#<0@'5@O8X[)QX1M MHB0#+G+_1A?GI/_C!N=OQB&.3\CK&7%R0Q-*!!>4!!5B!I=B ",%N:5"B=S( M9G\0UD'FWAREUMYOD=$7FPTBFQ=[S3NGLM KP;3P9?URN_Q7.TVS\N?Z5 M_*+Q*.RTXG\,4[4"5K",O&DR)@-E;$>+<\K+<.SIV /JOC.G5LR7B_ M%N9[3#C^4EWP.M/SY=FL-CB[DM&+^1P7\W_#D_S+=/8AD)^NE/=)J0ST)^%S MDH$C@&"-#XIYEKS=/ 2SXT.?]6R% =N2N 81UEO">5@V+U*J=W7GOTX7."=Q MOYF&R?QZN746IY4F,\$0I.>)%F,DN"P%%).CM4RC";+)#MGK,I[U>MW^>3AM M:5 1N/)-'?GHLM6Z;O29;)*2! 1I$O DF,S,&8UMIO:LA/.LBNN/\GW9:]#* M_<7)R?2/*B_:W5]-S^*BG)U6D#D,.'M.6+ M EYX#EE('107684V_OM "QPJ"?Q87H=CU*MC24W?6N8R SLNXW1N/-6\"0;M MDL ,W-2Z+Q_J;#/%()N4K-/21]:F+F8#L$,EJ8]2EQXRD/?DM$$R\P%X%VF; M;0 V37YOA'B8#'BOQ&ZO-'NPKM]R*UJVUB(I4(,04'*B&C_9>; M6G=DC+4F\D8YGAT!#^\,]4S]0XK5B+>V8!"Y3X(9T3;($*DL.+M+? MN(RAD#=-"MGFL'E$Z?0.$=N7]-QQOOB"CB;#;50)+"D/*)LD1.-I!T&'*DG. MM6[3*&57Q$\[)M5%U_>(VN^N PWR\[=PKSM]WDSG\W\EMMY._C$;+_#5](_) MB'/NBB\9M*T#@.D+\#DG8,DI'B2B-FWZA.V*^%EWM]+=5CK0;^J^P^LV/__= MI:S?XW)$<;U^,Q^9Z+)RJ;9"E@64DAZB\@(D<[O 03XGY^>(BMSO)[W&.A.C3^6H0BV?6"!#)V#J( MEP0IA )-7[(<1/6/4:^.)7?: M7C;+^'SR-EBE!"@70^VM+2"Z&,&*HI)27),[_$A?N6\AD]M)LP=_^SIK6.L< MS2; OX;3JX9?6\ >+DV\/?##)(^/49<>BK,T5H0CTF,R$+/T=#Y'L" M%F=DE^C:9$5D#2J& $UHUGK>_WK2P5V@;@<\7GGL1VKMW; MA97#% R+Y*0/&JRN?5ZT*N!,-Z^P3&NG$4U*;/2L^VVI-%S*.J.+3UN$2 MGD3!D>Q]I50 1Q8-%!E%=!Z=%FU2,T^HXK,3]3U5?';AK4%]T&4*:-G ]#S' MOGS'C:?UIM/?7#8(*&\"M9Y MF]PK]V0+@$W-IHT0#V,V]4+H%DJR/QL-#L#-0(6.3DA9'5I11^LQ>E>2JZ-V MT1L1A7&YS:6^ ZG+!G/I,-K2A80AHW[*1Z$4<>=Y,*",K5UAF*D-W.L$7BEX MNF-+'W_4KV!H05?G%D4RA7*PLB8R(OA:#&>93.@PC9:T47H@PTJU+K> $4/QM=J;!L8+=4Z*!)=(4O"I#S(*71\@PH[T;75 MH,(NLFX0 [L^8B_,L _G!9;G)14A"ID='8ID$^E:?FHA6AE!E:B2-!B];C3B MY"%8ST;) T9);WPVZ!)V@>7B7=H&3%MSY":< YD@_=%U5Q'VEG6+X^86*)]= M,29I,,+2UA=H_W-)(_E@V2CZB?:NS?W[ 8C?9&0,Q'L7$?<;J?H'+>L"RV5( MQ6B7BPP@ Z\]1;2"J L#(ZT7(EIM\4[H2#H[+I$S[4%ZR8&L%83@E ?'"M,290Y^D$89-T$]&P%;WSW8F;'\XFSU.EAII0&I4=$AK1)$46K= MB??.N,R\W5P6W>F1![^1O0]3TP'$?) .;A_.3D_#[.NT_"W\YW2VK(/"^;2< M_UZ8Y,O10F.<7Q9)80XW/Z&_UF_]8>F_9UPC.=UI-F==UJ(4S0R/RFKE;+#9 M1<,%RN4PMX:XCOWZ\)NK*^#>ZA@9#T!2JIW=M0%R*2(@USED;U-V;HA#[IB[ MU)TKP-O2H37)BSA?3A8;Q5#GA,@,=BE?G35M6D% T$Y)J[VE [*)?/< ??#3 MY6@T_M[\A($TH76[N@UM]L+\$XF]_J>.<_]"&]MD,:<%A()9)B#\!E02$KPP M IC15B8;>4IMAMKO#7UXA1Y,4?9HIK@_RZV+]/>>X<2"M\Q:LDNMSZ!R4>!" ME, 860&:)WX]4O7MF?W##J][/:DYV^GLZ^6D*+0UY4M>-.H:F7>!?)WB M([ 72Y% MJTRG0C"01*DM$4B; JOS1XLTD0OE0Z, 68^+>%;:ULPW*$+L]/XMPN3CF$Z$ M<[E?KD!PSUT,$0*]<(2[5NB*5">:19T425+?+74^Q :[$ONSRC;BN4%-2H<5 M+(?N7< ^7\-(:U2LWK]ULB9MDZU]2XV#I(L75@HG4YO@P5ZPG_6S?W9[S)5V MZ[%[ZVVBWY_/1\45:SD&\)A(8L@4^&P%H&&*AZA,"1NBU?M">/H:-BA)]Y7+ M'D"Y:LIG]@5'CF=.3EL!*S4AES67%)T#GHUAG*&.8G,ASYX@GA6L9Z+NJY@[ M0%3^TBBHI?:RA@-,T9)>#F%J>RT'-@OAI[VNDWU:$PD,4T60:[5^J%.!8FQF!"T$+K-S8A]D3]GC-9I\Z Z<1SQ M^'?A:XW 7KZ4"E/DB2M@6#OE^># V10AR108B9 9;%/>N3?TX;5Z6&W9/_B^ M!]4'U]49?7VSHN-B#=9C\8K,994(N4+CZ64W],9;%X)!8PP?8+[GCNB?-;8M MX8?-$KT[K]:L4=F?<$+D+M[&D_''6R80BP277C9Z!64URA,CH\OR6I+)3&U* MP!4[M/INL8YG11Y*"0Z;8[H9%KO!P(AAL"YR#6XYAM:7]8QHW7E!1I%M _!Y%-F>Q'8>*K4+*P<91::UC$XZ#9X9!BK4=O"U13PZ MQ4**CKLP^)YUQ*/(VFI-%S*.:!198L'&6%,?LA8LY$+B49H._*Q=M0$"J@'2 MHH][%%DGZGL:1=:%MR%:%]5;J?/%LB7H>%)O]RV^?L!T-EMFQZ[:X-SXK9T; M$^W\I+W;#O6SQCM-A3A*:7S24@2G-!IO<\P)B<:8HHALM/-3=_:4;GS6=6 = MH]8>>8)29 :5B@,O2=,]IA)YE"KJS;-Z5GWROCO?N4C^AHM/TWSC\VM36E%W M=C!"TEMIB@ O!$((A4OG"_I&3>'7 !INY^J#PKO[5!]2[G?NT#FB:RR_A/'L M/\+)&;[]7,4Z*L9CH46!J:.T55J6CO) K.54Z."7A9>-"KOA(8^3TYZ%UZ2- MYK6&B8BT#R(]FRL#*B8#3M$?R?!@2_"2C+I&*:$G\N[N*LT6/C'.QE_(D/F" MUQI7KK^YO*DS4E8(7S0#*9M"KW+O\=B MS]OKO>@JK3&9VI*3>5:CAB62D1TK=\['$GC!I+I8'8/4/?2\5^\EE&.I'_AE M/ F3- XGKR=S>E[]R*53[HVO%J\%K>BT44;5*44^@72&(WJOM&R3#UH#:.AX MZ][\3ON78S @_ M"&ZU8[%-P.PA5(_='NM-XDV=\9=D]-?K,#A84=&^*56 H&P),DK:.C?7U#WP@ /D@GLC MX6XH?G\)MLBN7*)Z-T,\_5S7_?[UQT]7\W.L05\;M$*IEVO)_$8(T7%0NC@N M"C?*FXX$KW[24V2Z!YGV^"K/9XO1A_0)\]D)OBVKLWWWOXM8RT:7>UO1@9-J MDF','".TW$"T28)PSFDF61!L*^>6@-S8_NFKNUO_OD@?JT4Y*$,]AO4K[G6X M+MZG;9!UL36WTJ&',0UK80[+[;0I,3UO2AL0$@(OA+>00QT[*LBN\IPI,%IY M)5"%D+;*#A^MRJRQ-X]58[KPT:\E^N*GUY.?\,O%,9J]U,QF"UX4.J*7$XYM M5!"EB2(E.EM#W&B:W/K(X6R0OL4\[4%&_5J7__[WO[^Y'"/-I'"V"!!6L-I9 MB/10+QN^\5@X#UY+OY&HZ\]["BSM*)U^7Z>7L^ED.K_L9O+#)1Y.#_;" (_1 MU*'?&;S' I%,&!?%SQDS8%NYN? MU[9LM^-Z[Q3OLJ)C=BR@EDJQP$(MFQ.^+/-2.H6'BWNY-F]3D]AC[Z6!1.]G\0EO!NGI6%;/7HHY0 M*)+>?"OI94T\0<@^)N/H%19M\F9;P1L^#M)(AU8W?^B3G'X-EE7X;B"[6SYK M2_(6,0%SL=Z@E0F0A*Q)B4W$CYIJ<\1XHW9A,!\ .F< M!Z4#0A#5]"=O(G",5OHV%RNWPS=4[[>![(<&I!RZE"/[&9?Y,9F99*TU>RI@MYPT;*R8'FG";4>V=I3.P9,UUS\<3VBW^+76#M:"LC:IFDU/:YNHZ;36 M>SU6HD%9I+8^JAQ#B-QX56WWRJI6#Z=I-CUYL"2-JXWU&1;P2*:.0ET@%N9! M)^N(P9Q3:=/O:[@DS>K/?_O'!&?S3^//[\BYHZ_#1QR5G$.4W(%PHG;SJDTJ M.9E$+##MBM$I%=E$&%M#/.K@7!==VJX7S+XDM:A?OHOQU[,JP&GY\"G,<%X1 MY_?TH]DX+3"/A%(^6(505%#DZ(L$P:(#'8M'7[S(;/._.0490#YM[C% ML 7:\QM](V4C#R@"9$8@%5ER$$/RD-$''Z75)F[;6VCKAW[36K*#W/O-]URK MZ3FJ-]/T^UG=ZL;3/(H^1I-JD3ZBIVVN#GPD904?C+98T!B]>>-XZ E/D?O> M)-H@Q[-FS5<)Y^NNQR/O3!V'*"&(S&NIF <790%>JD=.SGK,0]HAJS ^.>UI M3%.#B8#K*EH*N:4%HX!8S2)E7(:@7*3]S>"R(:0I;^DOR>!+$=TO)XL+;!W9(W=4E)3A [" M0_#UR PR@)..@8VFD%_&C+=N1TW8\.AO1SWZY."^SK@V9LN&/>_%)/]]0L\_ MJ=\Z_X11,=*41+Z\RYI<^^*J^+2&PG)8]D?WT0UHYW1?P9-3R8-2?%]5_4!E M>3R2GM2^^<:$>O(Z <'1^U52XE;13Z5MT^3HT9;E[:-<#4@Y=%G>54NZ2[/N MIZ]7?_VW,O;_ +GIQ?LTV9\ND&'<[H?9/4(.V2E?0_H:A!BIN!S"N\%[>Q]\";-.F7)W@'JBU:0/> MUZE6,](.KFF<7!7#D@/OZP @QF\] ERX(S.LL FO;JM%]4,.; M\@WI7*W+18S)^[^)7YY)@DB@NVFI04M:TL(U@PR[ M&%.#DM=CQG:+6L%MD#W?8^B-V^VKTG\]ADYB7G>/H8N,#CZX\F;I;RT2'[#">N7CABNQWKS:.S762ENO' O! M,*<\LZYHXY#E$C!$*3?,L=SXZ,&*K'.0TI++!B63?BL3!+@2"]@87%*HC8V/ MM1/.51;J6N[_&--#SA;O,>3QR5<2-LY.QY-J+EXWUUA1UQMI%\ @&#@GR94@ MOY;V<1[)P2W!*%5"<)LO;/6#Y:@3,UV4Z5ZN<%"6VL[FO-NJY3^F])Y_/*_[ M&P4=BDC2 KF[]=).\1 $'1!,<1*=8%GS;79Z=G(^MW"9E1Q%F8*0G-0<60#E@P9/U@8D02>3S+&H MV.:"3*L5/3E-/2H5:#!298=UO9K^,=EF96A0!C0&,-3P34%!+VT(D'P=("X3 M3V*KR_-#*/>6:WI6[[9JT*PROM/*KDO@:B.O%Y/)63BY6 PO3AB;.#CAZK # M)H&DFZ$(Q0)&II"WF>WU;AWLGLLP>_>1Y 32F?)*(IU-)OB;GG]VT$I M:,G!+4YN89 ^H>Z-.YJD#:7>8R5^QR1*B"5Y\JK(B8H.E'("O',*C.)D=_A0 M2%3/]6-];4 -2#ET_=C>,?3D7=+")0C&%5 8/CJT MD]+TE0[M0M[ O;FV0/:<#NV-VPY-NG8@9EC5D=%R78JF'3YY4+G0R8U:@E/> M"A8-"OL\@V= C>G"1[,V4\%;;7)&,%J3GRIC.*\VX4E'+AWR(C??'CK2-E.= M!+RRS507Z1P\"UIQ7__"RY,PGX_+&',XKR^3;9*AVSZU;4YTI[7?28VBBJEP MZWC.3BER?@.+-A=OF:L.L'PX-;HM@CV\XQ56NP_3M+X9!RJ?KP,)VD95YM.WD]/3GZ9SFKL;:0"\]PD =R&3+X*+=@C M;FN\>,Z0/U077&-N]Q" M67[,2%IRM3EY,LK6X+!%#4YH#H4CTGEEOWOLY(#UF@?7,^VN LPF)(, M= ]EQ_7\*Q%;XXNO)^GDC,[;UY/+D5I\I)R,TELRRDQM/<>5A^BPML]5]1*^ M4HJU&4D_S/J>7Y!C5J@&F>7>MX%:ZF&9T1"XI4,92?BT' 6&16$2]\[Q\%:N(Y]L3^8])NKK@0 MM5"C!%D''N4 (9"-4)@O@CN#6C7V(A^%5F]_3?PQ*'47TH=HOGRW/N0R<([2 MECK\1 M#YQ2S#ISE&;1G(D:?M5.;#;0N3WRLCM:^%&_J7-8#/\=TR9S>.^9% M0/ Z5MF8.FN)!1"1>YN%X.2'?I-5%7T9BX,R-.Q-\FV0/9=.],9MAXEX.Q S M;.D$P]HUSTN0L3:T9\Y#Y)'77A_!E%0XEO2H5:;91+PV&M.%CV:E$UJQH%1, MX+A0=6H*_\WG,^$&O$*^ MYH'#72+?9L5W:B5"DBYCD(@"53!UKD=RQ0>5G?4RVNVOD:]Y>+]E$LQ&Q[*/ M4 QW9/_X#+Y$!3EY4:S5]$.V\55M42:Q>DM==4N8^8!.!PZT9=9T8* W,F@- M)IG$$5E@JFQS!/74FO>@5[S[H'GW:5E=F#C0M*R+.3PF**ZU<\#H^ 6E. >7 MC0/-C ^2>^-CCY.RAIY_U*<6-!;N$)&8RY[D2Z2OR\]_DL:.YYA'P1G#DR", M/@I0CAQ)QUT$+4-DPF05Q:Y3L-8]\XDI02^B[7?0U3;:^O/)^..XWOJ;SMZ= MS=*G,,>1];IDK V=6(RU4[T")U0![CA:1_^?=AY!LO'A3TPK^A5VCY> U^OQ MU2'V$.J84BC2*) FD) <[6FNSL,P41C/C/+:;?9K]@#PQ-2D?Z'W>^MV->H7 M'S_.\&-8X.5FM]P#1]SK9 L20J'K50A#NJUYH%V/!<$-%]*)'75C]1.?F#+T M(-8AQEO]H[ICD\750;?*#%8"M:Q#'LGA\V3_> ,>"UG%*F7G&2M&[WJ2;/'X M)Z87?0N\QVE4O4\@R<'&4%R @$A&$S>U\Y5!R'18!FM1JD:S/?I:P>/4O8/R M.,2@K-UFO&F?A,I9@_=.@\JJ-K[P!41,T0LA(N@-#((23)@(GD66(WP-;Z0<%23@/9F?\=Q/QU8./@0EFW /H_[Z9_W M_<;][$#:P37-UO//D X$K@.!CHY NP0J>2\%CRKKX2Z#/,YQ/X,I6!>N!A[W MP[E724@$QVJ+-U&K_QRO()57U;XRVPU&^);&_72BL\.XGRY3.5EARQA5?4]L<,QDI<#6H@U5,(%+2@!73@24$5&*-BJR&M"CMWMZD'.# MZXJ_S<)D3@[:G!S\#SC[,D[DFKTM*]#.?Z./G*_^T>4KLL5:FMI!?:[F0&92 M'VHR/3*.&YQNO:[)V3IEK2 (*<-YFBX@TO9@.+G)TAF);=J)'+^^;C*ZCEU= MNU#;0$W/2T4^+*;I]\OC/B4,66C(/ALR'D(!7Y(%JW*RSG)DH8VNW8,RO,%U M.&:G?=+2P I[A;/QEV7]X_5"WX_GOY]/XXHND)5(2T-6.V!&"]YH7F^*!Z6R MB^C:J,Q#J!Z[/=:;Q!LT;[_&]G(Z6"(>1"C$$PK= :"K\B0-DER*3TP##%SIV/.;=I@#Z\D&RR5P^A(%_FW MJ!&]A/1NAGCZN8)\__KCIWI9]?S4$TX67C2=H8R!\LS7$<8:@I28N-<,MVC^ MN I$KR[!%N^RA>HR(1>JX[C&^H8F;!6) FFU%&NWGMPL3C@V:&1 M.?I0=B1^2P1/6#-:<-#SE>B]+F]:5:0(/$$LN9!35!AXY0MD&:*G+9!+L&T&,U)/J4+OL:B:=0B%- M]&W:7ZR$NWU]Z]J[N9ADB\O MG9Q_8^>6/JV [-WJ9Q )W6D!Y%+0DLM4-&K%?*J1,R9UQ.CIQ$AB57%(+Z#Z MRI>]N;H6(ZV+CDORE(QWM?(2H=YM Y]U2H7[:!J55:\ TU\^\+:(1RJS;&HO M+EH2O=6I=H-DEIQ%984RTAF+;8I^UR$Z9&1X-^[7Y_[VD'4#=^O-=/+Q-YR= MOL*X&)%IP,EM\!"],[2;2PL.C0*; C-.(TNNS77;FR@>/]<[R[1)SC\NKC?5 MJRUSE.I($)D"%(,!5"'_,3(ZPK4W/,:D<[A[5[&W5WPEH,?/>A^2;E"V?;W, M\YB!S$G1;RD(TBI0Z#Q9@TB;CE*>)V:"B%ME:O;8VP>=:]YN(^\NSV.YW_I@ MA8MD 1W9:6!=(4/>,0,N(((0RDOE6431YA XIAK"7MCN4D?81>I#EX9M@^VY MCG!'+KO4B.U"Q.!UA!XCSTQ"(7>O5DU$LG>$ Z>+8460%63]$U&2?>H(F^E( M%_FWN$LZG>'XX^3G/].G,/EX!? B7"2"JT:[=O)Z XHS"AMYDW MFD/S$*QCJSOJPN#=NX.]B7^@JPOSRP&-/WW]-\P?QY./[_%\F&1M:;5\5;1) MJD19B^CJT+NH/'B4'IB7CC'I%'>MHQ%=\#Y54Z5GIAJX.BM@7;Q2VP!K:L&L MA78\YDO?_$Y;DM/@Y%H/T-;)!CH+2 8SJ$STAJ(=1.=U5@5M2&T22@-KS0[V MS,&4I@LG#93E5UQ<5V-#?^?S;!3G&%$"KD2[W1 M(SVLSTZRN< M3$_'D[# 7,%>G%<^\ABE0B@%"5[MWQX]V4?1BYKX99S.LHV5R=L\Z1#!C3XH MF;:3YZ$*D:YR@G^?UY&O)R']_B%]HM^>GP]JT4SS7C2:^'1+@]N4FBT MMP3N%!9ISK5G.OML@T(F@PHLQ:!($USVFJTL+-H%1/^%1#$PS4R.(+(CMRBQ M4LOL%23!C+%D!K/LHO=2#K.LBT"N"0\*CD!40I:NK., M9\$*RZW;DJP$=AQ%!UTT87V@;G_)-XWX7EQ8H-TY!4O.GY-8NR>0[1]U LVC MIE/ EN):5\\=O/B@'[J[R_-8B@_NZNA5B3IWW@E=;!TO;D#546DA:%Z_#$H: M7VQIHQSK$!V+V]R)Y6D#:3?PDE;ANAQJOP6RIN[S>FR'<:#[X7 +Q=B#@&%5 MI$Y/C#(ST+Y.2V.6? JIR9VPF67AM FZC?$TM&IL<*:'UHPN/>^;R.]N(ML>$NS+Q8W*,=>%#2P M.._B^_G/SY@6F&L]]@5"=-%F12LGXU>"DIF.4ZX2\&RUX*8.(=^J:<#>2G(? MVY-5DSUI&& O6>KP?TQKONID>=?^O&+&:"=X"A!3RJ "CQ"#>MBJ@[(VN3^]L>XY/5G9YH:9 P7+O%-CV.&:1/I1CF@VS>V/=X[_/L$UKK3>I-;_VM*##?!MOS?9X=N>QR M5V,7(@:__)5C8;88T#F0T1V=HSW4DPTN+-.^WE5);;SEQW6?IYF.=)%_RV;" M:WI8>]HHI5<"@@B"CMC:#SU7?[X6_>9B(W.;ZU@>85_P3K1T[ O>1:8]AM V M=+7V=!1JZ0PPDV+M=Z\@\*" "VZ,BNA+ZLKT,?<%[X7@W278W\C29V>708 "F8EN2] UAX=V9Y."R^E =I. MD*>8R3KBK];CQZV$?'.PI_V(;D>C9TED/#G#2 QLUBDK9W&4F-[ MS#)@FBDF,Z9<5'\4WGST(Z1P9\FM?0L;UU[_A!_'D\EX\C%,\L^37 M_PPG] M%LZGY9?QGY@_UY33W:D<],L7)ER_G2![0].D2KN-K.Z4;L=0G"[H5;&H&',N M<%4O@W*7>''"K"S=[@U9__7_WTRC7.#P9+V^"OI^>G/PRG?T19GD4A9?!T(9?&"<+0'H+T2@/)M,WL\LQZS:M M8H99WW%4EW?1R[7#Z(]'#QJ4#.VSRG^,%Y_NK91L6W+FHS$,4*K:\\]QB#D6 MD#YX91GW5K?)N?2_EN&U^!BUKL<7HP>5:=&WJ4^ASV]+_;)'Q.M).CDC"^#U MY.KW/+U/K4Z:- MZC7(T#;80H*,UDH10&,TH,B0!I]104R*9UH\VD:9_M:GSOX7SY32R7&R?7@A M'U%S1!?/]K$$]Y'GL5P\N]+2G[Y>_?7?QC@C9)^^ MOL$O>+*,2WI,253AZ.0]J+QL5T([1$G9<>&Y,[Q-_]OM\!U+)J63!JS;\?MC MHJ5)=*,>;'X?[T6^I/ZT/7#VV![KA_>D#NL^VXKO*AD22E&H;32Q42/P:-@AEF!9)L^W ION^?W=4Q%'O:QH^&]>W7AX)W\>2XEOE8FTQHH3YJ'42]<)=9K14CN!K/4!(VA4K MLG=\N"ORQSMAZEB4K9]A55U(;[!3KY^0L@VPYV%5_?*[]=RA7<@95'LP!H5% M,2C!U&M5GM7!DAP,8P+1)"NQ37;P20RK:J,T73AIH"P/C$TR@FQ2C@:X<*EV M:_00F+"0,"D=5731MG$]'\>PJD[$;3^LJHO4AT[WJ>!5D3;2&F4$97V"6 ?3 MUH+(F%)$M&TJ(+)Z="!PZ<[@-MN?,X8Y<=LD*[4+$T)E#4X0I+#+0 MA);>D.# BQ(@>)'I8#9!A]8UNX\A<]A,1[K(OT4HZ^%1UH1$<8; >=T^Z50& M)U( $05](0O]?Z,BN$*"EY#KR@4>(VT MY*2U5M9&CFULV4>05=Y'$_86=LNV9+<[+*'56-!E,,%K4)ZX)-XDQG /"_&)^@?':B[X\$HVW0D8' M(=0^6,H8@N@=2,5XO1S+O&MSYW,+< >+A^_)Y+U00[\T-/ J?YU.\A7*"TCT M/B0Z-PT1Y^BU(.L80BX1?&TDZG1M[MQ&,U: >2*:L*^8&^P1JPRLY89H6+3D M0@2@]9+-%.EOL10/7!:E7'*%3/$F]*]#]&R7]D]IL@:RI;;H> MVV<WXXW$(Q]B!@H#WG<@"K5[HHX<&Y&M)G(D/,U4-7GEDIR?OG\DFHQ@8K M=6C-Z"+W!AKQ=O$)9R_/9C.RB):UZ)<1FU2LCC8A!.8X*.<,'8S6 09GE$]" M<]'&9UF':'A+I"_6I@U$WL 47>*Z!4B:Q$.D548E')V2F4$H=0QB+CP[K9AE M;:YAWX/RM,C?69M@C)>XF),.C8G@^'*^&&/@HQ @'4\R M"VXTNY/:6A'^?O 1CY[47F78(.R]!'O1KT*.X> ]:DG->U@//7D_,\S8?:".\6.N\S#YXPL5RSZC%# MX/1E,27Q1-A]VOR:;_&@1\]R WFN=0(;7WU^-\-%^//ODQF&D_%_8ZXURO-: MI(S]7G?>XCE-KCAW7=^=:\TAI4P;,V3F[$?492JR)R M$>#1&EHKDQ =;:,Q&:%$"9I>W29KW0#L.%JN=]&$N^=6GY)O6CI^,4\+O:*U M&1".R%*J6 *&'NAEY\Z7+J^I4'9E462HZSDLB MC\KZ.A?30.VS%Y+F5F/K7?%XKA/LQ7:7.P!=I#YT6?VLRP 1FXY4/XOD.0$L=Z2+_ Y2%&I^3C &A!"3? M,63:.U$CZ.*QRB0$HQ]VE8ZV++0_6CJ6AW:1:8\6YH;ZY.122#Q&*#K5)+&O MM0%!090Z)L&0"9,[,GW,TX=[(7AW":Y]E1L'0WZNY1Z+^;3MYF>?I[AI[J!DCW>?\BD-S1- BMM9'6WJUR)DI/*H0E6:<6BL5(S MIU46DMND5X9?>D/6L!G,M?M6K+,RD.G-PG+0-Z.ST[-$!D&T]$H8S1KU-=H. M7S])Y9LR?CTAO5I*^CX_5QT2L$QG]"JGDS"?C\OX(O<^R;^%/TO6=&U0'_^\WS( M4_W%Z8361[\TPS#'5WC^W_,EOLC_>7:1.;A8':9ZUZ9D2)Q$K!*=MA[IM-4\ M"%HO=ZS1X*2VZ_KFE'M@56CJ#&_;MN:GK^?K_["@$[7^^JI"S-LNXWGPB4=3 MI,@&LA9D#S)/KW2]$&:2B"R@X3RU#MVV7N/P4>%F:G^DBO$H8M#9.\:,**!3 MK>7Q1=6J'@/)AZ1,TEFK-N64QQV#/BY%ZA+>[D+HT!'+;; ]A[=WY+)+Z'(7 M(@8?CE%"(I0%8G!U[D]!<#E:X,'*++/VG+?V/1]#>+N9CG21_^ M;C!(Y6J3 M#LF4!)6U@9@RF0L, T^AZ1"UN.C'8J<5-%_'W&P>_P'5>EI[HD)U, M3\?+VW*O,%[!4\AI?1J,=WS6%0'Q;9[T! AO(=.C MXD3.8?TB?,9R?XMEQE N9O:U[Z';U1TSQ.%[_\3LB)KN*M8PE6GMS0:S/@#K$-YFWYIR MWZ3OBX",=OHENA*9=4I*\/5.GE*60Y3>@=$J)>8$RVXH+;F) MZ]M0DYV9:!*KJ=H>Y;>A0SVQU&12Q%VLJ\V"%W&^# *.6 V[^D(R*8BU*#9! M-#("#U(9:;QTW VD50\C_38TJT>V&O2&O8_WQ>ETMAC_]](K>EMNW D>.2^Y M,*R CRQGF\6(DK'>>1P>9!Q*19O6R7TTS1,E9'=+.TE"[US9XOW%]ZX'$ QZ9 M(YFD5K;&=NB IU?$5;.1/(L074FQH)6EU7#H[1 >@WH=ZHCLQ$Z#YI37,9G[ MB.?70IF?)[,*8:156W"82-%-)&&@3C701W!5<=&W:3S6">9PI9ZMM:@=.\=2 MK$FNR'BV_,BZIIK;7V8K$@O1!YF@U$D7M\\-#"O[J.Z3%]L@:MI)GD=LL,DDOM@;Z-"["'Z(54CI!"TXQY0T$NF M2C80I#60D^%TTG(E1)LN[<.JQ(8L\9 :T47B#33AW;E(SO?$6]OD15*R-HR/ MV@0RK&IGGNP8>!DRZ**XC^0>)-FF<<0F9,,;OOUP.&U(0*L;@^_(V)Y=K?[6 M.;H*DT^-6>Y51GL07+YR]KH<3Q;%OG\]/5G4JWI M_\_>FR['D2/9PD_D<[$O/U525;?FJDHRJ;K;YOM#P^*0:$UE:I*DNO4]_74D MF1*77"(R@4@RU6,S-115%3CAQP-P .['O]'G81773-5,G$R; =H<('@4M!45 M6?""*:A.VHR#(3[5LY\Q'K3[[*<%/Y/<]Z]N"'^[OB)SK'#>@_\>JYD)P-OR M&QDN7/P/AL498XY"?E_/7ZN\KJ75/1@1P&8C:%I0SK&I3K3W?8>?PQ4G8;A# ME/^P:/_U[#;L?#'+]X.&M_'B_.--ON.9-Y&9P .X4ESM3E%D4K)H MW>?L>R^XI^B!_7GK<+4TA/L>G 3ZVZGGMX4"SEFLA?MID,G!)CRZ',(KO^0A2%?BHI:6FUY7T" MH>=P*M[%(\98_!BGXCZ@T9HQD(23YD6.$(*B72CGR5M6O&9]VID^HU/Q41R. M/14?0\ 3.15G'NGKD 8\>L=/Z$\/?>3> ML*<;D^YOW88;Y.\@;CUM"(PQ$>=PLMM_Y+L#RP,H>$CB ?;K\<6NKM.R2R9: M!1ACHETYV3V&J("C%\PJ+XL>=)+Q-&C<$ RV9W&,V1JS]WOX]_GGZ\^W0)R( MC@:K*C6JAA1"0% R0);%^$RO15-+,_[N#3W=:GN0\>>EIR[^!)@.OM2>VFX/Z^%+B)DA]]D8E70( MR?L2F)"N.%.47R-9W!S?8=N"K0/]D%?^<9(;E%)"\ BV++MC4UP;:@)I.CJ ML!7_<#5/__PTOZ"G7=ZT;2%C7%QGFA;>U4(DXN3>B_PQG]6+!S(]/?'CJC+\ M3--4G4URD*U40*;SX)BE5XDFHE#&<=7GC*\-_B/X8R\7>7AA-3V_'4X4MWVR MZQM&W/ZZ:NDK6OZ\(^_!H@0HLB9$:0*DZ$NV*I,%^UQ='8+Z=#UR,BX[7,[O M@;VB#@)ESED#LRAI+U!59DL0B%4?11+]D/[W]\[P#^.F@([(%Z9;BS M6#QR1(3B)()",I3S64#.*OJ8M-"F3].! T#_Q_\.9;)#M>Y#8+^1$0<$U3=* MQ[?EQS_F<=JA\FR#AFK+FH,3(* C(S*32O&>E]*K4JKA:YRNHQZ/[<>NJ[NX M[CR=WT-;<285E*Y?5\0J\,\,0J@;OV*%SISH*GOUH?C>O'?FL[]]^\P>BM M5Z5FQB*O^X][(N>$(3H*5M%!3LK1 M6^@"T3L.QGGKD.F$I4\63X]SPFXW'#>9&D$8&6J3(2M*U1?C'ER@@)\QI]&A M%R'TD8,;@W*JU/YIS^][T?14DOR_MQ)9=6I?:6+?*#5DGX+*%K1Q!521#GR. M$0QBTKI8EV6OP_PML(Z57M7/&1X=U;!=$9*9/O?9@B--O-1I0.CZ&V8./ M#AD(=X"NR5_^T1I]E7-7!$N&)]"J%H3?J*UB@>(3&F:9E*;/S#(.YY/,<-F' M\,UNU9JMAI/2Y_E=H#?W0/NERWM;^%S7T4V4E)B.OL'$V$P&VB MO;?$8*UCQCQH'+"FJ^4A"$[-?:8DI,.]_QWL?R[(SV]Z6CWR]L($PY@<1/J) M4-8>5T8%<"HDQYFHV3*]YZ8M^$[-J3JRL_$6?\(\ZT=7P=VRIS>.U#TG>M@[ M/LATUH(;7D6*T"<5BXS>9I4-\Y@3RS;NS'3>.&K;NZ$?'OCV^NKM]CSJVX.$ M[\=7@D7!I69@@B1GU:B@^BAPBSPHS%:K/EF\#5^B08O%E6SY_5CCLBH)S2[I M2_N*B\MP\;;<_N+7?]^>Z=Z5S%\%U6?1ZJ1T%""DSJ"20HC9T3\T)BE02ZGZ MM -J_"+'*"\]CF>O:?]X-(_HL/7Y<7I8KQ8W1$5GCDPD3/4JX>6-3L!RD62T M,!9:'5%UT@,=!._G=<;V[/708EC,Z?.H(,^8#)8Q&C\FYD&YZ,$S*\$E9D4. M6OA.?O0#P\_K+'ORT&$O\] B0^UP<\&1*.R2EEO0] -0Y!S!YQ+!2F4+5]E: MT2=%X"#84]U2/A5OFX[CYW&C:3CM"\B>4,2R2Q)WX)6W(()$R[!(R_I$?D_R M1G-"[QAUQ3F&I=\KSB%W'\581*L4A&@9H74!?%W*69$FJ2P3 M$WT4T)_Z354#<@^[E1K#S!%O//_ J[_-PDT_2,RU]6C=/]R^@TI,>AD5V& , M*%L/S)/W@-IJ%D)A3O7)'6^!_J@W$Z>B"WMD7I[6MH9Z1C M FGK$JJ\9>+@2I+@I3+:!!&4Z9/OV^@%_N.HC4EN>*!QZ)VRL%+8X@L45F$[ MY6GI,1*$B4'I1%^9?5#M=4J7_+V<:TI6.M1:#[Q+CIP7X\@47M0ZAL ,1%O/ M:A)J5\A0J?^\]E1O^B>?;+!5D->H*CA YN%&0TA( M6RI4.7;J'7((ZI_O.&LRCI_0-<#M;FT(^LYZ_X?@/U97@*G\I9&C'D!VEPX# M![T%1\TB\Q9"L56:FB)45ZH>-IGCJ&XR?DH:LD MR"2TDRR"P)KO;ZR&*"@^BCZ($A06&9_6LG\\N?OIO*21@^Y!\11BOQ]NKE_? MXY=Z#E73I)9_?A6NPDI7?N^TTQ'//CC1=-_W>)!:FJ15WAEG<)FVDUVD':@5 M3BJ70L[B;,0X!UYH/QCH]:S,%Y_#K5UN?1+.AZ [?#+]BK-KK,E5RQZ1(5W]X_SJTTO:YM'WM/B>V?>BIO1>XE(= MQB2KHZ*U)GE6R""&HGG&))C@BI'&H\!>:_QHL--/F\U]ZO'DV)>RAIQV'-%,8?+V[%=4(.U8&(#HP$W24 MEE3TT(A]/#N>!1.23<5#5I+3ZUH/WFM?^XSXK'(N9( NWK$&S EZQ*$F[W#I ML-*IND%TZYI_X-594-:K2/.8UJGVF"D*HL,"W&8FE$<;99]LD4V(3M ?FAB_ M@_QIS2RY+7Q\._OUW_7=K\\O/RVSTLLKC%=G2M"^U[,$+%,<3G,7@XA9@F,\ MJI"=1>S317PGM!-TD[9T=) X;5UD1TZN&=88RF4%"LE8@0?Z!G+1F4,=[<,+RJ9$U<*# $"Y6F_%ZL.=3%%Q)!B((0[ M=^<[!CDA!VELT0Z"I#> /F"Z7I"1\;*>,\VOR10AGU]\>X6T%E.87J_X?POG MB[^'BVM\_?D+_5C1U[=Z,9M=4SS_>7Y-CBO1:Z<]!UXT R6M 1S'[VJH: (Z+9T!-+3@ M*UV3*J.AR-$K3M& 8ZK36KD3V@GZ5ELZUIP2-A8(J$?JY[-K,L7MUO-[:Z15 M0M._D1;NJT4@ /11++XM;;1)BED:AC;1A)VEI_F;MB:UF1=9#E4QZ'A1?5RM MXTN=H),^%1=8X]X'GX+_Z%R^Q8R_?+O]RYM\/>4BDTYE*#$+LJ7/X(2,D W+ M*I?H?*\KS_%@IRH[[^Z$O8DZ=A5Y;<>NM3V/_Q/K=/9N,<_7Z>KR_A*&T6'FA,G6RE-EC(48#()T MVH90?.0/TW'6W$9N'^-H1Z'[V'[>PW"-D\47X>+/>0PIS>]#$MP*1R\+6.@? MJ@0&GFL./EFK561)9[^3RTU/?Z8L-C%6VR_R'S31W,=22M"R( .I/,61M?P[ M6%L%3%R1P7IEW&[B'CWVF3)VF'EZM-RXN%B6TJV6AI4N$JT!(B8/@@M"%2SY MCJ =AJ#=A,T\AZ/,^1[886GJ)-QL.= ^T'WP7Z*9U_66;?_AYFUR6D MJ^L%+GZ(@-QL0UM5+NXQ9O.*QD/?^T&EH^!1<)ZJ1(I5/D9/&ZMH?!"6*VM* M>'2IM,?X$U1 9L:M3IR#20EI06$9?&VX&6+.FN %V:GESA05D*NTA/=XHW8S M?T->]'$YQ@>\NKJY_#KSG-N27 ":!VK/4>6K5%P 'JS % WJ/.B&:J_LW9WP MGNB5_!B_69?!VY:6#L>5^QR].&5BJM7PQMFJA8,%'%,6$DM,!A>82/^Y6V_M M3;V)>@IWZS\^D)?A\D8DA,>,%.Y+D"@UJ$B1I?/60_+22*=D=GE0I?:@*[3' MXS^G$]%1;,^;6;WQ9>I]-'_2?[&*80=@:GZ?O@G-]/?IA[*TD? #33P5_8'1 M'B:K",RH*L82&7@O)""/6BL>B@F#4J^?(.U;[M*G8'V,9=L>MFS=*RSB^=5- MZN*[,,.+5YC.J[E6QP[28LDZ@TC<@7(:P>G H&X[11'V;]X.&G_:F],V MU,VGMGNW5FC?+P;>S&\;Z-0/(R)M5'4J]/:.(NE2-#AT I+AV5E) 37K4\>\ M!=2IQP^M>>EP0K@!VNT7- 1#3&C0597] M'+('A:4VF-8"F+!>%9^+2^)4W&3'[>QQO&0, 1V\8XV8P^K*42N3 T5D0M2V MT8$GB!AJ8P:7)&TCI.F/U!I2MUM$8P^[M[WJ7=7'O)C=J#G6HOP? M<@XK>7'&?9?4SCAUR$BGP'8/HW:8!/X(-5+^ M7NN^G/&TQ>B5%Y!K':#B-7C*R"$JU(Q9*;CNDZ:S!LS/$G0>RD,'?:6E^YY_ MOE%+J*('EW_,KUY< K*($ M0BLT6 R$54B"626*N316),.<2'T2AX_G,SOBT*.XS!@:&I^9??G\XQK]SWD% M2/-MN,!50)1RTJ+4E$B3:TLPF:MD)4+BUH6H;=)<[(PX=HURC&BC-2WS/C;M M<4F[-1'6>4W!5#&@+;VY\O3F,3H&Q>:D<@XI=MJ3GDPMP2%!2#MN.@C]W<\" M&P+FYZXE&$77UISR?6S=O98@V9**Q@1HG20_5QQ"R@B2>94E.H.^4W_S)UY+ MT([W,2:>M); ))99C!Z"" )4+HA9]Y+<$HVP^N)1ACN(9K M?\;SLS?X,5S\.KLZO_IV$]8RDTKM1>)%X* 4\Q"=U<-;==P,GZ$Q[BD-)>1H-"[K6'34^!PP_+: MC<(Q)FN[CK[[='YQ_N7W^6)Q?OFW#R]6.T!#+U*D!8PA@:(I!:(4M"',TC*, M1(;9W;9C[:.G6S4/,_*\H84:KI-;%$<0BPL*%="NG^(!&3,$J5-=P[DE'\T& M!Q4!_22:3/OFCS:P?D-YZJU*$T,P_7R:3*.8&J+,LX^9)Y/E2LK[A!I*D.3E MQF>(@98H(3*M3\;';'H*M3TM3:;FS(^Q;L_TC ?%BMK1)!9$ F.8KH>X"6K5 M(X1HJBD,) MD(8[5ACGZ/JT3GT6JER'^$-#PV^<&'HV-+T-F.;E5I @S/)?D?ZK3_3#2UQ< MD7V6"2D_(66*Y>C>MP_ M]4 P^Y^J?A_XW8*>]>^'P]])S?\4%A_Q\LWW:K]83'+TOV"#<*!BH=U581:8 M+)%)8[05NR]B]Q__T)FTYMC=Z$A_Q%GZ]B*EQ76X>+>8?UW6 YS)2"]0"DWT MO%A0NE#L8)V@_5Z5WDJ66R^[3*4[@$TWET[G'@\GVY;2M4.J1T7/&UUN47K:?LI,,CVW\HD%<+3>\DT-!R[8'C=T6/DM)TQ40(J MK-J?F" H%:N2)(HDK(X''K0>^8)D(F:W7(^,L7#/(_4A.$[P>F24^3>=K>]C MNYY$F24D7==CXRQ4./KD35%Y %S<+YP\*4JD:!! M\$P42-'F&+)1/)=FIZ#'E]68=MUL8/.&=;#;"\@'8/JY1#5&L31(7F$/$T\E MJJ%<$LHF SK5O#?E?,V82L"B3#SY*@OX!8(H_%@A6% M')IA!*]X@B**U#XXP[I><_XL0=QZM3,$T\^7^3"*J2'WW_N8>;)N M5*PH&VBG*451]2@X@]?9@!'> %;'"!ML/%*^E9U%:&09TJ MGW<-\;0[B/;,=*\@'@+FYZX@'D77UDK2?6S=O8)8)*>*L0IB< 1*&@?>^E++ M/73,RC'^L(O1\R'^H KB=KR/,?&D%<0BY2"TK)=@A18PSFO'ET0+6.VEB?C$]FUNMF)^D&ZJDV>RGO!K MQI1BW&LLM# SRZV2VI;'36P>/OVP.?0]7EXMKJN^,CV[JLN\F&7Z'2Z^XIOO MF5XN62%1T&;!,@-*VP2QY +1.(?"%%XZR1K30AH MFRSZZOSRR_PR7/QE,;_^\GJ6+JXSO3[]-BUS6Z\QWYZUT';M][#X)]9O\T7^ M3'1YD&",-W '9"/O4$ MF&L;^(QYFYM_=TG=;6.G&_36\6A*B."BK@75Z&F1EQDX11&V(!/!\Z9^MP'( MS^MG+9CIIW'=YAWM&61KD!\J;H\E]-T+KCH M@=S?<)36*=7GP'\$R*FZ]'5WH5[$'+O89JT!WUV$VW8/0J$KQ4 PAH'*0M9V MZQFRR/2;@,[F/BZV%L[Q-5<:<[]M;=N+@P['Q(] K6I-!L#J>F.P =AQ[@X: M4+?+&0ZP^X1NX;SW' L"3T(!A>06O".@ 7FQ(M?/8X+XM[<[[+A1F,X;QIB[ M[=;Z'[2L?K\PJ3M__'B>ZI*[.AS/&%C )(% <% $BU;;HB ;EG/,P7&]N_)W MURA'#E;W96+>QXP=DH^V!%9+IY:^ZCW8 #G4,T:M:;T+NEZ49:=$XIK+R0^W M?[I8X4!>.IR-U/S\!R982=$, -8U;M@([0E$#H<2.>_)0HF3CS"Q>XR))";SCC'&;QM5O)Y]II$_A$E_./W\^O[J3*,,I=L5"TY3WEK8^PM(FJ-;?.YF=X"B, MZ)2HO@G1<_>!IA:?/"G9EZRXMA&$<+1J64]O; 6"UY*FFN",-:J+.SRII.2I MMPSM..EPAW8_76\(F)\['7D475O34O>Q=?=TY*RCDXH9X"$+4-(6"D:$ ,UC MX"DKAIV*69YZ.G([WL>8N&V0_W81+F[++^[GTP:;O%).0=:E:E4K!9XY!]'( MI**4&?F.?-4M3S]V"O(H>\_;&JNQ%.3VK&BDS81C%,K0@I0)F&80HK40M;+" M.AO]PQR'9Y=.OB>7#0W7_C#_/A:OT7AE);CH/"@C$KTA00M*HS18*V*'G=Z? M F^'F:=#>/VWV?7E=;AXNW@]*PO\WVL"5E,<;KKT.!^*0 /GV M[Z]?<;\Z,8Z^Q*AY/:ZR=2&U$'2*8+!DX06M?D+M# _N/7+ZT*"AI><-S-3A M\OY>DOW+BW!Y>5[.TTW^:_73S%30K/8&$K577*'7'KO-WJU*!\!;Q=$# '8-&W9"/$[HT)38X4YS "L=0HC=0*/4A>=, MDZD/",H6#SX'"5F83+"5%J;/=="1W&9'*'%Y#)?T!_QC_G5 MAJK#FZ75*NNLE0C2VP"*YE[P*3H(I:"-1AM30G\?&@YX^OBF,?7;'*L3;QU" MHM>S-/^,/\[8PT68)?SP";&FUKS(>4E*N*CO<#&_O%[@Y2_?[KWKY8YJQ9L= M@)$FI*B!:UF6V3@0DDQ@N=<\"@J"99_:]VG>[]0#M"?H)8^_A;T[Z:[]A'L$(<2Q_7='<'K"[CN&_\:"7%?X^SFM91<7^.62A>2C!)5+!L(CP4M79,J1>?_@5&;=_>F6$8XO/T#T#?S.QL] MYWQRJFH,:]2@6&3@JNIMH#ZR4*]O?EX["JVDZNL"LX&@.L: MA6V%]R1BK?W)'.8D!S#1(0S:#C)IXQG7 H3!VCDV([BB:\V(2E)$QR3V"7:. MX";C0IJ)O&0, 6VCC8$Z7:O4%E>,2%Z T9H1NE#%=+(%RQS*(G3D3.\,/T8- M.7T\TI"I^01FGD([]!7&J\/U0M<^Y6"-T-W8'NB">E1,R)2<8TH));VCSY;Y ME!A'RTT\6_O$ W>A],C7LQJJ+%WJN^I,MKJ4Q!0PH6K&;D[@T2=(Q9=4C)0Y M],G'V@#HX$3M3_/%U9^X^/S+?+&8_XO\G69-8:/*,5 DC8G>440(C*)K9G@Q MS&3+L8^LU1HP1]C=-&#^4:[V@5;ND4UP[S5_"PE??)Y?SZ[./%/.(,V2M5 0 ME+,.7'("T"CCG7")IS[;EDV(3L,%FMB[QW';/5S51\^\T$PQ5<#&)$#1_T#D MEM:VB#DSHX/04WA Q7**W(^V<<.4XZK5>0_,KW6IK7'V$I7STA9E(CD?)U2L MJJLE[6F*8LB%,EGGN#-:W#+ \Z:SH?$ZU-S=A_9+N#R__/!E@2&_G?T]4 6 M*7JD")F?&7M*5CX8IY8^\ M^>7\*\Y"_?^KKDN8?_WE]9^O7ES-7\^N<(&7Y/%?R.,K\//Y[T3+Y^O/9QJY M8X8VV4[4ENF!=MJ!<0Y:UT F4BQ3=I]P-X'RO!WG*(0T3#A<@W\8[K,8)3E# MH=C757F#4!+0"U@P$F.Q)HC\,.0K3HGD8%"7FR;-/E)XI!5&S2E:,JK/[G,SIN?M)(UMWN%J MY,U\]K&&4$LL*(O/GCDP7-;]$.V,O(P(HA2EJ[ B#WV2K>ZB. W&][;K8X[= MX=*#7\*W9>7[V_(WFH;2]0+S$A@/OC#:Z((.\K;ENROTFB&&$B)#"JK[Z(=L MA'0:[+>Q^&-7\&UW*JOEJ0;#RS/\_ X7B?XB?,2SG)+4-8"QF?A3"2,$O3S& M#\BM2Z8X/<%>91O&TW"63IRL.;!J?'+Y'C-^_E(-_FYQGO .SNB1H_0(P6@' MRE,L[+$VDQ"U'JQ/>>- @*?H.&W86.,U#22N?\R&]]9%+7RB^-=!-H)1 M[$-+8O!" RN!=N&&"2O[3#&;$)V&7S2Q]QI'.%AMX2]DDHI?T-7&OHRJ6 M)=/G".5G\:;&'*QQDX/+OE27*D,<.C'.@ >H[E2@6SS2$AD1PIRJJW5\Z&#(ZFY>!M*!BG M2,>=TH5VR8\\ 0\:P\KDGO-VAJO:P>0,#YI"].)KXDTH$)FW5=[+)(W>.)PB MR-D(\-@A< MV1[G/?M1T2(Z^FZ!U(]2-29SY9G-#', M_OFV%%Q@KOC>O/[E[?O;M4B'Y .7"5@T"$KJ"#$(!5B\2]:J$D*?,&$0O.F# MA$-Y?)RDU)B$#@'!2X)T7JMVSB_.K[[=U!9K&7(4!;@5% 99:\!KCR!LB580 MG-0IO> QEE,)"@ZTBBON(5@H! S!U#0S6H3I.:' H8UL=X !S=U@LUF(K MMFAE"R&R6/LYHZ4="VVE8]9:%AU9$N69N\".$&$*#QACY0[,O\>O\XNOM67K M/7"KE2-[QFGIB])"-M:#*N3S+CL+/@63%5."\SZ9S.O0G$I0<+"E M.[1A>8AII: X %77P& ]KN.$!H?SML,1#C!ZG[WD.G3*Z&!8*("Q;IC1T5Z9 M:08B*Y<29N2Q3RK.E*ZP(T28RA/&V+J'!YS/\&VY6:QN%RDF$^ET7;:[')89)GHSNU+WK,9;I X(6+#TD_C 3=X@#/N#L?+[X8WZ%*RDH9P)* MQQVD4O4\HBVTS,E,$V82C->*.M\G#^(1E).@_# #=[]=7,YER=O(F(P@#&M"^6,LIQ+U'6CE'GUT[B&Z(VL[!->$Z2S'5D@_E+FM MCG"@V;M/!W?PA2P]PY@HP F$SR0#3G@%*=!>. 7'(INB_.S(@N-3><,8:[?5 MX]QP3/'J&E] Z<8W. MQ?#QCIT_LB\]\]ZV;1@'$LB_?7CU"F?SS^>S6BA[-U*)S-(*2""$W^=FRK@+<)FN*WT&H:6[*)?"Y8>F6F6-5'L&"S M#TJ'DO@ &;Q=HYPNQ7O9L>'E[19H>@7-613H)(.D2ZJJT'7A$ J\2I()89VV M.\21!XQRNA3O9<>VXG6;H)D5-&NBI9C 0E+&D/QZJNZC,OA:8BMC?% MYN0IWLN.;>7DUD"3RK-;58DE2K%:3NI10_$L@T_)@G+.T7)B(]@252S,)35 M0V[$@"=)?!/K;I2+:ZQO_V?5B%\L\\4N#Y*X7_>@)BKW.Q$^$+H7,HH<"@K- ME7(HHK/),?H!93TI]6>;'MI'ZUY[PP6G&9WQZ$#)6'/NE('""[,6I>6YSW5V M)ZW[A\4'7ZX7Z5.XQ'Q'C1N);5F;NBN6E]7]$;S)&HQ7S-#+QRRG$,=="^[8 M4\Y^GK&K!.10%KIKXV\5PPHE>*Q(=8D!5*QGW#QQ$$AKHV99:YSBE.]Y")2U MA7A5:$[G"APMEZ"X*1"$I9T0A,-ZV M3Z6>?FU*!'0>I,(JD49O$S3SD&R1R#,JK;H5&CSI]+%1# ])'QMCZ>ER MA8:@^KG3QT;Q-BQI:!^C3^<26KJD%7TY3M5.1TQE>A^SO2Q M#IXPQM8=/&!-H@N/4M!>^^;UE-4T >;,(=7.0*(HE)TZ,3W=3*)1'.W.)!IA MX.[;C!MI!N4XCX5!+"I7:08&P:"&;$I*.DB!LD_!Z=/.)#HD #C0RAUJS3<> MY W!]7-G$HUB;FCNR#YFGS*3*--J,'KJ MF41=O&&,M;NG'@BGUQ_(,U6<+\6#EX505C6?J+P "HF,+K0:6+=[ M$I-2#U":6Y08! ]%V##@2?I $^MVSW)2 M#SW5KT3SM ^1&P\N:TVS%7FJIQ"GZCK6?%EM]$.AHH$^L&' T_2!%M;MG@;E M'T0MTJUD$:*67-=S4:&1(E=6FQ!+3SY+_Y(D:Z *^_C I@%/T@>:6'=C&E0# M'Z@VX$S<]U2Y\E2E&84ME@$S2M=CS7H^*@)(&U!$CB$^;*BWTP>V#GAJ/M#. MNH]]8.]>F6M1F@<@]0IDY"S39E77/H\1E$0%S@@+5%^LBZGU<8--XI^@! M36S[V %<\US(US/Z$?\,_\;+/\)B$:[.O^+>^9#;'G9P3N1@I _R(I/%I%SA M0GFNHK-1!LZB#=IYCYC#V;8'[_VYO9Y]Q M)3BG:YT2$<\\;1'%[C.7=4\^8%[X]7^OE[I(5Y_F^<>C7W_^$LX7]:ALA8B>PI>S>[#PEVC3#<'M.#FSJ??U'P=K@EO\'VH_5O) MH'CYCW-">GWU'D,^O_A&;HZ+.FW%"_R-$/\]7%SC#_"UY=6+V>PZ7-RF5@8= MG9-<@DY%@4)>^Q+1[E;01K:D$*46?7K^-'V-Y^ELQV>T[4'E'MGQL>_1:P!V(VL$U-!*G+&D!D9S4@R&J,(J=CLE%2Q6#TH88F W)E: MZ$\/IY5#D4Z=WG"P9\R/P%##Z:+BWH1KE=PS -F8](=!/K0=T[2)#]-R.^]* MS+2NXZ)02!,S1&5MU80R0!\6;?T,3\GP;)EL-^T39VLSS!C9J MF^SPWW_[VYM;$+2-DMHL5\&ZL]()P7/F@)O(98XLHM]=OOOC>:? TI[6V?@Y M-3QR>DE1Y_GL(\X2[5[^^SHO8\[+=^$\AUE^MYA_/:^SUF69+_ZA6LEM %?X]]28I#92IL?JFXT*V?8A.GP MPHV[3_[V*GP.'W%I]^6^_4P$BSXH!HS1=Z_H9R#:%!BTJ7B?:8WMI0F^%=@Q M4OJ;^,7C:HYV!/00BO_^=7W JZN;;?JJ>O4L*;H2WE6,]P]F,(P MTJ][GGMBY06U^'B_?SBXK?YXE]AD<\P,,U%B) < M!>7*$8^A> '92!-=1&=3/#<14R MRL!KV%[JK82FV!TMB&H"9NOQ99C04Q[ .[:W'$SK(*!9L2YH MSBUX%+4O2ZVH\Y(X9J6FNGG+M9S09;X#^SF<93\>)IM?WH5OR\W#&>TK3"GD MNM(LE;]X+;(5#$HJVA5+VUDQJ9?P?0PA2NH=B>\=;@T:=4?T((G^]))_YURO\,K\\OSJ3MM [4>B89216 MDO#UGI"#IKVU)VI?FP'/SC :F2W[MY,+WIS$Y>UM\+5BN)8 MNXQ')%0*:NAW&,J\@+&^0G@^Z9'H]_K)K\%H3.FQFV\=7B?31WQ":& M8&I^'[T)S?0WT8>RM)'P TT\%?W<,A.9#N3.6H$J51VD2 8Q(T5/>QNBA9U7D9)F44!E)B%,7:0%%L$ ZX9FA"8BPI ML3.HVS[&M#>3;2B8][!?VZOD7V#T#652MI,[;C MJ"6UX7" 8QQ P$3SQ6IBI)G*:6-JI1[6%K.UUPPOP%,QTF?+1*?;U:E=8X=R MTM2>,<;N'3SBQ>4E7JU6LYQL[0P6P"JK*79- :()$F0T4HO"7/1]]-SOHIC^ M/*\5._-&INV;6'$5KJXO;SQ:B"H.;XF04D^M*()Q4G$H#GTVKB@O>C5CRZ;%*R3&I*L M6QJ5.42A#!@"&HM&)M(TL\(Q590G\H0QMN[@ >]PEFG>^P'N=K%*.L>8E*+) MC]M:P^LA)MHS1TNQ#Z/(AQ:Q+BZP = 1KO@:\#5O;^R&D4'&\[,W^#%<_$IK MW]6WI8<+:Q%=B1"RH6C'9P41108O6$(GZ / O(7W2TS_]7'^]?_0HV\HIQ^6 M3"\Y7C/@":SYAYJQH0!6A7*#XM9;A^ 8L+COIO7NJ-,NW0>;?][0=@UGZ$=X MC.2,>:%INUGKCF*@GUP1X HKM9\<9[CM0.\I<+AAS>U&X1B3M;TX>??I_.+\ MR^_SQ>+\\F\?7JRT$:VG3:26@)+7W'I:03QG$;A+UAKI4*?=:F-K'SW=^GB8 MD><-+=1CD_QP6?CEVQ^T^"_P;;F;-%4=-,N ,=:VZ=K5&C,D5W7*@F;HG(^B M=B*<)@5F(\836%P[$]-0>'!#@MT-RE7P. !:YXY%&\$=JVU1'UZWIXP>3$K_ M%/1[$!T6FWSM&BV8 Q5*@JA-A&Q$=,Z8@'R2Q.+^_K*SM]'1W64,%VUCBOLW MVI?O\9(\TP,QN37_MXA&,GV1[ PKHL MVP--V#8;8U5E]^N_O]"'@._QHJHJ_CE_=%+@(Y,HR9^9K*^=:?4,B=<*3F.SI0U0T+$>#II"/AH-Q!(#HA#D MI5-4%G:LUU^9\R*^2);Y]*V6>[F&XO(Q^[['/U*A^NXR7^[W55S_Q:NQ!_NVT[;D6, MP88 K,'E3@#AUX 5JE,QXIV#ZN^6[7D7@_HB=V(C*+Z87ON!B;O<(R]!M;M M 0:A.+7-C:!_!&8BI"P#CRI[_[ &L8\G M'.L4O!%=VYU@#ULW/#3:4#EM>9+<&05AV3D&+8*+)D&0N6!2Q3LYJ/KD-.0B M]HD.&ABVX='"UCK<(9A^+KF(42P-$0[8Q\13R448CSPPEH"7Q&\SO0)-/Q*% MDB%G&]V@_*DG2/LXN8CFK(^Q;-OSXM>S?/[U/%^'BP^?Y_^DZ>S%2OC@;L6\ MMRFA2PJ2K_H8M8*2UAH)T=FB62K1F=U]=P<-]404!T81,N]HS<8:$G]^N 46 M[@+[[>+\XZ>K%U?U^C;,OF=7..VCB=&!8>3C@0O8[61\U MY,1-SYJ3-9_ TFV__Q6T!;Z<7UZ]QS3_BHMO-T>;*W1)6F1&$R:-&530%H+P M";QU7 C!N=!QIQ\,&.AY?_NM+=F6YU^_AB_SQ>,4&B6"KOJ]45512^>JG*_W M8!PJ-(8\G^_N'K/^V<^;S0;V:GOA]_;J$RYHEU'%B6Y3HNY.4]%GBX)F*%FL MKYG:&GPR :(W7H="P :T0]X^QO,FM*'])JCTOBFH"4EJI#E".ZSR UI3P%D\ M)+1*6.FTUIWT\9]^J?\AY_ '&WNZ4O\AJ'[N4O]1O TK\-['Z-.5^J?D3&95 MLPQCS3G)%IQG&HP-M7M2X0P[Y>X]\5+_#IXPQM83EOKG:!F/.8'@2=R\:;31 M (;$5 A"*=.GN.2IE_J/XFM@J?\88[?=K=\B^K%/7>6:K+0H153)UXX^4M:N M[^];=;/+^=7V#^Y5M]9WR[>$/_ MY<5?Z@YRMFR1L&IDF6A"8Z( =^@H]M41HI06(B\J1=J T$L,97S,P"?B!=UL MW?@"9@FL8OD+SC\NPI=/YX1PN<:E1*_H/(6]%8\2DG:B1"XXHZ/Q.61KQ9"9 M?UCS\4TP3F OT,[,#7/YEJ!NTKON0OKN^[M!-;]]VPCG"'W#V] U[V7KQM=P MF\%)HZ7S%.B6+*JF%4U*/M,?L12;HI+H7#O9]HD=8%L7\ GY'V/BEKQ??5F< MO7YS%G5 :V@\X>KP22>(K"@(R3#&(@].;3OY60G'U,?=,%Q_^B$= I ?/*U;;6'Z+VHXB<:8\08Q+9/<1!1?_S^ M[(D:::G67]3O+\Y\T+PPIT'G0+LX5;N_Z)& M6JIEW%N'_^W-60H4Q2=C:\(DA=V&(GQ?O^JBZ=_UF=4$MT.)^NWY3WTC+;7Q MQ+I7^?M;VDY]/<=_S/?[WSZ\N&VP<7L'\V.?]T=8+$(MKFE3 M(]\ 0-M"^M86>5!MKZV@[0]*H:TA7S!>1YNXT-+ZE!VW9ZW!="O)]XX58V@3 MQV/6H!Q'H-T=.3>3: 5&QLL4TCD3E^0GXY2(M@ Z7FO!:2?K@S%09"E:LFA= MF*(_WY,OR1_C'7N4Y(^A88*2_/E-0?D'O"KSQ9_TH5Z<%4>+@M2$RTE&+>GQY._$XH53)KM3W3:"" M18@Y.=".TZKN';W 83P_&/#4:3_$OETK]^^A_-NL/, IM*EUY(PFGT+[Y$*. M&ID-((*Q.@6NHL\'^<&C(4_=$PZS<VJ,0QQN232BT, ?8?)8Z1! [67-C'^I.Z1^)6<6$T M9)DCJ*P<^( >>& V2I.5<7UZ0#X/)8X^7C'&Z),I<6!R)KG &4P58J,EE/, MM-,1(F65.);4IPO8DU?B&$77("6.,;9N>%:\KO=.PKG(811=3<#&6*AQD:6C\D M\U?@).9L&+UMEK* 4D) 2+0NMLZ:\X>'/F\X6%FN;I/;' M?+8)E%+*BA3J::FN:E>9-O,\.UHUN75:<4>+STX:-S__>3/9R&Z-0^G-19*T M%7=)&HH<5'*T+]0(/H1$,81),NBJ=M6P:O29E([ONW]J8^;)2L>'@/HY2\=' MT36H='@?6T]6.L[0*Z51TA["U')9%R#&2'-=#,'2=,>EPN?J 'N5CK?G?XR) M&_*>YM>SJ\6WLY)!;7D5+/%A-L85-L:#?1O+JQN'VB3<\ MW_[AQ\W#C_&>2BWE*,//#[):ZTKR%__WS 5E"@5ZX):%1U79QD<6(9CLM4F> M8H8AI&VM>WWQ?Y\S5_M8JG4E.?E)$CX*(24(5=5F/,O@O:>Y+\>41=#!YH,K MR9_W1[6/I5I7DK_\\TR4*)3U$5RJ6KTR)?JT"P-IN.+96ZWCP5_4RS^?/U'C M+-5ROW);R&Z"Y&B3!L$5X4?A('#C**1S+/BH4A0G5/*_-U$C+=5R%!T++2 M%JN.1 ;%$,'5RV%;%2:RIS#''"Q+\W343O8F:J2E&M:*W S_X4PX[KPR%HI4 MM$2*1',P_1-B9A$YFBC3X;(T'YX_4>,L]9@H>QA1;\\L;0%$2!Q\-A1TBD*[ M R\TH&;D09KKH+9=10XCZNWS)VJILCUUV=/U$A+/2;*'T;4?Y_Y0AL ZPTDSY9I10:BUA9H M!\Q#UW\^?J'&66K/A/5#D[G_.5$[)9(&TC_.$/28!D1D%3!!V M N(4&Y+!NIVI_WG^3(VSU!JF#CN;>/O7LZ"L=(@>&$]<'\K4 MN^/_ZC-$:67LZ N::_IJ-!U=B!!$E0ZV-H&WXH4R]?_WL MF1IIJ35,'78\\>@J^.(YFCF%0&GO3!L]\__O[LF1IIJ35, MF;XJGP]R8'ZDV+31\-SY^+8*G>/>YH'^IM<4A6OO:;FR2HL4L5 TR&.D/SB? MU=FXH;JI:PJ/6&CM!/2)/-)F!4ZZ#-QX)[75@;[](1D 3T!=@ZA^%K: M)'SPR6LW7F]ORW@GZ :MK-M!&^$!TG4(LXI5)$I#XJDV?N*T*!=D(&MJ5N$4 M$N5M6^5F>KNGZ"N=:&B8([ !X8N4%M?A@E;EK^Q,66US58F@2:LV?\, M(=F MF!.^>K,3V5/@+Y'VPB) 4:*H1.^"2;>+--9!>/8N,BD'#;,E=J2<YC##M5I?,03#]7H?LHEH:4/.]CXJGH M=RPZ8UF"I$HA;$C8T$>0TF?)1#+>#UH3GB#MXPK=F[,^QK)M:V,?'/$]JN,E MG.\6YS3%?<%5'2_CRFGG@%Z5U31<"[$6(A;4JOAH17JH$+R[W'+WL$^D"G,4 M41NK,!M;N>WIU'JLX2[6ORP09RNDU>>#B@ZLXK6NVZN;_/G@4Q%1%,;-;F7P MD8.>HC>TL? 4L\,]I&_"(GP^7T'%J%SD-!5*(6IA,=9&EXF"9!4L+Y%QRT?7 M8N\<]>2]87\;=RW"7^NXM,4XOUA!C9(Y+HL$SGB=Q0+M;76I/6ZD=Y9;+]7N MX^NQHYZ\.^QOXX9G3^MD%8ND'7()!@(3@E[9)' ""V23"S*!/,\Z!,<)ZKN.,O\F<=!];-=3WS5P[9:-6U.L?>,H@ 2O8TVH,<$Y MA9*I(24-[O*3YX+)-7M(> [;-5#KT MC1_F+@7&BE;,&^V5MBY*KA/3QG'A>?3L[-#!NV4S92-C3L*!()<&A;9 E I! MU/H]EH34;)">R9/,9MJ68,%R0)4+[5>UK556:"$@[5=,5#0I!S0X0&'MF::O MC"%]O_25,=;MF\&$B_-Y+O/%*TRXN#HOYYB7G][-O'QY-?^-]BNO9_G\ZWF^ M#A>WPH O/I*)+Z]>T5H]RV%V=7F6;!3"T,M$^L)!.>4@1L6 6VN9XR= LQU@&^CN3G&'HPH[X_#DU.6^S MQ.QOP8:Y3J-;+Y>HD!8T1I,3X[P#[;93[^7MTK7JV'MF10B\IGTQ5BNFN7?@N62@4[3&%A%,&)V&OWO8 M$_2)QK9NJ'6SPW]_>^"]WMOHO(K@O*GBR>AJ;:( 9HJRS.MB6#QHAOCMYYH? M#K%O0R&=HPY1^&DD'QW$LRS:X?>AO?#+=I0 MD.E^=E9R9J[5UVP(OG]:[1TQ1610N*21B*#!+5X7/#:KAG3W\WV[94*JHW MC*OBKMJRJ+KDZIQBV4+C3%C-1=$*@G-5\2 IB%7W*I0@5;04L+#=68_;QS@% MJAM:L:6^T8Y$'L>1 MCUW\M*5O^S+?Q,7 6V% M[B,/W D]Z'CA-(JF]XD.&ABV92^7K8T;!V#ZN8JF1[$TJ$_T'B:>K&A:.*MK MCPWM96V4*B5XY31PIB(WVELO!FT-GB#MXXJFF[,^QK)M\_,W=53E7#+F,J\- M5#@%+SD3(A9 YI)]"I8EO;OZ\6FWH1UE]-T-A<=8K&T*ZR-$R^Z+*U@R,0P4 M@!;O)?DJ#^"Y*%",9PZC*N9AMS5 MR_DGG+V<7UR$QV M^XU]8C-U>WMW_N[?XWEUW5G^)940,0JTI,LKW4R M"5"[8AEAE&*/&6#3<"?&>A.KMDW-?CPQ+>>B\UM@A1LFC<^0N!6@E"X0>.% MO]=&D7>RLL<'?F^,$^-X?_NU3\Q[$WQOCQ(C>WWX-$ZO7Z3/PE)!7":O( M,ZTB,=?3WE@@ZF1\R,@H@-QR*/;E(D,0M02LF'%&^16,3E-,NJ;]N(Q]]*! M_W%^]>E=^%83-2]?_ ^&Q=L%?;CXXN/\+- 6)#D=P"Q;UM:??,F*HMABHK+6 M*CNZ)=; L9]4&O889]B<<=_#ZET%9G;U\O+%:LV9!69DE425 KQ-"(4'5XQS M.>;1];G/J6-:&[=H:>6V<$D/ AJ>2(RH*8S%A:*S!N:00G]./X6@D)8X+0/-:TP7-86+G.)W\(RQA7LA 94WH"(2O,08R)*C*UE*0[L!-WD?T(:'@+L>/@ M-C(,)64!)>18>[5EB/4>U ;4RF>16#'3[,6>2F%@.Q_8R\C'+@SA[D(!6YTTCP'T7HCJYH(PP[58;W$$P_5X+_*)8& M=47;P\13T1\+UY96)8ID1 ET8+S-H+@PF>3O48IGBGM([NBM69]C&4[YQ2^ M.?_R976-+HK5Z )8AZIJ%A2@]Y:04C#1<9MYV2,W_,< 3R0'893QM^0@[&FY MSLG^?Z$GGX=;7+F0QW+%P$:LJ4]*02RU,B6'I$/=I\@]4L?N#G%BG.YMO7X6+E;<'96#!;X*X0 M+AXM+?O9@0[>)X7:%R7&LWIWB!-C=6_K-4S(78?K#RSE%I7)R>A<"_QXB* L M<@C9)W &95*,!YMV]^S9,L"),;JGY1[S>8AF\6,_"Y_*]?^_6A.8L%*X6M 1 MR,^<5^"6A3N)B^ TYFSW*4N_,\2)<;JW]1ZS>H@P\2-*[ MTQ4G# I=@"'YF[**00R: 6,Y,!^$C0.:G&T=XL2(W=MZ:VAM6VG^7Z_FUQ\O MPJHL6B)33$C"YBNVFOCB,'A@7"$R9)(_U(T=M'F]/\J)D7N(#=?PV_38ZYU[8YP8L?O; M;PVS38^=?L'%C^,PQR1Z7F_&6=4J<-Q!T(:!XW>($^-U;^NM MH;7IN=.',*-_>;Z*[9+/41@-VF0*V2V]<^".IA+EF$8;4G%[2+;<&^/$B-W? M?FN8;7H"]4>@J [_,E_@[\LYY;]IE##[\Q.>7[Z8Y3=AEE?*(\EY3$$B<"49 MH&UJ:'6DLWO TFC,PND*.A<@@J5O'M MZFVB:(Z&7I3ODXWQ8X 3HW1/RZW)PVAZD/7[_0 QFTBQOP#D98G,@X]>00J1 M%X&6B[3'>AS$8:(P MS:5:N87TK%H(\O:AT!=I'#F.8/6 -_5\P^.AV&W1:=/,U2]__04_72TO\X/! M26'"9,]/N*!2WJ'A\'^&?3UQ)TF^O MUXT2Y-V3U;HP=+Y>85DR.6V0@0_<&*%-\1-UJ6^1Y@QZQ9J!/05CP1.9[@V^ MBU23#HG;+M?7F1 W7F\'#&$$Z T[%@Y(%[V6=%C73)C*K.QT958&8 *#B,Y) M"C#\R9O"@:EP "5R+Y /42+W06B*<&C'/&@K?7'2229LG2>'A@14)C,))034+/M'@O=1;!)DR8SCU _E#=IHL#.,]2'H#_!V7FW@-[F[(4@ MK4$*3"L=R7$Y9%*#CZ)>ISZM"CQ-LSB00YG7*OJ /KTUW/NRF.KAW6:&BM.C M CTOQ$+G1HA):D&1%TC*'8RNHA YK@[*+C&I.- M-, D*5 MB46=,M,Y6>83<(86$ITQ2M1/*;2.>:3!S_#OBP^W'RJ WR]7+RXO MO\5"ZH"K&WI26<=,%,>\4;K66'H6@@464Z;WS7D.[G"%U)X%CHH/MH]:'YU' M6N$WP:ED1]1M3*'3%52VXICKL%MD'I-CG(2RB?Y+8E^N[@QI8(>HOB'(VR*+ MN6E@UU/0ZX?\@,O?5O#Q_46"RW7D54 YJ06PG(RER(N^\[78A$.FA]36B:?3 MY$\?HP'LX8F=4_]](&ZI]YN/ MJ\7W/RURUL5+KQD 1UJ>>P8!,W,0 (7,*IE]95T/UP3UX^XT7+_[?%%PO\R\ M%7N-P%X.1ZIA5+>#M]@9+NV:X(<'PTBRR+RTCLG,/5KA,I>=9CVU$D$XP4U1B6I"JHM&.(0=? M9"BB8*?2VR-4>S^R]N9:[X-LVQO?S:;H&G,\%(#7U@Q> A,D!-,\2MK.BF'H MI3/!\9CL@!:U1RL<205]+_CW-90/Q&[VU.[KF_>X>OMA^:^[>:Q_0?K7[U]> MPO7UBU27N6Z3Z>V\3-O$[["G>Y('+J58KF4.27#MLPT^&:F+\.ALE* 6PY:< M+"T,'E%G"CAL=)YI&S+SPAL658Q*.T@\S3&:;9I)MVLD7RUO7N+JYJ)<8+X; MPKK(#KW6%&"%0D^N;:I=^-PRZ>D@Q ,X90^3U'1;ZZB2Q7V4O6=D:0-4)\\; M?[HO029A+SY3 MB=30-FS9.I-Y67Z&J]L"Z>9VA:OKA40Z#T?RZ+7-@6EI.9V4R:REC))K#AJC MZKL[;%WIY'4^!:(-#Z6;XOT=5_DBW5S_^O$]7N8%YP*++Z72]M S!P\L0K(L MT@X60\24\3#WT=XESE#%(S!L6/Q-9C%AJ%ERLQ;IT'K.Z M!/2QB[FUO+_5VNOWM _-LEWY=A'J>M[^]U-7I]F\(UO,9@K56*1.9LD+6 MRTXZCV(.3"A 8R$[]W0$Q^D8P*#;WPGTWP/BUK>_+WY91&XDA9>).2OI,52M MA5*R,)>XEC)SD*Y+D]C>V]\7OQS+[6\OL)?#D6IY^UN7?_EBX504VJ)GH3*0 M:U"Z%JT)Y@*@18$AYGV)ETZ*>OGBY!75$ZG6;]2WWRVD=SY58O&24AV/1?M$ M++JPR-$[3#HEV!OJ'Y(-4Q0/-3=..!":4@L.5XO?85B/@JH0ZTX*IF- MQ'V5+B=6H31843V1:IAY6"__XT\+*X02E0G4JT@':D\F$D36K' -7$(; >OF?R$YBDKIRK)(0==0MY-K[DYC7'#D8 B.AR);GRA5QD26;-<,O(>@(%-4)%-5Y1/YZ^HOHAM>7 .RXU M\?.K!3C%DU61Y2PYT[5^+^1,WE((XQQXC7+TWO?SJ]/75#^DMFAJ7&[BU=\7 M*EKCLP],^J+(4A!9,'3B5IA4--XCC_M8^CIIZM7?3UY3/9':HJEQR8E7?UW0 MB2"*4OD)!/I*9T7[+CC)N(JU,=6!A-'IOE=_/7U-]4-JBZ;&92=>_7.!D=,/ M.6?>*4$G!-J'?0[UBK"4[(I$>#KR>("F_GGZFNJ'U!9-C4M/O/[+HG@Z!9@J M.Z^L4TXX!I&.=@GIWZJ2K9=RK*9>_^7D-=43J2V:&I>?>/VWA8RTR[I:O:_H MK%UKVQC0=DRR*PPH51!BO*;^=OJ:ZH?4%DV-2U"\_F6A9%)"TXG;0-!,)V'H M[08*<#27-FCA>=Y7_-Y-4Z=_?]@3J2V:&I>A>/-B(;,B.TF1^5@YE 1)$BRG MHT(I"1%-D$^G5/;7U)O3SU#T1&J+I@:G*%(M*%Q]6KSY94&>4-!?(,L*:GVW MCRP:(YE7J9A"%J1T%V7=?^*=ON[_\%EEG]<[9:T-1&V+XL:E+-Z^7 CI(HB( MK(3:S<;K#-.B%7-"21ER<1C2V%?L[>G?*/9$:LO5[[B4Q;O_7B 823$,;<$6 M',HO6*6:D%"6$J$+>1VO125/O_OOD-=43J2V:&I>R^,>/"RFRY.0AZ3RG MD-PF/44(J; BDM>-B 7[Y8"!UML1P8R%#K M8U5FH0!GSADK(D4[4G2YJ>_FMDZ[6FD@:EL4-Z8!Y)L5 7;]_N7R\O9#O("W MB_K^ R:*6G5,AQM!#BYSRIIL#N,6 M'0_.?6RCRD^RY%""8TG*ZGPC1;J!9V:3-9:3.%'LZP0Y]9D=0XKXQ\+8L'QM M@T^_BQQG.+.C%_R[!CX,P:YAS>B&/%P8K6JEB;%5'@6"^<3)-J,H!DD;6+I$ M.ROM$"CIE>A&59(CUYBBC(&\>/;,%$\_%ZF@.,R,UY$W0"Z8K<.OM3:&Q<0M2X+< M=$H\2--[YLJVA4Y>FZ/1:_LVOH0KR!=P]6X9(:7E%^WS#].P4[8Q147F%FK& M7"GF57:,!^U25@)5$ =5>WB=T]-L8^S:$A!L&IEU.I!E*9:E)B-+,K"@'+#B M,A1E!+>N0W/ZZ;^0XY!I6:F_G:W-1Z]!*LZR<#61'A2+P=19E4E8LAXCGY($ MG3-%Y=#FX9' 3JKFQS,Z.LCTO"@J>VFI"UGA$(CGHJATJ0#W8$@[MB8X(->9 MI+(Z_J!344@Q_8FJO1]%97.M]T&V;4AU3ZOW8ANMWKW#T:$DX6E34]FNX[W, M/"^6(2BI+$&!&@ZZXL/K' E=92]5+*?"<0+FMUW3MPQ9K*IEJD)6GU5K50$K M(9V@0-'Q4#1.--;Y).88#G'I+2&?@#UH]Q"N+H+]9XYA3P5VGE@W!/V&WN"P M@,)BIEV=Q'*VUC=98 'I$.*T!BW1>2X[!0#';A8#YQA.8Q5]0)_>&AYR0$HY M(Y-C)<A&'75^%+[).+_<(+J.3R3I3?$PF M+P:M.!G1=0B&1$V%)5=;; 5%.R'%7$\V6633!(/MB:[[4.V&[)/VG*5B M#=.F)C[K5#]IO,E*>=JZYWCJHV<\[F,=0QB/>ZBA[:51)W[>3%L3G0TMBZ(@ MB>=IC_?>D+0B.NUI2RZ]>7"/G_%XB,ZG0'06BNLU*]SU'Q'O9P(YES]L:6F ]!>7V-H$?\X._>\P/[C%DE'4F-(_U%!@R@Y@+R]9[ M[PH*X28:&--'S),WI.F5TY"9ZU"B.: &E173"FMM?V6WC-6^,6F#:$FP?10; M9TC>WNZX,0CDKTW>OJVOK$R:XF1.D.0 S N,)']1RB%&$;I,K,4Y?&J!.IZVZBPCZ0S5Y)ZGRF];U@24B*$ISG]*PQ,EF$SR8%T#AU M2/ZG-&?@5YN!W3!]LTNF>X/O(M6DY0W;Y?HZM0WC]7; $$: /L$]]@[IL!1T M&H %A\"TY82Y+Z(/U!!;PCO0'-WCU.,]\ M[Z\2N4*5R4ME[^HFJ WS004&VD8!LAAN]HU(&6X%NV7Z"KF9!EI;3@)YPQ!A M_^P?9ST&TS2"-[)2M.34:FU[ M;]+8]$&ML=/>UH:3M77!<195JC4"PE;^/C).*8O-,M,C=HK:SJ3W<*";'@EL MPZO6_8UQ'61Z9KV'?;34J?=P ,2S]1YZ+Z6K_,3"9++NI%BTNO9F@?-2AYA= M.Z=\U+V'K;7>!]FV2?CMU^PT+%T'_91QG(R)-M6UW;HC10**[MU9"Z12)KB"0;%2"8KU0BI4YKB#ZKY M='I,AVFY,8X[7^:I>D5>O?GY1?Y_M]4.3\PYJ>A91A/#TSCR2< MMDHR\,JM]\FB2&="'K#'7NL=5>5='Z4?*.%L@.XLG1U[2L\_/\SK*UPH,.0; M16'" YVJZ$6E$Z_3+(O 3>#%)3C,0S12B+,PEAGU,$NKR(NSE"9071PA05=B9N="O2=009"A*A5"M'GH6;42Y(SMJ7I-#)MA<+VBN7O M"ON90T QM*VM) MO_OW1TPWM?K]&]PN-2A=Z?UK*MA'IH6F%X#3!HNUV\;EK,O3V3Y=&UBZ"7#R MYC(C_E^]J:5VV!@ PV3QM>8S&N9S<@R,3O M[T.[5\N;>]^[ "S")V^8RD &S^V:-8WKE\L/'R\OX"IAE?V[:T+WCW7A&5XOP$B MRJCHA,A,QXPLY!3I,7SDJ>B:,!N]5>P5X>P-IJD.-FUG\(2\0W+O%]HE4%%' M8%EESS18BL(3!>5%NHPBB*#<2!_SO*VF'?J;)C-X-M^FT+]@OEW?B[Q;U@LQ MDAXN23X!7D>RW-JJQ)E6HC"HVR'8C$:%9+/O0-G09:DS-(0&F&Y)S(WO]?E2 MRF_A _R&UV^7M[^]O_D[7-[B F12RB3/?#$DH4.2T,G"C ]9OIQD'HJO!3BQ=M1H M!^WX\D^EFZ27>CMUD_2!>;8F@BY"/<]NDE[JZM1-, 3KV0Q!"2FDJ?->4:[S MLH75XS/C/ED1?'%T*#I5 QC43=)>_WT@;JGW.I3YU3_KJ=<;1,EXKG12W-=J MOI)KD,LQ&A1CI;([* M%#K\.<&"1D&.71AA>/#"CGLUCXKQJHD*^T#6MHQQ^YQ>2X+S.KS5&G1UMD3- MXR;#%#>NV*"2?3K1Y00F&?<"^= DXSX(3=_RRK//)NK"H/:+Z)B!Q?I%02VD M#H8$W1?"G%G+Z]!J^55B%S(WP26 MZB0IK>HD(4'O"SDAC-EAD&JJ=_VX6EZ;:[T/LO.WO J?'/I28PQ>:T(]>:[L MZ 3F@[315?+JP\23I]/RVDL9_5I>^R#9MNUHKW22<_U%>]^]N,%J&1W4VQ-, MM1@X480IR>QEB9'^1B+$<8K?L?)\EC"%XCK:1 O49]P,2%RS35QZ> 6<7A4UR8D,[G!#VI"5GXN1C$:][3B:0^+:K3:M'7A3/ O6YCHK M(S P7+$4O98!E)K;%CY>=B)*-1;]CQTT%MIGGD+AAJTU7RI*@)),ZJ2JNKU=-FLYKTEIAP'LU M\L2R8^7G8B2C46_;]W- 7,&WB9MX*M;*S**IWK%XRX()=1\LF%-,HJ3#J>8A M*S\3(QF/>ML.H$/BBFWBRA2XS+3G.3)MIA$*\\EGEGA$;I%G.3;WL6/EYV(D MHU%OV^IS2%RY=>.SM/5I+5D"01M?4<"\DI'9)%2=#YD$I-%&LFWEYV(DHU%O MV]QS2%RU35R,"2608_1T9*]IQ52'_%EFO/3:R*"-&[^3;%OYN1C):-1;=@-U MD'=K\L^JG)STM5FM#BHR.C.??6)&HS$N^U$$-RPJ"J4,.(UDZN#UZ%3)]J6?BYV,Q[UE'U '@>TV@1_B M*5M+)($,&@,R;0WM@B6&.F)-&V4BP/CS\#X!GHO1M-+!%M.9,!LKW%9;%S*! M#NC($(JL-!X4A ?+F3>2.]HODXIRM-%L7?JYF,MXW+<8RH096>&W"NQ5TD$Z MP8220-X30N7X-TP5@3(ESVT>GTC9NO1S,93QN&\QE FSLB)L%3A+H;R(D0FK M0CVQV3K"+;&L,VI1T'(\3(8Q:.GG8BCC<=]B*!-F9B7?*G D7RA54,P6BL*U ME%@'K7OF5-%!"%VB.\R+,6CI9V(H#7#?8BB396??K>#J>JV'?R*LUI4S]1D> M(JL0:*]3A5EI:W.0+"R8-7VJS,%$YY0?Z7_VKO\L3*:=!K;8S80)V_7EY-9[ M[\0SI 2&>6U5[?W3#%3D+,BH'*B0BAD=WNY<_5G83"OTMUC,X.SMWA&SBEON MP1HZG57R")TC UDOJ#+2Z2R'(KH-VCO'B=Q#6AN:@3TMT^SCX;)=I'K>$[E[ MZ:W;'.8AH#>L?#T@70#:'-'5=%\=86.-(,OG2)L6&N767-H3C2 Y\HG<$UA" M'ZPGL( -5OY[;Z6$"6 @LQ3R^@!5"RGIX&V53AIT*ACB)":P0Z"CF<7=2U_+ M]F W;))X$.L-7F7R?1MB01:5)H1.1$77BNOH&"03F4(IZ!0="C[M3&UD SL$ M.@L;: %VVQZ(#>ZW]5:GN7,%*/J)N=0+0EZ8+R"9LQ)]\MZE#O=M6S_Z#,*\ M)JBUK1K=D.?>5KM(M#V\ZZ+/KQ&KM0%_CR9'(#?QF_D@68DNES7Q0>44#UHR MSX5F(2GGA$P('4HF9M7ECF!K-E7V *PQY\-:C-=7>+_-EQ!S5L(R%Y*@!R-7 M[ZV&RK\5K55)-D$G[;]HG>2O/MC>2^)$9(;"XXA.DN2 MH&1!:(I5.)ALE<\E'F[@>O*AIZ^I8?A,<'#Y\2HM/^"?''<_U?^A(EEW#QF5 M#("%I6H_VE%D#9G"-3#:1.OH*Z9) M<]0IU!U-,:^H8=$0=$N[?\+L)-FNK: M*][7R7@U4V8W(QFAB?DVD0RDAX*F, Z'LU8>+@S"NA*Y(8I51,U%(VRF (P5WQ1#I,7W;B?>EO$ MABCSYT(:JFK9$N>=4>!4,]37$]\>QH'_>D5+T@_6N#P:$O?;"M??-!JN/FS- MME/7&SSWDW'LR3ONHY,0*')T/D%4(#)%)$YK94M8-%A_LCGMH58M%I]9UJ&0 MC:;"@)O$3.91"V,HB)II$L%/8^>T#QVX:H,K#I5B2:"X>TW!UE&^2"< 7BB0 M[$:L_:PFXO:QF[$37:"F:0( 5TK(;2A+RBCYDYF=#C/ MFW,L,SQ&V<1XD+_V#(]M7*_%J!P]A9$&D***@)X%%\B29<%:2!Z@G#/I="_U M[2&=[@/CE$3%7>0X0]+I7O#O8BP>@MVDNBRR$.2!&1[KO#E#9[W:E1Q1%)DR M.9>G_&='I\,>I--M5-@#LCE(IWGBF.AHSE#73G*E2!0;)#.6>U5R25)VN(8X M,M+I7B ?(IWN@]#TI-,DOBB9)\8K497F,C//LV5UNG!1=$I6!KJ$3.=!.CW$ M.38 MB&KX%XZUBXR/2_2Z5Y:ZD(_/ 3BN4BG)6#)24?&C2;9R+P9^1C+,IA" MQP/,H#L=CXY0[?U(I]MKO0>R;;UPO]S5PPTK.310T3,O:NN]HD>/.M(Y7KE2 M*D%SZM"O,63E(Z&E[J6NY7Q8SYYQ_AYI%;C\H;::7*VE_@G^N+Z]N&F37#[X M\6WSR/V>YDG*6 J9* C+=7;ZQ0A19T2AP \>?1NT6^IR;+#,0D+WDJ63*DE MHB&QH#VGHX-%[W51"2=JK&F>':97ZA['=RO(^'+YX*Y44,(6Y3IB&Q"#DPNBDI+-R41AQF'2CVUI'E=+MH^Q'&]4$J$Z>Q/WT M(J75+5R^62U_OZCB+ASMTM);SZ*D+]IJQR)7Y+2Y4="QD73G]HV4@@9,O=TX+E^B,/DWQQ-$F^=O9P""0OW:2 M?^>C?//I%=S0=O>Z/+;RNW8KB8XGRTJD4X ./I%E S 9HO3Q#S'7C.#O1QJ?/WZYM)'%VWS-#_6HW/U>+7"='/Q^SI O[VZN"MZ^[-.C>.:!H0V62/(I<= (G/ZPG.J'0O)^7#P MP--OS:\=UH[0U'(.F*>_BS'11I&38THA/7,&S[P2P*"@L E!H>FT4YS'7L_!"(Y[J+"4+'DKAAZ%QFVI-U>PBD+/HSUT&$ MC8D9)Z/V?G!]FV/GYG4OB!C<$$QX.4S'GC*ALI,@#K6:)PQCJ5L]"' MR=4.+'(D-RR]E+"1N&R"8$-_O:UZ)\JHB\Z"&0$D"HIZAU0++2EF$#&;PJ/: M\P*?>AGA$.\\%L:&<_4V2GRZR'&&982]X-]5@S8$NRG+"(4L!;E6+& "I@M& M%E/*S&A'SB2!4V(?Q= QZ+!'&6$3%?:!;(XR0JP3:>YF1]2#&6C/HJICP278 MF)!+8PZ[RF,K(^P%\J$RPCX(M>4S>+&^@_]AM;S]>"^+RQI3*9Z5(LD9<.5K M::0F8Y0H7(S@]>&A31L?>WJ:&H?,SO=JJNJ/[WZ'C\O5F]4RWZ:;SZ$<7.4? M_^OUV\\_:%,,TG>UMK4AHY[U2:F(]EYQ9PT'5!IX#%DF ;$6CLD2- RGVL&MJZJWW" MT<^OEY<7&6XP?U]?4GQ'6\CEF]O5Q^4U/L@N(F0)M&O;>N#1Y%FK7Z _!J== M@)2%.YR,'RW&R5O+[+J8X:)O+=3K\H:>@'Y8RO5"\(S29,,@@:930,.&_:>$/LM7TV/4_+F[>OUS>KFZ^)1N_?HLW M"V6*"X5.;!Q]Y?ZM^10D*-#G$#, 5WB8"JS7DB=O!)-BW###1'(^"/;N_<4J MK_OF[[.9UPLTQA=C"BM0V5Y- 1:S=\QE'HS$''3.!Q6_^_//0T#&9U-+!8>F*]U>JDX+968PPMLD>WD;6,B-31D MS>W,JO%N^8A3@T=(7IE$7HJ3Q"J92DVJ&2JN=8V?'S'GS4MZ\EC,\S&?R933 MD'YPT]M]"Q_@-[R^GP]3[V+^#I>WN'#292U)O]G'-7^X9S&&S)P6VM(625[N M0+:F\UHG;P+3H+JI]L%#O Y;N=)'J>8]BZJ6W;@-XAH ^GTDX%7(*RK %(:,8IK $OI@W?9VG0Y%U]=W,P2_K*0R3I7H3&96!8IGHU(,M)>5 M;IU^:YTR')X?O.O3CV:>3B_@EVU1:SU$8)TJ_Y&^_GZ1;^'R(1GR(!F=:Z6Q MF9'Q*K):6Q@4$RN_$%I>O.?R\%2= XN;Z_N,3\S:>W MZ?UR>?GMQ?7-ZB(]6& (/O& AB6,-;/M- N&SJ%9*2%R!),[W$5U7NY,--X8 MUX8W!@^/O6N 6U1"!@V9!54'RGHA&7!AF/18"C<@.#S/:7E##*(EV UO"OX4 MZS9>X__51C%(F)BWB1 B08P3A.I[1#H MC(YP+2"?8C?8%.NA,*V#8),>Y':*]G7.-@H1J _P8ENMX#2EY=1'WTE*7?M(A$,_515PBQ"*K M8;M:VZ1#(.NN/2%<63K'6H?=DKA'J/9^7<3-M=X'V;:YH+M^@].'1_-N_^PCZ1GN!?FR)5YM4[6UK>->"'+]+@2R MR (4:^IH!//)6^8=?0LA!A?]0:5]_KS35M1 7&9OBWI1.\%6M]=?-NN\?0\K M?+^\) D>70]\^1??XNKB=ZAL,P^9Y3:M4U-(U+:]:G+,GK1@ 1=2JZP-B/I^ M*^#%6>^BW04>2KZ_Q+\+1Q66Z*2Z"C5',T+#4B M^/WN?PBT3V\QW:X(^[OZ[.7MS2\(^>+R$X&)JP\75S54_QXN5NNBJ]=_7.'J M^OW%QS<4_5J.@508&\;AB2^0CTQPS<*>F-B(<9R]O(LC-9<[!&-IB MV388WM7JL20/6KM]KA=.@7;%(I/!P!W] 9AD&9WYM;+&& 6VKYXWESE#/8_$ M>^/K[B\N[7L$GUGF]*-8(3,(Q:Z5E.I7UB 7.%$KMT)'-6AAJ ITD M.&/K:*^!"6Y.._0?9XM.$2),BUQG2?O,@N&.>>4I;O2 V(UO[=S;P(=8ST1J M:-BYM=N^'X2LO8./.Y 7DEN-,0K?:A1R#0#Z6WJU=12O "RCR M@ZRL&YD]C\QG7CETG%7"04YBMIJ>([S@[Z7JCN5_?2"?M;ZKBV#_*?_KJ<#. MA5Y#T)_5/)SGUM>!;MPX54EY%0M 41'0\3Q[!6CT;)7"1UC^-XU5] %]MO(_ M:< $62(3]8BMG:[M#$+1(8L+[VV*WDYSB73TY7^]U-6I_*\/UHW+_]ZF]YAO M+_%UN;O1^1EOWB_SCU>_X_5-C4DV?XKX"C[AI.1IT6.=R2K,$AD;USPPH2R%P+5(-EB#K)*:VY"D*.*$ M1L@_20[7+F%<,X ^W#DFKUPQ-2KG@3;+0-]YZP,K*MJBA"JA?R70QBI'E6;O MH^#=:?9Q2$Y=[U7OE)&])QL3-4>1-9\)!_3@GQ+:/,\" MCR&&,I$:)NB]5>DB MV'\NW7HJL//URA#TY[V3E2$FFP5++G&F);D]KRVOI (V%[36FFD"C].X=)O& M*OJ /MNE&\7 FA=79_!E\JE:4NP3A6.FH$"I-40S$5G7L5^Z]5)7ITNW/EA/ MS[DALT\I1LV<#63D6@ +R=/CBH@^.>T2YBZ:/P_.C2'100-@&U][[6Q_[B+3 M\^+BW/#":YT5)FT4P>O:CHY^3H30OH8:NFQC[Q3/=X1JKT? MYT9SK?=!MG&;X3K[_L F[89X+U[^.O;=QM$+J68",DJ>C!9*4>R9CXDBB8< M'D/>P6A^O M.F]H.QK^94/L&NZJ&_)XCS'*F)E)F=>9>(I%D8%QE(6#SR7N908]!AWNB%,G M4V$?R-HZQ#?O+RXO/OZ\7*TNKG]]^^)AH[>!VQ(RJQ-,FW+93J\R1/ M&;PPYL)]YNBT=J$2- I1 'PI!10^J90ZL-!DI5*Y@-912(92DB/'*)AW5C.T M69K >3MBRN^;.YL39D7SB?:'#8L=92M#.# M02 ?2RW%UFEJJECO# +SULI*^,(96$LN&9$\6 S<355Y<_S#)WLINIGO?PR5YZZS9R< CH\YE$41&3*)YA\70J4TXR7[(GSP8Z&VV\ M5?/L"L/#ZZ%Y>TXD ;3U*7K:VH^=69#!,@G<6Y,1N3M,L74J M,PM[J:''S,(>&$X0(^ZJ^I'.Y5 PLAA4)004A7D)A16OM2A&DS7/TG]^I/63 M8SQ_"\@GJ+S>,W"G@V#_J9_LJ<#NTZD&H#]K_61,MC:1>):*J+VLBM/I*2M6 M(*3(.2KY]-;V-,UB8/WD-%;1!_39ZBECFN6 B82T,XCO&"A,LW+ M8%#$2.>5TJE*_@C5WJ]^LKG6^R [?=U6!EI<^L1,2D"/5^>"V)AJ=1/W:!3/ M_HDW/ZFZK5Y@[Z_;ZH/4[)?5/]S""JYN$*_A*K^^>8^KMQ]HG5]R>(QW&+BMCM:+? MS#B03%=N,XAT[J ?!QU$EIC"J5UZTP>]+B]7F"]NOH=T<5E9>N#?%Q]N/WRS M7*V6?ZRYZ3_2W]Q\6GB1M?7&W=7LZ10E"_)N.IW*+FKDQDWS_#VD/*J+\#X6 MLYFVGD@U$Z0[_WQ'7\?+AV*4>UF_^_?'Y?7M"A9,/X4J:'B\,.4DU;/K%5KJ]4/C%:;P<, M803H\YF$LP!&%P )^ MP=^7E[_7$/C+ /F^'=/$P$-M,7*5Q][DP&*E'D?/G3(F) E219 IA&E, M85.6,XH31@(]09W%EQ(]XA;N(M>D<<(NR;Y.I#!6P=RYJ1>_K7!]+'V@ M2=*!1PZ:B5P*^:F064CDIV+P(B:7@RGIX"7,UH^>W\FW 7W9$+$)//N7T<;: M4'56J0AZ'J1GH2@F1!:U=,R"X4KJ $Y/0]>]*?:10#P)OOE4VCBX:VN(8#Y%.,[3%, MQOU3,($#7GP."^B#\A09'ZR7O0_W8?<^*8',IHY$395(4RLZPOH2'2O9:5 R M>JTG&EZ_19KY'?]X/3U-]8P%N6\5QOV/ZY<(U_A__]?_!U!+ P04 " ] M45Q3(EJL4=!9 0!V@ X $P &UO+3(P,C$P.3,P7VQA8BYX;6SLO6USW#B6 M+OA]?@6V)V;#%2%4\04DP=Z9N2%+=K>G7;;6=G7?C8J-#+Q*G$IE:DA*MN;7 M+T R,ZE\(T""%"=B)^[MDB42..#@X."_=N?_)^] M/P&Q8FN>K6[_[4^_?7L/\9_^U[__TS_]Z_\!X?]^^^4CN%ZSQWNQ*L%5+D@I M./B>E7?@'UP4?P"9K^_!/];Y']D3@?#?JY>NU@_/>79[5X+ "_S]O^9_#A"+ MXS3U8"(X@8AS"5.6$(BEC\(P#A(>B(O;/Q./$B$1A0&BZC'D1Y!*[L%8I#CT M28"$GU2-+K/5'W_6_T-)(8!2;E54__RW/]V5Y<.??_GE^_?O/_^@^?+G=7[[ M2^!YX2^;I__4//[CX/GO8?6TGZ;I+]5?MX\6V;$'5;/^+__[UX]?V9VX)S!; M%259,=U!D?VYJ'[Y<*1BB]" OW?W[Y\.-EE^HM^XI>5N-4C>R/R;,V_EB0O/Q(JEDKZJK7R^4'\ MVY^*[/YA*3:_N\N%/-[L,L]?M*JE3+64?JRE_.=3G?TR0'Q'\I:'LCH0KE+W MDRL9SV'ZR9FXWQ0_B/$%;G4S6.3Z@WJWXE-]N]NN!HL^OL2N/HMU2983?!:[ M;EHB+_4O/JJ?FFYT0V?(M.JGH>Z6J.)'*59?%@] MB:+4RUZA>A0?2G%?+ (12"]**.1!Z$$42@DICE+(N2 \CCT:H611;C_IA5C! MW[YN>J^Z.-O^GRST*D_,SUP4Z\><[5:V^^6QY4JM5'IMP[^LR+TH'DCS@A)2 M&P&UW/_>DA'\KJ4$E9C_[[_^LE/('L3EV- L_R>BPALCJ[(0QD3G14?CH=1& M!LAU#E[ ]HW0I3B-V)J]D&NI#:=UOH_'FG7A4?/0_1IJ0]1+0Z_BF%,O_7(P M:I?Y1A"2LPYPFR=^86ME]CV4\,57J,UD(XG+M=% U[BH+O\$UCD7N3+CCXC? M_NBN!2T_**,TKP;_:KTJULN,:ZY]]_;#M^O+*+_D 6 M<1+[/@\1E+Z/(/)X M,D3&!$N$QB98%C&A@R7C\)YL:)6@N0;=6X *RE"*@U M >5:/5+K D2M#,BU-L8H=@+HI!%II9WG_[GM@K5.@"M!-!:@(T:H-'C FA-@%(%['0!O]?:F)NJ MO<:JP1&7H)F#;[Q"C3V($RT_HPU+T! H3RX_O1J=:O$9HG%KZ1G4 MC-W"\UC 6T(>%A_71:'6N#);W8H54WVQ_)$L;\ASM=%:"#^,O$0M+&D<48@( M2B'AB=KTJ)V/YV..$A(L#GR7)^>96:]&T\K,/>MR:FW$,R,L0X#/+PX.\9IF M+=""@I:DH!'U G2B9\PP=J#L?*^%TJ="1)*"5BHU+?VBN>87L2R+S6\J]H&> MWQPD_;-AEY/0C9WZ&W:Q?*L?F?Q5\%O5\+4HLMM5M=!=K^])MEI(S'CH>3&4 M(9,0<^UJ(9V3R>T9@3B K#1 MS<@>6%F31A<03NGB9&>3$D67ROL4T?E\/W+X6J[9'U_$@_I>[D@A;O+U;4[N M+Q_+NW6>_;?@E_?KQU7I+^+8#W@:)3"0THS(TS\D;LGR5U)JFKE<\=W6,1/%[N.,?.K+ M5,< >?HX GL!I$+]#VDD,D+9T%?D&KNQ749: M7M (#,B*@Q>62#DEL?DE'/T[J2;, X\"A9O=R7A73SG^55+GBV M.=I)$^1)R@.(4Q1"Q*(0IG&00!)2&2'"",;(CG0..YD;Q]0R@K4$M926IVAG M\32EEV$HCQ(?5FQ]+ZX>\UP9KG50^ELAU[GX M1GXL2"0B/_:ILD\(AXB($)(T2"&.B=K#D80$1"S:X>&=<\&I?#U.O48FFWHO M78!\JZ;@.G9I)4H@2+Y2-%^ -\MU48CB)SL"M67T%J: M@4HU\$(W4"MW 1KU0*W?!:"5AD"IZ(XQ1T'>*=6ZE7!2CAX%W'UR'Z>3G@<) M[$[PQZ7X++_E@A2/^7/E%'S[?*5%;'E,B*^HE0R'#BRR2) M*0NL-J6&_<[-9-R(K6VBK]5!0LL%KF-+GK+RV?(DP7 $#$\2W.,ZML]/"Z;Q MW @,ZK.%^AZ'D>_/_B#!#B6W!PF&?4][D& 'R,%!@N7KU@<)NPX^K5)6'E8R[R73A7=:&E^H!V$TAX""<\QA +O<4E6, T4,8K#SQ, MXX G-)&&YPT.Q)DSLRFEX NM0%NM=JACI9BQ3][%*'8>=4P\-F.?L_8?%AL& M'6.DC ]9)AZQB;[CHH^ICH$[6O8 K;:2>D-\UMK(:5;6(MR0E5A>"Y;I?&S-T:1(<4 )]6 4L B MIE@=8QG!Q/.$+R-.DS@RW ?WEV)N%-YEH>^4 94V8*..\99JP(AU[GFG&8>1 M";SW$-C??ATP%L:[VFG&9*+-[(AC8[.G'8[IR:WL@*:GVL$.U[ZU<770F/6B M]1^/R^? \]/JY.0@[KR98)Y :J_O*OF=K9J$Z?F^NR MA*(4A0F"$G$/(AG$,$VP@ B%H9<*["%FY22RZGUNQ*WE!)6@8"MIY5+X=/GW MGO>4[4;#S/TS&L8CT_DP>*T=-;U@]89WFX&0FH7*EQ>$C^* MA%-F?MG#I,Q[5+E]9CW^D!USWFGXU+)ZGF! M2$11*"*%C9#*X.,,DL2GD- $$XFC($I2$].OHY^Y&7D;(4$M)6C$-)O?79B> MG^D.D1IYSM=2 ENLC&>Z(1)'YGPAV,^WZZ=?5 OU=%<_5+.\FM]=[4XRTPV5 MV\QYT\>M?77O_NM1-?JK*._6?)?ZL>JVOMRA[ M?&O!W0CU.:E?W8J%+WR?ADD":65P!0)#&D<$8C\BF$J/"20M$M^YE%CUIC2[ PU8G\(8\/.3K']F]$G?Y;'B?R/6H M^R'GA$J8Q)[.[X$Y3!%7H\[3,.0)\T3,#1VY4P_WE"M*I1JXKW0#V5:Y"\#_ MQW\!G2[E5QK7L=>_>DAKM5JU*2Y :U(WJH&-;DVRI&I(=[Z."[#3\%6&T-B9 M_4I#.9'/>^HAM?&/CX#\23>ZR[ZF\K:/@$_+*3]&ZST#@87,5H*_%2OU0ZG3 MW6URZ^L$R&HYCB*:!!%D"1,0R5!"RDD" QKXH?J_%)N%_9AU-[=E=ELB@BGA M+(,TS^-JYI]QA];(BUTM[Y4Q0#P_\'6>*A%R12A"ZM,_7\"$ M*B;Q)0VDV>F??==S(Y=:4'W11T&=K4C^7&<9+9*OF%T/M\-.CX7M) M@%(U$%X:J=&@%$'B2PGU&6U*4^0G/#7SOX\['A,YY[M&Y.7N:)(1ZKD; M2U]Y("SOB5J,B!GQC(/SR#RTA?BJ#7%+;M (7GDI'!9'LD?+*4M9=#\I:=G# MLL]A/5JPH[0B+Q=?U#(K'--$DCC$1F>2 M>^W.C8STJI 59<9T,NA=>*5E&/(^>.>I90 D(_-&;S2,B>*$[N=80+W28@#U MK_W9O]_F)%/[A"*;>7OJSWUCRRXY5P-=-/_YJ+C 7Z#4\V-.?.CKVB"(XQ12 MD2:0(IR*R,,R#&*[R+(CO!_;\]'4&U]BN MIKY(]0@O.X/$@."R8ZU.'%IV1K'#P+)S#UL?,EBD3RCJ9P]-W##Q:)Q2#%,4 MQFKG$0J8BA#!*$H$0B&/_$@8'CPX$&=N5/(R(9'.0K21NL\.Q-&0=?J^)QZ( ML0]1+7/1%#J.9#=.9MN8,<;)V&\^\7A-Y$N?9-QL_.L.83[I(=X MM'SS+ENU3VU[M B?DD)GTA7[Q?@6E&&!DP3#F$8,(B\B^LZ%5!N'($V)'[.$ MFD;5VO4\MW6NSA)]6,>S2L%7:0#(KA0E.5^*4'8TM*?*'>L2=:NDL;V0.YT?UJZYR5+!]M*RG?6U7P.C)WBM2T?4 M=2(^9H1F2[50B6)!A.DX.QJN2\C/V51T26?GD7!,4BFCFX7 LW-:--*J=W^1JL+P!J]]$\[S4"MFDXVDFWN ML8A:.U M$Q?@OE;0W-?J9'R[O>)3C]K8E*<'[$-KP*ZV W9U?,"V%X\:Q<"7 M>L!^?94!,W>/3SUP4SG()QM *R^Y2[1/^\F=]#*9I]PE)FU?N=-V1_>(:,'4 MVE[_8T&31- 0)9#H(%5$F(Y4#2(8>Z'T,4-^XAO%E@P59'8+J741&]969S1? MR'O]*/;X=:5= M?DXMP'*M0RD7(0VI%PH$>4+U18 P@L03&#(4(X0P28/0:)=BW_7<:/3]-A6/ MOG0GZHMYNY0^=C1I,0)FQ#@.KB-3X:G;C<5%*Z4*V(GNCOOLX7+*=A;=3\IO M]K#L,UJ/%JS]+W\59%G>79%"6RD!HW8]M413$#O='DX MAG)D>GHE%(W]$([1G,C+X !5&_>!!4@GG0,F;4RU];?0I[6QMWFKGTWY13P) M9;"^5[(J4[7,"2O_D:DN'XMR?2_R2UI4OUN@T(NJ"^HA2SE$011 +"(".1,T MB8(TY;'5I5+#?N?&T(W80(\MV @.OF=Z9C2B@]\WPEM>73<="C/+<@2 1^9M M1]A:&Y662#FU*$W[GM2D4>LI(L6Z>% M"S^4B*;8AU% D*Z7[,.4Z,K)4OA!%#-"(F+#6=U=SHVN=A*#!R4RS'2ZVDIH M.VHR -N,E=Q".#(AM=#3TH),IQ&MY'T9'>".BLSA<_'OL^6(K\BI;A=Y\\+7W">Q@&"(HBD+K>E;\;R%"(J_ @SCR')[&[&OFA_ M;H32W/2L9 0;(6TOPKY$\#QQ.,!E;&^8%20];KP>57S 7=>7[4U\R_6H,H?W M6X\_UG>+HT]&=175;'6K]U&7*ZY^)_(G4:6%(DC&H4[+6.?$)WZ@S(0XA#B@ M,8DC@N+4J&R*87]SF](OQ 7?5/N]$F]UH6RZ:W&&W>B[%5O8>FQ,C,!PO"$Y MW^?$&Q$C XW(&:O67NP+QE[O'^L+AB><)BW"VE]6]=EM!K_8,PCX=.(:^0# MB!@GD*:^A#[&- EB'*?8-#7O$#GF1C^7;S_8^V,'#42GNWLJ>,?>ONS4 ">/ M[%Z6?ONV*?TV\9 8^\ZG&IJ)G.KC#I&-O]T%L"<=\8,:G\I#[P*!ENO>27/] M#-[J@LUE48BR^*34KF_:+!*U3XTC7? KU86A18)ABE,&620"/TB%)R2Q*P9Z MM!^;639-WO'Z?AJIY+2S:8\#:6;)#@9GY-6A1J46\ +L1'1GOIY%P*G1>KRG M24W5L\KN&ZCG'[8V2W5)T:LJ\NQ6K-CSU9)D]\6U8!D7_#UY6N>:8>JLUHN$ M,)H2!2$/8Z$VNZ'F ^%!XF$9>TQX-#'RB=MU.S>C%76X$!8J,>,8L]'0=?8?!P)Y8FL18=HVYB&/4 [ M:0G:M#65X==#OY:=U^=M5[7$/HGR1N396O%6\]O*V[$)%$CC)&0!E9#'::"X M'D<0IRA5"V@K_,R^^]JEOYY:+VQ#NS-C,0Q$1V9 M^H_7)-.EY3?R;_]4A8N]NO0AG)598('4FR?BR_",*SY?.U4+QQGZTTQVYCE3_ ^C$',10^S%41PG<8)]OT=BC^G'=/IL M(',?6K/5\]5FW]@1!?50[!2K@B"59J!1#;1U>U'&N#6P6L$+4*OH+!W=J-"/ M<%?'E82O<)W',;C';_RX[L2^$LA7=B?XXU)\EL?=Y(>_%>*3FCQ54 &*A8A1 MY$&/BP2BF"602NY#'!"UTOL\B(C1=:&A@LQNZ6Y7'%3/645T#!Z5\^P])=8C M$[4MS%:U2UQ@-+C8R2 A)JN.X@*J=CD5)^VYAC%7?"@XC0A/-Q9P7Q?/Z>Y[V+8CT]Y&5I!7 MPH+U"CRH!WJ=_5D-1%]OST!P7]/3L\6ZEAV\T3;!3QIR_??F8'%,#T\W=B-[ M=\X(\,J>G6YHNKTZ!FWT8[AM=C" 5^ GF8AA"%D8 D M"0E$/D=1'-"$!D;Q]$:]S8B5*'S_3UMU %DHP]@ M=R2_5 MP.R;P7V:Z$=0"1B#'$ MVKX.,?+B,&")QZTNQDXF^=Q(LWU"JR.D=LK7A@AXL]7_ITTU= ZJXI4-!J " MX0*T80 5#N E$'8,/-VW9,;?L_Q"1F;_"3\.\/NW^@Z9@@%4.#A<728?.Z=K MTW323[JR33XH^^OB] +TW Z0XD[_?WVT]T26VH%572//M ]<_Z&^0][Z1>O) M.OQQLT&Y%IN-2I,8^MT/=J=FO,ZV+]Y)*90Y&\4A32,6P1A':D=!H@@2B3"4 MV),12KR4,W]1KDNR--Q13"J^U?JZ56+,<_AF&_^&-\+_9+D3F7;T#3GC<;''YJY^_?8*&KH A0H^%P MT_4JH^AVWS:M"M-N_5YE> YVCZ\CQ=";IO6UIL_RPTIM:]6R?K4D15%GI_U( MOA>/65DL. YQG$KM,4,>1)%,(!8>A1RQD,K85_\O['?AU*#WN6T$JQM\K'V# M;[6]B9HU:@"F]0"D4@0L&TWZWILT&:+.$YEQ@1]Y-3F\-=G<_OTLP48#4*G0 M9+(&'R? O.^55OM9JTTC?P,=V M#;,O@HO[!]W\C5KSA%KBF/Y*;\7"3T3J)Z$/>:#3;'(O@2F2*4P%27WFL\!+ MD-VE5J-^Y[:2')39S+>2@PO]:.O0[+YD+'\4VAY?WXMOY(!R:)WFPDV35ZF#]NP M(]O+AC:@F['42$".S%1''!LZ27D#;"4T:*1VQU,]H'+*53;]3\I7/8#9YZP^ M3?1-BEQM,S.9L'%L1Z28<@)91!' M0BIK+*&0QMJM'1-EE,4RDB2RRYWL0JRY&6O[6@%]EU=M^=OI'^M\;"]4:R:R M;1YF)P-K1IO3#]?HH3A#1FK4\U6W6#M.&NU$M(ES2[N$\S %M=/6'93D+L[7 MJ2UV<4H[$F ^598I"V 0"@91)$*8)@S!A K*(LH2' 6]2W/W$&ANO%[?AP)_ M%4L.Y#H'7\D90VN<(3+?6//"O%]?K[:I&$)$IIP*'Z M05G6E'&(@Y!#3](DD''(:&QE6?<59&Z<>Y,+J&\JU?>7*MHE_#\?ZXOY^C93 M+I@:(* 6V.;>=Q4GL&R"C70V'5("N:L*OA35F5Q15E>E"K&TK(W6>X1[4/=( MXS8I9>MDT^4)KKZHLA:!-UJ7ZBYYI0[D2I^1R+H'HN.1M(TPKT?./2 [2\I] MVK,OWG;=G'2^5UV1Y?\C2/Y>_:98$,G2V.<>Q#$5$.E,J:G'8BA##W$D<(R9 MT=V>,WW,C4(W8H):3J %!96DYI7<3L%YGM0<@30V7]GC8U76K0.!7J7=3K4Y M67FW#J7:)=ZZ'K4/2U+K^FW%&5]%62ZK>S?OBC*[5UOMM;Q1/)*I;;7FDD7( M)$\XC2!*]/&QIV_Q^8F $?8%1YQ+ZAO=:;'J=6X$L)%2>[8>&CG!K1+4/.+% M'/'SC# :CB-SQ$YHL)/Z K21W4@._C(2LN8Q1*,@/%7LD"NDK2*&K!$['2ED MWM1D$4+6VK4C@^Q?[IDHZ)$6XK\>=?-/ZG]TB<7K];W^\$FBLWO0&!*N\YYY MG@=)&BKK33LKA8^C5!JE?>SL:6[$O1,45)(V=2=K86WS!9V$UVQCZ@2TD5FZ M)U[V:8.ZL'";,NAD;].F"^I2^B!54.<+/>N=Y;=DU=1UN%JOBO4RXYN+V#?J M<]JL49_E^VQ%5BPCRVW6HF*;88!&,2$Q95 D,5&D@CG$?A1"Y@E/!QP&(K7* M/.9$JKD14%NI"_!"KT\7Y4WR[AHZ/12_6-:W.SR<,:[Y#HPD^:0K9;,TP<TDD%"@Q#*A%*?14E*16QRBW^H(%96X@3W\;_I/JRR;@\> MBDXOXV0 3WR8VA7^K>Z78J;?'TK5L]7I!#%U_7]O=KYUY7C%\(+0A;& M*62QET(D8P%3$@C(292@@/L!"XQ"-CM[FIMGHI(6-.*"2MX+T$@,?J]E-O0W M=*/(@FB;"K5]%7E+D1)13IT!T-H>-PUR<",?1Y6CMYZBWNY+/.,5/OJYK,EB,8DB22,DTCH3.02DD2&4$2$^X)) M(9%1TI]CC<^-!FH!:[>1_0[L$+O.O>H@1,8^EW$,AO$.=! H$VTZV^ XV5N> M5/KD=O+PC:EVD"=E;6T:3S]C[W8[6@AVET9H+;_>$36X[Y99=3#U?IW?-.;2 M@G J4Q\+&"!!($H9AJE, V75^#+!$4,Q,TV!.4",N?%<4^7^OM(%9*U2RKO$ M9?HHMJ@4 J+1J+KQM]V6O"$/:EOYHPH^73X;9GT>.)S=SK]I!FELSV ]/K4: MH%WJ^N;%^-2Z@(TR0&D#-NI,,A[F7L5IQF4JE^.8XV/ED1P.ZVEWY8"V)_-E M#M>_[>ATT)JKO,XZ0%^E[4Q'$<2@@XVE"TT3@4!B% MW)MT-K>5ZES69K:5>FBVX!;8G2N,4PA'7D?.Y?Z]&@.]H:F5^Z$X@TS*!F@Z MR)I\"(]MDN16"Z^<$_E0E^X4R$?>Z9L:Y"GC8L4W&?T:'\K"%X@%NC:,'XD4 MHC@DD"!*882%P%X<$Y)2N\P?1_N9&\MNQ00/'2DKK= T\W@ZP&AD&MW!TXBX M#11RF1GC+ J.$U\<[VOBO!9G%3Y,6W'^<6N[ZZ^"+,N[*V7/7:V+JKS5D\B? MZ[SJQ;>^(E\H_9#"TFL\69$?XQ0Q#S*QD;C-.,RD34Y\OC86)O#<3UIA@YH>BK[=+CV+-VZ['A\>J7YU1_AWL5PV2R[CV,HONYH;,1R-%MZ(["#J>@_H[@,K=_"-?2@U+7+] ];[(_B:$>L'2(XY\+73[S1NPC1^EYL+]N_)6JDF?AZ)T1YN>*7G%=L3I:[ M],;%VV>KQ,B5N1$&DDI/QI"%80A1Y#$=Q^!!GZ91Z(N4QX%1[KQIQ9X;^;^\ M& @^$5TWHH=1.-&@F]F8\QO*T=VQUJ/8I]+2A*"Z+M(TA>A3UW>:<#B.E(:: MLO=^"]%[DN5_UUG5?Q5$BZ E_4=6WOVV6M-"Y$_::?YA]?"HRUMKU+-E5O6M M_O68YTJRMZ3(BBJ*6"<0U"=PM="Z M8[DNL;"86_$&K501%",/91"A&.,"0X M#" ).4NDOB006]T0F$;LN2U$OZUR09;511^=^[4 ;]1WHTP374.N%EX7D\OJ MRD;;O^EY 40=>[0+VK-,+C/1=V*V=LUO]$=>N[3"H-+X K1T!M^5TJ"M-:C5 M!B_UUI?%&LU!I7J3NN"B2K\*WF@ ?@(?6M_0!@1W2^.T8^9T:9Q(]$F7QFF' M8W]IG+AW:T?8;U^OK\5J?9^M= *P3^M2% &.O":F[_I1J"\E:#P.,8EB+V(2 M!I&4$,D@@E02"7F":,(BJ?98IOD;++J=V](4_*P$_9>J4H@H@!(5:%GM_3LV MR'=ZR4;"@0G@3*7PQ$<3&[K21H)[(M68'N1//6@_ 3GK9 M;-J:RN/60[^6]ZW/VSTS2>C8[(/;U)NTY5Y"":("$B_2@7TI@E1P"9D,!5;D M[G/$K7)%G.EL;HQ>R7HD\T#?Y.7G<#8S^UVA-S)_]P?./B># 2)NLRZQ!0CB(6/$.%Q1%BX>!(Y79M. M^)<=V'S%[6[&^Y@[,BV;@&8VJ?L#,?)TWN0Q&2'/_G&=W::9?MG%M&FECZIW MD$;Z^%.N[DM6IS/%AU5U12C3YS/:#?6N4)I\UW][%,4"$9GZ'"C,H,;H(-'Q\'] M4 M4;2^.FC3]RC=*+;3OOFIJT]CP\-R_KI?+[)ZL-LY:A(2@W(<^\2E$$<=0 M->'!1"U1$6.IES"CH/WNKN:V&AT-C=R(["#(= _HSD7%(7PCKQP3(]<_/+<_ M@J\9GFN.Y*"HW./@F$?E[KW_:E&YQ_4X%Y5[XHV>]_N%S%:"OQ4K]4-YHX;W M914;?=9!:Q GBDVMI0:-V$#+?0'V2URU@G4<9A"P!\QM5@&+ M_J?--& /S$'V@1Y-#$C-_#$C5#LW,[%)'DRDH!$+/,AB7^,^20([E,Q'W8U M?2+FD^H>3<-\^NF^%XO4#,ON;]3_K+F^3%Y\6I>72SU4=+DI%QZ&'@EPS"&2 M(M(EARA,XX0KEHA\R7'"O,@H9,VFT[F11",SJ(6^J)(I%#KP!VP%[WEV:30$ M9B3B&MB1*<4)ICTNW9B#Y/C*C$''$U]X,8?B\+J*Q;L]LS'OTF,6VQ#@SP_: M&/K[6KO2ZD29"S]EGJ<+=)+42R"*$(9$T!@RZB/J4^RGW-B19='OW"CJW<&= MC0L@]4V )RT_6#_4L?U/E0J;K,MOU!ZA_M$VM[+AX'0[OT:"?&Q/6(WVAS;: MNWL7X'.#=BU]DZ-W'(0MTR.[1WK:?,AN$+?/?VR'6T?"8\/&ILUP;*?A04IC MR]?[^MSR[$E]:$_BPZHH\\>Z]OR*_U7P6UW-B*D_5>;Q[IKD-_&C?*L4_6/A M4Q:F'@DA8@F&" =<[6^3!(H@3KPD$"1A5O&Y0X29V^KQ/EN1%_D&"#2Q MVV\X=(=^0 =M]J/77XFVZLER>X]N=?NA%/?;RFT)13C&$0P9Y1"A1,(4A2&4 M,D6*/6DB,+8AT//=S8TBOXK;ZAIM2UI0B=O38=@!MADCNH-P9,X;@)XUH9F! MXI2R.KJ4.3K2$>' @XFFT[*(.C[3SJB&&I_7J MBB<\\^90TJX"%:_41U06=5\+'GM,RC" 7%=#1RG2==%E"'V?A9X($LD#HR(6 M!GW-EZ:KT'7 *EG[DLDAM+;$/ BPR1FYDA;4XF[(PQUV?1EX$(:O1KU66 Y@ MW)/HF%+M80.OQ+$G-3E-KJ=?L6=5M6V_K;Z2BJF_B.)QN2W=G8J("S\1D'-E M^J(0"9B&20 ECKPT9K%G<7'H3#]S8]-O:TH86S?.KZI<@?[Q2N2E#F#;Q)UL M%+(/,CX+>C?7.H)R;)[= 51;88V@CN$RIU='L$U%K;WALV)5 U!.,^JYER=C M4P,-VDQJ\K@UB]8Q!Y]78I-GGDK*DS2"0>!'BCAQ!"E)8IABF; P\5)L3)Q[ M3<^-*VOQ@)+/>#KO@]5)> ,@&)GC=MK;L]H^#,9$-@".B;C+X*.P(:D3"I_D MI?WGIZ*B$W*VV.?4$W:$PT6V>*>,P?+YDG,U;L65^O%S_FW]?;7@"8OB*$20 MAUB'1R94%\U%T$_\)$ECSQ=F"=//]#$W"JK%!(V<%T!+"K2W1\EJ-AO/ 7J> MG1S!-#)-]4+(>(8:8'#D7*,0[.?;]=,OZNWZ2$/]4,WD:A:?:W.2Z6R@U&9> MFSS:[^QS;]MW3>[)K2@NOQ/5!J^B618>1ES@.(4LBH2R-(2GYCOR(/4#/^64 MA@D2-N>?W5W.;?HW(@)2RWA1!Q?:G7L: &UV]ND6OLD]81LL+S=8_OTLEM:G MH.;P.#T)->AVTM-08)!Z!.,0QI%X4R!B'26+L=>\EP-SHR*"^I58%*%U 2QG'E4=/#E?G9FOT M01B9U&:.OYNBKR[&83[U7ON-A[-*KUU@]BOR>K+56=1W[=+9M+1K9SO]#-\O M0GO:!=]DPM^L-3'U/2(9I$&80,08@VF28DB3((E3GW%IEJG^?#=S6U$VTJF9 M4]^DJ2MZ*K20W7 M\^KN&ZL=3_>];D'+71!R52\NB&B" QI#A(2$2(0QQ*GO04XP#5**XB"TJO5\ MV,7<*$%+V(K3[U7,[PB09A-_&#PC3WI+9'I<3#BEO./K!@?=3'R)X)2:AU<# M3C[I8H)O[VTM MEQTRO7KJ,<\K5]>NFHKNJC%5?4$#'/@8QH)1B$BB-@,R4$N_%+X,*!=1;'K0 M;M+?[,BAEAELA'Y1 ZB:(=9N#2/8$YS0(,9J#R8\;7&I 5!VEH 8)81RZJ$X M)6:)XD< ?IK,\1OHV09ZWH*>CP=]IP//-9PC\_AK?<+&CCC7>$[D=W. JXV' MS0:EDPXUHT:F\I_9:-1REUF]9KTH7MZO'Y6579_WE.LJ%/6&Y.7S(B$LD)C[ M,-*G+\BG$F+I49EP3KJ+BFUQ4U\YN'O,'91-N[N2@.(K# MQ \A0I$'$?9BB!F/8(AB',;83SW<\ZJ8O3!S(]7=7;*'6A? *F4N=+64K3K5 M?VVJQQAVDO.D(S,RB1^&ZC3J@*MF<-H: :424#K!2BFP MT6KHW;8>@]3W\MNX@_5JM^/&&+0!E^CZHVQZRZY'#Z]T#:\_%J?OZ0UHTVU] ML$_K\JLHRZ7@BY"%<9HD&!*&L=HGL C2(")J(*F71A$B06*:FM*PR[DM< :5 MOU;K4J>ZT-*[J2K5&@#;=JF*%<_9%\[QX4=PLYJ M;1V"U:^P5JN=6531.M3+M&36D3==!OJ& MH5#_I"%.?>')! WC\E-=_T_B].TVIKI&V][$#&6BDP/3E^-=P/V*7+\U;RND MKZ9 >BCWNT!\!FM #^0=K 5=X-FN"2?;>^6UH4O/[C6BLX5QZGW=Y-DZ_RKR MIXQ5T;MU"?$%EUB-2.##*-*9D@(60RR1#SGR0QJ+R./8\/AVF"#S.]6MY%2F M?R6H6BN*$KQAE:R&R>@'CLSYA6,ZM$=>1,S*A=6#T>A17QYX<]4Q&,[+AYW' M%_%>7=FN\RQ%]G3QE7+%U\SJ^SHLPS M^EC=<%A$,HX]&6*(/(+K2PI0B34ET_ M>/8IKFTO0%@KK9 MY7+]G2C-OZR72[G.=3"1_O%]_>/"2WU&4H$@CS"%* HY)!%.82*#@/FA\!#R M#?W@IGW.S2[?R@VV@H.6Y.!W_0_0"&\>2FT\!)W+U!C CKP>O3:FQHO+&-A. MM(HXPMAFI;!%Z^228-S05-QOJUF+Y*U?=7&Y\XMX4-_1'2D$?Z\^CSI4=!%[ M/,4A8]!'/-89A1C$1$BH=B$>2;'P4F(4G&G1Y]S8O+J?D;4N-^8[J8%4[P!2 MR3WD2NAQ\$T=T$XA'=W;O'=5M"4PT!*#R_-H#KPL>A:?$2^.'N_W%2^1G@7B M_(72\Z].5KGSDJH'"2L7@1=C&6 !2:P,390F'E1&J( \5/]'O5@B:I6*9H L M\R.OOJ4D-QI99[+H/XZF?#?)Z(S.@^,-S!05/OT"GUMYYE[?]SH]F6\'5YDK;X+FC5;FS,B'0TQ$>F3I=@6U-E+]"\A%W=B551\R];WXI,H/\MOY,?6N7JC@R#47KRL3P8)78IOZT\*$"69 M D>U?OMAI4A&%.6"1'$:RS2"/!$11 'Q])D=AYRBB-) 2C_!BW)=DJ4Q*;J4 MSXHVMU*..I-WZ@&Q20WX1HUQ(0K+*"_78VE,HJ\U0N/3;&MP:M7 &QU3^=,% M4#KJJ#"E9?NPJ5$4M#75][5?Z@HVRCIEY3%&P35O.Y5Q:F8? ^ CW#]*-];' M7>]6MTMQDZ_5PO-X7X/IG4(ELGQVH ^;.@RQWX(U,IM/B9GQ8 MY0Z_B8ZH!N)H1*2D"BJ%1&"5*0I3!B2<>"',96#[M5UBS W M#OZT?T.Z5*(#1AX 5=+J6E)Y+3Y8K:M?#2UDWSE&G3P] ?(C$_BYPO;-I5^M MAZ*D!_"V&89&%V7^5K\:?1B&W;]S.QRO?0_/P; ,OI1GCJC=Y3R#=E_UDIZY MWEV7]2Q:LEZ0/OS?G[\V]A(BPL?$URL+URFHB =3D3)(8U](C!,/FQT@OFAU M;LN&ELR8@EK@=))[/Y5'YFLME+U=W5+;F$S[J3\1/YX==!N".]3R)&>U'IV* MA@ZE:S'+D3_V\Q9_97>"/R[%9_E5W#:!$-H9H1T.2I R7YGV%,@ TC0,%;4$R/,3CT7"R%,P0(:Y$=%&A6J-KN4$6RU 2XT+ M0)^W3_Q>Z6)Y;-9GQ,S\OB./P\CL.,X06+MM!X#HU#7;1XY)W:\#@-IWL0YI MJF]I[,H?2W3D@K@F)6GN)"S\$'&L-_22"*8S?ZI-/F.*&WTO"7PJ& Z-N+&K MH[D18"TK: D+M+2;NSBV=;)/H'N>QUQB-KKOM!]/U43UP6YOB'$4>QB2! MS",2(H\RB)'D, D"C'S)D?"-JFP[DF=NY'(N^Q;9*K9Q'8I&-:!UVZ19!,NM M=D-]5G9#V]>/.-J O:)3<:?3QI'U[L58-7J!CZ\T5D.=C:.-V0P\CP['SH$3 MLA?2MAY)NTY>V3W9"Y%N7V6_9OM6Y7T@SU60G#+D[Y0!_TWD]_J:QB)!S/U0^K!.;]<+/1-M-<&5-R+_>D=R\984&5L0)#%#6,($(011ZON01FD" MN1 Q3^,$^=SH:W. M/MR/,,Z53V@*BA#BHTC$"/)$'YN&DD"<1K'ZIR0>XR*E-+%+7=K=JU;E)8QQ+2-(UJBQ*K[Q,F 0F\,/82&D06J0M'%K?'!G:*O(:;5,P/6FH[AAMK M7,UH\36':1HNK4M/OKP;]:96\B>@U;P QQ-J$ZF62/!%L"4IBDQFK,FTM%5V M\XC2UQT1CSP@3ME[+%DGI?R1 =]?)\;NSFYQ*$QC&B84"@C7==, MX0@I1QZ,N,"I)$C0P,A4;=J;FQUZF?^A4".%97SA!IWS5-I#YY$I[_++WRX_ M?;UT$$>XI]N9\W3]9,T<^J?=B?JFA4GF])ZXF[FW_^N^#OPGL7H4[U5OVM#3 MQ^S_R,J[*S43U?S-OXD?Y5LEQ!\+0C$.L=[MX81#1",/XCCT%(%2%BE<*&-6 M.>]-.Y[;K&OD;O*S;T0OZA.UC?36[GW#03#U]KN'=G3G?R7R2U!?8@I^UX*# M2G*'P7^V8#D^'C#L?.+3 CM(#@\/+-^WCN#Y[>OUM5BM[[.5W@OIX*J\?1>!%Z>:.-$^8)P6&02)]B+",(8VC$,K8(X3'W(LB8ABG8][KW$@K M_EGU]R\7NB"DSDVC)IJ6U?YB@@7NYZEJ-#1'YBDE-&A)79U-7H *7M"(?C$- MOL:!+^/@/%%XBQ7>3J)7[.$Z&:-BT=14D2CVVK7B37J\;!^J?=U\6-_4JPO" MTS2D!,'(HQ*BB :0",7E*!1$J#^)-$Q-0[/;#<^-GS>R 2V<>>#U"ZS.$^X0 M!$;F5#/EK<*HCVG:*VSZ14.3A4D?$[\=%GWT[WU\)'];2,8Y":@'&=?;NB2- M(.9"P" .:8*I'X3"*(RY:6]N$^MR28H_2"\/R=^,/"16&H_M(?EX^?5OEZ[\ M(W\SF#CG_2-_F](_\K?]B;+_:[OYP70RZ?QY<76YB&6$"$<9(KLFYS9+KLB*<-M9TD+H_$3II_?(<^7J\M/EM8.YG2/%S/F.8?NTG3:FJ2>7,H^F;J'/E+/^_B;ZM;7+ M+%PLL)"A3%($N1\&$#'$()$AA\KF\P-)@B1FV,:IV-'?W.;=3EQPJ^2M8P!_ M NL5X#NA[5R)78B;>1 =XCCVAGP'X5\J"#]N(+PV@-#:6V@(C%,G85>?D_H& M#0'8=PF:ON8D2/"2L?R1++^TZB;%DG(>XP3Z/D9J^TA]F.*40.IS%L4B%H@9 MK>'&/:XF]&-4S1')IRA0 X-8CL-SI@Q;$=Z?.LC=6^6HHP MA3Z7:I?M1PRF)! *=P\++%.>4"/ZL>IU;A2TE1S4HH.-[)4#MY8>:/'M_>86 M0]%Y+C$.P".STCRP-3Z3& ?CB/E MOCEDMH5LFVPU^HKM8[$@.!!^B C$)$UUN=D0DD@$D*1,I#A1!&]V*Z*KH[EQ M>I,4I1&VE;RI%M7;^';:<*Y0&YT.)@*L?R;^GL"]9AY^0P ')>$_ HMY"O[VRZ^6 M@/^(!N?2[Q][O&^)U>I>RB;RO[X=H"\ ?,P(U79;)@I=1Z7)'\<90TAR!H-$ M9^=+4@J5-17!-"))'"=!Z"=6GCN[[N=&L97_0NB[_Y7<@*V+TO*$P!)_,P_> M>*B.[#<6AFO=YPSB!SGAFL#I+B'07)-NG= MRT9>.:G=48VZD]8=?\V:A&L'X.5M+JKKI9/G?R?)1?):[7UX6A2@7DG.1 M8C^ /B4^1&&H^ TA#GF"8DZHY 'V[-)@F71K\^U.DPAK)R @6L(+()7TX$F+ M?P%N<[WL5W^PW38;C 'FOD\$)M!/.-&IR"C$3&(8)]*389@$(3,R[\<:@2D6 M'RTIJ$2M_79[^"#, M$7+L>3#H>&)_@SD4AUX&BW>=1#G6EO-G>;,DF?JEE,4B"#!E7JKCIW4X-5?& M+DT2IDL]\3!F/$P(&Q#E>-CCW+AGMX-[V,HX**3Q",AFQ.,4NE=T,-QTXS@T MHO$T-F-&-![I]34C&D^#T!'1>.9%^]WS^OY^O?I:KMD?X<]^$%7I JJ+O:'? M['32-/8]Y,>0!#)2%",4Q;#4@R26-$C2*(R#T'0KW=G;W.BE$O-?FBP*O+IU M'OH]]I#=,'?OM)V"-_:VNQ(65-)>@!%0DGL>A])G:5WI_.M;3Q+FNSBA[F-CJW,,]?7M9\; NR%)M[A\?/JS8\E&G6%:_K8NG/0K^ M^4'DU5)RR:J+N<4->=8R;.M72L4^*<&0L(!!)+D/*8\%9+XGPE199['TK)Q. M0R6:&Y%LI 0/M9B6WJC! V3HJIH2]K']6(TNH%+F FS5 6U]P%:A"[ =HT:G M$7C-&-$?M5D.(Q5Y*LU$J@ M>E4"ZAHGQ6^K-2U$7JT,'U8/CZ7ZLX)3O5/)V[X02[PX]8A/8!@R#R)$&:21 M)V <$9_2Q$N\R*H0^S1BSXW1VUYQI3C8]YN#-UOE?P(;]752@"T 554@94*U M,0 5". E"H,N2$_T49DM,//[5$9>A6;XE5@O6M,.FM.5;2+1)UW^IAV._35R MXM[[+:1UYO_JOD"5X9^H.](MF9-QME[,)D;=Z6HVE>R3+F<3#\C^>C9U]]8'HG\5 M9%G>79%<7*V+:L5\$OGS):O:#CP__73SZZYL3;$Y(TU8&K,(08_':H]'1 *I M\"(=AN''/$T90D;E;/L*,+\@G5NGP,/: MZ1O]M[K=%&%?A(0B'*<CL<4UN%Y#/M:AR=:G8EU M>%YG<^NPHYV!I]>5:[_X*)[$*F)E(GK43W1\$(<8)3Z40L8!D1[" MB562_3-]S6U):9\ UM)>@$I>8!MP; *TY3'L,/@F/#NU1J[_*>=I3,8YFCS2 MW^N<)YY6_.0AX)E7^I&(CFDDQ=U-OG[*N.!OGW\K!/^P^K!Z$H6^;J(I[*G* MEW-)BZJLYX)**@AB"N $^1!1C""AC$/B^3A)$A;':6!WZ=A>")M9,\T59*T MV&@ Z#-XHY4 V>HGL-4#[!2Q8Z >HV1&3.,B/S)?Z?@.2]C![QL]'#)9?Q"= M$EP/,2;EO?XP[=/A@):L]_G_\=MO'YNU7F#IRYBFD'JQ(KZ4)!![RK+R4Q'0 M5&WFP] HZ/I%JW,SG[1D]MN[%DJ=>^9^NH_,)8/5-MZJ]E-_HOVG&0PVN\I# M=4]N%5N/3K7_.Y2NM:D[\L=^1M;G\D[DS0%UFYTTB;U?KK]O3\,7L4]P$(44 M\M03.J=\!&DB/,@B1'P^P8&5.'.R:JHHG#J MS/D+X:=,"!3#V-<)3 .D:UQ@ 3UE!Q'AQ8AAHWK!YSJ9FQFT*U"]%;0IW="C M5/<^H.=IQQ5,(S-,#X3ZU?,^ <&PVM[[C4Y?Y_N$6D=K?I]Z=FC"XJLE*8I/ MZ_)*Y&4F,\'KS"(+''(_03Z"H4@#B+R002K3$-+0#Z67>,H,,3VF-.MQ;M._ M$A.LUB5@&T'[9MH]A7'G/LD]2%$P@L@I5Q"2=(@IA'W_=0HR-B@K[D1Z/6\YK'63Q&N)IQO+]7N$YQ5O'C5R#.O](S8'17WN)RQ:N417?KI7J_>/=? MCUGYO$A\RA -!8P2D:JMG,EX: M0T0D@6F4LLI[Y$6I#%._CTO[9(Z?TZ2ZG]T1WJG_4_=S]5C_^N!$K?9GSHVKRMMI"-R>J88 "$8<^C$3B M0>0%$4P)]J"'"2:IC/R 625 /-'/W'8ZC9A@)V?/L,53N)J1AP.T1F:-/D!9 MTT4'#$YYXE1?DQ)$A\+[S-#UN'T^:K(B/".K;VM*&%N_J!'5?,">\*E$H2YX MXD=0AS)#+!2<.%5[&QQZ(0J-"J\;]38W>MA(#!J17]8MZY%2N1OO3D^U6Q1' MIHU7 - \)[53(*?*23T04*MTU,8 G4Y'W=W$9.FHC;5IIZ,V?\F:?"]SFI5U M&HT;D6=K?KV^)]EJ(05-8YD097L% J*$I3#U0@X12JB/4\01-JT <**+N=%L M2TQ0RPE^KR4U9X93:';RJ0.,1B;1,>$Q9DL',$U$D7W@LJ'%#B1.<_1'9[5PI^^21RR@$;Y5R*F6 M_P*T-0 ;%=SMD7NCYW3W;"_%I/OJWB#M[[C[-V1M#M87:JH;RW6BQ0CC-/1I M #D)UMN(,7IC+?3DG:LMM./F)-1M49A$X$^5B*XK>5 M>D?]HHI[_RK*C4RT50S1N+2>#FK%>;?FNX7LP_T# MR?+J_J!D) P#M;R$C"004>)#@E@,61+'?BIQ&!&CG(P&?5P"#; M2GP!LJW,QK35"73GZN 2OI%7@@:Y6E;PH87= MWG\P \?U+8B.7J>^"V$&PI$;$88OVMMPJ]NEN,G7MV+U?*6:+CZ2%<^:G0\1 MQ/-XBB".> @1"R1,I4=A$*=>@@E/A3#U9Y[K9VY\4LD*&F%!)>T%J.2UWW&> MQ;?;;'.$VM@FVU2 F5MKCH";RE(; *"5H68 RVDC[=S+DQEH!AJTC3.3QWM6 MJ=Y6F_N8K<2'4MP7"QQ*'C)$8!+J FPZ.ILFG@?CA(?2YUY*S?RI9_J8&UFV M*DC^KH4$E926L=C'L#2SN@8B-#(QVH)C7\#YM/IN2S(?Z6?:(LNG%3THFWSF MT7Y3_:^"WV:KVR]B69?0NLL>FF LW^G).C/D1 MC$E%L'C\"FWGAJYS S?1@(S.7L/&8MI!<58\S]'@S*DV2I\)X[*$G@&DO0OI MG6M[)@533/2W**IGTEH_BU?UI=,W93)CU6?[7BEYN6991&F@%B_J(\B%3S'R=>4]JQVO:<=S6ZZNA11*0GW46^44*LD/VRH& MQIB;F<5C(#GR.K,O,M!S"UQ^OOJPS730W ^YT$F;W-G-ME@Y-:.-.Y_4JK:% M9-_(MGZ_'U&](_E*V?*%:J\*\?XF?I1OE1Y_+,) \$39T## %"MF0@2FOB10 MA@21( @X#:VNHISL:6Y4M!$4O-$9^43QD[YH4E]VL".DT]B:,9 3Q,8^NMB M=;/!"/RNY025H ZWYIU@..64T[U-2B*=2N^S1O<+_6CBFSXW?A +26%*1) ($D8$R\5*W))2\&_F MQ&'2M]&,2.L9<2#!F OR@VKJ3A^#B"ZL.+O%1&<4RY#6,[ W[*6);;V[P:7P6VVL,IT.N;@"#?#H5A MJF4KZ,T(W36@(W/[1MPZ@>'%IG;?1N:+>IMM&+G77C6)*81B&F,<0)5NN#+QDD:4*A3V-!!"'((Z8%KOKT/S>J M,G(X>=&>P\FY+_#X6 WUS X>@3FX9%\+?%<>V,&#,"?7:X_!<.AY/0ME7Y?K M\49GXFL]J[&YD_5\,SV=%D=#QC]_7RG6OLL>U.:'Z8_V5BPPB2CS=4 !CX4N M5(TAC<,$\H2+& F2\,CH!HUUSW-;;$[?IUEOA-=NCD9Z2S^'\7!(RJ.(ZN(" MG.OT3D19 $@7^"6$8A+PB")NEZQWE &9*&_OA, ;.IS& '-L!]3)2SH[?&^Z M\;7W1]EBY=8_9=S[M/XJ6U ._%?6#3CP9VTV1DW*$[V,;?QGBU@@+ /FPSB) M4YTE6#&6C!%D'O.$])$?I,*.L4R[GA]A;3( />09J[(OU;Z5XTX6\.:QX+N' M+#,Q&8]/#\>+(\PG=;ZTG"Z;4:@,Y9O.DXEA_A<#K,;SP9SK_/7\, :0G/7% MF+P_N/#>^OY!K H]TL_7Y%YU4UQ^)ZHI?KFLOH ZS]W&.@AIA!.* QB$#$/$ M8A]2ZC/USY@G:1K0T#=US P29&Y&H4#'0[2D(*"O9 UKC-H MU_IKE1_LA<&9JH3]VK-;T(J\7/R:K;+[Q_O&(QI)$M,P\-22A"*(1!!#3((( M!K'O^1%)6!K')BO40 G5\B!L$P,N<;(V#,#">U/6>ZJI=: M9JOZU[[)>MCJ)%/\I#*;.7OZ@>&7VV\$R8OUZOIJ?2=65^OEDN17=X1MRG)L MKKWS!(5>*F$:)WJR)@C2U ^ALC$#&<0D\I%1'$)O">8VJ8]>3VXTN0#7H%)& M+YM:'?7?2B$'5[_-AJO3FAQ_$,;V$0["?[*!Z'\[W_F O.:]?8<#,^ANOQ6H MYK?^S9I]M7P 5EJ?RQ1@UU#/VI#Y+5EE_UU]IO?*5<-6EL]/79;!<%.PQ?UO4>)[QYK -R6VG0MY+3%.4>"^*"5 MU* E=@WI!:@0WG@^+R:"V'AK,1+4$^TG["!WLFWH =C)O8)-6U-M$'KHU]H5 M]'G;!_R5?JZ6O^3KHKC)US(K%TQ04<6+1'$:0B0EAM1+8TB36-_Q23AARE1> MEV1IYB5IM6W%G]L>QOMJ*]' 0R6;G2.C#9B9#Z(G#".38(W S7D$K+?[1W1U MNE-OMS_I)ON(8OO[XV./6!Z0EP_YXOIJ@<,(^[K@5)3JZ%2>^I"&80 3ZG%. M">$X-C)LFO;F9KQ<9T699ZRZQGNU7C[>TXS8GHPW2'6U6>W]]-7BC'V7HX+=*LGRZ TDF;;DJK"W"Y-UPO-0,;U=S1I2.,G7+J M4)DF)5Y' .ZSLZMF^^R8WBU"3S!*!(-A@B1$J4\@CKP8>HS'DB B66!TRM>T M-S?[[5HL]?T4T6N7],YHEV2E\]B[I'6=JYW1NS.SWFQG]&[*G=&[ M_3FV_^NA]\C^+G*N]M_%;P]W8LD7A$O, XQARI3I@DB8PI13"8.0R"00TF/$ M:%_4U='<9M6G1SV7]%+VU,@)'BM!^UXMVL.U\\S$&5HCS\?#JT ;4<%O+@'K M>]>J/W"O=I?*%, !]Z2.HV)Z#VKO[5>ZYW18[ MPB]= O__&+\<8S-'P"O.S)%- 3U@&]5 HQO8* <:9<";C7[:N&I^^=,%V"H) M&BWK;!=;/=UY"48: *=> ];"]R1,+VUN/8GWMFOEP]9?EZ58WD4C-6 M<;->9NQYP:*4!YZ4, W5;J&JUH%I&D#"F(=]+N,PM4MT>:*CN5'/"SG!%W'[ MN.QQZ>PDK&96G NP1F:IESA5,EZ 6DKP>_/?<>IV=&#C-BWBJ M[0;"*OVKNX$P3^(PQ8!,E<=AM(&QRN P%-'321QZMSQ9'H>ANK=3.0QNJVXNDVW,$2@:5,K.(#N((V"BS;MF)B+;/$M)Y57 M]/F>KI>+R$L\KI@5"B1TV88P@C2(?"@\P2.?(2%"(UH]:'EN'-D(!VKIS#CO M$*[S!#8(A)'9R%!_8U(YJ>N9T"KU3DT.ZH==8-5A2Y-,[9,*;.;IZ0?ZF3][ M$0I-=M6OZ\?;N[(JX+9@ 8XE) QKA\=LLG(7E= 7X$F+;6>Q=.-N9I8X17/L0XN#.*--FN:O#9!_/PND MM6UA#(Y3 Z*[UTFM!&,0]DT!\Q?[4<\E8_GC_T?=NS7'C6MIHG\%$7-FNBI" MJ,T+2((S3RK9KE*'RU;8KM[140\9N$KLG6)JR$R[-+_^ "3SHLQD$B!!)CNB M>Y6 MENN",,4B.$W\-"80BR2 *(X"]1.)8! AXJ5"R)0P&Q;I(\3&AOWD?E*RUT!7/UPH,%-XZT&MDJ MG[9J_ S^VFKB\&)T")!N@]+Z"#)M)-H J$["SX:TU3-UCLA%09:JUUO^G.4Z MJ0599]]%XXBV8 D+?.G'$ !C?-;6]EW?K5.DS>8X:*VX0^ M'7U.F^3'#("3Q#^&KUG[>QP3UWW^5:S7RRJC[@-YU?&T"\D2'[,0P331F1!3 M#T$LDQ3Z6,HP1DD<<6+HV6'0W=Q,K>T^I=P)"M@3*1Y-:<40Y,NLXAZZD4GE MG"UTGX.]R*"1V2F(QBX4CL&0O4'X MI5;D%R"BW]S(U]M9AVYEL;@&9FFP-81F96+>'X114Z<'!J MH+7U-:EAUJ'PL4'6]7B_R?]%G]ULV+HB]@"Y&4=I'++_VM3.U5#\$,!4LH8*)-$16#&'6[=P(H[ZET $I>YG!7NCZ@+SVGK.+NK,< M#>.+.L<8CW]EMQ48?%@5(GO,P0[RO=PG&=L>B+X[9>S^;MX?7A/TDI&PF#$J0+R*B+)I0%WZEJ82$)1@B+XAPFG*,DK1OX==] M-W.CJ[-%++6X#@J''H#;>;3D"+*1V62IV4YY"(FOC*'$3V5 MB AY9)HL\V)'H6F '2_P;B.U-HK[ 7<,H&@>S_H917^RN:1J98CC( M.#H'C+EY].;MJQE(YW2X9"*=?;Z?D?15Y-FJJ J6-=]H$A*:1!A!G_I446>0 MPA0K0XDA$C!)XXA$5A[G)SW,C3-K 9N2>/T,I%,4S>RC0=B,3(MVL%@;1ZVJ M.[6-3GN9U#1J5?+8,FI_L(<[4IVK_S;GU3&MOF9K?)P^B:WY'C&4AIAZD 5^ M E&:AI!*XD&2J E.2>!)$AK[(W7W-[58?97-\)-]Z.-Y6+B/7: M;X1\I]GD&L^1:6('Y>WN7J"Z7G^_A?+3:%!:N"JYA70BH\H-M'8>2N9 77!1 M,FAD.A\E."E9O-;/\OI LJ(*'[S/7S;K\J/X+I;;BO&1#,/02P.8QKI0 M2L@0)(BFT ]BAH2/91H9%4HQZ&MNU*Q%K>-?;T M[0VHY 5A3^/L$M!F9IHC M^$9FXD'(6=MO!I@XM>0N]3>I36>@^+%U9_**HS2#=;64E?SZ1-2W]7Z9/69T M*3ZLB@?UF3VIS>,B]CP2$8_#1/HZ5U.L]G=)0F&8>$D0D%#Z>%B2P4X1YD8Y M[2D&\UWMF;)2!HA&&R#5UNBET0?\1%Y>BM7?V3-9B^7KS^"G+&]>^'E@TKON MX>P^AAM_D,8^H&M-<+>O#53K ;:*:-\*L%5E]#$8F';0Z5AG@P#$9GG/0 M&$[+C(/=[5XWWZ"QWIW9!LU;ZF?Z/I#7RI?LLWR7?<^XR'EYMWI^7N5?U]K- M//!D[/NQ6J%2?56;<@QQDG(H4TE9P#Q.9&17H>5RAT;3:]*"*SLIP0O).%CE M.G^@$A>46EX[\[<#;#,+V & TZP56T$U_WPN>):3XA7L9-9W$A6.7R_B:&T, MF\'CU![NZ')2D]A,_6.KV/"MGKGZSQ+;NTQ*H7TMQ:]B_4.(_(X4Q6N6/]X^ MKS:YWNW_F:L^EOI7=0N+,(T"1'T$?1$2B(CD$ NI]N-Q$*9)G 01M2I'[TJP M_SY&--_I!FBM'&"-=H!4ZE7'L)N=@E4^CO6K914!5P-N1HC7&,:KF=E[M4"C M%]@J!F[W([C7#;R_/(+VA0PWZIPTJK MO=!*WJV*0C =\Z_7F4V^3=S:G 5B$7F^KUT"=;XUE' &TR#2SH'"HY1XQ(M- M?8;L>IX;E;^5OG*1V\D/WBK0XV;';E"ZK\M&@WKLB[,9H6Q^DS8:VE/=J;E$ MW>IJK1=R[9=L=LU-=MW62\O#B[=^#?1-%%!DWZLD,/>Y#CS4_7[)RG_=_IV5 MBR3&/)3,@SY.$X@DCB#&-(4DB (?(S_!H96O^*7.YK8"[&4%>V'!7UI4R\NW MBQ";F=JN@!N9SWMAUB.I0#<8CC,+7.APXO0"W:J?YA@P>,?:L/P@N$XEI?./ M5[24E:7BI'TN@SJAW2(FD1\)Z4/NI\J@#!6^:1P*Z/%42I)P&B;"T* TZW%V M-+)/L5%GUS&V7PP1[K0.W>,V]B5^+3"H) 9[D6\.\Y4\C *FL1'H'M2)C#\7 MX-K8?'9 M=IZALU,9>/9:75@VUF^:$W+VDEK3_/O_U[KPBVK_)LHGA>*B+&( M>0+3$$N(?!% G&(&O1A+3[M4(6:4^^ER-[,C8.TNF.UDO0%B*RU0W3\;,\@E M9#LYV!%>HYMO"JK[ ZAV@H)OKJ R9EA'D$U$JWVALZ%2 T1:^?/2NU.1IH'\ M!TQI\K0U/1[5L7A0FVEM&#?U+&Y_$-4,KVNN1'Z*/#^F, @CK"^]=-6)((8X M#*6( D1BA@S9TKS7N9'G5M1=F1M2"VM>9-X<\$X2'0?&D3GUM-#-#M-MQ9M& M\JZ2-P.@-2;=<2">B(/=06W#RO:0M9*T15-3<;:]=@<4WN/EO@D/N1#/.D_4 M)Z61ZE%IIQY_W(8PU+=H;Z_9%EX:1X)@I&A=V<0H2!!,)0]@&GB"!C$CL31* M%C1$B+GQ_5X'D+]10EG0M1:V&1-[#(S9D>C8<(^\+AP@_59^L%7@IO$@N#EV M-'"9B[$_AHX3-?809.(LCOVA.DWQ.* M:YNW]F3]++\]905_(,7Z]2/Y4:H> MR@4F(68\(# B7@11'"KVXR*$F*92!(Q2(4SSI;7W,C>.VSMGK[6LX$4+"Y:- MM,;FUP58.RU9-V"-S% -3I\EJ,0$E9S@HT..M7?[$)0*VP_3.(Z"Q7=1T)4I)YSKQN8C/NQLO&]Y*V4F2LNZCV=A-)O;0Z$9>7[O MQ&M23HQ0D/$2 DYG^-F.)IWEEU0]GND7G^T9,JY/I70[#X7:B+WH0ZDO]X]/ MZZTO:$"1'R*?P0A'%*(T4/LBQ)F"DO@,T3@*)3&;^(8]SH\#FDB(K=@W8"\X M^))IR7LD!C3!GI,X8G&JP(YPH,PP1B!F@0=Q&F*BV-=GU"COQPC(3Y+[(_M; M),3<6WZMR4/#S9AOJ*1IU M=%$3*K9WZD!_*$TFONI,TOPF>,#X=7+_1*,R\I)P,"!?#P:DB=S<:@*^K<"O M8GM+7 ](G73N8;(!,;^KGV9@IKJ\'W6 K"[TA^/:?L,_H.W)KOR'ZW_H ^"@ MM1[Y7[E.I[ ARZ_/JW_I.[2<_R[(YBJ MW;*,$.9>S )3#R^C#N>V2.V%!HW450A[+7>=P+Q/UE(3Z#M7'>> CGX\=(+E M[4186J2 =8SI9#E@'7RG=BE@+8"ZD /6I)7IDL!:Z/0F"ZS->\-+F/RV5#\7 M7[)\O=JHKX"_VV2/ZN-HOO401=@7-($DT2?RH?0@Y2&"DOD)QW[(0L\T9[== MSW/C[K/%)FH-;D"C0S5+&BT<5/&X/#+=9TBCX3WV:=+;7,V&O] MO[OZZ0N6$$&CF$(A90S5HA'"-%1&OL=1&DD4L@ 3&U\.LV[GMDA44FM'MP?5 MZG:VWH!::KN+74/"5LAY332V+# MKB>]-K:#X_@BV?+M?@15'U^LRG4AUEE1'7?\*G(AL[6NY5Z^4S_E@C>_VE7J MHY1S3&&:\E2Q510IJ];#, T8B06COA#2SL^DAQ3SNX)^*W_/R@=]QL.,Q4;& M>&1*:TY-WT+<"%L"K<$(!1,&0.:4V_K(,2G1#0#JF/6&-&6]G:\Z4P1;; 3_ MF!&:+;-UMCNI"B,J$),^]"73N_%/,@%&&,C=))=74T-SNLGFN- MM.! 7/NMXF6 .S?ASF";A)TF0,QX+^T,N8FVS@,0M-DC&\'2NB6^_/94.V C M'0XVO&;/]X]*R*HLL>5MSO?!LZK]A10()8%.R4HE@\B+?)C*@$(2A9$7(((P M$W9FXH7>YF<.OA$/_*0+10(_Z!%XT(:OF=GG"+.1"?1 RNJ [(V<;@,2.L!P M'IO0UM_D80H=BI^+6.AZI1]I*"[:/&^6NBA'Q4VJIY="/.F$*3KI'UL]"QV* M_TFL/\MOY.^%(#B54<"4]26(LL-2 E,>IU!Z'J>4\3!($CLBL91@?N1RH$#C M@L4.50!+)?V%B>-D6,SX9T2H1^:D0XQK\^2-[* 6'ORDQ?^Y#K-82:!T<,=7 M/<%SRF&V,DS*:ST!.N:ZOLV,4@'P\P^UP?VB_E1DVM]H(0(=YXD32%&LD]R3 M4!&A'T.!_3#"*$41,0KT[-?]W#:G^W#X8B?C-K9SI44?K93?\;AT7R&/B_;8 M]\CFY>(J)6[ 7HU1<7=:NF\ _O,KVV<^#JY+]K7 .*A >)#X7D*:>1"B5 M.&&Q5:J MI[FMEA4@E9662-J'? ._JJDM;R::! MX78?WMK;M+OP+J5/]N"=+PPL9*\LVGV^_5NU9UQO3P@5=>D^E4&Q('D(6-X M4:>4_[HFQ=J,:=P+:C/9CL4=TV-#_9,)0-: BL='[3.L)J%-!OX1AQ:S5"T@ MR(.I1]4&!(6Z* *-(>(8,4GCA-"@&=KWN6%YUSD,[%;82895Y'Q&0VJV8EUW MD$9>ZK1RV\0W^NSFH!A,I2'X::?CSV"KI:[KN],3U'Y6/Y2FX%!54.OJ;K$< M;QRS,?K^H@]]3,(CE+?5K>%9/E0K+YG.HOYP@\3R4BL5O< M(8@H8I#JU5UB+ 5'1")N%#9MV-_<]A$[P4 AZ@/A]0HL]R&@A6 K\SSCIJ"; MD;1#*$=FW..$UZ"15>=E:*1UQYF&L#@EP*X^)V4S0P".JTF2R M*0KX>;.N/%R[3M^KVG.*@73.0Q]2)!*((A$K$N(2AHS&(<(A#XR256GSJ!@\;2C-NF&J&1B6_

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end

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 102 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 103 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 564 429 1 true 224 0 false 17 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.altria.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.altria.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.altria.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Earnings (Losses) Sheet http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses Condensed Consolidated Statements of Earnings (Losses) Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Earnings (Losses) Sheet http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarningsLosses Condensed Consolidated Statements of Comprehensive Earnings (Losses) Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Stockholders' (Deficit) Equity Sheet http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquity Condensed Consolidated Statements of Stockholders' (Deficit) Equity Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Parenthetical) Sheet http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityParenthetical Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Parenthetical) Statements 7 false false R8.htm 1007008 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 2101101 - Disclosure - Background and Basis of Presentation Sheet http://www.altria.com/role/BackgroundandBasisofPresentation Background and Basis of Presentation Notes 9 false false R10.htm 2106102 - Disclosure - Revenues from Contracts with Customers Sheet http://www.altria.com/role/RevenuesfromContractswithCustomers Revenues from Contracts with Customers Notes 10 false false R11.htm 2109103 - Disclosure - Assets Held for Sale Sheet http://www.altria.com/role/AssetsHeldforSale Assets Held for Sale Notes 11 false false R12.htm 2113104 - Disclosure - Investments in Equity Securities Sheet http://www.altria.com/role/InvestmentsinEquitySecurities Investments in Equity Securities Notes 12 false false R13.htm 2121105 - Disclosure - Financial Instruments Sheet http://www.altria.com/role/FinancialInstruments Financial Instruments Notes 13 false false R14.htm 2130106 - Disclosure - Benefit Plans Sheet http://www.altria.com/role/BenefitPlans Benefit Plans Notes 14 false false R15.htm 2134107 - Disclosure - Earnings (Losses) per Share Sheet http://www.altria.com/role/EarningsLossesperShare Earnings (Losses) per Share Notes 15 false false R16.htm 2137108 - Disclosure - Other Comprehensive Earnings/Losses Sheet http://www.altria.com/role/OtherComprehensiveEarningsLosses Other Comprehensive Earnings/Losses Notes 16 false false R17.htm 2141109 - Disclosure - Segment Reporting Sheet http://www.altria.com/role/SegmentReporting Segment Reporting Notes 17 false false R18.htm 2147110 - Disclosure - Debt Sheet http://www.altria.com/role/Debt Debt Notes 18 false false R19.htm 2151111 - Disclosure - Income Taxes Sheet http://www.altria.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 2156112 - Disclosure - Contingencies Sheet http://www.altria.com/role/Contingencies Contingencies Notes 20 false false R21.htm 2176113 - Disclosure - New Accounting Guidance Not Yet Adopted Sheet http://www.altria.com/role/NewAccountingGuidanceNotYetAdopted New Accounting Guidance Not Yet Adopted Notes 21 false false R22.htm 2202201 - Disclosure - Background and Basis of Presentation (Policies) Sheet http://www.altria.com/role/BackgroundandBasisofPresentationPolicies Background and Basis of Presentation (Policies) Policies http://www.altria.com/role/NewAccountingGuidanceNotYetAdopted 22 false false R23.htm 2208202 - Disclosure - Revenue from Contract with Customer (Policies) Sheet http://www.altria.com/role/RevenuefromContractwithCustomerPolicies Revenue from Contract with Customer (Policies) Policies http://www.altria.com/role/NewAccountingGuidanceNotYetAdopted 23 false false R24.htm 2303301 - Disclosure - Background and Basis of Presentation (Tables) Sheet http://www.altria.com/role/BackgroundandBasisofPresentationTables Background and Basis of Presentation (Tables) Tables http://www.altria.com/role/BackgroundandBasisofPresentation 24 false false R25.htm 2310302 - Disclosure - Assets Held for Sale (Tables) Sheet http://www.altria.com/role/AssetsHeldforSaleTables Assets Held for Sale (Tables) Tables http://www.altria.com/role/AssetsHeldforSale 25 false false R26.htm 2314303 - Disclosure - Investments in Equity Securities (Tables) Sheet http://www.altria.com/role/InvestmentsinEquitySecuritiesTables Investments in Equity Securities (Tables) Tables http://www.altria.com/role/InvestmentsinEquitySecurities 26 false false R27.htm 2322304 - Disclosure - Financial Instruments (Tables) Sheet http://www.altria.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.altria.com/role/FinancialInstruments 27 false false R28.htm 2331305 - Disclosure - Benefit Plans (Tables) Sheet http://www.altria.com/role/BenefitPlansTables Benefit Plans (Tables) Tables http://www.altria.com/role/BenefitPlans 28 false false R29.htm 2335306 - Disclosure - Earnings (Losses) per Share (Tables) Sheet http://www.altria.com/role/EarningsLossesperShareTables Earnings (Losses) per Share (Tables) Tables http://www.altria.com/role/EarningsLossesperShare 29 false false R30.htm 2338307 - Disclosure - Other Comprehensive Earnings/Losses (Tables) Sheet http://www.altria.com/role/OtherComprehensiveEarningsLossesTables Other Comprehensive Earnings/Losses (Tables) Tables http://www.altria.com/role/OtherComprehensiveEarningsLosses 30 false false R31.htm 2342308 - Disclosure - Segment Reporting (Tables) Sheet http://www.altria.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.altria.com/role/SegmentReporting 31 false false R32.htm 2348309 - Disclosure - Debt (Tables) Sheet http://www.altria.com/role/DebtTables Debt (Tables) Tables http://www.altria.com/role/Debt 32 false false R33.htm 2352310 - Disclosure - Income Taxes update (Tables) Sheet http://www.altria.com/role/IncomeTaxesupdateTables Income Taxes update (Tables) Tables 33 false false R34.htm 2357311 - Disclosure - Contingencies (Tables) Sheet http://www.altria.com/role/ContingenciesTables Contingencies (Tables) Tables http://www.altria.com/role/Contingencies 34 false false R35.htm 2377312 - Disclosure - New Accounting Guidance Not Yet Adopted (Tables) Sheet http://www.altria.com/role/NewAccountingGuidanceNotYetAdoptedTables New Accounting Guidance Not Yet Adopted (Tables) Tables http://www.altria.com/role/NewAccountingGuidanceNotYetAdopted 35 false false R36.htm 2404401 - Disclosure - Background and Basis of Presentation (Narrative) (Details) Sheet http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails Background and Basis of Presentation (Narrative) (Details) Details http://www.altria.com/role/BackgroundandBasisofPresentationTables 36 false false R37.htm 2405402 - Disclosure - Background and Basis of Presentation (Share Repurchase Table) (Details) Sheet http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails Background and Basis of Presentation (Share Repurchase Table) (Details) Details http://www.altria.com/role/BackgroundandBasisofPresentationTables 37 false false R38.htm 2407403 - Disclosure - Revenues from Contracts with Customers (Narrative) (Details) Sheet http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails Revenues from Contracts with Customers (Narrative) (Details) Details http://www.altria.com/role/RevenuesfromContractswithCustomers 38 false false R39.htm 2411404 - Disclosure - Assets Held for Sale (Narrative) (Details) Sheet http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails Assets Held for Sale (Narrative) (Details) Details http://www.altria.com/role/AssetsHeldforSaleTables 39 false false R40.htm 2412405 - Disclosure - Assets Held for Sale (Summary of Major Classes of Assets and Liabilities Classified as Held for Sale) (Details) Sheet http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails Assets Held for Sale (Summary of Major Classes of Assets and Liabilities Classified as Held for Sale) (Details) Details http://www.altria.com/role/AssetsHeldforSaleTables 40 false false R41.htm 2415406 - Disclosure - Investments in Equity Securities (Summary of Investments) (Details) Sheet http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails Investments in Equity Securities (Summary of Investments) (Details) Details http://www.altria.com/role/InvestmentsinEquitySecuritiesTables 41 false false R42.htm 2416407 - Disclosure - Investments in Equity Securities (Earnings in Equity Securities) (Details) Sheet http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails Investments in Equity Securities (Earnings in Equity Securities) (Details) Details http://www.altria.com/role/InvestmentsinEquitySecuritiesTables 42 false false R43.htm 2417408 - Disclosure - Investments in Equity Securities (Investment in ABI Narrative) (Details) Sheet http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails Investments in Equity Securities (Investment in ABI Narrative) (Details) Details http://www.altria.com/role/InvestmentsinEquitySecuritiesTables 43 false false R44.htm 2418409 - Disclosure - Investments in Equity Securities (Investment in JUUL Narrative) (Details) Sheet http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails Investments in Equity Securities (Investment in JUUL Narrative) (Details) Details http://www.altria.com/role/InvestmentsinEquitySecuritiesTables 44 false false R45.htm 2419410 - Disclosure - Investments in Equity Securities (JUUL Investment Classified as Level 3) (Details) Sheet http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details Investments in Equity Securities (JUUL Investment Classified as Level 3) (Details) Details http://www.altria.com/role/InvestmentsinEquitySecuritiesTables 45 false false R46.htm 2420411 - Disclosure - Investments in Equity Securities (Investment in Cronos Narrative) (Details) Sheet http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails Investments in Equity Securities (Investment in Cronos Narrative) (Details) Details http://www.altria.com/role/InvestmentsinEquitySecuritiesTables 46 false false R47.htm 2423412 - Disclosure - Financial Instruments (Aggregate Notional Amounts, Aggregate Fair Values and Carrying Values) (Details) Sheet http://www.altria.com/role/FinancialInstrumentsAggregateNotionalAmountsAggregateFairValuesandCarryingValuesDetails Financial Instruments (Aggregate Notional Amounts, Aggregate Fair Values and Carrying Values) (Details) Details http://www.altria.com/role/FinancialInstrumentsTables 47 false false R48.htm 2424413 - Disclosure - Financial Instruments (Aggregate Fair Value and Carrying Value) (Details) Sheet http://www.altria.com/role/FinancialInstrumentsAggregateFairValueandCarryingValueDetails Financial Instruments (Aggregate Fair Value and Carrying Value) (Details) Details http://www.altria.com/role/FinancialInstrumentsTables 48 false false R49.htm 2425414 - Disclosure - Financial Instruments (Fair Value Using Black-Scholes Option-Pricing Model) (Details) Sheet http://www.altria.com/role/FinancialInstrumentsFairValueUsingBlackScholesOptionPricingModelDetails Financial Instruments (Fair Value Using Black-Scholes Option-Pricing Model) (Details) Details http://www.altria.com/role/FinancialInstrumentsTables 49 false false R50.htm 2426415 - Disclosure - Financial Instruments (Beginning and Ending Balances of Fixed-price Preemptive Rights and Warrants) (Details) Sheet http://www.altria.com/role/FinancialInstrumentsBeginningandEndingBalancesofFixedpricePreemptiveRightsandWarrantsDetails Financial Instruments (Beginning and Ending Balances of Fixed-price Preemptive Rights and Warrants) (Details) Details http://www.altria.com/role/FinancialInstrumentsTables 50 false false R51.htm 2427416 - Disclosure - Financial Instruments (Fair Value Derivative Financial Instruments) (Details) Sheet http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails Financial Instruments (Fair Value Derivative Financial Instruments) (Details) Details http://www.altria.com/role/FinancialInstrumentsTables 51 false false R52.htm 2428417 - Disclosure - Financial Instruments (Pre-tax Unrealized Gains (Losses)) (Details) Sheet http://www.altria.com/role/FinancialInstrumentsPretaxUnrealizedGainsLossesDetails Financial Instruments (Pre-tax Unrealized Gains (Losses)) (Details) Details http://www.altria.com/role/FinancialInstrumentsTables 52 false false R53.htm 2429418 - Disclosure - Financial Instruments (Effects of Net Investment Hedges on Accumulated Other Comprehensive Losses) (Details) Sheet http://www.altria.com/role/FinancialInstrumentsEffectsofNetInvestmentHedgesonAccumulatedOtherComprehensiveLossesDetails Financial Instruments (Effects of Net Investment Hedges on Accumulated Other Comprehensive Losses) (Details) Details http://www.altria.com/role/FinancialInstrumentsTables 53 false false R54.htm 2432419 - Disclosure - Benefit Plans (Schedule Of Components Of Net Periodic Benefit Cost (Income)) (Details) Sheet http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails Benefit Plans (Schedule Of Components Of Net Periodic Benefit Cost (Income)) (Details) Details http://www.altria.com/role/BenefitPlansTables 54 false false R55.htm 2433420 - Disclosure - Benefit Plans (Narrative) (Details) Sheet http://www.altria.com/role/BenefitPlansNarrativeDetails Benefit Plans (Narrative) (Details) Details http://www.altria.com/role/BenefitPlansTables 55 false false R56.htm 2436421 - Disclosure - Earnings (Losses) per Share (Basic and Diluted Earnings Per Share) (Details) Sheet http://www.altria.com/role/EarningsLossesperShareBasicandDilutedEarningsPerShareDetails Earnings (Losses) per Share (Basic and Diluted Earnings Per Share) (Details) Details http://www.altria.com/role/EarningsLossesperShareTables 56 false false R57.htm 2439422 - Disclosure - Other Comprehensive Earnings/Losses (Changes in Each Component of Accumulated Other Comprehensive Losses) (Details) Sheet http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails Other Comprehensive Earnings/Losses (Changes in Each Component of Accumulated Other Comprehensive Losses) (Details) Details http://www.altria.com/role/OtherComprehensiveEarningsLossesTables 57 false false R58.htm 2440423 - Disclosure - Other Comprehensive Earnings/Losses (Reclassifications) (Details) Sheet http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails Other Comprehensive Earnings/Losses (Reclassifications) (Details) Details http://www.altria.com/role/OtherComprehensiveEarningsLossesTables 58 false false R59.htm 2443424 - Disclosure - Segment Reporting (Segment Data Schedule) (Details) Sheet http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails Segment Reporting (Segment Data Schedule) (Details) Details http://www.altria.com/role/SegmentReportingTables 59 false false R60.htm 2444425 - Disclosure - Segment Reporting (Non-Participating Manufacturer Adjustment Items) (Details) Sheet http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails Segment Reporting (Non-Participating Manufacturer Adjustment Items) (Details) Details http://www.altria.com/role/SegmentReportingTables 60 false false R61.htm 2445426 - Disclosure - Segment Reporting (Schedule of Tobacco and Health and Certain Other Litigation Items) (Details) Sheet http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails Segment Reporting (Schedule of Tobacco and Health and Certain Other Litigation Items) (Details) Details http://www.altria.com/role/SegmentReportingTables 61 false false R62.htm 2446427 - Disclosure - Segment Reporting (Narrative) (Details) Sheet http://www.altria.com/role/SegmentReportingNarrativeDetails Segment Reporting (Narrative) (Details) Details http://www.altria.com/role/SegmentReportingTables 62 false false R63.htm 2449428 - Disclosure - Debt (Narrative) (Details) Sheet http://www.altria.com/role/DebtNarrativeDetails Debt (Narrative) (Details) Details http://www.altria.com/role/DebtTables 63 false false R64.htm 2450429 - Disclosure - Debt (Tender Offers) (Details) Sheet http://www.altria.com/role/DebtTenderOffersDetails Debt (Tender Offers) (Details) Details http://www.altria.com/role/DebtTables 64 false false R65.htm 2453430 - Disclosure - Income Taxes - Summary of Income Taxes (Details) Sheet http://www.altria.com/role/IncomeTaxesSummaryofIncomeTaxesDetails Income Taxes - Summary of Income Taxes (Details) Details 65 false false R66.htm 2454431 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.altria.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 66 false false R67.htm 2455432 - Disclosure - Income Taxes (Details) Sheet http://www.altria.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.altria.com/role/IncomeTaxesupdateTables 67 false false R68.htm 2458433 - Disclosure - Contingencies (General Information) (Details) Sheet http://www.altria.com/role/ContingenciesGeneralInformationDetails Contingencies (General Information) (Details) Details http://www.altria.com/role/ContingenciesTables 68 false false R69.htm 2459434 - Disclosure - Contingencies (Judgments Paid and Provisions for Tobacco and Health Litigation) (Details) Sheet http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails Contingencies (Judgments Paid and Provisions for Tobacco and Health Litigation) (Details) Details http://www.altria.com/role/ContingenciesTables 69 false false R70.htm 2460435 - Disclosure - Contingencies (Schedule of Pending Cases) (Details) Sheet http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails Contingencies (Schedule of Pending Cases) (Details) Details http://www.altria.com/role/ContingenciesTables 70 false false R71.htm 2461436 - Disclosure - Contingencies (Overview of Altria and/or PM USA Tobacco-Related Litigation Narrative) (Details) Sheet http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails Contingencies (Overview of Altria and/or PM USA Tobacco-Related Litigation Narrative) (Details) Details http://www.altria.com/role/ContingenciesTables 71 false false R72.htm 2462437 - Disclosure - Contingencies (Non-Engle Progeny Litigation) (Details) Sheet http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails Contingencies (Non-Engle Progeny Litigation) (Details) Details http://www.altria.com/role/ContingenciesTables 72 false false R73.htm 2463438 - Disclosure - Contingencies (Engle Class Action And Engle Progeny Trial Results) (Details) Sheet http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails Contingencies (Engle Class Action And Engle Progeny Trial Results) (Details) Details http://www.altria.com/role/ContingenciesTables 73 false false R74.htm 2464439 - Disclosure - Contingencies (Engle Progeny Cases Trial Results - Pending and Concluded) (Details) Sheet http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails Contingencies (Engle Progeny Cases Trial Results - Pending and Concluded) (Details) Details http://www.altria.com/role/ContingenciesTables 74 false false R75.htm 2465440 - Disclosure - Contingencies (Florida Bond Statute) (Details) Sheet http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails Contingencies (Florida Bond Statute) (Details) Details http://www.altria.com/role/ContingenciesTables 75 false false R76.htm 2466441 - Disclosure - Contingencies (Other Smoking and Health Class Actions) (Details) Sheet http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails Contingencies (Other Smoking and Health Class Actions) (Details) Details http://www.altria.com/role/ContingenciesTables 76 false false R77.htm 2467442 - Disclosure - Contingencies (Health Care Cost Recovery Litigation) (Details) Sheet http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails Contingencies (Health Care Cost Recovery Litigation) (Details) Details http://www.altria.com/role/ContingenciesTables 77 false false R78.htm 2468443 - Disclosure - Contingencies (NPM Adjustment Disputes) (Details) Sheet http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails Contingencies (NPM Adjustment Disputes) (Details) Details http://www.altria.com/role/ContingenciesTables 78 false false R79.htm 2469444 - Disclosure - Contingencies (Other Disputes Under the State Settlement Agreements) (Details) Sheet http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails Contingencies (Other Disputes Under the State Settlement Agreements) (Details) Details http://www.altria.com/role/ContingenciesTables 79 false false R80.htm 2470445 - Disclosure - Contingencies (Federal Government's Lawsuit) (Details) Sheet http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails Contingencies (Federal Government's Lawsuit) (Details) Details http://www.altria.com/role/ContingenciesTables 80 false false R81.htm 2471446 - Disclosure - Contingencies (E-vapor Product Litigation and IQOS Litigation) (Details) Sheet http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails Contingencies (E-vapor Product Litigation and IQOS Litigation) (Details) Details http://www.altria.com/role/ContingenciesTables 81 false false R82.htm 2472447 - Disclosure - Contingencies (Antitrust Litigation and Shareholder Class Action and Shareholder Derivative Lawsuits) (Details) Sheet http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails Contingencies (Antitrust Litigation and Shareholder Class Action and Shareholder Derivative Lawsuits) (Details) Details http://www.altria.com/role/ContingenciesTables 82 false false R83.htm 2473448 - Disclosure - Contingencies (Lights/Ultra Lights Cases) (Details) Sheet http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails Contingencies (Lights/Ultra Lights Cases) (Details) Details http://www.altria.com/role/ContingenciesTables 83 false false R84.htm 2474449 - Disclosure - Contingencies (UST Litigations Narrative) (Details) Sheet http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails Contingencies (UST Litigations Narrative) (Details) Details http://www.altria.com/role/ContingenciesTables 84 false false R85.htm 2475450 - Disclosure - Contingencies (Guarantees and Other Similar Matters Narrative) (Details) Sheet http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails Contingencies (Guarantees and Other Similar Matters Narrative) (Details) Details http://www.altria.com/role/ContingenciesTables 85 false false R9999.htm Uncategorized Items - mo-20210930.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - mo-20210930.htm Cover 86 false false All Reports Book All Reports mo-20210930.htm exhibit311q32021.htm exhibit312q32021.htm exhibit321q32021.htm exhibit322q32021.htm exhibit991q32021.htm exhibit992q32021.htm mo-20210930.xsd mo-20210930_cal.xml mo-20210930_def.xml mo-20210930_lab.xml mo-20210930_pre.xml http://xbrl.sec.gov/stpr/2021 http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 http://xbrl.sec.gov/dei/2021 http://xbrl.sec.gov/country/2021 true true JSON 106 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mo-20210930.htm": { "axisCustom": 1, "axisStandard": 37, "contextCount": 564, "dts": { "calculationLink": { "local": [ "mo-20210930_cal.xml" ] }, "definitionLink": { "local": [ "mo-20210930_def.xml" ] }, "inline": { "local": [ "mo-20210930.htm" ] }, "labelLink": { "local": [ "mo-20210930_lab.xml" ] }, "presentationLink": { "local": [ "mo-20210930_pre.xml" ] }, "schema": { "local": [ "mo-20210930.xsd" ], "remote": [ "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 732, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 2, "http://www.altria.com/20210930": 4, "http://xbrl.sec.gov/dei/2021": 5, "total": 11 }, "keyCustom": 95, "keyStandard": 334, "memberCustom": 136, "memberStandard": 84, "nsprefix": "mo", "nsuri": "http://www.altria.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.altria.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106102 - Disclosure - Revenues from Contracts with Customers", "role": "http://www.altria.com/role/RevenuesfromContractswithCustomers", "shortName": "Revenues from Contracts with Customers", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109103 - Disclosure - Assets Held for Sale", "role": "http://www.altria.com/role/AssetsHeldforSale", "shortName": "Assets Held for Sale", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113104 - Disclosure - Investments in Equity Securities", "role": "http://www.altria.com/role/InvestmentsinEquitySecurities", "shortName": "Investments in Equity Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121105 - Disclosure - Financial Instruments", "role": "http://www.altria.com/role/FinancialInstruments", "shortName": "Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130106 - Disclosure - Benefit Plans", "role": "http://www.altria.com/role/BenefitPlans", "shortName": "Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2134107 - Disclosure - Earnings (Losses) per Share", "role": "http://www.altria.com/role/EarningsLossesperShare", "shortName": "Earnings (Losses) per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137108 - Disclosure - Other Comprehensive Earnings/Losses", "role": "http://www.altria.com/role/OtherComprehensiveEarningsLosses", "shortName": "Other Comprehensive Earnings/Losses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2141109 - Disclosure - Segment Reporting", "role": "http://www.altria.com/role/SegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2147110 - Disclosure - Debt", "role": "http://www.altria.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2151111 - Disclosure - Income Taxes", "role": "http://www.altria.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i503473da7ed148e2805b9efd533f401c_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.altria.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i503473da7ed148e2805b9efd533f401c_I20210930", "decimals": "-6", "lang": "en-US", "name": "mo:InventoryRawMaterialsPlantMaterialNetofReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2156112 - Disclosure - Contingencies", "role": "http://www.altria.com/role/Contingencies", "shortName": "Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2176113 - Disclosure - New Accounting Guidance Not Yet Adopted", "role": "http://www.altria.com/role/NewAccountingGuidanceNotYetAdopted", "shortName": "New Accounting Guidance Not Yet Adopted", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Background and Basis of Presentation (Policies)", "role": "http://www.altria.com/role/BackgroundandBasisofPresentationPolicies", "shortName": "Background and Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2208202 - Disclosure - Revenue from Contract with Customer (Policies)", "role": "http://www.altria.com/role/RevenuefromContractwithCustomerPolicies", "shortName": "Revenue from Contract with Customer (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Background and Basis of Presentation (Tables)", "role": "http://www.altria.com/role/BackgroundandBasisofPresentationTables", "shortName": "Background and Basis of Presentation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310302 - Disclosure - Assets Held for Sale (Tables)", "role": "http://www.altria.com/role/AssetsHeldforSaleTables", "shortName": "Assets Held for Sale (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314303 - Disclosure - Investments in Equity Securities (Tables)", "role": "http://www.altria.com/role/InvestmentsinEquitySecuritiesTables", "shortName": "Investments in Equity Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322304 - Disclosure - Financial Instruments (Tables)", "role": "http://www.altria.com/role/FinancialInstrumentsTables", "shortName": "Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331305 - Disclosure - Benefit Plans (Tables)", "role": "http://www.altria.com/role/BenefitPlansTables", "shortName": "Benefit Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2335306 - Disclosure - Earnings (Losses) per Share (Tables)", "role": "http://www.altria.com/role/EarningsLossesperShareTables", "shortName": "Earnings (Losses) per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i503473da7ed148e2805b9efd533f401c_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.altria.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i503473da7ed148e2805b9efd533f401c_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2338307 - Disclosure - Other Comprehensive Earnings/Losses (Tables)", "role": "http://www.altria.com/role/OtherComprehensiveEarningsLossesTables", "shortName": "Other Comprehensive Earnings/Losses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2342308 - Disclosure - Segment Reporting (Tables)", "role": "http://www.altria.com/role/SegmentReportingTables", "shortName": "Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2348309 - Disclosure - Debt (Tables)", "role": "http://www.altria.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "mo:SummaryOfIncomeTaxesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2352310 - Disclosure - Income Taxes update (Tables)", "role": "http://www.altria.com/role/IncomeTaxesupdateTables", "shortName": "Income Taxes update (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "mo:SummaryOfIncomeTaxesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2357311 - Disclosure - Contingencies (Tables)", "role": "http://www.altria.com/role/ContingenciesTables", "shortName": "Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2377312 - Disclosure - New Accounting Guidance Not Yet Adopted (Tables)", "role": "http://www.altria.com/role/NewAccountingGuidanceNotYetAdoptedTables", "shortName": "New Accounting Guidance Not Yet Adopted (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i33693bcc9b6d47e48094cbb1bb3c5f74_D20201201-20210429", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404401 - Disclosure - Background and Basis of Presentation (Narrative) (Details)", "role": "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails", "shortName": "Background and Basis of Presentation (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i33693bcc9b6d47e48094cbb1bb3c5f74_D20201201-20210429", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i87c434bf861c4058b94849e22ee0fe19_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockValueAcquiredCostMethod", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Background and Basis of Presentation (Share Repurchase Table) (Details)", "role": "http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails", "shortName": "Background and Basis of Presentation (Share Repurchase Table) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i66dae12b306e4c15a45bf2cedaae9792_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:TreasuryStockValueAcquiredCostMethod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i503473da7ed148e2805b9efd533f401c_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Revenues from Contracts with Customers (Narrative) (Details)", "role": "http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails", "shortName": "Revenues from Contracts with Customers (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i503473da7ed148e2805b9efd533f401c_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i4d91b3c8886d4970bfefc99ee9bd77ec_I20211001", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - Assets Held for Sale (Narrative) (Details)", "role": "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails", "shortName": "Assets Held for Sale (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i4d91b3c8886d4970bfefc99ee9bd77ec_I20211001", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i87c434bf861c4058b94849e22ee0fe19_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Earnings (Losses)", "role": "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses", "shortName": "Condensed Consolidated Statements of Earnings (Losses)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i87c434bf861c4058b94849e22ee0fe19_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherCostOfOperatingRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i503473da7ed148e2805b9efd533f401c_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412405 - Disclosure - Assets Held for Sale (Summary of Major Classes of Assets and Liabilities Classified as Held for Sale) (Details)", "role": "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails", "shortName": "Assets Held for Sale (Summary of Major Classes of Assets and Liabilities Classified as Held for Sale) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i11c3f27b7191493b8194d2564e1cbc32_I20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i503473da7ed148e2805b9efd533f401c_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Investments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415406 - Disclosure - Investments in Equity Securities (Summary of Investments) (Details)", "role": "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails", "shortName": "Investments in Equity Securities (Summary of Investments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i72200b393daa452fb6e8b503937f1675_I20210930", "decimals": "-6", "lang": "en-US", "name": "mo:EquityInvestmentFairValueOption", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i87c434bf861c4058b94849e22ee0fe19_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416407 - Disclosure - Investments in Equity Securities (Earnings in Equity Securities) (Details)", "role": "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails", "shortName": "Investments in Equity Securities (Earnings in Equity Securities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "ic62d4fc827d0412695035c4816dc2a17_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i503473da7ed148e2805b9efd533f401c_I20210930", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsFairValueDisclosure", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417408 - Disclosure - Investments in Equity Securities (Investment in ABI Narrative) (Details)", "role": "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails", "shortName": "Investments in Equity Securities (Investment in ABI Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "ife49fc973ca746f092aa4d83bca9d740_D20210101-20210930", "decimals": "2", "lang": "en-US", "name": "mo:EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "ia17ccdc17eaa43c2895a3756a03e1e51_I20201031", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418409 - Disclosure - Investments in Equity Securities (Investment in JUUL Narrative) (Details)", "role": "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails", "shortName": "Investments in Equity Securities (Investment in JUUL Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "ia17ccdc17eaa43c2895a3756a03e1e51_I20201031", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i134145e8cb494481a64026d08e24f670_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419410 - Disclosure - Investments in Equity Securities (JUUL Investment Classified as Level 3) (Details)", "role": "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details", "shortName": "Investments in Equity Securities (JUUL Investment Classified as Level 3) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i134145e8cb494481a64026d08e24f670_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i0b7b05662cb744f89da910b211c223dc_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420411 - Disclosure - Investments in Equity Securities (Investment in Cronos Narrative) (Details)", "role": "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails", "shortName": "Investments in Equity Securities (Investment in Cronos Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "ib5afb831a7af4995b73bda6b83b376f7_I20201231", "decimals": "3", "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i503473da7ed148e2805b9efd533f401c_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423412 - Disclosure - Financial Instruments (Aggregate Notional Amounts, Aggregate Fair Values and Carrying Values) (Details)", "role": "http://www.altria.com/role/FinancialInstrumentsAggregateNotionalAmountsAggregateFairValuesandCarryingValuesDetails", "shortName": "Financial Instruments (Aggregate Notional Amounts, Aggregate Fair Values and Carrying Values) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "ic10cda982ea5415199ad34d94e8b02ba_I20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i503473da7ed148e2805b9efd533f401c_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424413 - Disclosure - Financial Instruments (Aggregate Fair Value and Carrying Value) (Details)", "role": "http://www.altria.com/role/FinancialInstrumentsAggregateFairValueandCarryingValueDetails", "shortName": "Financial Instruments (Aggregate Fair Value and Carrying Value) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i503473da7ed148e2805b9efd533f401c_I20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "ia4d49e3b18b5423e972b0489f00c3c44_I20210930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssetMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "cadPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425414 - Disclosure - Financial Instruments (Fair Value Using Black-Scholes Option-Pricing Model) (Details)", "role": "http://www.altria.com/role/FinancialInstrumentsFairValueUsingBlackScholesOptionPricingModelDetails", "shortName": "Financial Instruments (Fair Value Using Black-Scholes Option-Pricing Model) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "ia4d49e3b18b5423e972b0489f00c3c44_I20210930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssetMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "cadPerShare", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i87c434bf861c4058b94849e22ee0fe19_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Earnings (Losses)", "role": "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarningsLosses", "shortName": "Condensed Consolidated Statements of Comprehensive Earnings (Losses)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i87c434bf861c4058b94849e22ee0fe19_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i888b21f50f1241039283cfc1fe265126_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426415 - Disclosure - Financial Instruments (Beginning and Ending Balances of Fixed-price Preemptive Rights and Warrants) (Details)", "role": "http://www.altria.com/role/FinancialInstrumentsBeginningandEndingBalancesofFixedpricePreemptiveRightsandWarrantsDetails", "shortName": "Financial Instruments (Beginning and Ending Balances of Fixed-price Preemptive Rights and Warrants) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "ia80bd4793ddf4b2d915e5f5ea7d8ca62_I20191231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "idaabb1ac00dc4de9afa2e9b2a864fa5b_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427416 - Disclosure - Financial Instruments (Fair Value Derivative Financial Instruments) (Details)", "role": "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails", "shortName": "Financial Instruments (Fair Value Derivative Financial Instruments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "idaabb1ac00dc4de9afa2e9b2a864fa5b_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i87c434bf861c4058b94849e22ee0fe19_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:UnrealizedGainLossOnDerivatives", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428417 - Disclosure - Financial Instruments (Pre-tax Unrealized Gains (Losses)) (Details)", "role": "http://www.altria.com/role/FinancialInstrumentsPretaxUnrealizedGainsLossesDetails", "shortName": "Financial Instruments (Pre-tax Unrealized Gains (Losses)) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i87c434bf861c4058b94849e22ee0fe19_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:UnrealizedGainLossOnDerivatives", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i641562cd01894f84aa15b3d08486a81e_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429418 - Disclosure - Financial Instruments (Effects of Net Investment Hedges on Accumulated Other Comprehensive Losses) (Details)", "role": "http://www.altria.com/role/FinancialInstrumentsEffectsofNetInvestmentHedgesonAccumulatedOtherComprehensiveLossesDetails", "shortName": "Financial Instruments (Effects of Net Investment Hedges on Accumulated Other Comprehensive Losses) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i641562cd01894f84aa15b3d08486a81e_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "ib46d19a7eb014c0d80e8454b5ba93ecc_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432419 - Disclosure - Benefit Plans (Schedule Of Components Of Net Periodic Benefit Cost (Income)) (Details)", "role": "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails", "shortName": "Benefit Plans (Schedule Of Components Of Net Periodic Benefit Cost (Income)) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "ib46d19a7eb014c0d80e8454b5ba93ecc_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i92dcd11d5d934931ab51a35b59f2acd1_D20210101-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433420 - Disclosure - Benefit Plans (Narrative) (Details)", "role": "http://www.altria.com/role/BenefitPlansNarrativeDetails", "shortName": "Benefit Plans (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i92dcd11d5d934931ab51a35b59f2acd1_D20210101-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i87c434bf861c4058b94849e22ee0fe19_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436421 - Disclosure - Earnings (Losses) per Share (Basic and Diluted Earnings Per Share) (Details)", "role": "http://www.altria.com/role/EarningsLossesperShareBasicandDilutedEarningsPerShareDetails", "shortName": "Earnings (Losses) per Share (Basic and Diluted Earnings Per Share) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i87c434bf861c4058b94849e22ee0fe19_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "mo:ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i3df7c108f2c5403c96f58e273f0dc0d1_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439422 - Disclosure - Other Comprehensive Earnings/Losses (Changes in Each Component of Accumulated Other Comprehensive Losses) (Details)", "role": "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails", "shortName": "Other Comprehensive Earnings/Losses (Changes in Each Component of Accumulated Other Comprehensive Losses) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i811d953ad6844425a1abf068a0bef5ea_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i87c434bf861c4058b94849e22ee0fe19_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440423 - Disclosure - Other Comprehensive Earnings/Losses (Reclassifications) (Details)", "role": "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails", "shortName": "Other Comprehensive Earnings/Losses (Reclassifications) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i88fcf49918a84402902b9a4fd578a532_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i87c434bf861c4058b94849e22ee0fe19_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443424 - Disclosure - Segment Reporting (Segment Data Schedule) (Details)", "role": "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails", "shortName": "Segment Reporting (Segment Data Schedule) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i8712c39f1b4b407d8d3f616cd0f6d0b2_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i9bf636ab56ad4d7cb37b9d77019eed37_I20191231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' (Deficit) Equity", "role": "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquity", "shortName": "Condensed Consolidated Statements of Stockholders' (Deficit) Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "ib231dbdd7b5c42a4892838893be458cb_I20191231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mo:ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i01fb7d5238cf4de6af35e1b8ee70534b_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GainLossRelatedToLitigationSettlement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444425 - Disclosure - Segment Reporting (Non-Participating Manufacturer Adjustment Items) (Details)", "role": "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails", "shortName": "Segment Reporting (Non-Participating Manufacturer Adjustment Items) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mo:ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i01fb7d5238cf4de6af35e1b8ee70534b_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GainLossRelatedToLitigationSettlement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i74d52c13d1e44d56853af2d044689b8c_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyAccrualProvision", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445426 - Disclosure - Segment Reporting (Schedule of Tobacco and Health and Certain Other Litigation Items) (Details)", "role": "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails", "shortName": "Segment Reporting (Schedule of Tobacco and Health and Certain Other Litigation Items) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i74d52c13d1e44d56853af2d044689b8c_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyAccrualProvision", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i87c434bf861c4058b94849e22ee0fe19_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446427 - Disclosure - Segment Reporting (Narrative) (Details)", "role": "http://www.altria.com/role/SegmentReportingNarrativeDetails", "shortName": "Segment Reporting (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:CostOfGoodsAndServicesSold", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i986e7568db0547edb5f58a6f3d032e05_D20200701-20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i503473da7ed148e2805b9efd533f401c_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShortTermBorrowings", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449428 - Disclosure - Debt (Narrative) (Details)", "role": "http://www.altria.com/role/DebtNarrativeDetails", "shortName": "Debt (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ShortTermBorrowings", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i0b7b05662cb744f89da910b211c223dc_I20201231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShortTermBorrowings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "ic85fd5bdf74f4f0091c93c498eb3cc11_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentRepurchasedFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450429 - Disclosure - Debt (Tender Offers) (Details)", "role": "http://www.altria.com/role/DebtTenderOffersDetails", "shortName": "Debt (Tender Offers) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "ic85fd5bdf74f4f0091c93c498eb3cc11_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentRepurchasedFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mo:SummaryOfIncomeTaxesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i87c434bf861c4058b94849e22ee0fe19_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2453430 - Disclosure - Income Taxes - Summary of Income Taxes (Details)", "role": "http://www.altria.com/role/IncomeTaxesSummaryofIncomeTaxesDetails", "shortName": "Income Taxes - Summary of Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mo:SummaryOfIncomeTaxesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i87c434bf861c4058b94849e22ee0fe19_D20210701-20210930", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i87c434bf861c4058b94849e22ee0fe19_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454431 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://www.altria.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i0b7b05662cb744f89da910b211c223dc_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455432 - Disclosure - Income Taxes (Details)", "role": "http://www.altria.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i0b7b05662cb744f89da910b211c223dc_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i503473da7ed148e2805b9efd533f401c_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "mo:LossContingencyNumberofStatesThatCapBondorRequireNoBond", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458433 - Disclosure - Contingencies (General Information) (Details)", "role": "http://www.altria.com/role/ContingenciesGeneralInformationDetails", "shortName": "Contingencies (General Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i503473da7ed148e2805b9efd533f401c_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "mo:LossContingencyNumberofStatesThatCapBondorRequireNoBond", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i3df7c108f2c5403c96f58e273f0dc0d1_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2459434 - Disclosure - Contingencies (Judgments Paid and Provisions for Tobacco and Health Litigation) (Details)", "role": "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails", "shortName": "Contingencies (Judgments Paid and Provisions for Tobacco and Health Litigation) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i3df7c108f2c5403c96f58e273f0dc0d1_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i87c434bf861c4058b94849e22ee0fe19_D20210701-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Parenthetical)", "role": "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityParenthetical", "shortName": "Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "link:footnote", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i87c434bf861c4058b94849e22ee0fe19_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "ia5ed554a97e64e58a2f7dff3f260635e_I20201027", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyPendingClaimsNumber", "reportCount": 1, "unique": true, "unitRef": "claim", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460435 - Disclosure - Contingencies (Schedule of Pending Cases) (Details)", "role": "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails", "shortName": "Contingencies (Schedule of Pending Cases) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "ia5ed554a97e64e58a2f7dff3f260635e_I20201027", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyPendingClaimsNumber", "reportCount": 1, "unique": true, "unitRef": "claim", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "ibf6d7d9ce89842c7976f502120165e8c_I20201027", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyPendingClaimsNumber", "reportCount": 1, "unitRef": "claim", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2461436 - Disclosure - Contingencies (Overview of Altria and/or PM USA Tobacco-Related Litigation Narrative) (Details)", "role": "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails", "shortName": "Contingencies (Overview of Altria and/or PM USA Tobacco-Related Litigation Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i90fcd7f5574440a5ab359cb20e1a04c8_D19990101-20211025", "decimals": "INF", "lang": "en-US", "name": "mo:LossContingencyClaimsDecided", "reportCount": 1, "unique": true, "unitRef": "case", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i052ec416024f4823bef90cd01d8b4153_I20200229", "decimals": "-6", "first": true, "lang": "en-US", "name": "mo:LossContingencyCompensatoryDamagesAwardedValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2462437 - Disclosure - Contingencies (Non-Engle Progeny Litigation) (Details)", "role": "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails", "shortName": "Contingencies (Non-Engle Progeny Litigation) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i052ec416024f4823bef90cd01d8b4153_I20200229", "decimals": "-6", "first": true, "lang": "en-US", "name": "mo:LossContingencyCompensatoryDamagesAwardedValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i5287e7b9447640e785f900c6e40cbb09_I20000731", "decimals": "-9", "first": true, "lang": "en-US", "name": "mo:LossContingencyPunitiveDamagesAwardedValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2463438 - Disclosure - Contingencies (Engle Class Action And Engle Progeny Trial Results) (Details)", "role": "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails", "shortName": "Contingencies (Engle Class Action And Engle Progeny Trial Results) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i5287e7b9447640e785f900c6e40cbb09_I20000731", "decimals": "-9", "first": true, "lang": "en-US", "name": "mo:LossContingencyPunitiveDamagesAwardedValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i73ae2282abd0496a96c1fcd57396db0e_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "mo:LossContingencyCompensatoryDamagesAwardedValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2464439 - Disclosure - Contingencies (Engle Progeny Cases Trial Results - Pending and Concluded) (Details)", "role": "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails", "shortName": "Contingencies (Engle Progeny Cases Trial Results - Pending and Concluded) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i73ae2282abd0496a96c1fcd57396db0e_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "mo:LossContingencyCompensatoryDamagesAwardedValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i91285291d0224d41a9f6b6f098c51c67_I20090630", "decimals": "INF", "first": true, "lang": "en-US", "name": "mo:MaximumBondForAllDefendants", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2465440 - Disclosure - Contingencies (Florida Bond Statute) (Details)", "role": "http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails", "shortName": "Contingencies (Florida Bond Statute) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i91285291d0224d41a9f6b6f098c51c67_I20090630", "decimals": "INF", "first": true, "lang": "en-US", "name": "mo:MaximumBondForAllDefendants", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "icdad9497490d4094a88132d419cbfe76_I20211025", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyPendingClaimsNumber", "reportCount": 1, "unitRef": "claim", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2466441 - Disclosure - Contingencies (Other Smoking and Health Class Actions) (Details)", "role": "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "shortName": "Contingencies (Other Smoking and Health Class Actions) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i5e74537c0b4c4859a3f2089a42ce56ae_D19960501-20210930", "decimals": "INF", "lang": "en-US", "name": "mo:LossContingencyClassNotCertifiedNumber", "reportCount": 1, "unique": true, "unitRef": "case", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "ibf6d7d9ce89842c7976f502120165e8c_I20201027", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyPendingClaimsNumber", "reportCount": 1, "unitRef": "claim", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2467442 - Disclosure - Contingencies (Health Care Cost Recovery Litigation) (Details)", "role": "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails", "shortName": "Contingencies (Health Care Cost Recovery Litigation) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i94453f2294bb47798d15011e7260b27b_D19981101-19981130", "decimals": "INF", "lang": "en-US", "name": "mo:LossContingencyNumberofStateswithSettledLitigation", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i53eb33b5a5a54692bf19b84768b69b6f_D20210701-20210930", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2468443 - Disclosure - Contingencies (NPM Adjustment Disputes) (Details)", "role": "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails", "shortName": "Contingencies (NPM Adjustment Disputes) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i0c5082287da0495e8408464c2a0a26c2_D20180101-20181231", "decimals": "INF", "lang": "en-US", "name": "mo:LossContingencyNumberofStateswithSettledLitigationSettlementOne", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i52787a392f8143ad96b8a01791362efb_D20210101-20210131", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LitigationSettlementAmountAwardedFromOtherParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2469444 - Disclosure - Contingencies (Other Disputes Under the State Settlement Agreements) (Details)", "role": "http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails", "shortName": "Contingencies (Other Disputes Under the State Settlement Agreements) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i52787a392f8143ad96b8a01791362efb_D20210101-20210131", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LitigationSettlementAmountAwardedFromOtherParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i87c434bf861c4058b94849e22ee0fe19_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i37765c8db4d14257a1db295453135743_D20060801-20060831", "decimals": null, "first": true, "lang": "en-US", "name": "mo:FederalTradeCommissionDisclosurePeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2470445 - Disclosure - Contingencies (Federal Government's Lawsuit) (Details)", "role": "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails", "shortName": "Contingencies (Federal Government's Lawsuit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i37765c8db4d14257a1db295453135743_D20060801-20060831", "decimals": null, "first": true, "lang": "en-US", "name": "mo:FederalTradeCommissionDisclosurePeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i0b7b05662cb744f89da910b211c223dc_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "mo:LossContingencyNumberOfCasesWithCourtDatesSet", "reportCount": 1, "unique": true, "unitRef": "case", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2471446 - Disclosure - Contingencies (E-vapor Product Litigation and IQOS Litigation) (Details)", "role": "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails", "shortName": "Contingencies (E-vapor Product Litigation and IQOS Litigation) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i0b7b05662cb744f89da910b211c223dc_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "mo:LossContingencyNumberOfCasesWithCourtDatesSet", "reportCount": 1, "unique": true, "unitRef": "case", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "if859d02a78924c39895c8fe236aea331_I20201130", "decimals": "INF", "first": true, "lang": "en-US", "name": "mo:LossContingencyNumberOfComplaints", "reportCount": 1, "unique": true, "unitRef": "complaint", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2472447 - Disclosure - Contingencies (Antitrust Litigation and Shareholder Class Action and Shareholder Derivative Lawsuits) (Details)", "role": "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails", "shortName": "Contingencies (Antitrust Litigation and Shareholder Class Action and Shareholder Derivative Lawsuits) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "if859d02a78924c39895c8fe236aea331_I20201130", "decimals": "INF", "first": true, "lang": "en-US", "name": "mo:LossContingencyNumberOfComplaints", "reportCount": 1, "unique": true, "unitRef": "complaint", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i72c3cdb7c38d49a39f60eaafddfc2f55_I20211025", "decimals": "INF", "first": true, "lang": "en-US", "name": "mo:LossContingencyClaimsNotCertifiedNumber", "reportCount": 1, "unique": true, "unitRef": "case", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2473448 - Disclosure - Contingencies (Lights/Ultra Lights Cases) (Details)", "role": "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails", "shortName": "Contingencies (Lights/Ultra Lights Cases) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i72c3cdb7c38d49a39f60eaafddfc2f55_I20211025", "decimals": "INF", "first": true, "lang": "en-US", "name": "mo:LossContingencyClaimsNotCertifiedNumber", "reportCount": 1, "unique": true, "unitRef": "case", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "ibadad7f290d443d29bbe99b6abd7399f_I20211025", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyPendingClaimsNumber", "reportCount": 1, "unique": true, "unitRef": "claim", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2474449 - Disclosure - Contingencies (UST Litigations Narrative) (Details)", "role": "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails", "shortName": "Contingencies (UST Litigations Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "ibadad7f290d443d29bbe99b6abd7399f_I20211025", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyPendingClaimsNumber", "reportCount": 1, "unique": true, "unitRef": "claim", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i503473da7ed148e2805b9efd533f401c_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GuaranteeObligationsMaximumExposure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2475450 - Disclosure - Contingencies (Guarantees and Other Similar Matters Narrative) (Details)", "role": "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails", "shortName": "Contingencies (Guarantees and Other Similar Matters Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i503473da7ed148e2805b9efd533f401c_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GuaranteeObligationsMaximumExposure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Background and Basis of Presentation", "role": "http://www.altria.com/role/BackgroundandBasisofPresentation", "shortName": "Background and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i083f183560914b169a2b47229664ba43_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i0b7b05662cb744f89da910b211c223dc_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - mo-20210930.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - mo-20210930.htm", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mo-20210930.htm", "contextRef": "i0b7b05662cb744f89da910b211c223dc_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 224, "tag": { "country_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CANADA", "terseLabel": "Canada [Member]" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails", "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "country_PR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PUERTO RICO", "terseLabel": "Puerto Rico [Member]" } } }, "localname": "PR", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r728" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r729" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails", "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails", "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails", "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails", "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails", "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails", "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails", "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails", "http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails", "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails", "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails", "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r729" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r729" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r737" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r729" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r729" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r729" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r729" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails", "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails", "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails", "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails", "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails", "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails", "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails", "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails", "http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails", "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails", "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails", "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r725" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "mo_ABInBevMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AB InBev [Member]", "label": "AB InBev [Member]", "terseLabel": "ABI [Member]" } } }, "localname": "ABInBevMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/IncomeTaxesNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" ], "xbrltype": "domainItemType" }, "mo_AccruedSettlementLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Settlement Liability, Current", "label": "Accrued Settlement Liability, Current", "terseLabel": "Settlement charges" } } }, "localname": "AccruedSettlementLiabilityCurrent", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "mo_AccumulatedEquityMethodInvestmentsAttributableToParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accumulated Equity Method Investments Attributable To Parent [Member]", "label": "Accumulated Equity Method Investments Attributable To Parent [Member]", "terseLabel": "ABI [Member]" } } }, "localname": "AccumulatedEquityMethodInvestmentsAttributableToParentMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails", "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails" ], "xbrltype": "domainItemType" }, "mo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustment To Additional Paid In Capital, Share Based Compensation, Restricted And Deferred Stock Awards and the tax benefits associated with vestings of prior period restricted and deferred stock awards", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition and Income Tax Effect, Net", "terseLabel": "Stock award activity" } } }, "localname": "AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionandIncomeTaxEffectNet", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "mo_AltriaGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Altria Group", "label": "Altria Group [Member]", "terseLabel": "Altria Group [Member]" } } }, "localname": "AltriaGroupMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails", "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "domainItemType" }, "mo_AmountAwardedtoOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount Awarded to Other Party", "label": "Amount Awarded to Other Party", "terseLabel": "Amount awarded to other party" } } }, "localname": "AmountAwardedtoOtherParty", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "monetaryItemType" }, "mo_ArbitrationPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arbitration Period", "label": "Arbitration Period [Axis]", "terseLabel": "Arbitration Period [Axis]" } } }, "localname": "ArbitrationPeriodAxis", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "stringItemType" }, "mo_ArbitrationPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arbitration Period [Domain]", "label": "Arbitration Period [Domain]", "terseLabel": "Arbitration Period [Domain]" } } }, "localname": "ArbitrationPeriodDomain", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_BritishColumbiaSaskatchewanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "British Columbia, Saskatchewan [Member]", "label": "British Columbia, Saskatchewan [Member]", "terseLabel": "British Columbia and Saskatchewan [Member]" } } }, "localname": "BritishColumbiaSaskatchewanMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "domainItemType" }, "mo_COVID19Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "COVID-19 [Member]", "label": "COVID-19 [Member]", "terseLabel": "COVID-19 [Member]" } } }, "localname": "COVID19Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_CanadianTobaccoManufacturersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Canadian Tobacco Manufacturers [Member]", "label": "Canadian Tobacco Manufacturers [Member]", "terseLabel": "Canadian Tobacco Manufacturers [Member]" } } }, "localname": "CanadianTobaccoManufacturersMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails", "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "domainItemType" }, "mo_CashDiscountsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Discounts", "label": "Cash Discounts [Policy Text Block]", "terseLabel": "Cash Discounts" } } }, "localname": "CashDiscountsPolicyTextBlock", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "mo_ClassActionLawsuitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Action Lawsuit [Member]", "label": "Class Action Lawsuit [Member]", "terseLabel": "Class Action Lawsuit [Member]" } } }, "localname": "ClassActionLawsuitMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails" ], "xbrltype": "domainItemType" }, "mo_CommonStock0.3313ParValueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, 0.33 1/3 Par Value [Member]", "label": "Common Stock, 0.33 1/3 Par Value [Member]", "terseLabel": "Common Stock, $0.33 1/3 par value [Member]" } } }, "localname": "CommonStock0.3313ParValueMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mo_CommonStock1.000NotesDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, 1.000% Notes Due 2023 [Member]", "label": "Common Stock, 1.000% Notes Due 2023 [Member]", "terseLabel": "1.000% Notes due 2023 [Member]" } } }, "localname": "CommonStock1.000NotesDue2023Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mo_CommonStock1.700NotesDue2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, 1.700% Notes Due 2025 [Member]", "label": "Common Stock, 1.700% Notes Due 2025 [Member]", "terseLabel": "1.700% Notes due 2025 [Member]" } } }, "localname": "CommonStock1.700NotesDue2025Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mo_CommonStock2.200NotesDue2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, 2.200% Notes Due 2027 [Member]", "label": "Common Stock, 2.200% Notes Due 2027 [Member]", "terseLabel": "2.200% Notes due 2027 [Member]" } } }, "localname": "CommonStock2.200NotesDue2027Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mo_CommonStock3.125NotesDue2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, 3.125% Notes Due 2031 [Member]", "label": "Common Stock, 3.125% Notes Due 2031 [Member]", "terseLabel": "3.125% Notes due 2031 [Member]" } } }, "localname": "CommonStock3.125NotesDue2031Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mo_CommonStockDividendIncreasePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Dividend Increase, Percentage", "label": "Common Stock, Dividend Increase, Percentage", "terseLabel": "Common stock, dividend increase, percentage" } } }, "localname": "CommonStockDividendIncreasePercentage", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails" ], "xbrltype": "percentItemType" }, "mo_CommonStockDividendRateAnnualPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Dividend Rate, Annual, Per Share", "label": "Common Stock, Dividend Rate, Annual, Per Share", "terseLabel": "Common stock, dividend rate, annual (in usd per share)" } } }, "localname": "CommonStockDividendRateAnnualPerShare", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "mo_CreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Credit Agreement [Member]", "label": "Credit Agreement [Member]", "terseLabel": "Credit Agreement [Member]" } } }, "localname": "CreditAgreementMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_CronosGroupInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cronos Group Inc. [Member]", "label": "Cronos Group Inc. [Member]", "verboseLabel": "Cronos [Member]" } } }, "localname": "CronosGroupInc.Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" ], "xbrltype": "domainItemType" }, "mo_DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Consolidated EBITDA to Interest Expense Ratio", "label": "Debt Instrument, Consolidated EBITDA to Interest Expense Ratio", "terseLabel": "Debt instrument, consolidated EBITDA to interest expense ratio" } } }, "localname": "DebtInstrumentConsolidatedEBITDAtoInterestExpenseRatio", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "pureItemType" }, "mo_DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Consolidated EBITDA to Interest Expense Ratio, Minimum", "label": "Debt Instrument, Covenant, Consolidated EBITDA to Interest Expense Ratio, Minimum", "terseLabel": "Debt instrument, covenant, consolidated EBITDA to interest expense ratio, minimum" } } }, "localname": "DebtInstrumentCovenantConsolidatedEBITDAtoInterestExpenseRatioMinimum", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "pureItemType" }, "mo_DebtInstrumentExtensionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Extension Term", "label": "Debt Instrument, Extension Term", "terseLabel": "Debt instrument, extension term" } } }, "localname": "DebtInstrumentExtensionTerm", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "durationItemType" }, "mo_DisposalGroupIncludingDiscontinuedOperationAssetsCurrentGross": { "auth_ref": [], "calculation": { "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Assets, Current, Gross", "label": "Disposal Group, Including Discontinued Operation, Assets, Current, Gross", "totalLabel": "Total assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsCurrentGross", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "mo_DisposalGroupIncludingDiscontinuedOperationAssetsCurrentReserve": { "auth_ref": [], "calculation": { "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Assets, Current, Reserve", "label": "Disposal Group, Including Discontinued Operation, Assets, Current, Reserve", "negatedTerseLabel": "Reserve" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsCurrentReserve", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "mo_DisposalGroupIncludingDiscontinuedOperationsDispositionRelatedCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operations, Disposition Related Costs", "label": "Disposal Group, Including Discontinued Operations, Disposition Related Costs", "terseLabel": "Disposal group disposition related costs" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationsDispositionRelatedCosts", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails", "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mo_DisposalGroupIncludingDiscontinuedOperationsMarketingAdministrationAndResearchCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operations, Marketing, Administration And Research Costs", "label": "Disposal Group, Including Discontinued Operations, Marketing, Administration And Research Costs", "terseLabel": "Disposal group, total pre-tax charges" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationsMarketingAdministrationAndResearchCosts", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails", "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mo_ETSSmokingandHealthCaseFlightAttendantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ETS Smoking and Health Case, Flight Attendants [Member]", "label": "ETS Smoking and Health Case, Flight Attendants [Member]", "terseLabel": "ETS Smoking and Health Case, Flight Attendants [Member]" } } }, "localname": "ETSSmokingandHealthCaseFlightAttendantsMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesBergerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Berger [Member]", "label": "Engle Progeny Cases, Berger [Member]", "terseLabel": "Engle Progeny Cases, Berger [Member]" } } }, "localname": "EngleProgenyCasesBergerMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesChadwellMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Chadwell [Member] [Member]", "label": "Engle Progeny Cases, Chadwell [Member]", "terseLabel": "Engle Progeny Cases, Chadwell [Member]" } } }, "localname": "EngleProgenyCasesChadwellMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesCooperMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Cooper [Member]", "label": "Engle Progeny Cases, Cooper [Member]", "terseLabel": "Engle Progeny Cases, Cooper [Member]" } } }, "localname": "EngleProgenyCasesCooperMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesCuddiheeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Cuddihee", "label": "Engle Progeny Cases, Cuddihee [Member]", "terseLabel": "Engle Progeny Cases, Cuddihee [Member]" } } }, "localname": "EngleProgenyCasesCuddiheeMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesD.BrownMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, D. Brown [Member]", "label": "Engle Progeny Cases, D. Brown [Member]", "terseLabel": "Engle Progeny Cases, D. Brown [Member]" } } }, "localname": "EngleProgenyCasesD.BrownMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesDuignanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Duignan [Member]", "label": "Engle Progeny Cases, Duignan [Member]", "terseLabel": "Engle Progeny Cases, Duignan [Member]" } } }, "localname": "EngleProgenyCasesDuignanMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesFederalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Federal [Member]", "label": "Engle Progeny Cases, Federal [Member]", "terseLabel": "Engle Progeny Cases, Federal [Member]" } } }, "localname": "EngleProgenyCasesFederalMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesFreemanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Freeman [Member]", "label": "Engle Progeny Cases, Freeman [Member]", "terseLabel": "Engle Progeny Cases, Freeman [Member]" } } }, "localname": "EngleProgenyCasesFreemanMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesGarciaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Garcia", "label": "Engle Progeny Cases, Garcia [Member]", "terseLabel": "Engle Progeny Cases, Garcia [Member]" } } }, "localname": "EngleProgenyCasesGarciaMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesGlogerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Gloger [Member]", "label": "Engle Progeny Cases, Gloger [Member]", "terseLabel": "Engle Progeny Cases, Gloger [Member]" } } }, "localname": "EngleProgenyCasesGlogerMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesGlogerRintoulandDuignamMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Gloger, Rintoul and Duignam [Member]", "label": "Engle Progeny Cases, Gloger, Rintoul and Duignam [Member]", "terseLabel": "Engle Progeny Cases, Gloger, Rintoul and Duignam [Member]" } } }, "localname": "EngleProgenyCasesGlogerRintoulandDuignamMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesGoreMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Gore [Member]", "label": "Engle Progeny Cases, Gore [Member]", "terseLabel": "Engle Progeny Cases, Gore [Member]" } } }, "localname": "EngleProgenyCasesGoreMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesHollimanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Holliman [Member]", "label": "Engle Progeny Cases, Holliman [Member]", "terseLabel": "Engle Progeny Cases, Holliman [Member]" } } }, "localname": "EngleProgenyCasesHollimanMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesJordanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Jordan [Member]", "label": "Engle Progeny Cases, Jordan [Member]", "terseLabel": "Engle Progeny Cases, Jordan [Member]" } } }, "localname": "EngleProgenyCasesJordanMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesKaplanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Kaplan [Member]", "label": "Engle Progeny Cases, Kaplan [Member]", "terseLabel": "Engle Progeny Cases, Kaplan [Member]" } } }, "localname": "EngleProgenyCasesKaplanMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesLandiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Landi [Member]", "label": "Engle Progeny Cases, Landi [Member]", "terseLabel": "Engle Progeny Cases, Landi [Member]" } } }, "localname": "EngleProgenyCasesLandiMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesLippMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Lipp", "label": "Engle Progeny Cases, Lipp [Member]", "terseLabel": "Engle Progeny Cases, Lipp [Member]" } } }, "localname": "EngleProgenyCasesLippMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesM.BrownMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, M. Brown [Member]", "label": "Engle Progeny Cases, M. Brown [Member]", "terseLabel": "Engle Progeny Cases, M. Brown [Member]" } } }, "localname": "EngleProgenyCasesM.BrownMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesMahfuzMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Mahfuz [Member]", "label": "Engle Progeny Cases, Mahfuz [Member]", "terseLabel": "Engle Progeny Cases, Mahfuz [Member]" } } }, "localname": "EngleProgenyCasesMahfuzMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesMcCallMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, McCall [Member]", "label": "Engle Progeny Cases, McCall [Member]", "terseLabel": "Engle Progeny Cases, McCall [Member]" } } }, "localname": "EngleProgenyCasesMcCallMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases [Member]", "label": "Engle Progeny Cases [Member]", "terseLabel": "Engle Progeny Cases [Member]" } } }, "localname": "EngleProgenyCasesMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails", "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesNaugleGoreMBrownJordanTheisAndLandiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Naugle, Gore, M. Brown, Jordan, Theis, and Landi", "label": "Engle Progeny Cases, Naugle, Gore, M. Brown, Jordan, Theis, and Landi [Member]", "terseLabel": "Engle Progeny Cases, Naugle, Gore, M. Brown, Jordan, Theis and Landi [Member]" } } }, "localname": "EngleProgenyCasesNaugleGoreMBrownJordanTheisAndLandiMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesNaugleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Naugle [Member]", "label": "Engle Progeny Cases, Naugle [Member]", "terseLabel": "Engle Progeny Cases, Naugle [Member]" } } }, "localname": "EngleProgenyCasesNaugleMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesNeffMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Neff [Member]", "label": "Engle Progeny Cases, Neff [Member]", "terseLabel": "Engle Progeny Cases, Neff [Member]" } } }, "localname": "EngleProgenyCasesNeffMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesPearsonDCohenCollarChaconMemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Pearson, D Cohen, Collar, Chacon [Member] [Member]", "label": "Engle Progeny Cases, Pearson, D Cohen, Collar, Chacon [Member] [Member]", "terseLabel": "Engle Progeny Cases, Pearson, D Cohen, Collar, Chacon [Member]" } } }, "localname": "EngleProgenyCasesPearsonDCohenCollarChaconMemberMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesPollariMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Pollari [Member]", "label": "Engle Progeny Cases, Pollari [Member]", "terseLabel": "Engle Progeny Cases, Pollari [Member]" } } }, "localname": "EngleProgenyCasesPollariMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesR.DouglasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, R. Douglas [Member]", "label": "Engle Progeny Cases, R. Douglas [Member]", "terseLabel": "Engle Progeny Cases, R. Douglas [Member]" } } }, "localname": "EngleProgenyCasesR.DouglasMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesRJReynoldsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, R.J. Reynolds", "label": "Engle Progeny Cases, R.J. Reynolds [Member]", "terseLabel": "Engle Progeny Cases, R.J. Reynolds [Member]" } } }, "localname": "EngleProgenyCasesRJReynoldsMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesReiderandBanksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Reider and Banks [Member]", "label": "Engle Progeny Cases, Reider and Banks [Member]", "terseLabel": "Engle Progeny Cases, Reider and Banks [Member]" } } }, "localname": "EngleProgenyCasesReiderandBanksMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesRintoulMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Rintoul", "label": "Engle Progeny Cases, Rintoul [Member]", "terseLabel": "Engle Progeny Cases, Rintoul [Member]" } } }, "localname": "EngleProgenyCasesRintoulMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesSantoroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Santoro [Member]", "label": "Engle Progeny Cases, Santoro [Member]", "terseLabel": "Engle Progeny Cases, Santoro [Member]" } } }, "localname": "EngleProgenyCasesSantoroMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesSommersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Sommers [Member]", "label": "Engle Progeny Cases, Sommers [Member]", "terseLabel": "Engle Progeny Cases, Sommers [Member]" } } }, "localname": "EngleProgenyCasesSommersMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesStateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, State [Member]", "label": "Engle Progeny Cases, State [Member]", "terseLabel": "Engle Progeny Cases, State [Member]" } } }, "localname": "EngleProgenyCasesStateMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails", "http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesTheisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Theis [Member]", "label": "Engle Progeny Cases, Theis [Member]", "terseLabel": "Engle Progeny Cases, Theis [Member]" } } }, "localname": "EngleProgenyCasesTheisMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "domainItemType" }, "mo_EngleProgenyCasesWeingartandHancockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Engle Progeny Cases, Weingart and Hancock [Member]", "label": "Engle Progeny Cases, Weingart and Hancock [Member]", "terseLabel": "Engle Progeny Cases, Weingart and Hancock [Member]" } } }, "localname": "EngleProgenyCasesWeingartandHancockMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails" ], "xbrltype": "domainItemType" }, "mo_EquityContractPreemptiveRIghtsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Contract, Preemptive RIghts [Member]", "label": "Equity Contract, Preemptive RIghts [Member]", "terseLabel": "Fixed-price Preemptive Rights [Member]", "verboseLabel": "Equity Contract, Preemptive Rights [Member]" } } }, "localname": "EquityContractPreemptiveRIghtsMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails", "http://www.altria.com/role/FinancialInstrumentsFairValueUsingBlackScholesOptionPricingModelDetails", "http://www.altria.com/role/FinancialInstrumentsPretaxUnrealizedGainsLossesDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" ], "xbrltype": "domainItemType" }, "mo_EquityContractWarrantAndEquityContractPreemptiveRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Contract, Warrant And Equity Contract, Preemptive Rights", "label": "Equity Contract, Warrant And Equity Contract, Preemptive Rights [Member]", "terseLabel": "Equity Contract, Warrant And Equity Contract, Preemptive Rights [Member]" } } }, "localname": "EquityContractWarrantAndEquityContractPreemptiveRightsMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_EquityContractWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Contract, Warrant [Member]", "label": "Equity Contract, Warrant [Member]", "terseLabel": "Equity Contract, Warrant [Member]", "verboseLabel": "Cronos Warrant [Member]" } } }, "localname": "EquityContractWarrantMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails", "http://www.altria.com/role/FinancialInstrumentsFairValueUsingBlackScholesOptionPricingModelDetails", "http://www.altria.com/role/FinancialInstrumentsPretaxUnrealizedGainsLossesDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" ], "xbrltype": "domainItemType" }, "mo_EquityInvestmentFairValueOption": { "auth_ref": [], "calculation": { "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_Investments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity Investment, Fair Value Option", "label": "Equity Investment, Fair Value Option", "terseLabel": "JUUL" } } }, "localname": "EquityInvestmentFairValueOption", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "mo_EquityInvestmentsFairValueOptionVotingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Investments, Fair Value Option, Voting Shares", "label": "Equity Investments, Fair Value Option, Voting Shares", "terseLabel": "Equity investments, fair value option, voting shares (in shares)" } } }, "localname": "EquityInvestmentsFairValueOptionVotingShares", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails" ], "xbrltype": "sharesItemType" }, "mo_EquityMethodInvestmentAggregateExercisePrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Aggregate Exercise Price", "label": "Equity Method Investment, Aggregate Exercise Price", "terseLabel": "Equity method investment, aggregate exercise price" } } }, "localname": "EquityMethodInvestmentAggregateExercisePrice", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mo_EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Difference Between Carrying Amount and Fair Value, Percentage", "label": "Equity Method Investment, Difference Between Carrying Amount and Fair Value, Percentage", "negatedTerseLabel": "Difference between carrying amount and fair value, percentage (approximately)", "terseLabel": "Equity method investment, difference between carrying amount and fair value, percentage (approximately)" } } }, "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountandFairValuePercentage", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails" ], "xbrltype": "percentItemType" }, "mo_EquityMethodInvestmentImpairment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Impairment", "label": "Equity Method Investment, Impairment", "terseLabel": "Equity method investment, impairment" } } }, "localname": "EquityMethodInvestmentImpairment", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/IncomeTaxesNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mo_EquityMethodInvestmentNumberofSharesEligibleForPurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Number of Shares Eligible For Purchase", "label": "Equity Method Investment, Number of Shares Eligible For Purchase", "terseLabel": "Equity method investment, number of shares eligible for purchase (approximately) (in shares)" } } }, "localname": "EquityMethodInvestmentNumberofSharesEligibleForPurchase", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails" ], "xbrltype": "sharesItemType" }, "mo_EquityMethodInvestmentNumberofSharesOwnedCommon": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Number of Shares Owned, Common", "label": "Equity Method Investment, Number of Shares Owned, Common", "terseLabel": "Number of ordinary shares owned (in shares)", "verboseLabel": "Number of ordinary shares owned (approximately) (in shares)" } } }, "localname": "EquityMethodInvestmentNumberofSharesOwnedCommon", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails" ], "xbrltype": "sharesItemType" }, "mo_EquityMethodInvestmentNumberofSharesOwnedRestricted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Number of Shares Owned, Restricted", "label": "Equity Method Investment, Number of Shares Owned, Restricted", "terseLabel": "Number of restricted shares owned (in shares)" } } }, "localname": "EquityMethodInvestmentNumberofSharesOwnedRestricted", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails" ], "xbrltype": "sharesItemType" }, "mo_EquityMethodInvestmentPercentageofSharesEligibleForPurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Percentage of Shares Eligible For Purchase", "label": "Equity Method Investment, Percentage of Shares Eligible For Purchase", "terseLabel": "Equity method investment, percentage of shares eligible for purchase (approximately)" } } }, "localname": "EquityMethodInvestmentPercentageofSharesEligibleForPurchase", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails" ], "xbrltype": "percentItemType" }, "mo_EquityMethodInvestmentPricePerShareIfExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Price Per Share If Exercised", "label": "Equity Method Investment, Price Per Share If Exercised", "terseLabel": "Equity method investment, shares purchased, (CAD per share)" } } }, "localname": "EquityMethodInvestmentPricePerShareIfExercised", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails" ], "xbrltype": "perShareItemType" }, "mo_EquityMethodInvestmentReductionInSharePricePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Reduction In Share Price, Percentage", "label": "Equity Method Investment, Reduction In Share Price, Percentage", "terseLabel": "Equity method investment, reduction in share price, percentage" } } }, "localname": "EquityMethodInvestmentReductionInSharePricePercentage", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails" ], "xbrltype": "percentItemType" }, "mo_EquityMethodInvestmentWarrantExercisedOwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Warrant Exercised, Ownership Percentage", "label": "Equity Method Investment, Warrant Exercised, Ownership Percentage", "terseLabel": "Equity method investment, warrant exercised, ownership percentage" } } }, "localname": "EquityMethodInvestmentWarrantExercisedOwnershipPercentage", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails" ], "xbrltype": "percentItemType" }, "mo_EquityMethodInvestmentsFairValueOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investments, Fair Value Option", "label": "Equity Method Investments, Fair Value Option [Member]", "terseLabel": "Equity Method Investments, Fair Value Option [Member]" } } }, "localname": "EquityMethodInvestmentsFairValueOptionMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details" ], "xbrltype": "domainItemType" }, "mo_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Securities Without Readily Determinable Fair Value, Ownership Percentage", "label": "Equity Securities Without Readily Determinable Fair Value, Ownership Percentage", "terseLabel": "Equity securities, ownership percentage" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails" ], "xbrltype": "percentItemType" }, "mo_EvaporLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "E-vapor Litigation [Member]", "label": "E-vapor Litigation [Member]", "terseLabel": "E-vapor Litigation [Member]" } } }, "localname": "EvaporLitigationMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails", "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails" ], "xbrltype": "domainItemType" }, "mo_FederalGovernmentsLawsuitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Federal Government's Lawsuit [Member]", "label": "Federal Governments Lawsuit [Member]", "terseLabel": "Federal Governments Lawsuit [Member]" } } }, "localname": "FederalGovernmentsLawsuitMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails" ], "xbrltype": "domainItemType" }, "mo_FederalTradeCommissionDisclosurePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Federal Trade Commission, Disclosure Period", "label": "Federal Trade Commission, Disclosure Period", "terseLabel": "Disclosure period" } } }, "localname": "FederalTradeCommissionDisclosurePeriod", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails" ], "xbrltype": "durationItemType" }, "mo_ForeignCurrencyDenominatedDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign Currency Denominated Debt [Member]", "label": "Foreign Currency Denominated Debt [Member]", "terseLabel": "Foreign Currency Denominated Debt [Member]", "verboseLabel": "Foreign currency denominated debt [Member]" } } }, "localname": "ForeignCurrencyDenominatedDebtMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsAggregateNotionalAmountsAggregateFairValuesandCarryingValuesDetails", "http://www.altria.com/role/FinancialInstrumentsEffectsofNetInvestmentHedgesonAccumulatedOtherComprehensiveLossesDetails" ], "xbrltype": "domainItemType" }, "mo_HealthCareCostRecoveryActions2004NPMAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Cost Recovery Actions, 2004 NPM Adjustment [Member]", "label": "Health Care Cost Recovery Actions, 2004 NPM Adjustment [Member]", "terseLabel": "Health Care Cost Recovery Actions, 2004 NPM Adjustment [Member]" } } }, "localname": "HealthCareCostRecoveryActions2004NPMAdjustmentMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_HealthCareCostRecoveryActions20052007NPMAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Cost Recovery Actions, 2005-2007 NPM Adjustment", "label": "Health Care Cost Recovery Actions, 2005-2007 NPM Adjustment [Member]", "terseLabel": "Health Care Cost Recovery Actions, 2005-2007 NPM Adjustment" } } }, "localname": "HealthCareCostRecoveryActions20052007NPMAdjustmentMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_HealthCareCostRecoveryActions2005NPMAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Cost Recovery Actions, 2005 NPM Adjustment [Member]", "label": "Health Care Cost Recovery Actions, 2005 NPM Adjustment [Member]", "terseLabel": "Health Care Cost Recovery Actions, 2005 NPM Adjustment [Member]" } } }, "localname": "HealthCareCostRecoveryActions2005NPMAdjustmentMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_HealthCareCostRecoveryActions2006NPMAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Cost Recovery Actions, 2006 NPM Adjustment [Member]", "label": "Health Care Cost Recovery Actions, 2006 NPM Adjustment [Member]", "terseLabel": "Health Care Cost Recovery Actions, 2006 NPM Adjustment [Member]" } } }, "localname": "HealthCareCostRecoveryActions2006NPMAdjustmentMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_HealthCareCostRecoveryActions2007NPMAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Cost Recovery Actions, 2007 NPM Adjustment [Member]", "label": "Health Care Cost Recovery Actions, 2007 NPM Adjustment [Member]", "terseLabel": "Health Care Cost Recovery Actions, 2007 NPM Adjustment [Member]" } } }, "localname": "HealthCareCostRecoveryActions2007NPMAdjustmentMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_HealthCareCostRecoveryActions2008NPMAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Cost Recovery Actions, 2008 NPM Adjustment [Member]", "label": "Health Care Cost Recovery Actions, 2008 NPM Adjustment [Member]", "terseLabel": "Health Care Cost Recovery Actions, 2008 NPM Adjustment [Member]" } } }, "localname": "HealthCareCostRecoveryActions2008NPMAdjustmentMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_HealthCareCostRecoveryActions2009NPMAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Cost Recovery Actions, 2009 NPM Adjustment [Member]", "label": "Health Care Cost Recovery Actions, 2009 NPM Adjustment [Member]", "terseLabel": "Health Care Cost Recovery Actions, 2009 NPM Adjustment [Member]" } } }, "localname": "HealthCareCostRecoveryActions2009NPMAdjustmentMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_HealthCareCostRecoveryActions2010NPMAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Cost Recovery Actions, 2010 NPM Adjustment [Member]", "label": "Health Care Cost Recovery Actions, 2010 NPM Adjustment [Member]", "terseLabel": "Health Care Cost Recovery Actions, 2010 NPM Adjustment [Member]" } } }, "localname": "HealthCareCostRecoveryActions2010NPMAdjustmentMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_HealthCareCostRecoveryActions2011NPMAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Cost Recovery Actions, 2011 NPM Adjustment [Member]", "label": "Health Care Cost Recovery Actions, 2011 NPM Adjustment [Member]", "terseLabel": "Health Care Cost Recovery Actions, 2011 NPM Adjustment [Member]" } } }, "localname": "HealthCareCostRecoveryActions2011NPMAdjustmentMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_HealthCareCostRecoveryActions2012NPMAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Cost Recovery Actions, 2012 NPM Adjustment [Member]", "label": "Health Care Cost Recovery Actions, 2012 NPM Adjustment [Member]", "terseLabel": "Health Care Cost Recovery Actions, 2012 NPM Adjustment [Member]" } } }, "localname": "HealthCareCostRecoveryActions2012NPMAdjustmentMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_HealthCareCostRecoveryActions2013NPMAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Cost Recovery Actions, 2013 NPM Adjustment [Member]", "label": "Health Care Cost Recovery Actions, 2013 NPM Adjustment [Member]", "terseLabel": "Health Care Cost Recovery Actions, 2013 NPM Adjustment [Member]" } } }, "localname": "HealthCareCostRecoveryActions2013NPMAdjustmentMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_HealthCareCostRecoveryActions2014NPMAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Cost Recovery Actions, 2014 NPM Adjustment [Member]", "label": "Health Care Cost Recovery Actions, 2014 NPM Adjustment [Member]", "terseLabel": "Health Care Cost Recovery Actions, 2014 NPM Adjustment [Member]" } } }, "localname": "HealthCareCostRecoveryActions2014NPMAdjustmentMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_HealthCareCostRecoveryActions2015NPMAdjustmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Cost Recovery Actions, 2015 NPM Adjustments [Member]", "label": "Health Care Cost Recovery Actions, 2015 NPM Adjustments [Member]", "terseLabel": "Health Care Cost Recovery Actions, 2015 NPM Adjustments [Member]" } } }, "localname": "HealthCareCostRecoveryActions2015NPMAdjustmentsMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Cost Recovery Actions, 2016 NPM Adjustments [Member]", "label": "Health Care Cost Recovery Actions, 2016 NPM Adjustments [Member] [Member]", "terseLabel": "Health Care Cost Recovery Actions, 2016 NPM Adjustments [Member]" } } }, "localname": "HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_HealthCareCostRecoveryActions2017NPMAdjustmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Cost Recovery Actions, 2017 NPM Adjustments [Member]", "label": "Health Care Cost Recovery Actions, 2017 NPM Adjustments [Member]", "terseLabel": "Health Care Cost Recovery Actions, 2017 NPM Adjustments [Member]" } } }, "localname": "HealthCareCostRecoveryActions2017NPMAdjustmentsMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_HealthCareCostRecoveryActions2018NPMAdjustmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Cost Recovery Actions, 2018 NPM Adjustments [Member]", "label": "Health Care Cost Recovery Actions, 2018 NPM Adjustments [Member]", "terseLabel": "Health Care Cost Recovery Actions, 2018 NPM Adjustments [Member]" } } }, "localname": "HealthCareCostRecoveryActions2018NPMAdjustmentsMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_HealthCareCostRecoveryActions2019NPMAdjustmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Cost Recovery Actions, 2019 NPM Adjustments [Member]", "label": "Health Care Cost Recovery Actions, 2019 NPM Adjustments [Member]", "terseLabel": "Health Care Cost Recovery Actions, 2019 NPM Adjustments [Member]" } } }, "localname": "HealthCareCostRecoveryActions2019NPMAdjustmentsMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_HealthCareCostRecoveryActions2020NPMAdjustmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Cost Recovery Actions, 2020 NPM Adjustments", "label": "Health Care Cost Recovery Actions, 2020 NPM Adjustments [Member]", "terseLabel": "Health Care Cost Recovery Actions, 2020 NPM Adjustments [Member]" } } }, "localname": "HealthCareCostRecoveryActions2020NPMAdjustmentsMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_HealthCareCostRecoveryActionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Cost Recovery Actions [Member]", "label": "Health Care Cost Recovery Actions [Member]", "terseLabel": "Health Care Cost Recovery Actions [Member]" } } }, "localname": "HealthCareCostRecoveryActionsMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails", "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails", "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails" ], "xbrltype": "domainItemType" }, "mo_HealthCareCostRecoveryActionsTransitionYears20042020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Cost Recovery Actions, Transition Years 2004-2020 [Member]", "label": "Health Care Cost Recovery Actions, Transition Years 2004-2020 [Member]", "terseLabel": "Health Care Cost Recovery Actions, Transition Years 2004-2018 [Member]" } } }, "localname": "HealthCareCostRecoveryActionsTransitionYears20042020Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_HelixInnovationsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Helix Innovations LLC [Member]", "label": "Helix Innovations LLC [Member]", "terseLabel": "Helix Innovations LLC [Member]" } } }, "localname": "HelixInnovationsLLCMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_IQOSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IQOS", "label": "IQOS [Member]", "terseLabel": "IQOS" } } }, "localname": "IQOSMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails" ], "xbrltype": "domainItemType" }, "mo_ImplementationofCorrectiveCommunicationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Implementation of Corrective Communications [Member]", "label": "Implementation of Corrective Communications [Member]", "terseLabel": "Implementation of Corrective Communications [Member]" } } }, "localname": "ImplementationofCorrectiveCommunicationsMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails" ], "xbrltype": "domainItemType" }, "mo_IncomeLossFromEquityInvestments": { "auth_ref": [], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses": { "order": 6.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income (Loss) from Equity Investments", "label": "Income (Loss) from Equity Investments", "negatedTerseLabel": "(Income) losses from equity investments", "terseLabel": "Income (losses) from equity investments", "totalLabel": "Income (losses) from equity investments" } } }, "localname": "IncomeLossFromEquityInvestments", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses", "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails", "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "monetaryItemType" }, "mo_IncomeLossFromEquityInvestmentsFairValueOption": { "auth_ref": [], "calculation": { "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails": { "order": 2.0, "parentTag": "mo_IncomeLossFromEquityInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income (Loss) from Equity Investments, Fair Value Option", "label": "Income (Loss) from Equity Investments, Fair Value Option", "terseLabel": "JUUL", "verboseLabel": "Income (loss) from equity investments, fair value option" } } }, "localname": "IncomeLossFromEquityInvestmentsFairValueOption", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mo_IncreaseDecreaseInSettlementPayable": { "auth_ref": [], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net change during the period in Settlement payable.", "label": "Increase (Decrease) In Settlement Payable", "terseLabel": "Accrued settlement charges" } } }, "localname": "IncreaseDecreaseInSettlementPayable", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "mo_IndividualSmokingAndHealthCasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Individual Smoking and Health Cases [Member]", "label": "Individual Smoking And Health Cases [Member]", "terseLabel": "Individual Smoking and Health Cases [Member]" } } }, "localname": "IndividualSmokingAndHealthCasesMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails" ], "xbrltype": "domainItemType" }, "mo_InterestAndOtherDebtExpenseNetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest And Other Debt Expense, Net [Member]", "label": "Interest And Other Debt Expense, Net [Member]", "terseLabel": "Interest and other debt expense, net [Member]" } } }, "localname": "InterestAndOtherDebtExpenseNetMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails" ], "xbrltype": "domainItemType" }, "mo_InterestExpenseRelatedToLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Expense Related To Litigation [Member]", "label": "Interest Expense Related To Litigation [Member]", "terseLabel": "Related Interest Costs [Member]" } } }, "localname": "InterestExpenseRelatedToLitigationMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails" ], "xbrltype": "domainItemType" }, "mo_InventoryDisposalCostsandOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventory Disposal Costs and Other [Member]", "label": "Inventory Disposal Costs and Other [Member]", "terseLabel": "Inventory Disposal Costs and Other [Member]" } } }, "localname": "InventoryDisposalCostsandOtherMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_InventoryRawMaterialsPlantMaterialNetofReserves": { "auth_ref": [], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of products consisting of plant matter that is not used in the growth of plant goods", "label": "Inventory, Raw Materials, Plant Material, Net of Reserves", "terseLabel": "Leaf tobacco" } } }, "localname": "InventoryRawMaterialsPlantMaterialNetofReserves", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "mo_InventoryWriteOffMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventory Write-Off [Member]", "label": "Inventory Write-Off [Member]", "terseLabel": "Inventory Write-Off [Member]" } } }, "localname": "InventoryWriteOffMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_InvestmentsInEquitySecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investments In Equity Securities [Member]", "label": "Investments In Equity Securities [Member]", "terseLabel": "Investments In Equity Securities [Member]" } } }, "localname": "InvestmentsInEquitySecuritiesMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "mo_InvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Investments [Table]", "label": "Investments [Line Items]", "terseLabel": "Investments [Line Items]" } } }, "localname": "InvestmentsLineItems", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/IncomeTaxesNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details", "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" ], "xbrltype": "stringItemType" }, "mo_InvestmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investments [Table]", "label": "Investments [Table]", "terseLabel": "Investments [Table]" } } }, "localname": "InvestmentsTable", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/IncomeTaxesNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details", "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" ], "xbrltype": "stringItemType" }, "mo_JUULMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "JUUL [Member]", "label": "JUUL [Member]", "terseLabel": "JUUL [Member]" } } }, "localname": "JUULMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails", "http://www.altria.com/role/IncomeTaxesNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details", "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" ], "xbrltype": "domainItemType" }, "mo_January2021ShareRepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "January 2021 Share Repurchase Program", "label": "January 2021 Share Repurchase Program [Member]", "terseLabel": "January 2021 Share Repurchase Program [Member]" } } }, "localname": "January2021ShareRepurchaseProgramMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails", "http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails" ], "xbrltype": "domainItemType" }, "mo_July2019ShareRepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "July 2019 Share Repurchase Program [Member]", "label": "July 2019 Share Repurchase Program [Member]", "terseLabel": "July 2019 Share Repurchase Program [Member]" } } }, "localname": "July2019ShareRepurchaseProgramMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_LightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lights [Member]", "label": "Lights [Member]", "terseLabel": "Lights [Member]" } } }, "localname": "LightsMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails" ], "xbrltype": "domainItemType" }, "mo_LitigationCasesResultsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Litigation Cases Results [Member]", "label": "Litigation Cases Results [Member]", "terseLabel": "Tobacco and Health and Certain Other Litigation [Member]" } } }, "localname": "LitigationCasesResultsMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails" ], "xbrltype": "domainItemType" }, "mo_LitigationEscrowDeposit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Litigation Escrow Deposit", "label": "Litigation Escrow Deposit", "terseLabel": "Security posted for appeal of judgments" } } }, "localname": "LitigationEscrowDeposit", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails" ], "xbrltype": "monetaryItemType" }, "mo_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Litigation Settlement, Amount Expected To Be Awarded from Other Party", "label": "Litigation Settlement, Amount Expected To Be Awarded from Other Party", "terseLabel": "Litigation settlement, amount expected to be awarded from other party" } } }, "localname": "LitigationSettlementAmountExpectedToBeAwardedFromOtherParty", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "monetaryItemType" }, "mo_LitigationSettlementAnnualLegalFeesPayableMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Litigation Settlement, Annual Legal Fees Payable, Maximum", "label": "Litigation Settlement, Annual Legal Fees Payable, Maximum", "terseLabel": "State settlement agreements attorney fees annual cap" } } }, "localname": "LitigationSettlementAnnualLegalFeesPayableMaximum", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails" ], "xbrltype": "monetaryItemType" }, "mo_LitigationSettlementAnnualPaymentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Litigation Settlement, Annual Payment Amount", "label": "Litigation Settlement, Annual Payment Amount", "terseLabel": "State settlement agreements annual payments" } } }, "localname": "LitigationSettlementAnnualPaymentAmount", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails" ], "xbrltype": "monetaryItemType" }, "mo_LitigationSettlementEstimateofPossibleGain": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Litigation Settlement, Estimate of Possible Gain", "label": "Litigation Settlement, Estimate of Possible Gain", "terseLabel": "Estimate of possible gain" } } }, "localname": "LitigationSettlementEstimateofPossibleGain", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "monetaryItemType" }, "mo_LossContingencyClaimsDecided": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Claims Decided", "label": "Loss Contingency, Claims Decided", "terseLabel": "Number of verdicts returned" } } }, "localname": "LossContingencyClaimsDecided", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyClaimsDecidedFavorableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Claims Decided Favorable, Number", "label": "Loss Contingency, Claims Decided Favorable, Number", "terseLabel": "Number of favorable verdicts" } } }, "localname": "LossContingencyClaimsDecidedFavorableNumber", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyClaimsDecidedUnfavorableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Claims Decided Unfavorable, Number", "label": "Loss Contingency, Claims Decided Unfavorable, Number", "terseLabel": "Number of unfavorable verdicts" } } }, "localname": "LossContingencyClaimsDecidedUnfavorableNumber", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyClaimsNotCertifiedNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Claims Not Certified, Number", "label": "Loss Contingency, Claims Not Certified, Number", "terseLabel": "Claims not certified, number" } } }, "localname": "LossContingencyClaimsNotCertifiedNumber", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyClaimsResolvedNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Claims Resolved, Number", "label": "Loss Contingency, Claims Resolved, Number", "terseLabel": "Number of claims resolved" } } }, "localname": "LossContingencyClaimsResolvedNumber", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyClassActionLawsuit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Class Action Lawsuit", "label": "Loss Contingency, Class Action Lawsuit", "terseLabel": "Loss contingency, class action lawsuit" } } }, "localname": "LossContingencyClassActionLawsuit", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails", "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyClassNotCertifiedNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Class Not Certified, Number", "label": "Loss Contingency, Class Not Certified, Number", "terseLabel": "Class not certified" } } }, "localname": "LossContingencyClassNotCertifiedNumber", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyCompensatoryDamagesAwardedAllocationPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Compensatory Damages Awarded, Allocation Percentage", "label": "Loss Contingency, Compensatory Damages Awarded, Allocation Percentage", "terseLabel": "Compensatory damages award, allocation percentage" } } }, "localname": "LossContingencyCompensatoryDamagesAwardedAllocationPercentage", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails" ], "xbrltype": "percentItemType" }, "mo_LossContingencyCompensatoryDamagesAwardedValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Compensatory Damages Awarded, Value", "label": "Loss Contingency, Compensatory Damages Awarded, Value", "terseLabel": "Compensatory damages awarded" } } }, "localname": "LossContingencyCompensatoryDamagesAwardedValue", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails", "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails" ], "xbrltype": "monetaryItemType" }, "mo_LossContingencyDamagesRecoverableValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Damages Recoverable, Value", "label": "Loss Contingency, Damages Recoverable, Value", "terseLabel": "Loss contingency, damages recoverable, value" } } }, "localname": "LossContingencyDamagesRecoverableValue", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails" ], "xbrltype": "monetaryItemType" }, "mo_LossContingencyNumberOfCases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of Cases", "label": "Loss Contingency, Number Of Cases", "verboseLabel": "Number of cases" } } }, "localname": "LossContingencyNumberOfCases", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyNumberOfCasesWithCourtDatesSet": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number of Cases With Court Dates Set", "label": "Loss Contingency, Number of Cases With Court Dates Set", "terseLabel": "Loss contingency, number of cases with set court dates" } } }, "localname": "LossContingencyNumberOfCasesWithCourtDatesSet", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyNumberOfCasesWithPaymentsAYearOrMoreAgo": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of Cases With Payments A Year Or More Ago", "label": "Loss Contingency, Number Of Cases With Payments A Year Or More Ago", "terseLabel": "Loss contingency, number of cases with payments a year or more ago" } } }, "localname": "LossContingencyNumberOfCasesWithPaymentsAYearOrMoreAgo", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyNumberOfComplaints": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of Complaints", "label": "Loss Contingency, Number Of Complaints", "terseLabel": "Loss contingency, number of complaints" } } }, "localname": "LossContingencyNumberOfComplaints", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyNumberOfConsolidatedDerivativeLawsuits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of Consolidated Derivative Lawsuits", "label": "Loss Contingency, Number Of Consolidated Derivative Lawsuits", "terseLabel": "Loss contingency, number of consolidated derivative lawsuits" } } }, "localname": "LossContingencyNumberOfConsolidatedDerivativeLawsuits", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyNumberOfInactiveCases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of Inactive Cases", "label": "Loss Contingency, Number Of Inactive Cases", "terseLabel": "Loss contingency, number of inactive cases" } } }, "localname": "LossContingencyNumberOfInactiveCases", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyNumberOfInactiveClassActionLawsuits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of Inactive Class Action Lawsuits", "label": "Loss Contingency, Number Of Inactive Class Action Lawsuits", "terseLabel": "Loss contingency, number of inactive class action lawsuits" } } }, "localname": "LossContingencyNumberOfInactiveClassActionLawsuits", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyNumberOfPendingCasesConsolidated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of Pending Cases Consolidated", "label": "Loss Contingency, Number Of Pending Cases Consolidated", "terseLabel": "Loss contingency, number of pending cases consolidated" } } }, "localname": "LossContingencyNumberOfPendingCasesConsolidated", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyNumberOfShareholdersFilingClassActionLawsuits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of Shareholders Filing Class Action Lawsuits", "label": "Loss Contingency, Number Of Shareholders Filing Class Action Lawsuits", "terseLabel": "Loss contingency, number of shareholders filing class action lawsuits" } } }, "localname": "LossContingencyNumberOfShareholdersFilingClassActionLawsuits", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyNumberOfShareholdersFilingDerivativeLawsuits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of Shareholders Filing Derivative Lawsuits", "label": "Loss Contingency, Number Of Shareholders Filing Derivative Lawsuits", "terseLabel": "Loss contingency, number of shareholders filing derivative lawsuits" } } }, "localname": "LossContingencyNumberOfShareholdersFilingDerivativeLawsuits", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyNumberOfStatesInComplianceWithEscrowStatues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of States In Compliance With Escrow Statues", "label": "Loss Contingency, Number Of States In Compliance With Escrow Statues", "terseLabel": "Loss contingency, number of states in compliance with escrow statues" } } }, "localname": "LossContingencyNumberOfStatesInComplianceWithEscrowStatues", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of States Not In Compliance With Escrow Statues", "label": "Loss Contingency, Number Of States Not In Compliance With Escrow Statues", "terseLabel": "Loss contingency, number of states not in compliance with escrow statues" } } }, "localname": "LossContingencyNumberOfStatesNotInComplianceWithEscrowStatues", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyNumberOfStatesNotSettled": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of States Not Settled", "label": "Loss Contingency, Number Of States Not Settled", "terseLabel": "Loss contingency, number of states not settled" } } }, "localname": "LossContingencyNumberOfStatesNotSettled", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyNumberOfStatesNotSettledArbitrationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of States Not Settled, Arbitration Period", "label": "Loss Contingency, Number Of States Not Settled, Arbitration Period", "terseLabel": "Loss contingency, number of states not settled, arbitration period" } } }, "localname": "LossContingencyNumberOfStatesNotSettledArbitrationPeriod", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "durationItemType" }, "mo_LossContingencyNumberOfStatesWithConcludedHearings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of States With Concluded Hearings", "label": "Loss Contingency, Number Of States With Concluded Hearings", "terseLabel": "Loss contingency, number of states with concluded hearings" } } }, "localname": "LossContingencyNumberOfStatesWithConcludedHearings", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number of Additional States Extended with Settled Litigation", "label": "Loss Contingency, Number of Additional States Extended with Settled Litigation", "terseLabel": "Loss contingency, number of additional states extended with settled litigation" } } }, "localname": "LossContingencyNumberofAdditionalStatesExtendedwithSettledLitigation", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyNumberofCasesSetforTrial": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number of Cases Set for Trial", "label": "Loss Contingency, Number of Cases Set for Trial", "terseLabel": "Number of cases set for trial" } } }, "localname": "LossContingencyNumberofCasesSetforTrial", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyNumberofManufacturers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number of Manufacturers", "label": "Loss Contingency, Number of Manufacturers", "terseLabel": "Number of manufacturers" } } }, "localname": "LossContingencyNumberofManufacturers", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails", "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyNumberofStatesThatCapBondorRequireNoBond": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number of States That Cap Bond or Require No Bond", "label": "Loss Contingency, Number of States That Cap Bond or Require No Bond", "terseLabel": "Number of states that cap bond or require no bond" } } }, "localname": "LossContingencyNumberofStatesThatCapBondorRequireNoBond", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesGeneralInformationDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyNumberofStateswithSettledLitigation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number of States with Settled Litigation", "label": "Loss Contingency, Number of States with Settled Litigation", "terseLabel": "Number of states with settled litigation" } } }, "localname": "LossContingencyNumberofStateswithSettledLitigation", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyNumberofStateswithSettledLitigationSettlementOne": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number of States with Settled Litigation, Settlement One", "label": "Loss Contingency, Number of States with Settled Litigation, Settlement One", "terseLabel": "Loss contingency, number of states with settled litigation including New York, subsequent expansion" } } }, "localname": "LossContingencyNumberofStateswithSettledLitigationSettlementOne", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Pending Claims, Consolidated For Pre-Trial Purposes, Number", "label": "Loss Contingency, Pending Claims, Consolidated For Pre-Trial Purposes, Number", "terseLabel": "Number of pending claims, consolidated for pre-trial purposes" } } }, "localname": "LossContingencyPendingClaimsConsolidatedForPreTrialPurposesNumber", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Period for Decertified Class Members to File Individual Actions Against Defendants", "label": "Loss Contingency, Period for Decertified Class Members to File Individual Actions Against Defendants", "terseLabel": "Loss contingency, period for decertified class members to file individual actions against defendants" } } }, "localname": "LossContingencyPeriodforDecertifiedClassMemberstoFileIndividualActionsAgainstDefendants", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails" ], "xbrltype": "durationItemType" }, "mo_LossContingencyPunitiveDamagesAwardedValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Punitive Damages Awarded, Value", "label": "Loss Contingency, Punitive Damages Awarded, Value", "terseLabel": "Punitive damages awarded" } } }, "localname": "LossContingencyPunitiveDamagesAwardedValue", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails", "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails", "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails" ], "xbrltype": "monetaryItemType" }, "mo_LossContingencyReductionToCostOfSales": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Reduction To Cost Of Sales", "label": "Loss Contingency, Reduction To Cost Of Sales", "terseLabel": "Loss contingency, reduction to cost of sales" } } }, "localname": "LossContingencyReductionToCostOfSales", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "monetaryItemType" }, "mo_LossContingencyStateCourtsNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, State Courts, Number", "label": "Loss Contingency, State Courts, Number", "terseLabel": "Number of state courts" } } }, "localname": "LossContingencyStateCourtsNumber", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyUnfavorableVerdictsPendingReversed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Unfavorable Verdicts Pending/Reversed", "label": "Loss Contingency, Unfavorable Verdicts Pending/Reversed", "terseLabel": "Number of claims with unfavorable verdicts pending/reversed" } } }, "localname": "LossContingencyUnfavorableVerdictsPendingReversed", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyVerdictReversedNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Verdict Reversed, Number", "label": "Loss Contingency, Verdict Reversed, Number", "terseLabel": "Number of verdicts reversed" } } }, "localname": "LossContingencyVerdictReversedNumber", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyVerdictsUpheld": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Verdicts Upheld", "label": "Loss Contingency, Verdicts Upheld", "terseLabel": "Number of verdicts upheld" } } }, "localname": "LossContingencyVerdictsUpheld", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyZeroDamagesVerdictModified": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Zero Damages Verdict Modified", "label": "Loss Contingency, Zero Damages Verdict Modified", "terseLabel": "Zero damages verdict modified" } } }, "localname": "LossContingencyZeroDamagesVerdictModified", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails" ], "xbrltype": "integerItemType" }, "mo_LossContingencyZeroDamagesVerdicts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Zero Damages Verdicts", "label": "Loss Contingency, Zero Damages Verdicts", "terseLabel": "Zero damages verdicts" } } }, "localname": "LossContingencyZeroDamagesVerdicts", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails" ], "xbrltype": "integerItemType" }, "mo_MarketingAdministrationAndResearchCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketing Administration And Research Costs [Member]", "label": "Marketing Administration And Research Costs [Member]", "terseLabel": "Marketing Administration And Research Costs [Member]" } } }, "localname": "MarketingAdministrationAndResearchCostsMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails", "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_MarketingAdministrationandResearchCosts": { "auth_ref": [], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as research and development costs and all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. Research and development costs represent the aggregate costs incurred during an accounting period to research and develop new products/technologies when the technological feasibility has not been reached. General and administrative expenses include salaries of nonsales personnel, rent, utilities, communication, etc.", "label": "Marketing, Administration and Research Costs", "terseLabel": "Marketing, administration and research costs" } } }, "localname": "MarketingAdministrationandResearchCosts", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses" ], "xbrltype": "monetaryItemType" }, "mo_MaximumBondForAllDefendants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum Bond For All Defendants", "label": "Maximum Bond For All Defendants", "terseLabel": "Maximum bond for all defendants" } } }, "localname": "MaximumBondForAllDefendants", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails" ], "xbrltype": "monetaryItemType" }, "mo_MeasurementInputWeightedAverageExpectedTermMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input, Weighted Average Expected Term [Member]", "label": "Measurement Input, Weighted Average Expected Term [Member]", "terseLabel": "Weighted Average Expected Term [Member]" } } }, "localname": "MeasurementInputWeightedAverageExpectedTermMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "mo_NonEngleProgenyCasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non Engle Progeny Cases [Member]", "label": "Non Engle Progeny Cases [Member]", "terseLabel": "Non Engle Progeny Cases [Member]" } } }, "localname": "NonEngleProgenyCasesMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_NonEngleProgenySmokingAndHealthCasePrincipeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-Engle Progeny Smoking And Health Case, Principe", "label": "Non-Engle Progeny Smoking And Health Case, Principe [Member]", "terseLabel": "Non-Engle Progeny Smoking And Health Case, Principe [Member]" } } }, "localname": "NonEngleProgenySmokingAndHealthCasePrincipeMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails" ], "xbrltype": "domainItemType" }, "mo_NonEngleProgenySmokingandHealthCaseGentileMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-Engle Progeny Smoking and Health Case, Gentile", "label": "Non-Engle Progeny Smoking and Health Case, Gentile [Member]", "terseLabel": "Non-Engle Progeny Smoking and Health Case, Gentile [Member]" } } }, "localname": "NonEngleProgenySmokingandHealthCaseGentileMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails" ], "xbrltype": "domainItemType" }, "mo_NonEngleProgenySmokingandHealthCaseGreeneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-Engle Progeny Smoking and Health Case, Greene [Member]", "label": "Non-Engle Progeny Smoking and Health Case, Greene [Member]", "terseLabel": "Non-Engle Progeny Smoking and Health Case, Greene [Member]" } } }, "localname": "NonEngleProgenySmokingandHealthCaseGreeneMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails" ], "xbrltype": "domainItemType" }, "mo_NonEngleProgenySmokingandHealthCaseLaramieMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-Engle Progeny Smoking and Health Case, Laramie [Member] [Member]", "label": "Non-Engle Progeny Smoking and Health Case, Laramie [Member]", "terseLabel": "Non-Engle Progeny Smoking and Health Case, Laramie [Member]" } } }, "localname": "NonEngleProgenySmokingandHealthCaseLaramieMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails" ], "xbrltype": "domainItemType" }, "mo_NonParticipatingManufacturerArbitrationPanelDecisionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-Participating Manufacturer Arbitration Panel Decision [Member]", "label": "Non-Participating Manufacturer Arbitration Panel Decision [Member]", "terseLabel": "Non-Participating Manufacturer Arbitration Panel Decision" } } }, "localname": "NonParticipatingManufacturerArbitrationPanelDecisionMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails" ], "xbrltype": "domainItemType" }, "mo_NoncontrollingInterestRemainingInterestPurchasedByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noncontrolling Interest, Remaining Interest Purchased By Parent", "label": "Noncontrolling Interest, Remaining Interest Purchased By Parent", "terseLabel": "Noncontrolling interest, remaining interest purchased by parent" } } }, "localname": "NoncontrollingInterestRemainingInterestPurchasedByParent", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails" ], "xbrltype": "percentItemType" }, "mo_NpmAdjustmentToCostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NPM Adjustment to Cost Of Sales [Member]", "label": "NPM Adjustment to Cost Of Sales [Member]", "terseLabel": "NPM Adjustment to Cost Of Sales [Member]" } } }, "localname": "NpmAdjustmentToCostOfSalesMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails" ], "xbrltype": "domainItemType" }, "mo_NumberOfThirdPartyLawsuits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Third Party Lawsuits", "label": "Number Of Third Party Lawsuits", "terseLabel": "Number of third party lawsuits" } } }, "localname": "NumberOfThirdPartyLawsuits", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails" ], "xbrltype": "integerItemType" }, "mo_OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Income (Loss) Before General Corporate Expenses and Amortization Of Intangibles", "label": "Operating Income (Loss) Before General Corporate Expenses and Amortization Of Intangibles", "terseLabel": "OCI" } } }, "localname": "OperatingIncomeLossBeforeGeneralCorporateExpensesandAmortizationOfIntangibles", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "monetaryItemType" }, "mo_OralTobaccoSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Oral Tobacco Segment [Member]", "label": "Oral Tobacco Segment [Member]", "terseLabel": "Oral Tobacco Segment [Member]", "verboseLabel": "Oral Tobacco Segment [Member]" } } }, "localname": "OralTobaccoSegmentMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/SegmentReportingNarrativeDetails", "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "domainItemType" }, "mo_OtherAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Accrued Liabilities [Member]", "label": "Other Accrued Liabilities [Member]", "terseLabel": "Other Accrued Liabilities [Member]" } } }, "localname": "OtherAccruedLiabilitiesMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "mo_OtherDisputesUndertheStateSettlementAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Disputes Under the State Settlement Agreements [Member]", "label": "Other Disputes Under the State Settlement Agreements [Member]", "terseLabel": "Other Disputes Under the State Settlement Agreements [Member]" } } }, "localname": "OtherDisputesUndertheStateSettlementAgreementsMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails" ], "xbrltype": "domainItemType" }, "mo_OtherInventoryRawMaterialsNetofReserves": { "auth_ref": [], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Inventory, Raw Materials, Net of Reserves", "label": "Other Inventory, Raw Materials, Net of Reserves", "terseLabel": "Other raw materials" } } }, "localname": "OtherInventoryRawMaterialsNetofReserves", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "mo_OtherTabaccoRelatedCasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Tabacco-Related Cases [Member]", "label": "Other Tabacco-Related Cases [Member]", "terseLabel": "Other Tabacco-Related Cases [Member]" } } }, "localname": "OtherTabaccoRelatedCasesMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails" ], "xbrltype": "domainItemType" }, "mo_ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted": { "auth_ref": [], "calculation": { "http://www.altria.com/role/EarningsLossesperShareBasicandDilutedEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Participating Securities, Distributed and Undistributed Earnings (Loss), Basic and Diluted", "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Basic and Diluted", "negatedLabel": "Less: Distributed and undistributed earnings attributable to share-based awards" } } }, "localname": "ParticipatingSecuritiesDistributedandUndistributedEarningsLossBasicandDiluted", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/EarningsLossesperShareBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "mo_PendingIndividualLawsuitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pending Individual Lawsuits [Member]", "label": "Pending Individual Lawsuits [Member]", "terseLabel": "Pending Individual Lawsuits [Member]" } } }, "localname": "PendingIndividualLawsuitsMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails", "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails", "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_PendingLawsuitFiledBySchoolDistrictMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pending Lawsuit Filed By School District [Member]", "label": "Pending Lawsuit Filed By School District [Member]", "terseLabel": "Pending Lawsuit Filed By School District [Member]" } } }, "localname": "PendingLawsuitFiledBySchoolDistrictMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails" ], "xbrltype": "domainItemType" }, "mo_PendingLawsuitsFiledByStateOrLocalGovernmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pending Lawsuits Filed By State Or Local Governments [Member]", "label": "Pending Lawsuits Filed By State Or Local Governments [Member]", "terseLabel": "Pending Lawsuits Filed By State Or Local Governments [Member]" } } }, "localname": "PendingLawsuitsFiledByStateOrLocalGovernmentsMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails" ], "xbrltype": "domainItemType" }, "mo_PeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period One", "label": "Period One [Member]", "terseLabel": "Period One" } } }, "localname": "PeriodOneMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_PeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period Two", "label": "Period Two [Member]", "terseLabel": "Period Two" } } }, "localname": "PeriodTwoMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "mo_PhilipMorrisUSAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Philip Morris USA [Member]", "label": "Philip Morris USA [Member]", "terseLabel": "PM USA [Member]" } } }, "localname": "PhilipMorrisUSAMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails", "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails", "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails", "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails", "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails", "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails", "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails", "http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails", "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails", "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails", "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails" ], "xbrltype": "domainItemType" }, "mo_PhilipMorrisUSAandAltriaGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Philip Morris USA and Altria Group [Member]", "label": "Philip Morris USA and Altria Group [Member]", "terseLabel": "Philip Morris USA and Altria Group [Member]" } } }, "localname": "PhilipMorrisUSAandAltriaGroupMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_ProvisionRecordedNumberOfCases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Provision Recorded, Number Of Cases", "label": "Provision Recorded, Number Of Cases", "terseLabel": "Provision recorded, number of cases" } } }, "localname": "ProvisionRecordedNumberOfCases", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails" ], "xbrltype": "integerItemType" }, "mo_ReceivablesNetCurrentIncludingAssetsHeldForSale": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivables, Net Current, Including Assets Held For Sale", "label": "Receivables, Net Current, Including Assets Held For Sale", "terseLabel": "Receivables, Net Current, Including Assets Held For Sale" } } }, "localname": "ReceivablesNetCurrentIncludingAssetsHeldForSale", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mo_RestrictedSharesLockupPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Shares, Lock-up Period", "label": "Restricted Shares, Lock-up Period", "terseLabel": "Restricted shares, lock-up period" } } }, "localname": "RestrictedSharesLockupPeriod", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails" ], "xbrltype": "durationItemType" }, "mo_RevolvingCreditFacilityDueAugust2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving Credit Facility Due August 2024 [Member]", "label": "Revolving Credit Facility Due August 2024 [Member]", "terseLabel": "Revolving Credit Facility Due August 2024 [Member]" } } }, "localname": "RevolvingCreditFacilityDueAugust2024Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Non-Participating Manufacturer Adjustment Items", "label": "Schedule of Non-Participating Manufacturer Adjustment Items [Table Text Block]", "terseLabel": "Schedule of Non-Participating Manufacturer Adjustment Items" } } }, "localname": "ScheduleOfNonParticipatingManufacturerAdjustmentItemsTableTextBlock", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "mo_ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Schedule of Pre-tax Tobacco and Health Litigation Charges [Table]", "label": "Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]", "terseLabel": "Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]" } } }, "localname": "ScheduleofPretaxTobaccoandHealthLitigationChargesLineItems", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails" ], "xbrltype": "stringItemType" }, "mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Pre-tax Tobacco and Health Litigation Charges [Table]", "label": "Schedule of Pre-tax Tobacco and Health Litigation Charges [Table]", "terseLabel": "Schedule of Pre-tax Tobacco and Health Litigation Charges [Table]" } } }, "localname": "ScheduleofPretaxTobaccoandHealthLitigationChargesTable", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails" ], "xbrltype": "stringItemType" }, "mo_ScheduleofPretaxTobaccoandHealthLitigationChargesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Table Text Block] for Schedule of Pre-tax Tobacco and Health Litigation Charges [Table]", "label": "Schedule of Pre-tax Tobacco and Health Litigation Charges [Table Text Block]", "terseLabel": "Schedule of Tobacco and Health and Certain Other Litigation Items" } } }, "localname": "ScheduleofPretaxTobaccoandHealthLitigationChargesTableTextBlock", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "mo_SmokeableProductsSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Smokeable Products Segment [Member]", "label": "Smokeable Products Segment [Member]", "terseLabel": "Smokeable Products Segment [Member]" } } }, "localname": "SmokeableProductsSegmentMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/SegmentReportingNarrativeDetails", "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails", "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails", "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "domainItemType" }, "mo_SmokingAndHealthClassActionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Smoking and Health Class Actions and Aggregated Claims Litigation [Member]", "label": "Smoking And Health Class Actions [Member]", "terseLabel": "Smoking and Health Class Actions and Aggregated Claims Litigation [Member]" } } }, "localname": "SmokingAndHealthClassActionsMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails", "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails", "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_SteMichelleTransactionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ste. Michelle Transaction", "label": "Ste. Michelle Transaction [Member]", "terseLabel": "Ste. Michelle Transaction [Member]" } } }, "localname": "SteMichelleTransactionMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails", "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_SteMichelleTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ste. Michelle Transactions", "label": "Ste. Michelle Transactions [Member]", "terseLabel": "Ste. Michelle Transaction [Member]" } } }, "localname": "SteMichelleTransactionsMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails", "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails" ], "xbrltype": "domainItemType" }, "mo_StockRepurchaseProgramIncreaseAuthorizedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Repurchase Program, Increase Authorized Amount", "label": "Stock Repurchase Program, Increase Authorized Amount", "terseLabel": "Stock repurchase program, increase authorized amount" } } }, "localname": "StockRepurchaseProgramIncreaseAuthorizedAmount", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mo_StockRepurchaseProgramRescindedAuthorizedRepurchaseAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Repurchase Program, Rescinded Authorized Repurchase Amount", "label": "Stock Repurchase Program, Rescinded Authorized Repurchase Amount", "terseLabel": "Stock repurchase program, rescinded authorized repurchase amount" } } }, "localname": "StockRepurchaseProgramRescindedAuthorizedRepurchaseAmount", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mo_SummaryOfIncomeTaxesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Income Taxes", "label": "Summary of Income Taxes [Table Text Block]", "terseLabel": "Summary of Income Taxes" } } }, "localname": "SummaryOfIncomeTaxesTableTextBlock", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/IncomeTaxesupdateTables" ], "xbrltype": "textBlockItemType" }, "mo_TobaccoandHealthJudgmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tobacco and Health Judgment [Member]", "label": "Tobacco and Health Judgment [Member]", "terseLabel": "Tobacco and Health Judgment [Member]" } } }, "localname": "TobaccoandHealthJudgmentMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails" ], "xbrltype": "domainItemType" }, "mo_TobaccoandHealthLitigationCasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tobacco and Health Litigation Cases [Member]", "label": "Tobacco and Health Litigation Cases [Member]", "terseLabel": "Tobacco and Health Litigation Cases [Member]" } } }, "localname": "TobaccoandHealthLitigationCasesMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails" ], "xbrltype": "domainItemType" }, "mo_USDDenominatedDebt10200PercentDue2039Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "USD Denominated Debt, 10.200 Percent, Due 2039", "label": "USD Denominated Debt, 10.200 Percent, Due 2039 [Member]", "terseLabel": "10.200%, Notes Due 2039 [Member]" } } }, "localname": "USDDenominatedDebt10200PercentDue2039Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/DebtTenderOffersDetails" ], "xbrltype": "domainItemType" }, "mo_USDDenominatedDebt6200PercentDue2059Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "USD Denominated Debt, 6.200 Percent, Due 2059", "label": "USD Denominated Debt, 6.200 Percent, Due 2059 [Member]", "terseLabel": "6.200%, Notes Due 2059 [Member]" } } }, "localname": "USDDenominatedDebt6200PercentDue2059Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/DebtTenderOffersDetails" ], "xbrltype": "domainItemType" }, "mo_USDDenominatedNotes2850PercentDue2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "USD Denominated Notes, 2.850 Percent, Due 2022", "label": "USD Denominated Notes, 2.850 Percent, Due 2022 [Member]", "terseLabel": "2.850%, Notes Due 2022 [Member]" } } }, "localname": "USDDenominatedNotes2850PercentDue2022Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/DebtTenderOffersDetails" ], "xbrltype": "domainItemType" }, "mo_USDDenominatedNotes2950PercentDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "USD Denominated Notes, 2.950 Percent, Due 2023", "label": "USD Denominated Notes, 2.950 Percent, Due 2023 [Member]", "terseLabel": "2.950%, Notes Due 2023 [Member]" } } }, "localname": "USDDenominatedNotes2950PercentDue2023Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/DebtTenderOffersDetails" ], "xbrltype": "domainItemType" }, "mo_USDDenominatedNotes3490PercentDue2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "USD Denominated Notes, 3.490 Percent, Due 2022", "label": "USD Denominated Notes, 3.490 Percent, Due 2022 [Member]", "terseLabel": "USD Denominated Notes, 3.490 Percent, Due 2022 [Member]" } } }, "localname": "USDDenominatedNotes3490PercentDue2022Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_USDDenominatedNotes3800PercentDue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "USD Denominated Notes, 3.800 Percent, Due 2024", "label": "USD Denominated Notes, 3.800 Percent, Due 2024 [Member]", "terseLabel": "3.800%, Notes Due 2024 [Member]" } } }, "localname": "USDDenominatedNotes3800PercentDue2024Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/DebtTenderOffersDetails" ], "xbrltype": "domainItemType" }, "mo_USDDenominatedNotes4000PercentDue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "USD Denominated Notes, 4.000 Percent, Due 2024", "label": "USD Denominated Notes, 4.000 Percent, Due 2024 [Member]", "terseLabel": "4.000%, Notes Due 2024 [Member]" } } }, "localname": "USDDenominatedNotes4000PercentDue2024Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/DebtTenderOffersDetails" ], "xbrltype": "domainItemType" }, "mo_USDDenominatedNotes4400PercentDue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "USD Denominated Notes, 4.400 Percent, Due 2026", "label": "USD Denominated Notes, 4.400 Percent, Due 2026 [Member]", "terseLabel": "4.400%, Notes Due 2026 [Member]" } } }, "localname": "USDDenominatedNotes4400PercentDue2026Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/DebtTenderOffersDetails" ], "xbrltype": "domainItemType" }, "mo_USDDenominatedNotes4800PercentDue2029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "USD Denominated Notes, 4.800 Percent, Due 2029", "label": "USD Denominated Notes, 4.800 Percent, Due 2029 [Member]", "terseLabel": "4.800%, Notes Due 2029 [Member]" } } }, "localname": "USDDenominatedNotes4800PercentDue2029Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/DebtTenderOffersDetails" ], "xbrltype": "domainItemType" }, "mo_USDDenominatedNotes9950PercentDue2038Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "USD Denominated Notes, 9.950 Percent, Due 2038", "label": "USD Denominated Notes, 9.950 Percent, Due 2038 [Member]", "terseLabel": "9.950%, Notes Due 2038 [Member]" } } }, "localname": "USDDenominatedNotes9950PercentDue2038Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/DebtTenderOffersDetails" ], "xbrltype": "domainItemType" }, "mo_USDDenominatedNotesDue2032Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "USD Denominated Notes Due 2032", "label": "USD Denominated Notes Due 2032 [Member]", "terseLabel": "USD Denominated Notes Due 2032 [Member]" } } }, "localname": "USDDenominatedNotesDue2032Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_USDDenominatedNotesDue2041Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "USD Denominated Notes Due 2041", "label": "USD Denominated Notes Due 2041 [Member]", "terseLabel": "USD Denominated Notes Due 2041 [Member]" } } }, "localname": "USDDenominatedNotesDue2041Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_USDDenominatedNotesDue2051Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "USD Denominated Notes Due 2051", "label": "USD Denominated Notes Due 2051 [Member]", "terseLabel": "USD Denominated Notes Due 2051 [Member]" } } }, "localname": "USDDenominatedNotesDue2051Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_USDDenominatedNotesDue2061Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "USD Denominated Notes Due 2061", "label": "USD Denominated Notes Due 2061 [Member]", "terseLabel": "USD Denominated Notes Due 2061 [Member]" } } }, "localname": "USDDenominatedNotesDue2061Member", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_USDDenominatedNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "USD Denominated Notes [Member]", "label": "USD Denominated Notes [Member]", "terseLabel": "USD Denominated Notes [Member]" } } }, "localname": "USDDenominatedNotesMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_USTLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UST Litigation [Member]", "label": "UST Litigation [Member]", "terseLabel": "UST Litigation [Member]" } } }, "localname": "USTLitigationMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails", "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_ValuationAllowanceDeferredTaxAssetDecreaseInAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Valuation Allowance, Deferred Tax Asset, Decrease In Amount", "label": "Valuation Allowance, Deferred Tax Asset, Decrease In Amount", "negatedTerseLabel": "Reductions to valuation allowance credited to income tax benefit" } } }, "localname": "ValuationAllowanceDeferredTaxAssetDecreaseInAmount", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "mo_ValuationAllowanceDeferredTaxAssetIncreaseInAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Valuation Allowance, Deferred Tax Asset, Increase In Amount", "label": "Valuation Allowance, Deferred Tax Asset, Increase In Amount", "terseLabel": "Additions to valuation allowance charged to income tax expense" } } }, "localname": "ValuationAllowanceDeferredTaxAssetIncreaseInAmount", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "mo_ValuationAllowanceForeignCurrencyTranslationAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Valuation Allowance, Foreign Currency Translation Adjustment", "label": "Valuation Allowance, Foreign Currency Translation Adjustment", "terseLabel": "Foreign currency translation" } } }, "localname": "ValuationAllowanceForeignCurrencyTranslationAdjustment", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "mo_ValuationAllowanceRollforwardRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Valuation Allowance Rollforward [Roll Forward]", "label": "Valuation Allowance Rollforward [Roll Forward]", "terseLabel": "Valuation Allowance Rollforward [Roll Forward]" } } }, "localname": "ValuationAllowanceRollforwardRollForward", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "mo_WineBusinessStrategicResetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wine Business Strategic Reset [Member]", "label": "Wine Business Strategic Reset [Member]", "terseLabel": "Wine Business Strategic Reset [Member]" } } }, "localname": "WineBusinessStrategicResetMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "mo_WineSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wine Segment [Member]", "label": "Wine Segment [Member]", "terseLabel": "Wine Segment [Member]" } } }, "localname": "WineSegmentMember", "nsuri": "http://www.altria.com/20210930", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails", "http://www.altria.com/role/SegmentReportingNarrativeDetails", "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r143", "r198", "r211", "r212", "r213", "r214", "r216", "r218", "r222", "r313", "r314", "r315", "r316", "r317", "r318", "r320", "r321", "r323", "r325", "r326" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails", "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails", "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r143", "r198", "r211", "r212", "r213", "r214", "r216", "r218", "r222", "r313", "r314", "r315", "r316", "r317", "r318", "r320", "r321", "r323", "r325", "r326" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails", "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails", "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails", "http://www.altria.com/role/IncomeTaxesNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details", "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails", "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails", "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails", "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails", "http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails", "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails", "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails", "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails", "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails", "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails", "http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails", "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails", "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails", "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails", "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails", "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]", "verboseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails", "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails", "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails", "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails", "http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails", "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails", "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails", "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails", "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails", "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails", "http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails", "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails", "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails", "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails", "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails", "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r331", "r371", "r495", "r500", "r622", "r623", "r624", "r625", "r626", "r627", "r647", "r700", "r702", "r723", "r724" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altria.com/role/BenefitPlansNarrativeDetails", "http://www.altria.com/role/FinancialInstrumentsFairValueUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r331", "r371", "r495", "r500", "r622", "r623", "r624", "r625", "r626", "r627", "r647", "r700", "r702", "r723", "r724" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r331", "r371", "r439", "r495", "r500", "r622", "r623", "r624", "r625", "r626", "r627", "r647", "r700", "r702", "r723", "r724" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altria.com/role/BenefitPlansNarrativeDetails", "http://www.altria.com/role/FinancialInstrumentsFairValueUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r331", "r371", "r439", "r495", "r500", "r622", "r623", "r624", "r625", "r626", "r627", "r647", "r700", "r702", "r723", "r724" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altria.com/role/BenefitPlansNarrativeDetails", "http://www.altria.com/role/FinancialInstrumentsFairValueUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails", "http://www.altria.com/role/IncomeTaxesNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details", "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r226", "r227", "r404", "r407", "r701", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails", "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails", "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails", "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails", "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r226", "r227", "r404", "r407", "r701", "r712", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails", "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails", "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails", "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails", "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails" ], "xbrltype": "stringItemType" }, "stpr_AK": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ALASKA", "terseLabel": "Alaska [Member]" } } }, "localname": "AK", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_AR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ARKANSAS", "terseLabel": "Arkansas [Member]" } } }, "localname": "AR", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "domainItemType" }, "stpr_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CALIFORNIA", "terseLabel": "California [Member]" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_CT": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONNECTICUT", "terseLabel": "Connecticut [Member]" } } }, "localname": "CT", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_DC": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DISTRICT OF COLUMBIA", "terseLabel": "District of Columbia [Member]" } } }, "localname": "DC", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "domainItemType" }, "stpr_DE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DELAWARE", "terseLabel": "Delaware [Member]" } } }, "localname": "DE", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "domainItemType" }, "stpr_FL": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FLORIDA", "terseLabel": "Florida [Member]" } } }, "localname": "FL", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails", "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails", "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails" ], "xbrltype": "domainItemType" }, "stpr_IA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IOWA", "terseLabel": "Iowa [Member]" } } }, "localname": "IA", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "domainItemType" }, "stpr_IL": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ILLINOIS", "terseLabel": "Illinois [Member]" } } }, "localname": "IL", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails" ], "xbrltype": "domainItemType" }, "stpr_KS": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "KANSAS", "terseLabel": "Kansas [Member]" } } }, "localname": "KS", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "domainItemType" }, "stpr_LA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LOUISIANA", "terseLabel": "Louisiana [Member]" } } }, "localname": "LA", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_MA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MASSACHUSETTS", "verboseLabel": "Massachusetts [Member]" } } }, "localname": "MA", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails", "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails" ], "xbrltype": "domainItemType" }, "stpr_MD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MARYLAND", "terseLabel": "Maryland [Member]" } } }, "localname": "MD", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "domainItemType" }, "stpr_MI": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MICHIGAN", "terseLabel": "Michigan [Member]" } } }, "localname": "MI", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "domainItemType" }, "stpr_MN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MINNESOTA", "terseLabel": "Minnesota [Member]" } } }, "localname": "MN", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "domainItemType" }, "stpr_MO": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MISSOURI", "terseLabel": "Missouri [Member]" } } }, "localname": "MO", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_MS": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MISSISSIPPI", "terseLabel": "Mississippi [Member]" } } }, "localname": "MS", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_MT": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MONTANA", "terseLabel": "MONTANA" } } }, "localname": "MT", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "stpr_NH": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW HAMPSHIRE", "terseLabel": "New Hampshire [Member]" } } }, "localname": "NH", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_NJ": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW JERSEY", "terseLabel": "New Jersey [Member]" } } }, "localname": "NJ", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_NM": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW MEXICO", "terseLabel": "New Mexico [Member]" } } }, "localname": "NM", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails" ], "xbrltype": "domainItemType" }, "stpr_NV": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEVADA", "terseLabel": "Nevada [Member]" } } }, "localname": "NV", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "domainItemType" }, "stpr_NY": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW YORK", "terseLabel": "New York [Member]" } } }, "localname": "NY", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails", "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_OH": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OHIO", "terseLabel": "Ohio [Member]" } } }, "localname": "OH", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_OK": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OKLAHOMA", "terseLabel": "Oklahoma [Member]" } } }, "localname": "OK", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "domainItemType" }, "stpr_OR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OREGON", "terseLabel": "Oregon [Member]" } } }, "localname": "OR", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "domainItemType" }, "stpr_PA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PENNSYLVANIA", "terseLabel": "Pennsylvania [Member]" } } }, "localname": "PA", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_RI": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RHODE ISLAND", "terseLabel": "Rhode Island [Member]" } } }, "localname": "RI", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_SC": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SOUTH CAROLINA", "terseLabel": "South Carolina [Member]" } } }, "localname": "SC", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "domainItemType" }, "stpr_TN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TENNESSEE", "terseLabel": "Tennessee [Member]" } } }, "localname": "TN", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_TX": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TEXAS", "terseLabel": "Texas [Member]" } } }, "localname": "TX", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "domainItemType" }, "stpr_WI": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WISCONSIN", "terseLabel": "Wisconsin [Member]" } } }, "localname": "WI", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails" ], "xbrltype": "domainItemType" }, "stpr_WV": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WEST VIRGINIA", "terseLabel": "West Virginia [Member]" } } }, "localname": "WV", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "Accumulated Other Comprehensive Income [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r56", "r614" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "terseLabel": "Accrued liabilities:" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedMarketingCostsCurrent": { "auth_ref": [], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Marketing Costs, Current", "terseLabel": "Marketing" } } }, "localname": "AccruedMarketingCostsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r79", "r86", "r94", "r95", "r96", "r544" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Benefit Plans [Member]" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails", "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember": { "auth_ref": [ "r81", "r86", "r94", "r95", "r96", "r544" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to prior service cost (credit) component of defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]", "terseLabel": "Prior service cost/credit [Member]" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember": { "auth_ref": [ "r78", "r86", "r94", "r95", "r96", "r544" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]", "terseLabel": "Net loss [Member]" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r54", "r277" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r44", "r83", "r85", "r86", "r680", "r707", "r710" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive losses" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r94", "r95", "r599", "r600", "r601", "r602", "r603", "r605" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r82", "r86", "r94", "r95", "r96", "r144", "r145", "r146", "r544", "r703", "r704", "r738" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "verboseLabel": "Accumulated Other Comprehensive Losses [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquity", "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r76", "r86", "r94", "r95", "r96", "r544", "r600", "r601", "r602", "r603", "r605" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Currency Translation Adjustments and Other [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails", "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r42" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r144", "r145", "r146", "r502", "r503", "r504", "r581" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net earnings (losses) to operating cash flows:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllOtherSegmentsMember": { "auth_ref": [ "r194", "r211", "r212", "r213", "r214", "r216" ], "lang": { "en-us": { "role": { "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.", "label": "Other Segments [Member]", "terseLabel": "All Other [Member]" } } }, "localname": "AllOtherSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables": { "auth_ref": [ "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.", "label": "Allowance for Doubtful Accounts, Premiums and Other Receivables", "terseLabel": "Allowance for doubtful accounts, receivables" } } }, "localname": "AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r131", "r270", "r272" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "negatedLabel": "Amortization of intangibles" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r139", "r206", "r213", "r220", "r249", "r313", "r314", "r315", "r317", "r318", "r319", "r320", "r322", "r324", "r326", "r327", "r539", "r545", "r594", "r612", "r614", "r654", "r676" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r22", "r23", "r71", "r139", "r249", "r313", "r314", "r315", "r317", "r318", "r319", "r320", "r322", "r324", "r326", "r327", "r539", "r545", "r594", "r612", "r614" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Member]", "terseLabel": "Assets [Member]" } } }, "localname": "AssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets [Abstract]", "terseLabel": "Assets held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r3", "r4", "r12", "r14", "r17", "r275", "r281" ], "calculation": { "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel": "Assets held for sale", "totalLabel": "Assets held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails", "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails", "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r558", "r563" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails", "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation, Policy" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r491", "r496" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r491", "r496", "r532", "r533" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r531" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Business combination, acquisition related costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r20", "r51", "r133" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets", "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]", "terseLabel": "Cash, cash equivalents and restricted cash:" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r127", "r133", "r134" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": { "auth_ref": [ "r127", "r133", "r134" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations", "terseLabel": "Restricted cash included in assets held for sale" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r127", "r598" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase (decrease)" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r137", "r139", "r169", "r170", "r175", "r178", "r180", "r191", "r192", "r193", "r249", "r313", "r318", "r319", "r320", "r326", "r327", "r369", "r370", "r372", "r373", "r594", "r730" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r381", "r382", "r383", "r384" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails", "http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r65", "r299", "r661", "r686" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "verboseLabel": "Contingencies (Note 12)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "verboseLabel": "Dividends declared (usd per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails", "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r144", "r145", "r581" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquity", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r40", "r614" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, par value $0.33 1/3\u00a0per share (2,805,961,317 shares issued)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r90", "r92", "r93", "r104", "r668", "r694" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarningsLosses": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive earnings (losses) attributable to Altria" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarningsLosses" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r90", "r92", "r103", "r537", "r538", "r549", "r667", "r693" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarningsLosses": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "negatedTerseLabel": "Comprehensive (earnings) losses attributable to noncontrolling interests" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarningsLosses" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r90", "r92", "r102", "r536", "r549", "r666", "r692" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarningsLosses": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive earnings (losses)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarningsLosses" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r101", "r113", "r665", "r691" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Other Comprehensive Earnings/Losses" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLosses" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r385", "r386", "r405" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r211", "r212", "r213", "r214", "r216", "r222", "r224" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate, Non-Segment [Member]", "verboseLabel": "General corporate [Member]" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails", "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r108", "r648" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses", "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of Sales [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails", "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails", "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r136", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r345", "r352", "r353", "r355", "r363" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r33", "r34", "r35", "r138", "r143", "r328", "r329", "r330", "r331", "r332", "r333", "r335", "r341", "r342", "r343", "r344", "r346", "r347", "r348", "r349", "r350", "r351", "r357", "r358", "r359", "r360", "r609", "r655", "r656", "r675" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails", "http://www.altria.com/role/DebtNarrativeDetails", "http://www.altria.com/role/DebtTenderOffersDetails", "http://www.altria.com/role/FinancialInstrumentsAggregateNotionalAmountsAggregateFairValuesandCarryingValuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt instrument, basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r328", "r357", "r358", "r608", "r609", "r610" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r343", "r357", "r358", "r593" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair value" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsAggregateNotionalAmountsAggregateFairValuesandCarryingValuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r62", "r329" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, interest rate, stated percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails", "http://www.altria.com/role/DebtTenderOffersDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails", "http://www.altria.com/role/DebtTenderOffersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r63", "r138", "r143", "r328", "r329", "r330", "r331", "r332", "r333", "r335", "r341", "r342", "r343", "r344", "r346", "r347", "r348", "r349", "r350", "r351", "r357", "r358", "r359", "r360", "r609" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails", "http://www.altria.com/role/DebtNarrativeDetails", "http://www.altria.com/role/DebtTenderOffersDetails", "http://www.altria.com/role/FinancialInstrumentsAggregateNotionalAmountsAggregateFairValuesandCarryingValuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r673" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r673" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "auth_ref": [ "r673" ], "lang": { "en-us": { "role": { "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period One [Member]", "terseLabel": "Debt Instrument, Redemption, Period One [Member]" } } }, "localname": "DebtInstrumentRedemptionPeriodOneMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r673" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Debt instrument, redemption price, percentage" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentRepurchasedFaceAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of the original debt instrument that was repurchased.", "label": "Debt Instrument, Repurchased Face Amount", "terseLabel": "Debt instrument, repurchased face amount" } } }, "localname": "DebtInstrumentRepurchasedFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtTenderOffersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r63", "r138", "r143", "r328", "r329", "r330", "r331", "r332", "r333", "r335", "r341", "r342", "r343", "r344", "r346", "r347", "r348", "r349", "r350", "r351", "r354", "r357", "r358", "r359", "r360", "r376", "r377", "r378", "r379", "r607", "r608", "r609", "r610", "r674" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails", "http://www.altria.com/role/DebtTenderOffersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r131", "r140", "r515", "r523", "r524", "r525" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income tax provision (benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r507", "r508" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r513" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of year" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent": { "auth_ref": [ "r36", "r415", "r416", "r438" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.", "label": "Liability, Defined Benefit Pension Plan, Noncurrent", "terseLabel": "Accrued pension costs" } } }, "localname": "DefinedBenefitPensionPlanLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r417", "r455", "r479", "r485", "r486" ], "calculation": { "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedLabel": "Net loss" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r417", "r456", "r480", "r485", "r486" ], "calculation": { "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "verboseLabel": "Prior service cost (credit)" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r432", "r440", "r442", "r483", "r485", "r486" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Defined benefit plan, plan assets, contributions by employer" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BenefitPlansNarrativeDetails", "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear": { "auth_ref": [ "r483", "r486" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in remainder of current fiscal year. Excludes contribution previously paid by employer in current fiscal year.", "label": "Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year", "terseLabel": "Anticipated additional employer contributions" } } }, "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r417", "r454", "r478", "r485", "r486" ], "calculation": { "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r417", "r421", "r453", "r477", "r485", "r486" ], "calculation": { "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r451", "r475", "r485", "r486" ], "calculation": { "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net periodic benefit (income) cost" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]", "terseLabel": "Amortization:" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r419", "r452", "r476", "r485", "r486" ], "calculation": { "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "verboseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r131", "r201" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetMeasurementInput": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative asset.", "label": "Derivative Asset, Measurement Input", "terseLabel": "Derivative asset, measurement input" } } }, "localname": "DerivativeAssetMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsAggregateNotionalAmountsAggregateFairValuesandCarryingValuesDetails", "http://www.altria.com/role/FinancialInstrumentsBeginningandEndingBalancesofFixedpricePreemptiveRightsandWarrantsDetails", "http://www.altria.com/role/FinancialInstrumentsEffectsofNetInvestmentHedgesonAccumulatedOtherComprehensiveLossesDetails", "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails", "http://www.altria.com/role/FinancialInstrumentsFairValueUsingBlackScholesOptionPricingModelDetails", "http://www.altria.com/role/FinancialInstrumentsPretaxUnrealizedGainsLossesDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r72", "r73", "r74", "r561", "r629" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Fair Value of Assets", "verboseLabel": "Derivative asset, fair value, gross asset" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r72", "r73", "r74", "r561", "r629" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Fair Value of Liabilities" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r560" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "negatedTerseLabel": "(Gain) loss on Cronos-related financial instruments", "terseLabel": "Gain (loss) on Cronos-related financial instruments" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses", "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r73", "r559", "r562", "r567", "r572" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsAggregateNotionalAmountsAggregateFairValuesandCarryingValuesDetails", "http://www.altria.com/role/FinancialInstrumentsBeginningandEndingBalancesofFixedpricePreemptiveRightsandWarrantsDetails", "http://www.altria.com/role/FinancialInstrumentsEffectsofNetInvestmentHedgesonAccumulatedOtherComprehensiveLossesDetails", "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails", "http://www.altria.com/role/FinancialInstrumentsFairValueUsingBlackScholesOptionPricingModelDetails", "http://www.altria.com/role/FinancialInstrumentsPretaxUnrealizedGainsLossesDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r579", "r584" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Financial Instruments" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r556", "r559", "r567" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsAggregateNotionalAmountsAggregateFairValuesandCarryingValuesDetails", "http://www.altria.com/role/FinancialInstrumentsEffectsofNetInvestmentHedgesonAccumulatedOtherComprehensiveLossesDetails", "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r556", "r559", "r567", "r572", "r573", "r576", "r578" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsEffectsofNetInvestmentHedgesonAccumulatedOtherComprehensiveLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsEffectsofNetInvestmentHedgesonAccumulatedOtherComprehensiveLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsAggregateNotionalAmountsAggregateFairValuesandCarryingValuesDetails", "http://www.altria.com/role/FinancialInstrumentsBeginningandEndingBalancesofFixedpricePreemptiveRightsandWarrantsDetails", "http://www.altria.com/role/FinancialInstrumentsFairValueUsingBlackScholesOptionPricingModelDetails", "http://www.altria.com/role/FinancialInstrumentsPretaxUnrealizedGainsLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r552", "r554" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Foreign currency contracts (notional amounts)" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsAggregateNotionalAmountsAggregateFairValuesandCarryingValuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r551", "r553", "r554", "r556", "r557", "r564", "r567", "r574", "r575", "r578", "r579" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsAggregateNotionalAmountsAggregateFairValuesandCarryingValuesDetails", "http://www.altria.com/role/FinancialInstrumentsBeginningandEndingBalancesofFixedpricePreemptiveRightsandWarrantsDetails", "http://www.altria.com/role/FinancialInstrumentsFairValueUsingBlackScholesOptionPricingModelDetails", "http://www.altria.com/role/FinancialInstrumentsPretaxUnrealizedGainsLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument [Member]" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails", "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails", "http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails", "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails", "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails", "http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails", "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r14", "r273", "r283" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]" } } }, "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails", "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails", "http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails", "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "auth_ref": [ "r3", "r4", "r12", "r281" ], "calculation": { "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails": { "order": 4.0, "parentTag": "mo_DisposalGroupIncludingDiscontinuedOperationAssetsCurrentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "terseLabel": "Receivables", "verboseLabel": "Disposal group, including discontinued operation, accounts, notes and loans receivable, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails", "http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": { "auth_ref": [ "r3", "r4", "r12", "r275", "r281" ], "calculation": { "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": { "auth_ref": [ "r3", "r4", "r12", "r275", "r281" ], "calculation": { "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "auth_ref": [ "r3", "r4", "r12", "r281" ], "calculation": { "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails": { "order": 2.0, "parentTag": "mo_DisposalGroupIncludingDiscontinuedOperationAssetsCurrentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Disposal group, including discontinued operation, consideration" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent": { "auth_ref": [ "r3", "r4", "r12", "r275", "r281" ], "calculation": { "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails": { "order": 3.0, "parentTag": "mo_DisposalGroupIncludingDiscontinuedOperationAssetsCurrentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Current", "terseLabel": "Other intangible assets, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "auth_ref": [ "r3", "r4", "r12", "r275", "r281" ], "calculation": { "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails": { "order": 6.0, "parentTag": "mo_DisposalGroupIncludingDiscontinuedOperationAssetsCurrentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Inventory, Current", "terseLabel": "Inventories" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": { "auth_ref": [ "r3", "r4", "r12", "r275", "r281" ], "calculation": { "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails": { "order": 1.0, "parentTag": "mo_DisposalGroupIncludingDiscontinuedOperationAssetsCurrentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current", "terseLabel": "Other assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": { "auth_ref": [ "r3", "r4", "r12", "r275", "r281" ], "calculation": { "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current", "terseLabel": "Other liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationCurrent": { "auth_ref": [ "r4", "r12", "r281" ], "calculation": { "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as defined benefit plan benefit obligations attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Pension Plan Benefit Obligation, Current", "terseLabel": "Accrued pension costs" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": { "auth_ref": [ "r3", "r4", "r12", "r275", "r281" ], "calculation": { "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails": { "order": 5.0, "parentTag": "mo_DisposalGroupIncludingDiscontinuedOperationAssetsCurrentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current", "terseLabel": "Property, plant and equipment, net of accumulated depreciation" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "auth_ref": [ "r131", "r274", "r279" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "terseLabel": "Assets and liabilities held for sale, net" } } }, "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": { "auth_ref": [ "r131", "r274", "r279" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down", "terseLabel": "Pre-tax charge for adjustment to record the assets and liabilities at fair value less costs to sell" } } }, "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r18", "r285" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Assets Held for Sale" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSale" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r491", "r496" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails", "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails", "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r380" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedTerseLabel": "Cash dividends declared" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r26", "r60" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends Payable, Current", "terseLabel": "Dividends payable" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Per share data:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r105", "r154", "r155", "r156", "r157", "r158", "r165", "r169", "r178", "r179", "r180", "r184", "r185", "r582", "r583", "r669", "r695" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic earnings (losses) per share attributable to Altria (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r105", "r154", "r155", "r156", "r157", "r158", "r169", "r178", "r179", "r180", "r184", "r185", "r582", "r583", "r669", "r695" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted earnings (losses) per share attributable to Altria (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r181", "r182", "r183", "r186" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings (Losses) per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/EarningsLossesperShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/IncomeTaxesSummaryofIncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EnvironmentalCostsPolicy": { "auth_ref": [ "r286", "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for obligations that resulted from improper or other-than normal operation of a long-lived asset in the past. This accounting policy may address (1) whether the related remediation costs are expensed or capitalized, (2) whether the obligation is measured on a discounted basis, (3) the event, situation, or set of circumstances that generally triggers recognition of loss contingencies arising from the entity's environmental remediation-related obligations, and (4) the timing of recognition of any recoveries.", "label": "Environmental Costs, Policy [Policy Text Block]", "terseLabel": "Environmental Regulation" } } }, "localname": "EnvironmentalCostsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails", "http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r94", "r95", "r96", "r144", "r145", "r146", "r150", "r159", "r161", "r190", "r253", "r375", "r380", "r502", "r503", "r504", "r516", "r517", "r581", "r599", "r600", "r601", "r602", "r603", "r605", "r703", "r704", "r705", "r738" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquity", "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails", "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityContractMember": { "auth_ref": [ "r73", "r440", "r571" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to share prices.", "label": "Equity Contract [Member]", "terseLabel": "Equity Contract [Member]" } } }, "localname": "EquityContractMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsBeginningandEndingBalancesofFixedpricePreemptiveRightsandWarrantsDetails", "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": { "auth_ref": [ "r247" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.", "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity", "terseLabel": "Equity method investment, difference between carrying amount and underlying equity" } } }, "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "auth_ref": [ "r99", "r126", "r131", "r689" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.", "label": "Proceeds from Equity Method Investment, Distribution", "terseLabel": "Dividends from ABI" } } }, "localname": "EquityMethodInvestmentDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity method investment, ownership percentage", "verboseLabel": "Ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r52", "r207", "r244" ], "calculation": { "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_Investments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "verboseLabel": "Investments in equity securities" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsFairValueDisclosure": { "auth_ref": [ "r242" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investments accounted under the equity method.", "label": "Equity Method Investments, Fair Value Disclosure", "terseLabel": "Fair value of equity investment" } } }, "localname": "EquityMethodInvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r52", "r126", "r246", "r594" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investments [Policy Text Block]", "terseLabel": "Equity Method Investments" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityMethodInvestmentsTextBlock": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.", "label": "Equity Method Investments [Table Text Block]", "terseLabel": "Equity Method Investments" } } }, "localname": "EquityMethodInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount": { "auth_ref": [ "r239" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount", "terseLabel": "Equity securities without readily determinable fair value, downward price adjustment, cumulative amount" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount": { "auth_ref": [ "r239" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount", "negatedTerseLabel": "Impairment of JUUL equity securities", "terseLabel": "Impairment of JUUL equity securities" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses", "http://www.altria.com/role/IncomeTaxesNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails", "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": { "auth_ref": [ "r240" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount", "terseLabel": "Equity securities without readily determinable fair value, upward price adjustment, cumulative amount" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r589" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r589", "r592" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r585", "r592" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r343", "r357", "r358", "r440", "r442", "r443", "r444", "r445", "r446", "r447", "r485", "r586", "r619", "r620", "r621" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsBeginningandEndingBalancesofFixedpricePreemptiveRightsandWarrantsDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r343", "r440", "r442", "r447", "r485", "r586", "r619" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r343", "r357", "r358", "r440", "r442", "r443", "r444", "r445", "r446", "r447", "r485", "r586", "r621" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsBeginningandEndingBalancesofFixedpricePreemptiveRightsandWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "auth_ref": [ "r590" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "terseLabel": "Unrealized gains (losses) included in income (losses) from equity investments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r589" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesJUULInvestmentClassifiedasLevel3Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r343", "r357", "r358", "r440", "r442", "r443", "r444", "r445", "r446", "r447", "r485", "r619", "r620", "r621" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsBeginningandEndingBalancesofFixedpricePreemptiveRightsandWarrantsDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]", "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsBeginningandEndingBalancesofFixedpricePreemptiveRightsandWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "auth_ref": [ "r589", "r591" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings": { "auth_ref": [ "r590", "r591" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings", "terseLabel": "Pre-tax earnings (losses) recognized in net earnings (losses)" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsBeginningandEndingBalancesofFixedpricePreemptiveRightsandWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": { "auth_ref": [ "r585", "r591" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at begging of period" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsBeginningandEndingBalancesofFixedpricePreemptiveRightsandWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r558", "r564", "r576" ], "lang": { "en-us": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r235", "r236", "r238", "r239", "r240", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r354", "r374", "r579", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r730", "r731", "r732", "r733", "r734", "r735", "r736" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r73", "r440", "r570" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign currency contracts [Member]", "verboseLabel": "Foreign Currency Contract [Member]" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsAggregateNotionalAmountsAggregateFairValuesandCarryingValuesDetails", "http://www.altria.com/role/FinancialInstrumentsEffectsofNetInvestmentHedgesonAccumulatedOtherComprehensiveLossesDetails", "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain (Loss) Related to Litigation Settlement", "negatedTerseLabel": "Loss (gain) related to litigation settlement" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r131", "r361", "r362" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.altria.com/role/DebtNarrativeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on early extinguishment of debt", "negatedTotalLabel": "Loss on early extinguishment of debt", "terseLabel": "Loss on early extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses", "http://www.altria.com/role/DebtNarrativeDetails", "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost": { "auth_ref": [ "r361", "r362" ], "calculation": { "http://www.altria.com/role/DebtNarrativeDetails": { "order": 1.0, "parentTag": "us-gaap_GainsLossesOnExtinguishmentOfDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.", "label": "Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost", "negatedTerseLabel": "Loss on extinguishment of debt, premiums and fees" } } }, "localname": "GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r110" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "negatedTerseLabel": "General corporate expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r266", "r267", "r614", "r653" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r106", "r139", "r206", "r212", "r216", "r219", "r222", "r249", "r313", "r314", "r315", "r318", "r319", "r320", "r322", "r324", "r326", "r327", "r594" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses" ], "xbrltype": "monetaryItemType" }, "us-gaap_GuaranteeObligationsMaximumExposure": { "auth_ref": [ "r311" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.", "label": "Guarantor Obligations, Maximum Exposure, Undiscounted", "terseLabel": "Contingent liability related to performance surety bonds" } } }, "localname": "GuaranteeObligationsMaximumExposure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r556", "r573" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsAggregateNotionalAmountsAggregateFairValuesandCarryingValuesDetails", "http://www.altria.com/role/FinancialInstrumentsEffectsofNetInvestmentHedgesonAccumulatedOtherComprehensiveLossesDetails", "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r98", "r206", "r212", "r216", "r219", "r222", "r652", "r663", "r671", "r697" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Earnings (losses) before income taxes", "totalLabel": "Earnings (losses) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses", "http://www.altria.com/role/IncomeTaxesSummaryofIncomeTaxesDetails", "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r99", "r131", "r203", "r244", "r662", "r689" ], "calculation": { "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails": { "order": 1.0, "parentTag": "mo_IncomeLossFromEquityInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "(Income) losses from equity investments", "verboseLabel": "Income (losses) from investments under equity method of accounting" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails", "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r491", "r496" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails", "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails", "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails", "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails", "http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r4", "r6", "r7", "r8", "r9", "r10", "r11", "r13", "r15", "r16", "r17", "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails", "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails", "http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r280", "r293" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails", "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails", "http://www.altria.com/role/SegmentReportingNarrativeDetails", "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails", "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails", "http://www.altria.com/role/SegmentReportingNarrativeDetails", "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r141", "r511", "r512", "r514", "r521", "r526", "r528", "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r142", "r160", "r161", "r204", "r509", "r522", "r527", "r698" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision (benefit) for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses", "http://www.altria.com/role/IncomeTaxesSummaryofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r130" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r130" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "verboseLabel": "Income taxes" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r130" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Cash effects of changes:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet": { "auth_ref": [], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net", "negatedLabel": "Accrued liabilities and other current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPensionAndPostretirementObligations": { "auth_ref": [ "r130" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for pension and other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Increase (Decrease) in Obligation, Pension and Other Postretirement Benefits", "negatedTerseLabel": "Decrease in accrued postretirement health care cost liability" } } }, "localname": "IncreaseDecreaseInPensionAndPostretirementObligations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r130" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Receivables" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r269", "r271" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "verboseLabel": "Other intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r670" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses": { "order": 7.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "negatedTerseLabel": "Interest and other debt expense, net", "terseLabel": "Interest and other debt expense, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses", "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r660", "r688" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest Payable", "terseLabel": "Accrued interest on long-term debt" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterimPeriodCostsNotAllocableDomain": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred.", "label": "Interim Period, Costs Not Allocable [Domain]", "terseLabel": "Interim Period, Costs Not Allocable [Domain]" } } }, "localname": "InterimPeriodCostsNotAllocableDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r49", "r265" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished product" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r21", "r69", "r614" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Inventory, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory, Net [Abstract]", "verboseLabel": "Inventories:" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r50", "r265" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r246", "r696" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investment, Policy" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTableTextBlock": { "auth_ref": [ "r237", "r241", "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment.", "label": "Investment [Table Text Block]", "terseLabel": "Investment" } } }, "localname": "InvestmentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTextBlock": { "auth_ref": [ "r237", "r241", "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investment.", "label": "Investment [Text Block]", "terseLabel": "Investments in Equity Securities" } } }, "localname": "InvestmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_Investments": { "auth_ref": [ "r687" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "totalLabel": "Investments", "verboseLabel": "Investments in equity securities ($1,740 million and $1,868 million at September 30, 2021 and December 31, 2020, respectively, measured at fair value)" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets", "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments [Abstract]", "terseLabel": "Investments [Abstract]" } } }, "localname": "InvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r585" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Investments, fair value disclosure" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Contingencies" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/Contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit [Member]" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r59", "r139", "r214", "r249", "r313", "r314", "r315", "r318", "r319", "r320", "r322", "r324", "r326", "r327", "r540", "r545", "r546", "r594", "r612", "r613" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "verboseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r47", "r139", "r249", "r594", "r614", "r659", "r683" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders\u2019 (Deficit) Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r61", "r139", "r249", "r313", "r314", "r315", "r318", "r319", "r320", "r322", "r324", "r326", "r327", "r540", "r545", "r546", "r594", "r612", "r613", "r614" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities [Abstract]", "terseLabel": "Liabilities held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r3", "r4", "r12", "r14", "r17", "r275", "r281" ], "calculation": { "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "terseLabel": "Liabilities held for sale", "totalLabel": "Liabilities held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleSummaryofMajorClassesofAssetsandLiabilitiesClassifiedasHeldforSaleDetails", "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit line available under the agreement" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit [Member]" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount awarded from other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded from Other Party", "terseLabel": "Loss contingency, credits to offset payments", "verboseLabel": "Amount ordered to be paid from other party" } } }, "localname": "LitigationSettlementAmountAwardedFromOtherParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails", "http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Litigation settlement" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails", "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails", "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest expense (income) directly attributable to an award in settlement of litigation.", "label": "Litigation Settlement Interest", "netLabel": "Litigation settlement interest expense (income)" } } }, "localname": "LitigationSettlementInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails", "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails", "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails", "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails", "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails", "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails", "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails", "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails", "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails", "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails", "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails", "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails", "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR) [Member]" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r35", "r342", "r356", "r357", "r358", "r656", "r678" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Carrying value" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails", "http://www.altria.com/role/FinancialInstrumentsAggregateFairValueandCarryingValueDetails", "http://www.altria.com/role/FinancialInstrumentsAggregateNotionalAmountsAggregateFairValuesandCarryingValuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r58" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Fair value" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsAggregateFairValueandCarryingValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r63" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails", "http://www.altria.com/role/DebtNarrativeDetails", "http://www.altria.com/role/DebtTenderOffersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r63", "r312" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails", "http://www.altria.com/role/DebtNarrativeDetails", "http://www.altria.com/role/DebtTenderOffersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r299", "r300", "r301", "r303", "r304", "r305", "r307", "r309", "r310" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails", "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails", "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails", "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails", "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails", "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails", "http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails", "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails", "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails", "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails", "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails", "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails", "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails", "http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails", "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails", "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails", "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r299", "r300", "r301", "r303", "r304", "r305", "r307", "r309", "r310" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails", "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails", "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails", "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails", "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails", "http://www.altria.com/role/ContingenciesFloridaBondStatuteDetails", "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails", "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails", "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails", "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails", "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails", "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails", "http://www.altria.com/role/ContingenciesOtherDisputesUndertheStateSettlementAgreementsDetails", "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails", "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails", "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "periodEndLabel": "Accrued liability for tobacco and health litigation items at end of period", "periodStartLabel": "Accrued liability for tobacco and health litigation items at beginning of period" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualPayments": { "auth_ref": [ "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow reducing loss contingency liability.", "label": "Loss Contingency Accrual, Payments", "negatedTerseLabel": "Payments" } } }, "localname": "LossContingencyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualProvision": { "auth_ref": [ "r299" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.", "label": "Loss Contingency Accrual, Provision", "terseLabel": "Provision related to litigation recorded" } } }, "localname": "LossContingencyAccrualProvision", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails", "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails", "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails", "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails", "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Loss Contingency Accrual [Roll Forward]", "terseLabel": "Loss Contingency Accrual [Roll Forward]" } } }, "localname": "LossContingencyAccrualRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyClaimsSettledNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of claims settled.", "label": "Loss Contingency, Claims Settled, Number", "terseLabel": "Loss contingency, claims settled, number" } } }, "localname": "LossContingencyClaimsSettledNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyDamagesAwardedValue": { "auth_ref": [ "r299", "r302", "r306" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of damages awarded to the plaintiff in the legal matter.", "label": "Loss Contingency, Damages Awarded, Value", "terseLabel": "Damages awarded, value" } } }, "localname": "LossContingencyDamagesAwardedValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails", "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails", "http://www.altria.com/role/ContingenciesNonEngleProgenyLitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesPaidValue": { "auth_ref": [ "r299", "r302", "r306" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of damages paid to the plaintiff in the legal matter.", "label": "Loss Contingency, Damages Paid, Value", "terseLabel": "Judgments paid (approximately)" } } }, "localname": "LossContingencyDamagesPaidValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails", "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r299", "r302", "r306" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Loss contingency, damages sought, value" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r299", "r300", "r301", "r303", "r304", "r305", "r307", "r309", "r310" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesFederalGovernmentsLawsuitDetails", "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.", "label": "Loss Contingency, Number of Plaintiffs", "terseLabel": "Number of plaintiffs" } } }, "localname": "LossContingencyNumberOfPlaintiffs", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails", "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyPendingClaimsNumber": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Number of pending claims pertaining to a loss contingency.", "label": "Loss Contingency, Pending Claims, Number", "terseLabel": "Claims filed, number", "verboseLabel": "Number of cases pending" } } }, "localname": "LossContingencyPendingClaimsNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails", "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails", "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails", "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails", "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails", "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails", "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails", "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Segment Reconciling Items [Member]" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails", "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails", "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]", "terseLabel": "Expected Dividend Yield [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Expected Life [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Expected Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]", "verboseLabel": "Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]", "terseLabel": "Share price [Member]" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r68", "r139", "r249", "r313", "r318", "r319", "r320", "r326", "r327", "r594", "r658", "r682" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfExpenseAxis": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cost or expense.", "label": "Nature of Expense [Axis]", "terseLabel": "Nature of Expense [Axis]" } } }, "localname": "NatureOfExpenseAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r127" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash Provided by (Used in) Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r127" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash Provided by (Used in) Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r127", "r129", "r132" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash Provided by (Used in) Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r17", "r88", "r91", "r96", "r100", "r132", "r139", "r149", "r154", "r155", "r156", "r157", "r160", "r161", "r176", "r206", "r212", "r216", "r219", "r222", "r249", "r313", "r314", "r315", "r318", "r319", "r320", "r322", "r324", "r326", "r327", "r583", "r594", "r664", "r690" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.altria.com/role/EarningsLossesperShareBasicandDilutedEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net earnings (losses) attributable to Altria", "verboseLabel": "Net earnings (losses) attributable to Altria" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses", "http://www.altria.com/role/EarningsLossesperShareBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r88", "r91", "r96", "r160", "r161", "r542", "r548" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedTerseLabel": "Net (earnings) losses attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": { "auth_ref": [ "r107" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.", "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest", "terseLabel": "Net earnings attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r154", "r155", "r156", "r157", "r165", "r166", "r177", "r180", "r206", "r212", "r216", "r219", "r222" ], "calculation": { "http://www.altria.com/role/EarningsLossesperShareBasicandDilutedEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Earnings (losses) for basic EPS" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/EarningsLossesperShareBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r168", "r171", "r172", "r173", "r174", "r177", "r180" ], "calculation": { "http://www.altria.com/role/EarningsLossesperShareBasicandDilutedEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Earnings (losses) for diluted EPS" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/EarningsLossesperShareBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": { "auth_ref": [ "r366", "r542", "r543" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.", "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest", "terseLabel": "Net earnings (losses)" } } }, "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedging [Member]" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsAggregateNotionalAmountsAggregateFairValuesandCarryingValuesDetails", "http://www.altria.com/role/FinancialInstrumentsEffectsofNetInvestmentHedgesonAccumulatedOtherComprehensiveLossesDetails", "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": { "auth_ref": [ "r417" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.", "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component", "negatedLabel": "Net periodic benefit income, excluding service cost", "terseLabel": "Net periodic benefit income, excluding service cost" } } }, "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses", "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails", "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]", "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r2", "r147", "r148", "r151", "r152", "r162", "r163", "r164", "r233", "r234", "r254", "r255", "r408", "r409", "r410", "r411", "r505", "r518", "r519", "r520", "r580", "r595", "r596", "r597", "r611", "r649", "r650", "r651", "r706", "r707", "r708", "r709", "r710", "r739" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "terseLabel": "New Accounting Guidance Not Yet Adopted" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/NewAccountingGuidanceNotYetAdopted" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements, Policy" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r144", "r145", "r146", "r380", "r534" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-controlling Interests [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument [Member]" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OciEquityMethodInvestmentAfterTax": { "auth_ref": [ "r243" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarningsLosses": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of other comprehensive income (loss) (OCI) for proportionate share of equity method investee's OCI.", "label": "OCI, Equity Method Investment, after Tax", "terseLabel": "ABI" } } }, "localname": "OciEquityMethodInvestmentAfterTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarningsLosses" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r206", "r212", "r216", "r219", "r222" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income", "verboseLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses", "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLossMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing operating income (loss).", "label": "Operating Income (Loss) [Member]", "terseLabel": "Operating Income (Loss) [Member]" } } }, "localname": "OperatingIncomeLossMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r211", "r212", "r213", "r214", "r216", "r222" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails", "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r19", "r550" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Background and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r25", "r26", "r27", "r60" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "verboseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r70", "r614" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r558", "r576" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other Assets [Member]" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r55" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "verboseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "auth_ref": [ "r86", "r94", "r95", "r599", "r601", "r605" ], "calculation": { "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "terseLabel": "Other comprehensive earnings (losses) before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r86", "r94", "r95", "r97", "r599", "r601", "r605" ], "calculation": { "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "totalLabel": "Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": { "auth_ref": [ "r84", "r94" ], "calculation": { "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax", "negatedLabel": "Deferred income taxes" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": { "auth_ref": [ "r77", "r83", "r566", "r569", "r577" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax", "terseLabel": "Gain (Loss) Recognized in Net Earnings (Losses)" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsEffectsofNetInvestmentHedgesonAccumulatedOtherComprehensiveLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r75" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarningsLosses": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Currency translation adjustments and other" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarningsLosses" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r568" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Gain (Loss) Recognized in Accumulated Other Comprehensive Losses" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsEffectsofNetInvestmentHedgesonAccumulatedOtherComprehensiveLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r89", "r92", "r94", "r95", "r97", "r101", "r375", "r599", "r604", "r605", "r665", "r691" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarningsLosses": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other comprehensive earnings (losses), net of deferred income taxes", "verboseLabel": "Other comprehensive earnings (losses), net of deferred income taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarningsLosses", "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquity", "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "verboseLabel": "Other comprehensive earnings (losses), net of deferred income taxes:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarningsLosses" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r80", "r83" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarningsLosses": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedTerseLabel": "Benefit plans" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarningsLosses" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCostOfOperatingRevenue": { "auth_ref": [ "r109" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses": { "order": 3.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other costs incurred during the reporting period related to other revenue generating activities.", "label": "Other Cost of Operating Revenue", "terseLabel": "Excise taxes on products" } } }, "localname": "OtherCostOfOperatingRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r558", "r576" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other Current Assets [Member]" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesMember": { "auth_ref": [ "r558", "r576" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other liabilities.", "label": "Other Liabilities [Member]", "terseLabel": "Other Liabilities [Member]" } } }, "localname": "OtherLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsFairValueDerivativeFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r64" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "verboseLabel": "Other, net" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r414", "r415", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r442", "r443", "r444", "r445", "r446", "r447", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r465", "r468", "r472", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r489", "r490", "r491", "r492", "r493", "r494" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefits Plan [Member]", "verboseLabel": "Postretirement [Member]" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BenefitPlansNarrativeDetails", "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent": { "auth_ref": [ "r36", "r415", "r416", "r438" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan, classified as noncurrent. Excludes pension plan.", "label": "Liability, Other Postretirement Defined Benefit Plan, Noncurrent", "terseLabel": "Accrued postretirement health care costs" } } }, "localname": "OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r115", "r118" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedTerseLabel": "Other, net" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r121" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "auth_ref": [ "r123" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "negatedTerseLabel": "Premiums and fees related to early extinguishment of debt" } } }, "localname": "PaymentsOfDebtExtinguishmentCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r121" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid on common stock" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": { "auth_ref": [ "r116" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.", "label": "Payments to Acquire Additional Interest in Subsidiaries", "terseLabel": "Payments to acquire additional interest in subsidiaries" } } }, "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r117" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PendingLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.", "label": "Pending Litigation [Member]", "terseLabel": "Pending Litigation [Member]" } } }, "localname": "PendingLitigationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails", "http://www.altria.com/role/ContingenciesJudgmentsPaidandProvisionsforTobaccoandHealthLitigationDetails", "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails", "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitContributions": { "auth_ref": [ "r128" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for pension and other postretirement benefits. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree.", "label": "Payment for Pension and Other Postretirement Benefits", "negatedLabel": "Pension plan contributions" } } }, "localname": "PensionAndOtherPostretirementBenefitContributions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r439", "r441", "r447", "r464", "r466", "r467", "r468", "r469", "r470", "r485", "r487", "r488", "r489", "r501" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash": { "auth_ref": [ "r131" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense (reversal of expense) for pension and other postretirement benefits.", "label": "Pension and Other Postretirement Benefits Expense (Reversal of Expense), Noncash", "terseLabel": "Pension provisions and postretirement, net" } } }, "localname": "PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r413", "r415", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r465", "r468", "r472", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r489", "r490", "r496", "r497", "r498", "r499" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension [Member]", "verboseLabel": "Pension [Member]" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BenefitPlansNarrativeDetails", "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r114" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from divestiture of businesses" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r119" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "verboseLabel": "Proceeds from issuance of debt" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r119" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Long-term debt issued" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r120", "r124" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other, net" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromShortTermDebt": { "auth_ref": [ "r119" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from Short-term Debt", "terseLabel": "Proceeds from short-term borrowings" } } }, "localname": "ProceedsFromShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r17", "r88", "r91", "r96", "r125", "r139", "r149", "r160", "r161", "r206", "r212", "r216", "r219", "r222", "r249", "r313", "r314", "r315", "r318", "r319", "r320", "r322", "r324", "r326", "r327", "r536", "r541", "r543", "r548", "r549", "r583", "r594", "r671" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarningsLosses": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "negatedLabel": "Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings (losses)", "terseLabel": "Net earnings (losses)", "totalLabel": "Net earnings (losses)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.altria.com/role/CondensedConsolidatedStatementsofComprehensiveEarningsLosses", "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses", "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r53", "r276" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "verboseLabel": "Property, plant and equipment, at cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r29", "r30", "r278", "r614", "r672", "r685" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseCommitmentMember": { "auth_ref": [ "r37", "r657", "r679" ], "lang": { "en-us": { "role": { "documentation": "Purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. Excludes long-term commitments.", "label": "Purchase Commitment [Member]", "terseLabel": "Purchase Commitment [Member]" } } }, "localname": "PurchaseCommitmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r41", "r48", "r614", "r684", "r711" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "terseLabel": "Receivables" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets", "http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "auth_ref": [ "r86", "r94", "r95", "r599", "r603", "r605" ], "calculation": { "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails": { "order": 1.0, "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "negatedLabel": "Amounts reclassified to net earnings (losses)" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r86", "r94", "r95", "r97", "r599", "r603", "r605" ], "calculation": { "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTotalLabel": "Amounts reclassified to net earnings (losses), net of deferred income taxes" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodTax": { "auth_ref": [ "r84", "r87", "r94" ], "calculation": { "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails": { "order": 2.0, "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).", "label": "Reclassification from AOCI, Current Period, Tax", "terseLabel": "Deferred income taxes" } } }, "localname": "ReclassificationFromAociCurrentPeriodTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Member]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLossesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "auth_ref": [ "r364", "r365", "r367", "r368" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "terseLabel": "Redeemable noncontrolling interest" } } }, "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r122" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Long-term debt repaid", "terseLabel": "Long-term debt repaid" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfShortTermDebt": { "auth_ref": [ "r122" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Repayments of Short-term Debt", "negatedLabel": "Repayment of short-term borrowings" } } }, "localname": "RepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfUnsecuredDebt": { "auth_ref": [ "r122" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.", "label": "Repayments of Unsecured Debt", "terseLabel": "Repayments of senior unsecured debt" } } }, "localname": "RepaymentsOfUnsecuredDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r20", "r28", "r134" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash included in other current assets" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r24", "r31", "r134", "r713" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash included in other assets" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r131", "r290", "r295", "r296" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r291", "r292", "r296", "r297" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r43", "r380", "r506", "r614", "r681", "r706", "r710" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Earnings reinvested in the business" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r144", "r145", "r146", "r150", "r159", "r161", "r253", "r502", "r503", "r504", "r516", "r517", "r581", "r703", "r705" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Earnings Reinvested in the Business [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r413", "r414", "r415", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r465", "r468", "r472", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r489", "r490", "r491", "r492", "r493", "r494", "r496", "r497", "r498", "r499" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BenefitPlansNarrativeDetails", "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r413", "r414", "r415", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r465", "r468", "r472", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r489", "r490", "r491", "r492", "r493", "r494", "r496", "r497", "r498", "r499" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BenefitPlansNarrativeDetails", "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r197", "r198", "r211", "r217", "r218", "r225", "r226", "r229", "r403", "r404", "r648" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "verboseLabel": "Net revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofEarningsLosses", "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r135", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r412" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue from Contract with Customer" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/RevenuefromContractwithCustomerPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r406", "r412" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenues from Contracts with Customers" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/RevenuesfromContractswithCustomers" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.", "label": "Revenue, Performance Obligation, Description of Timing", "terseLabel": "Expected period for satisfaction of performance obligation" } } }, "localname": "RevenuePerformanceObligationDescriptionOfTiming", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/RevenuesfromContractswithCustomersNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesGuaranteesandOtherSimilarMattersNarrativeDetails", "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r86", "r604", "r605" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/OtherComprehensiveEarningsLossesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r63", "r143", "r357", "r359", "r376", "r377", "r378", "r379", "r607", "r608", "r610", "r674" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt Instruments" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r471", "r472", "r473", "r474", "r485" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BenefitPlansNarrativeDetails", "http://www.altria.com/role/BenefitPlansScheduleOfComponentsOfNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r559", "r567", "r573" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Pre-tax Effects of Net Investment Hedges on Accumulated Other Comprehensive Losses" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r4", "r6", "r7", "r8", "r9", "r10", "r11", "r13", "r15", "r16", "r17", "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Disposal Groups, Including Discontinued Operations" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/EarningsLossesperShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]", "terseLabel": "Schedule of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r17", "r139", "r248", "r249", "r594" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]", "terseLabel": "Schedule of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesEarningsinEquitySecuritiesDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinABINarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinJUULNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock": { "auth_ref": [ "r299", "r300", "r301", "r303", "r304", "r305", "r307", "r309", "r310" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.", "label": "Schedule of Loss Contingencies by Contingency [Table Text Block]", "terseLabel": "Schedule of Contingencies" } } }, "localname": "ScheduleOfLossContingenciesByContingencyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Schedule of Net Periodic Benefit (Income) Cost" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r565" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Schedule of Derivative Liabilities at Fair Value" } } }, "localname": "ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r153", "r156", "r187", "r188" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]", "terseLabel": "Recent Accounting Guidance Not Yet Adopted" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/NewAccountingGuidanceNotYetAdoptedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r291", "r292", "r293", "r294", "r296", "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r206", "r209", "r215", "r268" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails", "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r206", "r209", "r215", "r268" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information, by Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": { "auth_ref": [ "r381", "r382", "r383", "r384" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table Text Block]", "terseLabel": "Schedule of Share Repurchase Activity" } } }, "localname": "ScheduleOfTreasuryStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r194", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r211", "r212", "r213", "r214", "r216", "r217", "r218", "r219", "r220", "r222", "r229", "r294", "r298", "r699" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]", "verboseLabel": "Reporting Segment [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails", "http://www.altria.com/role/SegmentReportingNarrativeDetails", "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails", "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails", "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r194", "r195", "r196", "r206", "r210", "r216", "r220", "r221", "r222", "r223", "r225", "r228", "r229", "r230" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails", "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes [Member]" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails", "http://www.altria.com/role/DebtTenderOffersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SettledLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.", "label": "Settled Litigation [Member]", "terseLabel": "Settled Litigation [Member]" } } }, "localname": "SettledLitigationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails", "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails", "http://www.altria.com/role/ContingenciesNPMAdjustmentDisputesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails", "http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails", "http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r32", "r614", "r655", "r677" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt", "terseLabel": "Short-term debt" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r5", "r194", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r211", "r212", "r213", "r214", "r216", "r217", "r218", "r219", "r220", "r222", "r229", "r268", "r282", "r294", "r298", "r699" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails", "http://www.altria.com/role/SegmentReportingNarrativeDetails", "http://www.altria.com/role/SegmentReportingNonParticipatingManufacturerAdjustmentItemsDetails", "http://www.altria.com/role/SegmentReportingScheduleofTobaccoandHealthandCertainOtherLitigationItemsDetails", "http://www.altria.com/role/SegmentReportingSegmentDataScheduleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r38", "r39", "r40", "r137", "r139", "r169", "r170", "r175", "r178", "r180", "r191", "r192", "r193", "r249", "r313", "r318", "r319", "r320", "r326", "r327", "r369", "r370", "r372", "r373", "r375", "r594", "r730" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r67", "r94", "r95", "r96", "r144", "r145", "r146", "r150", "r159", "r161", "r190", "r253", "r375", "r380", "r502", "r503", "r504", "r516", "r517", "r581", "r599", "r600", "r601", "r602", "r603", "r605", "r703", "r704", "r705", "r738" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]", "verboseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquity", "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails", "http://www.altria.com/role/OtherComprehensiveEarningsLossesReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r144", "r145", "r146", "r190", "r648" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "verboseLabel": "Planned share repurchase program" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Stock repurchase program, remaining authorized repurchase amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r40", "r45", "r46", "r139", "r232", "r249", "r594", "r614" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders\u2019 (deficit) equity attributable to Altria" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r95", "r139", "r144", "r145", "r146", "r150", "r159", "r249", "r253", "r380", "r502", "r503", "r504", "r516", "r517", "r534", "r535", "r547", "r581", "r594", "r599", "r600", "r605", "r704", "r705", "r738" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 (deficit) equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets", "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquity", "http://www.altria.com/role/OtherComprehensiveEarningsLossesChangesinEachComponentofAccumulatedOtherComprehensiveLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Stockholders\u2019 (Deficit) Equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets", "http://www.altria.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedLabel": "Other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r606", "r615" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails", "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails", "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails", "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails", "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails", "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails", "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails", "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails", "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails", "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r606", "r615" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails", "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails", "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails", "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails", "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails", "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails", "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails", "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails", "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails", "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r606", "r615" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/AssetsHeldforSaleNarrativeDetails", "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails", "http://www.altria.com/role/ContingenciesAntitrustLitigationandShareholderClassActionandShareholderDerivativeLawsuitsDetails", "http://www.altria.com/role/ContingenciesEngleClassActionAndEngleProgenyTrialResultsDetails", "http://www.altria.com/role/ContingenciesEngleProgenyCasesTrialResultsPendingandConcludedDetails", "http://www.altria.com/role/ContingenciesEvaporProductLitigationandIQOSLitigationDetails", "http://www.altria.com/role/ContingenciesLightsUltraLightsCasesDetails", "http://www.altria.com/role/ContingenciesOtherSmokingandHealthClassActionsDetails", "http://www.altria.com/role/ContingenciesOverviewofAltriaandorPMUSATobaccoRelatedLitigationNarrativeDetails", "http://www.altria.com/role/ContingenciesScheduleofPendingCasesDetails", "http://www.altria.com/role/ContingenciesUSTLitigationsNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of subsidiary's or equity method investee's stock owned by parent immediately after all stock transactions.", "label": "Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions", "terseLabel": "Subsidiary ownership percentage" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.", "label": "Summary of Valuation Allowance [Table Text Block]", "terseLabel": "Summary of Valuation Allowance" } } }, "localname": "SummaryOfValuationAllowanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/IncomeTaxesupdateTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ThreatenedLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risk of loss associated with the outcome of threatened litigation against the entity.", "label": "Threatened Litigation [Member]", "terseLabel": "Threatened Litigation [Member]" } } }, "localname": "ThreatenedLitigationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/ContingenciesHealthCareCostRecoveryLitigationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r235", "r236", "r238", "r239", "r240", "r354", "r374", "r579", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r730", "r731", "r732", "r733", "r734", "r735", "r736" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/InvestmentsinEquitySecuritiesInvestmentinCronosNarrativeDetails", "http://www.altria.com/role/InvestmentsinEquitySecuritiesSummaryofInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "verboseLabel": "Average price per share of shares repurchased (usd per share)" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "terseLabel": "Shares repurchased (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r66", "r381" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Cost of Repurchased Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r40", "r375", "r380" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Repurchase of common stock (shares)", "verboseLabel": "Total number of shares repurchased (shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationNarrativeDetails", "http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r66", "r381", "r384" ], "calculation": { "http://www.altria.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Cost of repurchased stock (967,321,022 shares at September 30, 2021 and 947,542,152 shares at December 31, 2020)" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r375", "r380", "r381" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Repurchases of common stock", "terseLabel": "Aggregate cost of shares repurchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/BackgroundandBasisofPresentationShareRepurchaseTableDetails", "http://www.altria.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r291", "r292", "r296", "r297" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnDerivatives": { "auth_ref": [ "r131" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Gain (Loss) on Derivatives", "terseLabel": "Unrealized gain (loss) on derivatives" } } }, "localname": "UnrealizedGainLossOnDerivatives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/FinancialInstrumentsPretaxUnrealizedGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnusualOrInfrequentItemAxis": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Item, or Both [Axis]", "terseLabel": "Unusual or Infrequent Item, or Both [Axis]" } } }, "localname": "UnusualOrInfrequentItemAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnusualOrInfrequentItemDomain": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Item, or Both [Domain]", "terseLabel": "Unusual or Infrequent Item, or Both [Domain]" } } }, "localname": "UnusualOrInfrequentItemDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r168", "r180" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average shares for diluted EPS (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/EarningsLossesperShareBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "Shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) are considered outstanding common shares and included in the computation of basic Earnings Per Share as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent). Outstanding common shares that are contingently returnable (that is, subject to recall) are treated in the same manner as contingently issuable shares. Contingently issuable shares include shares that (a) will be issued in the future upon the satisfaction of specified conditions, (b) have been placed in escrow and all or part must be returned if specified conditions are not met, or (c) have been issued but the holder must return all or part if specified conditions are not met. The number of contingently issuable shares is determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares, Contingently Issuable", "terseLabel": "Plus: contingently issuable performance stock units (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesContingentlyIssuable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/EarningsLossesperShareBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r165", "r180" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares for basic EPS (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/EarningsLossesperShareBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "auth_ref": [ "r111" ], "calculation": { "http://www.altria.com/role/DebtNarrativeDetails": { "order": 2.0, "parentTag": "us-gaap_GainsLossesOnExtinguishmentOfDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.", "label": "Write off of Deferred Debt Issuance Cost", "terseLabel": "Write-off of amortized debt discounts and issuance costs, debt extinguishment" } } }, "localname": "WriteOffOfDeferredDebtIssuanceCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altria.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" } }, "unitCount": 17 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693" }, "r164": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2646-109256" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r18": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e725-108305" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e765-108305" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e639-108305" }, "r19": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r230": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r237": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r241": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "321", "URI": "http://asc.fasb.org/topic&trid=75115024" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=125513658&loc=d3e32014-111567" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=124268079&loc=d3e32472-111569" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r251": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r252": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "325", "URI": "http://asc.fasb.org/topic&trid=2197064" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2599-110228" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2473-110228" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r285": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6393242&loc=d3e13185-110859" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6393242&loc=d3e13231-110859" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6571209&loc=d3e13669-110860" }, "r289": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "410", "URI": "http://asc.fasb.org/subtopic&trid=2175709" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r308": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r363": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(12)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(16)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(3)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "14", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "15", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r412": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r501": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r584": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r725": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r726": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r727": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r728": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r729": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r730": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r731": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r732": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r733": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r734": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r735": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r736": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r737": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(dd)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" } }, "version": "2.1" } ZIP 107 0000764180-21-000127-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000764180-21-000127-xbrl.zip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